0000021076-24-000030.txt : 20240808 0000021076-24-000030.hdr.sgml : 20240808 20240808162220 ACCESSION NUMBER: 0000021076-24-000030 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 152 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CLOROX CO /DE/ CENTRAL INDEX KEY: 0000021076 STANDARD INDUSTRIAL CLASSIFICATION: SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 310595760 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07151 FILM NUMBER: 241188760 BUSINESS ADDRESS: STREET 1: THE CLOROX COMPANY STREET 2: 1221 BROADWAY CITY: OAKLAND STATE: CA ZIP: 94612-1888 BUSINESS PHONE: 5102717000 MAIL ADDRESS: STREET 1: P.O. BOX 24305 CITY: OAKLAND STATE: CA ZIP: 94612-1305 10-K 1 clx-20240630.htm 10-K clx-20240630
False2024FY0000021076273http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://www.clorox.com/20240630#OtherExpenseIncomeNethttp://www.clorox.com/20240630#OtherExpenseIncomeNethttp://fasb.org/us-gaap/2024#AssetImpairmentChargeshttp://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrentiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureclx:hedgingInstrumentclx:productionPlantclx:optionclx:segment00000210762023-07-012024-06-3000000210762023-12-2900000210762024-07-2300000210762024-04-012024-06-300000021076clx:AngelaHiltMember2023-07-012024-06-300000021076clx:AngelaHiltMember2024-04-012024-06-300000021076clx:AngelaHiltMember2024-06-3000000210762022-07-012023-06-3000000210762021-07-012022-06-3000000210762024-06-3000000210762023-06-300000021076us-gaap:CommonStockMember2021-06-300000021076us-gaap:AdditionalPaidInCapitalMember2021-06-300000021076us-gaap:RetainedEarningsMember2021-06-300000021076us-gaap:TreasuryStockCommonMember2021-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000021076us-gaap:NoncontrollingInterestMember2021-06-3000000210762021-06-300000021076us-gaap:RetainedEarningsMember2021-07-012022-06-300000021076us-gaap:NoncontrollingInterestMember2021-07-012022-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012022-06-300000021076us-gaap:AdditionalPaidInCapitalMember2021-07-012022-06-300000021076us-gaap:TreasuryStockCommonMember2021-07-012022-06-300000021076us-gaap:CommonStockMember2022-06-300000021076us-gaap:AdditionalPaidInCapitalMember2022-06-300000021076us-gaap:RetainedEarningsMember2022-06-300000021076us-gaap:TreasuryStockCommonMember2022-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000021076us-gaap:NoncontrollingInterestMember2022-06-3000000210762022-06-300000021076us-gaap:RetainedEarningsMember2022-07-012023-06-300000021076us-gaap:NoncontrollingInterestMember2022-07-012023-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012023-06-300000021076us-gaap:AdditionalPaidInCapitalMember2022-07-012023-06-300000021076us-gaap:TreasuryStockCommonMember2022-07-012023-06-300000021076us-gaap:CommonStockMember2023-06-300000021076us-gaap:AdditionalPaidInCapitalMember2023-06-300000021076us-gaap:RetainedEarningsMember2023-06-300000021076us-gaap:TreasuryStockCommonMember2023-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000021076us-gaap:NoncontrollingInterestMember2023-06-300000021076us-gaap:RetainedEarningsMember2023-07-012024-06-300000021076us-gaap:NoncontrollingInterestMember2023-07-012024-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012024-06-300000021076us-gaap:AdditionalPaidInCapitalMember2023-07-012024-06-300000021076us-gaap:TreasuryStockCommonMember2023-07-012024-06-300000021076us-gaap:CommonStockMember2024-06-300000021076us-gaap:AdditionalPaidInCapitalMember2024-06-300000021076us-gaap:RetainedEarningsMember2024-06-300000021076us-gaap:TreasuryStockCommonMember2024-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000021076us-gaap:NoncontrollingInterestMember2024-06-300000021076srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-06-300000021076srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-06-300000021076srt:MinimumMemberus-gaap:LandImprovementsMember2024-06-300000021076srt:MaximumMemberus-gaap:LandImprovementsMember2024-06-300000021076srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-06-300000021076srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-06-300000021076srt:MinimumMemberus-gaap:ComputerEquipmentMember2024-06-300000021076srt:MaximumMemberus-gaap:ComputerEquipmentMember2024-06-300000021076srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-06-300000021076srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-06-300000021076srt:MinimumMember2024-06-300000021076srt:MaximumMember2024-06-300000021076us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberclx:ArgentinaBusinessMember2024-03-200000021076us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberclx:ArgentinaBusinessMember2024-01-012024-03-310000021076us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberclx:ArgentinaBusinessMember2023-07-012024-06-300000021076us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberclx:ArgentinaBusinessMember2022-07-012023-06-300000021076clx:CyberattackMember2023-07-012024-06-300000021076clx:CyberattackMember2024-04-012024-06-300000021076us-gaap:CostOfSalesMemberclx:CyberattackMember2023-07-012024-06-300000021076us-gaap:SellingGeneralAndAdministrativeExpensesMemberclx:CyberattackMember2023-07-012024-06-300000021076clx:CostOfGoodsAndServicesSoldMember2022-07-012023-06-300000021076clx:CostOfGoodsAndServicesSoldMember2023-07-012024-06-300000021076us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012024-06-300000021076us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012023-06-300000021076us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012023-06-300000021076us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012024-06-300000021076clx:OtherIncomeExpenseNetMember2022-07-012023-06-300000021076clx:OtherIncomeExpenseNetMember2023-07-012024-06-300000021076clx:OtherIncomeExpenseNetMemberus-gaap:EmployeeSeveranceMember2023-07-012024-06-300000021076clx:OtherIncomeExpenseNetMemberus-gaap:EmployeeSeveranceMember2022-07-012023-06-300000021076clx:OtherIncomeExpenseNetMemberclx:AssetImpairmentsMember2023-07-012024-06-300000021076clx:OtherIncomeExpenseNetMemberclx:AssetImpairmentsMember2022-07-012023-06-300000021076us-gaap:EmployeeSeveranceMember2023-06-300000021076us-gaap:OtherRestructuringMember2023-06-300000021076us-gaap:EmployeeSeveranceMember2023-07-012024-06-300000021076us-gaap:OtherRestructuringMember2023-07-012024-06-300000021076us-gaap:EmployeeSeveranceMember2024-06-300000021076us-gaap:OtherRestructuringMember2024-06-300000021076us-gaap:LandAndLandImprovementsMember2024-06-300000021076us-gaap:LandAndLandImprovementsMember2023-06-300000021076us-gaap:BuildingMember2024-06-300000021076us-gaap:BuildingMember2023-06-300000021076us-gaap:MachineryAndEquipmentMember2024-06-300000021076us-gaap:MachineryAndEquipmentMember2023-06-300000021076us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-06-300000021076us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-06-300000021076us-gaap:ComputerEquipmentMember2024-06-300000021076us-gaap:ComputerEquipmentMember2023-06-300000021076us-gaap:ConstructionInProgressMember2024-06-300000021076us-gaap:ConstructionInProgressMember2023-06-300000021076us-gaap:PropertyPlantAndEquipmentMember2023-07-012024-06-300000021076us-gaap:PropertyPlantAndEquipmentMember2022-07-012023-06-300000021076us-gaap:PropertyPlantAndEquipmentMember2021-07-012022-06-300000021076us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-07-012024-06-300000021076us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-07-012023-06-300000021076us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-07-012022-06-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2022-06-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2022-06-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2022-06-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2022-06-300000021076us-gaap:CorporateNonSegmentMember2022-06-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2022-07-012023-06-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2022-07-012023-06-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2022-07-012023-06-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2022-07-012023-06-300000021076us-gaap:CorporateNonSegmentMember2022-07-012023-06-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2023-06-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2023-06-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2023-06-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2023-06-300000021076us-gaap:CorporateNonSegmentMember2023-06-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2023-07-012024-06-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2023-07-012024-06-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2023-07-012024-06-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2023-07-012024-06-300000021076us-gaap:CorporateNonSegmentMember2023-07-012024-06-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2024-06-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2024-06-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2024-06-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2024-06-300000021076us-gaap:CorporateNonSegmentMember2024-06-300000021076us-gaap:TrademarksMember2024-06-300000021076us-gaap:TrademarksMember2023-06-300000021076us-gaap:TrademarksMember2024-06-300000021076us-gaap:TrademarksMember2023-06-300000021076us-gaap:OtherIntangibleAssetsMember2024-06-300000021076us-gaap:OtherIntangibleAssetsMember2023-06-300000021076clx:BetterHealthVitaminsMineralsAndSupplementsReportingUnitMember2022-07-012023-06-300000021076clx:InternationalReportingUnitMember2022-07-012023-06-300000021076us-gaap:TrademarksMember2022-07-012023-06-300000021076us-gaap:TrademarksMember2023-03-310000021076clx:BetterHealthVitaminsMineralsAndSupplementsReportingUnitMember2023-06-300000021076clx:SeniorLongTermNotesAndDebentures3.10400DueOctober2027Member2024-06-300000021076clx:SeniorLongTermNotesAndDebentures3.10400DueOctober2027Member2023-06-300000021076clx:SeniorLongTermNotesAndDebentures3.90500DueMay2028Member2024-06-300000021076clx:SeniorLongTermNotesAndDebentures3.90500DueMay2028Member2023-06-300000021076clx:SeniorLongTermNotesAndDebentures440500DueMay2029Member2024-06-300000021076clx:SeniorLongTermNotesAndDebentures440500DueMay2029Member2023-06-300000021076clx:SeniorLongTermNotesAndDebentures180500DueMay2030Member2024-06-300000021076clx:SeniorLongTermNotesAndDebentures180500DueMay2030Member2023-06-300000021076clx:SeniorLongTermNotesAndDebentures460600DueMay2032Member2024-06-300000021076clx:SeniorLongTermNotesAndDebentures460600DueMay2032Member2023-06-300000021076us-gaap:SeniorNotesMember2022-05-310000021076clx:SeniorLongTermNotesAndDebentures440500DueMay2029Memberus-gaap:SeniorNotesMember2022-05-310000021076clx:SeniorLongTermNotesAndDebentures460600DueMay2032Memberus-gaap:SeniorNotesMember2022-05-310000021076clx:SeniorLongTermNotesAndDebentures3.05600DueSeptember2022Memberus-gaap:SeniorNotesMember2022-06-300000021076clx:SeniorLongTermNotesAndDebentures3.50500DueDecember2024Memberus-gaap:SeniorNotesMember2022-06-300000021076clx:SeniorLongTermNotesAndDebentures3.50500DueDecember2024Memberus-gaap:SeniorNotesMember2022-06-012022-06-300000021076clx:SeniorLongTermNotesAndDebentures3.80300DueNovember2021Memberus-gaap:SeniorNotesMember2021-11-012021-11-300000021076clx:SeniorLongTermNotesAndDebentures3.80300DueNovember2021Memberus-gaap:SeniorNotesMember2021-11-300000021076clx:RevolvingCreditAgreementMaturesMarch2027Memberus-gaap:RevolvingCreditFacilityMember2023-06-300000021076clx:RevolvingCreditAgreementMaturesMarch2027Memberus-gaap:RevolvingCreditFacilityMember2024-06-300000021076us-gaap:RevolvingCreditFacilityMember2024-06-300000021076us-gaap:RevolvingCreditFacilityMember2023-06-300000021076us-gaap:ForeignLineOfCreditMember2024-06-300000021076us-gaap:ForeignLineOfCreditMember2023-06-300000021076clx:ForeignAndOtherCreditLinesMember2024-06-300000021076clx:ForeignAndOtherCreditLinesMember2023-06-300000021076clx:GladBusinessMember2023-06-300000021076clx:GladBusinessMember2024-06-300000021076clx:TotalCommodityPurchaseDerivativeContractsMember2023-07-012024-06-300000021076clx:TotalCommodityPurchaseDerivativeContractsMember2024-06-300000021076clx:SoybeanOilFuturesMember2024-06-300000021076clx:JetFuelSwapsMember2024-06-300000021076clx:TotalCommodityPurchaseDerivativeContractsMember2023-06-300000021076clx:SoybeanOilFuturesMember2023-06-300000021076clx:JetFuelSwapsMember2023-06-300000021076us-gaap:ForeignExchangeContractMemberclx:PurchasesofInventoryMember2024-06-300000021076us-gaap:ForeignExchangeContractMemberclx:PurchasesofInventoryMember2023-06-300000021076us-gaap:InterestRateContractMember2021-07-012022-06-300000021076clx:SeniorLongTermNotesAndDebentures440500DueMay2029Memberus-gaap:InterestRateContractMember2021-07-012022-06-300000021076clx:SeniorLongTermNotesAndDebentures460600DueMay2032Memberus-gaap:InterestRateContractMember2021-07-012022-06-300000021076us-gaap:CommodityContractMember2023-07-012024-06-300000021076us-gaap:CommodityContractMember2022-07-012023-06-300000021076us-gaap:CommodityContractMember2021-07-012022-06-300000021076us-gaap:ForeignExchangeContractMember2023-07-012024-06-300000021076us-gaap:ForeignExchangeContractMember2022-07-012023-06-300000021076us-gaap:ForeignExchangeContractMember2021-07-012022-06-300000021076us-gaap:InterestRateContractMember2023-07-012024-06-300000021076us-gaap:InterestRateContractMember2022-07-012023-06-300000021076us-gaap:CommodityContractMember2024-06-300000021076us-gaap:CommodityContractMember2023-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-07-012024-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000021076us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000021076us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000021076us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000021076us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000021076us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000021076us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000021076us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000021076us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000021076us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000021076us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberclx:NotesAndLoansPayableMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberclx:NotesAndLoansPayableMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberclx:NotesAndLoansPayableMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberclx:NotesAndLoansPayableMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LongTermDebtMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LongTermDebtMember2024-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LongTermDebtMember2023-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LongTermDebtMember2023-06-300000021076clx:AlamedaCountyCaliforniaMatterMember2024-06-300000021076clx:AlamedaCountyCaliforniaMatterMember2023-06-300000021076clx:AlamedaCountyCaliforniaMatterMember2023-07-012024-06-300000021076clx:DickinsonCountyMichiganMatterMember2024-06-300000021076clx:DickinsonCountyMichiganMatterMember2023-06-300000021076clx:DickinsonCountyMichiganMatterMember2023-07-012024-06-300000021076us-gaap:OperatingLeaseLeaseNotYetCommencedMember2024-06-300000021076us-gaap:FinancingLeaseLeaseNotYetCommencedMember2024-06-3000000210762023-12-142023-12-1400000210762023-12-1400000210762022-05-252022-05-2500000210762022-05-250000021076us-gaap:SubsequentEventMember2024-07-302024-07-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000021076us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012022-06-300000021076us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012022-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012022-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000021076us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012023-06-300000021076us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-07-012023-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012023-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000021076us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012024-06-300000021076us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-07-012024-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012024-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000021076us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-3000000210762021-11-012021-11-300000021076us-gaap:CostOfSalesMember2023-07-012024-06-300000021076us-gaap:CostOfSalesMember2022-07-012023-06-300000021076us-gaap:CostOfSalesMember2021-07-012022-06-300000021076us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012022-06-300000021076us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012022-06-300000021076us-gaap:EmployeeStockOptionMember2022-07-012023-06-300000021076us-gaap:EmployeeStockOptionMember2021-07-012022-06-300000021076us-gaap:EmployeeStockOptionMembersrt:MinimumMember2021-07-012022-06-300000021076us-gaap:EmployeeStockOptionMembersrt:MaximumMember2021-07-012022-06-300000021076us-gaap:EmployeeStockOptionMember2023-07-012024-06-300000021076us-gaap:EmployeeStockOptionMember2024-06-300000021076us-gaap:RestrictedStockMembersrt:MinimumMember2023-07-012024-06-300000021076us-gaap:RestrictedStockMembersrt:MaximumMember2023-07-012024-06-300000021076us-gaap:RestrictedStockMember2024-06-300000021076us-gaap:RestrictedStockMember2023-07-012024-06-300000021076us-gaap:RestrictedStockMember2022-07-012023-06-300000021076us-gaap:RestrictedStockMember2021-07-012022-06-300000021076us-gaap:RestrictedStockMember2023-06-300000021076us-gaap:PerformanceSharesMember2023-07-012024-06-300000021076us-gaap:PerformanceSharesMember2024-06-300000021076us-gaap:PerformanceSharesMember2022-07-012023-06-300000021076us-gaap:PerformanceSharesMember2021-07-012022-06-300000021076us-gaap:PerformanceSharesMember2023-06-300000021076clx:DeferredStockUnitsForNonemployeeDirectorsMember2024-06-300000021076clx:DeferredStockUnitsForNonemployeeDirectorsMember2023-07-012024-06-300000021076us-gaap:CapitalLossCarryforwardMemberus-gaap:DomesticCountryMember2024-06-300000021076clx:SubjectToExpirationMemberus-gaap:DomesticCountryMember2024-06-300000021076clx:NotSubjectToExpirationMemberus-gaap:DomesticCountryMember2024-06-300000021076clx:SubjectToExpirationMemberus-gaap:ForeignCountryMember2024-06-300000021076clx:NotSubjectToExpirationMemberus-gaap:ForeignCountryMember2024-06-300000021076clx:IncomeTaxCreditCarryforwardMemberus-gaap:DomesticCountryMemberclx:SubjectToExpirationMember2024-06-300000021076clx:IncomeTaxCreditCarryforwardMemberus-gaap:DomesticCountryMemberclx:NotSubjectToExpirationMember2024-06-300000021076clx:IncomeTaxCreditCarryforwardMemberus-gaap:ForeignCountryMemberclx:SubjectToExpirationMember2024-06-300000021076clx:IncomeTaxCreditCarryforwardMemberus-gaap:ForeignCountryMemberclx:NotSubjectToExpirationMember2024-06-300000021076clx:IncomeTaxCreditCarryforwardMember2024-06-300000021076us-gaap:CapitalLossCarryforwardMemberus-gaap:DomesticCountryMember2023-06-300000021076clx:SubjectToExpirationMemberus-gaap:DomesticCountryMember2023-06-300000021076clx:NotSubjectToExpirationMemberus-gaap:DomesticCountryMember2023-06-300000021076clx:SubjectToExpirationMemberus-gaap:ForeignCountryMember2023-06-300000021076clx:NotSubjectToExpirationMemberus-gaap:ForeignCountryMember2023-06-300000021076clx:IncomeTaxCreditCarryforwardMemberus-gaap:DomesticCountryMemberclx:SubjectToExpirationMember2023-06-300000021076clx:IncomeTaxCreditCarryforwardMemberus-gaap:DomesticCountryMemberclx:NotSubjectToExpirationMember2023-06-300000021076clx:IncomeTaxCreditCarryforwardMemberus-gaap:ForeignCountryMemberclx:NotSubjectToExpirationMember2023-06-300000021076clx:IncomeTaxCreditCarryforwardMember2023-06-300000021076country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012024-06-300000021076country:US2023-07-012024-06-300000021076country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012023-06-300000021076country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012022-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-06-300000021076us-gaap:DefinedBenefitPostretirementHealthCoverageMember2023-06-300000021076us-gaap:DefinedBenefitPostretirementHealthCoverageMember2022-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012024-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012023-06-300000021076us-gaap:DefinedBenefitPostretirementHealthCoverageMember2023-07-012024-06-300000021076us-gaap:DefinedBenefitPostretirementHealthCoverageMember2022-07-012023-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-06-300000021076us-gaap:DefinedBenefitPostretirementHealthCoverageMember2024-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012022-06-300000021076us-gaap:DefinedBenefitPostretirementHealthCoverageMember2021-07-012022-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FixedIncomeFundsMember2023-06-300000021076us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberclx:DefinedBenefitPlanBondsFundsMember2024-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberclx:DefinedBenefitPlanBondsFundsMember2023-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2024-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2023-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2024-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2023-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberclx:DefinedBenefitPlanShortTermInvestmentMember2024-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberclx:DefinedBenefitPlanShortTermInvestmentMember2023-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberclx:DefinedBenefitPlanOtherMember2024-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberclx:DefinedBenefitPlanOtherMember2023-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-06-300000021076us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-06-300000021076clx:DomesticDefinedContributionPlanMember2023-07-012024-06-300000021076clx:DomesticDefinedContributionPlanMember2022-07-012023-06-300000021076clx:DomesticDefinedContributionPlanMember2021-07-012022-06-300000021076clx:InternationalDefinedContributionPlanMember2023-07-012024-06-300000021076clx:InternationalDefinedContributionPlanMember2022-07-012023-06-300000021076clx:InternationalDefinedContributionPlanMember2021-07-012022-06-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2021-07-012022-06-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2021-07-012022-06-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2021-07-012022-06-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2021-07-012022-06-300000021076us-gaap:OperatingSegmentsMember2023-07-012024-06-300000021076us-gaap:OperatingSegmentsMember2022-07-012023-06-300000021076us-gaap:OperatingSegmentsMember2021-07-012022-06-300000021076us-gaap:CorporateNonSegmentMember2021-07-012022-06-300000021076clx:OperatingSegmentsAndCorporateNonSegmentMember2023-07-012024-06-300000021076clx:OperatingSegmentsAndCorporateNonSegmentMember2022-07-012023-06-300000021076clx:OperatingSegmentsAndCorporateNonSegmentMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:CyberattackMemberclx:HealthAndWellnessMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:CyberattackMemberclx:HouseholdMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:CyberattackMemberclx:LifestyleMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:CyberattackMemberclx:InternationalMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:CorporateNonSegmentMemberclx:CyberattackMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:CyberattackMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:HealthAndWellnessMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:HealthAndWellnessMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:HealthAndWellnessMember2022-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:HouseholdMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:HouseholdMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:HouseholdMember2022-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:LifestyleMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:LifestyleMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:LifestyleMember2022-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:InternationalMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:InternationalMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberclx:RestructuringAndRelatedCostsBenchmarkMemberclx:InternationalMember2022-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:CorporateNonSegmentMemberclx:RestructuringAndRelatedCostsBenchmarkMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:CorporateNonSegmentMemberclx:RestructuringAndRelatedCostsBenchmarkMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:CorporateNonSegmentMemberclx:RestructuringAndRelatedCostsBenchmarkMember2022-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:RestructuringAndRelatedCostsBenchmarkMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:RestructuringAndRelatedCostsBenchmarkMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:RestructuringAndRelatedCostsBenchmarkMember2022-07-012024-06-300000021076clx:WalmartStoresIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076clx:WalmartStoresIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076clx:WalmartStoresIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:CleaningMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:CleaningMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:CleaningMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:ProfessionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:ProfessionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMemberclx:ProfessionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:HealthAndWellnessMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:HealthAndWellnessMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:HealthAndWellnessMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:BagsAndWrapsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:BagsAndWrapsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:BagsAndWrapsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:CatLitterMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:CatLitterMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:CatLitterMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:GrillingMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:GrillingMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:HouseholdMemberclx:GrillingMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:HouseholdMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:HouseholdMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:HouseholdMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:FoodProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:FoodProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:FoodProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:WaterFiltrationMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:WaterFiltrationMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:WaterFiltrationMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:NaturalPersonalCareMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:NaturalPersonalCareMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:LifestyleMemberclx:NaturalPersonalCareMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:InternationalMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:InternationalMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:OperatingSegmentsMemberus-gaap:RevenueFromContractWithCustomerMemberclx:InternationalMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:CorporateNonSegmentMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:CorporateNonSegmentMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:CorporateNonSegmentMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:CleaningMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:CleaningMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:CleaningMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:BagsAndWrapsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:BagsAndWrapsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:BagsAndWrapsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:FoodProductsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:FoodProductsMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:FoodProductsMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:CatLitterMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012024-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:CatLitterMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012023-06-300000021076us-gaap:ProductConcentrationRiskMemberclx:CatLitterMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012022-06-300000021076country:US2023-07-012024-06-300000021076us-gaap:NonUsMember2023-07-012024-06-300000021076country:US2022-07-012023-06-300000021076us-gaap:NonUsMember2022-07-012023-06-300000021076country:US2021-07-012022-06-300000021076us-gaap:NonUsMember2021-07-012022-06-300000021076country:US2024-06-300000021076us-gaap:NonUsMember2024-06-300000021076country:US2023-06-300000021076us-gaap:NonUsMember2023-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 10-K
__________________
Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the fiscal year endedJune 30, 2024
OR
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from __________to__________.
Commission file number: 1-07151
CLX logo.jpg
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)
Delaware31-0595760
(State or other jurisdiction of(I.R.S. Employer
incorporation or organization)Identification Number)
1221 Broadway, Oakland, California 94612-1888
(Address of principal executive offices) (ZIP code)
(510)271-7000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock – $1.00 par valueCLXNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
None
(Title of class)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10d-1(b).
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No
The aggregate market value of the registrant’s common stock held by non-affiliates as of December 29, 2023 (the last business day of the registrant’s most recently completed second fiscal quarter) was approximately $17.7 billion.
As of July 23, 2024, there were 123,861,545 shares of the registrant’s common stock outstanding.
Documents Incorporated by Reference:
Portions of the registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders (the “Proxy Statement”), to be filed within 120 days after June 30, 2024, are incorporated by reference into Part III, Items 10 through 14 of this Annual Report on Form 10-K.



THE CLOROX COMPANY
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED JUNE 30, 2024
TABLE OF CONTENTS
Page
 



PART I
This Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (this Report), including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including, among others, statements regarding the expected or potential impact of the Company’s operational disruption stemming from a cyberattack, and any such forward-looking statements involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed below. Important factors that could affect performance and cause results to differ materially from management’s expectations are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Report, as updated from time to time in the Company’s U.S. Securities and Exchange Commission (SEC) filings.
The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.
In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us” and “our” refer to The Clorox Company and its subsidiaries.
ITEM 1. BUSINESS
Overview of Business
The Clorox Company is a leading multinational manufacturer and marketer of consumer and professional products with fiscal year 2024 net sales of $7.1 billion and about 8,000 employees worldwide as of June 30, 2024. The Company has operations in approximately 25 countries or territories and sells its products in more than 100 markets, primarily through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet and military stores; third-party and owned e-commerce channels; and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach, cleaning and disinfecting products; Pine-Sol® and Tilex® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Glad® bags and wraps; Fresh Step® cat litter; Kingsford® grilling products; Hidden Valley® dressings, dips, seasonings and sauces; Brita® water-filtration products; Burt’s Bees® natural personal care products; and Natural Vitality®, RenewLife®, NeoCell® and Rainbow Light® vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro and Clorox Healthcare® brand names. About 80% of the Company’s sales are generated from brands that hold the No. 1 or No. 2 market share positions in their categories. The Company was founded in Oakland, California, in 1913 and is incorporated in Delaware.
The Company's IGNITE strategy accelerates innovation in key areas of the business to drive growth and deliver value for all Company stakeholders. IGNITE focuses on four strategic choices aimed at fueling long-term, profitable growth; innovating consumer experiences; reimagining how the company and its people work; and continuously evolving the product portfolio. In addition, integrated environmental, social and governance (ESG) goals help drive long-term value for the Company and its stakeholders.
Business Performance
Guided by its IGNITE strategy and underpinned by its enduring values, the Company remained focused on making significant investments in its strong brands, strategic digital capabilities and streamlined operating model to drive long-term value creation.
The Company entered fiscal year 2024 having delivered strong execution against its IGNITE goals during the prior fiscal year. In August 2023, a cyberattack created significant disruption to the Company's operations. Together with factors such as continued inflation, a consumer who remains under pressure and economic volatility in certain geographic markets, this created a dynamic operating environment as the Company continued its efforts to drive growth, rebuild margin and deliver transformation.
1

Despite these headwinds, in fiscal year 2024 the Company has recovered from the cyberattack while advancing its goals to build a stronger, more resilient company. While net sales decreased mainly due to the disruptions caused by the cyberattack, the Company rebuilt gross margin primarily due to the benefit of pricing actions and continued positive returns from its trademark cost savings program. Diluted net earnings per share (EPS) increased 88% compared to the year-ago period, largely driven by a lapping noncash impairment charge in the Better Health Vitamins, Minerals and Supplements (VMS) business from the year-ago period, partially offset by the loss relating to the divestiture of the Argentina business, continued investments in the Company's long-term strategic digital capabilities and productivity enhancements and charges relating to implementation of the Company's streamlined operating model.
The Company also launched numerous innovations and new products in fiscal year 2024, including seven new Hidden Valley Ranch flavors, a new lineup of Pine-Sol concentrated multi-surface cleaners, new Scentiva Disinfecting Mist and Toilet Bowl Cleaning Gel, Clorox Toilet Bomb Foaming Toilet Bowl Cleaner, Kingsford High Heat and Low and Slow charcoal briquettes and the Brita Refillable Water Filtration System.
In March of 2024, the Company completed the divestiture of its Argentina business, which consisted of its production plants in Argentina as well as the rights to the Company's brands in Argentina, Uruguay and Paraguay. The transaction is in support of the Company's IGNITE strategy and the commitment to evolve its portfolio to increase focus on its core business to drive more consistent, profitable growth.
The Company's transformation efforts continued throughout fiscal year 2024. As announced in August 2021, the Company plans to invest in transformative technologies and processes over a five-year period. This investment began in fiscal year 2022, and includes replacement of the Company's enterprise resource planning system and transitioning to a cloud-based platform as well as the implementation of a suite of other digital technologies. The total incremental transformational investment is expected to be $560 to $580 million, compared to the previous estimate of approximately $500 million. The increased estimate includes impacts from delays as a result of the cyberattack. The implementation timeline is unchanged. It is expected that these implementations will generate efficiencies and transform the Company's operations in the areas of supply chain, digital commerce, innovation, brand building and more over the long term.
In fiscal year 2024, the Company completed the implementation of its streamlined operating model to help meet its objectives of driving growth and productivity. The streamlined operating model is expected to enhance the Company's ability to respond more quickly to changing consumer behaviors and innovate faster. The implementation of this new model resulted in the reduction of certain staffing levels and is expected to achieve cost savings of approximately $100 million annually.
Clorox continued to work toward its environmental, social and governance (ESG) goals, which are embedded into the IGNITE strategy and throughout the business. The Company prioritizes greenhouse gas emission reductions and reducing plastic and other waste. Clorox continues to invest in talent development initiatives across all levels and functions. Through both funding and employee volunteering, The Clorox Company Foundation extends Clorox’s people-centered impact by promoting well-being and inclusivity within communities. The Foundation works to support communities on important matters including health and safety, education and racial justice.
The Company has been broadly recognized throughout fiscal year 2024 for its integrated ESG efforts. For the second consecutive year, Clorox earned the top ranking on Barron’s 100 Most Sustainable U.S. Companies list, which considers a number of metrics, including activities in support of sustainability, employee experience, inclusive representation and corporate governance structure. The Company was also recognized by Fortune as One of America's Most Innovative Companies and listed as One of The Most Trustworthy Companies in America by Newsweek. Clorox was also named to Wall Street Journal's 250 Best Managed Companies and Newsweek's America's Most Responsible Companies and America's Greenest Companies lists.
Clorox also continued its longtime commitment to providing value to shareholders through regular dividends. During fiscal year 2024, the Company paid $595 million in dividends to shareholders. In July 2024, Clorox announced an increase of 2% in its quarterly dividend — the 22nd consecutive year it has done so.
For fiscal year 2025, Clorox will continue to invest in its brands and capabilities to build a stronger, more resilient company that delivers consistent, profitable growth over time.
For additional information on recent business developments, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Exhibit 99.1, incorporated herein by reference.

2

Financial Information about Operating Segments and Principal Products
The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International.Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. The four reportable segments consist of the following:
Health and Wellness consists of cleaning, disinfecting and professional products marketed and sold in the United States. Products within this segment include home care cleaning and disinfecting products and laundry additives, primarily under the Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; and professional food service products under the Hidden Valley brand.
Household consists of bags and wraps, cat litter and grilling products marketed and sold in the United States. Products within this segment include bags and wraps under the Glad brand; cat litter primarily under the Fresh Step and Scoop Away brands; and grilling products under the Kingsford brand.
Lifestyle consists of food, water-filtration and natural personal care products marketed and sold in the United States. Products within this segment include dressings, dips, seasonings and sauces, primarily under the Hidden Valley brand; water-filtration products under the Brita brand; and natural personal care products under the Burt’s Bees brand.
International consists of products sold outside the United States. Products within this segment include laundry additives; home care products; bags and wraps; cat litter; water-filtration products; professional cleaning and disinfecting products; natural personal care products; food; grilling products and digestive health products marketed primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands.
The Company’s products are marketed and sold globally. The following table provides the Company’s global product lines, which were sold in the United States (including products sold in the Professional Products SBU) and internationally, that accounted for 10% or more of consolidated net sales for the fiscal years ended June 30:
202420232022
Cleaning products43 %42 %42 %
Bags and wraps15 %16 %16 %
Food products11 %11 %11 %
Cat litter products10 %10 %%
Principal Markets and Methods of Distribution
In the United States, most of the Company’s products are nationally advertised and sold to mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, military stores and other retail outlets primarily through a direct sales force; to grocery stores and grocery wholesalers primarily through a combination of direct sales teams and a network of brokers; and through e-commerce retailers. The Company also sells many of its products through alternative retail channels. Some brands are sold using the direct-to-consumer model. The Company sells institutional, janitorial, food-service and healthcare products through a direct sales force and a network of brokers to distributors and redistributors. Outside the United States, the Company sells products to the retail trade through subsidiaries, licensees, distributors and joint-venture arrangements with local partners.
Sources and Availability of Raw Materials
The Company purchases raw materials from numerous unaffiliated U.S. and international suppliers, some of which are sole source or single-source suppliers. Interruptions in the delivery of these materials could adversely impact the Company. Key raw materials used by the Company include resin, non-woven fabrics for wipes products, sodium hypochlorite, corrugated cardboard, soybean oil, solvent, derivatives of amines and other chemicals and agricultural commodities. Raw materials were generally available during fiscal year 2024 with minimal constraints. While the Company does not expect supply constraints in fiscal year 2025, supply risk may result from external factors outside of the Company's control.
The Company generally utilizes supply contracts to help ensure availability and a number of forward-purchase contracts to help reduce the volatility of the pricing of raw materials needed in its operations. However, the Company is highly exposed to changes in the prices of commodities and transportation used in manufacturing and shipping of its products. For further information regarding the impact of changes in commodity prices, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Exhibit 99.1, “Risk Factors – Volatility and increases in the costs of raw materials,
3

energy, transportation, labor and other necessary supplies or services have negatively impacted, and may continue to negatively impact, the Company’s net earnings and cash flow” and “Risk Factors – Supply chain issues can result in product shortages or disruptions to the Company’s business” in Item 1.A.
Patents and Trademarks
Most of the Company’s brand name consumer products are protected by registered trademarks. The Company’s brand names and trademarks are highly important to its business, and the Company vigorously protects its trademarks from apparent infringements. Maintenance of brand equity value is critical to the Company’s success. The Company’s patent rights are also material to its business and are asserted, where appropriate, against apparent infringements.
Seasonality
Most sales of the Company’s grilling products occur during the months of March through September each calendar year. The volume and sales of grilling products may be affected by weather conditions.
Customers
Net sales to the Company’s largest customer, Walmart Stores, Inc. and its affiliates, were 25%, 26% and 25% of consolidated net sales for each of the fiscal years ended June 30, 2024, 2023 and 2022, respectively, and occurred across all of the Company’s reportable segments. No other individual customer accounted for 10% or more of the Company’s consolidated net sales in any of these fiscal years. The Company’s five largest customers accounted for nearly half of the Company’s consolidated net sales for each of the fiscal years 2024, 2023 and 2022.
Competition
The markets for consumer products are highly competitive. The Company’s products compete with other nationally advertised brands and with “private label” brands within each category. Competition comes from similar and alternative products, some of which are produced and marketed by major multinational or national companies having financial resources greater than those of the Company. In addition, the Company faces competition from retailers, including club stores, grocery stores, drugstores, dollar stores, mass merchandisers, e-commerce retailers and subscription services. Furthermore, heightened competitive activity is expected as inflation continues to increase and consumers experience reduced purchasing power. The Company’s products generally compete on the basis of product performance, brand reputation and recognition, image and price. A newly introduced consumer product (whether improved or newly developed) usually encounters intense competition requiring substantial expenditures for advertising, sales promotion and trade merchandising support. If a product gains consumer acceptance, it typically requires continued advertising and promotional support and ongoing product innovation to maintain its relative market position. For further information regarding the intense competition the Company faces, see “Risk Factors – The Company faces intense competition in its markets, which could lead to reduced net sales, net earnings and cash flow” in Item 1.A.
Environmental Matters
For information regarding noncapital expenditures related to environmental matters, see the discussions below under “Risk Factors – Environmental matters create potential liabilities that could adversely affect the Company’s financial condition and results of operations” in Item 1.A. No material capital expenditures relating to environmental compliance are presently anticipated.
HUMAN CAPITAL MANAGEMENT
Purpose and Values
The Clorox Company is led by its purpose to champion people to be well and thrive every single day, including employees, consumers and communities served around the world.
Clorox employees are committed to making a meaningful, positive impact through their work and to authentically living the Company’s values: to do the right thing, put people at the center and play to win. These foundational values underpin everything the Company does and are essential to achieving long-term success.
The Company’s purpose and values also are fully embedded in its IGNITE strategy, which accelerates innovation in key areas of the business to drive growth and deliver value for all Company stakeholders. IGNITE focuses on four strategic choices aimed at fueling long-term, profitable growth; innovating consumer experiences; reimagining how the Company and its people work; and continuously evolving the product portfolio. In addition, integrated goals for ESG performance promote healthy lives, a clean world and thriving communities, all supported by strong corporate governance.

4

Workforce
As of June 30, 2024, the Company employed about 8,000 people worldwide, with 76% in the United States and 24% working outside the United States. Clorox's U.S. workforce includes 47% nonproduction employees and 53% production employees, while the workforce outside the United States includes 62% nonproduction employees and 38% production employees. The number of employees during fiscal year 2024 was impacted by the divestiture of the Company's Argentina business and the implementation of the streamlined operating model.
Inclusion, Diversity, Equity & Allyship (IDEA)
People are essential to Clorox's efforts to drive growth and deliver value for all stakeholders. One of the ways the Company puts people at the center is through its continued commitment to inclusion, diversity, equity and allyship. This work builds a workplace that values diverse backgrounds, experiences and perspectives to create stronger teams, unlock more innovation and – ultimately – contribute to greater success both individually and collectively.
In fiscal year 2024, Clorox continued to make strides on its IDEA journey by prioritizing three focus areas - building teams comprised of diverse backgrounds and perspectives, fostering inclusion and allyship to establish a culture where people can be their best selves, and engaging with the Company's multicultural consumer base through purposeful brands.
Clorox continues to conduct annual pay equity analyses for non-production employees in addition to monitoring pay trends throughout the year. This effort proactively identifies potential discrepancies and helps to ensure each employee is compensated fairly, regardless of race, ethnicity or gender.
More than a dozen employee resource groups (ERGs) help drive inclusion within Clorox and foster belonging, in part through greater understanding of different backgrounds and perspectives. These groups are an important forum for talent recruiting and retention, professional development and open dialog that strengthens the Company’s workplace culture and, through regular volunteer opportunities, the communities employees call home. The ERGs also serve the business by serving as internal focus groups, inspiring product innovations, accelerating product placement plans and deepening knowledge of the Company's multicultural consumer base.
The Company was named by Forbes to its 2023 list of The World’s Top Companies for Women and as One of America’s Best Employers for Diversity.
Workforce diversity. As of June 30, 2024, people of color1 represented 42% of Clorox's total U.S. workforce, 24% of U.S. senior executives, 35% of U.S. managers2, 51% of other U.S. nonproduction employees and 44% of U.S. production employees. Women made up 36% of the Company's global workforce, 48% of global senior executives, 50% of global managers, 57% of other global nonproduction employees and 19% of global production employees.
Board and leadership diversity. As of June 30, 2024, the Clorox Executive Committee was composed of 54% women, including Chair and Chief Executive Officer Linda Rendle, and 15% people of color. Additionally, 50% of the board are women and 25% are people of color, with the Nominating, Governance and Corporate Responsibility Committee (NGCRC) and the Audit Committee chaired by people of color. The Company's NGCRC chair is also a woman.
Hiring and Development
Clorox looks to continuously attract, develop and retain the best talent to deliver against its strategy and commitments, prioritizing career growth and leadership development to establish a strong foundation for long-term success. Company investments include a suite of training and education for people managers to help them become effective coaches and leaders; mentoring programs and initiatives to help build a pipeline of diverse talent; and summer internship, co-op and rotational programs for college hires. In addition, the Company works closely with ERGs and establishes partnerships with external organizations focused on advancing equity and opportunity for the communities they represent. Clorox also conducts a robust talent review and leader succession planning process to ensure a strong pipeline for key roles.
Additionally, supported by its strategic investment in digital transformation and related productivity enhancements, the Company continues to strengthen new ways of working, such as hybrid work experiences as well as implementing new tools and technologies that allow employees to collaborate more effectively, work smarter and make faster, more informed decisions.
1 Management defines people of color (POC) as any race that is not White (Asian, Black, Latino, Native American, Native Hawaiian, or two or more races). Gender and ethnicity information is provided by employees on a voluntary, self-identification basis. To the extent that the employees do not voluntarily report, the data would not be included in the respective calculation.
2 Management defines manager as an employee at Grade 26 through 31 for U.S. employees and Grade 25 through 31 for employees outside of the United States with regards to the Company’s compensation structure. “Senior Executive” is defined as an employee at Grade 32 or Grade EX.
5

Finally, in order to attract key prospective talent and continue to advance Clorox as an employer of choice, the Company continues to invest in its employer value proposition and career development and talent acquisition strategies.
Employee Engagement and Retention
In support of its efforts to actively listen to its workforce, engage in effective two-way dialog and embrace continuous improvement, Clorox conducts both annual and periodic pulse surveys. The Company surveys its employees to assess their perception of Clorox as a place to work as well as their views of leadership, the Company's IGNITE strategy and related transformation, sense of inclusion and more. In fiscal year 2024, just over 82% of employees said they feel engaged at Clorox, which was consistent with the Company's fiscal year 2023 results and above the 50th percentile for Fortune 500 and industry benchmarks3. Company leadership then uses the engagement survey results to develop and deploy related action plans aimed at addressing employee feedback, strengthening the overall workplace culture and, importantly, retaining top talent.
Employee Safety and Well-Being
As a health and wellness company dedicated to helping people be well and thrive every single day, Clorox takes a holistic approach to caring for its employees, with benefits and programs designed to support physical, mental and financial well-being.
Consistent with its core value of putting people at the center, the Company invests in workplace safety through a combination of education, training and related policies, while operating in compliance with applicable regulations, including Occupational Safety and Health Administration (OSHA) guidelines in the United States. In fiscal year 2024, the Company’s reportable incident rate (RIR) was 0.47. This was significantly lower than the 3.2 average RIR for goods-producing manufacturing companies in 2022, which is the latest available data from the U.S. Bureau of Labor Statistics4.
The Company has continued to prioritize the mental health of its employees, partnering with external vendors to provide free and confidential mental health and lifestyle services as well as other related resources, tools and forums to employees and their families.
The Company also provides parents with support such as paid parental leave, adoption resources, family-forming benefits and subsidized childcare.
To support employees' financial well-being, the Company provides competitive compensation – including short- and long-term incentives – to attract and retain top talent. In addition, Clorox supports its employees' retirement readiness by contributing up to 10% of an employee's annual salary to their 401(k) plan each year and offering third-party financial planning services.
Societal Well-Being
In fiscal year 2024, The Clorox Company Foundation continued to support the Company’s purpose of championing people to be well and thrive every single day by focusing on programs in three key areas: community wellness, disease prevention and disaster relief and preparedness.
Since its inception in 1980, the Foundation has awarded cash grants to nonprofit organizations, schools and colleges across the globe. The Foundation provides cash grants (including matching employee donations) to support communities on important matters including health and safety, education and racial justice. The Company also provides product donations while implementing cause marketing programs to nonprofit organizations in support of causes that are consistent with the Company's brands' purposes. The Company continues to embrace and support employee volunteerism, recognizing the value it brings to the communities it serves and in fostering a culture of giving back. For every hour employees spend volunteering outside of work, they receive $10, allowing them to contribute up to $300 annually to the nonprofit organization of their choice.
ENVIRONMENTAL SUSTAINABILITY
Clorox has continued to work toward its ESG goals, which are embedded in the IGNITE strategy and throughout the business. Its IGNITE environmental goals prioritize taking climate action and reducing plastic and other waste by reducing virgin plastic and fiber packaging; increasing recyclable, reusable or compostable packaging; increasing post-consumer recycled plastic in packaging; and reducing waste to landfill in our global facilities and plants.
3 Employee engagement surveys may vary across companies on a year-to-year basis.
4 The Company's fiscal year 2024 RIR of 0.47 means that for every 100 full-time equivalent Clorox employees globally, the Company averaged less than one reportable incident during the past year. The criteria used to determine RIR follows the U.S. Department of Labor’s OSHA guidelines and is applied globally. The RIR does not include workers at offices with fewer than 10 employees, but it does include remote workers.
6

As part of its climate action goals, the Company set science-based targets to reduce scopes 1 and 2, and elements of scope 3 greenhouse gas emissions by 2030 from a 2020 baseline year, which have been approved by the Science Based Targets initiative, and committed to net-zero greenhouse gas emissions by 2050. To contribute to its scopes 1 and 2 greenhouse gas emission reduction goal, which the Company achieved, the Company has committed to maintain 100% electricity from renewable energy for its U.S. and Canada operations. The Company entered into two virtual power purchase agreements as an integral part of that commitment.
Available Information
The Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) or 15(d) of the Exchange Act are available on the Company’s website, free of charge, as soon as reasonably practicable after the reports are electronically filed with or furnished to the SEC. These reports are available at TheCloroxCompany.com under Investors/Financial Information/SEC Filings. Additionally, the Company routinely posts additional important information, including press releases, on its website and recognizes its website as a channel of distribution to reach public investors and as a means of disclosing material non-public information for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our website in addition to our SEC filings and public webcasts. These items are available at TheCloroxCompany.com under Investors/Investor News and Events.
Information relating to corporate governance at Clorox, including the Company's Code of Conduct, the Clorox Company Board of Directors Governance Guidelines and Board Committee charters for the Management Development and Compensation Committee, the Audit Committee, and the Nominating, Governance and Corporate Responsibility Committee, is available at TheCloroxCompany.com under Company/Corporate Governance or https://www.thecloroxcompany.com/company/corporate-governance/. The Company will provide any of the foregoing information without charge upon written request to Corporate Communications, The Clorox Company, 1221 Broadway, Oakland, CA 94612-1888. The information contained on the Company's website is not included as a part of, or incorporated by reference into, this Report.
ITEM 1.A. RISK FACTORS
The risks and uncertainties set forth below, as well as other factors described elsewhere in this Report or in other filings by the Company with the SEC, could adversely affect the Company’s business, financial condition and results of operations. Additional risks and uncertainties that are not currently known to the Company or that are not currently believed by the Company to be material may also harm the Company’s business, financial condition and results of operations.
Business and Industry Risks
Unfavorable and uncertain general economic and geopolitical conditions beyond the Company's control could negatively impact its financial results.
Unfavorable general economic factors that are beyond the Company's control have materially adversely affected, and could continue to materially adversely affect, its business, results of operations, financial condition and liquidity. These factors include, but are not limited to, supply chain disruptions, labor shortages, wage pressures, ongoing elevated levels of inflation, recession and economic slowdown, as well as housing markets, consumer credit availability, consumer debt levels, fuel and energy costs (for example, the price of gasoline or alternative energy sources), rising interest rates, tax rates and policy, unemployment trends, the impact of natural disasters, pandemics/epidemics, civil disturbances and terrorist activities, foreign currency exchange rate fluctuations, conditions affecting the retail environment for the Company's products and other matters that influence consumer demand, spending and preferences that could impact the demand for the Company's products and negatively impact its net sales and results of operations.
In addition, geopolitical instability, including the conflicts in Ukraine and the Middle East and rising tensions between China and Taiwan, actual and potential shifts in U.S. and foreign trade, economic and other policies, including as a result of escalating trade tensions between the U.S. and its trading partners, including China, as well as other global events, have significantly increased global macroeconomic uncertainty and volatility. Sustained macroeconomic uncertainty and volatility and geopolitical instability, including relating to the results of elections, could undermine global consumer confidence and could continue to reduce consumers’ purchasing power, thereby reducing demand for the Company's products, and continue to disrupt global supply chains, impacting the availability and cost of transportation, logistics, raw materials, commodities, labor and packaging. This uncertainty and volatility also make it difficult for the Company, as well as its customers, suppliers, distributors and business partners to anticipate the resulting impacts and to accurately forecast and plan future business activities, which may, in turn, cause customers to limit their purchase orders or affect their ability to pay amounts owed to the Company in a timely manner or at all, or adversely affect its business partners' ability to supply or provide services. These situations are evolving, and there is significant uncertainty as to their full or related impacts on the global economy and geopolitical relations, in general, and on the Company’s business, in particular. These geopolitical conflicts and tensions may also heighten other risks
7

disclosed in this Report, any of which could have an adverse impact on the Company’s business, results of operations, cash flows and/or financial condition.
The Company has experienced, and expects to continue to experience, the indirect impacts of the conflicts in Ukraine and the Middle East, including increases in the cost of raw and packaging materials and commodities (including the price of oil), supply chain and logistics challenges, and it is not possible to predict the broader or longer-term consequences of these conflicts or the sanctions and export controls imposed in response to each conflict. The situation continues to evolve and significant uncertainties regarding the full impact of these conflicts or the related impacts on the global economy and geopolitical relations remain.
Increasing unfavorable macroeconomic and geopolitical conditions have caused, and may also lead to, recession risk, increased credit and collectability risks, higher borrowing costs or reduced availability of capital and credit markets, reduced liquidity, asset impairments, declines in the value of the Company's financial instruments, and failures of counterparties including financial institutions and insurers. If any financial institution party to the Company's credit or other financing arrangements were to declare bankruptcy or become insolvent, they may be unable to perform under their agreements with the Company, which could result in reduced borrowing capacity. In addition, if any parties with which the Company conducts business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties’ ability to continue to fund their business and perform their obligations to the Company could be adversely affected. Any of these factors could negatively and materially impact the Company's business, financial condition, and results of operations.
Sales growth objectives may be difficult to achieve, and market and category declines and changes to the Company’s product and geographic mix may adversely impact the Company’s financial condition and results of operations.
A large percentage of the Company’s revenues comes from mature markets that are subject to high levels of competition. During fiscal year 2024, 84% of the Company’s net sales were attributable to U.S. markets, including U.S. territories. The Company’s ability to achieve sales growth depends on its ability to drive growth through innovation, including as part of its IGNITE Strategy, expand into new products and categories, channels and countries, invest in its established brands and enhanced merchandising, grow categories with retailers and capture market share from competitors. The Company has implemented price increases and may implement additional price increases in the future, including to account for increasing costs, which may adversely affect sales volumes. In addition, competitors may or may not take competitive actions, which may lead to sales declines and loss of market share. If the Company is unable to increase market share in existing product lines, develop product innovations, undertake sales, marketing and advertising initiatives that grow its product categories, effectively adopt and leverage existing and emerging technologies, such as artificial intelligence or machine learning, and/or develop, acquire or successfully launch new products or brands, it may not achieve its sales growth objectives. Furthermore, a general decline in the markets for certain product categories has had and may in the future have a negative impact on the Company’s financial condition and results of operations. In addition, changes to the mix of products that the Company sells, as well as the mix of countries in which its products are sold, may adversely impact the Company’s net sales, profitability and cash flow.
The changing retail environment and changing consumer preferences could adversely affect the Company’s business, financial condition and results of operations.
The Company’s sales are largely concentrated in the traditional retail grocery, mass retail outlet, warehouse club and dollar store channels, in addition to e-commerce channels. Alternative retail channels, including hard discounters, subscription services and buying clubs, have become and may continue to be more prevalent and popular than traditional retailers. In addition, a growing number of alternative sales channels and business models, such as niche brands, native online brands, private label and store brands, direct-to-consumer brands and channels and discounter channels, have emerged. In particular, the growing presence of, and increasing sales through, e-commerce retailers have affected, and may continue to affect, consumer behavior or preferences (as consumers increasingly shop online and via mobile and social applications) and market dynamics, including any pricing pressures for consumer goods as retailers face added costs to build their e-commerce capacity. Further, consumer preferences continue to evolve due to a number of factors, including inflation which could cause consumers to purchase a smaller pack or quantity of a product or a lower priced alternative to the Company's products; fragmentation of the consumer market and changes in consumer demographics, which includes the aging of the general population and the emergence of millennial and younger generations who have different spending, consumption and purchasing habits; evolving consumer concerns or perceptions regarding ESG practices of manufacturers, including the environmental impacts of products and the sourcing and sustainability of packaging materials, such as single-use plastics; a growing demand for natural or organic products and ingredients; evolving consumer concerns or perceptions (whether accurate or inaccurate) regarding the effects of ingredients or substances present in certain consumer products; changing consumer sentiment toward non-local products or sources; and changing perceptions of environmental impacts (including packaging, energy and water use and waste management). Any significant changes in consumer preferences or behavior, such as time spent at home or in shared public spaces, could materially and/or negatively impact demand for the Company's products and, in turn, the Company's net sales and results of operations. Consumer preferences are also influenced by perception of the brand image of the Company and its
8

products, the success of advertising and marketing campaigns, the Company’s ability to engage with consumers in the manner they prefer, including through the use of digital media or assets, and the perception of the Company’s advertising, use of social media and engagement in political and social issues, and geopolitical events. If the Company is not successful in continuing to adapt to rapidly changing consumer preferences and market dynamics or expanding sales through e-commerce retailers or alternative retail channels, consumers may reduce the purchase of the Company's products, which could negatively impact its business, financial condition and results of operations. In addition, e-commerce and alternative retail channels may create significant pricing pressures for consumer goods, presenting additional challenges to increasing prices in response to commodity or other cost increases in all of the channels into which the Company sells. If these e-commerce and alternative retail channels were to take significant market share away from traditional retailers and/or the Company is not successful in these channels or business models, its net sales and results of operations may be materially and negatively impacted.
The Company faces intense competition in its markets, which could lead to reduced net sales, net earnings and cash flow.
The Company faces intense competition from consumer product companies both in the U.S. and in its international markets. Most of the Company’s products compete with other widely advertised, promoted and merchandised brands within each product category. The Company also faces competition from retailers, including club stores, grocery stores, drugstores, dollar stores, mass merchandisers, e-commerce retailers and subscription services, which are increasingly offering “private label” brands that are typically sold at lower prices and compete with the Company’s products in certain categories. Increased purchases of “private label” products or other lower priced brands could negatively impact net sales of the Company’s higher-margin products or there could be a shift in product mix to lower-margin offerings, especially at a time of ongoing inflationary pressure, and this would negatively impact its net earnings and profits. The Company’s products generally compete on the basis of product performance, brand reputation and recognition, image and price, thereby requiring substantial expenditures for advertising, sales promotion and trade merchandising to gain and maintain market position. The Company is also increasingly using digital media marketing and promotional programs to reach consumers. If the Company’s advertising, marketing and promotional programs, including its use of digital and social media, are not effective or adequate, the Company’s net sales may be negatively impacted.
Some of the Company’s competitors are larger than the Company and have greater financial resources. These competitors, as well as new market entrants, may be able to spend more aggressively on advertising and promotional activities, introduce competing products more quickly, adopt new technology, such as artificial intelligence and machine learning, more quickly and successfully, and respond more effectively to changing business and economic conditions and consumer preferences than the Company can. Heightened competitive activity from strong local competitors, other large multinational companies, and new entrants into the market may result in more aggressive product claims and marketing challenges, increased promotional spending and geographic expansion, and marketing of new products. Furthermore, the Company’s competitors may attempt to gain market share by offering products at prices at or below those typically offered by the Company. Competitive activity may require the Company to increase its spending on advertising and promotions and/or reduce prices, which could lead to reduced sales, margins and/or net earnings.
Harm to the Company’s reputation or the reputation of one or more of its leading brands or products could have an adverse effect on the business, financial condition and results of operations.
Maintaining a strong reputation with consumers, customers and trade and other third-party partners is critical to the success of the Company’s business. The Company devotes significant time and resources to programs designed to protect and preserve its reputation such as ethics and compliance, brand protection, product safety and quality, and enterprise risk management, and has published ESG goals, including relating to environmental impact and sustainability and inclusion and diversity, as part of its IGNITE Strategy. The Company could be the subject of negative publicity in spite of or as a result of these efforts, including relating to product safety, quality or efficacy, ingredients or substances present or allegedly present in the Company’s products or packaging, or ESG and related issues, including if the Company is not successful in achieving its ESG goals or provides inaccurate information. In addition, the Company’s products have, in the past, and could, in the future, face withdrawal, recall or other quality issues, which could lead to decreased demand for and reputational damage to the related brands. The Company’s products, especially its dietary supplement and related products, are dependent on consumers’ perception of their efficacy, safety and quality. Emerging studies have, in the past, and could, in the future, prove or allege that ingredients or substances that are present or allegedly present in the Company's products, the products themselves, or similar products of other companies, are ineffective or harmful to consumers. The Company also licenses certain of its brands to third parties. Such licenses and partnerships may create additional exposure for those brands to product safety, quality, sustainability and other concerns.
Widespread use of social media and networking sites by consumers has greatly increased the accessibility and speed of dissemination of information and misinformation. Negative publicity, posts or comments about the Company, its brands, its products, its marketing activities, whether accurate or inaccurate, or disclosure of non-public sensitive information about the Company, could be widely disseminated through the use of social media or in other formats. Additionally, marketing initiatives
9

may not have the desired effect on a brand’s or product’s image. Such events, if they were to occur, could harm the Company’s image and adversely affect its business, financial condition and results of operations, as well as require resources to rebuild the Company’s reputation.
In addition, the legal, regulatory and ethical landscape around the use of artificial intelligence and machine learning is rapidly evolving. The Company’s ability to adopt this emerging technology in an effective and ethical manner may impact its reputation and ability to compete, and this technology could be, among other things, false, biased, or inconsistent with the Company’s values and strategies. Further, the use of generative artificial intelligence tools may compromise confidential or sensitive information, put the Company’s intellectual property at risk, or subject the Company to claims of intellectual property infringement, all of which could damage the Company's reputation.
Dependence on key customers could adversely affect the Company’s business, financial condition and results of operations.
A limited number of customers account for a large percentage of the Company’s net sales. Net sales to the Company’s largest customer, Walmart Stores, Inc. and its affiliates, were 25%, 26% and 25% of consolidated net sales for the fiscal years ended June 30, 2024, 2023 and 2022, respectively, and occurred across all of the Company’s reportable segments. The Company’s five largest customers accounted for nearly half of the Company’s consolidated net sales for each of the fiscal years 2024, 2023 and 2022, and a significant portion of the Company’s future revenues may continue to be derived from a small number of customers. As a result, changes in the strategies of the Company’s largest customers, including a reduction in the number of brands they carry, a shift of shelf space to “private label” or competitors’ products or a decision to lower pricing of consumer products, including branded products, may harm the Company’s net sales or net earnings, and reduce the ability of the Company to offer new, innovative products to consumers. Any loss of a key customer or a significant reduction in net sales to a key customer of the Company or a business unit could have a material adverse effect on the Company’s business, financial condition and results of operations. In addition, the use of the latest technology by its customers regarding pricing may lead to category pricing pressures. Consistent with the ongoing variability in information technology (IT) systems industry-wide, the Company's IT platforms may not be fully compatible at all times with those used by its customers and may not be able to respond to customer data or technology demands.
With the growing trend towards retailer consolidation, both in the U.S. and internationally, the continued growth of e-commerce and the integration of traditional and digital operations at key retailers, the Company is increasingly dependent on certain retailers. This trend has resulted in the increased size and influence of large consolidated retailers, who have in the past changed, and may in the future change, their business strategies; demand lower pricing or higher trade discounts; impose other burdensome requirements on product suppliers; or move away from branded products to "private label." These large consolidated companies could also exert additional competitive pressure on the Company’s other customers, which could in turn lead to such customers demanding lower pricing, higher trade discounts or special packaging or imposing other onerous requirements on the Company. If a significant customer ceases doing business with or materially decreases its purchase of the Company's products, the Company’s business, financial condition and results of operations may be harmed.
The Company’s business is based primarily upon individual sales orders, and the Company typically does not enter into long-term contracts with its customers. Accordingly, customers could reduce their purchasing levels or cease buying products from the Company at any time. If the Company does not effectively respond to the demands of its customers, they could decrease their purchases, causing the Company’s net sales and net earnings to decline. Furthermore, unfavorable market conditions or competitive pressures may cause customers to reevaluate the number and mix of brands they sell, resulting in lower purchases of the Company’s products by these customers. The Company may also modify key customer credit limits due to customer financial strength, which may have an adverse impact on future sales.
The Company may not successfully introduce new products and line extensions, or expand into adjacent categories and countries, which could adversely impact its financial condition and results of operations.
The Company’s future performance and growth depends on innovation and its ability to successfully develop or license capabilities to introduce new products, brands, line extensions and product innovations or enter or expand into adjacent product categories, sales channels or countries. The Company’s ability to anticipate changes in consumer preferences and quickly innovate in order to adapt its products (including product packaging, environmental impact and sustainability profile) to meet changing consumer demands and/or evolving regulatory requirements is essential, especially in light of the reduction in barriers for even small competitors, and these innovations may result in increased costs. This risk is further heightened by the continued evolution of consumer needs, habits and preferences as a result of shifts in U.S. demographics. The Company cannot be certain that it will successfully achieve its innovation goals. New product and product packaging development and marketing efforts, including efforts to enter markets or product categories in which the Company has limited or no prior experience, not only incur substantial capital expenditures but also contain inherent risks. These risks include product development or launch delays, noncompliance with applicable laws or regulations, or infringement of third-party intellectual property, any of which could result in the Company not being first to market, and the failure of new products, brands and line extensions to achieve
10

anticipated levels of market acceptance. In addition, success in launching new products is also dependent on the Company’s ability to deliver effective and efficient marketing in an evolving media landscape (including digital), which is subject to dynamic and increasingly restrictive privacy requirements. The Company may not be able to fully recoup the cost of unsuccessful product introductions or may experience a decline in sales of existing products as a result of consumer adoption of its new products, both of which could materially adversely affect the Company’s business, net earnings, margins, financial condition and results of operations.
Loss of, or inability to attract, key personnel could adversely impact the Company’s business.
The Company’s success depends, in part, on its continuing ability to identify, hire, develop and retain highly qualified and diverse personnel. The Company's ability to attract and retain talent has been and may continue to be impacted by a number of factors, including employee morale, its reputation, competition from other employers and availability of qualified individuals in key geographic areas such as the San Francisco Bay Area, and challenges in the labor market, particularly in the U.S., which has increasing labor costs, sustained labor shortages, and changing worker and talent market expectations around flexible work models and relocation. Increased labor costs as a result of increased competition for employees, higher employee turnover rates, increased employee benefit costs, or labor union organizing efforts could increase the Company’s operating expenses, and its growth and results of operations could be adversely impacted.
The Company continues executing organizational change, which may impact hiring and retention efforts. Related activities to identify, hire and onboard qualified talent at increasing compensation costs may require significant time and expense which could further adversely affect the Company’s operations and financial results. The Company’s success also depends on its ability to retain its key personnel, including its executive officers and senior management team, and to continue to implement its succession plans for senior management and other key employees. The unexpected loss or unavailability of one or more of the Company’s key leaders could disrupt its business.
Acquisitions, new venture investments and divestitures may not be successful, which could have an adverse effect on the Company’s business, financial condition and results of operations.
In connection with its strategy, the Company expects to continue to seek acquisition, joint venture and investment opportunities. However, the Company may not be able to identify and successfully negotiate suitable strategic transactions at attractive prices. In addition, an increase in regulatory restrictions or continued market volatility could hinder the Company’s ability to execute strategic business activities including any acquisitions or investments. Furthermore, all acquisitions and investments entail numerous risks, including risks relating to the Company’s ability to:
•    successfully integrate acquired companies, brands, products, technologies, systems or personnel into the Company’s existing business operations in an effective, timely and cost-efficient manner;
•    maintain uniform standards, controls, procedures and policies throughout acquired companies, including effective integration of acquired companies into the Company’s internal control over financial reporting;
•    successfully enter categories, markets and business models in which the Company may have limited or no prior experience;
•    achieve expected synergies and obtain the desired financial or strategic benefits from acquisitions within the anticipated time periods, if at all;
•    achieve distribution expansion related to products, categories and markets from acquisition and retain key relationships and or personnel of acquired companies;
•    identify and manage any legal or reputational risks that may predate or be associated with a transaction, which could negatively impact the Company following the consummation of such transaction; and
•    manage other unanticipated problems or liabilities, including relating to a system shutdown, service disruption, or cyberattack on an acquired company’s IT/operational technology (OT) systems.
Acquired companies or operations, joint ventures or investments may not be profitable or may not achieve sales levels and profitability and cash flow expectations. Furthermore, acquisitions or ventures could also result in dilutive issuances of equity securities, the incurrence of debt, the assumption of contingent liabilities (such as those relating to advertising claims, environmental issues and litigation, negative reputational issues), an increase in expenses related to intangible assets, including trademarks and goodwill, and increased operating expenses, all of which could adversely affect the Company’s financial condition, margins and results of operations. Future acquisitions of foreign companies or new foreign ventures would subject the Company to local regulations and could potentially lead to risks related to, among other things, increased exposure to foreign exchange rate changes, tax or labor laws, government price controls, or repatriation of profits and liabilities relating to the Foreign Corrupt Practices Act (“FCPA”). In addition, to the extent that the economic benefits associated with an acquisition
11

or investment diminish in the future or the performance of an acquired company or business is less robust than expected, the Company may be required to record impairments of intangible assets. Any impairment charges could adversely affect the Company’s financial condition, margins and results of operations.
The Company has divested and may, in the future, divest certain assets, businesses or brands. A divestiture could affect the profitability of the Company as a result of the gains or losses on such sale of a business or brand, the loss of the operating income or sales resulting from such sale or the costs or liabilities that are not assumed by the acquirer that may negatively impact profitability and cash flow subsequent to any divestiture. If the Company is unable to complete a divestiture or successfully transition a divested business, including the effective management of the related separation and overhead costs, transition services, and the maintenance of relationships with customers, suppliers, and other business partners, its business and financial results could be negatively impacted. The Company may also be required to recognize impairment charges or other losses as a result of a divestiture. For example, in March 2024, the Company completed the sale of its Argentina business, which consisted of two production plants in Argentina as well as the rights to the Company’s brands in Argentina, Uruguay and Paraguay, and in July 2024, the Company entered into a definitive agreement to sell its Better Health VMS business. The Better Health VMS transaction is expected to close in the first quarter of fiscal year 2025. As a result of these transactions, the Company recorded a loss for the sale of its Argentina business in the third quarter of fiscal year 2024 and expects to record a loss for the sale of its Better Health VMS business during the first quarter of fiscal year 2025.
The Company may also encounter difficulty finding potential acquirers or other divestiture options on favorable terms.
In addition, any potential future acquisitions, new ventures or divestitures may divert the attention of management and resources from other business priorities. The occurrence of any of these risks or uncertainties may have a material adverse effect on the Company’s business, financial condition and results of operations.
The COVID-19 pandemic and related impacts has had, and could continue to have, an adverse effect on the Company’s business, financial condition and results of operations.
The COVID-19 pandemic has affected and could continue to negatively affect the Company's business by causing or contributing to, among other things:
Disruptions in business operations and in the ability of significant third-party vendors, manufacturers and other business partners, including customers, to meet their obligations to us;
Worldwide, regional and local adverse economic and financial market conditions, all of which could impact the manufacturing operations of the Company or third-party partners;
Adverse impacts on the supply chain, including manufacturing by the Company or third-party partners, due to raw material, packaging or other supply shortages, labor shortages or reduced availability of commercial transport and port operational disruptions; and
Sustained labor shortages or increased turnover rates.
Although the World Health Organization and the federal government have declared an end to COVID-19 as a global and national health emergency, respectively, risks related to COVID-19 have adversely affected and may continue to adversely affect the Company’s business, results of operations, cash flows and financial condition.
Operational Risks
Failure of key technology systems, cyberattacks, privacy breaches or data breaches could have a material adverse effect on the Company’s business, financial condition, results of operations and reputation.
To conduct its business, the Company relies extensively on IT and OT systems, many of which are managed, hosted, provided and/or used by third parties and their vendors. These systems include, but are not limited to, programs and processes relating to communicating within the Company and with customers, consumers, business partners, investors and other parties; ordering and managing materials from suppliers; converting materials to finished products; receiving and processing purchase orders and shipping products to customers; processing transactions; storing, processing and transmitting data, including personal confidential information and historical payment card industry data; hosting, processing and sharing confidential and proprietary research, business and financial information; and complying with financial reporting, regulatory, legal and tax requirements.
On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its IT systems. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including
12

manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the quarter ended September 30, 2023 and negatively impacted fiscal year 2024 results, though some of the anticipated net sales not recognized in the first quarter of fiscal year 2024 as a result of the disruptions were recognized in the later quarters of fiscal year 2024.
The impacts of these system disruptions included order processing delays and significant product outages, resulting in a negative impact on net sales and earnings. The Company has since transitioned back to automated order processing. The Company experienced lessening operational impacts starting in the second quarter of fiscal year 2024 and has since returned to substantially normalized operations. The cyberattack may also lead to additional regulatory scrutiny or litigation exposure.
The Company is in the process of a multi-year phased upgrade of its digital capabilities, including enhancing operating efficiencies and transitioning to a cloud-based platform, as well as replacing its enterprise resource planning system. It also uses various other hardware, software and operating systems that may need to be upgraded or replaced in the near future as such systems cease to be supported by third-party service providers, and may be vulnerable to increased risks, including the risk of further security breaches, system failures and disruptions. Any such upgrade could take time, oversight and be costly to the Company, and may include potential challenges, such as the cost of training personnel, migration of data, the potential instability of the new system and cost overruns. If such systems are not successfully upgraded or replaced in a timely manner, system outages, disruptions or delays, or other issues may arise. If a new system does not function properly or is not adequately supported by third-party service providers and processes, it could adversely affect the Company’s business and operations, which, in turn, could adversely impact the Company’s results of operations and cash flows.
The IT/OT systems of the Company, its customers, business partners, suppliers, and third-party providers have been, and will continue to be, subject to cyber-threats such as computer viruses or other malicious codes, security breaches, ransomware, unauthorized access attempts, business email compromise, cyber extortion, denial of service attacks, phishing, deepfakes, social engineering, unintentional or malicious actions of employees or contractors, hacking and other cyberattacks attempting to exploit vulnerabilities by hackers, criminal groups, nation-states and nation-state-sponsored organizations and social-activist organizations. These activities may result in unauthorized access, disclosure and misuse of customer, employee, vendor, Company, or consumer information, including personal consumer information obtained through online and e-commerce sales, and online activities, including promotions, rebates and customer loyalty programs, as well as increased costs related to the Company’s involvement in investigations or notifications conducted by the Company’s business partners.
The Company has seen and may continue to see an increase in the number of such attacks, especially as the Company continues operating under a hybrid working model under which employees can work and access the Company’s technology infrastructure remotely. The rapid evolution and increased adoption of emerging technologies, such as artificial intelligence, may also increase the frequency and magnitude of cyberattacks on the Company and amplify its cybersecurity risks. In addition, while the Company has purchased cybersecurity insurance, costs related to a cyberattack may exceed the amount of insurance coverage or be excluded under the terms of its cybersecurity insurance policy. The Company may be unable to obtain cybersecurity insurance in amounts and on terms the Company views as appropriate for its operations.
The security efforts of the Company and its third-party providers may not prevent or timely detect future attacks and resulting breaches or breakdowns of its databases or systems. The Company has in place disaster recovery and business continuity plans to address these incidents, but if these plans or those of its third-party providers do not effectively resolve such breaches or breakdowns on a timely basis or at all, the Company may experience interruptions in its ability to manage or conduct business, as well as reputational harm, governmental fines, penalties, regulatory proceedings, and litigation and remediation expenses. The need to coordinate with various third-party service providers, including with respect to timely notification and access to personnel and information concerning an incident, may complicate the Company’s efforts to address issues that arise. As a result, the Company is subject to the risk that the activities associated with its third-party service providers can adversely affect its business, financial condition and results of operations, even if the attack or breach does not directly impact its systems or information.
Cyber-threats and techniques are becoming more sophisticated and are constantly evolving, including through the use of emerging technologies such as artificial intelligence, and are being made by groups and individuals with a wide range of expertise and motives, and this increases the difficulty of detecting and successfully defending against them. Continued geopolitical instability has also heightened the risk of cyberattacks. The Company has incurred, and will continue to incur, expenses to comply with privacy and data protection standards and protocols imposed by law, regulation, industry standards and contractual obligations. Increased regulation of data collection, use, and retention practices, including self-regulation and industry standards, changes in existing laws and regulations, including reporting requirements, enactment of new laws and regulations, increased enforcement activity, and changes in interpretation of laws, could increase the Company's cost of compliance and operation, limit its ability to grow its business or otherwise harm its business.
13

In addition, data breaches or theft of personal information collected by the Company and its third-party service providers as well as data breaches or theft of Company information and assets have occurred in the past and may occur in the future. The Company is subject to the laws and regulations of various countries where it operates or does business related to solicitation, collection, processing, transferring, storing or use of consumer, customer, business partner or employee information or related data. These laws and regulations change frequently, and new legislation continues to be introduced and may include different standards and requirements, be interpreted and applied differently from jurisdiction to jurisdiction and create inconsistent or conflicting requirements. The changes introduced by data privacy and protection regulations increase the complexity of regulations enacted to protect business and personal data and they subject the Company to additional costs and have required, and may in the future require, costly changes to the Company’s security systems, policies, procedures and practices. These laws and regulations also may result in the Company incurring additional expenses and liabilities in the event of unauthorized access to or disclosure of personal data.
Volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services have negatively impacted, and may continue to negatively impact, the Company’s net earnings and cash flow.
Volatility and increases in the cost of raw materials, including resin, non-woven fabrics for wipes products, sodium hypochlorite, corrugated cardboard and other packaging materials, soybean oil, solvent, derivatives of amines, and other chemicals and agricultural commodities, and rapid increases in the cost of energy, transportation, labor and other necessary supplies or services, have harmed, and are likely to continue to harm, the Company’s results of operations. Significant inflationary pressures have impacted the Company's gross margin in fiscal years 2023 and, to a lesser extent, 2024, and it expects inflationary pressures to continue into fiscal year 2025.
Many of the raw and packaging materials and supplies used in the production of the Company's products are subject to price volatility and fluctuations in availability caused by many factors, including macroeconomic and geopolitical developments and uncertainty, supplier or transport capacity constraints, changes in supply and demand, weather conditions and natural disasters (including the potential effects of climate change, which could also pose physical risks to the Company's facilities as well as those of its key external manufacturers and suppliers), fire, growing and harvesting conditions, energy costs, health epidemics, pandemics or other contagious outbreaks, labor shortages, currency fluctuations, governmental actions (including import and export requirements such as new or increased tariffs, sanctions, quotas or trade barriers), port congestions or delays, cybersecurity incidents or other disruptions, loss or impairment of key manufacturing sites, acts of terrorism and other factors beyond the Company's control.
The Company has also experienced and may continue to experience disruption in its manufacturing operations and supply chain, as a result of the factors set forth above. Although the Company is unable to predict the impact on its ability to source raw and packaging materials and services in the future, it expects limited supply pressures and market disruptions to continue into fiscal year 2025. If such cost pressures are incurred or exceed the Company’s estimates and the Company is not able to increase the prices of its products (or sustain such price increases) or achieve cost savings to offset such cost increases, its margins would be harmed. Sustained price increases may also lead to declines in sales volumes and loss of market share, as competitors may not adjust their prices or customers may decide to purchase a lower-priced alternative. The Company’s projections may not accurately predict the volume impact of price increases, which could adversely affect its business, financial condition and results of operations.
To reduce the cost volatility associated with anticipated purchases of certain commodities, the Company uses derivative instruments, including commodity futures and swaps. The extent of the Company’s derivative position at any given time depends on the Company’s assessment of the markets for these commodities, the cost volatility in the markets and the cost of the derivative instruments. Many of the commodities used by the Company in its products do not have actively traded derivative instruments. If the Company does not or is unable to take a derivative position and costs subsequently increase, or if it executes a position and costs subsequently decrease, the Company’s costs may be greater than anticipated or higher than its competitors’ costs and the Company’s financial results and margins could be adversely affected.
Supply chain issues can result in product shortages or disruptions to the Company’s business.
The Company has a complex global network of suppliers that may, in the future, expand and further evolve in response to market conditions. The Company also relies on a number of single-source suppliers for certain commodities and raw material inputs, including packaging, product components, finished products and other necessary supplies. The Company has experienced and could continue to experience material disruptions in production and other supply chain issues, including as a result of supply chain dependencies, which could result in out-of-stock conditions. The Company has business continuity and disaster recovery plans to address disruptions to the manufacturing or sourcing of products or raw materials, and these plans may not be sufficient. Significant disruptions have and could, in the future, interrupt product supply and, if not remedied in a timely manner or at all, could have an adverse impact on the Company's business, results of operations, cash flows and financial condition.
14

The Company also requires new and existing suppliers to meet its ethical and business partner standards. If the Company's existing or new suppliers fail to meet such standards or any other relevant governmental, industry, customer or Company standards; if the Company is unable to contract with suppliers on favorable terms or at the quantity, quality and price levels needed for its business; if any of the Company’s key suppliers becomes insolvent, ceases or significantly reduces its operations or experiences financial distress; or if any environmental, economic or other outside factors impact its operations, the Company's business, results of operations, cash flows and financial condition could be adversely affected. In addition, the Company may increase production in-house and reduce its supply and manufacturing arrangements with third parties, which may lead to additional costs connected to such transition and unwinding of certain manufacturing relationships.
The Company is subject to risks related to its international operations and international trade.
In fiscal year 2024, 16% of the Company’s net sales were attributable to international markets. The Company has faced and will continue to face substantial risks associated with its foreign operations, including, but not limited to:
•    unfavorable and uncertain macroeconomic and geopolitical conditions and potential operational or supply chain disruptions as a result of these developments;
•    environmental events, civil unrest, work stoppages, labor disputes, widespread health emergencies, pandemics or epidemics, terrorism, kidnapping, and drug‐related or other types of violence;
•    foreign currency fluctuations, including devaluations, currency controls and inflation, which may adversely affect the Company’s ability to do business in certain markets and reduce the U.S. dollar value of revenues, profits or cash flows it generates in non-U.S. markets;
•    difficulty in obtaining non-local currency (e.g., U.S. dollars) to pay for the raw materials needed to manufacture the Company’s products and contract-manufactured products;
•    the imposition of tariffs, trade restrictions or sanctions, price, profit, capital or other government controls, labor laws, immigration restrictions, travel restrictions, including as a result of pandemics or epidemics, import and export laws or other government actions generating a negative impact on the Company’s business, including changes in trade policies that may be implemented and the impact of geopolitical events generally;
•    employment litigation related to employees, contractors and suppliers;
•    potential loss of distribution channels as a result of retailer consolidation;
•    increased credit risk of customers, suppliers and distributors, and defaults on obligations of foreign governments;
•    potential harm to third parties, the Company’s employees and/or surrounding communities, and related liabilities and damages to the Company’s reputation, from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach, whether such actions are undertaken by the Company or by the Company’s business partners;
•    lack of well-established or reliable, and impartial legal systems in certain countries where the Company operates, including difficulties in enforcing intellectual property and contractual rights;
•    challenges relating to enforcement of or compliance with local laws and regulations and with U.S. laws affecting operations outside of the U.S., including without limitation, the FCPA and intellectual property laws and protections;
•   the possibility of nationalization, expropriation of assets or other similar government actions.
All of the foregoing risks could have a significant adverse impact on the Company’s ability to commercialize its products on a competitive basis in international markets and may have a material adverse effect on its business, financial condition and results of operations. The Company’s small sales volume in some countries, relative to some multinational and local competitors, could exacerbate such risks.
Reliance on third-party service providers could have an adverse effect on the Company's business.
The Company relies on third-party service providers for certain areas of its business operations, including aspects of the implementation of the Company’s transformational initiatives (such as its digital capabilities upgrade including enhancing operating efficiencies, transitioning to a cloud-based platform and replacing its enterprise resource planning system), IT, procurement, supply chain, manufacturing, certain finance and accounting functions, including financial reporting, and legal, regulatory and tax compliance. Failure by these third parties to meet their contractual, regulatory and other obligations to the Company, or failure to adequately monitor their performance, has in the past and could continue to result in the Company's
15

inability to achieve expected cost savings or efficiencies and result in additional costs to correct errors made by such service providers. Depending on the function involved and despite the availability of contractual remedies against these providers, such errors can also lead to business disruption, systems performance degradation, processing inefficiencies or other systems disruptions, the loss of or damage to intellectual property or sensitive data through security breaches or otherwise, incorrect or adverse effects on financial reporting, litigation, claims, legal or regulatory proceedings, inquiries or investigations, fines or penalties, remediation costs, damage to the Company’s reputation or have a negative impact on employee morale, all of which can adversely affect the Company’s business.
Legal and Regulatory Risks
Government regulations could impose material costs.
Generally, the manufacture, processing, formulation, packaging, labeling, storage, distribution, advertising and sale of the Company’s products and its business operations must comply with extensive federal, state and foreign laws and regulations, including, in the U.S., the Environmental Protection Agency, the Food and Drug Administration (including applicable current good manufacturing practice regulations), the Consumer Product Safety Commission, the Federal Trade Commission, and the Occupational Safety and Health Administration. There is also an increased risk of fraud or corruption in certain foreign jurisdictions and related difficulties in maintaining effective internal controls. Additionally, the Company could be subject to future inquiries or investigations by governmental and other regulatory bodies. Any determination that the Company’s operations or activities are not in compliance with applicable law could expose the Company to future impairment charges or significant fines, penalties or other sanctions that may result in a reduction in net income or otherwise adversely impact the business and reputation of the Company.
The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company's multi-year phased upgrade to its digital capabilities will result in changes to its processes and procedures which, in turn, could result in changes to its internal controls over financial reporting, which may require significant effort and judgment. Any failure to maintain an effective system of internal control over financial reporting could limit the Company’s ability to report its results of operations accurately and on a timely basis, or to detect and prevent fraud and could expose it to regulatory enforcement action and stockholder claims, which could have a material adverse effect on the Company’s business, financial condition and results of operations.
Fluctuations in federal, state, local and foreign taxes or a change to uncertain tax positions, including related interest and penalties, may also impact the Company’s effective tax rate and the Company’s results of operations. Changes in tax laws, including additional guidance issued by the U.S. Treasury Department, the U.S. Internal Revenue Service or similar bodies of state, local and foreign governments could create uncertainty, impact the Company's recorded liability in future periods and have a material impact on the Company’s results of operations. For example, on December 20, 2021, the Organization for Economic Development released a set of model rules designed to ensure that large multinational enterprises pay a minimum 15% tax on income arising in each jurisdiction in which they operate. The model rules are known as the Global Anti-Base Erosion rules (GloBE rules) or “Pillar Two”. Many countries have agreed to implement Pillar Two, and the Company will be subject to Pillar Two in certain foreign jurisdictions beginning with its fiscal year ending June 30, 2025. The Company does not expect Pillar Two to materially impact its effective tax rate or cash flows. The Company will continue to monitor and evaluate new legislation and guidance, which could impact this assessment.
The, Company, because of the its extensive international operations, could be adversely affected by violations, or allegations of violations, of the FCPA and similar international anti-bribery laws. These anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business. The Company cannot provide assurance that its internal controls policies and procedures that mandate compliance with these laws will protect the Company from reckless, intentional or unintentional criminal acts committed by its employees, joint-venture partners or agents. Alleged or actual violations of these laws could disrupt the Company's business and adversely affect its reputation and its business, financial condition and results of operations.
Federal, state and foreign governments may introduce new or expand existing legislation and regulations, or courts or governmental authorities could impose more stringent interpretations of existing legislation and regulations, affecting the Company’s operations, which may require the Company to increase its resources, capabilities and expertise in certain areas. For example, the Company is subject to regulations regarding the transportation, storage or use of certain chemicals to protect the environment, including as a result of evolving climate change standards, and is and may become subject to increased costs or mandatory funding or financial support requirements for recycling and waste management programs under extended producer responsibility regulation or laws, through plastic or packaging taxes, or restrictions on certain products and materials or on the use of certain types of packaging. Such regulations could negatively impact the Company’s ability to obtain raw materials or could increase its acquisition and compliance costs or cause the Company to contribute funds to recycling and other waste management infrastructure, thus making its products more costly, less competitive than other competitive products or reduce
16

consumer demand. Furthermore, additional or amended legislation in the areas of ESG disclosure, healthcare reform, sustainability of packaging, including plastic packaging, executive compensation and corporate governance, could also increase the Company’s costs. The Company is also required to comply with increasingly complex and changing laws and regulations enacted to protect business and personal data in the U.S. and other jurisdictions, which have and could continue to subject the Company to additional compliance costs.
If the Company is found to be noncompliant with applicable laws and regulations in these or other areas, it could be subject to governmental or regulatory actions, including fines, import detentions, injunctions, product withdrawals or recalls or asset seizures, as well as potential criminal sanctions, any of which could have a material adverse effect on its business. Loss of or failure to obtain necessary permits and registrations, particularly with respect to its charcoal business, could delay or prevent the Company from meeting current product demand, introducing new products, building new facilities or acquiring new businesses and could adversely affect its financial condition and results of operations. In addition, the Company markets and sells products that are subject to regulations relating to dietary supplements. In order to comply with any changes in these laws and regulations, including any changes that result from newly published clinical studies and emerging studies that may assert or prove that ingredients in the Company's products or the products themselves are ineffective or harmful to consumers, the Company may be required to make changes to product formulation, labeling or marketing claims, perform additional testing to substantiate its product claims, make costly changes in its manufacturing processes or supply chain or stop selling certain products until corrective actions have been taken. Any of these developments could increase the Company’s costs significantly, which could have a material adverse effect on the Company’s financial condition and results of operations.
ESG issues, including those related to climate change and sustainability, may have an adverse effect on the Company's business, financial condition and results of operations and could damage its reputation.
Companies across all industries are facing increasing scrutiny relating to their ESG policies. In particular, customers, consumers, investors and other stakeholders are increasingly focusing on environmental issues, including climate change, water use, deforestation, biodiversity, plastic waste, responsible sourcing and other sustainability concerns. Changing consumer preferences may also result in increased demands regarding plastics and packaging materials, including single-use and non-recyclable plastic packaging, and other components of the Company's products and their environmental impact on sustainability; a growing demand for natural or organic products and ingredients; or increasing consumer concerns or perceptions (whether accurate or inaccurate) regarding the effects of ingredients or substances present in certain consumer products. These demands could impact the profitability of some of the Company's products, cause it to incur additional costs, to make changes to its operations, or to make additional commitments, set targets or establish additional goals and take actions to meet them, which could expose the Company to market, operational and execution costs or risks. In addition, governmental and non-governmental organizations, investors, customers, consumers, employees and other stakeholders have placed increasing importance on ESG matters, such as animal welfare, labor and employment practices and human rights, and depending on their assessment of its ESG practices, certain investors may reconsider their investment in the Company, which may hinder the Company’s access to capital.
The Company is subject to climate-related transition risks, including increased energy costs due to increasing demand for alternative energy sources and new or increased legal and regulatory requirements to reduce or mitigate impacts to the environment. Increased regulatory requirements, including in relation to various aspects of ESG, such as extended producer responsibility, or environmental causes may result in increased compliance or input costs of energy, raw materials or compliance with emissions standards, which may cause disruptions in the manufacture of the Company's products or an increase in operating costs. The Company may undertake additional costs to control, assess and report on ESG metrics as the nature, scope and complexity of ESG reporting, diligence and disclosure requirements expand. The ability to achieve any stated goal, target, or objective is subject to numerous factors and conditions, many of which are outside of the Company's control. For example, working towards achieving the Company's goals will require significant effort by and resources from the Company and stakeholders, including suppliers and business partners, governmental entities and the development and adoption of technology that may not currently exist or exist at scale. Lack of progress on or failure to achieve its ESG goals or a perception (whether or not valid) of its failure to act responsibly with respect to the environment and other sustainability matters, such as single-use plastic, or to effectively respond to new, or changes in, legal or regulatory requirements concerning environmental or other ESG matters, or increased operating or manufacturing costs due to increased regulation or environmental causes could lead to negative publicity, which could result in reduced demand for the Company’s products, damage to its reputation or increase the risk of litigation, regulatory proceedings, inquiries or investigations and could adversely affect the Company’s business and reputation.
Product liability and labeling claims, commercial claims or other legal proceedings could adversely affect the Company’s financial condition and results of operations.
The Company has in the past paid, and may be required in the future to pay, for losses or injuries purportedly caused by its products. Such claims may be based on allegations that, among other things, the Company’s products contain contaminants or
17

provide inadequate instructions or warnings regarding their use, have defective packaging, fail to perform as advertised, or damage property or persons. Product liability, advertising and labeling claims could result in negative publicity that could harm the Company’s reputation, sales and results of operations and the reputation of the Company’s brands. In addition, if any of the Company’s products is found to be defective, the Company may recall such products, which could result in adverse publicity, additional litigation, fines, penalties or other losses. Although the Company maintains product liability insurance coverage, potential product liability claims may be subject to a deductible, exceed the amount of insurance coverage or be excluded under the terms of the policies.
In addition, the Company is, and may in the future become, the subject of, or party to, various pending or threatened legal actions, government investigations and proceedings relating to, among other things, advertising disputes with competitors, consumer class actions, including those related to advertising claims, labor claims, breach of contract claims, antitrust litigation, securities litigation, premises liability claims, data privacy and security disputes, employment litigation related to employees, contractors and suppliers, including class action lawsuits, and litigation in foreign jurisdictions. The Company has been, and may in the future be, subject to additional claims, proceedings and actions with respect to its dietary supplements products. In general, claims made by or against the Company in litigation, investigations, disputes or other proceedings have been and may in the future be expensive and time-consuming to bring or defend against and could result in settlements, injunctions or damages that could significantly affect its business, financial condition and results of operations and harm its reputation. While it is not possible to predict the final resolution of any current or future litigation, investigations, disputes or proceedings and any reserves taken in connection therewith may not be consistent with their final resolutions, the impact of these matters, including any reserves taken in connection with such matters, on the Company’s business, financial condition and results of operations could be material. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the Notes to Consolidated Financial Statements in Exhibit 99.1 for additional information related to these matters.
Environmental matters create potential liabilities that could adversely affect the Company’s financial condition and results of operations.
The Company must comply with various environmental laws and regulations in the jurisdictions in which it operates, including those relating to air emissions, water discharges, handling and disposal of solid and hazardous wastes, remediation of contamination associated with the use and disposal of hazardous substances and climate change. The Company has incurred, and will continue to incur, significant expenditures and other costs in complying with environmental laws and regulations and in providing physical security for its worldwide operations, and such expenditures reduce the cash flow available to the Company for other purposes.
The Company is currently involved in or has potential liability with respect to the remediation of past contamination in the operation of some of its current and former facilities. In addition, some of its present and former facilities have or had been in operation for many years and, over that time, some of those facilities may have used substances or generated and disposed of wastes that are or may be considered hazardous. It is possible that those sites, as well as disposal sites owned by third parties to whom the Company has sent waste, may be identified and become the subject of remediation. In addition, the Company also handles and/or transports hazardous substances, including but not limited to chlorine, at some of its international production facilities. A release of any hazardous substances, whether in transit or at the Company’s facilities, due to accident or an intentional act, could result in substantial liability and business disruptions. The Company could also become subject to additional environmental liabilities in the future, whether as a result of new laws and regulations or otherwise, that could result in a material adverse effect on its financial condition and results of operations.
The Company had a recorded liability of $28 million as of both June 30, 2024 and 2023 for its share of aggregate future remediation costs related to certain environmental matters, including response actions at various locations. Two matters, relating to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California and another relating to former operations in Dickinson County, Michigan account for a significant portion of the recorded liability. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the ability of third parties to pay their share of the response and remediation obligations, the efficacy of any remediation efforts, changes in any remediation requirements, and the future availability of alternative clean-up technologies, and the Company’s exposure may exceed the amount recorded for these matters. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the Notes to Consolidated Financial Statements in Exhibit 99.1 for additional information related to these liabilities.
Failure to effectively utilize, successfully assert or successfully defend, the Company’s intellectual property rights could impact its competitiveness. If the Company is found to have infringed the intellectual property rights of others or cannot obtain necessary intellectual property rights, its competitiveness could be negatively impacted.
The Company's intellectual property rights are a significant and valuable aspect of its business, and the Company utilizes trademark, trade secret, copyright, and patent laws to protect its brands, products, product packaging, goodwill, inventions and
18

confidential information. If the Company fails to obtain, perfect, enforce, or adequately protect its intellectual property rights; license intellectual property rights necessary to support new product introductions and product innovations; or if changes in laws diminish or remove the current legal protections available to them, the competitiveness of the Company’s products may be eroded and its business could suffer. The Company also licenses certain of its brands to third parties, including for the co-development of products or devices, or promotion and sales relationships with companies in industries operating in public spaces. These licensees' actions or inaction may dilute or diminish the value of the Company’s brands and products in the marketplace, or create additional exposure to litigation, investigations, disputes or other proceedings, as well as product safety, quality, sustainability and other concerns.
The Company could come into conflict with third parties over intellectual property rights, including to assert and defend those rights, which could result in costly and disruptive litigation. If the Company is found to have violated a third party’s intellectual property rights, the Company may be required to cease use of such intellectual property and pay a substantial amount for past infringement or for continued use of those intellectual property rights. Any of the foregoing could have a material adverse effect on the Company’s business, financial condition and results of operations.
The Company’s business could be negatively impacted as a result of stockholder activism or an unsolicited takeover proposal or a proxy contest.
In recent years, proxy contests and other forms of stockholder activism have been directed against numerous public companies. During fiscal years 2012 and 2011, the Company was the target of an unsolicited takeover proposal from a stockholder activist, which resulted in significant costs to the Company. If such a proposal were to be made again, the Company would likely incur significant costs, which could have an adverse effect on the Company’s financial condition and results of operations.
Stockholder activists may also seek to involve themselves in the governance, strategic direction and operations of the Company through stockholder proposals or otherwise. Such proposals may disrupt the Company’s business and divert the attention of the Company’s management and employees, and any perceived uncertainties as to the Company’s future direction resulting from such a situation could result in the loss of potential business opportunities, the perception that the Company needs a change in the direction of its business, or the perception that the Company is unstable or lacks continuity, which may be exploited by its competitors, cause concern to its current or potential customers, and make it more difficult for the Company to attract and retain qualified personnel and business partners, which could adversely affect the Company’s business. In addition, actions of activist stockholders may cause significant fluctuations in the Company's stock price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of its business.
The Company's amended and restated bylaws designate specific courts as the exclusive forum for certain stockholder litigation, which could limit the Company's stockholders’ ability to obtain a judicial forum of their choice.
The Company's amended and restated bylaws provide that, unless it consents in writing to the selection of an alternative forum, the state courts of Delaware (or if no state court has jurisdiction, the federal district court of the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for certain types of actions or proceedings under Delaware statutory or common law. The choice of forum provision in the Company's bylaws does not waive its compliance with its obligations under the federal securities laws and the rules and regulations thereunder. Moreover, the provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act or by the Securities Act.
The Company's exclusive forum provision may limit the ability of its stockholders to bring a claim in a judicial forum of such stockholders’ choice for disputes with the Company or its directors, officers or employees, which may discourage such lawsuits, even though an action, if successful, might benefit its stockholders. If a court were to find the exclusive forum provision either to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions, all of which may increase costs of litigation. Any person or entity purchasing or otherwise acquiring any interest in shares of the Company's capital stock will be deemed to have notice of, and consented to, the provisions of its amended and restated bylaws described in the preceding sentences.
Financial and Economic Risks
Profitability and cash flow could suffer if the Company is unable to generate anticipated cost savings, successfully implement its transformational initiatives or strategies, or efficiently manage supply chain and manufacturing processes.
The Company continues to make progress to improve its competitive position, generate efficiencies and transform the Company's operations through implementing certain transformational initiatives (such as its digital capabilities upgrade including enhancing operating efficiencies, transitioning to a cloud-based platform and replacing its enterprise resource planning system), optimizing its supply chain and generating savings through its long-standing cost savings program intended to reduce material costs and manufacturing inefficiencies and realize productivity gains, distribution and logistical efficiencies and overhead reductions. If the Company cannot successfully implement its transformational initiatives or cost savings plans or
19

optimize its supply chain, the Company may experience system outages and operating inefficiencies following these implementations and may not realize all anticipated operational and efficiency benefits and cost savings, which could adversely affect its business and long-term strategies. The Company also continues to seek to enter new markets and introduce new products and product innovations. These goals and strategies may not be implemented or may fail to achieve the desired results. The Company may also not be able to successfully implement any future price increases, including to account for increased costs, which may negatively affect its profitability and cash flow, and any such price increases may also negatively affect sales volumes. In addition, the Company expects to continue to restructure its operations as necessary to improve operational efficiency, including occasionally opening or closing offices, facilities or plants. Gaining additional efficiencies may become increasingly difficult over time, there may be one-time and other costs and negative impacts on employee, customer or supplier relations or sales growth relating to facility or plant closures or other restructurings and anticipated cost savings, and the Company’s strategies may not be implemented or may fail to achieve desired results. If the Company is unable to generate anticipated cost savings; successfully implement its strategies; implement new pricing; efficiently manage its supply chain and manufacturing processes; is ineffective or slow in developing and implementing its transformational initiatives; or is unable to achieve the anticipated benefits or cost savings from its digital capabilities upgrade or streamlined operating model, the Company’s results of operations could suffer. These plans and strategies could also have a negative impact on the Company’s relationships with employees or customers, which could also adversely affect the Company’s business, financial condition and results of operations.
The estimates and assumptions on which the Company’s financial projections are based may prove to be inaccurate, which may cause its actual results to materially differ from such projections, which may adversely affect the Company’s future profitability, cash flows and stock price.
The Company’s financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are dependent on certain estimates and assumptions related to, among other things, category growth, development and launch of innovative new products, market share projections, product pricing and sale, volume and product mix, foreign exchange rates and volatility, tax rates, commodity prices, distribution, cost savings, accruals for estimated liabilities, including measurement of benefit obligations for postretirement benefit plans, and the Company’s ability to generate sufficient cash flow to reinvest in its existing business, fund internal growth, repurchase its stock, make acquisitions, pay dividends and meet debt obligations. The Company’s financial projections are based on historical experience, various other estimates and assumptions that the Company believes to be reasonable under the circumstances and at the time they are made, and these assumptions and estimates may be adversely affected by the risks described in this Report. The Company’s actual results may differ materially from its financial projections. Any material variation between the Company’s financial projections and its actual results may adversely affect the Company’s future profitability, cash flows and stock price.
Increases in the estimated fair value of The Procter & Gamble Co. (“P&G’s”) interest in the Company’s Glad business increase the value of the Company’s obligation to purchase P&G’s interest in the Glad business upon the termination of the venture agreement and may, in the future, adversely affect the Company’s net earnings and cash flow.
In January 2003, the Company entered into a venture agreement with P&G related to the Company’s Glad bags and wraps business. In connection with this agreement, P&G provides research and development support to the Glad business. The agreement with P&G expires in January 2026 unless the parties agree to extend the term. The agreement requires the Company to purchase P&G’s 20% interest at the expiration of its term for cash at fair value as established by predetermined valuation procedures. As of June 30, 2024, 2023 and 2022, the estimated fair value of P&G’s interest was $531 million, $527 million and $635 million, respectively, of which $510 million, $495 million and $468 million, respectively, has been recognized by the Company and is reflected in Other liabilities in the Company’s Consolidated Balance Sheets. The difference between the estimated fair value and the amount recognized, and any future changes in the fair value of P&G’s interest, is charged to Cost of products sold in accordance with the effective interest method over the remaining life of the agreement. As the agreement nears its expiration, there may be increased volatility in the Company’s net earnings and cash flow, as the estimated fair value of P&G’s interest may continue to change up until any such purchase by the Company of P&G’s interest. The final cost of the Company’s repurchase obligation may also differ from the estimated fair value. The key assumptions and estimates used to arrive at the estimated fair value include, but are not limited to, tax rates, the rate at which future cash flows are discounted (discount rate), commodity prices, future volume estimates, net sales and expense growth rates, changes in working capital, capital expenditures, foreign exchange rates, inflation and terminal growth rates. Any changes in such assumptions or estimates could significantly affect such estimated fair value and, accordingly, the value of the Company’s repurchase obligation and may adversely affect the Company’s net earnings up until any such purchase and cash flow at the time of any such purchase. For additional information, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Notes to Consolidated Financial Statements in Exhibit 99.1.

20

The Company’s indebtedness could have a material adverse effect on its business, financial condition and results of operations and prevent the Company from fulfilling its financial obligations, and the Company may not be able to maintain its current credit ratings, continue to pay dividends or repurchase its stock or remain in compliance with existing debt covenants.
As of June 30, 2024, the Company had approximately $2.5 billion of debt. The Company’s indebtedness could have important consequences. For example, it could:
•    require the Company to dedicate a substantial portion of its cash flow from operations to payments on its indebtedness, which would reduce the availability of its cash flow to fund working capital requirements, capital expenditures, future acquisitions, dividends, repurchase the Company’s common stock and for other general corporate purposes;
•    limit the Company’s flexibility in planning for or reacting to general adverse economic conditions or changes in its business and the industries in which it operates;
•    place the Company at a competitive disadvantage compared to its competitors that have less debt; and
•    limit, along with the financial and other restrictive covenants in the Company’s debt documents, its ability to borrow additional funds.
The Company may also incur substantial additional indebtedness in the future to fund acquisitions, repurchase stock or fund other activities for general business purposes.
Further, certain terms of the agreements governing the Company’s over-the-counter derivative instruments contain provisions that require the Company’s credit ratings, assigned by Standard & Poor’s and Moody’s to the Company, to remain at investment-grade or above. As of June 30, 2024, the Company’s Standard & Poor’s and Moody’s ratings were both investment-grade. However, if these credit ratings were to fall below investment-grade, the counterparties to the derivative instruments in net liability positions could request full collateralization, and it may negatively impact the Company’s other financial arrangements, including the supply chain financing arrangement offered by a financial institution to the Company's suppliers, which could, in turn, impact its working capital.
The Company has historically declared and paid quarterly cash dividends on its common stock and has been authorized to repurchase its stock subject to certain limitations under its stock repurchase programs. Any determinations by the board of directors to continue to declare and pay cash dividends on the Company’s common stock or to repurchase the Company’s common stock, however, will be based on a number of factors, including the board of directors’ continuing determination that the repurchase programs and the declaration and payment of dividends are in the best interests of the Company’s stockholders. In the event the Company does not declare and pay a quarterly dividend or repurchase its stock, the Company’s stock price could be adversely affected.
ITEM 1.B. UNRESOLVED STAFF COMMENTS
None.
ITEM 1.C. CYBERSECURITY
Risk Management and Strategy
The Company maintains a comprehensive program and processes designed to assess, identify, evaluate and manage vulnerabilities to the Company’s business and operations, and other material risks from cybersecurity threats, as part of its overall Enterprise Risk Management (ERM) and cybersecurity risk management program and processes.
The Company’s cybersecurity risk management program includes the following features.
Leverages the National Institute of Standards and Technology (NIST) and Zero Trust Architecture frameworks for managing cybersecurity risks;
Maintenance of security policies and standards, regular updates to response planning and protocols, and implementation of new technology to monitor new vulnerabilities, emerging threats and risks;
A cybersecurity incident response plan designed to facilitate cross-functional coordination across the Company (including escalation based on the severity of the impact of an incident), mitigate brand and reputational damage, and comply with applicable legal obligations, which includes guidance to support the Company’s assessment of whether an incident is considered “material” for purposes of U.S. securities laws;
Executive and IT team tabletop exercises;
21

A cybersecurity insurance program to reimburse covered costs, losses and claims relating to a data or security breach;
Use of consultants, third-party service providers and information security firms to provide technology systems or administer aspects of this program, conduct assessments of the Company's cybersecurity practices and penetration testing, and cybersecurity, risk management and legal experts;
A third-party risk assessment process that utilizes a risk-based approach for vendors engaged through the Company’s procurement process; and
Regular phishing and cybersecurity awareness and engagement training for all employees who have access to Company email and connected devices.
The Company’s business strategy, results of operations and financial condition have been materially affected by our previously disclosed August 2023 cyberattack. See “Risk Factors” in Item 1A of this Annual Report on Form 10-K for more information on risks from cybersecurity threats that are reasonably likely to materially affect the Company’s business strategy, results of operations and financial condition.
The August 2023 cyberattack resulted in wide-scale disruptions to the Company’s business operations. Impacts of these system disruptions included order processing delays and significant product outages, resulting in a negative impact on net sales and earnings. The costs incurred included third-party consulting services, such as IT recovery and forensic experts, and other professional services to investigate and remediate the attack, as well as incremental operating costs from the resulting disruption to the Company’s business operations. These costs have been partially offset by recognized insurance recoveries in fiscal year 2024. See Notes to the Consolidated Financial Statements for additional details regarding the impact of the August 2023 cyberattack.
Governance
Management
The Chief Information Security and Infrastructure Officer (CISIO) is responsible for the Company’s cybersecurity risk management program. The CISIO oversees the Company’s technology risk management team. This team works in partnership with the legal, financial reporting controls and internal audit functions to review information technology-related internal controls with the Company’s independent auditors as part of the overall internal controls process.
The CISIO has information technology and information security experience, including enterprise risk management leadership, and holds a Certified Information Security Manager certification from the Information Systems Audit and Control Association (ISACA). The CISIO reports to the Chief Information and Data Officer (CIDO), who is a member of the Clorox Executive Committee and reports directly to the CEO. The CIDO has experience overseeing and executing technology strategies and implementations in complex, global organizations. The CIDO has been in this role for the Company since June 2020 and has experience leading technology strategy in the consumer packaged goods, manufacturing and retail industries.
The Company has established the Clorox Information Security Executive Committee (CISEC) which oversees the information security strategy, policies and practices of the Company. The CISEC supports the Company’s objective of maintaining a strong security culture by overseeing alignment between the Company’s security objectives and business goals, risk exposure, and compliance requirements. The CISEC is chaired by the CISIO and includes in its membership the CIDO and Chief Legal Officer, who are both members of the Clorox Executive Committee, as well as the Chief Accounting Officer and Controller and VP, Internal Audit. The CISIO also provides periodic reports to the Clorox Executive Committee and quarterly reports to the Audit Committee. These reports may include updates on critical information security and cybersecurity risks and the threat landscape; cybersecurity improvement initiatives, the internal control environment, and ongoing internal audit activities; and, if relevant, the status of actions taken with respect to significant cybersecurity incidents.
Board of Directors
The Board, through the Audit Committee, is responsible for the oversight of the Company’s compliance with legal and regulatory requirements relating to data privacy, cybersecurity and IT risks and its framework and guidelines with respect to risk assessment and risk management. The Audit Committee receives quarterly updates from the CISIO on the topics set forth above, in addition to the Chief Legal Officer and CIDO.
The Board retains responsibility for the overall process for assessing and managing major risks facing the Company and receives updates regarding information security and cybersecurity risks as part of its oversight of ERM. The CIDO and Chief Legal Officer provide quarterly updates to the Board on topics that may include information security and cybersecurity matters. The Board may also be notified and engaged as part of the Company's cybersecurity incident response plans, depending on the
22

severity of the impact of an incident. The Board and Audit Committee include directors with knowledge, skills and experience in data security, privacy, IT governance, and management of cyber risks.
ITEM 2. PROPERTIES
The Company owns or leases various manufacturing, distribution, office and research and development facilities, including a leased facility in Pleasanton, CA, which houses the Company’s primary research and development group, as well as other administrative and operational support personnel, and a leased office space in Oakland, CA for its corporate headquarters. Management believes the Company’s facilities are adequate to support the business efficiently.
ITEM 3. LEGAL PROCEEDINGS
The Company is subject to routine litigation incidental to its business in the United States and in international locations, including various lawsuits and claims relating to issues such as contract disputes, product liability, patents and trademarks, advertising, commercial, administrative, employment, antitrust, securities, consumer class actions and other matters. Although the results of claims and litigation cannot be predicted with certainty, based on management’s analysis, it is the opinion of management that the ultimate disposition of these matters, to the extent not previously provided for or disclosed in the Company’s consolidated financial statements in Exhibit 99.1, will not have a material adverse effect, individually or in the aggregate, on the Company’s consolidated financial statements taken as a whole.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.

23

INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The names, ages, year first elected and current titles of each of the executive officers of the Company as of August 8, 2024, are set forth below:
NameAgeYear First
Elected
Executive
Officer
Title
Linda Rendle462016
Chair and Chief Executive Officer
Nina Barton
502024
Executive Vice President - Group President - Care and Connection
Stacey Grier612019
Executive Vice President – Executive Chief of Staff
Angela Hilt522020Executive Vice President – Chief Legal Officer
Chris Hyder
492021
Executive Vice President - Group President - Health and Hygiene
Kevin B. Jacobsen582018Executive Vice President – Chief Financial Officer
Kirsten Marriner512016Executive Vice President – Chief People and Corporate Affairs Officer
Eric Reynolds542015
Executive Vice President – Chief Operating and Strategy Officer
Chau Banks552020
Senior Vice President – Chief Information and Data Officer
Shanique Bonelli-Moore442022Vice President – Chief Diversity and Social Impact Officer
Gina Kelly
612024
Senior Vice President - Chief Customer Officer
Michael Ott552022Senior Vice President – Chief Research and Development Officer
Eric Schwartz522022Senior Vice President – Chief Marketing Officer
There is no family relationship between any of the above-named persons, or between any of such persons and any of the directors of the Company. See Item 10 of Part III of this Report for additional information.
Linda Rendle is the chair and chief executive officer of the Company, a position she has held since September 2020, having taken on the role of chair in January 2024. Prior to this role, she served as the president of the Company from May 2020 to September 2020. She served as executive vice president – cleaning, international, strategy and operations from July 2019 to May 2020. From January 2019 to July 2019, she served as executive vice president – strategy and operations. From June 2018 to January 2019, she served as executive vice president – cleaning and strategy. She served as senior vice president – general manager, cleaning division of the Company, from August 2016 to June 2018, having taken on responsibility for the professional products division in April 2017. She served as vice president – general manager, home care from October 2014 to August 2016. From April 2012 to October 2014, she served as vice president – sales, cleaning division. From August 2011 to April 2012, she served as director of sales planning – litter, food & charcoal. From January 2010 to August 2011, she served as director of sales – supply chain. Ms. Rendle joined the Company in 2003.
Nina Barton is the executive vice president and group president - care & connection for the Company, a position she has held since July 2024. Prior to joining Clorox, she was the chief executive officer of Vytalogy Wellness LLC (including its predecessor companies Jarrow Formulas Inc. and Natrol LLC) from July 2021 to November 2023, and senior advisor from November 2023 to July 2024. Previously, she was strategic advisor at The Kraft Heinz Company from November 2020 through May 2021; global chief growth officer from September 2019 through November 2020; zone president of Canada and president of digital growth from January 2019 to September 2019; and president, global digital and online growth from October 2017 to September 2019. From July 2015 to October 2017, she served as senior vice president of marketing, innovation and research & development for the U.S. business at The Kraft Heinz Company. From July 2013 through July 2015, she served as vice president, marketing at Kraft Foods Group, Inc., and senior marketing director from February 2011 through July 2013. Earlier in her career, she held a variety of marketing and leadership positions in the consumer products industry, including at Johnson & Johnson, L’Oréal and Procter & Gamble.
Stacey Grier is the executive vice president – executive chief of staff for the Company, a position she has held since January 2024. Prior to this role, she served as executive vice president - chief growth and strategy officer from March 2022 to January 2024. From January 2019 to March 2022, she served as senior vice president – chief marketing officer, having taken on additional responsibility for enterprise strategy since September 2020. Prior to this role, she served as vice president - brand engagement and enhanced wellness marketing from October 2018 to January 2019. She served as vice president - brand and marketing strategy from October 2016 through October 2018. Prior to joining the Company, she served as chief strategic officer at DDB Worldwide from April 1996 to June 2016. Ms. Grier joined the Company in 2016.

24

Angela Hilt is the executive vice president – chief legal officer of the Company, a position she has held since October 2022. She was appointed to senior vice president - chief legal officer in December 2020. Prior to this role, she served as vice president – corporate secretary and deputy general counsel from September 2018 to December 2020, and vice president – corporate secretary and associate general counsel from October 2008 to September 2018. She served as senior corporate counsel from December 2005 to October 2008. Ms. Hilt joined the Company in 2005.
Chris Hyder is the executive vice president and group president – health and hygiene of the Company, a position he has held since October 2022, having taken on the role as executive vice president in May 2024. Prior to this role he served as senior vice president - general manager, cleaning and professional products since September 2021. Previously, he was vice president – general manager, cleaning division since July 2019 and vice president – general manager, homecare from September 2018 to July 2019. From January 2016 through September 2018, he was vice president of marketing – cleaning and general manager – laundry. Mr. Hyder joined the Company in 2003 and subsequently held positions of increasing responsibility.
Kevin B. Jacobsen is the executive vice president – chief financial officer of the Company, a position he has held since January 2019. Prior to this role, he served as senior vice president – chief financial officer from April 2018 to January 2019. He served as vice president – financial planning and analysis, from November 2011 through March 2018. Mr. Jacobsen joined the Company in 1995 and has held a number of senior leadership roles in the Company’s finance department over the years, including serving as the finance leader for the specialty division, head of finance for Brazil operations, the product supply organization and various business units.
Kirsten Marriner is the executive vice president – chief people and corporate affairs officer of the Company, a position she has held since December 2020. She was appointed to executive vice president - chief people officer in January 2019. Prior to this role she served as senior vice president – chief people officer from March 2016 to January 2019. Prior to joining the Company, she served as senior vice president and chief human resources officer at Omnicare, from March 2013 to August 2015. She served in various leadership roles, including as senior vice president, director of talent management and development at Fifth Third Bank, from October 2004 to March 2013. Ms. Marriner joined the Company in 2016.
Eric Reynolds is the executive vice president - chief operating and strategy officer of the Company, a position he has held since September 2020, having taken on additional responsibility for enterprise strategy in January 2024. Prior to this role, he served as executive vice president - household and lifestyle of the Company from July 2019 to September 2020. He served as executive vice president – cleaning and Burt’s Bees from January 2019 to July 2019. From January 2015 to January 2019, he served as senior vice president – chief marketing officer. He served as vice president – general manager, Europe, Middle East, Africa and Asia from May 2012 to January 2015. From May 2011 to April 2012, he was director, international business development. From June 2008 to April 2011, he was general manager, Caribbean. Mr. Reynolds joined the Company in 1998.
Chau Banks is the senior vice president – chief information and data officer of the Company, a position she has held since June 2020, having taken on responsibility for enterprise analytics since September 2020. Prior to this role, she served as chief technology and digital officer at Revlon Consumer Products Company from January 2018 to June 2020. From September 2013 to November 2017, she was EVP, CIO and channel integration at New York & Company, Inc. (now RetailWinds Inc.). She has held leadership positions at leading global retailers including COACH, Abercrombie & Fitch and LBrands. She previously served as a management consultant at Capgemini and Ernst & Young. She also previously held positions at Energizer and Kimberly-Clark. Ms. Banks joined the Company in 2020.
Shanique Bonelli-Moore is the vice president – chief diversity and social impact officer of the Company, a position she has held since July 2022. Prior to joining Clorox, she was executive director of inclusion at United Talent Agency from January 2019 to June 2022, and director of corporate communications from April 2018 to December 2018. From November 2016 to April 2018, she was senior director of global internal communications and diversity & inclusion lead at BuzzFeed Entertainment. Earlier in her career, she held positions at leading companies including Anheuser-Busch InBev, NBCUniversal and GE where she focused on corporate communication, diversity, inclusion and belonging.
Gina Kelly is the senior vice president - chief customer officer of the Company, a position she has held since June 2024. Prior to this role, she served as vice president - general manager, Walmart and leading-edge retailers from January 2022 to June 2024. She served as vice president - ecommerce and strategic accounts from July 2019 to January 2022. Ms. Kelly joined the Company in 1988 and subsequently held positions of increasing responsibility over the years, including vice president of sales - business development, acting vice president - grocery, natural and pet, senior director - Kroger and the natural channel.
Michael Ott is the senior vice president – chief research & development officer of the Company, a position he has held since June 2022. Previously, he served as interim sustainability officer, a position he held from November 2021 to February 2023, while also serving as vice president, research & development – specialty division, from August 2018 through May 2022. Previously, he was vice president, research & development – cleaning, international, and professional products divisions, from
25

October 2014 to August 2018. Dr. Ott joined the Company in 1996 as a scientist and has since held positions of increasing responsibility in research & development.
Eric Schwartz is the senior vice president and chief marketing officer of the Company, a position he has held since March 2022. Previously, he was senior vice president and general manager – specialty, from July 2019 to March 2022. Prior to joining Clorox, he was chief marketing officer and general manager at Tyson Foods, poultry segment, from January 2017 to February 2019. Earlier in his career, he held positions of increasing responsibility at Tyson Foods and Henkel. Mr. Schwartz rejoined the Company in 2019 after serving as brand manager at the Company from 2000 to 2004.
26

PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
The Company’s common stock is listed on the New York Stock Exchange. The ticker symbol is CLX.
Holders
The number of record holders of the Company’s common stock as of July 23, 2024, was 8,435 based on information provided by the Company’s transfer agent.
Equity Compensation Plan Information
See Part III, Item 12 hereof, which is incorporated herein by reference.
Issuer Purchases of Equity Securities
In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (Open-Market Program), which has no expiration date.
In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.
The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the fourth quarter of fiscal year 2024.
 [a][b][c][d]
Period
Total Number of
Shares Purchased
Average Price Paid
per Share (1)
Total Number of
Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number (or
Approximate Dollar
Value) of Shares that May Yet Be Purchased Under the Plans or Programs
April 1 to 30, 2024
— $— — $993 million
May 1 to 31, 2024
— — — $993 million
June 1 to 30, 2024
— — — $993 million
— $— — 

(1)Average price paid per share in the period includes commission.

ITEM 6. RESERVED
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This information appears under “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Exhibit 99.1, which is incorporated herein by reference.
ITEM 7.A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
This information appears under “Quantitative and Qualitative Disclosures about Market Risk” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Exhibit 99.1, which is incorporated herein by reference.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
These statements and data appear in Exhibit 99.1, which is incorporated herein by reference.

27

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9.A. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s chief executive officer and executive vice president – chief financial officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the chief executive officer and executive vice president – chief financial officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding disclosure.
Management’s Report on Internal Control Over Financial Reporting
Management’s report on internal control over financial reporting is set forth in Exhibit 99.1, and is incorporated herein by reference. The Company’s independent registered public accounting firm, Ernst & Young, LLP, has audited the effectiveness of the Company’s internal control over financial reporting as of June 30, 2024. See “Report of Independent Registered Public Accounting Firm,” which appears in Exhibit 99.1.
Change in Internal Control Over Financial Reporting
No change in the Company’s internal control over financial reporting occurred during the fourth fiscal quarter of the fiscal year ended June 30, 2024, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its Information Technology (IT) systems; see Note 3 in the consolidated financial statements in Exhibit 99.1. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the first fiscal quarter of the fiscal year ended June 30, 2024.
During the disruptions caused by the cyberattack, we deployed additional interim controls in response to taking certain systems offline during the period to maintain our internal control over financial reporting.
The Company is in the process of implementing a new enterprise resource planning (ERP) system along with a suite of other digital technologies. In the first quarter of fiscal year 2025, we will begin implementing the new ERP system. As this implementation occurs during fiscal years 2025 and 2026, the Company will change its processes and procedures which, in turn, could result in changes to its internal control over financial reporting. As such changes occur, the Company will evaluate quarterly whether such changes materially affect our internal control over financial reporting.
ITEM 9.B. OTHER INFORMATION
Rule 10b5-1 trading plans
On June 7, 2024, Angela Hilt, EVP – Chief Legal Officer, entered into a trading plan designed to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for sales of up to 1,733 shares of the Company's common stock. The plan also provides for the sale of up to 25% of shares of restricted stock units and performance units vesting during the duration of the plan, excluding any shares withheld by the Company to satisfy income tax withholding remittance obligations. Ms. Hilt’s plan begins on September 6, 2024 and ends June 6, 2025 or when all of the shares have been sold.
Each trading plan is in accordance with the Company's insider trading policy. Actual sale transactions will be disclosed publicly in filings with the SEC in accordance with applicable securities laws, rules and regulations.
28


ITEM 9.C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
29

PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
See “Information about our Executive Officers” in Part I of this Report.
The Company has adopted a Code of Conduct that applies to its principal executive officer, principal financial officer and principal accounting officer, among others. The Code of Conduct is located on the Company’s website at TheCloroxCompany.com under Company/Leadership and Governance/Codes of Conduct or https://www.thecloroxcompany.com/company/policies-and-practices/codes-of-conduct/. The Company intends to satisfy the requirement under Item 5.05 of Form 8-K regarding disclosure of amendments to, or waivers from, provisions of its Code of Conduct by posting such information on the Company’s website. The Company’s website also contains its corporate governance guidelines and the charters of its principal board committees.
Information regarding the Company’s directors and corporate governance set forth in the Proxy Statement is incorporated herein by reference.
The Company has adopted an insider trading policy governing the purchase, sale, and/or other dispositions of its securities by its directors, officers, employees and independent contractors that the Company believes is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the exchange listing standards applicable to the Company. It is the Company’s policy to comply with all applicable securities and state laws (including appropriate approvals by the Company’s board of directors or appropriate committee, if required) when engaging in transactions in the Company’s securities.
ITEM 11. EXECUTIVE COMPENSATION
Information regarding executive and director compensation, Management Development and Compensation Committee interlocks and insider participation and the report of the Management Development and Compensation Committee of the Company’s board of directors set forth in the Proxy Statement is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Information regarding security ownership of certain beneficial owners, management and directors and securities authorized for issuance under equity compensation plans set forth in the Proxy Statement is incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Information regarding certain relationships and related transactions and director independence set forth in the Proxy Statement is incorporated herein by reference.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Information regarding principal accountant fees and services set forth in the Proxy Statement is incorporated herein by reference.

30

PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)Financial Statements and Schedules:
    Consolidated Financial Statements and Reports of Independent Registered Public Accounting Firm included in Exhibit 99.1, incorporated herein by reference.
    Reports of Ernst & Young, LLP, Independent Registered Public Accounting Firm (PCAOB ID: 42).
    Consolidated Statements of Earnings for the fiscal years ended June 30, 2024, 2023 and 2022.
    Consolidated Statements of Comprehensive Income for the fiscal years ended June 30, 2024, 2023 and 2022.
    Consolidated Balance Sheets as of June 30, 2024 and 2023.
    Consolidated Statements of Stockholders’ Equity for the fiscal years ended June 30, 2024, 2023 and 2022.
    Consolidated Statements of Cash Flows for the fiscal years ended June 30, 2024, 2023 and 2022.
    Notes to Consolidated Financial Statements.
(b)Exhibits:
INDEX TO EXHIBITS
Incorporated by Reference
Exhibit
Number
Exhibit DescriptionFormFile No.ExhibitFiling Date
3.110-K001-071513.1August 14, 2018
3.28-K001-071513.2May 26, 2023
3.38-K001-071513.1July 19, 2011
4.1S-3ASR333-2007224.1December 4, 2014
4.2S-3ASR333-2007224.5December 4, 2014
4.38-K001-071514.1December 9, 2014
4.48-K001-071514.1September 28, 2017
4.58-K001-071514.1May 9, 2018
4.68-K001-071514.1May 8, 2020
4.78-K001-071514.1May 11, 2022
4.8
8-K
001-07151
4.3May 11, 2022
4.9
8-K
001-07151
4.4May 11, 2022
4.1010-K001-071514.10August 14, 2019
10.1*10-Q001-0715110.55May 2, 2008
31

Incorporated by Reference
Exhibit
Number
Exhibit DescriptionFormFile No.ExhibitFiling Date
10.2*10-K001-0715110(x)August 27, 2004
10.3*10-K001-0715110.3August 16, 2016
10.4*10-Q001-0715110.1November 1, 2023
10.5*DEF 14A001-07151App. AOctober 6, 2021
10.6*
10-Q
001-07151
10.2February 1, 2024
10.7*
10-Q001-0715110.2November 1, 2022
10.8*
10-Q001-0715110.4November 1, 2021
10.9*
10-Q
001-07151
10.3February 1, 2024
10.10*
10-Q001-0715110.1November 1, 2022
10.11*
10-Q001-0715110.3November 1, 2021
10.12*
10-Q001-0715110.5November 2, 2020
10.13*
10-Q
001-07151
10.4February 1, 2024
10.14*
10-Q001-0715110.3November 1, 2022
10.15*
10-Q001-0715110.5November 1, 2021
10.16*
10-Q001-0715110.2November 2, 2020
10.17*
10-Q
001-07151
10.5February 1, 2024
10.18*
10-K001-0715110.18August 19, 2008
10.19*
10-K001-0715110.18August 26, 2011
10.20*
10-K001-0715110.13August 16, 2016
10.21*
10-Q001-0715110.17November 3, 2009
10.22*
10-Q001-0715110.21November 3, 2011
10.23*
10-Q001-0715110.2November 2, 2012
32

Incorporated by Reference
Exhibit
Number
Exhibit DescriptionFormFile No.ExhibitFiling Date
10.24*
10-Q001-0715110.1May 2, 2018
10.25*
10-Q001-0715110.27May 4, 2010
10.26*
8-K001-0715110.2November 17, 2021
10.27*
8-K001-0715110.3November 17, 2021
10.28*
10.29*
10-K001-0715110.29August 26, 2011
10.30*
10-K001-0715110.24August 16, 2016
10.31*
10-K001-0715110.26August 14, 2018
10.328-K001-0715110.1March 28, 2022
10.3310-K/A001-0715110.26September 30, 2016
10.3410-Q001-0715110.2February 2, 2018
10.3510-Q001-0715110.1February 2, 2018
10.3610-Q001-0715110.2February 4, 2021
19
21
23
31.1
31.2
32
97
33

Incorporated by Reference
Exhibit
Number
Exhibit DescriptionFormFile No.ExhibitFiling Date
99.1    
99.2
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).
____________________

(*)    Indicates a management or director contract or compensatory plan or arrangement required to be filed as an exhibit to this report.


ITEM 16. FORM 10-K SUMMARY
None.
34


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
THE CLOROX COMPANY
 
Date: August 8, 2024
By:/s/ Linda Rendle
Linda Rendle
 
Chair and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
SignatureTitleDate
/s/ A. BanseDirectorAugust 8, 2024
A. Banse
/s/ J. DenmanDirectorAugust 8, 2024
J. Denman
/s/ S. C. FleischerDirectorAugust 8, 2024
S. C. Fleischer
/s/ E. LeeDirectorAugust 8, 2024
E. Lee
/s/ A. D. D. MackayDirectorAugust 8, 2024
A. D. D. Mackay
/s/ P. ParkerDirectorAugust 8, 2024
P. Parker
/s/ S. PlainesDirectorAugust 8, 2024
S. Plaines
/s/ M. J. Shattock
Director
August 8, 2024
M. J. Shattock
/s/ K. Tesija DirectorAugust 8, 2024
K. Tesija
/s/ R. J. WeinerDirectorAugust 8, 2024
R. J. Weiner
/s/ C. J. WilliamsDirectorAugust 8, 2024
C. J. Williams
/s/ L. Rendle
Chair and Chief Executive Officer
(Principal Executive Officer)
August 8, 2024
L. Rendle
/s/ K. B. JacobsenExecutive Vice President – Chief Financial Officer
(Principal Financial Officer)
August 8, 2024
K. B. Jacobsen
/s/ L. PeckVice President – Chief Accounting Officer and Corporate Controller (Principal Accounting Officer)August 8, 2024
L. Peck



35
EX-10.28 2 fy24ex1028thecloroxcompany.htm EX-10.28 Document


THE CLOROX COMPANY
SECOND AMENDED AND RESTATED
EXECUTIVE RETIREMENT PLAN
(Effective May 20, 2024)
ARTICLE I.
PURPOSE
This Plan is designed to provide for additional retirement benefits for selected executives of The Clorox Company. This Plan was originally adopted effective as of July 1, 2011, was amended with respect to subsequent elections effective as of July 1, 2016 and was first amended and restated effective as of November 14, 2023. This Plan is hereby amended and restated for the second time as set forth herein effective as of May 20, 2024, except as otherwise expressly set forth herein.
This Plan is intended to be a plan that is unfunded and that is maintained by The Clorox Company primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees within the meaning of the Employee Retirement Income Security Act. This Plan also is intended to comply with the requirements of Section 409A of the Code.
ARTICLE II.
DEFINITIONS
In this Plan, the following terms have the meanings indicated below.
2.01    “Account” means a bookkeeping entry used to record deferrals and contributions made on a Participant’s behalf under Article III of the Plan and gains and losses credited to these deferrals and contributions under Article IV of the Plan.
2.02    “Beneficiary” means the person or persons, natural or otherwise, designated in writing, to receive a Participant’s vested Account if the Participant dies before distribution of his or her entire vested Account. A Participant may designate one or more primary Beneficiaries and one or more secondary Beneficiaries. A Participant’s Beneficiary designation will be made pursuant to such procedures as the Committee may establish and delivered to the Committee before the Participant’s death. The Participant may revoke or change this designation at any time before his or her death by following such procedures as the Committee may establish. If the Committee has not received a Participant’s Beneficiary designation before the Participant’s death or if the Participant does not otherwise have an effective Beneficiary designation on file when he or she dies, the Participant’s vested Account will be distributed to the Participant’s spouse if surviving at the Participant’s death, or if there is no such spouse, the Participant’s children in equal shares, or if none, the Participant’s estate.
2.03    “Board” means the Board of Directors of the Company.
2.04    “Change in Control” means:
(a)The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of (i) 50% of either the total fair market value or the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”), or (ii) during a 12 month period ending on the date of the most recent acquisition by such Person, 30% of the Outstanding Company Voting Securities; provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition directly from the Company, (ii) any acquisition by the Company, including any acquisition which by reducing the number of shares outstanding, is the sole cause for increasing the percentage of shares beneficially owned by any such Person to more than the applicable percentage set forth above, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any



corporation controlled by the Company or (iv) any acquisition by any corporation pursuant to a transaction which complies with clauses (i), (ii) and (iii) of subsection (c) of this Section 2.05; or
(b)Individuals who, as of the Effective Date, constitute the Board (the “Incumbent Board”) cease for any reason within any period of 12 months to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the Company’s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board, shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
(c)Consummation by the Company of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company or the acquisition of assets of another corporation (a “Business Combination”), in each case, unless, following such Business Combination, (i) more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) is represented by Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which such Outstanding Company Common Stock and Outstanding Company Voting Securities were converted pursuant to such Business Combination) and such ownership of common stock and voting power among the holders thereof is in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination and (iii) at least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination.
(d)Notwithstanding any other provision in this Section 2.05, any transaction defined in Section 2.05(a) through (c) above that does not constitute a “change in the ownership or effective control” of the Company, or “change in the ownership of a substantial portion of the assets” of the Company within the meaning of Treasury Regulations 1.409A-3(a)(5) and 1.409A-3(i)(5) shall not be treated as a Change in Control for purposes of this Plan.
2.05    “Code” means the Internal Revenue Code of 1986, as amended.
2.06    “Committee” means the Management Development and Compensation Committee of the Company’s Board of Directors. The Committee has full, discretionary authority to administer and interpret the Plan, to determine eligibility for Plan benefits, to select employees for Plan participation, and to correct errors. The Committee may delegate its duties and responsibilities and, unless the Committee expressly provides to the contrary, any such delegation will carry with it the Committee’s full discretionary authority to accomplish the delegation. Decisions of the Committee and its delegate will be final and binding on all persons.
2.07    “Company” means The Clorox Company, a Delaware corporation.
2.08    “Disability” means the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous



period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under the Company’s insurance plans.
2.09    “Effective Date” means May 20, 2024.
2.10    “Eligible Employee” means an employee of the Company or of a Subsidiary who has been selected by the Committee, and notified by the Company of eligibility, for Plan participation. Unless otherwise determined by the Committee, an individual will cease to be an Eligible Employee on the earliest of (i) the date the individual ceases to be employed by the Company and all Subsidiaries, (ii) the date the Plan is terminated, or (iii) the date the Committee, in its discretion, determines that the individual is no longer an Eligible Employee. In addition to the foregoing, the Committee may, in its discretion, deny eligibility to any employee or group of employees who may previously have been Eligible Employees.
2.11    “Employer” means the entity for whom services are performed and with respect to whom the legally binding right to compensation arises, and all entities with whom such entity would be considered a single employer under Section 414(b) of the Code; provided that in applying Section 1563(a)(1), (2), and (3) of the Code for purposes of determining a controlled group of corporations under Section 414(b) of the Code, the language “at least 50 percent” is used instead of “at least 80 percent” each place it appears in Section 1563(a)(1), (2), and (3) of the Code, and in applying Treasury Regulation § 1.414(c)-2 for purposes of determining trades or businesses (whether or not incorporated) that are under common control for purposes of Section 414(c) of the Code, “at least 50 percent” is used instead of “at least 80 percent” each place it appears in Treasury Regulation § 1.414(c)-2; provided, however, “at least 20 percent” shall replace “at least 50 percent” in the preceding clause if there is a legitimate business criteria for using such lower percentage.
2.12    “Exchange Act” means the Securities Exchange Act of 1934, as amended.
2.13    “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
2.14    “Identification Date” means each December 31.
2.15    “Measuring Fund” means one or more of the investment funds selected by the Committee pursuant to Article IV.
2.16    “Participant” means a current or former Eligible Employee who retains an Account and/or has been selected by the Committee as eligible to receive contributions pursuant to Section 3.01.
2.17    “Plan” means The Clorox Company Executive Retirement Plan, as amended from time to time.
2.18    “Plan Year” means a calendar year.
2.19     “Retirement Contribution” means a contribution credited to a Participant’s Account by the Company pursuant to Section 3.01.
2.20    “Section 409A” means Section 409A of the Code, as the same may be amended from time to time, and any successor statute to such section of the Code. References to Section 409A or any requirement under Section 409A, as the same may be interpreted, construed or applied to this Plan at any particular time, shall be deemed to mean and include, to the extent then applicable and then in force and effect (but not to the extent overruled, limited or superseded), published rulings and similar announcements issued by the Internal Revenue Service under or interpreting Section 409A, regulations issued by the Secretary of the Treasury under or interpreting Section 409A, decisions by any court of competent jurisdiction involving a Participant or a Beneficiary and any closing agreement made under Section 7121 of the Code that is approved by the Internal Revenue Service and involves a Participant, all as determined by the Board in good faith, which determination may (but shall not be required to) be made in reliance on the advice of such tax counsel or other tax professional(s) with whom the Board from time to time may elect to consult with respect to any such matter.
2.21    “Separation from Service” means termination of employment with the Employer, other than by reason of death. A Participant shall not be deemed to have Separated from Service if the Participant continues to provide services to the Company or any of its Subsidiaries in a capacity other than as an employee and if the former



employee is providing services at an annual rate that is fifty percent or more of the services rendered, on average, during the immediately preceding thirty-six months of employment with the Employer (or if employed by the Employer less than thirty-six months, such lesser period); provided, however, that a Separation from Service will be deemed to have occurred if a Participant’s service with the Employer is reduced to an annual rate that is less than twenty percent of the services rendered, on average, during the immediately preceding thirty-six months of employment with the Employer (or if employed by the Employer less than thirty-six months, such lesser period).
2.22    “Specified Employee” means a Participant who, on an Identification Date, is a “Specified Employee” as such term is defined in Section 409A. As of the Effective Date, a Specified Employee is:
(a)An officer of the Company having annual compensation greater than the compensation limit in Section 416(i)(1)(A)(i) of the Code, provided that no more than fifty officers of the Company shall be determined to be Specified Employees as of any Identification Date;
(b)A five percent owner of the Company regardless of compensation; or
(c)A one percent owner of the Company having annual compensation from the Company of more than $150,000.
If a Participant is identified as a Specified Employee on an Identification Date, then such Participant shall be considered a Specified Employee for purposes of the Plan during the period beginning on the first April 1 following the Identification Date and ending on the next March 31.
2.23    “Subsidiary” means shall mean any entity (other than the Company) in an unbroken chain of entities beginning with the Company, provided each entity (other than the last entity) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of equity in one of the other entities in such chain.
2.24    “Unforeseeable Emergency” shall have the meaning given to it in Section 409A. As of the Effective Date, the term means a severe financial hardship to the Participant or Beneficiary resulting from:
(a)An illness or accident of the Participant or Beneficiary, the Participant’s or Beneficiary’s spouse, or the Participant’s or Beneficiary’s dependent (as defined in Section 152(a) of the Code); or
(b)Loss of the Participant’s property due to casualty (including the need to rebuild a home following damage to a home not otherwise covered by insurance); or
(c)Other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant.
Hardship shall not constitute an Unforeseeable Emergency under the Plan to the extent that it is, or may be, relieved by:
(x)Reimbursement or compensation, by insurance or otherwise;
(y)Liquidation of the Participant’s assets to the extent that the liquidation of such assets would not itself cause severe financial hardship. Such assets shall include but not be limited to stock options, Company stock, and 401(k) plan balances; or
(z)Cessation of deferrals under the Plan.
An Unforeseeable Emergency under the Plan does not include (among other events):
(A)Sending a child to college; or
(B)Purchasing a home.
ARTICLE III.
CONTRIBUTIONS



3.01     Retirement Contributions. Accounts for the Participants may be credited with discretionary contributions as described below.
(a)Contributions. For each Plan Year of the Company or at such other times as the Committee may determine, the Company may credit a Participant with a discretionary contribution under the Plan. Such Retirement Contribution, if any, and the amount thereof, will be determined in the sole and absolute discretion of the Committee, and to such Participants or groups or categories of Participants as shall be determined in the sole and absolute discretion of the Company. In the event that the Company credits Participants with a discretionary contribution under the Plan for a Plan Year in which a Participant retires after having reached (1) twenty (20) or more years of Vesting Service (as defined below) or (2) age fifty-five with ten (10) or more years of Vesting Service, such Participant shall be credited with a prorated portion of the contribution credited to individuals who were Participants for the entire Plan Year.
(b)Crediting. Retirement Contributions will be credited to Participants’ Accounts as of the date specified by the Committee.
(c)Vesting. Unless otherwise determined by the Committee or provided elsewhere in the Plan, Participants will vest in their Retirement Contributions one-third on each December 31 of the first three Plan Years immediately following the end of the Plan Year with respect to which the applicable Retirement Contribution is made, subject to the Participant’s continued employment with the Company through the applicable vesting date; provided, however, that from and after the date a Participant attains the earlier of (1) twenty (20) or more years of “vesting service,” which solely for purposes of this Plan, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Participant with respect to the 401(k) Plan (“Vesting Service”) or (2) age fifty-five with ten (10) or more years of Vesting Service, the Participant will be considered fully vested in all Retirement Contributions under the Plan. Furthermore, in the event of a Participant’s Separation from Service by reason of his or her death or Disability, all unvested Retirement Contributions shall become immediately and fully vested as of immediately prior to such Separation from Service.
ARTICLE IV.
EARNINGS
4.01    General. A Participant’s Account shall be credited with earnings in accordance with this Article IV.
4.02    Investment Options. The Committee shall select the Measuring Funds whose performance will measure the amounts to be credited under Section 4.03 to the Participants’ Accounts. The selection of Measuring Funds shall be for bookkeeping purposes only, and the Company shall not be obligated actually to invest any money in the Measuring Funds, or to acquire or maintain any actual investment. The Committee may, in its discretion, change its selection of the Measuring Funds at any time. If a Participant has elected pursuant to this Section 4.02 to invest all or a portion of his Account in a Measuring Fund which the Committee decides to discontinue, such portion of his Account shall be invested after such discontinuance in the continuing Measuring Fund which the Committee determines, in its discretion, most nearly resembles the discontinued Measuring Fund. The Committee shall provide each Participant with a list of the Measuring Funds available for hypothetical investment, and the Participant shall designate, on a form provided by the Committee, one or more of such Measuring Funds in which his Account will be deemed to be invested. The Committee, in its discretion, shall designate the times, procedures and limitations for the designation of hypothetical investments by Participants of their Accounts among the Measuring Funds (including, but not limited to, the times when a Participant may change his hypothetical investments, the increments (expressed as a dollar amount or as a percentage of the Participant’s Account) in which a Participant may chose to make a hypothetical investment in a Measuring Fund, and any minimum increment (expressed as a dollar amount or as a percentage of the Participant’s Account) that may be deemed to be invested in a Measuring Fund); provided, however, that a Participant may make a selection of a hypothetical investment in a Measuring Fund on a prospective basis only.



4.03    Earnings Credits. The Committee shall determine, in its discretion, the exact times and methods for crediting or charging each Participant’s Account with the earnings, gains, losses, and changes in value of the Measuring Funds selected by the Participant. The Committee may, at any time, change the timing or methods for crediting or debiting earnings, gains, losses, and changes in value of Measuring Funds.
ARTICLE V.
DISTRIBUTIONS
5.01    Distribution Elections.
(a)Initial Election. Upon commencement of participation in the Plan and for each subsequent Plan Year, prior to the commencement of such Plan Year, a Participant will elect, in writing, which of the distribution options described in Section 5.02 will govern payment of the deferrals and applicable earnings credited thereon to Participant’s Account for the following Plan Year. Subject to Section 5.01(b) below, the election made under this subsection (a) shall be irrevocable as of the first day of the applicable Plan Year.
(b)Subsequent Election. A Participant may change the form of a distribution election with respect to all or a portion of his or her Account by submitting the change to the Committee, in writing, at least one calendar year before the originally scheduled distribution date. Unless otherwise approved by the Administrator in its sole discretion, only one change election under this paragraph (b) can be made for amounts credited to a Participant’s Account for any specific Plan Year. Any such change election will defer the timing of commencement of the distribution for five years after the originally scheduled distribution date. A change election made under this paragraph (b) shall be irrevocable as of the date that is one year prior to the originally scheduled distribution date. If such a subsequent election is not valid because, for example, it is not made in a timely manner, the Participant’s most recent effective distribution election will govern the payment of the Participant’s Account.
5.02    Distribution Options.
(a)Separation from Service. A Participant’s vested Account will be distributed to the Participant upon the Participant’s Separation from Service. A Participant may elect a distribution upon his or her Separation from Service in one of the following forms, subject to the timing requirements outlined in paragraph (c) below:
(i)Lump Sum. Payment in one lump sum within 90 days following the date of the Participant’s Separation from Service.
(ii)Installments. Payment in up to fifteen annual installments. Installment distributions will commence on January 1 of the calendar year immediately following the Participant’s Separation from Service. For purposes of this Plan, installment payments shall be treated as a single distribution under Section 409A of the Code.
(b)Timing. Subject to the provisions of paragraph (d) below, payments made pursuant to paragraph (a) above, will be made as soon as administratively practicable, but not later than 90 days after the applicable date or dates determined under Section 5.02(a) above.
(c)Default Distribution. If the Committee does not have a proper distribution election on file for a portion or all of a Participant’s Account, the vested portion of that Participant’s Account will be distributed to the Participant, following the Participant’s Separation from Service, in one lump sum as soon as administratively practicable, but not later than 90 days after the Participant’s Separation from Service.
(d)Delayed Distribution to Specified Employees. Notwithstanding any other provision of this Section 5.02 to the contrary, a distribution scheduled to be made to a Participant upon his or her Separation from Service who is identified as a Specified Employee as of the date he Separates from Service shall be delayed for a minimum of six months following the Participant’s Separation from Service. Any payment that otherwise would have been made pursuant to this Section 5.02 during the six-month period following the Participant’s Separation from Service shall be made as soon as administratively practicable, but not later than 90 days after the six-month anniversary of the Participant’s Separation from Service. The identification of a Participant as a



Specified Employee shall be made by the Committee in its sole discretion in accordance with Section 2.23 of the Plan and Sections 416(i) and 409A of the Code and the regulations promulgated thereunder.
(e)Limited Cashout. Notwithstanding the foregoing or anything in this Plan to the contrary, to the extent that the sum of Participant’s Account and account balance for any other plan or arrangement with respect to which deferrals of compensation are treated as having been deferred under a single nonqualified deferred compensation plan under Treasury Regulation § 1.409A-1(c)(2) is less than the limit under Section 402(g)(1)(A) of the Code at the time of Separation from Service, to the extent permitted by Section 409A and the regulations promulgated thereunder, the Company may cause the Account to be paid in a lump sum.
5.03    Subsequent Credits. Amounts, if any, that become payable to a Participant’s Account after distributions have begun from that Account, and before the Participant is rehired or dies, will, be paid out pursuant to the distribution election in effect for that Participant upon his or her Separation from Service.
5.04    Death or Disability. If a Participant dies or becomes Disabled with a vested amount in his or her Account, whether or not the Participant was receiving distributions from that Account at the time of his or her death or Disability, the Participant or his or her Beneficiary will receive the entire vested amount in the Participant’s Account in accordance with the distribution election made by the Participant. Such election must be made no later than the time of the Participant’s initial deferral election made in accordance with Article V in one of the following forms, subject to the timing requirements outlined in Section 5.02(b) above:
(a)Lump Sum. Payment in one lump sum.
(b)Installments. Payment in up to fifteen annual installments. Installment distributions will commence on January 1 of the calendar year immediately following the Participant’s death or Disability. For purposes of this Plan, installment payments shall be treated as a single distribution under Section 409A of the Code.
If no valid election is on file, the vested portion of Participant’s Account shall be distributed in a single lump sum. Distributions under this Section 5.04 shall be made as soon as administratively practicable, but not later than 90 days after Participant is determined to have a Disability or Participant’s death, as applicable.
5.05    Unforeseeable Emergency. In the event of a Participant’s Unforeseeable Emergency, and upon application by such Participant, the Committee may determine at its sole discretion that payment of all, or part, of such Participant’s Account shall be made in one lump sum payment with the last payroll of the month following the month in which the distribution is approved by the Committee. Payments due to a Participant’s Unforeseeable Emergency shall be permitted only to the extent reasonably required to satisfy the Participant’s need.
5.06    Prohibition on Acceleration. Notwithstanding any other provision of the Plan to the contrary, no distribution will be made from the Plan that would constitute an impermissible acceleration of payment as defined in Section 409A(a)(3) of the Code and the regulations promulgated thereunder.
5.07    Withholding. The Company will deduct from Plan distributions, or from other compensation payable to a Participant or Beneficiary, amounts required by law to be withheld for taxes with respect to benefits under this Plan. The Company reserves the right to reduce any deferral or contribution that would otherwise be made to this Plan on behalf of a Participant by a reasonable amount, and to use all or a portion of this reduction to satisfy the Participant’s tax liabilities under this Section 5.07.
ARTICLE VI.
MISCELLANEOUS
6.01    Limitation of Rights. Participation in this Plan does not give any individual the right to be retained in the service of the Company or of any related entity.
6.02    Satisfaction of Claims. Payments to a Participant, the Participant’s legal representative, or Beneficiary in accordance with the terms of this Plan will, to the extent thereof, be in full satisfaction of all claims that person may have hereunder against the Committee, the Company, and all Subsidiaries, any of which may



require, as a condition to payment, that the recipient execute a receipt and release in a form determined by the Committee, the Company, or an Subsidiary.
6.03    Claims and Review Procedure.
(a)Informal Resolution of Questions. Any Participant or Beneficiary who has questions or concerns about his or her benefits under the Plan is encouraged to communicate with The Clorox Company Executive Compensation Manager. If this discussion does not give the Participant or Beneficiary satisfactory results, a formal claim for benefits may be made within one year of the event giving rise to the claim in accordance with the procedures of this Section 6.03.
(b)Formal Benefits Claim — Review by Executive Compensation Manager. A Participant or Beneficiary may make a written request for review of any matter concerning his or her benefits under this Plan. The claim must be addressed to The Clorox Company Executive Retirement Plan, Attn: Executive Compensation Manager 1221 Broadway, Oakland, California 94612-1888. The Executive Compensation Manager shall decide the action to be taken with respect to any such request and may require additional information if necessary to process the request. The Executive Compensation Manager shall review the request and shall issue his or her decision, in writing, no later than 90 days after the date the request is received, unless the circumstances require an extension of time. If such an extension is required, written notice of the extension shall be furnished to the person making the request within the initial 90-day period, and the notice shall state the circumstances requiring the extension and the date by which the Executive Compensation Manager expects to reach a decision on the request. In no event shall the extension exceed a period of 90 days from the end of the initial period.
(c)Notice of Denied Request. If the Executive Compensation Manager denies a request in whole or in part, he or she shall provide the person making the request with written notice of the denial within the period specified in paragraph (b) above. The notice shall set forth the specific reason for the denial, reference to the specific Plan provisions upon which the denial is based, a description of any additional material or information necessary to perfect the request, an explanation of why such information is required, and an explanation of the Plan’s appeal procedures and the time limits applicable to such procedures, including a statement of the claimant’s right to bring a civil action under Section 502(a) of ERISA following an adverse benefit determination on review.
(d)Appeal to Committee.
(i)A person whose request has been denied in whole or in part (or such person’s authorized representative) may file an appeal of the decision in writing with the Committee within 60 days of receipt of the notification of denial. The appeal must be addressed to: The Clorox Company Executive Retirement Plan, 1221 Broadway, Oakland, California94612-1888. The Committee, for good cause shown, may extend the period during which the appeal may be filed for another 60 days. The appellant and/or his or her authorized representative shall be permitted to submit written comments, documents, records and other information relating to the claim for benefits. Upon request and free of charge, the applicant should be provided reasonable access to and copies of, all documents, records or other information relevant to the appellant’s claim.
(ii)The Committee’s review shall take into account all comments, documents, records and other information submitted by the appellant relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. The Committee shall not be restricted in its review to those provisions of the Plan cited in the original denial of the claim.
(iii)The Committee shall issue a written decision within a reasonable period of time but not later than 60 days after receipt of the appeal, unless special circumstances require an extension of time for processing, in which case the written decision shall be issued as soon as possible, but not later than 120 days after receipt of an appeal. If such an extension is required, written notice shall be furnished to the appellant within the initial 60-day period. This notice shall state the circumstances requiring the extension and the date by which the Committee expects to reach a decision on the appeal.



(iv)If the decision on the appeal denies the claim in whole or in part written notice shall be furnished to the appellant. Such notice shall state the reason(s) for the denial, including references to specific Plan provisions upon which the denial was based. The notice shall state that the appellant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claim for benefits. The notice shall describe any voluntary appeal procedures offered by the Plan and the appellant’s right to obtain the information about such procedures. The notice shall also include a statement of the appellant’s right to bring an action under Section 502(a) of ERISA.
(v)The decision of the Committee on the appeal shall be final, conclusive and binding upon all persons and shall be given the maximum possible deference allowed by law.
(e)Exhaustion of Remedies. No legal or equitable action for benefits under the Plan shall be brought unless and until the claimant has submitted a written claim for benefits in accordance with paragraph (b) above, has been notified that the claim is denied in accordance with paragraph (c) above, has filed a written request for a review of the claim in accordance with paragraph (d) above, and has been notified in writing that the Committee has affirmed the denial of the claim in accordance with paragraph (d) above; provided, however, that an action for benefits may be brought after the Executive Compensation Manager or Committee has failed to act on the claim within the time prescribed in paragraph (b) and paragraph (d), respectively.
6.04    Indemnification. The Company and its Subsidiaries will indemnify the Committee, the Board, and employees of the Company and its Subsidiaries to whom responsibilities have been delegated under the Plan for all liabilities and expenses arising from an act or omission in the management of the Plan if the person to be indemnified did not act dishonestly or otherwise in willful violation of the law under which the liability or expense arises.
6.05    Assignment.
(a)General. To the fullest extent permitted by law, rights to benefits under the Plan are not subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment, or garnishment by creditors of a Participant or a Beneficiary.
(b)Domestic Relations Orders. The procedures established by the Company for the determination of the qualified status of domestic relations orders and for making distributions under qualified domestic relations orders, as provided in Section 206(d) of ERISA, shall apply to the Plan, to the extent pertinent. Amounts awarded to an alternate payee under a qualified domestic relations order shall be distributed in the form of a lump sum distribution as soon as administratively feasible following the determination of the qualified status of the domestic relations order; provided, however, that no portion of the Participant’s unvested Account may be awarded to an alternate payee.
6.06    Lost Recipients. If the Committee cannot locate a person entitled to payment of a Plan benefit after a reasonable search, the Committee may at any time thereafter treat that person’s Account as forfeited and amounts credited to that Account will revert to the Company. If the lost person subsequently presents the Committee with a valid claim for the forfeited benefit amount, the Company will pay that person the amount forfeited.
6.07    Amendment. The Board may, at any time, amend the Plan in writing. In addition, the Committee may amend the Plan (other than this Section 6.07) in writing, provided that the amendment will not cause any substantial increase in cost to the Company or to any Subsidiary. No amendment may, without the consent of an affected Participant (or, if the Participant is deceased, the Participant’s Beneficiary), adversely affect the Participant’s or the Beneficiary’s rights and obligations under the Plan with respect to amounts already credited to a Participant’s Account, unless such amendment is required to comply with any provision of the Code, ERISA or other applicable law.
6.08    Suspension. The Board may, at any time, suspend the Plan.
6.09    Termination.



(a)General. The Board may terminate the Plan at any time and in the Board’s discretion the Accounts of Participants may be distributed within the period beginning twelve months after the date the Plan was terminated and ending twenty-four months after the date the Plan was terminated, or pursuant to Sections 5.02(a) of the Plan, if earlier. If the Plan is terminated and Accounts are distributed, the Company shall terminate all plans and arrangements (which would be treated as aggregated and having been deferred under a single plan under Treasury Regulation § 1.409A-1(c)(2)(i)(A)) with respect to all participants and shall not adopt a new account balance non-qualified deferred compensation plan for at least three years after the date the Plan was terminated.
(b)Change in Control. The Board, in its discretion, may terminate the Plan thirty days prior to or twelve months following a Change in Control and distribute the Accounts of the Participants (whether previously vested or unvested) within the twelve-month period following the termination of the Plan. If the Plan is terminated and Accounts are distributed, the Company shall terminate all plans and arrangements (which would be treated as aggregated and having been deferred under a single plan under Treasury Regulation § 1.409A-1(c)(2)(i)(A)) sponsored by the Company and all of the benefits of the terminated plans shall be distributed within twelve months following the termination of the plans.
(c)Dissolution or Bankruptcy. The Board, in its discretion, may terminate the Plan upon a corporate dissolution of the Company that is taxed under Section 331 of the Code or with the approval of a bankruptcy court pursuant to 11 U.S.C. Section 503(b)(1(A), provided that the Participants’ Accounts are distributed and included in the gross income of the Participants by the latest of (i) the calendar year in which the Plan terminates or (ii) the first calendar year in which payment of the Accounts is administratively practicable.
6.10    Applicable Law. To the extent not governed by Federal law, the Plan is governed by the laws of the State of California without choice of law rules.
6.11    Severability. If any one or more of the provisions contained in this Plan, or any application thereof, shall be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and all other applications thereof shall not in any way be affected or impaired thereby. This Plan shall be construed and enforced as if such invalid, illegal or unenforceable provision has never comprised a part hereof, and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the invalid, illegal or unenforceable provision or by its severance herefrom. In lieu of such invalid, illegal or unenforceable provisions there shall be added automatically as a part hereof a provision as similar in terms and economic effect to such invalid, illegal or unenforceable provision as may be possible and be valid, legal and enforceable.
6.12    No Funding. The Plan constitutes a promise by the Company and its Subsidiaries to make payments in the future in accordance with the terms of the Plan. Participants and Beneficiaries have the status of general unsecured creditors of the Company and its Subsidiaries. Plan benefits will be paid from the general assets of the Company and its Subsidiaries and nothing in the Plan will be construed to give any Participant or any other person rights to any specific assets of the Company or its Subsidiaries. In all events, it is the intention of the Company, all Subsidiaries and all Participants that the Plan be treated as unfunded for tax purposes and for purposes of Title I of ERISA.
6.13    Authority to Establish a Grantor Trust. The Committee is authorized in its sole discretion to establish a grantor trust for the purpose of providing security for the payment of Accounts under the Plan; provided, however, that no Participant or Beneficiary shall be considered to have a beneficial ownership interest (or any other sort of interest) in any specific asset of the Corporation or of its Subsidiaries as a result of the creation of such trust or the transfer of funds or other property to such trust. The Committee may establish such a trust at any time, including without limitation the time of a Change in Control.
6.14    Code Section 409A Compliance. To the extent applicable, it is intended that this Plan and any distributions hereunder comply with the requirements of Section 409A. Any provision that would cause the Plan or any distributions granted hereunder to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.




IN WITNESS WHEREOF, The Clorox Company has caused this Plan to be executed by its duly authorized representative on the date indicated below.
THE CLOROX COMPANY

_________________________________________ __________________________
NAME: DATE
_________________________________________
TITLE:

EX-19 3 fy24clxex19insidertradingp.htm EX-19 Document


imagea.jpg
Corporate Policy
Policy Title:
Insider Trading
Date Issued:
5/20/2024
Policy Category:
Ethics and Standards
References to “The Clorox Company”, “Clorox”, and “Company” refer to The Clorox Company and its subsidiary companies worldwide.
PURPOSE
Federal and state laws prohibit the buying, selling or making of other transfers of securities by persons who have material information regarding the issuer of those securities that is not generally known by or available to the public. These laws also prohibit persons with such information from disclosing it to others who then trade in the securities of the issuer to which the information relates.
The Company has adopted the following policy (this “Policy”) regarding transactions in securities of the Company when directors, officers, employees and independent contractors of the Company have Material Nonpublic Information. As discussed more fully below, “Material” information generally means information that is reasonably likely to be considered by a reasonable investor as important in making an investment decision to buy, hold or sell securities. “Nonpublic Information” is information that is not generally known by or available to the public.
You are responsible for ensuring that you do not violate federal or state securities laws or this Policy. We designed this Policy to promote compliance with the federal and state securities laws and to protect the Company and you from the serious liabilities and penalties that can result from violations of these laws.
If you violate the insider trading laws, you may have to pay civil fines of up to three times the profit gained or loss avoided by such trading, as well as criminal fines of up to $5 million per violation. You also may have to serve a jail sentence of up to 20 years. In addition, the Company could be subject to a civil fine of the greater of $1 million (as may be adjusted for inflation) or three times the profit gained or loss avoided as a result of an insider trading violation, as well as a criminal fine of up to $25 million per violation.
The Department of Justice (“DOJ”), the Securities and Exchange Commission (“SEC”) and the New York Stock Exchange (“NYSE”) are very effective at detecting and pursuing insider trading cases. The SEC and the DOJ have successfully prosecuted cases against employees and other insiders who traded through foreign accounts, insider trading by family members and friends of employees and other insiders, and insider trading involving only a small number of shares. Therefore, it is important that you understand the breadth of activities that constitute insider trading. This Policy sets out the Company’s policy in the area of insider trading and should be read carefully and complied with fully.
Directors, officers, employees and independent contractors of the Company should always consult Legal Services with any questions concerning this Policy.



POLICIES AND PROCEDURES
A.Trading Policy
Prohibited Trading
1.Trading While Aware of Material Nonpublic Information. Except to the extent permitted by Section E of “Policies and Procedures” hereof (Rule 10b5-1 Trading Plans), you may not trade in the stock or other securities of any company when you are aware of Material Nonpublic Information about that company.
This policy against “insider trading” applies to trading in both (a) Company securities, as well as to trading in (b) the securities of other companies, if you have Material Nonpublic Information with respect to that company gained through your work at the Company. For example, if you have Material Nonpublic Information that the Company is engaging in a confidential negotiation of a significant supply contract with Supplier A that may materially impact Supplier B, you may not trade in the stock or securities of the Company, Supplier A or Supplier B.
Transactions that you may think are necessary or justifiable for independent reasons (such as the need to raise money for a personal emergency expenditure) are not excepted from these restrictions. The securities laws do not recognize mitigating circumstances and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company’s reputation for adhering to the highest standards of conduct.
2.Tipping. You may not convey Material Nonpublic Information about a company to others or suggest that anyone purchase or sell any company’s securities while you are aware of Material Nonpublic Information about that company. This practice, known as “tipping”, violates the securities laws and can result in the same civil and criminal penalties that apply if you engage in insider trading directly, even if you do not receive any money or derive any benefit from trades made by persons to whom you passed Material Nonpublic Information. This policy against “tipping” applies to information about the Company and its securities, as well as to information about other companies. This policy does not restrict ordinary and legitimate business communications where you have a reasonable basis to expect that the other person will not trade while in possession of the information and will keep such information confidential.
3.Short Sales. Short sales of a security (i.e., the sale of a security that the seller does not own) by their nature reflect an expectation that the value of the security will decline. Short sales can create perverse incentives for the seller, and signal to the market a lack of confidence in the Company’s prospects. Accordingly, you are prohibited from engaging in a short sale of Company securities.
4.Publicly Traded Options. A put is a right to sell a security at a specific price before a set date, and a call is a right to buy a security at a specific price before a set date. Generally, put options are purchased when a person believes the value of a security will fall, and call options are purchased when a person believes the value of a security will rise. A transaction in options is, in effect, a bet on the short-term movement of the Company’s securities, and therefore creates the appearance of trading on the basis of material non-public information. Transactions in options may also focus your attention on short-term performance at the expense of the Company’s long-term objectives. Accordingly, you are prohibited from engaging in a put, call or other derivative security transaction relating to Company securities on an exchange or in any other organized market.
5.Hedging. You are prohibited from engaging in hedging transactions in Company securities. A hedging transaction is the purchase of a financial instrument to, or otherwise engaging in a transaction that is designed to, hedge or offset, any decrease in the market value of the Company’s equity securities that were granted to you as part of your compensation or that you hold directly or indirectly. Examples of hedging transactions include pre-paid forward contracts, equity swaps and collars. Because participating in these transactions may cause a person to no longer have the same objectives as the Company’s other shareholders, no person subject to this Policy may engage in such transactions.



6.Pledging. Directors, officers and their Related Entities are prohibited from holding Company securities in a margin account unless all Company securities held in such account are blocked from being margined. These persons are also prohibited from pledging Company securities as collateral. While holding Company securities in a margin account or pledging Company securities as collateral by independent contractors or employees is not prohibited by this Policy, such employees who are not directors, officers or their Related Entities should exercise caution when considering whether to do so. Because securities held in a margin account or pledged as collateral may be sold without consent if there is a failure to meet a margin call or if there is a default on a loan, a margin or foreclosure sale may result in insider trading.
The foregoing restrictions apply to all directors, officers, employees and independent contractors of the Company. The restrictions also apply to transactions in Company securities by any of the following individuals and entities (collectively, “Related Entities”):
anyone who lives in your household,
any family members whose transactions in Company securities are directed by, or are subject to, your influence or control,
any corporation or other entity controlled or managed by you, and
trusts for which you are the trustee or with respect to which you have the ability to vote or dispose of Company securities in the trust.
These restrictions apply to any Company securities over which you have voting or dispositive power, as well as Company securities that you own. The SEC and federal prosecutors may presume that trading by family members is based on information you supplied and may treat any such transactions as if you had traded yourself. There is no exception for small transactions or transactions that may seem necessary or justifiable for independent reasons, such as the need to raise money for an emergency expenditure.
For purposes of this Policy, references to “trading” and “transactions” include, among other things:
any purchases and sales of Company securities, including sales of Company securities obtained through the exercise of employee stock options granted by the Company, gifts of Company securities (including charitable donations); or
pledges of Company securities to secure a loan, as described in greater detail above.
Applicability of Policy to Benefit Plans
The restrictions in this Policy do not apply to
the exercise of Company stock options, including where you pay the exercise price and tax withholding using cash out-of-pocket or as a result of a net exercise of the options, if no shares are sold;
the vesting or settlement of Company stock options, performance shares, performance share units, restricted stock or restricted stock units if no shares are sold; or
the withholding by the Company of shares to satisfy a tax withholding obligation upon the vesting of performance shares, performance share units, restricted stock or restricted stock units if no shares are sold.
Therefore, you may freely exercise your stock options and have the Company withhold shares to satisfy your tax obligations without violating this Policy so long as no shares are sold in violation of this Policy.
The restrictions in this Policy also do not apply to periodic purchases of the Company stock fund in the Company’s 401(k) plan, provided that such purchases are the result of a payroll deduction election that you made (a) at a time when you were not aware of Material Nonpublic Information and (b) while the Window Period (defined below) was open (to the extent applicable to you). Thus, for example, if you made an election to contribute 5% of your income each pay period to the Company’s stock fund in the Company’s 401(k) plan and such election was made at a time when you were both not aware of Material Nonpublic Information and in conformance with the Window Period



requirements (to the extent applicable to you), periodic purchases through the Company’s 401(k) plan would not violate the restrictions in this Policy (even if, for example, the purchase occurs at a time when you are aware of Material Nonpublic Information).
The following elections may only be made at a time when you are not aware of Material Nonpublic Information and in conformance with the Window Period and preclearance requirements (to the extent applicable to you): (a) to begin or terminate investing in the Company stock fund of the 401(k) plan; (b) to increase or decrease the percentage of your periodic contributions that will be allocated to the Company stock fund of the 401(k) plan (for example, to reduce your periodic contribution to the Company stock fund from 5% of your income to a lower percentage of your income); (c) to make an intra-plan transfer of an existing account balance into or out of the Company stock fund (for example, to transfer $10,000 or another amount you have invested in the Company stock fund to another investment option under the Company’s 401(k) plan); (d) to borrow money, to the extent otherwise permitted, against your 401(k) plan account if you have invested in the Company stock fund of the 401(k) plan; and (e) to pre-pay a 401(k) plan loan if the pre-payment will result in allocation of loan proceeds to the Company stock fund.
This Policy does not apply to purchases of Company stock in the Company’s employee stock purchase plan resulting from your periodic contributions of money to the plan pursuant to a payroll deduction election made while the Window Period (to the extent applicable to you) was open and you were not in possession of Material Nonpublic Information, subject to the preclearance process (to the extent applicable to you). However, this Policy does apply to any: (a) election to participate in the plan for an enrollment period; (b) increase or decrease in your amount of periodic contributions to or direct purchase/sell orders under the plan; and (c) sales of Company stock pursuant to the plan.
To the extent that you participate in the Company’s Direct Stock Purchase and Dividend Reinvestment Plan, this Policy does not apply to purchases of Company stock under the plan resulting from an election to reinvest dividends made while the Window Period (to the extent applicable to you) was open and you were not in possession of Material Nonpublic Information, subject to the preclearance process (to the extent applicable to you). However, this Policy does apply to any: (a) election to participate in the plan; (b) increase or decrease in your level of participation in the plan; and (c) sale of Company stock purchased pursuant to the plan.
Directors, officers, employees and independent contractors of the Company should always consult Legal Services if they have any questions.
Company Transactions
From time to time, the Company may engage in transactions in its own securities. It is the Company’s policy to comply with all applicable securities and state laws (including appropriate approvals by the Board of Directors or appropriate committee, if required) when engaging in transactions in Company securities.
B.What is "Material Nonpublic Information"?
1.Material Information
Material information generally means information that is reasonably likely to be considered by a reasonable investor as important in making an investment decision to buy, hold, or sell securities. Either positive or negative information may be material. Depending on the circumstances, common examples of information that may be material include:
earnings, revenue, or similar financial information;
financial or operational results (both positive and negative);
unpublished financial or operational reports or projections;
extraordinary borrowing, liquidity or bankruptcy concerns or developments;
changes in control (e.g., mergers, acquisitions and dispositions or actions by activist investors);
changes in directors, senior management or auditors;



information about current, proposed, or contemplated transactions (including disposition/acquisitions of significant assets or a subsidiary), business plans, financial restructurings or significant expansions or contractions of operations;
changes in dividend policies or the declaration of a stock split or the proposed or contemplated issuance, redemption, or repurchase of securities (e.g., share buyback programs);
material defaults under agreements or actions by creditors, clients, or suppliers relating to a company’s credit rating;
information about major contracts, including the gain or loss of a substantial customer or supplier;
significant new product developments or innovations;
significant interruption of production or other aspects of a company’s business as a result of an accident, a fire, a natural disaster, a pandemic, a breakdown of labor negotiations, a cybersecurity incident, or otherwise;
significant cybersecurity incidents (e.g., breach of or unauthorized access to information technology infrastructure and/or data) and identified significant cybersecurity vulnerabilities;
significant product defects, modifications or product recalls;
significant pricing changes;
major environmental incidents; and
institution of, or developments in, major litigation, investigations, or regulatory actions or proceedings.
This list is for illustrative purposes only and is not an exhaustive list of all types of material information. Federal and NYSE investigators will scrutinize a questionable trade after the fact with the benefit of hindsight, so if information is not clearly immaterial or already public you should always err on the side of deciding that information is Material Nonpublic Information and not trade. If you have questions regarding specific information or transactions, please contact Legal Services.
2.Nonpublic Information
Nonpublic information is information that is not generally known or available to the public. We consider information to be available to the public only when:
it has been released to the public by the Company through appropriate channels (e.g., by means of a press release, public filing or a widely disseminated statement from a senior officer); and
enough time has elapsed to permit the investment market to absorb and evaluate the information. You should generally consider information to be nonpublic until one full trading day has elapsed following public disclosure.
C.Unauthorized Disclosure
All directors, officers, employees and independent contractors of the Company must maintain the confidentiality of Company information for competitive, security and other business reasons, as well as to comply with securities laws. All information you learn about the Company or its business plans is nonpublic information until we publicly disclose it. You should treat this information as confidential and proprietary to the Company. You may not disclose it to others, such as family members, other relatives, or business or social acquaintances. You must exercise caution when having confidential conversations or viewing, printing and distributing confidential information, including in the presence of family members, and abide by the guidelines set forth in the Company’s policies that address the handling of the Company’s confidential information. Furthermore, you are expressly prohibited from disclosing Company information to, or participating in, so-called “expert networks,” or entities that provide specialized or industry information to investment firms. Further, in order to help ensure that such information does not become



widely known and is not leaked, it is also our policy that internal dissemination of proprietary information is limited to those persons that have a business need to have such information in order to perform their duties within our organization.
Also, legal rules govern the timing and nature of our disclosure of material information to outsiders or the public. Violation of these rules could result in substantial liability, including criminal liability, for you, the Company and its management. For this reason, we permit only specifically designated representatives of the Company to discuss the Company with the news media, securities analysts and investors and only in accordance with the Company’s policies. If you receive inquiries of this nature, refer them to Corporate Communications.
Finally, this Policy prohibits the knowing dissemination of information about the Company that is false or misleading, whether you are the source of the statement or are transmitting a false or misleading statement produced by another.
D.When and How to Trade Company Securities
1.Overview
Directors, executive officers and certain other employees and independent contractors who are so designated from time to time and are informed of their status by Legal Services (such executive officers and designated employees and independent contractors, “Restricted Employees”) are for purposes of this Policy required to comply with the Window Period restrictions covered below. Even if you are not a director or a Restricted Employee, however, following the procedures listed below may assist you in complying with this Policy.
2.Window Periods
Except as permitted by Section E of “Policies and Procedures” hereof (Rule 10b5-1 Trading Plans), directors and Restricted Employees may only trade in Company securities from the date that is one full trading day after an earnings release is issued to the end of business on the date that is three weeks prior to the end of the quarter for which that earnings release is issued (such period, the “Window Period”). This Policy also applies to the Related Entities of directors and Restricted Employees.
However, even if the Window Period is open, except as permitted by Section E of “Policies and Procedures” hereof (Rule 10b5-1 Trading Plans), you may not trade in Company securities if you are aware of Material Nonpublic Information about the Company. You are responsible for determining whether you are aware or in possession of Material Nonpublic Information, and you should consult with Legal Services if you are uncertain or have any questions. In addition, except as permitted by Section E of “Policies and Procedures” hereof (Rule 10b5-1 Trading Plans), if you are subject to the Company’s preclearance process (described below), you must preclear transactions even if you initiate them when the Window Period is open.
From time to time, the Company may institute special restrictions on trading due to material developments or other reasons, such as a Pension Fund Blackout Period, as described below. In such events, Legal Services may notify directors, Restricted Employees and any person otherwise subject to this Policy that they should not engage in any transactions involving the purchase or sale of Company securities and should not disclose to others the fact that special restrictions on trading have been instituted that preclude them from trading in Company securities.
In general, directors and Restricted Employees are prohibited from directly or indirectly trading in Company securities during any period of more than three consecutive days during which at least 50% of the participants or beneficiaries in all “individual account” retirement plans of the Company or its subsidiaries are unable to purchase, sell or otherwise acquire or transfer an interest in the equity of the Company held in such plans due to a temporary suspension by the Company or a fiduciary (“Pension Fund Blackout Period”). “Individual account” retirement plans include, without limitation, defined contribution plans such as broad-based tax-qualified 401(k) plans and profit sharing plans, stock bonus plans and certain nonqualified deferred compensation arrangements. Transactions permitted by Section E of “Policies and Procedures” hereof (Rule 10b5-1 Trading Plans) and certain other transactions are exempt from this prohibition. Directors and Restricted Employees should consult with Legal Services prior to attempting a stock transaction during a Pension Fund Blackout Period other than pursuant to a Rule 10b5-1 plan entered into in accordance with Section E of “Policies and Procedures” hereof.



Even if the Window Period is closed, you may exercise Company stock options if no shares are sold and if you exercise a tax withholding right pursuant to which you elect to have the Company withhold shares subject to an option to satisfy tax withholding obligations, subject to any pre-clearance requirements (if applicable) as described elsewhere in this Policy. You may not, however, effect sales of stock issued upon the exercise of stock options or that you received as a result of the vesting or settlement of Company stock options, performance shares, performance share units, restricted stock or restricted stock units while the Window Period is closed. Except for approved transactions pursuant to a Rule 10b5-1 plan, all pending purchase and sale orders regarding Company securities that could be executed while the Window Period is open must be completed or cancelled before it closes.
In light of these restrictions, if you expect a need to sell Company stock at a specific time in the future, you may wish to consider entering into a prearranged Rule 10b5-1 trading plan, as discussed in Section E of “Policies and Procedures” hereof.
3.Preclearance Process
The Company requires its directors, executive officers, Grade 32 and above vice presidents, and certain employees designated from time to time (such officers and employees, “Preclearance Employees”) to obtain preclearance approval from the Chief Legal Officer or Corporate Secretary (and in the case of a Clorox Executive Committee member, copying the Chief Executive Officer and the Chief People Officer on such request) in advance of effecting any purchase, sale, gift or other trading of Company securities. The procedures for requesting preclearance approval have been or will be communicated to the Preclearance Employees. Preclearance Employees must obtain preclearance approval even if they are initiating a transaction while a Window Period is open. The Related Entities of Preclearance Employees also must obtain preclearance approval before purchasing, selling or otherwise trading in Company securities.
If a transaction is precleared under the preclearance process, the transaction must be executed within two business days after the preclearance is obtained, but regardless may not be executed if you acquire Material Nonpublic Information concerning the Company during that time. If a transaction is not completed within the period described above, the transaction must be precleared again before it may be executed.
If a proposed transaction is not precleared under the preclearance process, you should refrain from initiating any transaction in Company securities, and you should not inform anyone within or outside of the Company of the failure to receive preclearance. Transactions pursuant to a Rule 10b5-1 trading plan (discussed below in Section E) do not require preclearance at the time of the transaction, but entry into the Rule 10b5-1 trading plan requires preclearance.
E.Rule 10b5-1 Trading Plans
Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “1934 Act”), provides for an affirmative defense against insider trading liability if a trade occurs pursuant to a pre-arranged “trading plan” that meets specified conditions. Specifically, a purchase or sale will not be deemed to be made on the basis of Material Nonpublic Information and, therefore, will not violate the insider trading laws, if the trade is made pursuant to a trading plan that complies with the conditions in Rule 10b5-1, including that the plan: (a) specifies the terms under which securities are to be purchased or sold, and (b) is established during an open Window Period and at a time when you are not aware of Material Nonpublic Information. A trading plan under the rule may specify the amount, price and date of purchases or sales, set forth a formula for those requirements or specify trading parameters that another person has discretion to administer, but you must not exercise any subsequent discretion affecting the transactions, and, if your broker or any other person exercises discretion in implementing the trades, you must not influence his or her actions and he or she must not be aware of any Material Nonpublic Information at the time of the trades. Trading plans can be established for a single trade or a series of trades; however, in no event may any employee, officer or director have more than one Rule 10b5-1 trading plan in effect at any given time, subject to certain exceptions that are permissible under Rule 10b5-1. Further, if a Rule 10b5-1 trading plan is designed to effect the purchase or sale of Company securities in a single transaction, you may not have had another single-trade plan (Rule 10b5-1 or otherwise) during the prior 12-month period.



It is important that you properly document the details of a trading plan. In addition, there are a number of additional procedural conditions to Rule 10b5-1 that must be satisfied before you can rely on a trading plan as an affirmative defense against an insider trading charge. These requirements include, among other things, that you act in good faith, that you do not modify your trading instructions while you are aware of Material Nonpublic Information and that you not enter into or alter a corresponding or hedging transaction or position. Because this rule is complex, the Company recommends that you work with a broker and be sure you fully understand the limitations and conditions of the rule before you establish a trading plan.
Any adoption or amendment of a Rule 10b5-1 trading plan may occur only in an open Window Period when you are not aware of Material Nonpublic Information. No such plan can be adopted or amended during any periods in which special restrictions on trading are in effect, such as a Pension Fund Blackout Period. No trades under a plan may take place until the later of 90 days after the plan has been adopted or amended, or two business days after the Company has filed its 10-Q or 10-K for the quarter in which the trading plan was adopted. Any amendment or modification of a Rule 10b5-1 plan (including by canceling a trade or modifying the amount, price or timing of a purchase or sale) will be considered an adoption of a new Rule 10b5-1 plan and subject to these requirements.
All Rule 10b5-1 plans and instructions are required to be reviewed and approved by Legal Services, with notification to the Chief Executive Officer and Chief People Officer through the appropriate channels, prior to implementing any such plan or instruction. In addition, any amendment or termination of a Rule 10b5-1 trading plan must be reviewed and approved in advance by Legal Services, and the Chief Executive Officer and Chief People Officer notified through the appropriate channels.
F.Certification/Training
Restricted Employees will be required periodically to certify their understanding of and compliance with this Policy and complete training regarding insider trading.
G.Noncompliance
Each employee who fails to comply with this Policy or who refuses to certify that he or she has complied with it will be subject to disciplinary action, which could include termination of employment.
H.Post-Termination Transactions
This Policy continues to apply to transactions in Company securities even after termination of service with the Company. If an individual is in possession of Material Nonpublic Information when his or her service terminates, that individual may not trade in Company securities until that information has become public or is no longer material. Furthermore, Section 16 of the 1934 Act and Rule 144 under the Securities Act of 1933, as amended (the “1933 Act”), both of which are described below, may continue to apply to you for some time after your termination of service. The preclearance procedures specified under Section D.3. Preclearance Process of “Policies and Procedures” hereof will cease to apply to transactions in Company securities upon the expiration of any Company-imposed trading restrictions applicable at the time of the termination of service, including a closed Window Period.
ADDITIONAL SECURITIES LAW MATTERS
A.Section 16
Directors, executive officers, the principal accounting officer and beneficial owners of 10% or more of the Company’s common stock (each, a “Section 16 Insider”) will also be required to comply with the reporting obligations and limitations on short-swing transactions set forth in Section 16 of the 1934 Act (“Section 16”). The practical effect of these provisions is that (a) Section 16 Insiders will be required to report their beneficial ownership of common stock and other equity securities (including derivatives) of the Company and transactions in Company securities (usually within two business days of the date of the transaction) and (b) Section 16 Insiders are deterred from short -term speculative trading (generally defined as selling Company securities within six months following a purchase or buying Company securities within six months following a sale). Any Section 16 Insider who purchases and sells Company securities within a six-month period will be required to disgorge all deemed profits to the Company, regardless of whether they had knowledge of any Material Nonpublic Information. Since deemed profit



can exist due to how the Section 16 rules match any buy and sell trades in the period, even if there were an actual loss or a tax loss, Section 16 Insiders should consult with their external financial and tax advisors to fully understand the consequences of any trades conducted within a six-month period. For purposes of Section 16, Section 16 Insiders are treated as the beneficial owners of securities held by family members sharing their household.
The Company has provided separate materials to the directors and executive officers regarding compliance with Section 16 and its related rules.
B.Rule 144
If you are a director or an executive officer, you may be deemed to be an “affiliate” of the Company. Consequently, shares of Company common stock held by you may be considered to be “control securities,” the sale of which is subject to compliance with Rule 144 under the 1933 Act (or any other applicable exemption under the federal securities laws). If this is the case, note that Rule 144 places limits on the number of shares you may be able to sell and provides that certain procedures must be followed before you can sell shares of Company common stock. Contact Legal Services for more information on Rule 144.

EX-21 4 fy24clxex21subsidiaries.htm EX-21 Document

Exhibit 21
Name of CompanyJurisdiction of Incorporation
6570 Donlon Group, LLCDelaware
A & M Products Manufacturing CompanyDelaware
Iodine Holdings, Inc.Connecticut
Brita Canada CorporationNova Scotia
Brita Canada Holdings CorporationNova Scotia
Brita GPOntario
Brita GP, LLC
Delaware
Brita LPOntario
Brita Manufacturing CompanyDelaware
The Brita Products CompanyDelaware
BGP (Switzerland) S. a. r. l.Switzerland
Burt’s Bees, Inc.Delaware
Burt’s Bees International HoldingsDelaware
Burt’s Bees Licensing, LLCDelaware
The Burt’s Bees Products CompanyDelaware
Caltech Industries, Inc.Michigan
CBee (Europe) LimitedUnited Kingdom
Chesapeake Assurance LimitedHawaii
Clorox Africa (Proprietary) Ltd.South Africa
Clorox Africa Holdings (Proprietary) Ltd.South Africa
Clorox Australasia Holdings, Inc.Delaware
Clorox Australia Pty. Ltd.Australia
Clorox Brazil Holdings LLCDelaware
Clorox (Cayman Islands) Ltd.Cayman Islands
Clorox Chile S.A.Chile
Clorox China (Guangzhou) Ltd.Guangzhou, P.R.C.
Clorox Commercial CompanyDelaware
The Clorox Company of Canada, Ltd.
Canada (Federal)
Clorox de Centro America, S.A.Costa Rica
Clorox de Colombia S.A.Colombia
Clorox de Mexico, S de RL de C.V.
Mexico
Clorox de Panama S.A.Panama
Clorox del Ecuador S.A. EcuacloroxEcuador
Clorox Diamond Production CompanyDelaware
Clorox Healthcare Holdings, LLCDelaware
Clorox Holdings Pty. LimitedAustralia
Clorox Hong Kong LimitedHong Kong
The Clorox International CompanyDelaware
Clorox International Holdings, LLCDelaware
Clorox International Philippines, Inc.The Philippines
Clorox Ireland Limited
Ireland
Clorox Luxembourg S.a.r.l.Luxembourg
Clorox (Malaysia) Sdn. Bhd.Malaysia
Clorox Manufacturing CompanyDelaware
Clorox Manufacturing Company of Puerto Rico, Inc.Puerto Rico
Clorox Mexico Services Company S. de R.L. de C.V.
Mexico
Clorox New Zealand LimitedNew Zealand



The Clorox Outdoor Products CompanyDelaware
Clorox Peru S.A.Peru
The Clorox Pet Products CompanyTexas
Clorox Professional Products CompanyDelaware
The Clorox Sales CompanyDelaware
Clorox Services CompanyDelaware
Clorox Spain, S.L.Spain
Clorox Sub-Sahara Africa LimitedKenya
Clorox (Switzerland) S.a.r.l.Switzerland
The Consumer Learning Center, LLCDelaware
Corporacion Clorox de Venezuela, S.A.Venezuela
CLX Realty Co.Delaware
Dallarm Servicios Corporativos S.A.U.
Argentina
Everest NeoCell LLCDelaware
First Brands (Bermuda) LimitedBermuda
First Brands CorporationDelaware
First Brands do Brasil Ltda.Brazil
Fully Will LimitedHong Kong
Gazoontite, LLCDelaware
Glad Manufacturing CompanyDelaware
The Glad Products CompanyDelaware
The Household Cleaning Products Company of Egypt Ltd.Egypt
The HV Food Products CompanyDelaware
HV Manufacturing CompanyDelaware
Invermark S.A.Argentina
Jingles LLCDelaware
Kingsford Manufacturing CompanyDelaware
The Kingsford Products Company, LLCDelaware
Lerwood Holdings LimitedBritish Virgin Islands
The Mexco CompanyDelaware
Mohamed Ali Abudawood for Industry and Partners for Industry Company Ltd.Kingdom of Saudi Arabia
National Cleaning Products Company LimitedKingdom of Saudi Arabia
Nature’s Products, Inc. Florida
Nutranext, LLCDelaware
Nutranext Business, LLCDelaware
Nutranext Direct, LLCDelaware
Paulsboro Packaging Inc.New Jersey
Petroplus Productos Automotivos S.A.Brazil
Petroplus Sul Comercio Exterior S.A.Brazil
Rainbow Light Nutritional Systems, LLCDelaware
ReNew Life Formulas, LLCDelaware
ReNew Life Holdings CorporationDelaware
Round Ridge Production CompanyDelaware
Soy Vay Enterprises, Inc.California
STP do Brasil Ltda.Brazil
Yuhan-Clorox Co., Ltd.Korea

EX-23 5 fy24clxex23consentofindepe.htm EX-23 Document

Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-3 No. 333-264693) and in the related Prospectuses of The Clorox Company, and

(2)Registration Statements (Form S-8 Nos. 33-56563, 33-56565, 33-41131, including post effective amendments No. 1 and No. 2, 333-16969, 333-29375, 333-44675, 333-69455, including post effective amendment No. 1, 333-86783, 333-90386, including the post effective amendment No. 1, 333-131487, 333-193913 and 333-213161) of The Clorox Company;
of our reports dated August 8, 2024, with respect to the consolidated financial statements of The Clorox Company and the effectiveness of internal control over financial reporting of The Clorox Company included in this Annual Report (Form 10-K) of The Clorox Company for the year ended June 30, 2024.
/s/ Ernst & Young LLP
San Francisco, California
August 8, 2024


EX-31.1 6 fy24clxex311certificationo.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Linda Rendle, certify that:
1.I have reviewed this annual report on Form 10-K of The Clorox Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2024
/s/ Linda Rendle
Linda Rendle
Chair and Chief Executive Officer


EX-31.2 7 fy24clxex312certificationo.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Kevin B. Jacobsen, certify that:
1.I have reviewed this annual report on Form 10-K of The Clorox Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2024
/s/ Kevin B. Jacobsen
Kevin B. Jacobsen
Executive Vice President - Chief Financial Officer


EX-32 8 fy24clxex32certificationof.htm EX-32 Document

Exhibit 32
CERTIFICATION

In connection with the periodic report of The Clorox Company (the “Company”) on Form 10-K for the period ended June 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), we, Linda Rendle, Chair and Chief Executive Officer of the Company, and Kevin B. Jacobsen, Executive Vice President – Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to our knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: August 8, 2024

/s/ Linda Rendle 
Linda Rendle
Chair and Chief Executive Officer
 
  
/s/ Kevin B. Jacobsen 
Kevin B. Jacobsen
Executive Vice President – Chief Financial Officer


EX-97 9 fy24clxex97thecloroxcompan.htm EX-97 Document

THE CLOROX COMPANY
POLICY REGARDING CLAWBACK OF INCENTIVE COMPENSATION

As Amended and Restated
Approval Date: November 14, 2023
Effective Date: October 2, 2023
The Management Development and Compensation Committee of the Board of Directors of The Clorox Company (the “Committee”) has determined that it is in the best interest of The Clorox Company (“CLX”) and its shareholders to implement this Policy Regarding Clawback of Incentive Compensation, as it may be amended from time to time (this “Clawback Policy”, which shall constitute the Restatement Clawback Policy in Part A and the Detrimental Conduct Policy in Part B). With respect to terms defined in both Part A and Part B of this Clawback Policy, the terms shall have the meaning assigned to them in each of Part A and Part B, as the context requires.
Part A: Restatement Clawback Policy Under Dodd Frank
I.Introduction
This Restatement Clawback Policy (the “Restatement Clawback Policy”) is intended to be construed to the greatest extent consistent with, and is subject to amendment from time to time as the Committee may deem necessary in order to comply with, the rules related to clawback as may be required by the New York Stock Exchange (the “NYSE”), the Securities and Exchange Commission (the “SEC”) or other applicable regulatory agency, (the “Clawback Rules”) with such amendments having retroactive effect to the greatest extent permitted by applicable law.
This Restatement Clawback Policy establishes and reserves the right of CLX and its subsidiaries (as such term is defined in Rule 405 under the Securities Act of 1933, as amended, collectively and together with CLX, the “Company”) to recoup Incentive Compensation (as defined below) made to Covered Employees (as defined below) in circumstances involving a Financial Restatement (as defined below).
This Restatement Clawback Policy is effective with respect to all Incentive Compensation (as defined below) received by a Covered Employee on or after the Effective Date, including such Incentive Compensation deemed to be received by such employee within the meaning of the Clawback Rules.
II.Administration
The Committee shall have full authority to administer this Restatement Clawback Policy. However, the Committee's discretion in the interpretation or application of the Restatement Clawback Policy shall only be permitted to the extent permitted by the Clawback Rules. Any determinations made by the Committee shall be final and binding on all affected individuals and need not be uniform with respect to each individual covered by this Restatement Clawback Policy. Subject to any limitation under applicable law (including all prohibition on discretion in the Clawback Rules), the Board of Directors of CLX and/or the Committee may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Restatement Clawback Policy (other than with respect to any recovery under this Restatement Clawback Policy involving such officer or employee).
III.Defined Terms
For purposes of this Restatement Clawback Policy:
Applicable Recovery Period” shall mean the three completed fiscal years immediately preceding the date CLX is required to prepare an accounting restatement, determined in accordance with Section 303A.14 of the NYSE Listed Company Manual, including any transition period as contemplated by Section 303A.14 of the NYSE Listed Company Manual.



Covered Employee” shall mean any individual who is (or was at any time during the Applicable Recovery Period) an executive officer of CLX (within the meaning of the Clawback Rules), whether or not such individual is aware of such individual’s status as a “Covered Employee”.
“Financial Reporting Measure” shall mean any measure or measures that are determined and presented in accordance with the accounting principles used in preparing CLX's financial statements, and any measures that are derived wholly or in part from such measures (including stock price and total shareholder return, and regardless of whether such measure is presented within any financial statements or filed with the SEC).
Financial Restatement” shall mean CLX’s issuance of an accounting restatement due to the material noncompliance of CLX with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
Incentive Compensation” shall mean all compensation that is granted, earned, or vested wholly or in part upon the attainment of any Financial Reporting Measure.
Clawback” shall mean the recapture, recovery, cancellation or forfeiture of Incentive Compensation, whether or not such Incentive Compensation already has been vested or been paid.
IV.Clawback
a.Financial Restatement. On and after the Effective Date of this Restatement Clawback Policy, the Committee will reasonably promptly seek Clawback of any Incentive Compensation that was granted, promised, paid, earned, vested or otherwise awarded to a Covered Employee during the Applicable Recovery Period, but that is deemed to be erroneously awarded within the meaning of Section 303A.14 of the NYSE Listed Company Manual. Incentive Compensation is deemed received in the fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.
b.Amount and Method of Clawback. In the event that Clawback is required, the Committee has discretion to determine the methods by which to carry out the Clawback. The Committee shall seek to recover Incentive Compensation received during the relevant period in excess of the amount that otherwise would have been paid had the compensation amount been determined based on the Financial Restatement, except to the extent permitted to be waived pursuant to the Clawback Rules (e.g., where such pursuit of recovery would be impracticable, which includes situations in which the direct expense paid to a third party to assist in enforcing the recovery would exceed the amount to be recovered, or affect the tax status of certain qualified retirement plans). All calculations of Clawback shall be done on a pre-tax basis, regardless of whether the Covered Employee can recover previously paid taxes. For Incentive Compensation based on stock price or total shareholder return where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the applicable Financial Restatement, the amount shall be determined by the Committee based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive Compensation was received (in which case, the Company shall maintain documentation of such determination of that reasonable estimate and provide such documentation to the NYSE). The Committee (or its duly authorized delegate, if applicable) will act in accordance with the listing standard and requirements of NYSE in the implementation of and compliance with this Restatement Clawback Policy, including with respect to any supplementary documentation that may be required in connection with determinations under this Restatement Clawback Policy. The Committee is authorized to engage, on behalf of the Company, any third-party advisors it deems advisable in order to perform any calculations contemplated by this Restatement Clawback Policy. For the avoidance of doubt, recovery under this Restatement Clawback Policy with respect to a Covered Employee shall not require the finding of any misconduct by such Covered Employee or such Covered Employee being found responsible for the accounting error leading to a Financial Restatement.



c.Reporting and Disclosure. The Company shall file all disclosures with respect to this Restatement Clawback Policy in accordance with the requirements of U.S. federal securities laws, including any disclosure required by applicable SEC rules.
V.General Provisions
The Committee, in its discretion, may modify or amend, in whole or in part, any or all of the provisions of this Restatement Clawback Policy, to the extent that the Restatement Clawback Policy remains in compliance with the Clawback Rules and the listing exchange standards. Nothing in this Restatement Clawback Policy is intended or should be deemed to limit or restrict the Company from providing for Clawback of Incentive Compensation under any circumstances, including as required by statute or the rules of any exchange on which shares of CLX are listed for trading.
In no event shall any Covered Employee be entitled to any indemnification or insurance coverage by the Company or advancement of litigation expenses for any disputes concerning Clawback or this Restatement Clawback Policy. Further, the Company shall not enter into any agreement that exempts any Incentive Compensation from the application of this Restatement Clawback Policy or that waives the Company’s right to recovery of any erroneously awarded Incentive Compensation and this Clawback Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date). Any such purported indemnification (whether oral or in writing) shall be null and void.
The provisions hereof are intended to be effective only to the maximum extent permitted by applicable law. In the event any provision of this Restatement Clawback Policy is determined to be unenforceable or invalid under applicable law, such provision shall be applied to the maximum extent permitted by applicable law and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required by applicable law. This Restatement Clawback Policy shall be construed so as not to violate any contract, agreement, compensation plan, law or regulation. Nothing in this Restatement Clawback Policy is designed or intended to limit or restrict the Committee from taking any other action, including disciplinary or legal, as it deems appropriate.
This Restatement Clawback Policy shall be binding and enforceable against all Covered Employees and their beneficiaries, heirs, executors, administrators or other legal representatives, without regard to any acknowledgment of or execution of any agreement relating to the Restatement Clawback Policy by such individuals. Covered Employees shall be deemed to have accepted continuing employment on terms that include compliance with this Restatement Clawback Policy, to the extent of its otherwise applicable provisions, and to be contractually bound by its enforcement provisions. Covered Employees who cease employment or service with the Company shall continue to be bound by the applicable terms of this Restatement Clawback Policy. Notwithstanding the foregoing, the Board of Directors or the Committee may require that any employment agreement, equity award agreement, or any other agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Employee to agree to abide by the terms of this Restatement Clawback Policy.
Part B: Detrimental Conduct Clawback Policy
I.Introduction
The Committee has determined that it is in the best interest of CLX and its shareholders to implement this supplemental Detrimental Conduct Clawback Policy, as it may be amended from time to time (this “Detrimental Conduct Clawback Policy”, together with the Restatement Clawback Policy, the “Clawback Policy”).
This Detrimental Conduct Clawback Policy establishes and reserves the right of the Company to recoup Incentive Compensation (as defined below) made to Covered Employees (as defined below) in circumstances involving Detrimental Conduct (as defined below).
This Detrimental Conduct Clawback Policy applies with regards to circumstances only to the extent not covered in Part A of the Clawback Policy. The existence of this Detrimental Conduct Clawback Policy is not intended to result in the duplication of penalties.



This Detrimental Conduct Clawback Policy is effective with respect to all Incentive Compensation granted, promised or paid to a Covered Employee on or after the Effective Date.
II.Administration
The Committee shall have full discretionary authority to administer this Detrimental Conduct Clawback Policy, including discretionary authority to interpret and construe any and all of its provisions. The Committee will have full discretion, in the exercise of its judgment, to determine whether Detrimental Conduct has occurred or whether a Covered Employee’s fraud or intentional misconduct was a significant contributing factor and whether to pursue the Clawback of Incentive Compensation in connection therewith.
III.Defined Terms
For purposes of this Detrimental Conduct Clawback Policy:
Covered Employee” shall mean any individual who is (or was at any time during the three years preceding the Committee’s determination to exercise its right to Clawback) subject to the reporting requirements of Section 16(a) of the Securities Exchange Act of 1934, as amended, in respect of CLX, all Clorox Executive Committee Members (regardless of whether such individual is or was an executive officer for purposes of the Clawback Rules), and such other employees of the Company as may be determined and notified by the Committee;
Detrimental Conduct” shall mean any conduct materially detrimental to the Company, including, but not limited to, the name, business interests or corporate, brand, business or other reputation of the Company;
Incentive Compensation” shall mean all bonuses, cash-based awards, equity-based awards or other incentive compensation granted, promised, paid, earned, vested or otherwise awarded by the Company, including, but not limited to, the proceeds of any sale of equity received as a result thereof; and
Clawback” shall mean the recapture, recovery, cancellation or forfeiture of Incentive Compensation, whether or not such Incentive Compensation already has been vested or been paid.
IV.Clawback
a.Detrimental Conduct. On and after the Effective Date of this Detrimental Conduct Clawback Policy, the Committee may, in its sole discretion, determine whether (or not) to seek Clawback of any Incentive Compensation, where in its judgment, a Covered Employee has engaged in Detrimental Conduct. The Committee may seek Clawback based on Detrimental Conduct at any time up to three years after the end of the fiscal year in which the Incentive Compensation in question vested or was paid to the Covered Employee.
b.Amount and Method of Clawback. If the Committee determines to exercise its right to Clawback of any Incentive Compensation, it may do so with respect to any amount (up to the full amount of Incentive Compensation received by a Covered Employee (before deduction of taxes)) with respect to Clawback under Section 4(a) hereof and by any method, as it determines in its sole discretion (including, without limitation, by withholding the amount of Incentive Compensation from other sums owed by the Company to a Covered Employee). In making these determinations, the Committee may take into account such considerations as it deems appropriate.
c.In addition, and without prejudice to the application of Part A of the Clawback Policy to the maximum extent required by applicable law, in circumstances involving a Financial Restatement (as defined in Part A of this Clawback Policy), the Committee, in its sole discretion, may apply the terms of this Clawback Policy (as contemplated under Part A, Part B or a combination thereof) to any member of the Clorox Executive Committee (regardless of whether such individual is or was an executive officer for purposes of the Clawback Rules (as defined in Part A of this Clawback Policy)) and any individual designated by the Committee in its sole discretion (and such individuals shall be deemed to be "Covered Employees" as contemplated by any provisions in any award or similar agreements that include provisions related to any



clawback policy of the Company or its affiliates). The interpretation and application of this Clawback Policy with respect to such individuals shall be in the Committee’s sole discretion.
V.General Provisions
The Committee, in its discretion, may modify or amend, in whole or in part, any or all of the provisions of this Detrimental Conduct Clawback Policy and may suspend this Detrimental Conduct Clawback Policy from time to time. Nothing in this Detrimental Conduct Clawback Policy is intended or should be deemed to limit or restrict the Company from providing for Clawback of Incentive Compensation under any circumstances, including as required by statute or the rules of any exchange on which shares of CLX are listed for trading. Nothing in this Detrimental Conduct Clawback Policy is intended to supersede or limit the rights of the Company under any other policy, plan, agreement or arrangement concerning the matters addressed herein, whether adopted or in effect prior to, on or following the Effective Date, except as explicitly noted in such policy, plan, agreement or arrangement.
Notwithstanding the terms of any other policy, plan, agreement or arrangement concerning Incentive Compensation, in no event shall any Covered Employee be entitled to any indemnification by the Company or advancement of litigation expenses for any disputes concerning Clawback or this Detrimental Conduct Clawback Policy.
The provisions hereof are intended to be effective only to the maximum extent permitted by applicable law. In the event any provision of this Detrimental Conduct Clawback Policy is determined to be unenforceable or invalid under applicable law, such provision shall be applied to the maximum extent permitted by applicable law and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required by applicable law. This Detrimental Conduct Clawback Policy shall be construed so as not to violate any contract, agreement, compensation plan, law or regulation. Nothing in this Detrimental Conduct Clawback Policy is designed or intended to limit or restrict the Committee from taking any other action, including disciplinary or legal, as it deems appropriate.
This Detrimental Conduct Clawback Policy shall be binding and enforceable against all Covered Employees and their beneficiaries, heirs, executors, administrators or other legal representatives.


* * *

EX-99.1 10 clx-20240630_d2.htm EX-99.1 clx-20240630_d2


Exhibit 99.1
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The Clorox Company
(Dollars in millions, except per share data)
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. In certain instances, parenthetical references are made to relevant sections of the Notes to Consolidated Financial Statements to direct the reader to a further detailed discussion. This section should be read in conjunction with the consolidated financial statements and supplementary data included in this Annual Report on Form 10-K.
The following sections are included herein:
Executive Overview
Results of Operations
Financial Position and Liquidity
Contingencies
Quantitative and Qualitative Disclosures about Market Risk
Recently Issued Accounting Standards
Critical Accounting Estimates
Summary of Non-GAAP Financial Measures
EXECUTIVE OVERVIEW
The Clorox Company is a leading multinational manufacturer and marketer of consumer and professional products with fiscal year 2024 net sales of $7,093 and about 8,000 employees worldwide as of June 30, 2024. The Company has operations in approximately 25 countries or territories and sells its products in more than 100 markets, primarily through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet and military stores; third-party and owned e-commerce channels; and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning and disinfecting products; Pine-Sol and Tilex cleaners; Liquid-Plumr clog removers; Poett home care products; Glad bags and wraps; Fresh Step cat litter; Kingsford grilling products; Hidden Valley dressings, dips, seasonings and sauces; Brita water-filtration products; Burt's Bees natural personal care products; and Natural Vitality, RenewLife, NeoCell and Rainbow Light vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro and Clorox Healthcare brand names.
The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products, which can be found in about nine of 10 U.S. homes, compete with other nationally advertised brands within each category and with “private label” brands. About 80% of the Company's sales are generated from brands that hold the No. 1 or No. 2 market share position in their categories.

1



The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International.Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. The four reportable segments consist of the following:
Health and Wellness consists of cleaning, disinfecting and professional products marketed and sold in the United States. Products within this segment include home care cleaning and disinfecting products and laundry additives, primarily under the Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; and professional food service products under the Hidden Valley brand.
Household consists of bags and wraps, cat litter and grilling products marketed and sold in the United States. Products within this segment include bags and wraps under the Glad brand; cat litter primarily under the Fresh Step and Scoop Away brands; and grilling products under the Kingsford brand.
Lifestyle consists of food, water-filtration and natural personal care products marketed and sold in the United States. Products within this segment include dressings, dips, seasonings and sauces, primarily under the Hidden Valley brand; water-filtration products under the Brita brand; and natural personal care products under the Burt’s Bees brand.
International consists of products sold outside the United States. Products within this segment include laundry additives; home care products; bags and wraps; cat litter; water-filtration products; professional cleaning and disinfecting products; natural personal care products; food; grilling products and digestive health products marketed primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands.
Non-GAAP Financial Measures
This Executive Overview, the succeeding sections of MD&A and Exhibit 99.2 may include certain financial measures that are not defined by accounting principles generally accepted in the United States of America (U.S. GAAP). These measures, which are referred to as non-GAAP measures, are listed below:
Free cash flow and free cash flow as a percentage of net sales. Free cash flow is calculated as net cash provided by operations less capital expenditures.
Earnings before interest and income taxes (EBIT) margin (the ratio of EBIT to net sales).
Adjusted earnings (losses) before interest and income taxes (adjusted EBIT) represents earnings (losses) excluding interest income, interest expense, income taxes and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).
Adjusted EBIT margin (the ratio of adjusted EBIT to net sales).
Economic profit (EP) is defined by the Company as earnings before income taxes, excluding certain U.S. GAAP items (such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the cyberattack, asset impairments, charges related to implementation of the streamlined operating model, charges related to digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability) and interest expense; less income taxes (calculated based on the Company’s effective tax rate excluding the identified U.S. GAAP items), and less after tax profit attributable to noncontrolling interests, and less a capital charge (calculated as average capital employed multiplied by a cost of capital rate).
Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions or divestitures.
For a discussion of these measures and the reasons management believes they are useful to investors, refer to “Summary of Non-GAAP Financial Measures” below. To the extent applicable, this MD&A and Exhibit 99.2 include reconciliations of these non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.


2



Fiscal Year 2024 Financial Highlights
A detailed discussion of strategic goals, key initiatives and results of operations is included below. Key fiscal year 2024 financial results are summarized as follows:
The Company’s fiscal year 2024 net sales decreased by 4% to $7,093 from $7,389 in fiscal year 2023, primarily driven by lower shipments resulting from the impacts of the cyberattack and higher pricing.
Gross margin increased by 360 basis points to 43.0% in fiscal year 2024 from 39.4% in fiscal year 2023. The increase was primarily driven by the benefit of price increases as well as cost savings, partially offset by unfavorable foreign exchange rates.
The Company reported earnings before income taxes of $398 in fiscal year 2024, compared to $238 in fiscal year 2023. The Company reported earnings attributable to Clorox of $280 in fiscal year 2024, compared to $149 in fiscal year 2023.
The Company delivered diluted net earnings per share (EPS) of $2.25 in fiscal year 2024, an increase of approximately 88%, or $1.05, from fiscal year 2023 diluted net EPS of $1.20. The increase was primarily due to the noncash impairment charges on assets held by the Better Health Vitamins, Minerals and Supplements (VMS) business in the prior period and the benefits of pricing, cost savings and lower manufacturing and logistics costs in the current period, partially offset by losses relating to the divestiture of the Argentina business, the pension settlement charge, unfavorable foreign exchange rates, lower volume and higher advertising investments, all in the current period.
EP increased by $176 to $573 in fiscal year 2024, compared to $397 in fiscal year 2023 (refer to the reconciliation of EP to earnings before income taxes in Exhibit 99.2).
The Company’s net cash provided by operations was $695 in fiscal year 2024, compared to $1,158 in fiscal year 2023. Free cash flow was $483 or 6.8% of net sales in fiscal year 2024, compared to $930 or 12.6% of net sales in fiscal year 2023 (refer to the reconciliation of net cash provided by operations to free cash flow in “Financial Position and Liquidity - Investing - Free Cash Flow”).
The Company paid $595 in cash dividends to stockholders in fiscal year 2024, compared to $583 in cash dividends paid in fiscal year 2023. In July 2024, the Company announced an increase of 2% in its quarterly cash dividend from the prior year.
Strategic Goals and Initiatives
The Company's IGNITE strategy — underpinned by its purpose, enduring values and commitment to inclusion, diversity, equity and allyship — accelerates innovation in key areas of the business to drive growth and deliver value for all Clorox stakeholders. IGNITE focuses on four strategic choices aimed at fueling long-term growth; innovating consumer experiences; reimagining how the company and its people work; and continuously evolving the product portfolio. The Company’s long-term financial goals reflected in IGNITE include annual net sales growth of 3% to 5% — increased from 2% to 4% in 2021 — annual adjusted EBIT margin expansion of 25 to 50 basis points and annual free cash flow as a percentage of net sales of 11% to 13%.
In March of 2024, the Company completed the divestiture of its Argentina business, which consisted of its production plants in Argentina as well as the rights to the Company's brands in Argentina, Uruguay and Paraguay. The transaction was in support of the Company's IGNITE strategy and the commitment to evolve its portfolio to increase focus on its core business to drive more consistent, profitable growth.
As announced in August 2021, the Company plans to invest in transformative technologies and processes over a five-year period. This investment began in fiscal year 2022, and includes replacement of the Company's enterprise resource planning system and transitioning to a cloud-based platform as well as the implementation of a suite of other digital technologies. Total incremental transformational costs are expected to be $560 to $580 million, compared to the previous estimate of approximately $500 million. The increased estimate includes impacts from delays as a result of the cyberattack. The implementation timeline is unchanged. It is expected that these implementations will generate efficiencies and transform the Company's operations in the areas of supply chain, digital commerce, innovation, brand building and more over the long term.
Finally, in fiscal year 2024, the Company completed the implementation of its streamlined operating model to help meet its objectives of driving growth and productivity. The streamlined operating model is expected to enhance the Company's ability to respond more quickly to changing consumer behaviors and innovate faster. The implementation of this new model resulted in the reduction of certain staffing levels and is expected to achieve cost savings of approximately $100 million annually.

3



Recent Events Affecting the Company
Cyberattack
On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its Information Technology (IT) systems. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the quarter ended September 30, 2023.
The impacts of these system disruptions included order processing delays and significant product outages, resulting in a negative impact on net sales and earnings. The Company has since transitioned back to automated order processing. The Company experienced lessening operational impacts in the second quarter and has since returned to substantially normalized operations.
The effects of the cyberattack negatively impacted fiscal year 2024 results, though some of the anticipated net sales not recognized in the first quarter as a result of the disruptions were recognized in the remainder of fiscal year 2024 as customers rebuilt inventories.
The Company also incurred incremental costs, net of insurance recoveries, of approximately $29 in fiscal year 2024 as a result of the cyberattack. These costs relate to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs incurred from the resulting disruption to the Company’s business operations. The Company does not expect to incur significant costs related to the cyberattack in future periods.
The Company has recorded insurance recoveries of $30 in fiscal year 2024 related to the cyberattack. The timing of recognizing further insurance recoveries may differ from the timing of recognizing the associated expenses.
For the fiscal year ended June 30, 2024, the Company continued to experience an inflationary environment. Additionally, the Company is monitoring macroeconomic conditions as a result of increased interest rates and volatility in capital markets. These evolving challenges contributed to a highly dynamic operating environment as the Company continued its efforts to drive growth, rebuild margins and drive its transformation.
Other than the cyberattack, the Company has not experienced significant disruptions in its operations during fiscal year 2024. However, the risks of future negative impacts due to transportation, logistical or supply constraints and higher commodity costs for certain raw materials remain present, and the Company continues to experience corresponding incremental costs and gross margin pressures. For fiscal year 2025, the Company anticipates the operating environment will remain volatile and challenging. Inflationary headwinds are expected to continue and consumers may feel greater pressure as continued macroeconomic uncertainty impacts spending. The Company will continue to invest in its brands, capabilities and people to deliver consistent, profitable growth over time. The Company announced and began implementing a streamlined operating model in fiscal year 2023 and implementation of this new model was completed in fiscal year 2024.
The impact of continued inflationary pressures, macroeconomic conditions and geopolitical instability, including the ongoing conflict in the Middle East and Ukraine, rising tensions between China and Taiwan and actual and potential shifts in U.S. and foreign trade, economic and other policies, have increased global macroeconomic and political uncertainty regarding the duration and resolution of the conflicts, the potential escalation of tensions and potential economic and global supply chain disruptions. These factors are difficult to predict considering the rapidly evolving landscape as the Company continues to expect a variable operating environment going forward.
For further discussion of the possible impacts of inflationary pressures and other recent events on our business, financial conditions and results of operations, see “Risk Factors” in Part I, Item 1A of this Report.


4



RESULTS OF OPERATIONS
Unless otherwise noted, MD&A compares results of operations from fiscal year 2024 (the current year) to fiscal year 2023 (the prior year), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate. Discussions of fiscal year 2022 items and year-to-year comparisons between fiscal years 2023 and 2022 that are not included in this Annual Report on Form 10-K can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal years ended 2023 and 2022.
CONSOLIDATED RESULTS
% Change
 20242023
2024 to
2023
Net sales$7,093 $7,389 (4)%
Year Ended June 30, 2024
Percentage change versus the year-ago period
Reported (GAAP) Net Sales Growth / (Decrease)Reported Volume
Acquisitions & Divestitures (1)
Foreign Exchange Impact
Price/Mix/Other (2)
Organic Sales Growth / (Decrease) (Non-GAAP) (3)
Organic Volume (4)
Health and Wellness(2)%(4)%— %— %%(2)%(4)%
Household(7)(8)— — (7)(8)
Lifestyle(5)(6)— — (5)(6)
International (4)
(2)(5)(4)(21)23 23 — 
Total Company (4)(5)
(4)%(6)%(1)%(3)%5 % %(5)%

(1)The Argentina divestiture impact is calculated as net sales from the Argentina business after the sale date in the year-ago period.
(2)This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.
(3)Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions or divestitures. See “Summary of Non-GAAP Financial Measures” below for reconciliation of organic sales growth / (decrease) to net sales growth / (decrease), the most directly comparable GAAP financial measure.
(4)Organic volume represents volume excluding the effect of any acquisitions and divestitures. In the fiscal year ended June 30, 2024, the volume impact of divestitures was 19% and 3% for International and Total Company, respectively.
(5)Total Company includes Corporate and Other.
Net sales and volume in fiscal year 2024 decreased by 4% and 6%, respectively, primarily driven by lower shipments resulting from the impacts of the cyberattack and higher pricing. The variance between volume and net sales was primarily due to the impact of favorable price mix, partially offset by unfavorable foreign exchange rates.
% Change
202420232024 to
2023
Gross profit$3,048$2,9085 %
Gross margin43.0 %39.4 %
Gross margin increased by 360 basis points in fiscal year 2024 from 39.4% to 43.0%. The increase was primarily driven by the benefit of price increases as well as cost savings, partially offset by unfavorable foreign exchange rates.


5



Expenses
% Change% of Net sales
202420232024 to
2023
20242023
Selling and administrative expenses$1,167 $1,183 (1)%
16.5%
16.0%
Advertising costs832 734 13 
11.7
9.9 
Research and development costs126 138 (9)
1.8
1.9
Selling and administrative expenses, as a percentage of net sales, increased by 50 basis points in fiscal year 2024. The dollar decrease in selling and administrative expenses was primarily due to cost savings and lower incentive compensation expense partially offset by incremental costs associated with the cyberattack, net of insurance recoveries and an arbitral decision related to a commercial dispute. For further information on the cyberattack, see Notes to the Consolidated Financial Statements.
Advertising costs, as a percentage of net sales, increased 180 basis points in fiscal year 2024. The increase in advertising costs reflects the Company’s continued support behind its brands. The Company’s U.S. retail advertising spend as a percentage of net sales was 13% for fiscal year 2024 and 11% for fiscal year 2023, respectively.
Research and development costs, as a percentage of net sales, were essentially flat, while dollars decreased in the current year as compared to the prior year. The Company continues to invest behind product innovation and cost savings.
Loss on divestiture, pension settlement charge, goodwill, trademark and other asset impairments, Interest expense, Other expense (income), net and Effective tax rate on earnings
20242023
Loss on divestiture
$240 $— 
Pension settlement charge
171 — 
Goodwill, trademark and other asset impairments 445 
Interest expense90 90 
Other expense (income), net24 80 
Effective tax rate on earnings26.5 %32.4 %
Loss on divestiture of $240 in fiscal year 2024 reflects the loss on the divestiture of the Argentina business. See Notes to Consolidated Financial Statements for further information.

Pension settlement charge was $171 in fiscal year 2024 and reflects the settlement of the domestic qualified pension plan. See Notes to Consolidated Financial Statements for further information.
Goodwill, trademark and other asset impairments of $445 in the prior fiscal year reflected noncash impairment charges to goodwill and certain indefinite-lived trademarks related to the Better Health VMS business. See Notes to Consolidated Financial Statements for further information regarding the impairments recorded in fiscal year 2023.
Other expense (income), net was $24 and $80 in fiscal year 2024 and fiscal year 2023, respectively. The variance was primarily due to higher restructuring and related implementation costs associated with the streamlined operating model incurred in the prior year and the gain on the sale-leaseback transaction recorded in the current period, partially offset by the net impact of interest income and Argentina foreign exchange rates in the current period.
Restructuring and related costs
In the first quarter of fiscal year 2023, the Company began recognizing costs related to a plan that involves streamlining its operating model to meet its objectives of driving growth and productivity. The streamlined operating model is expected to enhance the Company’s ability to respond more quickly to changing consumer behaviors and innovate faster. The implementation of this new model was completed in fiscal year 2024.
The Company expects cost savings of approximately $100 annually. The benefits of the streamlined operating model are expected to increase future cash flows as a result of cost savings that will be generated primarily in the areas of selling and administration, supply chain, marketing and research and development.
The Company incurred $32 and $60 of costs in fiscal year 2024 and 2023, respectively. Costs incurred are expected to be settled primarily in cash.

6



Of the restructuring and implementation related costs, net incurred in fiscal years 2024 and 2023, $7 and $41 was related to employee-related costs, respectively, $6 and $0 was related to asset impairment costs, respectively, and $19 and $19 was related to other costs, respectively. For further details on the streamlined operating model and restructuring, refer to the Notes to Consolidated Financial Statements.
The effective tax rate on earnings was 26.5% and 32.4% in fiscal year 2024 and 2023, respectively. The lower tax rate in fiscal year 2024 compared to fiscal year 2023 was driven by the partial non-deductibility of impaired Better Health VMS goodwill in the prior period and an international legal entity reorganization in the current period, partially offset by the divestiture of the Argentina business in the current period.
Diluted net earnings per share
% Change
 202420232024 to
2023
Diluted net EPS$2.25 $1.20 88 %
Diluted net earnings per share (EPS) increased by $1.05, or 88%, in fiscal year 2024, primarily due to the noncash impairment charges on assets held by the Better Health Vitamins, Minerals and Supplements (VMS) business in the prior period and the benefits of pricing, cost savings and lower manufacturing and logistics costs in the current period, partially offset by losses relating to the divestiture of the Argentina business, the pension settlement charge, unfavorable foreign exchange rates, lower volume and higher advertising investments, all in the current period.


7



SEGMENT RESULTS
The following presents the results of the Company’s reportable segments and Corporate and Other (see Notes to Consolidated Financial Statements for further discussion of the principle measure of segment profitability used by management, segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT)):
Net sales
Fiscal year
20242023
Health and Wellness$2,485 $2,532 
Household1,950 2,098 
Lifestyle1,275 1,338 
International1,162 1,181 
Reportable segment total
6,872 7,149 
Corporate and Other221 240 
Total$7,093 $7,389 
Segment adjusted EBIT (1)
Fiscal year
20242023
Health and Wellness$719 $594 
Household260 308 
Lifestyle253 284 
International122 89 
Reportable segment total
1,354 1,275 
Corporate and Other(309)(358)
Total$1,045 $917 
Interest income23 16 
Interest expense(90)(90)
Loss on divestiture
(240)— 
Pension settlement charge
(171)— 
Cyberattack costs, net of insurance recoveries
(29)— 
VMS impairment
— (445)
Restructuring and related costs(32)(60)
Digital capabilities and productivity enhancements investment(108)(100)
Earnings (losses) before income taxes$398 $238 
(1)See “Summary of Non-GAAP Financial Measures” below for reconciliation of segment adjusted EBIT to earnings (losses) before income taxes, the most directly comparable GAAP financial measure.

8



Health and Wellness
% Change
202420232024 to
2023
Net sales$2,485 $2,532 (2)%
Segment adjusted EBIT719 594 21 
Fiscal year 2024 versus fiscal year 2023: Volume and net sales decreased by 4% and 2%, respectively, and segment adjusted EBIT increased by 21% during fiscal year 2024. The volume decrease was primarily due to pricing actions and the impacts resulting from the cyberattack. The variance between volume and net sales was primarily due to the benefit of price increases, partially offset by unfavorable mix. The increase in segment adjusted EBIT in the current period was primarily due to lower manufacturing and logistics costs, the benefits of both cost savings and pricing and favorable commodity costs, partially offset by higher advertising investments and unfavorable mix.
Household
% Change
202420232024 to
2023
Net sales$1,950 $2,098 (7)%
Segment adjusted EBIT260 308 (16)
Fiscal year 2024 versus fiscal year 2023: Volume, net sales and segment adjusted EBIT decreased by 8%, 7% and 16%, respectively, in fiscal year 2024. The volume decrease was primarily driven by lower consumption and distribution losses resulting from the cyberattack. The variance between volume and net sales was primarily due to the benefit of price increases, partially offset by higher trade promotion spending. The decrease in segment adjusted EBIT was mainly due to lower net sales and higher advertising investments, partially offset by cost savings.
Lifestyle
% Change
202420232024 to
2023
Net sales$1,275 $1,338 (5)%
Segment adjusted EBIT253 284 (11)
Fiscal year 2024 versus fiscal year 2023: Volume, net sales and segment adjusted EBIT decreased by 6%, 5% and 11%, respectively, during fiscal year 2024. The volume decrease was primarily due to distribution losses, supply chain constraints and the impact of the cyberattack. The variance between volume and net sales was mainly due to the benefit of price increases partially offset by higher trade promotion spending. The decrease in segment adjusted EBIT was primarily due to higher advertising investments and lower net sales, partially offset by favorable commodity costs.
International
% Change
202420232024 to
2023
Net sales$1,162 $1,181 (2)%
Segment adjusted EBIT122 89 37 
Fiscal year 2024 versus fiscal year 2023: Volume and net sales decreased by 5% and 2%, respectively, while segment adjusted EBIT increased by 37% during fiscal year 2024. The volume decrease was primarily due to the impact of the Argentina divestiture. The variance between volume and net sales was mainly due to the benefit of price increases, partially offset by the impact of unfavorable foreign exchange rates. The increase in segment adjusted EBIT was primarily due to the net impact of pricing, partially offset by unfavorable foreign exchange rates, higher manufacturing and logistics costs and unfavorable commodity costs.


9



Argentina
Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, and as a result, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina were recognized in Other (income) expense, net in the consolidated statements of earnings, utilizing the official Argentine government exchange rate.
On March 20, 2024, the Company completed the divestiture of its Argentina business. The financial results of the Argentina business through March 20, 2024 are reflected as part of the International reportable segment. See Notes to Consolidated Financial Statements for further information.
As of June 30, 2023, the net asset position, excluding goodwill, of Clorox Argentina was $48. Of these net assets, cash balances were approximately $28 as of June 30, 2023. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for both the fiscal years ended June 30, 2024 and 2023.
Corporate and Other
% Change
 202420232024 to
2023
Net Sales$221 $240 (8)%
Segment adjusted EBIT(309)(358)(14)%
Corporate and Other includes certain non-allocated administrative costs, the Better Health VMS business and various other non-operating income and expenses.
Fiscal year 2024 versus fiscal year 2023: Net sales decreased by 8% due to lower net sales in the Better Health VMS business. The decrease in segment adjusted losses before interest and income taxes was primarily due to lower Better Health VMS operating expenses and reductions in employee related expenses primarily due to cost savings and lower employee incentive compensation, partially offset by higher foreign exchange losses on Corporate and Other assets related to operations in Argentina.
FINANCIAL POSITION AND LIQUIDITY
Management’s discussion and analysis of the Company’s financial position and liquidity describes its consolidated operating, investing and financing activities from operations.
The Company’s cash position includes amounts held by foreign subsidiaries and, as a result, the repatriation of certain cash balances from some of the Company’s foreign subsidiaries could result in additional tax costs. However, these cash balances are generally available without legal restriction to fund local business operations. In addition, a portion of the Company’s cash balance is held in U.S. dollars by foreign subsidiaries, whose functional currency is their local currency. Such U.S. dollar balances are reported on the foreign subsidiaries’ books, in their functional currency, with the impact from foreign currency exchange rate differences recorded in Other (income) expense, net.
The Company’s financial condition and liquidity remained strong as of June 30, 2024. The following table summarizes cash activities for the years ended June 30:
20242023
Net cash provided by operations$695 $1,158 
Net cash used for investing activities(175)(223)
Net cash used for financing activities(655)(753)
Operating Activities
Net cash provided by operations was $695 in fiscal year 2024, compared with $1,158 in fiscal year 2023. The decrease was primarily driven by higher tax payments, an increase in working capital and higher employee incentive compensation payments in the current fiscal year; partially offset by higher cash earnings in the current fiscal year.
The increase in tax payments in the current fiscal year was primarily driven by payment of fiscal year 2023 income taxes previously deferred as a result of the relief provided by the IRS announced in January 2023 due to winter storms in California.

10



The increase in working capital in the current fiscal year is primarily due to a decrease in accounts payable and accrued liabilities due to the timing of payments.
Payment Terms Extension and Supply Chain Financing
The Company initiated the extension of its payment terms with its suppliers in the second half of fiscal year 2020 in order to improve working capital as part of and to fund the IGNITE strategy and in keeping with evolving market practices. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The Company’s operating cash flows are directly impacted as a result of the extension of payment terms with suppliers.
As part of those ongoing efforts, the Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. There would not be an expected material impact to the Company’s liquidity or capital resources if the financial institution or a supplier terminated the SCF arrangement. While the Company does not have direct access to information on, or influence over, which invoices a participating supplier elects to sell to the financial institution, the Company expects that the majority of these amounts have been sold to the financial institution. Refer to the Notes to Consolidated Financial Statements for detail on the SCF program.
Investing Activities
Net cash used for investing activities was $175 in fiscal year 2024, as compared to $223 in fiscal year 2023. The year-over-year decrease was mainly due to net cash proceeds from the sale of the Argentina business, a sale-leaseback transaction and lower capital spending in the current fiscal year.
Capital expenditures were $212 and $228 in fiscal years 2024 and 2023, respectively. Capital expenditures as a percentage of net sales were 3.0% and 3.1% for fiscal years 2024 and 2023, respectively.
Free cash flow
20242023
Net cash provided by operations$695 $1,158 
Less: capital expenditures(212)(228)
Free cash flow$483 $930 
Free cash flow as a percentage of net sales6.8 %12.6 %
Financing Activities
Net cash used for financing activities was $655 in fiscal year 2024, compared with $753 in fiscal year 2023. The year-over-year decrease was driven by lower net cash repayments on short-term borrowings in the current fiscal year.
Capital Resources and Liquidity
The Company's current liabilities may periodically exceed current assets as a result of the Company's debt management policies, including the Company's use of commercial paper borrowings which fluctuates depending on the amount and timing of operating and investing cash flows and payments for shareholder transactions such as dividends. The Company continues to take actions to address some of the effects of such cost increases, which include implementing price increases, driving cost savings and optimizing the Company’s supply chain.
Notwithstanding potential unforeseen adverse market conditions and as part of the Company’s regular assessment of its cash needs, the Company believes it will have the funds necessary to support our short- and long-term liquidity and operating needs, including the costs related to the announced streamlined operating model and its digital capabilities and productivity enhancements investment, as well as the costs and impacts of the business disruption associated with the cyberattack, based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings and current borrowing availability.


11



The Company may consider other transactions that require the issuance of additional long- and/or short-term debt or other securities to finance acquisitions, repurchase stock, refinance debt or fund other activities for general business purposes. Such transactions could require funds in excess of the Company’s current cash levels and available credit lines, and the Company’s access to or cost of such additional funds could be adversely affected by any decrease in credit ratings, which were the following as of June 30:
20242023
Short-termLong-termShort-termLong-term
Standard and Poor’sA-2BBB+A-2BBB+
Moody’sP-2Baa1P-2Baa1
Credit Arrangements
As of June 30, 2024, the Company maintained a $1,200 revolving credit agreement that matures in March 2027 (the Credit Agreement). There were no borrowings under the Credit Agreement as of June 30, 2024 and June 30, 2023, and the Company believes that borrowings under the Credit Agreement are and will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0, calculated as total earnings before interest, taxes, depreciation and amortization and other similar noncash charges and certain other items (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement.
The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of June 30, 2024, and anticipates being in compliance with all restrictive covenants for the foreseeable future.
As of June 30, 2024, the Company maintained $34 of foreign and other credit lines, of which $9 was outstanding and the remainder of $25 was available for borrowing.
As of June 30, 2023, the Company maintained $35 of foreign and other credit lines, of which $5 was outstanding and the remainder of $30 was available for borrowing.
Short-term Borrowings
The Company’s notes and loans payable primarily consist of U.S. commercial paper issued by the parent company and any borrowings under the Credit Agreement. These short-term borrowings have stated maturities of less than one year and provide supplemental funding for supporting operations. The level of U.S. commercial paper borrowings generally fluctuates depending upon the amount and timing of operating cash flows and payments for items such as dividends, income taxes, stock repurchases and pension contributions. The average balance of short-term borrowings outstanding was $168 and $232 for the fiscal years ended June 30, 2024 and 2023, respectively.
Long-term Borrowings
Long-term borrowings, consisting of senior unsecured notes and debentures, were $2,481 and $2,477 as of June 30, 2024 and 2023, respectively.
Stock Repurchases and Dividend Payments
As of June 30, 2024, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date and was authorized by the Board of Directors in May 2018, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date. During the fiscal years ended June 30, 2024 and 2023, no shares of common stock were purchased.
Dividends per share and total dividends paid to Clorox stockholders were as follows during the fiscal years ended June 30:
20242023
Dividends per share declared$4.80 $4.72 
Dividends per share paid4.80 4.72 
Total dividends paid595 583 
On July 30, 2024, the Company declared a 2% increase in the quarterly dividend, from $1.20 to $1.22 per share, payable on August 30, 2024 to common stockholders of record as of the close of business on August 14, 2024.

12



On July 27, 2023, the Company declared a 2% increase in the quarterly dividend, from $1.18 to $1.20 per share, payable on August 25, 2023 to common stockholders of record as of the close of business on August 9, 2023.
Material Cash Requirements
The following table summarizes the Company’s current and long-term material cash requirements as of June 30, 2024, which we intend to fund primarily with operating cash flows:
20252026202720282029ThereafterTotal
Long-term debt maturities including interest payments$90 $90 $90 $984 $559 $1,193 $3,006 
Notes and loans payable— — — 
Purchase obligations (1) (4)
181 128 81 43 27 45 505 
Operating and finance leases111 106 91 71 57 61 497 
Payments related to nonqualified retirement income and retirement health care plans (2)
15 14 13 13 13 48 116 
Venture Agreement terminal obligation (3)
— 531 — — — — 531 
Total$402 $870 $276 $1,111 $656 $1,347 $4,662 
(1)Purchase obligations are defined as purchase agreements that are enforceable and legally binding and that contain specified or determinable significant terms, including quantity, price and the approximate timing of the transaction. For purchase obligations subject to variable price and/or quantity provisions, an estimate of the price and/or quantity has been made. Examples of the Company’s purchase obligations include contracts to purchase raw materials, commitments to contract manufacturers, commitments for information technology and related services, advertising contracts, capital expenditure agreements, software acquisition and license commitments and service contracts. The raw material contracts included above are entered into during the regular course of business based on expectations of future purchases. Many of these raw material contracts are flexible to allow for changes in the Company’s business and related requirements. If such changes were to occur, the Company believes its exposure could differ from the amounts listed above. Any amounts reflected in the consolidated balance sheets as Accounts payable and accrued liabilities are excluded from the table above, as they are short-term in nature and expected to be paid within one year.
(2)These amounts represent expected payments through 2034. Based on the accounting rules for nonqualified retirement income and retirement health care plans, the liabilities reflected in the Company’s consolidated balance sheets differ from these expected future payments. Refer to the Notes to Consolidated Financial Statements for further details.
(3)The Company has a venture agreement with The Procter & Gamble Company (P&G) for the Company’s Glad bags and wraps business (the Venture Agreement). As of June 30, 2024, P&G had a 20% interest in the venture. Upon termination of the agreement in January 2026, the Company is required to purchase P&G’s 20% interest for cash at fair value as established by predetermined valuation procedures. Refer to the Notes to Consolidated Financial Statements for further details.
(4)Includes contracted spend through fiscal year 2026 related to the digital capabilities and productivity enhancements investment, which is expected to be funded through cash generated from operations.
CONTINGENCIES
A summary of contingencies is contained in the Notes to Consolidated Financial Statements and is incorporated herein by reference.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a multinational company, the Company is exposed to the impact of changes in commodity prices, foreign currency fluctuations, interest-rate risk and other types of market risk.
In the normal course of business, where available at a reasonable cost, the Company manages its exposure to market risk using contractual agreements and a variety of derivative instruments. The Company’s objective in managing its exposure to market risk is to limit the impact of fluctuations on earnings and cash flow through the use of derivative instruments, including exchange-traded futures and options contracts and over-the-counter swaps and forward purchase contracts. Over-the-counter derivative contracts are entered into for non-trading purposes with major credit-worthy institutions, thereby decreasing the risk of credit loss.
The Company uses different methodologies, when necessary, to estimate the fair value of its derivative contracts. The estimated fair values of the majority of the Company’s contracts are based on quoted market prices, exchange-traded market prices or broker price quotations, and represent the estimated amounts that the Company would pay or receive to terminate the contracts.
See Notes to Consolidated Financial Statements for further discussion of derivatives and hedging policies and fair value measurements.


13



Sensitivity Analysis for Derivative Contracts
For fiscal years 2024 and 2023, the Company’s exposure to market risk was estimated using sensitivity analyses, which illustrates the change in the fair value of a derivative financial instrument assuming hypothetical changes in commodity prices, foreign exchange rates or interest rates. The results of the sensitivity analyses for commodity, foreign currency and interest rate derivative contracts are summarized below. Actual changes in commodity prices, foreign exchange rates or interest rates may differ from the hypothetical changes, and any changes in the fair value of the contracts, real or hypothetical, would be partly to fully offset by an inverse change in the value of the underlying hedged items.
The changes in the fair value of derivatives are recorded as either assets or liabilities in the consolidated balance sheets with an offset to Net earnings or Other comprehensive (loss) income, depending on whether or not, for accounting purposes, the derivative is designated and qualified as an accounting hedge. For those derivative instruments designated and qualifying as hedging instruments, the Company must designate the hedging instrument either as a fair value hedge or as a cash flow hedge. The Company designates its commodity swaps and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory, and interest rate contracts for forecasted interest payments as cash flow hedges. During the fiscal years ended June 30, 2024 and 2023, the Company had no hedging instruments designated as fair value hedges. In the event the Company has contracts not designated as hedges for accounting purposes, the Company recognizes the changes in the fair value of these contracts in the consolidated statements of earnings.
Commodity Price Risk
The Company is exposed to changes in the price of commodities used as raw materials in the manufacturing of its products. The Company uses various strategies, where available at a reasonable cost to manage cost exposures on certain raw material purchases with the objective of obtaining more predictable costs for these commodities, including long-term commodity purchase contracts and commodity derivative contracts. During fiscal years 2024 and 2023, the Company had derivative contracts related to raw material exposures for soybean oil used for the food business and jet fuel used for the grilling business.
Based on a hypothetical decrease or increase of 10% in these commodity prices as of June 30, 2024 and June 30, 2023, the estimated fair value of the Company’s then-existing commodity derivative contracts would decrease or increase by $4 and $4, respectively, with the corresponding impact included in Other comprehensive (loss) income.
Foreign Currency Risk
The Company seeks to minimize the impact of certain foreign currency fluctuations by hedging transactional exposures related to inventory purchases with foreign currency forward contracts. Based on a hypothetical decrease of 10% in the value of the U.S. dollar as of June 30, 2024 and June 30, 2023, the estimated fair value of the Company’s then-existing foreign currency derivative contracts would decrease by $3 and $6, respectively, with the corresponding impact included in Other comprehensive (loss) income. Based on a hypothetical increase of 10% in the value of the U.S. dollar as of June 30, 2024 and June 30, 2023, the estimated fair value of the Company’s then-existing foreign currency derivative contracts would increase by $3 and $5, respectively.
Interest Rate Risk
The Company can be exposed to interest rate volatility with regard to short-term borrowings, using commercial paper or under the Credit Agreement, in addition to potential changes in interest rates relating to anticipated future issuances of long-term debt. Weighted average interest rates for short-term borrowings using commercial paper were 5.58% during fiscal year 2024 and 3.92% during fiscal year 2023. Assuming average commercial paper borrowing levels during fiscal years 2024 and 2023, a 100 basis point increase or decrease in interest rates would increase or decrease interest expense from short-term borrowings by approximately $2 and $2, respectively.
The Company can also be exposed to interest rate volatility with regard to anticipated future issuances of debt. The Company utilizes interest rate contracts to manage our exposure to interest rate volatility related to movements in U.S. Treasury and swap rates. As of June 30, 2024 and 2023, the Company had no outstanding interest rate contracts.
RECENTLY ISSUED ACCOUNTING STANDARDS
A summary of all recently issued accounting standards is contained in Note 1 of the Notes to Consolidated Financial Statements.

14




CRITICAL ACCOUNTING ESTIMATES
The methods, estimates and judgments the Company uses in applying its most critical accounting policies have a significant impact on the results the Company reports in its consolidated financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates or assumptions that are used. The most critical accounting estimates are those that are most important to the portrayal of the Company’s financial condition and results, and require the Company to make the most difficult and subjective judgments, often estimating the outcome of future events that are inherently uncertain. The Company’s most critical accounting estimates are related to:
Revenue recognition;
The valuation of goodwill and other intangible assets;
Income taxes; and
The Venture Agreement terminal obligation.
The Company’s critical accounting estimates have been reviewed with the Audit Committee of the Board of Directors. A summary of the Company’s significant accounting policies is contained in Note 1 of Notes to Consolidated Financial Statements.
Revenue Recognition
The Company’s revenue is primarily generated from the sale of finished products to customers. This revenue is reported net of certain variable consideration provided to customers, generally in the form of one-time and ongoing trade promotion programs. These trade promotion programs include shelf price reductions, in-store merchandising, consumer coupons and other trade-related activities. Amounts accrued for trade promotions are based on various factors such as contractual terms and sales volumes, and also incorporate estimates that include customer participation rates, the rate at which customers will achieve program performance criteria, product availability and historical consumer redemption rates. The actual amounts remitted to customers for these activities may differ from the Company’s estimates, depending on how actual results of the programs compare to the estimates. If the Company’s trade promotion accrual estimates as of June 30, 2024 were to increase or decrease by 10%, the impact on net sales would be approximately $14.
Goodwill and Other Intangible Assets
The Company tests its goodwill and other indefinite-lived intangible assets for impairment annually in the fiscal fourth quarter unless there are indications during a different interim period that these assets may have become impaired.
Goodwill
For fiscal year 2024, the Company’s SBUs were organized into the reporting units used for goodwill impairment testing purposes. These reporting units, which are also the Company’s operating segments, are the level at which discrete financial information is available and reviewed by the manager of the respective operating segments. The respective operating segment managers, who have responsibility for operating decisions, allocating resources and assessing performance within their respective segments, do not review financial information for components that are below the operating segment level.
In its evaluation of goodwill impairment, the Company has the option to first assess qualitative factors such as the maturity and stability of the reporting unit, the magnitude of the excess fair value over the carrying value from a prior period’s impairment testing, other reporting unit operating results, microeconomic and macroeconomic factors, as well as new events and circumstances impacting the operations at the reporting unit level. If the test indicates that it is more likely than not that a reporting unit is impaired, a quantitative test is performed. In the quantitative test, the Company compares the estimated fair value of each reporting unit to its carrying value. If the estimated fair value of any reporting unit is less than its carrying value, an impairment charge is recorded for the difference between the carrying value and the fair value of the reporting unit.
Determining the fair value of a reporting unit requires significant judgments, assumptions and estimates by management which are subject to uncertainty. The Company uses a discounted cash flow (DCF) method under the income approach for its quantitative test, as it believes that this approach is the most reliable indicator of the fair value of its businesses and the fair value of their future earnings and cash flows. Under this approach, the Company estimates the future cash flows of each reporting unit and discounts these cash flows at a rate of return that reflects their relative risk. The cash flows used in the DCF method are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced and the long-term business strategy. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates, commodity prices, foreign exchange rates, inflation and a terminal growth

15



rate. Future changes in the judgments, assumptions and estimates that are used in the impairment testing for goodwill could result in significantly different estimates of the fair values and future impairment charges.
During the third quarter of fiscal year 2023, management made a decision to narrow the focus on core brands and streamline investment levels in the Better Health VMS business. As a result, revisions were made to the internal financial projections and operational plans of the Better Health VMS business reflecting the Company's current estimates regarding the future financial performance of these operations and macroeconomic factors. The revised estimated cash flows reflected lower sales growth expectations and lower investment levels. These events were considered a triggering event requiring interim impairment assessments to be performed as part of the preparation of the quarterly financial statements on the global indefinite-lived trademarks, other long-term assets and the Better Health VMS reporting unit. Based on the outcome of these assessments, a $306 goodwill impairment charge was recorded during the third quarter of fiscal year 2023. There is no remaining goodwill associated with the impaired reporting unit.
No heightened risk of impairment or impairments were identified in fiscal year 2024 as a result of the Company’s impairment review performed annually during the fourth quarter or during any other quarters of fiscal year 2024.
Trademarks and Other Indefinite-Lived Intangible Assets
For trademarks and other intangible assets with indefinite lives, the Company has the option to first assess qualitative factors, such as the maturity and stability of the trademark or other intangible asset, the magnitude of the excess fair value over carrying value from a prior period’s impairment testing, other specific operating results, as well as new events and circumstances impacting the significant inputs used to determine the fair value of the intangible asset. If the result of a qualitative test indicates that it is more likely than not that the asset is impaired, a quantitative test is performed. When a quantitative test is performed, the estimated fair value of an asset is compared to its carrying value. If the carrying value of such asset exceeds its estimated fair value, an impairment charge is recorded for the difference between the carrying value and the estimated fair value. The Company uses a DCF method under the relief from royalty income approach to estimate the fair value of its trademarks and other intangible assets with indefinite lives. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows, including consideration of related net sales growth rates, as well as the appropriate discount and foreign exchange rates applied to those cash flows to determine fair value. Future changes in such estimates or the use of alternative assumptions could result in significantly different estimates of the fair values.
During the third quarter of fiscal year 2023, as a result of the interim impairment assessments performed on various Better Health VMS assets as noted above, an impairment charge of $139 was recorded to indefinite-lived intangible assets associated with the Better Health VMS business. The useful lives of the impaired trademarks, with a remaining net carrying value of $28 as of March 31, 2023, were changed from indefinite to finite beginning on April 1, 2023.
No heightened risk of impairment or significant impairments were identified in fiscal year 2024.
Finite-Lived Intangible Assets
Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying value of an asset (or asset group) may not be recoverable. The Company’s impairment review requires significant judgment by management, including estimating the future success of product lines, future sales volumes, revenue and expense growth rates, alternative uses for the assets and proceeds from the disposal of the assets. The Company reviews business plans for possible impairment indicators. The risk of impairment is initially assessed based on an estimate of the undiscounted cash flows at the lowest level for which identifiable cash flows exist. The asset (or asset group) is not recoverable when the carrying value of the asset exceeds the estimated future undiscounted cash flows generated by the asset. When impairment is indicated, an impairment charge is recorded for the difference between the asset’s (or asset group’s) carrying value and its estimated fair value. Depending on the asset, estimated fair value may be determined either by use of a DCF method or, if available, by reference to estimated selling values of assets in similar condition. These approaches require significant judgments in determining the assumptions utilized in the DCF or the selection of comparable assets, as applicable. Future changes in such estimates or the use of alternative assumptions could result in significantly different estimates of the fair values.
No significant impairments for finite-lived intangible assets were identified in fiscal year 2024.
Income Taxes
The Company’s effective tax rate is based on income by tax jurisdiction, statutory tax rates and tax planning opportunities available to the Company in the various jurisdictions in which the Company operates. Significant judgment is required in determining the Company’s effective tax rate and in evaluating its tax positions.

16



The Company maintains valuation allowances when it is likely that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances from period to period are included in the Company’s income tax provision in the period of change. In determining whether a valuation allowance is warranted, the Company takes into account many factors, including the specific tax jurisdiction, both historical and projected future earnings, carryback and carryforward periods and tax planning strategies. Many of the judgments made in adjusting valuation allowances involve assumptions and estimates that are highly subjective. Valuation allowances maintained by the Company relate mostly to deferred tax assets arising from the Company’s currently anticipated inability to use federal and state capital losses generated by the 2024 sale of the Company's Argentina business (see Notes to Consolidated Financial Statements). Other valuation allowances relate to deferred tax assets for net operating losses and tax credits in certain foreign countries.
In addition to valuation allowances, the Company establishes uncertain tax positions when such tax positions do not meet certain recognition thresholds or measurement standards as defined by generally accepted accounting principles. These uncertain tax positions are adjusted as a result of changes in factors such as tax legislation, interpretations of laws by courts, rulings by tax authorities, new audit developments, changes in estimates and the expiration of the statute of limitations. Amounts for uncertain tax positions are adjusted in quarters when new information becomes available or when positions are effectively settled. Many of the judgments made in adjusting uncertain tax positions involve assumptions and estimates regarding audit outcomes and the timing of audit settlements, which are often uncertain and subject to change.
Venture Agreement Terminal Obligation
The Company has a Venture Agreement with P&G for the Company’s Glad bags and wraps business. As of June 30, 2024 and June 30, 2023, P&G had a 20% interest in the venture. Upon termination of the agreement, currently set for January 2026, unless the parties agree to a further extension, the Company is required to purchase P&G’s 20% interest for cash at fair value as established by predetermined valuation procedures. The Company’s obligation to purchase P&G’s interest is reflected in Other liabilities. The $4 increase in the estimated fair value of P&G’s interest since June 30, 2023 was attributable to an increase in the estimated future cash flows since the prior valuation. The difference between the estimated fair value and the amount recognized, and any future changes in the fair value of P&G’s interest, is charged to cost of products sold in accordance with the effective interest method over the remaining life of the agreement. See Notes to Consolidated Financial Statements for additional information on the Venture Agreement.
The estimated fair value of P&G’s interest may increase or decrease up until any such purchase by the Company of P&G’s interest. The Company uses the DCF method under the income approach to estimate the fair value of P&G’s interest. Under this approach, the Company estimates the future cash flows and discounts these cash flows at a rate of return that reflects its risk. The cash flows used are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced and the long-term business strategy. The other key assumptions and estimates used include, but are not limited to, net sales and expense growth rates, commodity prices, foreign exchange rates, discount rates, inflation and terminal growth rates. Fair value determination requires significant judgment, assumptions and market factors which are uncertain and subject to change. Changes in the judgments, assumptions and market factors used could result in significantly different estimates of fair value. For perspective, if the discount rate as of June 30, 2024 were to increase or decrease by 100 basis points, the estimated fair value of P&G’s interest would decrease by approximately $54 or increase by approximately $69, respectively. Such changes would affect the amount of future charges to Cost of products sold.
SUMMARY OF NON-GAAP FINANCIAL MEASURES
The non-GAAP financial measures that may be included in this MD&A and Exhibit 99.2 and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.
Free cash flow is calculated as net cash provided by operations less capital expenditures. The Company’s management uses this measure and Free cash flow as a percentage of net sales to help assess the cash generation ability of the business and funds available for investing activities, such as acquisitions, investing in the business to drive growth and financing activities, including debt payments, dividend payments and stock repurchases. Free cash flow does not represent cash available only for discretionary expenditures since the Company has mandatory debt service requirements and other contractual and non-discretionary expenditures. Refer to “Free cash flow” and “Free cash flow as a percentage of net sales” above for a reconciliation of these non-GAAP measures.
EBIT represents earnings before income taxes, interest income and interest expense. EBIT margin is the ratio of EBIT to net sales. The Company’s management believes these measures provide useful additional information to investors to enhance their understanding about trends in the Company’s operations and are useful for period-over-period comparisons.

17



Adjusted earnings (losses) before interest and income taxes (adjusted EBIT) represents earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability). The Company uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance, and allocate resources to each segment. Management believes that the presentation of adjusted EBIT is useful to investors to assess operating performance on a consistent basis by removing the impact of the items that management believes does not directly reflect the performance of each segment's underlying operations. Adjusted EBIT margin is the ratio of adjusted EBIT to net sales.
Reconciliation of earnings (losses) before income taxes to adjusted EBIT
Fiscal year
202420232022
Earnings (losses) before income taxes$398 $238 $607 
Interest income(23)(16)(5)
Interest expense90 90 106 
Loss on divestiture (1)
240 — — 
Pension settlement charge (2)
171 — — 
Cyberattack costs, net of insurance recoveries (3)
29 — — 
VMS impairment (4)
— 445 — 
Streamlined operating model (5)
32 60 — 
Digital capabilities and productivity enhancements investment (6)
108 100 61 
Adjusted EBIT$1,045 $917 $769 
(1)Represents loss related to the divestiture of the Argentina business. Due to the nature, scope and magnitude of these costs, the Company’s management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the Company’s operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by Company management. See Notes to Consolidated Financial Statements for additional information.
(2)Represents costs related to the settlement of the domestic qualified pension plan recorded in fiscal year 2024. Due to the nature, scope and magnitude of these costs, the Company’s management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the Company’s operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by Company management. See Notes to Consolidated Financial Statements for additional information.
(3)Represents incremental costs, net of insurance recoveries, related to the cyberattack recorded in fiscal year 2024. Due to the nature, scope and magnitude of these costs, the Company’s management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the Company’s operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by Company management. See Notes to Consolidated Financial Statements for additional information.
(4)Represents a noncash impairment charge related to the Better Health VMS business recorded in fiscal year 2023. The Company’s management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the Company’s underlying operating results and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by Company management.
(5)Represents restructuring and related implementation costs, net for the streamlined operating model. Due to the nonrecurring and unusual nature of these costs, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.
(6)Represents expenses related to the Company's digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Due to the nature, scope and magnitude of this investment, these costs are considered by management to represent incremental transformational costs above the historical normal level of spending for information technology to support operations. Since these strategic investments, including incremental operating costs, will cease at the end of the investment period, are not expected to recur in the foreseeable future and are not considered representative of the company's underlying operating performance, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period-over-period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.
Of the total investment, approximately 70% is expected to represent incremental operating costs primarily recorded within selling and administrative expenses to be adjusted from reported Earnings (losses) before income taxes for purposes of disclosing adjusted EBIT over the course of the next five

18



years. About 70% of these operating costs are expected to be related to the implementation of the ERP, with the remaining costs primarily related to the implementation of complementary technologies.
During the fiscal years ended June 30, 2024 and 2023, the Company incurred approximately $108 and $100, respectively, of operating expenses related to its digital capabilities and productivity enhancements investment. The expenses relate to the following:
Fiscal year
20242023
External consulting fees (1)
$80 $79 
IT project personnel costs (2)
Other (3)
20 15 
Total$108 $100 

(1)Comprised of third-party consulting fees incurred to assist in the project management and end-to-end systems integration of this transformative investment. The company relies on consultants for certain capabilities required for these programs that the company does not maintain internally. These costs support the implementation of these programs incremental to the company's normal IT costs and will not be incurred following implementation.
(2)Comprised of labor costs associated with internal IT project management teams that are utilized to oversee the new system implementations. Given the magnitude and transformative nature of the implementations planned, the necessary project management costs are incremental to the historical levels of spend and will no longer be incurred subsequent to implementation. As a result of this long-term strategic investment, the company considers these costs not reflective of the ongoing costs to operate its business.
(3)Comprised of various other expenses associated with the company’s new system implementations, including company personnel dedicated to the project that have been backfilled with either permanent or temporary resources in positions that are considered part of normal operating expenses.
Economic profit (EP) is defined by the Company as earnings before income taxes, excluding certain U.S. GAAP items (such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the cyberattack, asset impairments, charges related to implementation of the streamlined operating model, charges related to digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability) and interest expense; less income taxes (calculated based on the Company’s effective tax rate excluding the identified U.S. GAAP items), and less after tax profit attributable to noncontrolling interests, and less a capital charge (calculated as average capital employed multiplied by a cost of capital rate). EP is a key financial metric that the Company’s management uses to evaluate business performance and allocate resources, and is a component in determining employee incentive compensation. The Company’s management believes EP provides additional perspective to investors about financial returns generated by the business and represents profit generated over and above the cost of capital used by the business to generate that profit. Refer to Exhibit 99.2 for a reconciliation of EP to earnings before income taxes.
Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions or divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions or divestitures, which results in a comparison of sales only from the businesses that the Company was operating and expects to continue to operate throughout the relevant periods, and the Company’s estimate of the impact of foreign exchange rate changes, which are difficult to predict, and out of the control of the Company and management.
The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:
Year Ended June 30, 2024
Percentage change versus the year-ago period
Health and Wellness HouseholdLifestyleInternational
Total Company (1)
Net sales growth / (decrease) (GAAP) (2)%(7)%(5)%(2)%(4)%
Add: Foreign Exchange — — — 21 
Add/(Subtract): Divestitures/Acquisitions (2)
— — — 
Organic sales growth / (decrease) (non-GAAP) (2)%(7)%(5)%23 %— %
(1) Total company includes Corporate and Other.
(2)The Argentina divestiture impact is calculated as net sales from the Argentina business after March 20, the divestiture date, until the end of the twelve month period for the year-ago period.


19



CAUTIONARY STATEMENT
This Annual Report on Form 10-K (this Report), including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements regarding the expected or potential impact of the Company’s operational disruption stemming from a cyberattack, and any such forward-looking statements involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect the Company's current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to:
unfavorable general economic and geopolitical conditions beyond the Company's control, including supply chain disruptions, labor shortages, wage pressures, rising inflation, the interest rate environment, fuel and energy costs, foreign currency exchange rate fluctuations, weather events or natural disasters, disease outbreaks or pandemics, such as COVID-19, terrorism, and unstable geopolitical conditions, including ongoing conflicts in the Middle East and Ukraine and rising tensions between China and Taiwan, as well as macroeconomic and geopolitical volatility and uncertainty as a result of a number of these and other factors, including actual and potential shifts between the U.S. and its trading partners, especially China;
the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;
the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;
our recovery from the cyberattack, and risks related to the Company’s use of and reliance on information technology systems, including potential and actual security breaches, cyberattacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, business, service or operational disruptions, or that impact the Company's financial results or financial reporting, or any resulting unfavorable outcomes, increased costs or legal proceedings;
intense competition in the Company’s markets;
volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services;
risks related to supply chain issues, product shortages and disruptions to the business, as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers;
the ability of the Company to implement and generate cost savings and efficiencies, and successfully implement its transformational initiatives or strategies, including achieving anticipated benefits and cost savings from the implementation of the streamlined operating model and digital capabilities and productivity enhancements;
the Company’s ability to maintain its business reputation and the reputation of its brands and products;
dependence on key customers and risks related to customer consolidation and ordering patterns;
the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;
the Company’s ability to attract and retain key personnel, which may continue to be impacted by challenges in the labor market, such as increasing labor costs and sustained labor shortages;
lower revenue, increased costs or reputational harm resulting from government actions and compliance with regulations, or any material costs imposed by changes in regulation;

20



changes to the Company's processes and procedures as a result of its digital capabilities and productivity enhancements that may result in changes to the Company's internal controls over financial reporting;
the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;
risks related to international operations and international trade, including changing macroeconomic conditions as a result of inflation, volatile commodity prices and increases in raw and packaging materials prices, labor, energy and logistics; global economic or political instability; foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls; changes in governmental policies, including trade, travel or immigration restrictions, new or additional tariffs, and price or other controls; labor claims and civil unrest; potential operational or supply chain disruptions from wars and military conflicts, including ongoing conflicts in the Middle East and Ukraine and rising tensions between China and Taiwan; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;
the impact of Environmental, Social, and Governance (ESG) issues, including those related to climate-related transition risks, changing consumer preferences, including the environmental impact of the Company's products and sustainability on sales, operating costs or reputation;
the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls;
risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill, in particular the impairment charges related to the carrying value of the company's Better Health VMS business and the divestiture of and related loss on the announced sale of the Better Health VMS business; and the ability to complete announced transactions and, if completed, integration costs and potential contingent liabilities related to those transactions;
the accuracy of the Company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based;
risks related to increases in the estimated fair value of P&G’s interest in the Glad business;
risks related to the Company's reliance on third-party service providers, including inability to meet cost savings or efficiencies, business or systems disruptions, and other liabilities, including legal or regulatory risk;
environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;
the Company’s ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by the Company of third-party intellectual property rights;
the effect of the Company’s indebtedness and credit rating on its business operations and financial results and the Company’s ability to access capital markets and other funding sources, as well as the cost of capital to the Company;
the COVID-19 pandemic and related impacts, including on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any significant disruption to such systems; on the demand for and sales of the Company’s products; and on worldwide, regional and local adverse economic conditions;
the Company’s ability to pay and declare dividends or repurchase its stock in the future;
the impacts of potential stockholder activism; and
risks related to any litigation associated with the exclusive forum provision in the Company’s bylaws.
The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws. In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.

21



MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process designed under the supervision of its Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external reporting in accordance with accounting principles generally accepted in the United States of America.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.
Management evaluated the effectiveness of the Company’s internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework published in 2013. Management, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company’s internal control over financial reporting as of June 30, 2024, and concluded that it is effective.
The Company’s independent registered public accounting firm, Ernst & Young LLP, has audited the effectiveness of the Company’s internal control over financial reporting as of June 30, 2024, as stated in their report, which is included herein.

22



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of The Clorox Company
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of The Clorox Company (the Company) as of June 30, 2024 and 2023, the related consolidated statements of earnings, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended June 30, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2024, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of June 30, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated August 8, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

23



Valuation of Venture Agreement Terminal Obligation
Description of the Matter

As discussed in Note 11 of the consolidated financial statements, the Company has an agreement with The Procter & Gamble Company (P&G) for the Company’s Glad bags and wraps business, for which the Company is required to purchase P&G’s 20% interest in the venture for cash at fair value of the global Glad business upon termination of the agreement. At June 30, 2024, $510 million of the estimated fair value of $531 million has been recognized as a venture agreement terminal obligation and represented 10% of total liabilities.
 
Auditing the Company’s Glad venture agreement terminal obligation is complex and highly judgmental and required the involvement of a valuation specialist due to the significant judgment in estimating the fair value of the global Glad business. In particular, the fair value estimate is sensitive to significant assumptions such as changes in net sales growth rates, gross margins, and discount rates. These assumptions are sensitive to and affected by expected future market or economic conditions, industry and company-specific qualitative factors.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the venture agreement terminal obligation valuation review process, including controls over the significant assumptions described above.
 
To test the estimated fair value of the venture agreement terminal obligation, we performed audit procedures that included, among others, assessing the methodologies and testing the significant assumptions discussed above and the underlying data used by the Company in its analysis. We compared the significant assumptions used by management to current industry and economic trends, the Company’s historical results and other guideline companies within the same industry, and we evaluated whether changes in the Company’s business and other factors, would affect the significant assumptions. We assessed the historical accuracy of management’s estimates and performed sensitivity analyses of significant assumptions to evaluate the change in the fair value of the venture agreement terminal obligation resulting from changes in these assumptions. We involved our valuation specialists to assist in reviewing the valuation methodology and testing the terminal growth rates and discount rates.

/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2003.
San Francisco, California
August 8, 2024


24



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of The Clorox Company
Opinion on Internal Control Over Financial Reporting
We have audited The Clorox Company’s internal control over financial reporting as of June 30, 2024, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, The Clorox Company (the Company) maintained, in all material respects, effective internal control over financial reporting as of June 30, 2024, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of June 30, 2024 and 2023, the related consolidated statements of earnings, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended June 30, 2024, and the related notes and our report dated August 8, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
San Francisco, California
August 8, 2024

25



CONSOLIDATED STATEMENTS OF EARNINGS
The Clorox Company
Years ended June 30
Dollars in millions, except per share data202420232022
Net sales$7,093 $7,389 $7,107 
Cost of products sold4,045 4,481 4,562 
Gross profit3,048 2,908 2,545 
Selling and administrative expenses1,167 1,183 954 
Advertising costs832 734 709 
Research and development costs126 138 132 
Loss on divestiture
240   
Pension settlement charge
171   
Goodwill, trademark and other asset impairments 445  
Interest expense90 90 106 
Other (income) expense, net24 80 37 
Earnings before income taxes398 238 607 
Income taxes106 77 136 
Net earnings292 161 471 
Less: Net earnings attributable to noncontrolling interests12 12 9 
Net earnings attributable to Clorox$280 $149 $462 
Net earnings per share attributable to Clorox
Basic net earnings per share$2.26 $1.21 $3.75 
Diluted net earnings per share$2.25 $1.20 $3.73 
Weighted average shares outstanding (in thousands)
Basic124,174 123,589 123,113 
Diluted124,804 124,181 123,906 

See Notes to Consolidated Financial Statements


26



CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
The Clorox Company
Years ended June 30  
Dollars in millions202420232022
Net earnings$292 $161 $471 
Other comprehensive (loss) income:
Foreign currency adjustments, net of tax206 3 (45)
Net unrealized gains (losses) on derivatives, net of tax(14)(22)100 
Pension and postretirement benefit adjustments, net of tax146 5 12 
Total other comprehensive (loss) income, net of tax338 (14)67 
Comprehensive income630 147 538 
Less: Total comprehensive income attributable to noncontrolling interests12 12 9 
Total comprehensive income attributable to Clorox$618 $135 $529 

See Notes to Consolidated Financial Statements


27



CONSOLIDATED BALANCE SHEETS
The Clorox Company
As of June 30
Dollars in millions, except per share data20242023
ASSETS  
Current assets
Cash and cash equivalents$202 $367 
Receivables, net695 688 
Inventories, net637 696 
Prepaid expenses and other current assets88 77 
Total current assets1,622 1,828 
Property, plant and equipment, net1,315 1,345 
Operating lease right-of-use assets360 346 
Goodwill1,228 1,252 
Trademarks, net538 543 
Other intangible assets, net143 169 
Other assets545 462 
Total assets$5,751 $5,945 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Notes and loans payable$4 $50 
Current operating lease liabilities84 87 
Accounts payable and accrued liabilities1,486 1,659 
Income taxes payable 121 
Total current liabilities1,574 1,917 
Long-term debt2,481 2,477 
Long-term operating lease liabilities334 310 
Other liabilities848 825 
Deferred income taxes22 28 
Total liabilities5,259 5,557 
Commitments and contingencies
Stockholders’ equity
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding
  
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of June 30, 2024 and 2023; and 124,201,807 and 123,820,022 shares outstanding as of June 30, 2024 and 2023, respectively
131 131 
Additional paid-in capital1,288 1,245 
Retained earnings250 583 
Treasury stock, at cost: 6,539,654 and 6,921,439 shares as of June 30, 2024 and 2023, respectively
(1,186)(1,246)
Accumulated other comprehensive net (loss) income(155)(493)
Total Clorox stockholders’ equity328 220 
Noncontrolling interests164 168 
Total stockholders’ equity492 388 
Total liabilities and stockholders’ equity$5,751 $5,945 

See Notes to Consolidated Financial Statements

28



CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
The Clorox Company
Common StockAdditional
Paid-in
Capital
Treasury StockAccumulated
Other
Comprehensive
Net (Loss) Income
Noncontrolling interests
Total Stockholders Equity
(Dollars in millions except per share data; shares in thousands)
AmountSharesRetained
Earnings
AmountShares
Balance as of June 30, 2021$131 130,741 $1,186 $1,036 $(1,396)(7,961)$(546)$181 $592 
Net earnings— — — 462 — — — 9 471 
Other comprehensive (loss) income— — — — — — 67 — 67 
Dividends to Clorox stockholders ($3.48 per share declared)
— — — (430)— — — — (430)
Dividends to noncontrolling interests— — — — — — — (17)(17)
Stock-based compensation— — 52 — — — — — 52 
Other employee stock plan activities— — (36)(20)75 524 — — 19 
Treasury stock purchased— — — — (25)(152)— — (25)
Balance as of June 30, 2022131 130,741 1,202 1,048 (1,346)(7,589)(479)173 729 
Net earnings— — — 149 — — — 12 161 
Other comprehensive (loss) income— — — — — — (14)— (14)
Dividends to Clorox stockholders ($4.72 per share declared)
— — — (588)— — — — (588)
Dividends to noncontrolling interests— — — — — — — (17)(17)
Stock-based compensation— — 73 — — — — — 73 
Other employee stock plan activities— — (30)(26)100 668 — — 44 
Balance as of June 30, 2023131 130,741 1,245 583 (1,246)(6,921)(493)168 388 
Net earnings— — — 280 — — — 12 292 
Other comprehensive (loss) income— — — — — — 338 — 338 
Dividends to Clorox stockholders ($4.80 per share declared)
— — — (600)— — — — (600)
Dividends to noncontrolling interests— — — — — — — (16)(16)
Stock-based compensation— — 74 — — — — — 74 
Other employee stock plan activities— — (31)(13)60 381 — — 16 
Balance as of June 30, 2024$131 130,741 $1,288 $250 $(1,186)(6,540)$(155)$164 $492 

See Notes to Consolidated Financial Statements


29



CONSOLIDATED STATEMENTS OF CASH FLOWS
The Clorox Company
Years ended June 30
Dollars in millions202420232022
Operating activities:
Net earnings$292 $161 $471 
Adjustments to reconcile net earnings to net cash provided by operations:
Depreciation and amortization235 236 224 
Stock-based compensation74 73 52 
Deferred income taxes(100)(149)5 
Loss on divestiture
238   
Pension settlement charge
171   
Goodwill, trademark and other asset impairments 445  
Settlement of interest rate derivative contracts  114 
Other26 38 19 
Changes in:
Receivables, net(34)(13)(84)
Inventories, net55 58 (18)
Prepaid expenses and other current assets25 (1)16 
Accounts payable and accrued liabilities(140)157 (47)
Operating lease right-of-use assets and liabilities, net 1 (1)
Income taxes payable/prepaid(147)152 35 
Net cash provided by operations695 1,158 786 
Investing activities:
Capital expenditures(212)(228)(251)
Proceeds from divestiture, net of cash divested
17   
Other20 5 22 
Net cash used for investing activities(175)(223)(229)
Financing activities:
Notes and loans payable, net(45)(188)237 
Long-term debt repayments  (1,405)
Long-term debt borrowings, net of issuance costs paid  1,085 
Treasury stock purchased  (25)
Cash dividends paid to Clorox stockholders(595)(583)(571)
Cash dividends paid to noncontrolling interests(16)(15)(15)
Issuance of common stock for employee stock plans and other1 33 5 
Net cash used for financing activities(655)(753)(689)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(26) (6)
Net increase (decrease) in cash, cash equivalents and restricted cash(161)182 (138)
Cash, cash equivalents and restricted cash:
Beginning of year368 186 324 
End of year$207 $368 $186 
Supplemental cash flow information:
Interest paid$102 $99 $89 
Income taxes paid, net of refunds347 73 100 
Noncash financing activities:
Cash dividends declared and accrued, but not paid16 16 14 


See Notes to Consolidated Financial Statements

30



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The Clorox Company
(Dollars in millions, except per share data)
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations and Basis of Presentation
The Company is principally engaged in the production, marketing and sale of consumer products through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. The consolidated financial statements include the statements of the Company and its wholly owned and controlled subsidiaries. All significant intercompany transactions and accounts were eliminated in consolidation.
Use of Estimates
The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to reach opinions as to estimates and assumptions that affect reported amounts and related disclosures. Specific areas requiring the application of management’s estimates and judgments include, among others, assumptions pertaining to accruals for consumer and trade promotion programs, future cash flows associated with impairment testing of goodwill and other long-lived assets, uncertain tax positions, tax valuation allowances, the valuation of the Venture Agreement terminal obligation, stock-based compensation, retirement income plans and legal, environmental and insurance matters. Actual results could materially differ from estimates and assumptions made.
Cash, Cash Equivalents and Restricted Cash
Cash equivalents consist of highly liquid interest-bearing accounts, time deposits held by financial institutions and money market funds with an initial maturity at purchase of 90 days or less. The fair value of cash and cash equivalents approximates the carrying amount.
The Company’s cash position includes amounts held by foreign subsidiaries and, as a result, the repatriation of certain cash balances from some of the Company’s foreign subsidiaries could result in additional withholding tax costs in certain foreign jurisdictions. However, these cash balances are generally available without legal restriction to fund local business operations. In addition, a portion of the Company’s cash balance is held in U.S. dollars by foreign subsidiaries whose functional currency is their local currency. Such U.S. dollar balances are reported on the foreign subsidiaries’ books in their functional currency, and the impact on such balances from foreign currency exchange rate differences is recorded in Other (income) expense, net.
As of June 30, 2024, 2023, 2022 and 2021, the Company had $5, $1, $3 and $5 of restricted cash, respectively, which was included in Prepaid expenses and other current assets and Other assets.
Inventories
The Company values its inventories using both the First-In, First-Out (FIFO) and the Last-In, First-Out (LIFO) methods. The FIFO inventory is stated at the lower of cost or net realizable value, which includes any costs to sell or dispose. In addition, appropriate consideration is given to obsolescence, excessive inventory levels, product deterioration and other factors in evaluating net realizable value. The LIFO inventory is stated at the lower of cost or market.

31

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Property, Plant and Equipment and Finite-Lived Intangible Assets
Property, plant and equipment and finite-lived intangible assets are stated at cost. Depreciation and amortization expense are primarily calculated by the straight-line method using the estimated useful lives or lives determined by reference to the related lease contract in the case of leasehold improvements. The table below provides estimated useful lives of property, plant and equipment by asset classification.
Estimated
Useful Lives
Buildings and leasehold improvements
5 - 40 years
Land improvements
10 - 30 years
Machinery and equipment
3 - 15 years
Computer equipment
3 - 5 years
Capitalized software costs
3 - 7 years
Finite-lived intangible assets are amortized over their estimated useful lives, which range from 7 to 30 years.
Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be fully recoverable. The risk of impairment is initially assessed based on an estimate of the undiscounted cash flows at the lowest level for which identifiable cash flows exist. Impairment occurs when the carrying value of the asset (or asset group) exceeds the estimated future undiscounted cash flows generated by the asset (or asset group). When impairment is indicated, an impairment charge is recorded for the difference between the carrying value of the asset (or asset group) and its estimated fair market value. Depending on the asset, estimated fair market value may be determined either by use of a discounted cash flow model or by reference to estimated selling values of assets in similar condition.
Capitalization of Software Costs
The Company capitalizes certain qualifying costs incurred in the acquisition and development of software for internal use, including the costs of the software, materials, consultants, interest and payroll and payroll-related costs for employees during the application development stage. Internal and external costs incurred during the preliminary project stage and post implementation-operation stage, mainly training and maintenance costs, are expensed as incurred. Once the application is substantially complete and ready for its intended use, qualifying costs are amortized on a straight-line basis over the software’s estimated useful life. Capitalized internal use software is included in Property, plant and equipment. Capitalized software as a service is included in Prepaid expenses and other current assets or Other assets and is amortized using the straight-line method over the term of the hosting arrangement which is typically no greater than 10 years.
Impairment Review of Goodwill and Indefinite-Lived Intangible Assets
The Company tests its goodwill, trademarks with indefinite lives and other indefinite-lived intangible assets annually for impairment in the fiscal fourth quarter unless there are indications during a different interim period that these assets may have become impaired.
With respect to goodwill, the Company has the option to first assess qualitative factors, such as the maturity and stability of the reporting unit, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other reporting unit specific operating results, microeconomic and macroeconomic factors, as well as new events and circumstances impacting the operations at the reporting unit level. The Company operates through strategic business units (SBUs) that are organized into the Company's operating segments. Reporting units for goodwill impairment testing purposes were identified as the Company's individual operating segments. If the result of a qualitative test indicates that it is more likely than not that a reporting unit is impaired, a quantitative test is performed. In the quantitative test, the Company compares the estimated fair value of the reporting unit to its carrying value. If the estimated fair value of any reporting unit is less than its carrying value, an impairment charge is recorded for the difference between the carrying value and the fair value of the reporting unit.
To determine the fair value of a reporting unit as part of its quantitative test, the Company uses the discounted cash flow (DCF) method under the income approach, as it believes that this approach is the most reliable indicator of the fair value of its businesses and the fair value of its future earnings and cash flows. Under this approach, which requires significant judgments, the Company estimates the future cash flows of each reporting unit and discounts these cash flows at a rate of return that reflects their relative risk. The cash flows used in the DCF method are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced, and the broader business strategy for the long term. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates,

32

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
commodity prices, foreign exchange rates, inflation and a terminal growth rate. Changes in such estimates or the application of alternative assumptions could produce different results.
For trademarks and other intangible assets with indefinite lives, the Company has the option to first assess qualitative factors, such as the maturity and stability of the trademark or other intangible asset, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other specific operating results, as well as new events and circumstances impacting the significant inputs used to determine the fair value of the intangible asset. If the result of a qualitative test indicates that it is more likely than not that the asset is impaired, a quantitative test is performed. When a quantitative test is performed, the estimated fair value of an asset is compared to its carrying value. If the carrying value of such asset exceeds its estimated fair value, an impairment charge is recorded for the difference between the carrying value and the estimated fair value. The Company uses the DCF method under the relief from royalty income approach to estimate the fair value of its trademarks and other intangible assets with indefinite lives. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows, as well as the appropriate discount and foreign exchange rates applied to those cash flows to determine fair value. Changes in such estimates or the use of alternative assumptions could produce different results.
Leases
The Company determines whether an arrangement contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration and other facts and circumstances. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date and initial direct costs incurred by the Company and excludes any lease incentives received from the lessor. The Company reviews ROU assets for impairment consistent with the approach applied for its other long-lived assets. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. The lease term may include an option to extend or terminate the lease when it is reasonably certain that the Company will exercise that option as of the commencement date of the lease, and is reviewed in subsequent periods if a triggering event occurs. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date based on the lease term and the currency of the lease on a collateralized basis. Variable lease payments are the portion of lease payments that are not fixed over the lease term. Variable lease payments are expensed as incurred, and include certain non-lease components, such as maintenance and other services provided by the lessor, and other charges included in the lease, as applicable. The Company elected to combine lease and non-lease components as a single lease component and to exclude short-term leases, defined as leases with an initial term of 12 months or less, from its consolidated balance sheet.
Restructuring Liabilities
The Company incurs restructuring costs in connection with workforce reductions; consolidation or closure of a facility; sale or termination of a line of business; and other actions. Such costs include employee termination benefits (one-time arrangements and benefits attributable to prior service), termination of contractual obligations, noncash asset charges and other direct incremental costs.
The Company records employee termination liabilities once they are both probable and estimable for severance provided under the Company’s existing severance policy. Employee termination liabilities outside of the Company’s existing severance policy are recognized at the time relevant employees are notified, unless the employees will be retained to render service beyond a minimum retention period for transition purposes, in which case the liability is recognized ratably over the future service period. Other costs associated with a restructuring plan or exit or disposal activities, such as consulting and professional fees, facility exit costs, employee relocation, outplacement costs, accelerated depreciation or asset impairments associated with a restructuring plan, are recognized in the period in which the liability is incurred or the asset is impaired.
Stock-based Compensation
The Company grants various nonqualified stock-based compensation awards to eligible employees, including stock options, restricted stock awards and performance shares.
For stock options, the Company estimates the fair value of each award on the date of grant using the Black-Scholes valuation model, which requires management to make estimates regarding expected option life, stock price volatility and other assumptions. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The Company estimates stock option forfeitures based on historical data for each employee grouping. The total number of stock options expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.

33

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
For restricted stock awards, the fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. Forfeitures are estimated based on historical data. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.
The Company’s performance shares provide for the issuance of common stock to certain managerial staff and executive management if the Company achieves specified performance targets. The number of shares issued is dependent upon the achievement of specified performance targets. The performance period is three years and the payout determination is made at the end of the three-year performance period. Performance shares receive dividends earned during the vesting period upon vesting. The fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. The total amount of compensation expense recognized reflects estimated forfeiture rates and management’s assessment of the probability that performance goals will be achieved. A cumulative adjustment is recognized to compensation expense in the current period to reflect any changes in the probability of achievement of performance goals.
Cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for stock-based payment arrangements (excess tax benefits) are classified as operating cash inflows.
Employee Benefits
The Company accounts for its retirement income and retirement health care plans using actuarial methods. These methods use an attribution approach that generally spreads “plan events” over the service lives or expected lifetime (for frozen plans) of plan participants. Examples of plan events are plan amendments and changes in actuarial assumptions such as the expected return on plan assets, discount rate, rate of compensation increase and certain employee-related factors, such as retirement age and mortality. The principle underlying the attribution approach is that employees render service over their employment period on a relatively “smooth” basis and, therefore, the statements of earnings effects of retirement income and retirement health care plans are recognized in the same pattern. One of the principal assumptions used in the net periodic benefit cost calculation is the expected return on plan assets. The expected return on plan assets may result in recognized expense or income that differs from the actual returns of those plan assets in any given year. Over time, however, the goal is for the expected long-term returns to approximate the actual returns and, therefore, the expectation is that the pattern of income and expense recognition should closely match the pattern of the services provided by the participants. The Company uses a market-related value method for calculating plan assets for purposes of determining the amortization of actuarial gains and losses. The differences between actual and expected returns are recognized in the net periodic benefit cost calculation over the average remaining service period or expected lifetime (for frozen plans) of the plan participants using the corridor approach. Under this approach, only actuarial gains (losses) that exceed 5% of the greater of the projected benefit obligation or the market-related value of assets are amortized to the Company’s net periodic benefit cost. In developing its expected return on plan assets, the Company considers the long-term actual returns relative to the mix of investments that comprise its plan assets and also develops estimates of future investment returns by considering external sources.
The Company recognizes an actuarial-based obligation at the onset of disability for certain benefits provided to individuals after employment, but before retirement, that includes medical, dental, vision, life and other benefits.


34

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Environmental Costs
The Company is involved in certain environmental remediation and ongoing compliance activities. Accruals for environmental matters are recorded on a site-by-site basis when it is probable that a liability has been incurred and based upon a reasonable estimate of the liability. The Company’s accruals reflect the anticipated participation of other potentially responsible parties in those instances where it is probable that such parties are legally responsible and financially capable of paying their respective shares of the relevant costs. These accruals are adjusted periodically as assessment and remediation efforts progress or as additional technical or legal information becomes available. Actual costs to be incurred at identified sites in future periods may vary from the estimates, given the inherent uncertainties in evaluating environmental conditions. The accrual for environmental matters is included in Accounts payable and accrued liabilities and Other liabilities in the Company’s consolidated balance sheets on an undiscounted basis due to uncertainty regarding the timing of future payments.
Revenue Recognition
The Company’s revenue is primarily generated from the sale of finished product to customers. Revenue is recognized at the point in time when performance obligations under the terms of customer contracts are satisfied, which is when ownership, risks and rewards transfer, and can be on the date of shipment or the date of receipt by the customer, depending upon the particular customer arrangement. Shipping and handling activities are accounted for as contract fulfillment costs and included within Cost of products sold. After the completion of the performance obligation, there is an unconditional right to consideration as outlined in the contract. A right is considered unconditional if nothing other than the passage of time is required before payment of that consideration is due. The Company typically collects its customer receivables within two months. All performance obligations under the terms of contracts with customers have an original duration of one year or less.
The Company has trade promotion programs, which primarily include shelf price reductions, in-store merchandising and consumer coupons. The costs of such activities, defined as variable consideration under Accounting Standards Codification 606, “Revenue from Contracts with Customers,” are netted against sales and recorded when the related sales take place. Accruals for trade promotion programs are established based on the Company’s best estimate of the amounts necessary to settle existing and future obligations for products sold as of the balance sheet date. Amounts accrued for trade promotions are based on various factors such as contractual terms and sales volumes, and also incorporate estimates that include customer participation rates, the rate at which customers will achieve program performance criteria, product availability and historical consumer redemption rates.
The Company provides an allowance for doubtful accounts based on its historical experience and ongoing assessment of its customers’ credit risk and aging. Customer receivables are presented net of an allowance for doubtful accounts of $5 and $3 as of June 30, 2024 and 2023, respectively. Receivables, net, include non-customer receivables of $39 and $14 as of June 30, 2024 and 2023, respectively, and related allowance of $3 as of both June 30, 2024 and 2023.
Cost of Products Sold
Cost of products sold represents the costs directly related to the manufacture and distribution of the Company’s products and primarily includes raw materials, packaging, contract manufacturing fees, shipping and handling, warehousing, package design, depreciation, amortization, direct and indirect labor and operating costs for the Company’s manufacturing and distribution facilities, including salary, benefit costs and incentive compensation, and royalties and other charges related to the Company’s Glad Venture Agreement (See Note 11).
Costs associated with developing and designing new packaging, including design, artwork, films and labeling, are expensed as incurred and included within Cost of products sold.
Selling and Administrative Expenses
Selling and administrative expenses represent costs incurred by the Company in generating revenues and managing the business and include market research, commissions and certain administrative expenses. Administrative expenses include salary, benefits, incentive compensation, professional fees and services and other operating costs (such as software and licensing costs) associated with the Company’s non-manufacturing, non-research and development operations.
Advertising and Research and Development Costs
The Company expenses advertising and research and development costs in the period incurred.
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective

35

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
tax basis. Management reviews the Company’s deferred tax assets to determine whether their value can be realized based upon available evidence. A valuation allowance is established when management believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s income tax provision in the period of change. In addition to valuation allowances, the Company provides for uncertain tax positions when such tax positions do not meet certain recognition thresholds or measurement standards. Amounts for uncertain tax positions are adjusted in quarters when new information becomes available or when positions are effectively settled.
Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion and determined that none of the undistributed earnings of its foreign subsidiaries are indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable.
The Company accounts for the tax on global intangible low-taxed income (GILTI) as a period cost.
Foreign Currency Transactions and Translation
Local currencies are the functional currencies for substantially all of the Company’s foreign operations. When the transactional currency is different than the functional currency, transaction gains and losses are included as a component of Other (income) expense, net. In addition, certain assets and liabilities denominated in currencies other than a foreign subsidiary’s functional currency are reported on the subsidiary’s books in its functional currency, with the impact from exchange rate differences recorded in Other (income) expense, net. Assets and liabilities of foreign operations are translated into U.S. dollars using the exchange rates in effect at the balance sheet date, while income and expenses are translated at the respective average monthly exchange rates during the year.
Gains and losses on foreign currency translations are reported as a component of Other comprehensive (loss) income. The income tax effect of currency translation adjustments is recorded as a component of deferred taxes with an offset to Other comprehensive (loss) income where appropriate.
Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, since it has experienced cumulative inflation of approximately 100 percent or more over a three-year period. As a result, beginning July 1, 2018, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina (collectively, “Clorox Argentina”). Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities for Clorox Argentina prior to divestment were recognized in Other (income) expense, net in the consolidated statements of earnings.
Derivative Instruments
The Company’s use of derivative instruments, principally exchange-traded futures and options contracts, and over-the counter swaps and forward contracts, is limited to non-trading purposes and is designed to partially manage exposure to changes in commodity prices, foreign currencies and interest rates. The Company’s contracts are hedges for transactions with notional amounts and periods consistent with the related exposures and do not constitute investments independent of these exposures.
The changes in the fair value (i.e., gains or losses) of a derivative instrument are recorded as either assets or liabilities in the consolidated balance sheets with an offset to Net earnings or Other comprehensive (loss) income depending on whether, for accounting purposes, it has been designated and qualifies as an accounting hedge and, if so, on the type of hedging relationship. The criteria used to determine if hedge accounting treatment is appropriate are: (a) formal designation and documentation of the hedging relationship, the risk management objective and hedging strategy at hedge inception; (b) eligibility of hedged items, transactions and corresponding hedging instrument; and (c) effectiveness of the hedging relationship both at inception of the hedge and on an ongoing basis in achieving the hedging objectives. For those derivative instruments designated and qualifying as hedging instruments, the Company must designate the hedging instrument either as a fair value hedge or as a cash flow hedge. The Company designates its commodity futures, options and swaps contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges. During the fiscal years ended June 30, 2024, 2023 and 2022, the Company had no hedging instruments designated as fair value hedges.
For derivative instruments designated and qualifying as cash flow hedges, gains or losses are reported as a component of Other comprehensive (loss) income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. From time to time, the Company may have contracts not designated as hedges for accounting purposes, for which it recognizes changes in the fair value in the consolidated statements of earnings in the current period. Cash flows from hedging activities are classified as operating activities in the consolidated statements of cash flows.

36

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
Recently Adopted Accounting Standards
In September 2022, the FASB issued ASU No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the consolidated financial statements, results of operations, or cash flows.

NOTE 2. DIVESTITURE OF ARGENTINA BUSINESS
On March 20, 2024, the Company completed the sale of its Argentina business, which consisted of two production plants in Argentina as well as the rights to the Company’s brands in Argentina, Uruguay and Paraguay, to Apex Capital and an investment group. The transaction is in support of the Company’s IGNITE strategy and the commitment to evolve the Company’s portfolio to increase focus on its core business to drive more consistent, profitable growth.
The transaction was executed pursuant to a stock purchase agreement, which covered all the outstanding stock of the Clorox Argentina S.A. and Clorox Uruguay S.A. As a result of the transaction, the Company recorded a pre-tax loss of $240 during the third quarter of fiscal year 2024, primarily due to the one-time noncash impact of the release of the cumulative translation adjustment losses of $223 related to these entities that had previously been recorded in Accumulated other comprehensive net (loss) income.
The major classes of assets and liabilities of the Argentina business divested as of March 20, 2024 were as follows:
Divestiture
Working capital, net
$31 
Property, plant and equipment, net
18 
Goodwill (1)
16 
Other assets
3 
Other liabilities
(3)
Net assets divested
$65 
(1)Goodwill corresponding to the International reportable segment.
The following table presents net sales of the Argentina business, which includes the financial results up to March 20, 2024, the date of sale, for fiscal years ended:

37

NOTE 2. DIVESTITURE OF ARGENTINA BUSINESS (CONTINUED)
20242023
Net sales
$123 $172 
The divestiture of the Company’s Argentina business does not meet the criteria to be reported as discontinued operations in the consolidated financial statements as the Company’s decision to divest this business did not represent a strategic shift that will have a major effect on the Company’s operations and financial results.
NOTE 3. CYBERATTACK
On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its Information Technology (IT) systems. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the quarter ended September 30, 2023.
The impacts of these system disruptions included order processing delays and significant product outages, resulting in a negative impact on net sales and earnings. The Company has since transitioned back to automated order processing. The Company experienced lessening operational impacts in the second quarter and has since returned to normalized operations.
The Company incurred incremental costs, net of insurance recoveries, of approximately $29 in fiscal year 2024 as a result of the cyberattack. The Company recognized insurance recoveries of $30 in the fourth quarter of fiscal year 2024. The following table summarizes the recognition of costs, net of insurance recoveries, as reflected in the consolidated statements of earnings and comprehensive income for the fiscal year ended June 30:
2024
Costs of products sold
$17 
Selling and administrative expenses
12 
Total$29 
The costs incurred relate primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs incurred from the resulting disruption to the Company’s business operations. The Company does not expect to incur significant costs related to the cyberattack in future periods. The timing of recognizing further insurance recoveries may differ from the timing of recognizing the associated expenses.
NOTE 4. SUPPLY CHAIN FINANCING PROGRAM
The Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier by selling the Company’s payables to the financial institution. Participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets, cash flows or liquidity. The Company has not pledged any assets as security or provided guarantees under the SCF program.
All outstanding amounts related to suppliers participating in the SCF program are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets and the associated June 30, 2024 and 2023, the amount due to suppliers participating in the SCF program and included in Accounts payable and accrued liabilities was $205 and $220, respectively.

38


NOTE 5. RESTRUCTURING AND RELATED COSTS
Beginning in the first quarter of fiscal year 2023, the Company recognized costs related to a plan that involves streamlining its operating model to meet its objectives of driving growth and productivity. The streamlined operating model is expected to enhance the Company’s ability to respond more quickly to changing consumer behaviors and innovate faster. The implementation of this new model was completed in fiscal year 2024.
The Company incurred $32 and $60 of costs in fiscal year 2024 and 2023, respectively. Costs incurred are expected to be settled primarily in cash.
The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model plan as reflected in the consolidated statements of earnings and comprehensive income for the fiscal years ended June 30 were:
20242023
Costs of products sold$ $(3)
Selling and administrative expenses16 12 
Research and development (1)
Other (income) expense, net:
Employee-related costs10 52 
Asset impairments6  
Total Other (income) expense, net:16 52 
Total, net$32 $60 
Employee-related costs primarily include severance and other termination benefits calculated based on salary levels, prior service and statutory requirements. Other costs primarily include consulting fees incurred for the organizational design and implementation of the streamlined operating model, related processes and other professional fees incurred.
The Company may, from time to time, decide to pursue additional restructuring-related initiatives that involve costs in future periods.
The following table reconciles the accrual for the streamlined operating model restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets as follows for the fiscal years ended June 30:
Employee-Related CostsOtherTotal
Accrual Balance as of June 30, 2023
$23 $5 $28 
Charges
10 19 29 
Cash payments
(25)(13)(38)
Accrual Balance as of June 30, 2024$8 $11 $19 

39


NOTE 6. INVENTORIES, NET
Inventories, net consisted of the following as of June 30:
20242023
Finished goods$556 $595 
Raw materials and packaging172 182 
Work in process9 8 
LIFO allowances(98)(87)
Total inventories, net639 698 
Non-current inventories, net (1)
2 2 
Total current inventories, net$637 $696 
(1)Non-current inventories, net is recorded in Other assets.
The LIFO method was used to value approximately 36% of inventories as of June 30, 2024 and 2023, respectively. The carrying values for all other inventories are determined on the FIFO method. The effect on earnings of the liquidation of LIFO layers was insignificant for each of the fiscal years ended June 30, 2024, 2023 and 2022.
NOTE 7. PROPERTY, PLANT AND EQUIPMENT, NET
The components of property, plant and equipment, net, consisted of the following as of June 30:
20242023
Land and improvements$174 $168 
Buildings816 810 
Machinery and equipment2,398 2,355 
Capitalized software costs413 400 
Computer equipment137 131 
Construction in progress198 186 
Total4,136 4,050 
Less: Accumulated depreciation and amortization(2,821)(2,705)
Property, plant and equipment, net$1,315 $1,345 

Depreciation and amortization expense related to property, plant and equipment, net, was $206, $206 and $193 in fiscal years 2024, 2023 and 2022, respectively, of which $10, $10 and $8 were related to amortization of capitalized software, respectively.
Noncash capital expenditures were $5, $9 and $6 for fiscal years, 2024, 2023 and 2022, respectively. There were no significant asset retirement obligations recorded and included in Buildings above for both fiscal years 2024 and 2023.

40


NOTE 8. GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS
The changes in the carrying amount of goodwill by reportable segment and Corporate and Other for the fiscal years ended June 30, 2024 and 2023 were as follows:
Goodwill
Health and Wellness
HouseholdLifestyleInternational
Corporate and Other (1)
Total
Balance as of June 30, 2022$323 $85 $244 $600 $306 $1,558 
Goodwill impairment
    (306)(306)
Balance as of June 30, 2023$323 $85 $244 $600 $ $1,252 
Divestiture (2)
   (16) (16)
Effect of foreign currency translation   (8) (8)
Balance as of June 30, 2024$323 $85 $244 $576 $ $1,228 
(1)Reflects goodwill related to the Better Health VMS reporting unit, which was previously included within the Health and Wellness reportable segment prior to the segment changes effective in the fourth quarter of fiscal year 2023.
(2)Reflects goodwill related to the divestiture of the Argentina business. See Note 2 for additional information.
The changes in the carrying amount of trademarks and other intangible assets for the fiscal years ended June 30, 2024 and 2023 were as follows:
As of June 30, 2024As of June 30, 2023
Gross
carrying
amount
Accumulated
amortization / Impairments
Net carrying
amount
Gross
carrying
amount
Accumulated
amortization / Impairments
Net carrying
amount
Trademarks with indefinite lives (1)
$493 $— $493 $494 $— $494 
Trademarks with finite lives (1)
83 38 45 89 40 49 
Other intangible assets with finite lives578 435 143 579 410 169 
Total$1,154 $473 $681 $1,162 $450 $712 
(1)As of June 30, 2023 reflects changes to the useful lives of certain Better Health VMS and International indefinite-lived trademarks to finite-lived effective April 1, 2023.
Amortization expense relating to the Company’s intangible assets was $29, $30 and $31 for the years ended June 30, 2024, 2023 and 2022, respectively. Estimated amortization expense for these intangible assets is $28, $28, $29, $28 and $11 for fiscal years 2025, 2026, 2027, 2028 and 2029, respectively.
Fiscal Year 2023 Impairments
During the third quarter of fiscal year 2023, management made a decision to narrow the focus on core brands and streamline investment levels in the Better Health VMS business. As a result, revisions were made to the internal financial projections and operational plans of the Better Health VMS business reflecting the Company’s current estimates regarding the future financial performance of these operations and macroeconomic factors. The revised estimated future cash flows reflected lower sales growth expectations and lower investment levels. These revisions were considered a triggering event requiring interim impairment assessments to be performed as part of the preparation of the quarterly financial statements on the global indefinite-lived trademarks, other long-term assets and the Better Health VMS reporting unit.
Based on the outcome of these assessments, the following pre-tax, noncash impairment charges were recorded during fiscal year 2023:
Impairment Charges
Better Health VMS reporting unit
International reporting unitTotal
Goodwill$306 $ $306 
Trademarks, net127 12 139 
Total$433 $12 $445 

41

NOTE 8. GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS (Continued)
In connection with recognizing these impairment charges, the Company recognized tax benefits related to the impairments of $83 due to the partial tax deductibility of these charges.
To determine the estimated fair values of the global indefinite-lived trademarks related to the Better Health VMS business, the Company used the DCF method under the relief from royalty income approach. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows as well as the appropriate discount rates applied to those cash flows to determine fair value. As a result of the interim impairment test, the Company concluded that the carrying value of the global indefinite-lived trademarks exceeded their estimated fair value, and recorded impairment charges of $139. In addition, the useful lives of the impaired trademarks, with a remaining net carrying value of $28 as of March 31, 2023, were changed from indefinite to finite beginning on April 1, 2023, which reflects the remaining expected useful lives of the trademarks based on the most recent financial and operational plans. The weighted-average estimated useful life of these trademarks is 20 years.
After adjusting the carrying values of the global indefinite-lived trademarks and concluding that the carrying amounts of the other long-lived assets were recoverable, the Company completed a quantitative impairment test for goodwill and recorded a goodwill impairment charge of $306 in the Better Health VMS reporting unit. To determine the fair value of the Better Health VMS reporting unit, the Company used a DCF method under the income approach. In accordance with this approach, the Company estimated the future cash flows of the Better Health VMS reporting unit and discounted these cash flows at a rate of return that reflects its relative risk. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates and a terminal growth rate. The decrease in projected cash flows due to the revisions adversely impacted key assumptions used in determining the fair value of the Better Health VMS reporting unit and assets contained therein, primarily projected net sales. There is no remaining goodwill associated with the impaired reporting unit.
No other significant impairments were identified as a result of the Company’s impairment reviews during fiscal years 2024, 2023 and 2022.
NOTE 9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities consisted of the following as of June 30:
20242023
Accounts payable$950 $1,021 
Compensation and employee benefit costs190 262 
Trade and sales promotion costs156 157 
Dividends25 23 
Other165 196 
Total$1,486 $1,659 

NOTE 10. DEBT
Short-term borrowings
Notes and loans payable are borrowings that mature in less than one year, primarily consisting of U.S. commercial paper issued by the Company and borrowings under the Company's revolving credit agreements. Notes and loans payable were $4 and $50 as of June 30, 2024 and 2023, respectively.
The weighted average interest rates incurred on average outstanding notes and loans payable during the fiscal years ended June 30, 2024, 2023 and 2022, including fees associated with the Company’s revolving credit agreements, were 4.77%, 3.48% and 0.54% respectively.


42

NOTE 10. DEBT (Continued)
Long-term borrowings
Long-term debt, carried at face value net of unamortized discounts, premiums and debt issuance costs, included the following as of June 30:
20242023
Senior unsecured notes and debentures:
3.10%, $400 due October 2027
$399 $398 
3.90%, $500 due May 2028
498 497 
4.40%, $500 due May 2029
495 495 
1.80%, $500 due May 2030
495 494 
4.60%, $600 due May 2032
594 593 
Total2,481 2,477 
Less: Current maturities of long-term debt  
Long-term debt$2,481 $2,477 
In May 2022, the Company issued $1,100 in senior notes, which included $500 of senior notes with an annual fixed interest rate of 4.40%, payable semi-annually in May and November, final maturity in May 2029 that carry an effective rate of 3.89% (May 2029 senior notes), which includes the impact from the settlement of interest rate contracts in May 2022, and $600 of senior notes with an annual fixed rate of 4.60%, payable semi-annually in May and November, final maturity in May 2032 that carry an effective rate of 3.25% (May 2032 senior notes), which includes the impact from the settlement of interest rate contracts in May 2022. The notes rank equally with all of the Company's existing senior indebtedness. Proceeds from the senior notes were used to redeem prior to maturity $600 of senior notes with an annual fixed interest rate of 3.05% due in September 2022 and $500 of senior notes with an annual fixed interest rate of 3.50% due in December 2024, which were redeemed in June 2022 prior to their maturities, and for general corporate purposes. In connection with the redemption prior to maturity of the $500 of senior notes due in December 2024, the Company recorded a loss on the early extinguishment of debt of $13, which is included in Interest expense in the Consolidated Statements of Earnings, representing the difference paid in cash between the redemption price and the carrying amount of the debt extinguished of $5 and the accelerated amortization of losses on settlement of interest rate contracts and issuance costs associated with the debt extinguished of $8.
In November 2021, $300 of the Company’s senior notes with annual fixed interest rate of 3.80% became due and were repaid using commercial paper borrowings.
The weighted average interest rates incurred on average outstanding long-term debt during the fiscal years ended June 30, 2024, 2023 and 2022, were 3.25%, 3.25% and 3.25%, respectively. The weighted average effective interest rates on long-term debt balances as of both June 30, 2024 and 2023 were 3.25% and 3.25%, respectively.
Long-term debt maturities as of June 30, 2024, were $0 in fiscal years 2025 through 2027, $900 in fiscal year 2028, $500 in fiscal year 2029 and $1,100 thereafter.
Credit arrangements
As of June 30, 2023, the Company maintained a $1,200 revolving credit agreement (the Credit Agreement) that matures in March 2027. There were no borrowings under the Credit Agreement as of June 30, 2024 and June 30, 2023, respectively, and the Company believes that borrowings under the Credit Agreement will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations consistent with the previous agreement, with which the Company was in compliance as of June 30, 2024 and June 30, 2023.
The Company’s borrowing capacity under the revolving credit agreements and other financing arrangements as of June 30 was as follows:
20242023
Revolving credit facility$1,200 $1,200 
Foreign and other credit lines34 35 
Total$1,234 $1,235 
Of the $34 of foreign and other credit lines as of June 30, 2024, $9 was outstanding and the remainder of $25 was available for borrowing. Of the $35 of foreign and other credit lines as of June 30, 2023, $5 was outstanding and the remainder of $30 was available for borrowing.

43


NOTE 11. OTHER LIABILITIES
Other liabilities consisted of the following as of June 30:
20242023
Venture Agreement terminal obligation, net$510 $495 
Employee benefit obligations263 259 
Taxes25 19 
Environmental liabilities24 24 
Other26 28 
Total$848 $825 
Venture Agreement
The Company has an agreement with The Procter & Gamble Company (P&G) for the Company’s Glad bags and wraps business. In connection with this agreement, P&G provides research and development (R&D) support to the Glad business. As of June 30, 2024 and 2023, P&G had a 20% interest in the venture. The Company pays a royalty to P&G for its interest in the profits, losses and cash flows, as contractually defined, of the Glad business, which is included in Cost of products sold. In December 2017, the Company and P&G extended the term of the agreement and the related R&D support provided by P&G. The term will expire in January 2026, unless the parties agree, on or prior to January 31, 2025, to further extend the term of the agreement for another seven years or agree to take some other relevant action. The agreement can be terminated under certain circumstances, including at P&G’s option upon a change in control of the Company or, at either party’s option, upon the sale of the Glad business by the Company.
Upon termination of the agreement, the Company is required to purchase P&G’s 20% interest for cash at fair value as established by predetermined valuation procedures. As of June 30, 2024, the estimated fair value of P&G’s interest in the venture was $531, of which $510 has been recognized and is reflected in Other liabilities as noted in the table above. The estimated fair value of P&G's interest in the venture was $527 as of June 30, 2023. The difference between the estimated fair value and the amount recognized, and any future changes in the fair value of P&G’s interest, is charged to Cost of products sold in accordance with the effective interest method over the remaining life of the agreement. Following termination, the Glad business will retain the exclusive core intellectual property licenses contributed by P&G on a royalty-free basis for the licensed products marketed.
NOTE 12. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments
The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.
Commodity Price Risk Management
The Company may use commodity futures, options and swap contracts to limit the impact of price volatility on a portion of its forecasted raw material requirements. These commodity derivatives may be exchange traded or over-the-counter contracts and generally have original contractual maturities of less than 2 years. Commodity purchase and option contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.
As of June 30, 2024, the notional amount of commodity derivatives was $38, of which $27 related to soybean oil futures used for the food business and $11 related to jet fuel swaps used for the grilling business. As of June 30, 2023, the notional amount of commodity derivatives was $41, of which $29 related to soybean oil futures and $12 related to jet fuel swaps.
Foreign Currency Risk Management
The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have original contractual maturities of less than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.
The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $29 and $51 as of June 30, 2024 and 2023, respectively.

44

NOTE 12. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Interest Rate Risk Management
The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have original contractual maturities of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.
The Company held no interest rate contracts as of both June 30, 2024 and 2023.
During fiscal year 2022, the Company entered into an additional $650 of interest rate contracts. All contracts represented interest rate swap lock agreements to manage the exposure to interest rate volatility associated with future interest payments on forecasted debt issuance, and were terminated in May 2022 upon issuance of $1,100 in senior notes (See Note 10). These contracts resulted in a $114 gain recorded in Other comprehensive (loss) income, comprised of $25 attributable to the May 2029 senior notes and $89 attributable to the May 2032 senior notes, which is being amortized into Interest expense in the consolidated statements of earnings over the 7-year and 10-year term of the notes.
Commodity, Foreign Exchange and Interest Rate Derivatives
The Company designates its commodity forward, futures and options contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory, and interest rate contracts for forecasted interest payments as cash flow hedges.
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows during the fiscal years ended June 30:
Gains (losses) recognized in Other comprehensive (loss) income
202420232022
Commodity purchase derivative contracts$(8)$(6)$17 
Foreign exchange derivative contracts  1 
Interest rate derivative contracts  89 
Total$(8)$(6)$107 
Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
202420232022
Commodity purchase derivative contractsCost of products sold$(6)$5 $23 
Foreign exchange derivative contractsCost of products sold 1  
Interest rate derivative contractsInterest expense13 13 (9)
Total$7 $19 $14 
The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of June 30, 2024 that is expected to be reclassified into Net earnings within the next twelve months is $8.
Counterparty Risk Management and Derivative Contract Requirements
The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions, $0 and $1 contained such terms as of June 30, 2024 and 2023, respectively. As of both June 30, 2024 and 2023, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.
Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the Company's credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both June 30, 2024 and 2023, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.

45

NOTE 12. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Certain of the Company’s exchange-traded futures and options contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of June 30, 2024 and 2023, the Company maintained required cash margin balances related to exchange-traded futures and options contracts of $3 and $0, respectively, which are classified as Prepaid expenses and other current assets on the consolidated balance sheets.
Trust Assets
The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the consolidated balance sheets. The gains and losses on the trust assets are recorded in Other (income) expense, net in the consolidated statements of earnings. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.
As of June 30, 2024, the balance of the trust assets related to the Company’s nonqualified deferred compensation plans increased by $25 as compared to June 30, 2023.
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of June 30, 2024 and 2023, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company's derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company's derivative instruments:
20242023
Balance Sheet ClassificationFair Value
Hierarchy
Level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Commodity purchase options contractsPrepaid expenses and other current assets1$ $ $2 $2 
Commodity purchase swaps contractsPrepaid expenses and other current assets21 1   
Foreign exchange forward contractsPrepaid expenses and other current assets2    
$1 $1 $2 $2 
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$2 $2 $ $ 
Commodity purchase swaps contractsAccounts payable and accrued liabilities2  1 1 
$2 $2 $1 $1 
The following table provides information about the balance sheet classification and the fair values of the Company's other assets and liabilities for which disclosure of fair value is required:

46

NOTE 12. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

20242023
Balance sheet classificationFair value
hierarchy
level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash equivalents (1)
1$95 $95 $243 $243 
Time deposits
Cash and cash equivalents (1)
29 9 9 9 
Trust assets for nonqualified deferred compensation plansOther assets1154 154 129 129 
$258 $258 $381 $381 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$4 $4 $50 $50 
Long-term debt
Long-term debt (3)
22,481 2,341 2,477 2,327 
$2,485 $2,345 $2,527 $2,377 
(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.
(3)Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
Furthermore, impairment charges of $445 were record during fiscal year 2023, of which $306 and $139 related to goodwill and certain indefinite-lived trademarks, respectively. These adjustments were included as noncash charges in the consolidated statements of earnings. The nonrecurring fair values utilized included unobservable Level 3 inputs based on management’s best estimates and assumptions. See Note 8 for additional information.
NOTE 13. OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of both June 30, 2024 and 2023 for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $12 of the recorded liability as of both June 30, 2024 and 2023 relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing groundwater at the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study related to groundwater. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators. In January 2023, the regulators issued a new order directing the Company and the current property owner to conduct a Remedial Investigation and then prepare a Feasibility Study to evaluate and remediate impacts to soil, groundwater, soil vapor and indoor air. While the Company believes its latest estimates of remediation costs (including any related to soil, groundwater, soil vapor and indoor air impacts) are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs in the aggregate of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability as of both June 30, 2024 and 2023. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing agreement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is

47

NOTE 13. OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS (Continued)
reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time.
The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements (including costs connected to the transition and unwinding of certain supply and manufacturing relationships), product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of both June 30, 2024 and 2023.
The Company was a party to letters of credit of $18 and $14 as of June 30, 2024 and 2023, respectively, primarily related to one of its insurance carriers, of which $0 had been drawn upon.
Commitments
The Company is a party to certain purchase obligations, which are defined as purchase agreements that are enforceable and legally binding and that contain specified or determinable significant terms, including quantity, price and the approximate timing of the transaction. For purchase obligations subject to variable price and/or quantity provisions, an estimate of the price and/or quantity must be made. Examples of the Company’s purchase obligations include contracts to purchase raw materials, commitments to contract manufacturers, commitments for information technology and related services, advertising contracts, capital expenditure agreements, software acquisition and license commitments and service contracts. The Company enters into purchase obligations based on expectations of future business needs. Many of these purchase obligations are flexible to allow for changes in the Company’s business and related requirements. As of June 30, 2024, the Company’s purchase obligations by purchase date were approximately as follows:
YearPurchase
Obligations
2025$181 
2026128 
202781 
202843 
202927 
Thereafter45 
Total$505 


48


NOTE 14. LEASES
The Company leases various property, plant and equipment, including office, warehousing, manufacturing and research and development facilities and equipment. These leases have remaining lease terms of up to 33 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Supplemental balance sheet information related to the Company’s leases as of June 30 was as follows:
Balance sheet classification20242023
Operating leases
Right-of-use assetsOperating lease right-of-use assets$360 $346 
Current lease liabilitiesCurrent operating lease liabilities$84 $87 
Non-current lease liabilitiesLong-term operating lease liabilities334 310 
Total operating lease liabilities$418 $397 
Finance leases
Right-of-use assetsOther assets$33 $29 
Current lease liabilitiesAccounts payable and accrued liabilities$13 $9 
Non-current lease liabilitiesOther liabilities21 21 
Total finance lease liabilities$34 $30 
Components of lease cost were as follows for the fiscal years ended June 30:
20242023
Operating lease cost$97 $89 
Finance lease cost:
Amortization of right-of-use assets$11 $9 
Interest on lease liabilities1 1 
Total finance lease cost$12 $10 
Variable lease cost$94 $87 
Short term lease cost$3 $4 
Supplemental cash flow information and noncash activity related to the Company’s leases were as follows during fiscal years ended June 30:
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases, net$97 $88 
Operating cash flows from finance leases1 1 
Financing cash flows from finance leases11 8 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$113 $84 
Finance leases17 21 

49

NOTE 14. LEASES (Continued)
Weighted-average remaining lease term and discount rate for the Company’s leases were as follows as of fiscal year ended June 30:
2024
Weighted-average remaining lease term:
Operating leases5 years
Finance leases3 years
Weighted-average discount rate:
Operating leases3.6 %
Finance leases5.1 %
Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:
YearOperating leasesFinance leases
2025$97 $14 
202694 12 
202784 7 
202869 2 
202956 1 
Thereafter61  
Total lease payments$461 $36 
Less: Imputed interest43 2 
Total lease liabilities$418 $34 
Operating and finance lease payments presented in the table above exclude $2 and $3, respectively, of minimum lease payments signed but not yet commenced as of June 30, 2024.
On December 14, 2023, the Company completed an asset sale-leaseback transaction on a warehouse in Fairfield, California. The Company received proceeds of $19, net of selling costs. The asset had a carrying value of $3 and the transaction resulted in a $16 gain, which was recognized in Other (income) expense, net in the Health and Wellness segment. The leaseback is accounted for as an operating lease. The term of the lease is 8 years with options to extend the lease for two 5 year periods.
On May 25, 2022, the Company completed an asset sale-leaseback transaction on a plant in Ontario, Canada. The Company received proceeds of $16, net of selling costs. The asset had a carrying value of $2, and the transaction resulted in a $14 gain, which was recognized in Other (income) expense, net, in Corporate and Other. The leaseback is accounted for as an operating lease. The term of the lease at inception date is 10 years, with the option to terminate the lease at 7 years.
NOTE 15. STOCKHOLDERS' EQUITY
Dividends per share paid to Clorox stockholders during the fiscal years ended June 30 were as follows:
202420232022
Dividends per share paid$4.80 $4.72 $4.64 
On July 30, 2024, a cash dividend was declared in the amount of $1.22 per share payable on August 30, 2024 to common stockholders of record as of the close of business on August 14, 2024.

50

NOTE 15. STOCKHOLDERS' EQUITY (Continued)


Accumulated Other Comprehensive Net (Loss) Income
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the fiscal years ended June 30:
Foreign currency
translation adjustments
Net
unrealized
gains
(losses) on
derivatives
Pension and
postretirement
benefit
adjustments
Accumulated
other
comprehensive net
(loss) income
Balance June 30, 2021$(403)$21 $(164)$(546)
Other comprehensive (loss) income before
reclassifications
(45)107 1 63 
Amounts reclassified from Accumulated other
comprehensive net (loss) income
 (14)15 1 
Income tax benefit (expense) 7 (4)3 
Net current period other comprehensive (loss) income
(45)100 12 67 
Balance June 30, 2022(448)121 (152)(479)
Other comprehensive (loss) income before
reclassifications
1 (6)1 (4)
Amounts reclassified from Accumulated other
comprehensive net (loss) income
 (19)6 (13)
Income tax benefit (expense)2 3 (2)3 
Net current period other comprehensive (loss) income
3 (22)5 (14)
Balance June 30, 2023(445)99 (147)(493)
Other comprehensive (loss) income before
reclassifications
(16)(8)17 (7)
Amounts reclassified from Accumulated other
comprehensive net (loss) income (1) (2)
223 (7)174 390 
Income tax benefit (expense)(1)1 (45)(45)
Net current period other comprehensive (loss) income
206 (14)146 338 
Balance June 30, 2024$(239)$85 $(1)$(155)
(1)Includes the release of currency translation adjustment from the Argentina business divestiture. See Note 2 for additional details.
(2)Includes recognition of pension settlement charge reclassified into Net earnings (losses). See Note 20 for additional details
NOTE 16. NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS for the fiscal years ended June 30:
202420232022
Basic124,174 123,589 123,113 
Dilutive effect of stock options and other630 592 793 
Diluted124,804 124,181 123,906 
Antidilutive stock options and other2,704 1,444 2,448 
Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.

51


NOTE 17. STOCK-BASED COMPENSATION PLANS
In November 2021, the Company’s stockholders voted to approve the amended and restated 2005 Stock Incentive Plan (the Plan). The Plan permits the Company to grant various nonqualified stock-based compensation awards, including stock options, restricted stock, performance shares, deferred stock units, stock appreciation rights and other stock-based awards. The Plan as amended and restated provides that the maximum number of shares which may be issued under the Plan will be 5 million common shares that may be issued for stock-based compensation purposes. As of June 30, 2024, the Company was authorized to grant up to approximately 5 million common shares, plus additional shares equal to shares that are potentially deliverable under an award that expires or are canceled, forfeited or settled without the delivery of shares, under the Plan. As of June 30, 2024, approximately 3 million common shares remained available for grant.
Compensation cost and the related income tax benefit recognized for stock-based compensation plans were classified as indicated below for the fiscal years ended June 30:
202420232022
Cost of products sold$7 $7 $6 
Selling and administrative expenses63 61 42 
Research and development costs4 5 4 
Total compensation costs$74 $73 $52 
Related income tax benefit$18 $17 $12 
Cash received during fiscal years 2024, 2023 and 2022 from stock options exercised under all stock-based payment arrangements was $23, $52 and $35, respectively. The Company issues shares for stock-based compensation plans from treasury stock. The Company may repurchase stock under its Evergreen Program to offset the estimated impact of dilution related to stock-based awards.
Details regarding the valuation and accounting for stock options, restricted stock awards, performance shares and deferred stock units for non-employee directors follow.
Stock Options
There were no stock option awards granted during the fiscal year 2024. The fair value of each stock option award granted during fiscal years 2023 and 2022 was estimated on the date of grant using the Black-Scholes valuation model and assumptions noted in the following table:
20232022
Expected life5.3 years
5.4 years
Weighted-average expected life5.3 years5.4 years
Expected volatility
24.2%
21.7% to 25.0%
Weighted-average volatility24.2%21.8%
Risk-free interest rate
3.7%
0.9% to 2.1%
Weighted-average risk-free interest rate3.7%0.9%
Dividend yield
3.4%
2.9% to 3.7%
Weighted-average dividend yield3.4%2.9%
The expected life of the stock options is based on historical exercise patterns. The expected volatility is based on implied volatility from publicly traded options on the Company’s stock at the date of grant, historical implied volatility of the Company’s publicly traded options and other factors. The risk-free interest rate is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected term of the option. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant.






52

NOTE 17. STOCK-BASED COMPENSATION PLANS (Continued)
Details of the Company’s stock option activities are summarized below:
Number of
Shares
(In thousands)
Weighted-
Average
Exercise
Price
per Share
Average
Remaining
Contractual
Life
Aggregate
Intrinsic
Value
Options outstanding as of June 30, 2023
4,075 $147 5 years$69 
Granted 
Exercised(234)104 
Canceled(51)170 
Options outstanding as of June 30, 2024
3,790 $150 4 years$16 
Options vested as of June 30, 2024
3,052 $148 4 years$16 
The weighted-average fair value per share of each option granted during fiscal years 2023 and 2022, estimated at the grant date using the Black-Scholes option pricing model, was $26.95 and $22.26, respectively. The total intrinsic value of options exercised in fiscal years 2024, 2023 and 2022 was $12, $27 and $18, respectively.
Stock option awards outstanding as of June 30, 2024, have been granted at prices that are equal to the market value of the stock on the date of grant. Stock option grants generally vest over 4 years and expire no later than 10 years after the grant date. The Company recognizes compensation expense on a straight-line basis over the vesting period. Awards to employees eligible for retirement prior to the award becoming full vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award. As of June 30, 2024, there was $5 of total unrecognized compensation cost related to non-vested options, which is expected to be recognized over a remaining weighted-average vesting period of 2 years, subject to forfeiture changes.
Restricted Stock Awards
The fair value of restricted stock awards is estimated on the date of grant based on the market price of the stock and is amortized to compensation expense on a straight-line basis over the related vesting periods, which are generally 3 to 4 years. Awards to employees eligible for retirement prior to the award becoming fully vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Restricted stock awards receive dividend distributions earned during the vesting period upon vesting.
As of June 30, 2024, there was $41 of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a remaining weighted-average vesting period of 2 years. The total fair value of the shares that vested in each of the fiscal years 2024, 2023 and 2022 was $28, $22 and $20, respectively. The weighted-average grant-date fair value of awards granted was $138.51, $143.20 and $157.50 per share for fiscal years 2024, 2023 and 2022, respectively.
A summary of the status of the Company’s restricted stock awards is presented below:
Number of
Shares
(In thousands)
Weighted-Average
Grant Date
Fair Value
per Share
Restricted stock awards as of June 30, 2023
544 $155 
Granted405 139 
Vested(173)162 
Forfeited(55)142 
Restricted stock awards as of June 30, 2024
721 $145 
Performance Shares
The fair value of performance shares is estimated on the date of grant based on the market price of the stock and is amortized to compensation expense on a straight line basis over the related vesting periods, which are generally 3 years. Awards to employees eligible for retirement prior to the award becoming fully vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award.

53

NOTE 17. STOCK-BASED COMPENSATION PLANS (Continued)
As of June 30, 2024, there was $15 in unrecognized compensation cost related to non-vested performance shares that is expected to be recognized over a remaining weighted-average performance period of 1 year. The weighted-average grant-date fair value of awards granted was $140.39, $141.90 and $162.46 per share for fiscal years 2024, 2023 and 2022, respectively.
A summary of the status of the Company’s performance share awards is presented below:
Number of
Shares
(In thousands)
Weighted-Average
Grant Date
Fair Value
per Share
Performance share awards as of June 30, 2023
368 $158 
Granted176 $140 
Distributed(39)$189 
Forfeited(22)$177 
Performance share awards as of June 30, 2024
483 $148 
Performance shares vested and deferred as of June 30, 2024
83 $164 
The non-vested performance shares outstanding as of June 30, 2024 and 2023 were 400,000 and 306,000, respectively, and the weighted average grant date fair value was $145.06 and $162.77 per share, respectively. During fiscal year 2024, 58,000 shares vested. The total fair value of shares vested was $12, $12 and $11 during fiscal years 2024, 2023 and 2022, respectively. Upon vesting, the recipients of the grants receive the distribution as shares or, if previously elected by eligible recipients, as deferred stock. Deferred shares continue to earn dividends, which are also deferred.
Deferred Stock Units for Nonemployee Directors
Nonemployee directors receive annual grants of deferred stock units under the Company’s director compensation program and can elect to receive all or a portion of their annual retainers and fees in the form of deferred stock units. The deferred stock units receive dividend distributions, which are reinvested as deferred stock units, and are recognized at their fair value on the date of grant. Each deferred stock unit represents the right to receive one share of the Company’s common stock following the completion of a director’s service.
During fiscal year 2024, the Company granted 19,000 deferred stock units, reinvested dividends of 4,000 units and distributed 24,000 shares, which had a weighted-average fair value on the grant date of $141.85, $145.15 and $89.91 per share, respectively. As of June 30, 2024, 127,000 units were outstanding, which had a weighted-average fair value on the grant date of $140.22 per share.
NOTE 18. OTHER (INCOME) EXPENSE, NET
The major components of Other (income) expense, net, for the fiscal years ended June 30 were:
202420232022
Amortization of trademarks and other intangible assets$29 $30 $31 
Trust investment (gains) losses, net(20)(14)21 
Net periodic benefit cost
14 16 16 
Foreign exchange transaction (gains) losses, net (1)
25 13 3 
Income from equity investees(5)(4)(6)
Interest income(23)(16)(5)
Restructuring costs (2)
16 52  
Gain on sale-leaseback transaction(16) (14)
Other4 3 (9)
Total$24 $80 $37 
(1)Foreign exchange losses are primarily related to the Company’s operations in Argentina, prior to the divestiture.
(2)Restructuring costs related to the Company's streamlined operating model plan (see Note 5).


54


NOTE 19. INCOME TAXES
The provision for income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:
202420232022
Current
Federal$132 $153 $71 
State18 33 17 
Foreign56 40 43 
Total current$206 $226 $131 
Deferred
Federal$(99)$(120)$6 
State(5)(28)(2)
Foreign4 (1)1 
Total deferred(100)(149)5 
Total$106 $77 $136 
Income taxes paid, net of refunds, were $347 and $73 for the fiscal year ended June 30, 2024 and 2023, respectively. The increase in payments in the current period was primarily driven by income tax payments for fiscal years 2023 and 2024 that were previously deferred as a result of tax relief provided by the IRS due to winter storms in California.
The components of Earnings before income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:
202420232022
United States$311 $154 $483 
Foreign87 84 124 
Total$398 $238 $607 
A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate on operations follows for the fiscal years ended June 30:
202420232022
Statutory federal tax rate21.0 %21.0 %21.0 %
State taxes (net of federal tax benefits)2.5 1.6 1.9 
Foreign tax rate differential7.7 8.6 3.1 
Federal excess tax benefits(0.3)(1.8)(0.9)
Net U.S. tax on foreign income(5.2)(2.3)(1.7)
Loss on divestiture
10.5   
International legal entity reorganization
(6.1)  
VMS goodwill impairment 8.6  
Federal research and development credits(1.2)(2.7)(0.8)
Other differences(2.4)(0.6)(0.2)
Effective tax rate26.5 %32.4 %22.4 %
The Inflation Reduction Act (the “Act”) was signed into law on August 16, 2022. The Act introduced a new 15% corporate minimum tax for certain large corporations, effective at the beginning of the Company’s fiscal 2024 and it enacted a 1% excise tax on the value of share repurchases, net of new share issuances, after December 31, 2022. These provisions, as well as other corporate tax changes included in the Act, have not had a material impact on the Company's consolidated financial statements and are not expected to have a material impact on the Company’s financial statements in the foreseeable future.
Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion. None of the undistributed earnings of its foreign subsidiaries were indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable. These withholding taxes had no significant impact on the Company’s consolidated results.
55

NOTE 19. INCOME TAXES (Continued)

The components of net deferred tax assets (liabilities) as of June 30 are shown below:
20242023
Deferred tax assets
Compensation and benefit programs$109 $123 
Loss and tax credit carryforwards
153 94 
Operating and finance lease liabilities111 104 
Accruals and reserves33 46 
Capitalized research and development43 34 
Inventory costs29 32 
Other33 34 
Subtotal511 467 
Valuation allowance(115)(59)
Total deferred tax assets$396 $408 
Deferred tax liabilities
Property, plant and equipment and intangible assets
$(84)$(157)
Lease right-of-use assets(100)(96)
Other(36)(36)
Total deferred tax liabilities(220)(289)
Net deferred tax assets (liabilities)$176 $119 
The net deferred tax assets and liabilities included in the consolidated balance sheet at June 30 were as follows:
Net deferred tax assets (1)
$198 $147 
Net deferred tax liabilities(22)(28)
Net deferred tax assets (liabilities)$176 $119 
(1)Net deferred tax assets are recorded in Other assets.
The Company reviews its deferred tax assets for recoverability on a quarterly basis. A valuation allowance is established when the Company believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Valuation allowances have been provided to reduce deferred tax assets to amounts considered recoverable.
Changes in the valuation allowance on deferred tax assets were as follows for the years ended June 30:
202420232022
Valuation allowance at beginning of year$(59)$(52)$(42)
Net increase/(decrease) for U.S. capital loss carryfowards(46)  
Net decrease/(increase) for other foreign deferred tax assets(2)(1)(1)
Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits(8)(6)(9)
Valuation allowance at end of year$(115)$(59)$(52)







56

NOTE 19. INCOME TAXES (Continued)

The Company's carryforwards for capital losses, net operating losses, and tax credits, with related valuation allowances were as follows as of June 30:
2024
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions46 (46) 
2029
Net operating losses
U.S. jurisdictions6 (5)1 2030 - 2042
U.S. jurisdictions (with no expiration)9 (8)1 N/A
Foreign jurisdictions18 (16)2 2025 - 2044
Foreign jurisdictions (with no expiration)8  8 N/A
Total net operating losses41 (29)12 
Income tax credits
U.S. jurisdictions30  30 2025 - 2034
U.S. jurisdictions (with no expiration)2  2 N/A
Foreign jurisdictions30 (30) 2026
Foreign jurisdictions (with no expiration)4 (3)1 
N/A
Total income tax credits66 (33)33 
Total carryforwards$153 $(108)$45 


57

NOTE 19. INCOME TAXES (Continued)

2023
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions   N/A
Net operating losses
U.S. jurisdictions4 (4) 2030 - 2042
U.S. jurisdictions (with no expiration)6 (5)1 N/A
Foreign jurisdictions21 (16)5 2024 - 2040
Foreign jurisdictions (with no expiration)9 (1)8 N/A
Total net operating losses40 (26)14 
Income tax credits
U.S. jurisdictions23  23 2024 - 2033
U.S. jurisdictions (with no expiration)2  2 N/A
Foreign jurisdictions (with no expiration)29 (28)1 N/A
Total income tax credits54 (28)26 
Total carryforwards$94 $(54)$40 
The Company files income tax returns in the U.S. federal and various state, local and foreign jurisdictions. The federal statute of limitations has expired for all tax years through June 30, 2015. Various income tax returns in state and foreign jurisdictions are currently in the process of examination.
The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of June 30, 2024 and 2023, the total balance of accrued interest and penalties related to uncertain tax positions was $3 and $2, respectively. Interest and penalties related to uncertain tax positions included in income tax expense resulted in an expense of $1 in fiscal year 2024 and a net benefit of $0 in both fiscal years 2023 and 2022.
The following is a reconciliation of the beginning and ending amounts of the Company’s gross unrecognized tax benefits:
202420232022
Unrecognized tax benefits at beginning of year$17 $17 $21 
Gross increases - tax positions in prior periods 1  
Gross decreases - tax positions in prior periods(4)(3)(7)
Gross increases - current period tax positions9 2 4 
Gross decreases - current period tax positions   
Lapse of applicable statute of limitations  (1)
Settlements   
Unrecognized tax benefits at end of year$22 $17 $17 
Included in the balance of unrecognized tax benefits as of June 30, 2024, 2023 and 2022, were potential benefits of $15, $14 and $14, respectively, which if recognized, would affect the effective tax rate. Unrecognized tax benefits are not expected to significantly increase or decrease within the next 12 months.
NOTE 20. EMPLOYEE BENEFIT PLANS
Retirement Income Plans
In the second quarter of fiscal year 2024, the Company settled plan benefits of its previously frozen domestic qualified pension plan (the Plan), following the Company’s Board of Directors' approval of a resolution to terminate the Plan in May 2022. The settlement occurred through a combination of an annuity contract purchase with a third-party insurance provider and lump sum payouts. These payments were made using Plan assets. The third-party insurance provider assumed the obligation to pay future pension benefits and provide administrative services, and started making direct payments to participants in January 2024. In

58

NOTE 20. EMPLOYEE BENEFIT PLANS (Continued)

conjunction with this settlement, a one-time noncash charge, net of curtailment gain, of $171 before taxes ($130 after tax) was recorded in the Company’s consolidated statements of earnings and comprehensive income primarily as a result of accelerating the recognition of actuarial losses previously included in Accumulated other comprehensive net (loss) income that would have been recognized in future periods. Following settlement, remaining excess plan assets of $19 was contributed to the Company’s domestic defined contribution plan during 2024.
The Company continues to maintain various other retirement income plans for eligible domestic and international employees. The remaining domestic retirement income plans are frozen.
The Company contributed $14, $14 and $15 to its domestic retirement income plans during fiscal years 2024, 2023 and 2022, respectively. The Company’s funding policy is to contribute amounts sufficient to meet benefit payments.
Retirement Health Care Plans
The Company provides certain health care benefits for employees who meet age, participation and length of service requirements at retirement. The plans pay stated percentages of covered expenses after annual deductibles have been met or stated reimbursements up to a specified dollar subsidy amount. Benefits paid take into consideration payments by Medicare for the domestic plan. The plans are funded as claims are paid, and the Company has the right to modify or terminate certain plans.
Benefit Obligation and Funded Status
Summarized information for the Company’s retirement income and retirement health care plans as of and for the fiscal years ended June 30 is as follows:
Retirement
Income
Retirement
Health Care
2024202320242023
Change in benefit obligations:
Benefit obligation as of beginning of year$476 $513 $26 $28 
Service cost1 1   
Interest cost12 18 1 1 
Actuarial loss (gain)(26)(11)(2)(1)
Plan amendments  (4) 
Plan settlement(312)   
Benefits paid(26)(45)(2)(2)
Translation and other adjustments(2)   
Benefit obligation as of end of year$123 $476 $19 $26 
Change in plan assets:
Fair value of assets as of beginning of year$381 $412 $ $ 
Actual return on plan assets(13)   
Employer contributions15 15 2 2 
Plan settlement
(312)   
Benefits paid(26)(45)(2)(2)
Transfer to domestic defined contribution plan
(19)   
Translation and other adjustments(1)(1)  
Fair value of plan assets as of end of year25 381   
Accrued benefit cost, net funded status$(98)$(95)$(19)$(26)
Amount recognized in the balance sheets consists of:
Pension benefit assets$7 $24 $ $ 
Current accrued benefit liability(12)(13)(2)(2)
Non-current accrued benefit liability(93)(106)(17)(24)
Accrued benefit cost, net$(98)$(95)$(19)$(26)

59

NOTE 20. EMPLOYEE BENEFIT PLANS (Continued)

For the retirement income plans, the benefit obligation is the projected benefit obligation (PBO). For the retirement health care plan, the benefit obligation is the accumulated benefit obligation (ABO).
The ABO for all retirement income plans was $105, $474 and $512 as of June 30, 2024, 2023 and 2022, respectively.
Retirement income plans with ABO or PBO in excess of plan assets as of June 30 were as follows:
ABO Exceeds the Fair Value of Plan AssetsPBO Exceeds the Fair Value of Plan Assets
2024202320242023
Projected benefit obligation$105 $119 $108 $121 
Accumulated benefit obligation104 118 105 119 
Fair value of plan assets  2 2 
Net Periodic Benefit Cost
The net cost of the retirement income and health care plans for the fiscal years ended June 30 included the following components:
Retirement IncomeRetirement Health Care
202420232022202420232022
Service cost$1 $1 $1 $ $ $ 
Interest cost12 18 15 1 1 1 
Expected return on plan assets(2)(10)(15)   
Amortization of unrecognized items     3 8 9 (2)(2)(1)
Curtailment gain recognized
(6)     
Settlement loss recognized179  7    
Total$187 $17 $17 $(1)$(1)$ 
Service cost component of the net periodic benefit cost is reflected in employee benefit costs, and all other components, except for the net settlement loss recognized in relation to the settlement of the Plan recognized in the second quarter of fiscal year 2024, are reflected in Other (income) expense, net.
Items not yet recognized as a component of postretirement expense as of June 30, 2024 consisted of:
Retirement
Income
Retirement
Health Care
Net actuarial loss (gain)$20 $(14)
Prior service benefit (4)
Net deferred income tax (assets) liabilities(5)4 
Accumulated other comprehensive loss (income)$15 $(14)
Net actuarial loss (gain) recorded in Accumulated other comprehensive net (loss) income for the fiscal year ended June 30, 2024 included the following:
Retirement
Income
Retirement
Health Care
Net actuarial loss (gain) as of beginning of year$213 $(14)
Amortization, curtailment and settlement during the year
(182)2 
Loss (gain) during the year(11)(2)
Net actuarial loss (gain) as of end of year$20 $(14)
The Company uses the straight-line amortization method for unrecognized prior service costs and benefits.


60

NOTE 20. EMPLOYEE BENEFIT PLANS (Continued)

Assumptions
Weighted-average assumptions used to estimate the actuarial present value of benefit obligations were as follows as of June 30:
Retirement IncomeRetirement Health Care
2024202320242023
Discount rate5.52 %4.37 %5.38 %5.10 %
Rate of compensation increase3.23 %3.62 %n/an/a
Interest crediting rate5.40 %2.67 %n/an/a
Weighted-average assumptions used to estimate the retirement income and retirement health care costs were as follows as of June 30:
Retirement Income
202420232022
Discount rate4.63 %3.72 %2.56 %
Rate of compensation increase3.20 %3.09 %3.02 %
Expected return on plan assets3.39 %2.67 %3.00 %
Interest crediting rate2.69 %2.69 %2.57 %
Retirement Health Care
202420232022
Discount rate5.10 %4.65 %2.61 %
The expected long-term rate of return assumption is based on prospective returns according to the fund’s current target asset allocation.
The actuarial benefit obligation gain incurred during fiscal year 2024 was primarily driven by increases in the discount rates for the retirement plans, partially offset by investment gains lower than expected return on assets.
The actuarial benefit obligation gain during fiscal year 2023 was primarily driven by increases in the discount rates for the retirement plans, partially offset by investment gains lower than expected return on assets.
Expected Benefit Payments
Expected benefit payments for the Company’s retirement income and retirement health care plans as of June 30, 2024, were as follows:
Retirement
Income
Retirement
Health Care
2025$15 $2 
202614 2 
202713 2 
202813 2 
202912 2 
Fiscal years 2030 through 203448 7 
Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.
Plan Assets
The target allocations and weighted average asset allocations by asset category of the investment portfolio for the Company’s qualified domestic retirement income plans as of June 30, 2023, prior to its termination, were as follows:
% Target Allocation% of Plan Asset
Fixed income80 %79 %
Cash equivalents20 %21 %
Total100 %100 %

61

NOTE 20. EMPLOYEE BENEFIT PLANS (Continued)

The target asset allocation was determined based on the optimal balance between risk and return and, at times, was adjusted to achieve the plan’s overall investment objective to generate sufficient resources to pay current and projected plan obligations over the life of the domestic retirement income plan.
The following table sets forth the retirement income plans’ assets carried at fair value as of June 30:
20242023
Cash equivalents — Level 1$ $74 
Total assets in the fair value hierarchy 74 
Common collective trusts measured at net asset value
Bond funds$6 $289 
International equity funds16 15 
Domestic equity funds  
Short-term investment fund 1 
Real estate fund2 2 
Other
1  
Total common collect trust measured at net asset value$25 $307 
Total assets at fair value$25 $381 
Common collective trust funds are not publicly traded and were valued at a net asset value unit price determined by the portfolio’s sponsor based on the fair value of underlying assets held by the common collective trust fund on June 30, 2024 and 2023.
The common collective trusts are invested in various trusts that attempt to achieve their investment objectives by investing primarily in other collective investment funds that have characteristics consistent with each trust’s overall investment objective and strategy.
Defined Contribution Plans
The Company has various defined contribution plans for eligible domestic and international employees. The aggregate cost of the domestic defined contribution plans was $63, $64 and $58 in fiscal years 2024, 2023 and 2022, respectively. The aggregate cost of the international defined contribution plans was $5, $6 and $6 for the fiscal years ended June 30, 2024, 2023 and 2022, respectively.
NOTE 21. SEGMENT REPORTING
The Company operates through strategic business units (SBUs) that are organized into the Company’s operating segments. Operating segments with shared economic and qualitative characteristics are aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. The four reportable segments consist of the following:
Health and Wellness consists of cleaning, disinfecting and professional products marketed and sold in the United States.
Household consists of bags and wraps, cat litter and grilling products marketed and sold in the United States.
Lifestyle consists of food, water-filtration and natural personal care products marketed and sold in the United States.
International consists of products sold outside the United States. Products within this segment include laundry additives; home care products; bags and wraps; cat litter; water-filtration products; professional cleaning and disinfecting products; natural personal care products; food; grilling products and digestive health products marketed primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands.
Corporate and Other includes certain non-allocated administrative costs, various other non-operating income and expenses, as well as the results of the Better Health VMS business. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes, as well as the assets related to the Better Health VMS business.
The principle measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding

62

NOTE 21. SEGMENT REPORTING (Continued)
interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, relating to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).
Management uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance and allocate resources to each segment as it removes the impact of the items that management believes do not directly reflect the performance of each segment's underlying operations.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other.
Net Sales
Fiscal year
202420232022
Health and Wellness$2,485 $2,532 $2,427 
Household1,950 2,098 1,984 
Lifestyle1,275 1,338 1,253 
International1,162 1,181 1,180 
Reportable segment total6,872 7,149 6,844 
Corporate and Other221 240 263 
Total$7,093 $7,389 $7,107 

Segment adjusted earnings (losses) before interest and income taxes
Fiscal year
202420232022
Health and Wellness$719 $594 $381 
Household260 308 234 
Lifestyle253 284 280 
International122 89 97 
Reportable segment total1,354 1,275 992 
Corporate and Other(309)(358)(223)
Total$1,045 $917 $769 
Interest income23 16 5 
Interest expense(90)(90)(106)
Loss on divestiture (1)
(240)  
Pension settlement charge (2)
(171)  
Cyberattack costs, net of insurance recoveries (3)
(29)  
VMS impairment (4)
 (445) 
Streamlined operating model (5)
(32)(60) 
Digital capabilities and productivity enhancements investment (6)
(108)(100)(61)
Earnings (losses) before income taxes$398 $238 $607 
(1)Represents the loss on divestiture of the Argentina business corresponding to International. See Note 2 for additional details.
(2)Represents costs related to the settlement of the domestic qualified pension plan corresponding to Corporate and Other. See Note 20 for additional details.

63

NOTE 21. SEGMENT REPORTING (Continued)
(3)Represents incremental costs, net of insurance recoveries, related to the cyberattack. See Note 3 for additional details relating to the cyberattack. All insurance recoveries are recorded in Corporate and Other. For informational purposes, the following table provides the approximate cyberattack costs, net of insurance recoveries, corresponding to the Company’s reportable segments as a percentage of total net costs:
2024
Health and Wellness30 %
Household24 
Lifestyle23 
International8 
Corporate and Other15 
Total100 %
(4)Represents a noncash impairment charge of $445 related to the Better Health VMS business recorded in fiscal year 2023.
(5)Represents restructuring and related implementation costs, net for the streamlined operating model of $32 and $60 in fiscal year 2024 and 2023, respectively. For informational purposes the following table provides the approximate restructuring and related implementation costs, net corresponding to the Company's segments as a percent of the total costs for the fiscal years ended June 30:
Inception to date ended
202420232024
Health and Wellness3 %6 %5 %
Household2 1 2 
Lifestyle 4 2 
International4 16 11 
Corporate and Other91 73 80 
Total100 %100 %100 %
(6)Represents expenses related to the Company's digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Fiscal
Year
Health and WellnessHouseholdLifestyleInternational
Corporate and Other
Total
Company
(Income) Loss from equity investees included in Other (income) expense, net
2024   (5) (5)
2023   (4) (4)
2022   (6) (6)
Total assets20241,124 1,088 1,110 1,327 1,102 5,751 
20231,184 1,082 1,091 1,410 1,178 5,945 
Capital expenditures202447 84 36 21 24 212 
202351 97 29 24 27 228 
202261 112 24 27 27 251 
Depreciation and amortization202458 77 24 45 31 235 
202359 78 25 46 28 236 
202257 67 24 47 29 224 
Significant noncash charges included in earnings (losses) before interest and income taxes:
Stock-based compensation202414 11 8 6 35 74 
202314 10 7 4 38 73 
202214 8 6 3 21 52 
All intersegment sales are eliminated and are not included in the Company’s reportable net sales.
Net sales to the Company’s largest customer, Walmart Stores, Inc. and its affiliates, were 25%, 26% and 25% of consolidated net sales for each of the fiscal years ended June 30, 2024, 2023 and 2022, respectively, and occurred across all of the Company’s reportable segments. No other customers accounted for 10% or more of the Company’s consolidated net sales in any of these fiscal years.

64

NOTE 21. SEGMENT REPORTING (Continued)
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the fiscal years ended June 30:
202420232022
Cleaning30 %30 %29 %
Professional Products5 %5 %4 %
Health and Wellness35 %35 %33 %
Bags and Wraps11 %12 %12 %
Cat Litter9 %9 %8 %
Grilling8 %7 %8 %
Household28 %28 %28 %
Food11 %10 %10 %
Water Filtration4 %4 %4 %
Natural Personal Care3 %4 %4 %
Lifestyle18 %18 %18 %
International16 %16 %17 %
Corporate and Other3 %3 %4 %
Total100 %100 %100 %
The Company’s products are marketed and sold globally. The following table provides the Company’s global product lines, which were sold in the U.S. and International, that accounted for 10% or more of consolidated net sales for the fiscal years ended June 30:
202420232022
Cleaning products43 %42 %42 %
Bags and wraps15 %16 %16 %
Food products11 %11 %11 %
Cat litter products10 %10 %9 %
Net sales and property, plant and equipment, net, by geographic area for and as of the fiscal years ended June 30 were as follows:
Fiscal
Year
United
States
ForeignTotal
Company
Net sales2024$5,956 $1,137 $7,093 
20236,237 1,152 7,389 
20225,951 1,156 7,107 
Property, plant and equipment, net20241,188 127 1,315 
20231,192 153 1,345 
NOTE 22. RELATED PARTY TRANSACTIONS
The Company holds various equity investments with ownership percentages of up to 50% in a number of consumer products businesses, which operate both within and outside the United States. The equity investments, presented in Other assets and accounted for under the equity method, were $45 and $43 as of the fiscal years ended June 30, 2024 and 2023, respectively. The Company has no ongoing capital commitments, loan requirements, guarantees or any other types of arrangements under the terms of its agreements that would require any future cash contributions or disbursements arising out of an equity investment.
Transactions with the Company’s equity investees typically represent payments for contract manufacturing and purchases of raw materials. Payments to related parties, including equity investees, for such transactions during the fiscal years ended June 30, 2024, 2023 and 2022 were $77, $87 and $117, respectively. Receipts from and ending accounts receivable and payable balances related to the Company’s related parties were not significant during or as of the end of each of the fiscal years presented.

65


NOTE 23. SUBSEQUENT EVENT
On July 24, 2024, the Company entered into a definitive agreement to sell the Better Health VMS business. The transaction is expected to close in the first quarter of fiscal year 2025 and is expected to result in a loss on sale. The results of the Better Health VMS business are included within Corporate and Other in the fiscal year 2024 consolidated financial statements. The closing of the transaction is subject to customary closing conditions, including regulatory approval.

66
EX-99.2 11 fy24clxex992reconciliation.htm EX-99.2 Document

Exhibit 99.2

THE CLOROX COMPANY
RECONCILIATION OF ECONOMIC PROFIT (UNAUDITED) (1)
Dollars in millions
FY24
FY23
FY22
Earnings before income taxes$398 $238 $607 
Add back:
Certain U.S. GAAP items (2)
580 605 61 
Interest expense90 90 106 
Earnings before income taxes,
certain U.S. GAAP items and interest expense
1,068 933 774 
Less:
Income taxes on earnings before
income taxes, certain U.S. GAAP items and interest expense (3)
215 220 174 
Adjusted after tax profit853 713 600 
Less: After tax profit attributable to noncontrolling interests12 12 
Adjusted after tax profit attributable to Clorox841 701 591 
Average capital employed (4)
2,978 3,383 3,428 
Less: Capital charge (5)
268 304 309 
Economic profit (1) (Adjusted after tax profit attributable to Clorox less capital charge)
$573 $397 $282 
(1) Economic profit (EP) is defined by the Company as earnings before income taxes, excluding certain U.S. GAAP items (such as the pension settlement charge, incremental costs, net of insurance recoveries, related to the cyberattack, asset impairments, charges related to implementation of the streamlined operating model, charges related to digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability) and interest expense; less income taxes (calculated based on the Company’s effective tax rate excluding the identified U.S. GAAP items), and less after tax profit attributable to noncontrolling interests, and less a capital charge (calculated as average capital employed multiplied by a cost of capital rate). EP is a key financial metric that the Company’s management uses to evaluate business performance and allocate resources, and is a component in determining employee incentive compensation. The Company’s management believes EP provides additional perspective to investors about financial returns generated by the business and represents profit generated over and above the cost of capital used by the business to generate that profit.
(2) Certain U.S. GAAP items include the loss on divestiture, the pension settlement charge, incremental costs, net of insurance recoveries, related to the cyberattack, incremental operating expenses related to the implementation of the Company’s digital capabilities and productivity enhancements investment, restructuring and related costs related to implementation of the streamlined operating model and noncash impairment charges related to the Vitamins, Minerals and Supplements (VMS) business. Refer to "Management's Discussion and Analysis: Summary of Non-GAAP Financial Measures" in Exhibit 99.1 for detail on the U.S. GAAP charges.
(3) The tax rate applied is the effective tax rate before the identified U.S. GAAP items and was 20.1%, 23.6% and 22.5% in fiscal years 2024, 2023, and 2022, respectively. The difference between the fiscal year 2024 effective tax rate on earnings of 26.5% is due to the tax rate impact of the FY24 divestiture of the Argentina business, the pension settlement charge, incremental operating expenses recorded related to the implementation of the Company's digital capabilities and productivity enhancements investment, incremental cyberattack costs, net of insurance recoveries, and costs related to the streamlined operating model of (8.6)%, 0.9%, 0.9%, 0.2%, and 0.2%, respectively. The difference between the fiscal year 2023 effective tax rate on earnings of 32.4% is due to the tax rate impact of the FY23 VMS impairment and incremental operating expenses recorded related to the implementation of the Company's digital capabilities and productivity enhancements investment of (8.9)% and 0.1%, respectively. The difference between the fiscal year 2022 effective tax rate on earnings of 22.4% is due to the tax rate impact of the incremental operating expenses recorded related to the implementation of the Company’s digital capabilities and productivity enhancements investment of 0.1%.
(4) Total capital employed represents total assets less non-interest bearing liabilities. Adjusted capital employed represents total capital employed adjusted to add back current year after tax U.S. GAAP items, as applicable, and deduct the current year after tax noncash, nonrecurring gain. Average capital employed is the average of adjusted capital employed for the current year and total capital employed for the prior year, based on year-end balances. See below for details of the average capital employed calculation.
(5) Capital charge represents average capital employed multiplied by a cost of capital, which was 9% for all fiscal years presented. The calculation of capital charge includes the impact of rounding numbers.




Exhibit 99.2


Dollars in millions
FY24
FY23
FY22
Total assets$5,751 $5,945 $6,158 
Less:
       Accounts payable and accrued liabilities (6)
1,473 1,650 1,463 
Current operating lease liabilities84 87 78 
Income taxes payable— 121 — 
Long-term operating lease liabilities334 310 314 
       Other liabilities (6)
827 804 778 
Deferred income taxes22 28 66 
Non-interest bearing liabilities2,740 3,000 2,699 
Total capital employed (4)
3,011 2,945 3,459 
After tax certain U.S. GAAP items (2)
0362 0
Adjusted capital employed (4)
$3,011 $3,307 $3,459 
Average capital employed$2,978 $3,383 $3,428 

(6) Accounts payable and accrued liabilities and Other liabilities are adjusted to exclude interest-bearing liabilities.

EX-101.SCH 12 clx-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - AUDIT INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - CYBERATTACK link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - SUPPLY CHAIN FINANCING PROGRAM link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - RESTRUCTURING AND RELATED COSTS link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - OTHER LIABILITIES link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - NET EARNINGS PER SHARE (EPS) link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - STOCK-BASED COMPENSATION PLANS link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - OTHER (INCOME) EXPENSE, NET link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952177 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 9952178 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9952179 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 9952180 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - CYBERATTACK (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - RESTRUCTURING AND RELATED COSTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - OTHER LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - OTHER (INCOME) EXPENSE, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Major Classes of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Net Sales (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - CYBERATTACK - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - CYBERATTACK - Schedule of Recognition of Costs, Net of Insurance Recoveries (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - SUPPLY CHAIN FINANCING PROGRAM (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - RESTRUCTURING AND RELATED COSTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - RESTRUCTURING AND RELATED COSTS - Schedule of Total Restructuring and Related Implementation Costs, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - RESTRUCTURING AND RELATED COSTS - Schedule of Accrual for Restructuring and Related Implementation Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - INVENTORIES, NET - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - INVENTORIES, NET - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - INVENTORIES, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Components of Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Pre-Tax, Noncash Impairment Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - DEBT - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - DEBT - Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - OTHER LIABILITIES - Schedule of Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - OTHER LIABILITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Schedule of Purchase Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - LEASES - Schedule of Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - LEASES - Schedule of Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information and Noncash Activity Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - LEASES - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - LEASES - Schedule of Maturities of Operating Lease and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - LEASES - Schedule of Maturities of Operating Lease and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Dividends Per Share Paid to Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - NET EARNINGS PER SHARE (EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - STOCK-BASED COMPENSATION PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Compensation Cost and Related Income Tax Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Fair Value of each Stock Option Award Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Performance Share Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - OTHER (INCOME) EXPENSE, NET (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - INCOME TAXES - Schedule of Provision for Income Taxes and Components of Earnings Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954543 - Disclosure - INCOME TAXES - Summary of Changes in Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - INCOME TAXES - Schedule of Carryforwards with Related Valuation Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - INCOME TAXES - Schedule of Carryforwards with Related Valuation Allowances (Details) link:presentationLink link:calculationLink link:definitionLink 9954545 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954546 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954547 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income and Retirement Health Care Plans and Amounts Recognized in Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9954548 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954549 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954550 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Items Not Yet Recognized as a Component of Postretirement Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954551 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954552 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954553 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Expected Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954554 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Target Allocation and Weighted Average Allocation of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954555 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans Assets Carried at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954556 - Disclosure - SEGMENT REPORTING - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954557 - Disclosure - SEGMENT REPORTING - Schedule of Reportable Segment Information and Reconciliation of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954558 - Disclosure - SEGMENT REPORTING - Schedule of Concentration Percentage (Details) link:presentationLink link:calculationLink link:definitionLink 9954559 - Disclosure - SEGMENT REPORTING - Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954560 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 clx-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 14 clx-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 15 clx-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Adjustments to reconcile net earnings to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Long-term debt repayments Repayments of Long-Term Debt International Defined Contribution Plan International Defined Contribution Plan [Member] International Defined Contribution Plan [Member] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Amount due to suppliers Supplier Finance Program, Obligation, Current Cover page. Cover [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Short-term investment fund Defined Benefit Plan, Short-Term Investment [Member] Defined Benefit Plan, Short-Term Investment Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Inventory costs Deferred Tax Assets, Inventory Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Trading Symbol Trading Symbol 2029 Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Non-NEOs Non-NEOs [Member] Finance lease cost: Lease, Cost, Finance [Abstract] Lease, Cost, Finance Related income tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Dividends per share declared (in dollars per share) Common Stock, Dividends, Per Share, Declared 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Summary of Tax Credit Carryforwards Summary of Tax Credit Carryforwards [Table Text Block] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Dividends to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Disposal Group Name [Domain] Disposal Group Name [Domain] Line of Credit Facility [Table] Line of Credit Facility [Table] Net Carryforwards Carryforwards, Net Of Valuation Allowance Carryforwards, Net Of Valuation Allowance Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Commodity Purchase Derivative Contracts [Axis] Commodity Purchase Derivative Contracts [Axis] Commodity Purchase Derivative Contracts [Axis] Issuance of common stock for employee stock plans and other Proceeds from Stock Options Exercised Unrecorded Unconditional Purchase Obligation [Line Items] Unrecorded Unconditional Purchase Obligation [Line Items] Award Timing Disclosures [Line Items] Settlement of interest rate derivative contracts Derivative, Gain (Loss) on Derivative, Net Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Segment Reporting Segment Reporting, Policy [Policy Text Block] Glad Glad Business [Member] Glad Business [Member] United States UNITED STATES Other assets Other Assets, Noncurrent Leases [Abstract] Gross carrying amount Finite-Lived Intangible Assets, Gross Other employee stock plan activities (in shares) Other Employee Stock Plan Activities, Shares Number of shares issued during the period as a result of exercises of employee stock options or the vesting of other share-based awards. Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Operating Segments Operating Segments [Member] Net cash provided by operations Net Cash Provided by (Used in) Operating Activities Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Performance Share Awards Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost Total Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Finance leases Finance Lease, Weighted Average Remaining Lease Term Environmental Costs Environmental Costs, Policy [Policy Text Block] Insider Trading Policies and Procedures [Line Items] Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Use of Estimates Use of Estimates, Policy [Policy Text Block] Professional Products Professional Products [Member] Professional Products [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Cumulative translation adjustment losses Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Income taxes payable/prepaid Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Financing Lease, Lease Not yet Commenced Financing Lease, Lease Not yet Commenced [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Transaction Type [Axis] Transaction Type [Axis] Entity Small Business Entity Small Business ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Tabular List, Table Tabular List [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Liability for aggregate future remediation costs Accrual for Environmental Loss Contingencies Expected return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Amortization, curtailment and settlement during the year Defined Benefit Plan Amortization, Curtailment, And Settlement During The Year The adjustment out of other comprehensive income for actuarial gains (losses) recognized as a component of net periodic benefit cost during the period. Antidilutive stock options and other (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Deferred stock units for nonemployee directors distributed (in shares) Deferred Stock Units For Non-Employee Directors, Distributed Deferred stock units for nonemployee directors distributed. Less: Imputed interest Finance Lease, Liability, Undiscounted Excess Amount Credit Facility [Domain] Credit Facility [Domain] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Vested And Nonvested Weighted-Average Grant Date Fair Value Per Share The weighted average fair value of vested and nonvested awards on equity-based plans excluding option plans outstanding. Noncash capital expenditures Non-Cash Capital Expenditures Amount of non-cash capital expenditures incurred during the period. Goodwill Beginning balance Ending balance Goodwill Total Commodity Purchase Derivative Contracts Total Commodity Purchase Derivative Contracts [Member] Total Commodity Purchase Derivative Contracts [Member] Performance period for performance awards (in years) Performance Period For Performance Awards Period over which performance is measured for performance-based awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. INVENTORIES, NET Inventory Disclosure [Text Block] Fixed income Fixed Income Funds [Member] Stock Option Share-Based Payment Arrangement, Option [Member] Foreign exchange forward contracts Foreign Exchange Forward [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Total comprehensive income attributable to Clorox Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income taxes payable Accrued Income Taxes, Current Finance leases Finance Lease, Weighted Average Discount Rate, Percent Cash equivalents Real estate fund Employee Benefit Plan, Real Estate [Member] Other differences Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 2025 Finance Lease, Liability, to be Paid, Year One Alameda County, California Matter Alameda County, California Matter [Member] Alameda County, California Matter [Member] Award Type [Axis] Award Type [Axis] Net deferred tax liabilities Deferred Tax Liabilities, Net Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Accelerated amortization of losses on settlement of interest rate contracts and issuance costs associated with debt extinguished Deferred Debt Issuance Cost, Writeoff Work in process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Dividends per share paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid International legal entity reorganization Effective Income Tax Rate Reconciliation, International Legal Entity Reorganization, Percent Effective Income Tax Rate Reconciliation, International Legal Entity Reorganization, Percent Options vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign Currency Transactions and Translations Foreign Currency Transactions and Translations Policy [Policy Text Block] Revolving credit facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Current operating lease liabilities Current lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Accumulated other comprehensive loss (income) Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Schedule of Items Not Yet Recognized as a Component of Postretirement Expense Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block] Property, plant and equipment, gross Property, Plant and Equipment, Gross Retirement Plan Name [Axis] Retirement Plan Name [Axis] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Gains (losses) recognized in Other comprehensive (loss) income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Allowance for credit loss Financing Receivable, Allowance for Credit Loss, Current Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted- Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and development costs Research and Development Expense [Member] Lapse of applicable statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Nature of Operations and Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Total Clorox stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Subtotal Deferred Tax Assets, Gross 2028 Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four Net sales Disposal Group, Including Discontinued Operation, Revenue Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Capitalized software costs Capitalized software costs Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Letter of credit, amount outstanding Letters of Credit Outstanding, Amount Selling and administrative expenses Selling, General and Administrative Expense PBO Exceeds the Fair Value of Plan Assets Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Accumulated benefit obligation Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Aggregate cost of the defined contribution plans Defined Contribution Plan, Cost Derivative, notional amount, additional contracts Derivative, Notional Amount, Additional Contracts Derivative, Notional Amount, Additional Contracts Costs of products sold Cost of products sold Cost of Sales [Member] Cash equivalents — Level 1 Defined Benefit Plan, Cash and Cash Equivalents [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Purchases of Inventory Purchases of Inventory [Member] Purchases of Inventory [Member] Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Dilutive effect of stock options and other (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Schedule of Accrual for Restructuring and Related Implementation Costs Schedule of Restructuring Reserve by Type of Cost [Table Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Average remaining contractual life, options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS   Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Total other comprehensive (loss) income, net of tax Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Domestic equity funds Defined Benefit Plan, Equity Securities, US [Member] Derivative Contract [Domain] Derivative Contract [Domain] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Gross carrying amount Indefinite-Lived Intangible Assets (Excluding Goodwill), Before Impairment Indefinite-Lived Intangible Assets (Excluding Goodwill), Before Impairment Dickinson County, Michigan Matter Dickinson County, Michigan Matter [Member] Dickinson County, Michigan Matter [Member] Actuarial loss (gain) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Capitalization of Software Costs Internal Use Software, Policy [Policy Text Block] Schedule of Reportable Segment Information and Reconciliation of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Average remaining contractual life, options vested (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Notes and loans payable, estimated fair value Short-Term Debt, Fair Value Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Supplier finance program, payment timing, period Supplier Finance Program, Payment Timing, Period Net carrying amount Finite-Lived Intangible Assets, Net Accounts payable Accounts Payable, Current Deferred stock units for nonemployee directors reinvested dividends (in shares) Deferred Stock Units For Non-Employee Directors, Reinvested Dividends Deferred Stock Units For Non-Employee Directors, Reinvested Dividends. Schedule of Fair Value of each Stock Option Award Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Earnings (losses) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Name Outstanding Recovery, Individual Name Summary of Changes in Valuation Allowance Summary of Valuation Allowance [Table Text Block] Unusual or Infrequent Item, or Both [Line Items] Unusual or Infrequent Item, or Both [Line Items] LIFO allowances Inventory, LIFO Reserve Summary of Net Assets Divested and Net Sales of Divested Business Disposal Groups, Including Discontinued Operations [Table Text Block] Variable lease cost Variable Lease, Cost Commodity Purchase Derivative Contracts [Domain] Commodity Purchase Derivative Contracts [Domain] Commodity Purchase Derivative Contracts [Domain] Goodwill impairment Goodwill impairment Goodwill Goodwill, Impairment Loss Goodwill Disposal Group, Including Discontinued Operation, Goodwill Cyberattack Cyberattack [Member] Cyberattack Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Cash dividends paid to Clorox stockholders Payments of Ordinary Dividends, Common Stock Diluted net earnings per share (in dollars per share) Earnings Per Share, Diluted Environmental liabilities Accrued Environmental Loss Contingencies, Noncurrent Counterparty Name [Domain] Counterparty Name [Domain] Schedule of Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Revenue Recognition and Cost of Products Sold Revenue from Contract with Customer [Policy Text Block] United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Maximum undiscounted costs Maximum Exposure, Undiscounted Cost Maximum potential amount of future payments (undiscounted) that the Company could incur over an estimated remediation period. Total current Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Non-customer receivables Nontrade Receivables, Current Retirement Benefits [Abstract] Foreign exchange transaction (gains) losses, net Gain (Loss), Foreign Currency Transaction, before Tax Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Receivables, net Increase (Decrease) in Receivables Employee Benefits Employee Benefits [Policy Text Block] Disclosure of accounting policy for the entity's various types of employee benefit plans, including retirement, postretirement and postemployment plans. Other Deferred Tax Liabilities, Other Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Net earnings Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Loss on divestiture Pre-tax loss on divestiture Loss on divestiture Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Income taxes Total Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Derivative, notional amount Derivative, Notional Amount Derivative assets Derivative Asset Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Compensation costs not yet recognized, period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net sales Net Sales Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Distributed (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Distributed Weighted-Average Grant Date Fair Value The weighted average fair value at grant date for distributed equity-based awards issued during the period on other than stock (or unit) option plans. Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Interest expense Interest expense Interest Expense, Operating and Nonoperating Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized All Adjustments to Compensation All Adjustments to Compensation [Member] Compensation and employee benefit costs Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Other intangible assets, net Other Intangible Assets, Net Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Charges Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Commitments and Contingencies Disclosure [Abstract] Soybean Oil Futures Soybean Oil Futures [Member] Soybean Oil Futures [Member] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Commodity purchase derivative contracts Commodity Contract [Member] Net unrealized gains (losses) on derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Finance leases Finance Lease Assets And Liabilities Lessee [Abstract] Finance Lease Assets And Liabilities Lessee Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Payments to related parties Related Party Transaction, Payments To Related Party Related Party Transaction, Payments To Related Party Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Valuation Allowances Carryforwards, Valuation Allowance Carryforwards, Valuation Allowance Derivative instruments subject to contractually defined counterparty liability position limits Derivative Instruments Subject To Contractually Defined Counterparty Liability Position Limits Derivative instruments subject to contractually defined counterparty liability position limits. Better Health VMS reporting unit Better Health - Vitamins, Minerals And Supplements Reporting Unit [Member] Better Health - Vitamins, Minerals And Supplements Reporting Unit Weighted-average grant date fair value per share of nonvested awards (in dollars per share) Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Restructuring and related costs Total, net Streamlined operating model Restructuring and Related Cost, Incurred Cost Restatement Determination Date Restatement Determination Date Estimated Fair Value Estimate of Fair Value Measurement [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Interest rate derivative contracts Interest Rate Contract [Member] Unrecorded Unconditional Purchase Obligation [Table] Unrecorded Unconditional Purchase Obligation [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] Operating lease right-of-use assets Right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Total finance lease cost Finance Lease, Cost Finance Lease, Cost Deferred stock units for nonemployee directors granted weighted average fair value on grant date (in dollars per share) Deferred Stock Units For Non-Employee Directors, Granted Weighted Average Fair Value On Grant Date The weighted-average grant date fair value of the deferred stock units for nonemployee directors granted during the period. Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Tax Credit Carryforwards Deferred Tax Assets, Tax Credit Carryforwards [Abstract] Maximum duration, commodity contracts (in years) Maximum Length of Time Hedged in Cash Flow Hedge Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Dividends Dividends Payable, Current Incurred incremental costs, net of insurance recoveries Cyberattack costs, net of insurance recoveries Other Nonrecurring Expense Total liabilities, estimated fair value Financial Liabilities Fair Value Disclosure Curtailment gain recognized Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment NET EARNINGS PER SHARE (EPS) Earnings Per Share [Text Block] Subsequent Event Subsequent Event [Member] Federal research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Increase in deferred compensation plan Increase (Decrease) Deferred Compensation Plan Assets Increase (Decrease) Deferred Compensation Plan Assets Trust investment (gains) losses, net Gain (Loss) on Investments Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsegments [Domain] Subsegments [Domain] Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Schedule of Maturities of Finance Lease Liabilities Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Income tax benefit (expense) Other Comprehensive Income (Loss), Tax Lifestyle Lifestyle [Member] Lifestyle [Member] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized Tax Benefits [Roll Forward] PEO PEO [Member] Name Trading Arrangement, Individual Name Accrued benefit cost, net funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Entity Public Float Entity Public Float Disposal Group Name [Axis] Disposal Group Name [Axis] Operating leases, remaining lease terms Lessee, Operating Lease, Remaining Lease Term Federal excess tax benefits Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Income from equity investees (Income) Loss from equity investees included in Other (income) expense, net Income (Loss) from Equity Method Investments Treasury stock, at cost: 6,539,654 and 6,921,439 shares as of June 30, 2024 and 2023, respectively Treasury Stock, Common, Value OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS Commitments Contingencies and Guarantees [Text Block] Benefit obligation as of beginning of year Benefit obligation as of end of year Defined Benefit Plan, Benefit Obligation Schedule of Concentration Percentage Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Cash dividends declared and accrued, but not paid Dividends Payable Grilling Grilling [Member] Grilling [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Number of hedging instruments designated as fair value hedges Number Of Hedging Instruments Designated As Fair Value Hedges The number of hedging instruments designated as fair value hedges held by the entity. Cash and cash equivalents, estimated fair value Cash and Cash Equivalents, Fair Value Disclosure Restructuring and Related Costs Benchmark Restructuring and Related Costs Benchmark [Member] Restructuring and Related Costs Benchmark Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Gain on sale-leaseback transaction Gain on sale-leaseback transaction Sale and Leaseback Transaction, Gain (Loss), Net Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Total gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Valuation allowance Valuation allowance at beginning of year Valuation allowance at end of year Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Foreign and other credit lines Foreign Line of Credit [Member] Other Other Restructuring [Member] Income tax credits Income Tax Credit Carryforward [Member] Income Tax Credit Carryforward Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in: Increase (Decrease) in Operating Capital [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value Assets and Liabilities Measured on Recurring Basis [Line Items] Maximum contract duration (in years) Maximum Length of Time, Foreign Currency Cash Flow Hedge Trademarks, net Trademarks, Net Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite or finite period of benefit. PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Operating Lease, Lease Not yet Commenced Operating Lease, Lease Not yet Commenced [Member] Common Stock Common Stock [Member] Impairment Review of Goodwill and Indefinite-Lived Intangible Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Long-term debt, weighted average interest rate, at point in time Long-Term Debt, Weighted Average Interest Rate, at Point in Time Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Cash margin balances amount Margin Deposit Assets Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For Foreign And US Net Operating Loss Carryforwards And Tax Credits Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized resulting from foreign and US net operating loss carryforwards and tax credits. Accrued interest and penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount STOCKHOLDERS' EQUITY Equity [Text Block] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Less: Current maturities of long-term debt Long-Term Debt, Current Maturities SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] 2025 Unrecorded Unconditional Purchase Obligation, to be Paid, Year One Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted Stock Restricted Stock [Member] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Measurement Basis [Axis] Measurement Basis [Axis] Argentina Business Argentina Business [Member] Argentina Business Title Trading Arrangement, Individual Title Right-of-use assets obtained in exchange for lease obligations: Right-of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-of-Use Asset Obtained In Exchange For Lease Liability 3.10%, $400 due October 2027 Senior Long-Term Notes And Debentures; 3.10%, $400 Due October 2027 [Member] Senior Long-Term Notes and Debentures; 3.10%, $400 Due October 2027 [Member] Schedule of Components of Earnings Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Unrecognized tax benefits at beginning of year Unrecognized tax benefits at end of year Unrecognized Tax Benefits Less: Total comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Option to terminate, period Sale Leaseback Transaction, Option To Terminate, Period Sale Leaseback Transaction, Option To Terminate, Period City Area Code City Area Code Current liabilities Liabilities, Current [Abstract] Auditor Location Auditor Location Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Dividends Payable [Table] Dividends Payable [Table] Weighted-average remaining lease term: Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Minimum percentage for calculating the amortization of actuarial gains and losses under the corridor approach Minimum Percentage For Calculating The Amortization Of Actuarial Gains And Losses Under The Corridor Approach Represents the minimum percentage of the greater of the projected benefit obligation or the market-related asset value that actuarial gains and losses must exceed in order to be amortized to pension expense under the corridor approach for purposes of determining the amortization of actuarial gains and losses related to the entity's employee benefits. Treasury stock purchased Payments for Repurchase of Common Stock Long-term debt Long-term debt Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Net earnings per share attributable to Clorox Earnings Per Share [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Effect of foreign currency translation Goodwill, Translation and Measurement Period Adjustments Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Net Sales Revenue from Contract with Customer Benchmark [Member] Canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Cash flow hedge gain (loss) to be reclassified within twelve months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Inventories, net Increase (Decrease) in Inventories Letter of credit Letter of Credit Borrowing capacity under the letter of credit without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding. 2026 Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Vested and deferred (in dollars per share) ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue Share based compensation arrangement by share based payment award equity instruments other than options vested and deferred in period weighted average grant date fair value. Total operating lease liabilities Total lease liabilities Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Performance Shares Performance Shares [Member] Number of renewal options Sale Leaseback Transaction, Number Of Renewal Options Sale Leaseback Transaction, Number Of Renewal Options Distributed (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] 2029 Finance Lease, Liability, to be Paid, Year Five Amendment Flag Amendment Flag Carrying Amount Reported Value Measurement [Member] Notes and loans payable Notes and loans payable, carrying value Commercial Paper Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Machinery and equipment Machinery and equipment Machinery and Equipment [Member] Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Subsequent Events [Abstract] Subsequent Events [Abstract] Selling and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] OTHER (INCOME) EXPENSE, NET Other Income and Other Expense Disclosure [Text Block] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) DEBT Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face value Debt Instrument, Face Amount Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising costs Advertising Expense Cash and cash equivalents Cash and cash equivalents, carrying value Cash and Cash Equivalents, at Carrying Value Schedule of Amounts Recognized in Balance Sheets Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Intangible asset impairment charges Trademarks, net Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Other Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Estimated useful lives (in years) Property, Plant and Equipment, Useful Life Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Net deferred tax assets (liabilities) Deferred Tax Assets (Deferred Tax Liabilities), Net Deferred Tax Assets (Deferred Tax Liabilities), Net Financing cash flows from finance leases Finance Lease, Principal Payments Amortization Amortization Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Translation and other adjustments Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted average shares outstanding (in thousands) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Total assets Total assets Assets Cost of products sold Cost of Goods and Services Sold Valuation Allowances Operating Loss Carryforwards, Valuation Allowance Capital expenditures Payments to Acquire Property, Plant, and Equipment Other liabilities Total Other Liabilities, Noncurrent Deferred stock units for nonemployee directors distributed weighted average fair value on grant date (in dollars per share) Deferred Stock Units For Non-Employee Directors Distributed Weighted Average Fair Value On Grant Date The weighted-average grant date fair value of the deferred stock units for nonemployee directors dividends distributed during the period. Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies Commitments and Contingencies Stock-based Compensation Share-Based Payment Arrangement [Policy Text Block] Schedule of Reconciliation of Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Bags and Wraps Bags and wraps Bags And Wraps [Member] Bags And Wraps [Member] 2025 Long-Term Debt, Maturity, Year One Water Filtration Water Filtration [Member] Water Filtration [Member] Debt Instrument [Axis] Debt Instrument [Axis] Net earnings attributable to Clorox Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] Fiscal years 2030 through 2034 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Schedule of Target Allocation and Weighted Average Allocation of Plan Assets and Retirement Income Plans Assets Carried at Fair Value Schedule of Allocation of Plan Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs Defined Benefit Plan, Assumptions [Table Text Block] Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Noncontrolling interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Capital losses Capital Loss Carryforward [Member] Not Subject to Expiration Not Subject to Expiration [Member] Foreign benefits not subject to expiration. Federal Current Federal Tax Expense (Benefit) Senior Long-Term Notes And Debentures; 3.50%, $500 Due December 2024 Senior Long-Term Notes And Debentures; 3.50%, $500 Due December 2024 [Member] Represents information pertaining to senior long term notes and debtentures 3.50%, due December 2024. Deferred stock units for nonemployee directors outstanding weighted average fair value on grant date (in dollars per share) Deferred Stock Units For Non-Employee Directors Outstanding Weighted Average Fair Value On Grant Date The weighted-average grant date fair value of the deferred stock units for nonemployee directors outstanding as of the end of the period. Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Health and Wellness Health And Wellness [Member] Health and Wellness [Member] Name Forgone Recovery, Individual Name Options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Operating leases Operating Lease, Weighted Average Remaining Lease Term Transaction [Domain] Transaction [Domain] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Property, Plant and Equipment and Finite-Lived Intangible Assets Property, Plant And Equipment And Finite-Lived Intangible Assets, Policy [Policy Text Block] Property, Plant And Equipment And Finite-Lived Intangible Assets, Policy [Policy Text Block] Other Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Deferred tax liabilities Components of Deferred Tax Liabilities [Abstract] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] VMS goodwill impairment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Gross decreases - tax positions in prior periods Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Land improvements Land Improvements [Member] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Impaired trademarks, remaining net carrying value Indefinite-Lived Intangible Assets, Remaining Carrying Value Indefinite-Lived Intangible Assets, Remaining Carrying Value Adjustment to Compensation: Adjustment to Compensation [Axis] Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Divestiture Goodwill, Written off Related to Sale of Business Unit Employee benefit obligations Employee Benefit Obligations The sum of the carrying amounts as of the balance sheet date of the portions of obligations to employees under pension, postretirement, and health benefit plans that are due beyond one year. 3.90%, $500 due May 2028 Senior Long-Term Notes And Debentures; 3.90%, $500 Due May 2028 [Member] Senior Long-Term Notes and Debentures; 3.90%, $500 Due May 2028 [Member] Issuance of common stock for employee stock plans and other Issuance Of Common Stock For Employee Stock Plans And Other The cash inflow associated with the amount received from holders exercising their stock options. Also includes the net cash inflow (outflow) from other financing activities. Accumulated other comprehensive net (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Restricted cash Restricted Cash and Cash Equivalents Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Net Carryforwards Tax Credit Carryforward, Amount, Net Of Valuation Allowance Tax Credit Carryforward, Amount, Net Of Valuation Allowance Non-current inventories, net Inventory, Noncurrent Walmart Stores, Inc. Walmart Stores, Inc. [Member] Walmart Stores, Inc. and its affiliates [Member] Proceeds from sale of productive assets Proceeds from Sale of Productive Assets Total stockholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest % Target Allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Entity Filer Category Entity Filer Category Loss Contingencies [Line Items] Loss Contingencies [Line Items] International reporting unit International Reporting Unit [Member] International Reporting Unit Operating lease right-of-use assets and liabilities, net Operating Lease, Right-of-Use Asset And Liability, Net Operating Lease, Right-of-Use Asset And Liability, Net Unusual or Infrequent Item, or Both [Table] Unusual or Infrequent Item, or Both [Table] Statistical Measurement [Domain] Range [Domain] Statistical Measurement [Domain] Capital expenditures Segment, Expenditure, Addition to Long-Lived Assets Schedule of Components of Lease Cost, Supplemental Cash Flow Information and Noncash Activity Related to Leases and Weighted-Average Remaining Lease Term and Discount Rate Lease, Cost [Table Text Block] Deferred stock units for nonemployee directors outstanding (in shares) Deferred Stock Units For Non-Employee Directors, Outstanding The number of shares of deferred stock units for nonemployee directors outstanding as of the end of the period. Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Working capital, net Disposal Group, Including Discontinued Operation, Working Capital, Net Disposal Group, Including Discontinued Operation, Working Capital, Net Other Other Obligations Other Obligations Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Carryforwards Tax Credit Carryforward, Amount Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Long-term debt Long-Term Debt [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Income taxes paid, net of refunds Income Taxes Paid, Net Equity method investments Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Derivative [Table] Derivative [Table] Restructuring Liabilities Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Restructuring and Related Activities [Abstract] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Other Performance Measure, Amount Other Performance Measure, Amount Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] LEASES Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance, common (in shares) Ending balance, common (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Gross decreases - current period tax positions Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions Operating lease cost Operating Lease, Cost Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Long-term operating lease liabilities Non-current lease liabilities Operating Lease, Liability, Noncurrent Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Interest on lease liabilities Finance Lease, Interest Expense Service cost Defined Benefit Plan, Service Cost Entity Tax Identification Number Entity Tax Identification Number Other Miscellaneous Other Expense (Income) Represents the sum of miscellaneous other income and expense recognized by the entity in the period that is not otherwise specified. Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Number of production plants disposed of Disposal Group, Including Discontinued Operation, Number Of Assets Disposed Of Disposal Group, Including Discontinued Operation, Number Of Assets Disposed Of Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Gross increases - tax positions in prior periods Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Treasury stock purchased (in shares) Treasury Stock, Shares, Acquired Retirement Plan Type [Axis] Retirement Plan Type [Axis] Foreign Deferred Foreign Income Tax Expense (Benefit) Interest-bearing investments, including money market funds Money Market Funds [Member] Selling and administrative expenses Selling and administrative expenses Selling and administrative expenses Selling, General and Administrative Expenses [Member] Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee CYBERATTACK Unusual or Infrequent Items, or Both, Disclosure [Text Block] Treasury Stock Treasury Stock, Common [Member] Thereafter Finance Lease, Liability, to be Paid, after Year Five Equity Components [Axis] Equity Components [Axis] Total lease payments Finance Lease, Liability, to be Paid 2026 Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two Proceeds from divestiture, net of cash divested Proceeds from Divestiture of Businesses, Net of Cash Divested Net actuarial loss (gain) Net actuarial loss (gain) as of beginning of year Net actuarial loss (gain) as of end of year Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Bond funds Defined Benefit Plan, Bonds Funds [Member] Defined Benefit Plan, Bonds Funds [Member] 2027 Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three Options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Noncash financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Geographical [Axis] Geographical [Axis] Schedule of Total Restructuring and Related Implementation Costs, Net Restructuring and Related Costs [Table Text Block] Net deferred tax assets Deferred Tax Assets, Net Interest income Interest income Investment Income, Interest and Dividend 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Operating and finance lease liabilities Deferred Tax Assets, Operating And Finance Lease Liabilities Deferred Tax Assets, Operating And Finance Lease Liabilities Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Household Household [Member] Household [Member] Receivables, net Receivables, Net, Current Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Segment adjusted earnings (losses) before interest and income taxes Segment Adjusted EBIT Segment Adjusted EBIT Stock conversion ratio Stock Conversion Ratio Stock Conversion Ratio Prior service benefit Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Cash payments Payments for Restructuring Beginning of year End of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Foreign Current Foreign Tax Expense (Benefit) Current assets Assets, Current [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Audit Information [Abstract] Audit Information Share-based Compensation [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Treasury stock, at cost (in shares) Beginning balance, treasury (in shares) Ending balance, treasury (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Short term lease cost Short-Term Lease, Cost Settlement of interest rate derivative contracts Settlement Of Interest Rate Derivative Contracts Cash inflows (outflows) related to the settlement of interest rate derivative contracts. Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Fair Value Measurements, Recurring [Table] Fair Value Measurements, Recurring [Table] Disclosure about financial instruments measured at fair value on a recurring basis. Raw materials and packaging Inventory, Raw Materials and Supplies, Net of Reserves Loss on divestiture Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Operating Activities Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Operating Activities Security Exchange Name Security Exchange Name Percentage of ownership by venture partner Percentage of Ownership by Venture Partner The percentage of ownership interest by the venture partner. Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price State Current State and Local Tax Expense (Benefit) Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development costs Research and Development Expense Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Total inventories, net Inventory, Current And Noncurrent, Net Inventory, Current And Noncurrent, Net Subsegments [Axis] Subsegments [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Retirement Plan Name [Domain] Retirement Plan Name [Domain] Concentration percentage Concentration Risk, Percentage Line of credit facility, borrowing capacity Total Line of Credit Facility, Maximum Borrowing Capacity Schedule of Purchase Obligations Unrecorded Unconditional Purchase Obligations Disclosure [Table Text Block] Computer equipment Computer equipment Computer Equipment [Member] Derivative liabilities Derivative Liability Venture Agreement terminal obligation, net Venture agreement terminal obligation, recognized Venture Agreement, Terminal Obligation, Net Venture Agreement, Terminal Obligation, Net Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Transfer to domestic defined contribution plan Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan Common stock, shares authorized (in shares) Common Stock, Shares Authorized ABO Exceeds the Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Other Defined Benefit Plan, Other [Member] Defined Benefit Plan, Other Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Restructuring costs Restructuring Costs Plan settlement Defined Benefit Plan, Plan Assets, Payment for Settlement Statement of Financial Position Location, Activity, Accrual [Axis] Statement of Financial Position Location, Activity, Accrual [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Entity Voluntary Filers Entity Voluntary Filers Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts Payable and Accrued Liabilities, Current [Abstract] Amortization of unrecognized items      Defined Benefit Plan, Amortization of Gain (Loss) Deferred income taxes Total deferred Deferred Income Tax Expense (Benefit) Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Settlement loss recognized Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Goodwill, trademark and other asset impairments Goodwill, trademark and other asset impairments Total Asset impairment charges VMS impairment Asset Impairment Charges Total Current maturities of long-term debt and Long-term debt, carrying value Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of assets as of beginning of year Fair value of plan assets as of end of year Total assets at fair value Defined Benefit Plan, Plan Assets, Amount Lease term Sale Leaseback Transaction, Lease Term Thereafter Long-Term Debt, Maturity, after Year Five Deferred stock units for nonemployee directors reinvested weighted average fair value on grant date (in dollars per share) Deferred Stock Units For Non-Employee Directors Reinvested Weighted Average Fair Value On Grant Date The weighted-average grant date fair value of the deferred stock units for nonemployee directors dividends reinvested during the period. Contract term (in years) Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment Finance leases, remaining lease terms Lessee, Finance Lease, Remaining Lease Term Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Document Annual Report Document Annual Report 2027 Finance Lease, Liability, to be Paid, Year Three Weighted average interest rate on notes and loans payable Weighted Average Interest Rate On Notes And Loans Payable Reflects the calculation as of the balance sheet date of average interest rate incurred during the reporting period weighted by the amount of short-term debt outstanding by type or by instrument during that time. Vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Trust assets for nonqualified deferred compensation plans, carrying value Deferred Compensation Plan Assets Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Net carrying amount Indefinite-Lived Intangible Assets (Excluding Goodwill) Amortization of intangible assets Amortization of Intangible Assets Foreign Non-US [Member] Liabilities Liabilities [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Name PEO Name Weighted-average dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Rate Share based compensation arrangement by share based payment award fair value assumptions weighted average expected dividend. Asset impairments Asset Impairments [Member] Asset Impairments Award Type [Domain] Award Type [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-current accrued benefit liability Liability, Defined Benefit Plan, Noncurrent Non-PEO NEO Non-PEO NEO [Member] Estimated useful life (in years) Finite-Lived Intangible Asset, Useful Life Trust assets for nonqualified deferred compensation plans, estimated fair value Investments, Fair Value Disclosure Additional Paid-in Capital Additional Paid-in Capital [Member] Non-current lease liabilities Finance Lease, Liability, Noncurrent Other assets Disposal Group, Including Discontinued Operation, Other Assets EMPLOYEE BENEFIT PLANS Retirement Benefits [Text Block] Domestic Defined Contribution Plan Domestic Defined Contribution Plan [Member] Domestic Defined Contribution Plan [Member] Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract] FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract] Financial Instruments and Fair Value Measurements [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] 2028 Finance Lease, Liability, to be Paid, Year Four Accumulated amortization / Impairments Finite-Lived Intangible Assets, Accumulated Amortization Schedule of Weighted Average Number of Shares Outstanding Schedule of Weighted Average Number of Shares [Table Text Block] Name Measure Name Carryforwards Carryforwards, Gross Carryforwards, Gross Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Deferred tax assets Components of Deferred Tax Assets [Abstract] Thereafter Unrecorded Unconditional Purchase Obligation, to be Paid, after Year Five New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Employee-related costs Employee-Related Costs Employee Severance [Member] RESTRUCTURING AND RELATED COSTS Restructuring and Related Activities Disclosure [Text Block] Maximum duration, interest rate contracts (in years) Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge Stock-based compensation Total compensation costs Share-Based Payment Arrangement, Noncash Expense Costs of products sold Cost Of Goods And Services Sold [Member] Cost Of Goods And Services Sold Total common collect trust measured at net asset value Fair Value Measured at Net Asset Value Per Share [Member] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Retirement Health Care Postretirement Health Coverage [Member] Loss (gain) during the year Defined Benefit Plan Gain (Loss) During The Year The accumulated change in the value of either the projected benefit obligation or the plans assets resulting from experience different from that assumed or from a change in an actuarial assumption that has not been recognized in net periodic benefit cost pursuant to FAS 87 and 106. Pension and postretirement benefit adjustments Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Annual fixed interest rate Debt Instrument, Interest Rate, Stated Percentage Corporate and Other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Capitalized research and development Deferred Tax Asset, In-Process Research and Development Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Auditor Firm ID Auditor Firm ID Effective tax rate Effective Income Tax Rate Reconciliation, Percent Projected benefit obligation Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Number of reportable segments Number of Reportable Segments Total liabilities and stockholders’ equity Liabilities and Equity SUBSEQUENT EVENT Subsequent Events [Text Block] Dividends to Clorox stockholders Dividends Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] International equity funds Defined Benefit Plan, Equity Securities, Non-US [Member] 2026 Finance Lease, Liability, to be Paid, Year Two Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net U.S. tax on foreign income Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Individual: Individual [Axis] Expiration Period [Domain] Expiration Period [Domain] Expiration Period [Domain] Buildings and leasehold improvements Building and Building Improvements [Member] Accumulated Other Comprehensive Net (Loss) Income Accumulated other comprehensive net (loss) income AOCI Attributable to Parent [Member] Expected life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories, net Total current inventories, net Inventory, Net Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Notes and loans payable Notes and Loans Payable [Member] Notes and Loans Payable Amortization of trademarks and other intangible assets Amortization Of Trademarks And Other Intangible Assets Amortization of trademarks and other intangible assets. Option to extend agreement (in years) Venture Agreement, Option To Extend Agreement Term Period Venture Agreement, Option To Extend Agreement Term Period Amortization period of settlement payment (in years) Amortization period of settlement payment Amortization period of settlement payment. Deferred Tax Assets, Valuation Allowance [Roll Forward] Deferred Tax Assets, Valuation Allowance [Roll Forward] Deferred Tax Assets, Valuation Allowance Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Schedule of Estimated Useful Lives of Property, Plant and Equipment Schedule of Components of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Other (income) expense, net Other Income (Expense), Net [Member] Other Income (Expense), Net Derivative Instruments Derivatives, Policy [Policy Text Block] Operating leases Operating Lease Assets And Liabilities Lessee [Abstract] Operating Lease Assets And Liabilities Lessee Minimum Minimum [Member] Adoption Date Trading Arrangement Adoption Date Related Party Transactions [Abstract] Related Party Transactions [Abstract] Schedule of Provision for Income Taxes Provision For Income Taxes On Continuing Operations By Tax Jurisdiction [Table Text Block] A schedule that reflects the provision for income taxes on continuing operations, by tax jurisdiction. Subject to Expiration Subject to Expiration [Member] Foreign benefits subject to expiration. Operating Segments and Corporate and Other Operating Segments And Corporate, Non-Segment [Member] Operating Segments And Corporate, Non-Segment Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Statutory federal tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Sale-leaseback transaction, carrying value Sale Leaseback Transaction, Net Book Value Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Schedule of Components of Net Deferred Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Arrangement Duration Trading Arrangement Duration Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Carryforwards Operating Loss Carryforwards Loss and tax credit carryforwards Deferred Tax Assets, Net Operating Loss And Tax Credit Carryforwards Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards and foreign tax credit carryforwards. LEASES Lessee, Finance Leases [Text Block] GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Stockholders’ equity Equity, Attributable to Parent [Abstract] Remediation period (in years) Remediation period Estimated time frame of disbursements over which remediation efforts are estimated to occur for an individual site. Cleaning Cleaning products Cleaning [Member] Cleaning [Member] U.S. jurisdictions Domestic Tax Jurisdiction [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Expiration Period [Axis] Expiration Period [Axis] Expiration Period [Axis] Total finance lease liabilities Total lease liabilities Finance Lease, Liability 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Reporting Unit [Axis] Reporting Unit [Axis] Buildings Building [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Current maturities of long-term debt and Long-term debt, estimated fair value Debt Instrument, Fair Value Disclosure Translation and other adjustments Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Hosting arrangement term (in years) (up to) Hosting Arrangement, Service Contract, Term Hosting Arrangement, Service Contract, Term Retirement Income Other Postretirement Benefits Plan [Member] Total net carrying amount Intangible Assets, Net (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Impairment tax benefit Impairment Of Intangible Assets (Excluding Goodwill), Income Tax Expense (Benefit) Impairment Of Intangible Assets (Excluding Goodwill), Income Tax Expense (Benefit) Percentage of LIFO inventory Percentage of LIFO Inventory 1.80%, $500 due May 2030 Senior Long-Term Notes And Debentures; 1.80%, $500 Due May 2030 [Member] Senior Long-Term Notes And Debentures; 1.80%, $500 Due May 2030 Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements Schedule of Line of Credit Facilities [Table Text Block] Loss on divestiture Effective Income Tax Rate Reconciliation, Disposition of Business, Percent Undistributed earnings of foreign subsidiaries Undistributed Earnings of Foreign Subsidiaries Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Current accrued benefit liability Liability, Defined Benefit Plan, Current Lender Name [Axis] Lender Name [Axis] Valuation Allowances Tax Credit Carryforward, Valuation Allowance Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Net assets divested Disposal Group, Including Discontinued Operation, Net Assets Disposal Group, Including Discontinued Operation, Net Assets Accounts payable and accrued liabilities Total Accounts Payable and Accrued Liabilities, Current Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Deferred income taxes Deferred Income Tax Liabilities, Net Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Schedule of Restricted Stock Awards Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Foreign tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Pension and postretirement benefit adjustments, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Federal Deferred Federal Income Tax Expense (Benefit) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial Instruments And Fair Value Measurements [Text Block] Financial Instruments And Fair Value Measurements Lease renewal term Sale Leaseback Transaction, Lease Renewal Term Sale Leaseback Transaction, Lease Renewal Term Change in benefit obligations: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Foreign and Other Credit Lines Foreign and Other Credit Lines [Member] Foreign and Other Credit Lines [Member] Measure: Measure [Axis] Venture agreement terminal obligation, fair value Venture Agreement. Terminal Obligation Venture Agreement. Terminal Obligation Schedule of Pre-Tax, Noncash Impairment Charges Schedule of Impaired Intangible Assets [Table Text Block] Gross increases - current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year One Stock option awards granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total liabilities Liabilities, Fair Value Disclosure 2029 Long-Term Debt, Maturity, Year Five Weighted-average discount rate: Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate Statement of Financial Position Location, Activity, Accrual [Domain] Statement of Financial Position Location, Activity, Accrual [Domain] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Amounts reclassified from Accumulated other comprehensive net (loss) income Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Equity Components [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Accrued benefit cost, net Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Digital capabilities and productivity enhancements investment Digital Capabilities and Productivity Enhancements Expense Digital Capabilities and Productivity Enhancements Expense Cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Angela Hilt [Member] Angela Hilt 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Schedule of Dividends Per Share Paid to Stockholders Dividends Declared [Table Text Block] Property, plant and equipment and intangible assets Deferred Tax Liabilities Property, Plant And Equipment And Intangible Assets The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of capital assets and intangible assets and the basis of capital assets and intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, attributable to different capitalization of costs, depreciation, or amortization methodologies, impairment charges, or other reasons will increase future taxable income when such basis difference is realized. Capital assets include but are not limited to assets such as land, real estate, leasehold improvements, machinery and equipment and furniture and fixtures. Supplier Finance Program [Table] Supplier Finance Program [Table] Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Revolving Credit Agreement, Matures March 2027 Revolving Credit Agreement, Matures March 2027 [Member] Revolving Credit Agreement, Matures March 2027 Consolidation Items [Domain] Consolidation Items [Domain] Jet Fuel Swaps Jet Fuel Swaps [Member] Jet Fuel Swaps [Member] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total assets in the fair value hierarchy Fair Value, Inputs, Level 1 [Member] Foreign currency adjustments, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Compensation and benefit programs Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Insurance recoveries Unusual or Infrequent Item, or Both, Insurance Proceeds Options vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 2027 Long-Term Debt, Maturity, Year Three Unusual or Infrequent Items, or Both [Abstract] Percentage ownership of equity investments, maximum Percentage Ownership Of Equity Investments, Maximum Maximum ownership percentage in equity investments. Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Trade and sales promotion costs Trade And Sales Promotion Carrying value as of the balance sheet date of obligations incurred through that date and payable for trade and sales promotion costs of the entity. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Senior Long-Term Notes And Debentures; 3.05%, $600 Due September 2022 Senior Long-Term Notes And Debentures; 3.05%, $600 Due September 2022 [Member] Senior Long-term Notes and Debentures Instrument Due September 2022 [Member] Weighted average fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029 4.40%, $500 due May 2029 Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029 [Member] Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029 Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Total Minimum lease payments signed but not yet commenced Unrecorded Unconditional Purchase Obligation Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Other intangible assets with finite lives Other Intangible Assets [Member] Net Carryforwards Operating Loss Carryforwards, Net Of Valuation Allowance Operating Loss Carryforwards, Net Of Valuation Allowance Time deposits Bank Time Deposits [Member] INCOME TAXES Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Taxes Liability for Uncertainty in Income Taxes, Noncurrent Plan settlement Defined Benefit Plan, Benefit Obligation, Payment for Settlement Domestic Plan Domestic Plan [Member] Percentage of liability for aggregate remediation and associated costs, other than legal fees Percentage Of Liability For Aggregate Remediation And Associated Costs, Other Than Legal Fees The percentage of costs that the entity has agreed to under cost-sharing arrangements with other potentially responsible parties for an individual site. Summary of Operating Loss Carryforwards Summary of Operating Loss Carryforwards [Table Text Block] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Notes and loans payable, net Proceeds from (Repayments of) Short-Term Debt Schedule of Major Components of Other (Income) Expense, Net Major Components Of Other (Income) Expense, Net [Table Text Block] Tabular disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. Advertising and Research and Development Costs Advertising and Research and Development Costs [Policy Text Block] Disclosure of accounting policy for recognition of (1) advertising costs and (2) research and development costs. Net cash used for financing activities Net Cash Provided by (Used in) Financing Activities Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Credit Facility [Axis] Credit Facility [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name International International [Member] International [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Gross profit Gross Profit State Deferred State and Local Income Tax Expense (Benefit) Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Pension benefit assets Assets for Plan Benefits, Defined Benefit Plan Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032 4.60%, $600 due May 2032 Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032 [Member] Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032 Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] Property, Plant and Equipment Property, Plant and Equipment [Member] Schedule of Compensation Cost and Related Income Tax Benefit Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Cash dividends paid to noncontrolling interests Payments of Ordinary Dividends, Noncontrolling Interest Food Food products Food Products [Member] Food Products [Member] Restatement Determination Date: Restatement Determination Date [Axis] Deferred Stock Units for Nonemployee Directors Deferred Stock Units for Nonemployee Directors [Member] Deferred Stock Units for Nonemployee Directors [Member] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of June 30, 2024 and 2023; and 124,201,807 and 123,820,022 shares outstanding as of June 30, 2024 and 2023, respectively Common Stock, Value, Issued Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Document Financial Statement Error Correction Flag Document Financial Statement Error Correction [Flag] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Amount recognized in the balance sheets consists of: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Asset retirement obligations Asset Retirement Obligation Schedule of Recognition of Costs, Net of Insurance Recoveries Schedule of Unusual or Infrequent Items, or Both [Table Text Block] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Weighted average interest rates on long-term debt, including the effect of interest rate swaps Debt Instrument, Interest Rate During Period Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax State taxes (net of federal tax benefits) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Other Deferred Tax Assets, Other Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Land and improvements Land and Land Improvements [Member] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Trademarks, net Impairment of Intangible Assets (Excluding Goodwill) Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] 2029 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding Preferred Stock, Value, Issued Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Long-term Debt, Fiscal Year Maturity [Abstract] Long-Term Debt, Fiscal Year Maturity [Abstract] Reporting Unit [Domain] Reporting Unit [Domain] Total deferred tax liabilities Deferred Tax Liabilities, Gross Basic net earnings per share (in dollars per share) Earnings Per Share, Basic Operating cash flows from operating leases, net Operating Lease, Payments Deferred stock units for nonemployee directors granted (in shares) Deferred Stock Units For Non-Employee Directors, Granted Deferred stock units for nonemployee directors granted. Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other Liabilities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Trademarks Trademarks [Member] Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] % of Plan Asset Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage Dividends Payable [Line Items] Dividends Payable [Line Items] Schedule of Goodwill [Table] Goodwill [Table] Total current liabilities Liabilities, Current OTHER LIABILITIES Other Liabilities Disclosure [Text Block] Weighted-average volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Schedule of Reconciliation of Gross Unrecognized Tax Benefits Summary of Income Tax Contingencies [Table Text Block] Line of credit facility, amount outstanding Long-Term Line of Credit SUPPLY CHAIN FINANCING PROGRAM Supplier Finance Program [Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Redemption price and carrying amount of debt extinguished Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff Net deferred income tax (assets) liabilities Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax Supplier Finance Program [Line Items] Supplier Finance Program [Line Items] Net increase/(decrease) for U.S. capital loss carryfowards Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For U.S. Capital Loss Carryforwards Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For U.S. Capital Loss Carryforwards Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Vested and deferred (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred The number of shares under a share-based award plan other than a stock option plan that were vested and deferred during the reporting period. Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Repayments of short-term debt Repayments of Short-Term Debt Other employee stock plan activities Other Employee Stock Plan Activities, Amount Amount includes the value of stock granted during the period as a result of exercises of employee stock options or vesting of other share-based awards. Other (income) expense, net Total Other Expense (Income), Net The net amount of other income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines. STOCK-BASED COMPENSATION PLANS Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Long-term debt borrowings, net of issuance costs paid Proceeds from Issuance of Long-Term Debt Natural Personal Care Natural Personal Care [Member] Natural Personal Care [Member] Leases Lessee, Leases [Policy Text Block] Weighted-average risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Risk Free Interest Rate Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Total intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Pension settlement charge Pension settlement charge Curtailment gain, before tax Pension settlement charge Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Net operating losses Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract] DIVESTITURE OF ARGENTINA BUSINESS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Interest and penalties related to uncertain tax positions included in income tax expense, expense (net benefit) Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Loss Contingencies [Table] Loss Contingencies [Table] Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Property, Plant and Equipment, Net [Abstract] Property, Plant and Equipment, Net [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Foreign jurisdictions Foreign Tax Jurisdiction [Member] Lease right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Finance leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Curtailment gain, after tax Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due To Settlement And Curtailment, Net Of Tax Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due To Settlement And Curtailment, Net Of Tax Net unrealized gains (losses) on derivatives, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Document Fiscal Year Focus Document Fiscal Year Focus Product Concentration Risk Product Concentration Risk [Member] Treasury stock purchased Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total assets, estimated fair value Assets, Fair Value Disclosure Other Other Accrued Liabilities, Current Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Current lease liabilities Finance Lease, Liability, Current Finished goods Inventory, Finished Goods, Net of Reserves Total lease payments Lessee, Operating Lease, Liability, to be Paid Nonvested awards outstanding (in shares) Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Insider Trading Arrangements [Line Items] Remaining valuations related to other foreign deferred tax assets Net decrease/(increase) for other foreign deferred tax assets Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For Other Foreign Deferred Tax Assets Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized resulting from other foreign deferred tax assets. 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Weighted-average expected life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Term Weighted average expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Foreign exchange derivative contracts Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Cat Litter Cat litter products Cat Litter [Member] Cat Litter [Member] Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Schedule of Other Liabilities Other Noncurrent Liabilities [Table Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Senior Long-Term Notes And Debentures; 3.80%, $300 Due November 2021 Senior Long-Term Notes And Debentures; 3.80%, $300 Due November 2021 [Member] Senior Long Term Notes And Debentures Instrument Due November Two Thousand Twenty One [Member] Schedule of Retirement Income and Retirement Health Care Plans Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Beginning accrual balance Ending accrual balance Restructuring Reserve Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 16 clx-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 17 clx-20240630_g1.jpg begin 644 clx-20240630_g1.jpg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imagea.jpg begin 644 imagea.jpg MB5!.1PT*&@H -24A$4@ :( V" 8 "%BYV. 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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htm IDEA: XBRL DOCUMENT v3.24.2.u1
COVER - USD ($)
$ in Billions
12 Months Ended
Jun. 30, 2024
Jul. 23, 2024
Dec. 29, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Current Fiscal Year End Date --06-30    
Document Period End Date Jun. 30, 2024    
Document Transition Report false    
Entity File Number 1-07151    
Entity Registrant Name THE CLOROX COMPANY    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 31-0595760    
Entity Address, Address Line One 1221 Broadway    
Entity Address, City or Town Oakland    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94612-1888    
City Area Code (510)    
Local Phone Number 271-7000    
Title of 12(b) Security Common Stock – $1.00 par value    
Trading Symbol CLX    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction Flag false    
Entity Shell Company false    
Entity Public Float     $ 17.7
Entity Common Stock, Shares Outstanding   123,861,545  
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders (the “Proxy Statement”), to be filed within 120 days after June 30, 2024, are incorporated by reference into Part III, Items 10 through 14 of this Annual Report on Form 10-K.    
Amendment Flag false    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000021076    

XML 21 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
AUDIT INFORMATION
12 Months Ended
Jun. 30, 2024
Audit Information [Abstract]  
Auditor Firm ID 42
Auditor Name Ernst & Young LLP
Auditor Location San Francisco, California
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]      
Net sales $ 7,093 $ 7,389 $ 7,107
Cost of products sold 4,045 4,481 4,562
Gross profit 3,048 2,908 2,545
Selling and administrative expenses 1,167 1,183 954
Advertising costs 832 734 709
Research and development costs 126 138 132
Loss on divestiture 240 0 0
Pension settlement charge 171 0 0
Goodwill, trademark and other asset impairments 0 445 0
Interest expense 90 90 106
Other (income) expense, net 24 80 37
Earnings (losses) before income taxes 398 238 607
Income taxes 106 77 136
Net earnings 292 161 471
Less: Net earnings attributable to noncontrolling interests 12 12 9
Net earnings attributable to Clorox $ 280 $ 149 $ 462
Net earnings per share attributable to Clorox      
Basic net earnings per share (in dollars per share) $ 2.26 $ 1.21 $ 3.75
Diluted net earnings per share (in dollars per share) $ 2.25 $ 1.20 $ 3.73
Weighted average shares outstanding (in thousands)      
Basic (in shares) 124,174 123,589 123,113
Diluted (in shares) 124,804 124,181 123,906
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]      
Net earnings $ 292 $ 161 $ 471
Other comprehensive (loss) income:      
Foreign currency adjustments, net of tax 206 3 (45)
Net unrealized gains (losses) on derivatives, net of tax (14) (22) 100
Pension and postretirement benefit adjustments, net of tax 146 5 12
Total other comprehensive (loss) income, net of tax 338 (14) 67
Comprehensive income 630 147 538
Less: Total comprehensive income attributable to noncontrolling interests 12 12 9
Total comprehensive income attributable to Clorox $ 618 $ 135 $ 529
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Current assets    
Cash and cash equivalents $ 202 $ 367
Receivables, net 695 688
Inventories, net 637 696
Prepaid expenses and other current assets 88 77
Total current assets 1,622 1,828
Property, plant and equipment, net 1,315 1,345
Operating lease right-of-use assets 360 346
Goodwill 1,228 1,252
Trademarks, net 538 543
Other intangible assets, net 143 169
Other assets 545 462
Total assets 5,751 5,945
Current liabilities    
Notes and loans payable 4 50
Current operating lease liabilities 84 87
Accounts payable and accrued liabilities 1,486 1,659
Income taxes payable 0 121
Total current liabilities 1,574 1,917
Long-term debt 2,481 2,477
Long-term operating lease liabilities 334 310
Other liabilities 848 825
Deferred income taxes 22 28
Total liabilities 5,259 5,557
Commitments and contingencies
Stockholders’ equity    
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding 0 0
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of June 30, 2024 and 2023; and 124,201,807 and 123,820,022 shares outstanding as of June 30, 2024 and 2023, respectively 131 131
Additional paid-in capital 1,288 1,245
Retained earnings 250 583
Treasury stock, at cost: 6,539,654 and 6,921,439 shares as of June 30, 2024 and 2023, respectively (1,186) (1,246)
Accumulated other comprehensive net (loss) income (155) (493)
Total Clorox stockholders’ equity 328 220
Noncontrolling interests 164 168
Total stockholders’ equity 492 388
Total liabilities and stockholders’ equity $ 5,751 $ 5,945
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2024
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 1.00 $ 1.00
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 130,741,461 130,741,461
Common stock, shares outstanding (in shares) 124,201,807 123,820,022
Treasury stock, at cost (in shares) 6,539,654 6,921,439
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Treasury Stock
Accumulated Other Comprehensive Net (Loss) Income
Noncontrolling interests
Beginning balance at Jun. 30, 2021 $ 592 $ 131 $ 1,186 $ 1,036 $ (1,396) $ (546) $ 181
Beginning balance, common (in shares) at Jun. 30, 2021   130,741,000          
Beginning balance, treasury (in shares) at Jun. 30, 2021         (7,961,000)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings 471     462     9
Other comprehensive (loss) income 67         67  
Dividends to Clorox stockholders (430)     (430)      
Dividends to noncontrolling interests (17)           (17)
Stock-based compensation 52   52        
Other employee stock plan activities 19   (36) (20) $ 75    
Other employee stock plan activities (in shares)         524,000    
Treasury stock purchased (25)       $ (25)    
Treasury stock purchased (in shares)         (152,000)    
Ending balance at Jun. 30, 2022 729 $ 131 1,202 1,048 $ (1,346) (479) 173
Ending balance, common (in shares) at Jun. 30, 2022   130,741,000          
Ending balance, treasury (in shares) at Jun. 30, 2022         (7,589,000)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings 161     149     12
Other comprehensive (loss) income (14)         (14)  
Dividends to Clorox stockholders (588)     (588)      
Dividends to noncontrolling interests (17)           (17)
Stock-based compensation 73   73        
Other employee stock plan activities 44   (30) (26) $ 100    
Other employee stock plan activities (in shares)         668,000    
Ending balance at Jun. 30, 2023 $ 388 $ 131 1,245 583 $ (1,246) (493) 168
Ending balance, common (in shares) at Jun. 30, 2023 123,820,022 130,741,000          
Ending balance, treasury (in shares) at Jun. 30, 2023 (6,921,439)       (6,921,000)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings $ 292     280     12
Other comprehensive (loss) income 338         338  
Dividends to Clorox stockholders (600)     (600)      
Dividends to noncontrolling interests (16)           (16)
Stock-based compensation 74   74        
Other employee stock plan activities 16   (31) (13) $ 60    
Other employee stock plan activities (in shares)         381,000    
Ending balance at Jun. 30, 2024 $ 492 $ 131 $ 1,288 $ 250 $ (1,186) $ (155) $ 164
Ending balance, common (in shares) at Jun. 30, 2024 124,201,807 130,741,000          
Ending balance, treasury (in shares) at Jun. 30, 2024 (6,539,654)       (6,540,000)    
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Statement of Stockholders' Equity [Abstract]      
Dividends per share declared (in dollars per share) $ 4.80 $ 4.72 $ 3.48
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Operating activities:      
Net earnings $ 292 $ 161 $ 471
Adjustments to reconcile net earnings to net cash provided by operations:      
Depreciation and amortization 235 236 224
Stock-based compensation 74 73 52
Deferred income taxes (100) (149) 5
Loss on divestiture 238 0 0
Pension settlement charge 171 0 0
Goodwill, trademark and other asset impairments 0 445 0
Settlement of interest rate derivative contracts 0 0 114
Other 26 38 19
Changes in:      
Receivables, net (34) (13) (84)
Inventories, net 55 58 (18)
Prepaid expenses and other current assets 25 (1) 16
Accounts payable and accrued liabilities (140) 157 (47)
Operating lease right-of-use assets and liabilities, net 0 1 (1)
Income taxes payable/prepaid (147) 152 35
Net cash provided by operations 695 1,158 786
Investing activities:      
Capital expenditures (212) (228) (251)
Proceeds from divestiture, net of cash divested 17 0 0
Other 20 5 22
Net cash used for investing activities (175) (223) (229)
Financing activities:      
Notes and loans payable, net (45) (188) 237
Long-term debt repayments 0 0 (1,405)
Long-term debt borrowings, net of issuance costs paid 0 0 1,085
Treasury stock purchased 0 0 (25)
Cash dividends paid to Clorox stockholders (595) (583) (571)
Cash dividends paid to noncontrolling interests (16) (15) (15)
Issuance of common stock for employee stock plans and other 1 33 5
Net cash used for financing activities (655) (753) (689)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (26) 0 (6)
Net increase (decrease) in cash, cash equivalents and restricted cash (161) 182 (138)
Cash, cash equivalents and restricted cash:      
Beginning of year 368 186 324
End of year 207 368 186
Supplemental cash flow information:      
Interest paid 102 99 89
Income taxes paid, net of refunds 347 73 100
Noncash financing activities:      
Cash dividends declared and accrued, but not paid $ 16 $ 16 $ 14
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations and Basis of Presentation
The Company is principally engaged in the production, marketing and sale of consumer products through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. The consolidated financial statements include the statements of the Company and its wholly owned and controlled subsidiaries. All significant intercompany transactions and accounts were eliminated in consolidation.
Use of Estimates
The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to reach opinions as to estimates and assumptions that affect reported amounts and related disclosures. Specific areas requiring the application of management’s estimates and judgments include, among others, assumptions pertaining to accruals for consumer and trade promotion programs, future cash flows associated with impairment testing of goodwill and other long-lived assets, uncertain tax positions, tax valuation allowances, the valuation of the Venture Agreement terminal obligation, stock-based compensation, retirement income plans and legal, environmental and insurance matters. Actual results could materially differ from estimates and assumptions made.
Cash, Cash Equivalents and Restricted Cash
Cash equivalents consist of highly liquid interest-bearing accounts, time deposits held by financial institutions and money market funds with an initial maturity at purchase of 90 days or less. The fair value of cash and cash equivalents approximates the carrying amount.
The Company’s cash position includes amounts held by foreign subsidiaries and, as a result, the repatriation of certain cash balances from some of the Company’s foreign subsidiaries could result in additional withholding tax costs in certain foreign jurisdictions. However, these cash balances are generally available without legal restriction to fund local business operations. In addition, a portion of the Company’s cash balance is held in U.S. dollars by foreign subsidiaries whose functional currency is their local currency. Such U.S. dollar balances are reported on the foreign subsidiaries’ books in their functional currency, and the impact on such balances from foreign currency exchange rate differences is recorded in Other (income) expense, net.
As of June 30, 2024, 2023, 2022 and 2021, the Company had $5, $1, $3 and $5 of restricted cash, respectively, which was included in Prepaid expenses and other current assets and Other assets.
Inventories
The Company values its inventories using both the First-In, First-Out (FIFO) and the Last-In, First-Out (LIFO) methods. The FIFO inventory is stated at the lower of cost or net realizable value, which includes any costs to sell or dispose. In addition, appropriate consideration is given to obsolescence, excessive inventory levels, product deterioration and other factors in evaluating net realizable value. The LIFO inventory is stated at the lower of cost or market.
Property, Plant and Equipment and Finite-Lived Intangible Assets
Property, plant and equipment and finite-lived intangible assets are stated at cost. Depreciation and amortization expense are primarily calculated by the straight-line method using the estimated useful lives or lives determined by reference to the related lease contract in the case of leasehold improvements. The table below provides estimated useful lives of property, plant and equipment by asset classification.
Estimated
Useful Lives
Buildings and leasehold improvements
5 - 40 years
Land improvements
10 - 30 years
Machinery and equipment
3 - 15 years
Computer equipment
3 - 5 years
Capitalized software costs
3 - 7 years
Finite-lived intangible assets are amortized over their estimated useful lives, which range from 7 to 30 years.
Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be fully recoverable. The risk of impairment is initially assessed based on an estimate of the undiscounted cash flows at the lowest level for which identifiable cash flows exist. Impairment occurs when the carrying value of the asset (or asset group) exceeds the estimated future undiscounted cash flows generated by the asset (or asset group). When impairment is indicated, an impairment charge is recorded for the difference between the carrying value of the asset (or asset group) and its estimated fair market value. Depending on the asset, estimated fair market value may be determined either by use of a discounted cash flow model or by reference to estimated selling values of assets in similar condition.
Capitalization of Software Costs
The Company capitalizes certain qualifying costs incurred in the acquisition and development of software for internal use, including the costs of the software, materials, consultants, interest and payroll and payroll-related costs for employees during the application development stage. Internal and external costs incurred during the preliminary project stage and post implementation-operation stage, mainly training and maintenance costs, are expensed as incurred. Once the application is substantially complete and ready for its intended use, qualifying costs are amortized on a straight-line basis over the software’s estimated useful life. Capitalized internal use software is included in Property, plant and equipment. Capitalized software as a service is included in Prepaid expenses and other current assets or Other assets and is amortized using the straight-line method over the term of the hosting arrangement which is typically no greater than 10 years.
Impairment Review of Goodwill and Indefinite-Lived Intangible Assets
The Company tests its goodwill, trademarks with indefinite lives and other indefinite-lived intangible assets annually for impairment in the fiscal fourth quarter unless there are indications during a different interim period that these assets may have become impaired.
With respect to goodwill, the Company has the option to first assess qualitative factors, such as the maturity and stability of the reporting unit, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other reporting unit specific operating results, microeconomic and macroeconomic factors, as well as new events and circumstances impacting the operations at the reporting unit level. The Company operates through strategic business units (SBUs) that are organized into the Company's operating segments. Reporting units for goodwill impairment testing purposes were identified as the Company's individual operating segments. If the result of a qualitative test indicates that it is more likely than not that a reporting unit is impaired, a quantitative test is performed. In the quantitative test, the Company compares the estimated fair value of the reporting unit to its carrying value. If the estimated fair value of any reporting unit is less than its carrying value, an impairment charge is recorded for the difference between the carrying value and the fair value of the reporting unit.
To determine the fair value of a reporting unit as part of its quantitative test, the Company uses the discounted cash flow (DCF) method under the income approach, as it believes that this approach is the most reliable indicator of the fair value of its businesses and the fair value of its future earnings and cash flows. Under this approach, which requires significant judgments, the Company estimates the future cash flows of each reporting unit and discounts these cash flows at a rate of return that reflects their relative risk. The cash flows used in the DCF method are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced, and the broader business strategy for the long term. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates,
commodity prices, foreign exchange rates, inflation and a terminal growth rate. Changes in such estimates or the application of alternative assumptions could produce different results.
For trademarks and other intangible assets with indefinite lives, the Company has the option to first assess qualitative factors, such as the maturity and stability of the trademark or other intangible asset, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other specific operating results, as well as new events and circumstances impacting the significant inputs used to determine the fair value of the intangible asset. If the result of a qualitative test indicates that it is more likely than not that the asset is impaired, a quantitative test is performed. When a quantitative test is performed, the estimated fair value of an asset is compared to its carrying value. If the carrying value of such asset exceeds its estimated fair value, an impairment charge is recorded for the difference between the carrying value and the estimated fair value. The Company uses the DCF method under the relief from royalty income approach to estimate the fair value of its trademarks and other intangible assets with indefinite lives. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows, as well as the appropriate discount and foreign exchange rates applied to those cash flows to determine fair value. Changes in such estimates or the use of alternative assumptions could produce different results.
Leases
The Company determines whether an arrangement contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration and other facts and circumstances. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date and initial direct costs incurred by the Company and excludes any lease incentives received from the lessor. The Company reviews ROU assets for impairment consistent with the approach applied for its other long-lived assets. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. The lease term may include an option to extend or terminate the lease when it is reasonably certain that the Company will exercise that option as of the commencement date of the lease, and is reviewed in subsequent periods if a triggering event occurs. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date based on the lease term and the currency of the lease on a collateralized basis. Variable lease payments are the portion of lease payments that are not fixed over the lease term. Variable lease payments are expensed as incurred, and include certain non-lease components, such as maintenance and other services provided by the lessor, and other charges included in the lease, as applicable. The Company elected to combine lease and non-lease components as a single lease component and to exclude short-term leases, defined as leases with an initial term of 12 months or less, from its consolidated balance sheet.
Restructuring Liabilities
The Company incurs restructuring costs in connection with workforce reductions; consolidation or closure of a facility; sale or termination of a line of business; and other actions. Such costs include employee termination benefits (one-time arrangements and benefits attributable to prior service), termination of contractual obligations, noncash asset charges and other direct incremental costs.
The Company records employee termination liabilities once they are both probable and estimable for severance provided under the Company’s existing severance policy. Employee termination liabilities outside of the Company’s existing severance policy are recognized at the time relevant employees are notified, unless the employees will be retained to render service beyond a minimum retention period for transition purposes, in which case the liability is recognized ratably over the future service period. Other costs associated with a restructuring plan or exit or disposal activities, such as consulting and professional fees, facility exit costs, employee relocation, outplacement costs, accelerated depreciation or asset impairments associated with a restructuring plan, are recognized in the period in which the liability is incurred or the asset is impaired.
Stock-based Compensation
The Company grants various nonqualified stock-based compensation awards to eligible employees, including stock options, restricted stock awards and performance shares.
For stock options, the Company estimates the fair value of each award on the date of grant using the Black-Scholes valuation model, which requires management to make estimates regarding expected option life, stock price volatility and other assumptions. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The Company estimates stock option forfeitures based on historical data for each employee grouping. The total number of stock options expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.
For restricted stock awards, the fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. Forfeitures are estimated based on historical data. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.
The Company’s performance shares provide for the issuance of common stock to certain managerial staff and executive management if the Company achieves specified performance targets. The number of shares issued is dependent upon the achievement of specified performance targets. The performance period is three years and the payout determination is made at the end of the three-year performance period. Performance shares receive dividends earned during the vesting period upon vesting. The fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. The total amount of compensation expense recognized reflects estimated forfeiture rates and management’s assessment of the probability that performance goals will be achieved. A cumulative adjustment is recognized to compensation expense in the current period to reflect any changes in the probability of achievement of performance goals.
Cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for stock-based payment arrangements (excess tax benefits) are classified as operating cash inflows.
Employee Benefits
The Company accounts for its retirement income and retirement health care plans using actuarial methods. These methods use an attribution approach that generally spreads “plan events” over the service lives or expected lifetime (for frozen plans) of plan participants. Examples of plan events are plan amendments and changes in actuarial assumptions such as the expected return on plan assets, discount rate, rate of compensation increase and certain employee-related factors, such as retirement age and mortality. The principle underlying the attribution approach is that employees render service over their employment period on a relatively “smooth” basis and, therefore, the statements of earnings effects of retirement income and retirement health care plans are recognized in the same pattern. One of the principal assumptions used in the net periodic benefit cost calculation is the expected return on plan assets. The expected return on plan assets may result in recognized expense or income that differs from the actual returns of those plan assets in any given year. Over time, however, the goal is for the expected long-term returns to approximate the actual returns and, therefore, the expectation is that the pattern of income and expense recognition should closely match the pattern of the services provided by the participants. The Company uses a market-related value method for calculating plan assets for purposes of determining the amortization of actuarial gains and losses. The differences between actual and expected returns are recognized in the net periodic benefit cost calculation over the average remaining service period or expected lifetime (for frozen plans) of the plan participants using the corridor approach. Under this approach, only actuarial gains (losses) that exceed 5% of the greater of the projected benefit obligation or the market-related value of assets are amortized to the Company’s net periodic benefit cost. In developing its expected return on plan assets, the Company considers the long-term actual returns relative to the mix of investments that comprise its plan assets and also develops estimates of future investment returns by considering external sources.
The Company recognizes an actuarial-based obligation at the onset of disability for certain benefits provided to individuals after employment, but before retirement, that includes medical, dental, vision, life and other benefits.
Environmental Costs
The Company is involved in certain environmental remediation and ongoing compliance activities. Accruals for environmental matters are recorded on a site-by-site basis when it is probable that a liability has been incurred and based upon a reasonable estimate of the liability. The Company’s accruals reflect the anticipated participation of other potentially responsible parties in those instances where it is probable that such parties are legally responsible and financially capable of paying their respective shares of the relevant costs. These accruals are adjusted periodically as assessment and remediation efforts progress or as additional technical or legal information becomes available. Actual costs to be incurred at identified sites in future periods may vary from the estimates, given the inherent uncertainties in evaluating environmental conditions. The accrual for environmental matters is included in Accounts payable and accrued liabilities and Other liabilities in the Company’s consolidated balance sheets on an undiscounted basis due to uncertainty regarding the timing of future payments.
Revenue Recognition
The Company’s revenue is primarily generated from the sale of finished product to customers. Revenue is recognized at the point in time when performance obligations under the terms of customer contracts are satisfied, which is when ownership, risks and rewards transfer, and can be on the date of shipment or the date of receipt by the customer, depending upon the particular customer arrangement. Shipping and handling activities are accounted for as contract fulfillment costs and included within Cost of products sold. After the completion of the performance obligation, there is an unconditional right to consideration as outlined in the contract. A right is considered unconditional if nothing other than the passage of time is required before payment of that consideration is due. The Company typically collects its customer receivables within two months. All performance obligations under the terms of contracts with customers have an original duration of one year or less.
The Company has trade promotion programs, which primarily include shelf price reductions, in-store merchandising and consumer coupons. The costs of such activities, defined as variable consideration under Accounting Standards Codification 606, “Revenue from Contracts with Customers,” are netted against sales and recorded when the related sales take place. Accruals for trade promotion programs are established based on the Company’s best estimate of the amounts necessary to settle existing and future obligations for products sold as of the balance sheet date. Amounts accrued for trade promotions are based on various factors such as contractual terms and sales volumes, and also incorporate estimates that include customer participation rates, the rate at which customers will achieve program performance criteria, product availability and historical consumer redemption rates.
The Company provides an allowance for doubtful accounts based on its historical experience and ongoing assessment of its customers’ credit risk and aging. Customer receivables are presented net of an allowance for doubtful accounts of $5 and $3 as of June 30, 2024 and 2023, respectively. Receivables, net, include non-customer receivables of $39 and $14 as of June 30, 2024 and 2023, respectively, and related allowance of $3 as of both June 30, 2024 and 2023.
Cost of Products Sold
Cost of products sold represents the costs directly related to the manufacture and distribution of the Company’s products and primarily includes raw materials, packaging, contract manufacturing fees, shipping and handling, warehousing, package design, depreciation, amortization, direct and indirect labor and operating costs for the Company’s manufacturing and distribution facilities, including salary, benefit costs and incentive compensation, and royalties and other charges related to the Company’s Glad Venture Agreement (See Note 11).
Costs associated with developing and designing new packaging, including design, artwork, films and labeling, are expensed as incurred and included within Cost of products sold.
Selling and Administrative Expenses
Selling and administrative expenses represent costs incurred by the Company in generating revenues and managing the business and include market research, commissions and certain administrative expenses. Administrative expenses include salary, benefits, incentive compensation, professional fees and services and other operating costs (such as software and licensing costs) associated with the Company’s non-manufacturing, non-research and development operations.
Advertising and Research and Development Costs
The Company expenses advertising and research and development costs in the period incurred.
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective
tax basis. Management reviews the Company’s deferred tax assets to determine whether their value can be realized based upon available evidence. A valuation allowance is established when management believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s income tax provision in the period of change. In addition to valuation allowances, the Company provides for uncertain tax positions when such tax positions do not meet certain recognition thresholds or measurement standards. Amounts for uncertain tax positions are adjusted in quarters when new information becomes available or when positions are effectively settled.
Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion and determined that none of the undistributed earnings of its foreign subsidiaries are indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable.
The Company accounts for the tax on global intangible low-taxed income (GILTI) as a period cost.
Foreign Currency Transactions and Translation
Local currencies are the functional currencies for substantially all of the Company’s foreign operations. When the transactional currency is different than the functional currency, transaction gains and losses are included as a component of Other (income) expense, net. In addition, certain assets and liabilities denominated in currencies other than a foreign subsidiary’s functional currency are reported on the subsidiary’s books in its functional currency, with the impact from exchange rate differences recorded in Other (income) expense, net. Assets and liabilities of foreign operations are translated into U.S. dollars using the exchange rates in effect at the balance sheet date, while income and expenses are translated at the respective average monthly exchange rates during the year.
Gains and losses on foreign currency translations are reported as a component of Other comprehensive (loss) income. The income tax effect of currency translation adjustments is recorded as a component of deferred taxes with an offset to Other comprehensive (loss) income where appropriate.
Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, since it has experienced cumulative inflation of approximately 100 percent or more over a three-year period. As a result, beginning July 1, 2018, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina (collectively, “Clorox Argentina”). Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities for Clorox Argentina prior to divestment were recognized in Other (income) expense, net in the consolidated statements of earnings.
Derivative Instruments
The Company’s use of derivative instruments, principally exchange-traded futures and options contracts, and over-the counter swaps and forward contracts, is limited to non-trading purposes and is designed to partially manage exposure to changes in commodity prices, foreign currencies and interest rates. The Company’s contracts are hedges for transactions with notional amounts and periods consistent with the related exposures and do not constitute investments independent of these exposures.
The changes in the fair value (i.e., gains or losses) of a derivative instrument are recorded as either assets or liabilities in the consolidated balance sheets with an offset to Net earnings or Other comprehensive (loss) income depending on whether, for accounting purposes, it has been designated and qualifies as an accounting hedge and, if so, on the type of hedging relationship. The criteria used to determine if hedge accounting treatment is appropriate are: (a) formal designation and documentation of the hedging relationship, the risk management objective and hedging strategy at hedge inception; (b) eligibility of hedged items, transactions and corresponding hedging instrument; and (c) effectiveness of the hedging relationship both at inception of the hedge and on an ongoing basis in achieving the hedging objectives. For those derivative instruments designated and qualifying as hedging instruments, the Company must designate the hedging instrument either as a fair value hedge or as a cash flow hedge. The Company designates its commodity futures, options and swaps contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges. During the fiscal years ended June 30, 2024, 2023 and 2022, the Company had no hedging instruments designated as fair value hedges.
For derivative instruments designated and qualifying as cash flow hedges, gains or losses are reported as a component of Other comprehensive (loss) income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. From time to time, the Company may have contracts not designated as hedges for accounting purposes, for which it recognizes changes in the fair value in the consolidated statements of earnings in the current period. Cash flows from hedging activities are classified as operating activities in the consolidated statements of cash flows.
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
Recently Adopted Accounting Standards
In September 2022, the FASB issued ASU No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the consolidated financial statements, results of operations, or cash flows.
XML 30 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DIVESTITURE OF ARGENTINA BUSINESS
12 Months Ended
Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
DIVESTITURE OF ARGENTINA BUSINESS DIVESTITURE OF ARGENTINA BUSINESS
On March 20, 2024, the Company completed the sale of its Argentina business, which consisted of two production plants in Argentina as well as the rights to the Company’s brands in Argentina, Uruguay and Paraguay, to Apex Capital and an investment group. The transaction is in support of the Company’s IGNITE strategy and the commitment to evolve the Company’s portfolio to increase focus on its core business to drive more consistent, profitable growth.
The transaction was executed pursuant to a stock purchase agreement, which covered all the outstanding stock of the Clorox Argentina S.A. and Clorox Uruguay S.A. As a result of the transaction, the Company recorded a pre-tax loss of $240 during the third quarter of fiscal year 2024, primarily due to the one-time noncash impact of the release of the cumulative translation adjustment losses of $223 related to these entities that had previously been recorded in Accumulated other comprehensive net (loss) income.
The major classes of assets and liabilities of the Argentina business divested as of March 20, 2024 were as follows:
Divestiture
Working capital, net
$31 
Property, plant and equipment, net
18 
Goodwill (1)
16 
Other assets
Other liabilities
(3)
Net assets divested
$65 
(1)Goodwill corresponding to the International reportable segment.
The following table presents net sales of the Argentina business, which includes the financial results up to March 20, 2024, the date of sale, for fiscal years ended:
20242023
Net sales
$123 $172 
The divestiture of the Company’s Argentina business does not meet the criteria to be reported as discontinued operations in the consolidated financial statements as the Company’s decision to divest this business did not represent a strategic shift that will have a major effect on the Company’s operations and financial results.
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CYBERATTACK
12 Months Ended
Jun. 30, 2024
Unusual or Infrequent Items, or Both [Abstract]  
CYBERATTACK CYBERATTACK
On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its Information Technology (IT) systems. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the quarter ended September 30, 2023.
The impacts of these system disruptions included order processing delays and significant product outages, resulting in a negative impact on net sales and earnings. The Company has since transitioned back to automated order processing. The Company experienced lessening operational impacts in the second quarter and has since returned to normalized operations.
The Company incurred incremental costs, net of insurance recoveries, of approximately $29 in fiscal year 2024 as a result of the cyberattack. The Company recognized insurance recoveries of $30 in the fourth quarter of fiscal year 2024. The following table summarizes the recognition of costs, net of insurance recoveries, as reflected in the consolidated statements of earnings and comprehensive income for the fiscal year ended June 30:
2024
Costs of products sold
$17 
Selling and administrative expenses
12 
Total$29 
The costs incurred relate primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs incurred from the resulting disruption to the Company’s business operations. The Company does not expect to incur significant costs related to the cyberattack in future periods. The timing of recognizing further insurance recoveries may differ from the timing of recognizing the associated expenses.
XML 32 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUPPLY CHAIN FINANCING PROGRAM
12 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
SUPPLY CHAIN FINANCING PROGRAM SUPPLY CHAIN FINANCING PROGRAM
The Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier by selling the Company’s payables to the financial institution. Participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets, cash flows or liquidity. The Company has not pledged any assets as security or provided guarantees under the SCF program.
All outstanding amounts related to suppliers participating in the SCF program are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets and the associated June 30, 2024 and 2023, the amount due to suppliers participating in the SCF program and included in Accounts payable and accrued liabilities was $205 and $220, respectively.
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RESTRUCTURING AND RELATED COSTS
12 Months Ended
Jun. 30, 2024
Restructuring and Related Activities [Abstract]  
RESTRUCTURING AND RELATED COSTS RESTRUCTURING AND RELATED COSTS
Beginning in the first quarter of fiscal year 2023, the Company recognized costs related to a plan that involves streamlining its operating model to meet its objectives of driving growth and productivity. The streamlined operating model is expected to enhance the Company’s ability to respond more quickly to changing consumer behaviors and innovate faster. The implementation of this new model was completed in fiscal year 2024.
The Company incurred $32 and $60 of costs in fiscal year 2024 and 2023, respectively. Costs incurred are expected to be settled primarily in cash.
The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model plan as reflected in the consolidated statements of earnings and comprehensive income for the fiscal years ended June 30 were:
20242023
Costs of products sold$— $(3)
Selling and administrative expenses16 12 
Research and development— (1)
Other (income) expense, net:
Employee-related costs10 52 
Asset impairments— 
Total Other (income) expense, net:16 52 
Total, net$32 $60 
Employee-related costs primarily include severance and other termination benefits calculated based on salary levels, prior service and statutory requirements. Other costs primarily include consulting fees incurred for the organizational design and implementation of the streamlined operating model, related processes and other professional fees incurred.
The Company may, from time to time, decide to pursue additional restructuring-related initiatives that involve costs in future periods.
The following table reconciles the accrual for the streamlined operating model restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets as follows for the fiscal years ended June 30:
Employee-Related CostsOtherTotal
Accrual Balance as of June 30, 2023
$23 $$28 
Charges
10 19 29 
Cash payments
(25)(13)(38)
Accrual Balance as of June 30, 2024$$11 $19 
XML 34 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVENTORIES, NET
12 Months Ended
Jun. 30, 2024
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NET
Inventories, net consisted of the following as of June 30:
20242023
Finished goods$556 $595 
Raw materials and packaging172 182 
Work in process
LIFO allowances(98)(87)
Total inventories, net639 698 
Non-current inventories, net (1)
Total current inventories, net$637 $696 
(1)Non-current inventories, net is recorded in Other assets.
The LIFO method was used to value approximately 36% of inventories as of June 30, 2024 and 2023, respectively. The carrying values for all other inventories are determined on the FIFO method. The effect on earnings of the liquidation of LIFO layers was insignificant for each of the fiscal years ended June 30, 2024, 2023 and 2022.
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1
PROPERTY, PLANT AND EQUIPMENT, NET
12 Months Ended
Jun. 30, 2024
Property, Plant and Equipment, Net [Abstract]  
PROPERTY, PLANT AND EQUIPMENT, NET PROPERTY, PLANT AND EQUIPMENT, NET
The components of property, plant and equipment, net, consisted of the following as of June 30:
20242023
Land and improvements$174 $168 
Buildings816 810 
Machinery and equipment2,398 2,355 
Capitalized software costs413 400 
Computer equipment137 131 
Construction in progress198 186 
Total4,136 4,050 
Less: Accumulated depreciation and amortization(2,821)(2,705)
Property, plant and equipment, net$1,315 $1,345 

Depreciation and amortization expense related to property, plant and equipment, net, was $206, $206 and $193 in fiscal years 2024, 2023 and 2022, respectively, of which $10, $10 and $8 were related to amortization of capitalized software, respectively.
Noncash capital expenditures were $5, $9 and $6 for fiscal years, 2024, 2023 and 2022, respectively. There were no significant asset retirement obligations recorded and included in Buildings above for both fiscal years 2024 and 2023.
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS
12 Months Ended
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS
The changes in the carrying amount of goodwill by reportable segment and Corporate and Other for the fiscal years ended June 30, 2024 and 2023 were as follows:
Goodwill
Health and Wellness
HouseholdLifestyleInternational
Corporate and Other (1)
Total
Balance as of June 30, 2022$323 $85 $244 $600 $306 $1,558 
Goodwill impairment
— — — — (306)(306)
Balance as of June 30, 2023$323 $85 $244 $600 $— $1,252 
Divestiture (2)
— — — (16)— (16)
Effect of foreign currency translation— — — (8)— (8)
Balance as of June 30, 2024$323 $85 $244 $576 $— $1,228 
(1)Reflects goodwill related to the Better Health VMS reporting unit, which was previously included within the Health and Wellness reportable segment prior to the segment changes effective in the fourth quarter of fiscal year 2023.
(2)Reflects goodwill related to the divestiture of the Argentina business. See Note 2 for additional information.
The changes in the carrying amount of trademarks and other intangible assets for the fiscal years ended June 30, 2024 and 2023 were as follows:
As of June 30, 2024As of June 30, 2023
Gross
carrying
amount
Accumulated
amortization / Impairments
Net carrying
amount
Gross
carrying
amount
Accumulated
amortization / Impairments
Net carrying
amount
Trademarks with indefinite lives (1)
$493 $— $493 $494 $— $494 
Trademarks with finite lives (1)
83 38 45 89 40 49 
Other intangible assets with finite lives578 435 143 579 410 169 
Total$1,154 $473 $681 $1,162 $450 $712 
(1)As of June 30, 2023 reflects changes to the useful lives of certain Better Health VMS and International indefinite-lived trademarks to finite-lived effective April 1, 2023.
Amortization expense relating to the Company’s intangible assets was $29, $30 and $31 for the years ended June 30, 2024, 2023 and 2022, respectively. Estimated amortization expense for these intangible assets is $28, $28, $29, $28 and $11 for fiscal years 2025, 2026, 2027, 2028 and 2029, respectively.
Fiscal Year 2023 Impairments
During the third quarter of fiscal year 2023, management made a decision to narrow the focus on core brands and streamline investment levels in the Better Health VMS business. As a result, revisions were made to the internal financial projections and operational plans of the Better Health VMS business reflecting the Company’s current estimates regarding the future financial performance of these operations and macroeconomic factors. The revised estimated future cash flows reflected lower sales growth expectations and lower investment levels. These revisions were considered a triggering event requiring interim impairment assessments to be performed as part of the preparation of the quarterly financial statements on the global indefinite-lived trademarks, other long-term assets and the Better Health VMS reporting unit.
Based on the outcome of these assessments, the following pre-tax, noncash impairment charges were recorded during fiscal year 2023:
Impairment Charges
Better Health VMS reporting unit
International reporting unitTotal
Goodwill$306 $— $306 
Trademarks, net127 12 139 
Total$433 $12 $445 
In connection with recognizing these impairment charges, the Company recognized tax benefits related to the impairments of $83 due to the partial tax deductibility of these charges.
To determine the estimated fair values of the global indefinite-lived trademarks related to the Better Health VMS business, the Company used the DCF method under the relief from royalty income approach. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows as well as the appropriate discount rates applied to those cash flows to determine fair value. As a result of the interim impairment test, the Company concluded that the carrying value of the global indefinite-lived trademarks exceeded their estimated fair value, and recorded impairment charges of $139. In addition, the useful lives of the impaired trademarks, with a remaining net carrying value of $28 as of March 31, 2023, were changed from indefinite to finite beginning on April 1, 2023, which reflects the remaining expected useful lives of the trademarks based on the most recent financial and operational plans. The weighted-average estimated useful life of these trademarks is 20 years.
After adjusting the carrying values of the global indefinite-lived trademarks and concluding that the carrying amounts of the other long-lived assets were recoverable, the Company completed a quantitative impairment test for goodwill and recorded a goodwill impairment charge of $306 in the Better Health VMS reporting unit. To determine the fair value of the Better Health VMS reporting unit, the Company used a DCF method under the income approach. In accordance with this approach, the Company estimated the future cash flows of the Better Health VMS reporting unit and discounted these cash flows at a rate of return that reflects its relative risk. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates and a terminal growth rate. The decrease in projected cash flows due to the revisions adversely impacted key assumptions used in determining the fair value of the Better Health VMS reporting unit and assets contained therein, primarily projected net sales. There is no remaining goodwill associated with the impaired reporting unit.
No other significant impairments were identified as a result of the Company’s impairment reviews during fiscal years 2024, 2023 and 2022.
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
12 Months Ended
Jun. 30, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities consisted of the following as of June 30:
20242023
Accounts payable$950 $1,021 
Compensation and employee benefit costs190 262 
Trade and sales promotion costs156 157 
Dividends25 23 
Other165 196 
Total$1,486 $1,659 
XML 38 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT
12 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
Short-term borrowings
Notes and loans payable are borrowings that mature in less than one year, primarily consisting of U.S. commercial paper issued by the Company and borrowings under the Company's revolving credit agreements. Notes and loans payable were $4 and $50 as of June 30, 2024 and 2023, respectively.
The weighted average interest rates incurred on average outstanding notes and loans payable during the fiscal years ended June 30, 2024, 2023 and 2022, including fees associated with the Company’s revolving credit agreements, were 4.77%, 3.48% and 0.54% respectively.
Long-term borrowings
Long-term debt, carried at face value net of unamortized discounts, premiums and debt issuance costs, included the following as of June 30:
20242023
Senior unsecured notes and debentures:
3.10%, $400 due October 2027
$399 $398 
3.90%, $500 due May 2028
498 497 
4.40%, $500 due May 2029
495 495 
1.80%, $500 due May 2030
495 494 
4.60%, $600 due May 2032
594 593 
Total2,481 2,477 
Less: Current maturities of long-term debt— — 
Long-term debt$2,481 $2,477 
In May 2022, the Company issued $1,100 in senior notes, which included $500 of senior notes with an annual fixed interest rate of 4.40%, payable semi-annually in May and November, final maturity in May 2029 that carry an effective rate of 3.89% (May 2029 senior notes), which includes the impact from the settlement of interest rate contracts in May 2022, and $600 of senior notes with an annual fixed rate of 4.60%, payable semi-annually in May and November, final maturity in May 2032 that carry an effective rate of 3.25% (May 2032 senior notes), which includes the impact from the settlement of interest rate contracts in May 2022. The notes rank equally with all of the Company's existing senior indebtedness. Proceeds from the senior notes were used to redeem prior to maturity $600 of senior notes with an annual fixed interest rate of 3.05% due in September 2022 and $500 of senior notes with an annual fixed interest rate of 3.50% due in December 2024, which were redeemed in June 2022 prior to their maturities, and for general corporate purposes. In connection with the redemption prior to maturity of the $500 of senior notes due in December 2024, the Company recorded a loss on the early extinguishment of debt of $13, which is included in Interest expense in the Consolidated Statements of Earnings, representing the difference paid in cash between the redemption price and the carrying amount of the debt extinguished of $5 and the accelerated amortization of losses on settlement of interest rate contracts and issuance costs associated with the debt extinguished of $8.
In November 2021, $300 of the Company’s senior notes with annual fixed interest rate of 3.80% became due and were repaid using commercial paper borrowings.
The weighted average interest rates incurred on average outstanding long-term debt during the fiscal years ended June 30, 2024, 2023 and 2022, were 3.25%, 3.25% and 3.25%, respectively. The weighted average effective interest rates on long-term debt balances as of both June 30, 2024 and 2023 were 3.25% and 3.25%, respectively.
Long-term debt maturities as of June 30, 2024, were $0 in fiscal years 2025 through 2027, $900 in fiscal year 2028, $500 in fiscal year 2029 and $1,100 thereafter.
Credit arrangements
As of June 30, 2023, the Company maintained a $1,200 revolving credit agreement (the Credit Agreement) that matures in March 2027. There were no borrowings under the Credit Agreement as of June 30, 2024 and June 30, 2023, respectively, and the Company believes that borrowings under the Credit Agreement will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations consistent with the previous agreement, with which the Company was in compliance as of June 30, 2024 and June 30, 2023.
The Company’s borrowing capacity under the revolving credit agreements and other financing arrangements as of June 30 was as follows:
20242023
Revolving credit facility$1,200 $1,200 
Foreign and other credit lines34 35 
Total$1,234 $1,235 
Of the $34 of foreign and other credit lines as of June 30, 2024, $9 was outstanding and the remainder of $25 was available for borrowing. Of the $35 of foreign and other credit lines as of June 30, 2023, $5 was outstanding and the remainder of $30 was available for borrowing.
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER LIABILITIES
12 Months Ended
Jun. 30, 2024
Other Liabilities Disclosure [Abstract]  
OTHER LIABILITIES OTHER LIABILITIES
Other liabilities consisted of the following as of June 30:
20242023
Venture Agreement terminal obligation, net$510 $495 
Employee benefit obligations263 259 
Taxes25 19 
Environmental liabilities24 24 
Other26 28 
Total$848 $825 
Venture Agreement
The Company has an agreement with The Procter & Gamble Company (P&G) for the Company’s Glad bags and wraps business. In connection with this agreement, P&G provides research and development (R&D) support to the Glad business. As of June 30, 2024 and 2023, P&G had a 20% interest in the venture. The Company pays a royalty to P&G for its interest in the profits, losses and cash flows, as contractually defined, of the Glad business, which is included in Cost of products sold. In December 2017, the Company and P&G extended the term of the agreement and the related R&D support provided by P&G. The term will expire in January 2026, unless the parties agree, on or prior to January 31, 2025, to further extend the term of the agreement for another seven years or agree to take some other relevant action. The agreement can be terminated under certain circumstances, including at P&G’s option upon a change in control of the Company or, at either party’s option, upon the sale of the Glad business by the Company.
Upon termination of the agreement, the Company is required to purchase P&G’s 20% interest for cash at fair value as established by predetermined valuation procedures. As of June 30, 2024, the estimated fair value of P&G’s interest in the venture was $531, of which $510 has been recognized and is reflected in Other liabilities as noted in the table above. The estimated fair value of P&G's interest in the venture was $527 as of June 30, 2023. The difference between the estimated fair value and the amount recognized, and any future changes in the fair value of P&G’s interest, is charged to Cost of products sold in accordance with the effective interest method over the remaining life of the agreement. Following termination, the Glad business will retain the exclusive core intellectual property licenses contributed by P&G on a royalty-free basis for the licensed products marketed.
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
12 Months Ended
Jun. 30, 2024
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments
The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.
Commodity Price Risk Management
The Company may use commodity futures, options and swap contracts to limit the impact of price volatility on a portion of its forecasted raw material requirements. These commodity derivatives may be exchange traded or over-the-counter contracts and generally have original contractual maturities of less than 2 years. Commodity purchase and option contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.
As of June 30, 2024, the notional amount of commodity derivatives was $38, of which $27 related to soybean oil futures used for the food business and $11 related to jet fuel swaps used for the grilling business. As of June 30, 2023, the notional amount of commodity derivatives was $41, of which $29 related to soybean oil futures and $12 related to jet fuel swaps.
Foreign Currency Risk Management
The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have original contractual maturities of less than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.
The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $29 and $51 as of June 30, 2024 and 2023, respectively.
Interest Rate Risk Management
The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have original contractual maturities of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.
The Company held no interest rate contracts as of both June 30, 2024 and 2023.
During fiscal year 2022, the Company entered into an additional $650 of interest rate contracts. All contracts represented interest rate swap lock agreements to manage the exposure to interest rate volatility associated with future interest payments on forecasted debt issuance, and were terminated in May 2022 upon issuance of $1,100 in senior notes (See Note 10). These contracts resulted in a $114 gain recorded in Other comprehensive (loss) income, comprised of $25 attributable to the May 2029 senior notes and $89 attributable to the May 2032 senior notes, which is being amortized into Interest expense in the consolidated statements of earnings over the 7-year and 10-year term of the notes.
Commodity, Foreign Exchange and Interest Rate Derivatives
The Company designates its commodity forward, futures and options contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory, and interest rate contracts for forecasted interest payments as cash flow hedges.
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows during the fiscal years ended June 30:
Gains (losses) recognized in Other comprehensive (loss) income
202420232022
Commodity purchase derivative contracts$(8)$(6)$17 
Foreign exchange derivative contracts— — 
Interest rate derivative contracts— — 89 
Total$(8)$(6)$107 
Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
202420232022
Commodity purchase derivative contractsCost of products sold$(6)$$23 
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense13 13 (9)
Total$$19 $14 
The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of June 30, 2024 that is expected to be reclassified into Net earnings within the next twelve months is $8.
Counterparty Risk Management and Derivative Contract Requirements
The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions, $0 and $1 contained such terms as of June 30, 2024 and 2023, respectively. As of both June 30, 2024 and 2023, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.
Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the Company's credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both June 30, 2024 and 2023, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.
Certain of the Company’s exchange-traded futures and options contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of June 30, 2024 and 2023, the Company maintained required cash margin balances related to exchange-traded futures and options contracts of $3 and $0, respectively, which are classified as Prepaid expenses and other current assets on the consolidated balance sheets.
Trust Assets
The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the consolidated balance sheets. The gains and losses on the trust assets are recorded in Other (income) expense, net in the consolidated statements of earnings. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.
As of June 30, 2024, the balance of the trust assets related to the Company’s nonqualified deferred compensation plans increased by $25 as compared to June 30, 2023.
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of June 30, 2024 and 2023, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company's derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company's derivative instruments:
20242023
Balance Sheet ClassificationFair Value
Hierarchy
Level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Commodity purchase options contractsPrepaid expenses and other current assets1$— $— $$
Commodity purchase swaps contractsPrepaid expenses and other current assets2— — 
Foreign exchange forward contractsPrepaid expenses and other current assets2— — — — 
$$$$
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$$$— $— 
Commodity purchase swaps contractsAccounts payable and accrued liabilities2— — 
$$$$
The following table provides information about the balance sheet classification and the fair values of the Company's other assets and liabilities for which disclosure of fair value is required:
20242023
Balance sheet classificationFair value
hierarchy
level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash equivalents (1)
1$95 $95 $243 $243 
Time deposits
Cash and cash equivalents (1)
2
Trust assets for nonqualified deferred compensation plansOther assets1154 154 129 129 
$258 $258 $381 $381 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$$$50 $50 
Long-term debt
Long-term debt (3)
22,481 2,341 2,477 2,327 
$2,485 $2,345 $2,527 $2,377 
(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.
(3)Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
Furthermore, impairment charges of $445 were record during fiscal year 2023, of which $306 and $139 related to goodwill and certain indefinite-lived trademarks, respectively. These adjustments were included as noncash charges in the consolidated statements of earnings. The nonrecurring fair values utilized included unobservable Level 3 inputs based on management’s best estimates and assumptions. See Note 8 for additional information.
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS
12 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of both June 30, 2024 and 2023 for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $12 of the recorded liability as of both June 30, 2024 and 2023 relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing groundwater at the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study related to groundwater. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators. In January 2023, the regulators issued a new order directing the Company and the current property owner to conduct a Remedial Investigation and then prepare a Feasibility Study to evaluate and remediate impacts to soil, groundwater, soil vapor and indoor air. While the Company believes its latest estimates of remediation costs (including any related to soil, groundwater, soil vapor and indoor air impacts) are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs in the aggregate of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability as of both June 30, 2024 and 2023. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing agreement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is
reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time.
The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements (including costs connected to the transition and unwinding of certain supply and manufacturing relationships), product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of both June 30, 2024 and 2023.
The Company was a party to letters of credit of $18 and $14 as of June 30, 2024 and 2023, respectively, primarily related to one of its insurance carriers, of which $0 had been drawn upon.
Commitments
The Company is a party to certain purchase obligations, which are defined as purchase agreements that are enforceable and legally binding and that contain specified or determinable significant terms, including quantity, price and the approximate timing of the transaction. For purchase obligations subject to variable price and/or quantity provisions, an estimate of the price and/or quantity must be made. Examples of the Company’s purchase obligations include contracts to purchase raw materials, commitments to contract manufacturers, commitments for information technology and related services, advertising contracts, capital expenditure agreements, software acquisition and license commitments and service contracts. The Company enters into purchase obligations based on expectations of future business needs. Many of these purchase obligations are flexible to allow for changes in the Company’s business and related requirements. As of June 30, 2024, the Company’s purchase obligations by purchase date were approximately as follows:
YearPurchase
Obligations
2025$181 
2026128 
202781 
202843 
202927 
Thereafter45 
Total$505 
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES
12 Months Ended
Jun. 30, 2024
Leases [Abstract]  
LEASES LEASES
The Company leases various property, plant and equipment, including office, warehousing, manufacturing and research and development facilities and equipment. These leases have remaining lease terms of up to 33 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Supplemental balance sheet information related to the Company’s leases as of June 30 was as follows:
Balance sheet classification20242023
Operating leases
Right-of-use assetsOperating lease right-of-use assets$360 $346 
Current lease liabilitiesCurrent operating lease liabilities$84 $87 
Non-current lease liabilitiesLong-term operating lease liabilities334 310 
Total operating lease liabilities$418 $397 
Finance leases
Right-of-use assetsOther assets$33 $29 
Current lease liabilitiesAccounts payable and accrued liabilities$13 $
Non-current lease liabilitiesOther liabilities21 21 
Total finance lease liabilities$34 $30 
Components of lease cost were as follows for the fiscal years ended June 30:
20242023
Operating lease cost$97 $89 
Finance lease cost:
Amortization of right-of-use assets$11 $
Interest on lease liabilities
Total finance lease cost$12 $10 
Variable lease cost$94 $87 
Short term lease cost$$
Supplemental cash flow information and noncash activity related to the Company’s leases were as follows during fiscal years ended June 30:
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases, net$97 $88 
Operating cash flows from finance leases
Financing cash flows from finance leases11 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$113 $84 
Finance leases17 21 
Weighted-average remaining lease term and discount rate for the Company’s leases were as follows as of fiscal year ended June 30:
2024
Weighted-average remaining lease term:
Operating leases5 years
Finance leases3 years
Weighted-average discount rate:
Operating leases3.6 %
Finance leases5.1 %
Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:
YearOperating leasesFinance leases
2025$97 $14 
202694 12 
202784 
202869 
202956 
Thereafter61 — 
Total lease payments$461 $36 
Less: Imputed interest43 
Total lease liabilities$418 $34 
Operating and finance lease payments presented in the table above exclude $2 and $3, respectively, of minimum lease payments signed but not yet commenced as of June 30, 2024.
On December 14, 2023, the Company completed an asset sale-leaseback transaction on a warehouse in Fairfield, California. The Company received proceeds of $19, net of selling costs. The asset had a carrying value of $3 and the transaction resulted in a $16 gain, which was recognized in Other (income) expense, net in the Health and Wellness segment. The leaseback is accounted for as an operating lease. The term of the lease is 8 years with options to extend the lease for two 5 year periods.
On May 25, 2022, the Company completed an asset sale-leaseback transaction on a plant in Ontario, Canada. The Company received proceeds of $16, net of selling costs. The asset had a carrying value of $2, and the transaction resulted in a $14 gain, which was recognized in Other (income) expense, net, in Corporate and Other. The leaseback is accounted for as an operating lease. The term of the lease at inception date is 10 years, with the option to terminate the lease at 7 years.
LEASES LEASES
The Company leases various property, plant and equipment, including office, warehousing, manufacturing and research and development facilities and equipment. These leases have remaining lease terms of up to 33 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Supplemental balance sheet information related to the Company’s leases as of June 30 was as follows:
Balance sheet classification20242023
Operating leases
Right-of-use assetsOperating lease right-of-use assets$360 $346 
Current lease liabilitiesCurrent operating lease liabilities$84 $87 
Non-current lease liabilitiesLong-term operating lease liabilities334 310 
Total operating lease liabilities$418 $397 
Finance leases
Right-of-use assetsOther assets$33 $29 
Current lease liabilitiesAccounts payable and accrued liabilities$13 $
Non-current lease liabilitiesOther liabilities21 21 
Total finance lease liabilities$34 $30 
Components of lease cost were as follows for the fiscal years ended June 30:
20242023
Operating lease cost$97 $89 
Finance lease cost:
Amortization of right-of-use assets$11 $
Interest on lease liabilities
Total finance lease cost$12 $10 
Variable lease cost$94 $87 
Short term lease cost$$
Supplemental cash flow information and noncash activity related to the Company’s leases were as follows during fiscal years ended June 30:
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases, net$97 $88 
Operating cash flows from finance leases
Financing cash flows from finance leases11 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$113 $84 
Finance leases17 21 
Weighted-average remaining lease term and discount rate for the Company’s leases were as follows as of fiscal year ended June 30:
2024
Weighted-average remaining lease term:
Operating leases5 years
Finance leases3 years
Weighted-average discount rate:
Operating leases3.6 %
Finance leases5.1 %
Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:
YearOperating leasesFinance leases
2025$97 $14 
202694 12 
202784 
202869 
202956 
Thereafter61 — 
Total lease payments$461 $36 
Less: Imputed interest43 
Total lease liabilities$418 $34 
Operating and finance lease payments presented in the table above exclude $2 and $3, respectively, of minimum lease payments signed but not yet commenced as of June 30, 2024.
On December 14, 2023, the Company completed an asset sale-leaseback transaction on a warehouse in Fairfield, California. The Company received proceeds of $19, net of selling costs. The asset had a carrying value of $3 and the transaction resulted in a $16 gain, which was recognized in Other (income) expense, net in the Health and Wellness segment. The leaseback is accounted for as an operating lease. The term of the lease is 8 years with options to extend the lease for two 5 year periods.
On May 25, 2022, the Company completed an asset sale-leaseback transaction on a plant in Ontario, Canada. The Company received proceeds of $16, net of selling costs. The asset had a carrying value of $2, and the transaction resulted in a $14 gain, which was recognized in Other (income) expense, net, in Corporate and Other. The leaseback is accounted for as an operating lease. The term of the lease at inception date is 10 years, with the option to terminate the lease at 7 years.
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY
12 Months Ended
Jun. 30, 2024
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY
Dividends per share paid to Clorox stockholders during the fiscal years ended June 30 were as follows:
202420232022
Dividends per share paid$4.80 $4.72 $4.64 
On July 30, 2024, a cash dividend was declared in the amount of $1.22 per share payable on August 30, 2024 to common stockholders of record as of the close of business on August 14, 2024.
Accumulated Other Comprehensive Net (Loss) Income
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the fiscal years ended June 30:
Foreign currency
translation adjustments
Net
unrealized
gains
(losses) on
derivatives
Pension and
postretirement
benefit
adjustments
Accumulated
other
comprehensive net
(loss) income
Balance June 30, 2021$(403)$21 $(164)$(546)
Other comprehensive (loss) income before
reclassifications
(45)107 63 
Amounts reclassified from Accumulated other
comprehensive net (loss) income
— (14)15 
Income tax benefit (expense)— (4)
Net current period other comprehensive (loss) income
(45)100 12 67 
Balance June 30, 2022(448)121 (152)(479)
Other comprehensive (loss) income before
reclassifications
(6)(4)
Amounts reclassified from Accumulated other
comprehensive net (loss) income
— (19)(13)
Income tax benefit (expense)(2)
Net current period other comprehensive (loss) income
(22)(14)
Balance June 30, 2023(445)99 (147)(493)
Other comprehensive (loss) income before
reclassifications
(16)(8)17 (7)
Amounts reclassified from Accumulated other
comprehensive net (loss) income (1) (2)
223 (7)174 390 
Income tax benefit (expense)(1)(45)(45)
Net current period other comprehensive (loss) income
206 (14)146 338 
Balance June 30, 2024$(239)$85 $(1)$(155)
(1)Includes the release of currency translation adjustment from the Argentina business divestiture. See Note 2 for additional details.
(2)Includes recognition of pension settlement charge reclassified into Net earnings (losses). See Note 20 for additional details
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
NET EARNINGS PER SHARE (EPS)
12 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
NET EARNINGS PER SHARE (EPS) NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS for the fiscal years ended June 30:
202420232022
Basic124,174 123,589 123,113 
Dilutive effect of stock options and other630 592 793 
Diluted124,804 124,181 123,906 
Antidilutive stock options and other2,704 1,444 2,448 
Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.
XML 45 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS
12 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
STOCK-BASED COMPENSATION PLANS STOCK-BASED COMPENSATION PLANS
In November 2021, the Company’s stockholders voted to approve the amended and restated 2005 Stock Incentive Plan (the Plan). The Plan permits the Company to grant various nonqualified stock-based compensation awards, including stock options, restricted stock, performance shares, deferred stock units, stock appreciation rights and other stock-based awards. The Plan as amended and restated provides that the maximum number of shares which may be issued under the Plan will be 5 million common shares that may be issued for stock-based compensation purposes. As of June 30, 2024, the Company was authorized to grant up to approximately 5 million common shares, plus additional shares equal to shares that are potentially deliverable under an award that expires or are canceled, forfeited or settled without the delivery of shares, under the Plan. As of June 30, 2024, approximately 3 million common shares remained available for grant.
Compensation cost and the related income tax benefit recognized for stock-based compensation plans were classified as indicated below for the fiscal years ended June 30:
202420232022
Cost of products sold$$$
Selling and administrative expenses63 61 42 
Research and development costs
Total compensation costs$74 $73 $52 
Related income tax benefit$18 $17 $12 
Cash received during fiscal years 2024, 2023 and 2022 from stock options exercised under all stock-based payment arrangements was $23, $52 and $35, respectively. The Company issues shares for stock-based compensation plans from treasury stock. The Company may repurchase stock under its Evergreen Program to offset the estimated impact of dilution related to stock-based awards.
Details regarding the valuation and accounting for stock options, restricted stock awards, performance shares and deferred stock units for non-employee directors follow.
Stock Options
There were no stock option awards granted during the fiscal year 2024. The fair value of each stock option award granted during fiscal years 2023 and 2022 was estimated on the date of grant using the Black-Scholes valuation model and assumptions noted in the following table:
20232022
Expected life5.3 years
5.4 years
Weighted-average expected life5.3 years5.4 years
Expected volatility
24.2%
21.7% to 25.0%
Weighted-average volatility24.2%21.8%
Risk-free interest rate
3.7%
0.9% to 2.1%
Weighted-average risk-free interest rate3.7%0.9%
Dividend yield
3.4%
2.9% to 3.7%
Weighted-average dividend yield3.4%2.9%
The expected life of the stock options is based on historical exercise patterns. The expected volatility is based on implied volatility from publicly traded options on the Company’s stock at the date of grant, historical implied volatility of the Company’s publicly traded options and other factors. The risk-free interest rate is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected term of the option. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant.
Details of the Company’s stock option activities are summarized below:
Number of
Shares
(In thousands)
Weighted-
Average
Exercise
Price
per Share
Average
Remaining
Contractual
Life
Aggregate
Intrinsic
Value
Options outstanding as of June 30, 2023
4,075 $147 5 years$69 
Granted— 
Exercised(234)104 
Canceled(51)170 
Options outstanding as of June 30, 2024
3,790 $150 4 years$16 
Options vested as of June 30, 2024
3,052 $148 4 years$16 
The weighted-average fair value per share of each option granted during fiscal years 2023 and 2022, estimated at the grant date using the Black-Scholes option pricing model, was $26.95 and $22.26, respectively. The total intrinsic value of options exercised in fiscal years 2024, 2023 and 2022 was $12, $27 and $18, respectively.
Stock option awards outstanding as of June 30, 2024, have been granted at prices that are equal to the market value of the stock on the date of grant. Stock option grants generally vest over 4 years and expire no later than 10 years after the grant date. The Company recognizes compensation expense on a straight-line basis over the vesting period. Awards to employees eligible for retirement prior to the award becoming full vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award. As of June 30, 2024, there was $5 of total unrecognized compensation cost related to non-vested options, which is expected to be recognized over a remaining weighted-average vesting period of 2 years, subject to forfeiture changes.
Restricted Stock Awards
The fair value of restricted stock awards is estimated on the date of grant based on the market price of the stock and is amortized to compensation expense on a straight-line basis over the related vesting periods, which are generally 3 to 4 years. Awards to employees eligible for retirement prior to the award becoming fully vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Restricted stock awards receive dividend distributions earned during the vesting period upon vesting.
As of June 30, 2024, there was $41 of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a remaining weighted-average vesting period of 2 years. The total fair value of the shares that vested in each of the fiscal years 2024, 2023 and 2022 was $28, $22 and $20, respectively. The weighted-average grant-date fair value of awards granted was $138.51, $143.20 and $157.50 per share for fiscal years 2024, 2023 and 2022, respectively.
A summary of the status of the Company’s restricted stock awards is presented below:
Number of
Shares
(In thousands)
Weighted-Average
Grant Date
Fair Value
per Share
Restricted stock awards as of June 30, 2023
544 $155 
Granted405 139 
Vested(173)162 
Forfeited(55)142 
Restricted stock awards as of June 30, 2024
721 $145 
Performance Shares
The fair value of performance shares is estimated on the date of grant based on the market price of the stock and is amortized to compensation expense on a straight line basis over the related vesting periods, which are generally 3 years. Awards to employees eligible for retirement prior to the award becoming fully vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award.
As of June 30, 2024, there was $15 in unrecognized compensation cost related to non-vested performance shares that is expected to be recognized over a remaining weighted-average performance period of 1 year. The weighted-average grant-date fair value of awards granted was $140.39, $141.90 and $162.46 per share for fiscal years 2024, 2023 and 2022, respectively.
A summary of the status of the Company’s performance share awards is presented below:
Number of
Shares
(In thousands)
Weighted-Average
Grant Date
Fair Value
per Share
Performance share awards as of June 30, 2023
368 $158 
Granted176 $140 
Distributed(39)$189 
Forfeited(22)$177 
Performance share awards as of June 30, 2024
483 $148 
Performance shares vested and deferred as of June 30, 2024
83 $164 
The non-vested performance shares outstanding as of June 30, 2024 and 2023 were 400,000 and 306,000, respectively, and the weighted average grant date fair value was $145.06 and $162.77 per share, respectively. During fiscal year 2024, 58,000 shares vested. The total fair value of shares vested was $12, $12 and $11 during fiscal years 2024, 2023 and 2022, respectively. Upon vesting, the recipients of the grants receive the distribution as shares or, if previously elected by eligible recipients, as deferred stock. Deferred shares continue to earn dividends, which are also deferred.
Deferred Stock Units for Nonemployee Directors
Nonemployee directors receive annual grants of deferred stock units under the Company’s director compensation program and can elect to receive all or a portion of their annual retainers and fees in the form of deferred stock units. The deferred stock units receive dividend distributions, which are reinvested as deferred stock units, and are recognized at their fair value on the date of grant. Each deferred stock unit represents the right to receive one share of the Company’s common stock following the completion of a director’s service.
During fiscal year 2024, the Company granted 19,000 deferred stock units, reinvested dividends of 4,000 units and distributed 24,000 shares, which had a weighted-average fair value on the grant date of $141.85, $145.15 and $89.91 per share, respectively. As of June 30, 2024, 127,000 units were outstanding, which had a weighted-average fair value on the grant date of $140.22 per share.
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER (INCOME) EXPENSE, NET
12 Months Ended
Jun. 30, 2024
Other Income and Expenses [Abstract]  
OTHER (INCOME) EXPENSE, NET OTHER (INCOME) EXPENSE, NET
The major components of Other (income) expense, net, for the fiscal years ended June 30 were:
202420232022
Amortization of trademarks and other intangible assets$29 $30 $31 
Trust investment (gains) losses, net(20)(14)21 
Net periodic benefit cost
14 16 16 
Foreign exchange transaction (gains) losses, net (1)
25 13 
Income from equity investees(5)(4)(6)
Interest income(23)(16)(5)
Restructuring costs (2)
16 52 — 
Gain on sale-leaseback transaction(16)— (14)
Other(9)
Total$24 $80 $37 
(1)Foreign exchange losses are primarily related to the Company’s operations in Argentina, prior to the divestiture.
(2)Restructuring costs related to the Company's streamlined operating model plan (see Note 5).
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES
12 Months Ended
Jun. 30, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The provision for income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:
202420232022
Current
Federal$132 $153 $71 
State18 33 17 
Foreign56 40 43 
Total current$206 $226 $131 
Deferred
Federal$(99)$(120)$
State(5)(28)(2)
Foreign(1)
Total deferred(100)(149)
Total$106 $77 $136 
Income taxes paid, net of refunds, were $347 and $73 for the fiscal year ended June 30, 2024 and 2023, respectively. The increase in payments in the current period was primarily driven by income tax payments for fiscal years 2023 and 2024 that were previously deferred as a result of tax relief provided by the IRS due to winter storms in California.
The components of Earnings before income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:
202420232022
United States$311 $154 $483 
Foreign87 84 124 
Total$398 $238 $607 
A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate on operations follows for the fiscal years ended June 30:
202420232022
Statutory federal tax rate21.0 %21.0 %21.0 %
State taxes (net of federal tax benefits)2.5 1.6 1.9 
Foreign tax rate differential7.7 8.6 3.1 
Federal excess tax benefits(0.3)(1.8)(0.9)
Net U.S. tax on foreign income(5.2)(2.3)(1.7)
Loss on divestiture
10.5 — — 
International legal entity reorganization
(6.1)—  
VMS goodwill impairment— 8.6 — 
Federal research and development credits(1.2)(2.7)(0.8)
Other differences(2.4)(0.6)(0.2)
Effective tax rate26.5 %32.4 %22.4 %
The Inflation Reduction Act (the “Act”) was signed into law on August 16, 2022. The Act introduced a new 15% corporate minimum tax for certain large corporations, effective at the beginning of the Company’s fiscal 2024 and it enacted a 1% excise tax on the value of share repurchases, net of new share issuances, after December 31, 2022. These provisions, as well as other corporate tax changes included in the Act, have not had a material impact on the Company's consolidated financial statements and are not expected to have a material impact on the Company’s financial statements in the foreseeable future.
Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion. None of the undistributed earnings of its foreign subsidiaries were indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable. These withholding taxes had no significant impact on the Company’s consolidated results.
The components of net deferred tax assets (liabilities) as of June 30 are shown below:
20242023
Deferred tax assets
Compensation and benefit programs$109 $123 
Loss and tax credit carryforwards
153 94 
Operating and finance lease liabilities111 104 
Accruals and reserves33 46 
Capitalized research and development43 34 
Inventory costs29 32 
Other33 34 
Subtotal511 467 
Valuation allowance(115)(59)
Total deferred tax assets$396 $408 
Deferred tax liabilities
Property, plant and equipment and intangible assets
$(84)$(157)
Lease right-of-use assets(100)(96)
Other(36)(36)
Total deferred tax liabilities(220)(289)
Net deferred tax assets (liabilities)$176 $119 
The net deferred tax assets and liabilities included in the consolidated balance sheet at June 30 were as follows:
Net deferred tax assets (1)
$198 $147 
Net deferred tax liabilities(22)(28)
Net deferred tax assets (liabilities)$176 $119 
(1)Net deferred tax assets are recorded in Other assets.
The Company reviews its deferred tax assets for recoverability on a quarterly basis. A valuation allowance is established when the Company believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Valuation allowances have been provided to reduce deferred tax assets to amounts considered recoverable.
Changes in the valuation allowance on deferred tax assets were as follows for the years ended June 30:
202420232022
Valuation allowance at beginning of year$(59)$(52)$(42)
Net increase/(decrease) for U.S. capital loss carryfowards(46)— — 
Net decrease/(increase) for other foreign deferred tax assets(2)(1)(1)
Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits(8)(6)(9)
Valuation allowance at end of year$(115)$(59)$(52)
The Company's carryforwards for capital losses, net operating losses, and tax credits, with related valuation allowances were as follows as of June 30:
2024
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions46 (46)— 
2029
Net operating losses
U.S. jurisdictions(5)2030 - 2042
U.S. jurisdictions (with no expiration)(8)N/A
Foreign jurisdictions18 (16)2025 - 2044
Foreign jurisdictions (with no expiration)— N/A
Total net operating losses41 (29)12 
Income tax credits
U.S. jurisdictions30 — 30 2025 - 2034
U.S. jurisdictions (with no expiration)— N/A
Foreign jurisdictions30 (30)— 2026
Foreign jurisdictions (with no expiration)(3)
N/A
Total income tax credits66 (33)33 
Total carryforwards$153 $(108)$45 
2023
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions— — — N/A
Net operating losses
U.S. jurisdictions(4)— 2030 - 2042
U.S. jurisdictions (with no expiration)(5)N/A
Foreign jurisdictions21 (16)2024 - 2040
Foreign jurisdictions (with no expiration)(1)N/A
Total net operating losses40 (26)14 
Income tax credits
U.S. jurisdictions23 — 23 2024 - 2033
U.S. jurisdictions (with no expiration)— N/A
Foreign jurisdictions (with no expiration)29 (28)N/A
Total income tax credits54 (28)26 
Total carryforwards$94 $(54)$40 
The Company files income tax returns in the U.S. federal and various state, local and foreign jurisdictions. The federal statute of limitations has expired for all tax years through June 30, 2015. Various income tax returns in state and foreign jurisdictions are currently in the process of examination.
The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of June 30, 2024 and 2023, the total balance of accrued interest and penalties related to uncertain tax positions was $3 and $2, respectively. Interest and penalties related to uncertain tax positions included in income tax expense resulted in an expense of $1 in fiscal year 2024 and a net benefit of $0 in both fiscal years 2023 and 2022.
The following is a reconciliation of the beginning and ending amounts of the Company’s gross unrecognized tax benefits:
202420232022
Unrecognized tax benefits at beginning of year$17 $17 $21 
Gross increases - tax positions in prior periods— — 
Gross decreases - tax positions in prior periods(4)(3)(7)
Gross increases - current period tax positions
Gross decreases - current period tax positions— — — 
Lapse of applicable statute of limitations— — (1)
Settlements— — — 
Unrecognized tax benefits at end of year$22 $17 $17 
Included in the balance of unrecognized tax benefits as of June 30, 2024, 2023 and 2022, were potential benefits of $15, $14 and $14, respectively, which if recognized, would affect the effective tax rate. Unrecognized tax benefits are not expected to significantly increase or decrease within the next 12 months.
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS
12 Months Ended
Jun. 30, 2024
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
Retirement Income Plans
In the second quarter of fiscal year 2024, the Company settled plan benefits of its previously frozen domestic qualified pension plan (the Plan), following the Company’s Board of Directors' approval of a resolution to terminate the Plan in May 2022. The settlement occurred through a combination of an annuity contract purchase with a third-party insurance provider and lump sum payouts. These payments were made using Plan assets. The third-party insurance provider assumed the obligation to pay future pension benefits and provide administrative services, and started making direct payments to participants in January 2024. In
conjunction with this settlement, a one-time noncash charge, net of curtailment gain, of $171 before taxes ($130 after tax) was recorded in the Company’s consolidated statements of earnings and comprehensive income primarily as a result of accelerating the recognition of actuarial losses previously included in Accumulated other comprehensive net (loss) income that would have been recognized in future periods. Following settlement, remaining excess plan assets of $19 was contributed to the Company’s domestic defined contribution plan during 2024.
The Company continues to maintain various other retirement income plans for eligible domestic and international employees. The remaining domestic retirement income plans are frozen.
The Company contributed $14, $14 and $15 to its domestic retirement income plans during fiscal years 2024, 2023 and 2022, respectively. The Company’s funding policy is to contribute amounts sufficient to meet benefit payments.
Retirement Health Care Plans
The Company provides certain health care benefits for employees who meet age, participation and length of service requirements at retirement. The plans pay stated percentages of covered expenses after annual deductibles have been met or stated reimbursements up to a specified dollar subsidy amount. Benefits paid take into consideration payments by Medicare for the domestic plan. The plans are funded as claims are paid, and the Company has the right to modify or terminate certain plans.
Benefit Obligation and Funded Status
Summarized information for the Company’s retirement income and retirement health care plans as of and for the fiscal years ended June 30 is as follows:
Retirement
Income
Retirement
Health Care
2024202320242023
Change in benefit obligations:
Benefit obligation as of beginning of year$476 $513 $26 $28 
Service cost— — 
Interest cost12 18 
Actuarial loss (gain)(26)(11)(2)(1)
Plan amendments— — (4)— 
Plan settlement(312)— — — 
Benefits paid(26)(45)(2)(2)
Translation and other adjustments(2)— — — 
Benefit obligation as of end of year$123 $476 $19 $26 
Change in plan assets:
Fair value of assets as of beginning of year$381 $412 $— $— 
Actual return on plan assets(13)— — — 
Employer contributions15 15 
Plan settlement
(312)— — — 
Benefits paid(26)(45)(2)(2)
Transfer to domestic defined contribution plan
(19)— — — 
Translation and other adjustments(1)(1)— — 
Fair value of plan assets as of end of year25 381 — — 
Accrued benefit cost, net funded status$(98)$(95)$(19)$(26)
Amount recognized in the balance sheets consists of:
Pension benefit assets$$24 $— $— 
Current accrued benefit liability(12)(13)(2)(2)
Non-current accrued benefit liability(93)(106)(17)(24)
Accrued benefit cost, net$(98)$(95)$(19)$(26)
For the retirement income plans, the benefit obligation is the projected benefit obligation (PBO). For the retirement health care plan, the benefit obligation is the accumulated benefit obligation (ABO).
The ABO for all retirement income plans was $105, $474 and $512 as of June 30, 2024, 2023 and 2022, respectively.
Retirement income plans with ABO or PBO in excess of plan assets as of June 30 were as follows:
ABO Exceeds the Fair Value of Plan AssetsPBO Exceeds the Fair Value of Plan Assets
2024202320242023
Projected benefit obligation$105 $119 $108 $121 
Accumulated benefit obligation104 118 105 119 
Fair value of plan assets— — 
Net Periodic Benefit Cost
The net cost of the retirement income and health care plans for the fiscal years ended June 30 included the following components:
Retirement IncomeRetirement Health Care
202420232022202420232022
Service cost$$$$— $— $— 
Interest cost12 18 15 
Expected return on plan assets(2)(10)(15)— — — 
Amortization of unrecognized items     (2)(2)(1)
Curtailment gain recognized
(6)— — — — — 
Settlement loss recognized179 — — — — 
Total$187 $17 $17 $(1)$(1)$— 
Service cost component of the net periodic benefit cost is reflected in employee benefit costs, and all other components, except for the net settlement loss recognized in relation to the settlement of the Plan recognized in the second quarter of fiscal year 2024, are reflected in Other (income) expense, net.
Items not yet recognized as a component of postretirement expense as of June 30, 2024 consisted of:
Retirement
Income
Retirement
Health Care
Net actuarial loss (gain)$20 $(14)
Prior service benefit— (4)
Net deferred income tax (assets) liabilities(5)
Accumulated other comprehensive loss (income)$15 $(14)
Net actuarial loss (gain) recorded in Accumulated other comprehensive net (loss) income for the fiscal year ended June 30, 2024 included the following:
Retirement
Income
Retirement
Health Care
Net actuarial loss (gain) as of beginning of year$213 $(14)
Amortization, curtailment and settlement during the year
(182)
Loss (gain) during the year(11)(2)
Net actuarial loss (gain) as of end of year$20 $(14)
The Company uses the straight-line amortization method for unrecognized prior service costs and benefits.
Assumptions
Weighted-average assumptions used to estimate the actuarial present value of benefit obligations were as follows as of June 30:
Retirement IncomeRetirement Health Care
2024202320242023
Discount rate5.52 %4.37 %5.38 %5.10 %
Rate of compensation increase3.23 %3.62 %n/an/a
Interest crediting rate5.40 %2.67 %n/an/a
Weighted-average assumptions used to estimate the retirement income and retirement health care costs were as follows as of June 30:
Retirement Income
202420232022
Discount rate4.63 %3.72 %2.56 %
Rate of compensation increase3.20 %3.09 %3.02 %
Expected return on plan assets3.39 %2.67 %3.00 %
Interest crediting rate2.69 %2.69 %2.57 %
Retirement Health Care
202420232022
Discount rate5.10 %4.65 %2.61 %
The expected long-term rate of return assumption is based on prospective returns according to the fund’s current target asset allocation.
The actuarial benefit obligation gain incurred during fiscal year 2024 was primarily driven by increases in the discount rates for the retirement plans, partially offset by investment gains lower than expected return on assets.
The actuarial benefit obligation gain during fiscal year 2023 was primarily driven by increases in the discount rates for the retirement plans, partially offset by investment gains lower than expected return on assets.
Expected Benefit Payments
Expected benefit payments for the Company’s retirement income and retirement health care plans as of June 30, 2024, were as follows:
Retirement
Income
Retirement
Health Care
2025$15 $
202614 
202713 
202813 
202912 
Fiscal years 2030 through 203448 
Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.
Plan Assets
The target allocations and weighted average asset allocations by asset category of the investment portfolio for the Company’s qualified domestic retirement income plans as of June 30, 2023, prior to its termination, were as follows:
% Target Allocation% of Plan Asset
Fixed income80 %79 %
Cash equivalents20 %21 %
Total100 %100 %
The target asset allocation was determined based on the optimal balance between risk and return and, at times, was adjusted to achieve the plan’s overall investment objective to generate sufficient resources to pay current and projected plan obligations over the life of the domestic retirement income plan.
The following table sets forth the retirement income plans’ assets carried at fair value as of June 30:
20242023
Cash equivalents — Level 1$— $74 
Total assets in the fair value hierarchy— 74 
Common collective trusts measured at net asset value
Bond funds$$289 
International equity funds16 15 
Domestic equity funds— — 
Short-term investment fund— 
Real estate fund
Other
— 
Total common collect trust measured at net asset value$25 $307 
Total assets at fair value$25 $381 
Common collective trust funds are not publicly traded and were valued at a net asset value unit price determined by the portfolio’s sponsor based on the fair value of underlying assets held by the common collective trust fund on June 30, 2024 and 2023.
The common collective trusts are invested in various trusts that attempt to achieve their investment objectives by investing primarily in other collective investment funds that have characteristics consistent with each trust’s overall investment objective and strategy.
Defined Contribution Plans
The Company has various defined contribution plans for eligible domestic and international employees. The aggregate cost of the domestic defined contribution plans was $63, $64 and $58 in fiscal years 2024, 2023 and 2022, respectively. The aggregate cost of the international defined contribution plans was $5, $6 and $6 for the fiscal years ended June 30, 2024, 2023 and 2022, respectively.
XML 49 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT REPORTING
12 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company operates through strategic business units (SBUs) that are organized into the Company’s operating segments. Operating segments with shared economic and qualitative characteristics are aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. The four reportable segments consist of the following:
Health and Wellness consists of cleaning, disinfecting and professional products marketed and sold in the United States.
Household consists of bags and wraps, cat litter and grilling products marketed and sold in the United States.
Lifestyle consists of food, water-filtration and natural personal care products marketed and sold in the United States.
International consists of products sold outside the United States. Products within this segment include laundry additives; home care products; bags and wraps; cat litter; water-filtration products; professional cleaning and disinfecting products; natural personal care products; food; grilling products and digestive health products marketed primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands.
Corporate and Other includes certain non-allocated administrative costs, various other non-operating income and expenses, as well as the results of the Better Health VMS business. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes, as well as the assets related to the Better Health VMS business.
The principle measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding
interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, relating to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).
Management uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance and allocate resources to each segment as it removes the impact of the items that management believes do not directly reflect the performance of each segment's underlying operations.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other.
Net Sales
Fiscal year
202420232022
Health and Wellness$2,485 $2,532 $2,427 
Household1,950 2,098 1,984 
Lifestyle1,275 1,338 1,253 
International1,162 1,181 1,180 
Reportable segment total6,872 7,149 6,844 
Corporate and Other221 240 263 
Total$7,093 $7,389 $7,107 

Segment adjusted earnings (losses) before interest and income taxes
Fiscal year
202420232022
Health and Wellness$719 $594 $381 
Household260 308 234 
Lifestyle253 284 280 
International122 89 97 
Reportable segment total1,354 1,275 992 
Corporate and Other(309)(358)(223)
Total$1,045 $917 $769 
Interest income23 16 
Interest expense(90)(90)(106)
Loss on divestiture (1)
(240)— — 
Pension settlement charge (2)
(171)— — 
Cyberattack costs, net of insurance recoveries (3)
(29)— — 
VMS impairment (4)
— (445)— 
Streamlined operating model (5)
(32)(60)— 
Digital capabilities and productivity enhancements investment (6)
(108)(100)(61)
Earnings (losses) before income taxes$398 $238 $607 
(1)Represents the loss on divestiture of the Argentina business corresponding to International. See Note 2 for additional details.
(2)Represents costs related to the settlement of the domestic qualified pension plan corresponding to Corporate and Other. See Note 20 for additional details.
(3)Represents incremental costs, net of insurance recoveries, related to the cyberattack. See Note 3 for additional details relating to the cyberattack. All insurance recoveries are recorded in Corporate and Other. For informational purposes, the following table provides the approximate cyberattack costs, net of insurance recoveries, corresponding to the Company’s reportable segments as a percentage of total net costs:
2024
Health and Wellness30 %
Household24 
Lifestyle23 
International
Corporate and Other15 
Total100 %
(4)Represents a noncash impairment charge of $445 related to the Better Health VMS business recorded in fiscal year 2023.
(5)Represents restructuring and related implementation costs, net for the streamlined operating model of $32 and $60 in fiscal year 2024 and 2023, respectively. For informational purposes the following table provides the approximate restructuring and related implementation costs, net corresponding to the Company's segments as a percent of the total costs for the fiscal years ended June 30:
Inception to date ended
202420232024
Health and Wellness%%%
Household
Lifestyle— 
International16 11 
Corporate and Other91 73 80 
Total100 %100 %100 %
(6)Represents expenses related to the Company's digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Fiscal
Year
Health and WellnessHouseholdLifestyleInternational
Corporate and Other
Total
Company
(Income) Loss from equity investees included in Other (income) expense, net
2024— — — (5)— (5)
2023— — — (4)— (4)
2022— — — (6)— (6)
Total assets20241,124 1,088 1,110 1,327 1,102 5,751 
20231,184 1,082 1,091 1,410 1,178 5,945 
Capital expenditures202447 84 36 21 24 212 
202351 97 29 24 27 228 
202261 112 24 27 27 251 
Depreciation and amortization202458 77 24 45 31 235 
202359 78 25 46 28 236 
202257 67 24 47 29 224 
Significant noncash charges included in earnings (losses) before interest and income taxes:
Stock-based compensation202414 11 35 74 
202314 10 38 73 
202214 21 52 
All intersegment sales are eliminated and are not included in the Company’s reportable net sales.
Net sales to the Company’s largest customer, Walmart Stores, Inc. and its affiliates, were 25%, 26% and 25% of consolidated net sales for each of the fiscal years ended June 30, 2024, 2023 and 2022, respectively, and occurred across all of the Company’s reportable segments. No other customers accounted for 10% or more of the Company’s consolidated net sales in any of these fiscal years.
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the fiscal years ended June 30:
202420232022
Cleaning30 %30 %29 %
Professional Products%%%
Health and Wellness35 %35 %33 %
Bags and Wraps11 %12 %12 %
Cat Litter%%%
Grilling%%%
Household28 %28 %28 %
Food11 %10 %10 %
Water Filtration%%%
Natural Personal Care%%%
Lifestyle18 %18 %18 %
International16 %16 %17 %
Corporate and Other3 %3 %4 %
Total100 %100 %100 %
The Company’s products are marketed and sold globally. The following table provides the Company’s global product lines, which were sold in the U.S. and International, that accounted for 10% or more of consolidated net sales for the fiscal years ended June 30:
202420232022
Cleaning products43 %42 %42 %
Bags and wraps15 %16 %16 %
Food products11 %11 %11 %
Cat litter products10 %10 %%
Net sales and property, plant and equipment, net, by geographic area for and as of the fiscal years ended June 30 were as follows:
Fiscal
Year
United
States
ForeignTotal
Company
Net sales2024$5,956 $1,137 $7,093 
20236,237 1,152 7,389 
20225,951 1,156 7,107 
Property, plant and equipment, net20241,188 127 1,315 
20231,192 153 1,345 
XML 50 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED PARTY TRANSACTIONS
12 Months Ended
Jun. 30, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
The Company holds various equity investments with ownership percentages of up to 50% in a number of consumer products businesses, which operate both within and outside the United States. The equity investments, presented in Other assets and accounted for under the equity method, were $45 and $43 as of the fiscal years ended June 30, 2024 and 2023, respectively. The Company has no ongoing capital commitments, loan requirements, guarantees or any other types of arrangements under the terms of its agreements that would require any future cash contributions or disbursements arising out of an equity investment.
Transactions with the Company’s equity investees typically represent payments for contract manufacturing and purchases of raw materials. Payments to related parties, including equity investees, for such transactions during the fiscal years ended June 30, 2024, 2023 and 2022 were $77, $87 and $117, respectively. Receipts from and ending accounts receivable and payable balances related to the Company’s related parties were not significant during or as of the end of each of the fiscal years presented.
XML 51 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUBSEQUENT EVENT
12 Months Ended
Jun. 30, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENT SUBSEQUENT EVENTOn July 24, 2024, the Company entered into a definitive agreement to sell the Better Health VMS business. The transaction is expected to close in the first quarter of fiscal year 2025 and is expected to result in a loss on sale. The results of the Better Health VMS business are included within Corporate and Other in the fiscal year 2024 consolidated financial statements. The closing of the transaction is subject to customary closing conditions, including regulatory approval.
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure      
Net Income (Loss) Attributable to Parent $ 280 $ 149 $ 462
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Insider Trading Arrangements
3 Months Ended 12 Months Ended
Jun. 30, 2024
shares
Jun. 30, 2024
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Angela Hilt [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On June 7, 2024, Angela Hilt, EVP – Chief Legal Officer, entered into a trading plan designed to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for sales of up to 1,733 shares of the Company's common stock. The plan also provides for the sale of up to 25% of shares of restricted stock units and performance units vesting during the duration of the plan, excluding any shares withheld by the Company to satisfy income tax withholding remittance obligations. Ms. Hilt’s plan begins on September 6, 2024 and ends June 6, 2025 or when all of the shares have been sold.
Name Angela Hilt  
Title EVP – Chief Legal Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date June 7, 2024  
Expiration Date June 6, 2025  
Arrangement Duration 273 days  
Aggregate Available 1,733 1,733
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Insider Trading Policies and Procedures
12 Months Ended
Jun. 30, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Nature of Operations and Basis of Presentation
Nature of Operations and Basis of Presentation
The Company is principally engaged in the production, marketing and sale of consumer products through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. The consolidated financial statements include the statements of the Company and its wholly owned and controlled subsidiaries. All significant intercompany transactions and accounts were eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to reach opinions as to estimates and assumptions that affect reported amounts and related disclosures. Specific areas requiring the application of management’s estimates and judgments include, among others, assumptions pertaining to accruals for consumer and trade promotion programs, future cash flows associated with impairment testing of goodwill and other long-lived assets, uncertain tax positions, tax valuation allowances, the valuation of the Venture Agreement terminal obligation, stock-based compensation, retirement income plans and legal, environmental and insurance matters. Actual results could materially differ from estimates and assumptions made.
Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash
Cash equivalents consist of highly liquid interest-bearing accounts, time deposits held by financial institutions and money market funds with an initial maturity at purchase of 90 days or less. The fair value of cash and cash equivalents approximates the carrying amount.
The Company’s cash position includes amounts held by foreign subsidiaries and, as a result, the repatriation of certain cash balances from some of the Company’s foreign subsidiaries could result in additional withholding tax costs in certain foreign jurisdictions. However, these cash balances are generally available without legal restriction to fund local business operations. In addition, a portion of the Company’s cash balance is held in U.S. dollars by foreign subsidiaries whose functional currency is their local currency. Such U.S. dollar balances are reported on the foreign subsidiaries’ books in their functional currency, and the impact on such balances from foreign currency exchange rate differences is recorded in Other (income) expense, net.
Inventories
Inventories
The Company values its inventories using both the First-In, First-Out (FIFO) and the Last-In, First-Out (LIFO) methods. The FIFO inventory is stated at the lower of cost or net realizable value, which includes any costs to sell or dispose. In addition, appropriate consideration is given to obsolescence, excessive inventory levels, product deterioration and other factors in evaluating net realizable value. The LIFO inventory is stated at the lower of cost or market.
Property, Plant and Equipment and Finite-Lived Intangible Assets
Property, Plant and Equipment and Finite-Lived Intangible Assets
Property, plant and equipment and finite-lived intangible assets are stated at cost. Depreciation and amortization expense are primarily calculated by the straight-line method using the estimated useful lives or lives determined by reference to the related lease contract in the case of leasehold improvements. The table below provides estimated useful lives of property, plant and equipment by asset classification.
Estimated
Useful Lives
Buildings and leasehold improvements
5 - 40 years
Land improvements
10 - 30 years
Machinery and equipment
3 - 15 years
Computer equipment
3 - 5 years
Capitalized software costs
3 - 7 years
Finite-lived intangible assets are amortized over their estimated useful lives, which range from 7 to 30 years.
Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be fully recoverable. The risk of impairment is initially assessed based on an estimate of the undiscounted cash flows at the lowest level for which identifiable cash flows exist. Impairment occurs when the carrying value of the asset (or asset group) exceeds the estimated future undiscounted cash flows generated by the asset (or asset group). When impairment is indicated, an impairment charge is recorded for the difference between the carrying value of the asset (or asset group) and its estimated fair market value. Depending on the asset, estimated fair market value may be determined either by use of a discounted cash flow model or by reference to estimated selling values of assets in similar condition.
Capitalization of Software Costs
Capitalization of Software Costs
The Company capitalizes certain qualifying costs incurred in the acquisition and development of software for internal use, including the costs of the software, materials, consultants, interest and payroll and payroll-related costs for employees during the application development stage. Internal and external costs incurred during the preliminary project stage and post implementation-operation stage, mainly training and maintenance costs, are expensed as incurred. Once the application is substantially complete and ready for its intended use, qualifying costs are amortized on a straight-line basis over the software’s estimated useful life. Capitalized internal use software is included in Property, plant and equipment. Capitalized software as a service is included in Prepaid expenses and other current assets or Other assets and is amortized using the straight-line method over the term of the hosting arrangement which is typically no greater than 10 years.
Impairment Review of Goodwill and Indefinite-Lived Intangible Assets
Impairment Review of Goodwill and Indefinite-Lived Intangible Assets
The Company tests its goodwill, trademarks with indefinite lives and other indefinite-lived intangible assets annually for impairment in the fiscal fourth quarter unless there are indications during a different interim period that these assets may have become impaired.
With respect to goodwill, the Company has the option to first assess qualitative factors, such as the maturity and stability of the reporting unit, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other reporting unit specific operating results, microeconomic and macroeconomic factors, as well as new events and circumstances impacting the operations at the reporting unit level. The Company operates through strategic business units (SBUs) that are organized into the Company's operating segments. Reporting units for goodwill impairment testing purposes were identified as the Company's individual operating segments. If the result of a qualitative test indicates that it is more likely than not that a reporting unit is impaired, a quantitative test is performed. In the quantitative test, the Company compares the estimated fair value of the reporting unit to its carrying value. If the estimated fair value of any reporting unit is less than its carrying value, an impairment charge is recorded for the difference between the carrying value and the fair value of the reporting unit.
To determine the fair value of a reporting unit as part of its quantitative test, the Company uses the discounted cash flow (DCF) method under the income approach, as it believes that this approach is the most reliable indicator of the fair value of its businesses and the fair value of its future earnings and cash flows. Under this approach, which requires significant judgments, the Company estimates the future cash flows of each reporting unit and discounts these cash flows at a rate of return that reflects their relative risk. The cash flows used in the DCF method are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced, and the broader business strategy for the long term. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates,
commodity prices, foreign exchange rates, inflation and a terminal growth rate. Changes in such estimates or the application of alternative assumptions could produce different results.
For trademarks and other intangible assets with indefinite lives, the Company has the option to first assess qualitative factors, such as the maturity and stability of the trademark or other intangible asset, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other specific operating results, as well as new events and circumstances impacting the significant inputs used to determine the fair value of the intangible asset. If the result of a qualitative test indicates that it is more likely than not that the asset is impaired, a quantitative test is performed. When a quantitative test is performed, the estimated fair value of an asset is compared to its carrying value. If the carrying value of such asset exceeds its estimated fair value, an impairment charge is recorded for the difference between the carrying value and the estimated fair value. The Company uses the DCF method under the relief from royalty income approach to estimate the fair value of its trademarks and other intangible assets with indefinite lives. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows, as well as the appropriate discount and foreign exchange rates applied to those cash flows to determine fair value. Changes in such estimates or the use of alternative assumptions could produce different results.
Leases
Leases
The Company determines whether an arrangement contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration and other facts and circumstances. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date and initial direct costs incurred by the Company and excludes any lease incentives received from the lessor. The Company reviews ROU assets for impairment consistent with the approach applied for its other long-lived assets. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. The lease term may include an option to extend or terminate the lease when it is reasonably certain that the Company will exercise that option as of the commencement date of the lease, and is reviewed in subsequent periods if a triggering event occurs. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date based on the lease term and the currency of the lease on a collateralized basis. Variable lease payments are the portion of lease payments that are not fixed over the lease term. Variable lease payments are expensed as incurred, and include certain non-lease components, such as maintenance and other services provided by the lessor, and other charges included in the lease, as applicable. The Company elected to combine lease and non-lease components as a single lease component and to exclude short-term leases, defined as leases with an initial term of 12 months or less, from its consolidated balance sheet.
Restructuring Liabilities
Restructuring Liabilities
The Company incurs restructuring costs in connection with workforce reductions; consolidation or closure of a facility; sale or termination of a line of business; and other actions. Such costs include employee termination benefits (one-time arrangements and benefits attributable to prior service), termination of contractual obligations, noncash asset charges and other direct incremental costs.
The Company records employee termination liabilities once they are both probable and estimable for severance provided under the Company’s existing severance policy. Employee termination liabilities outside of the Company’s existing severance policy are recognized at the time relevant employees are notified, unless the employees will be retained to render service beyond a minimum retention period for transition purposes, in which case the liability is recognized ratably over the future service period. Other costs associated with a restructuring plan or exit or disposal activities, such as consulting and professional fees, facility exit costs, employee relocation, outplacement costs, accelerated depreciation or asset impairments associated with a restructuring plan, are recognized in the period in which the liability is incurred or the asset is impaired.
Stock-based Compensation
Stock-based Compensation
The Company grants various nonqualified stock-based compensation awards to eligible employees, including stock options, restricted stock awards and performance shares.
For stock options, the Company estimates the fair value of each award on the date of grant using the Black-Scholes valuation model, which requires management to make estimates regarding expected option life, stock price volatility and other assumptions. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The Company estimates stock option forfeitures based on historical data for each employee grouping. The total number of stock options expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.
For restricted stock awards, the fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. Forfeitures are estimated based on historical data. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.
The Company’s performance shares provide for the issuance of common stock to certain managerial staff and executive management if the Company achieves specified performance targets. The number of shares issued is dependent upon the achievement of specified performance targets. The performance period is three years and the payout determination is made at the end of the three-year performance period. Performance shares receive dividends earned during the vesting period upon vesting. The fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. The total amount of compensation expense recognized reflects estimated forfeiture rates and management’s assessment of the probability that performance goals will be achieved. A cumulative adjustment is recognized to compensation expense in the current period to reflect any changes in the probability of achievement of performance goals.
Cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for stock-based payment arrangements (excess tax benefits) are classified as operating cash inflows.
Employee Benefits
Employee Benefits
The Company accounts for its retirement income and retirement health care plans using actuarial methods. These methods use an attribution approach that generally spreads “plan events” over the service lives or expected lifetime (for frozen plans) of plan participants. Examples of plan events are plan amendments and changes in actuarial assumptions such as the expected return on plan assets, discount rate, rate of compensation increase and certain employee-related factors, such as retirement age and mortality. The principle underlying the attribution approach is that employees render service over their employment period on a relatively “smooth” basis and, therefore, the statements of earnings effects of retirement income and retirement health care plans are recognized in the same pattern. One of the principal assumptions used in the net periodic benefit cost calculation is the expected return on plan assets. The expected return on plan assets may result in recognized expense or income that differs from the actual returns of those plan assets in any given year. Over time, however, the goal is for the expected long-term returns to approximate the actual returns and, therefore, the expectation is that the pattern of income and expense recognition should closely match the pattern of the services provided by the participants. The Company uses a market-related value method for calculating plan assets for purposes of determining the amortization of actuarial gains and losses. The differences between actual and expected returns are recognized in the net periodic benefit cost calculation over the average remaining service period or expected lifetime (for frozen plans) of the plan participants using the corridor approach. Under this approach, only actuarial gains (losses) that exceed 5% of the greater of the projected benefit obligation or the market-related value of assets are amortized to the Company’s net periodic benefit cost. In developing its expected return on plan assets, the Company considers the long-term actual returns relative to the mix of investments that comprise its plan assets and also develops estimates of future investment returns by considering external sources.
The Company recognizes an actuarial-based obligation at the onset of disability for certain benefits provided to individuals after employment, but before retirement, that includes medical, dental, vision, life and other benefits.
Environmental Costs
Environmental Costs
The Company is involved in certain environmental remediation and ongoing compliance activities. Accruals for environmental matters are recorded on a site-by-site basis when it is probable that a liability has been incurred and based upon a reasonable estimate of the liability. The Company’s accruals reflect the anticipated participation of other potentially responsible parties in those instances where it is probable that such parties are legally responsible and financially capable of paying their respective shares of the relevant costs. These accruals are adjusted periodically as assessment and remediation efforts progress or as additional technical or legal information becomes available. Actual costs to be incurred at identified sites in future periods may vary from the estimates, given the inherent uncertainties in evaluating environmental conditions. The accrual for environmental matters is included in Accounts payable and accrued liabilities and Other liabilities in the Company’s consolidated balance sheets on an undiscounted basis due to uncertainty regarding the timing of future payments.
Revenue Recognition and Cost of Products Sold
Revenue Recognition
The Company’s revenue is primarily generated from the sale of finished product to customers. Revenue is recognized at the point in time when performance obligations under the terms of customer contracts are satisfied, which is when ownership, risks and rewards transfer, and can be on the date of shipment or the date of receipt by the customer, depending upon the particular customer arrangement. Shipping and handling activities are accounted for as contract fulfillment costs and included within Cost of products sold. After the completion of the performance obligation, there is an unconditional right to consideration as outlined in the contract. A right is considered unconditional if nothing other than the passage of time is required before payment of that consideration is due. The Company typically collects its customer receivables within two months. All performance obligations under the terms of contracts with customers have an original duration of one year or less.
The Company has trade promotion programs, which primarily include shelf price reductions, in-store merchandising and consumer coupons. The costs of such activities, defined as variable consideration under Accounting Standards Codification 606, “Revenue from Contracts with Customers,” are netted against sales and recorded when the related sales take place. Accruals for trade promotion programs are established based on the Company’s best estimate of the amounts necessary to settle existing and future obligations for products sold as of the balance sheet date. Amounts accrued for trade promotions are based on various factors such as contractual terms and sales volumes, and also incorporate estimates that include customer participation rates, the rate at which customers will achieve program performance criteria, product availability and historical consumer redemption rates.
The Company provides an allowance for doubtful accounts based on its historical experience and ongoing assessment of its customers’ credit risk and aging.
Cost of Products Sold
Cost of products sold represents the costs directly related to the manufacture and distribution of the Company’s products and primarily includes raw materials, packaging, contract manufacturing fees, shipping and handling, warehousing, package design, depreciation, amortization, direct and indirect labor and operating costs for the Company’s manufacturing and distribution facilities, including salary, benefit costs and incentive compensation, and royalties and other charges related to the Company’s Glad Venture Agreement (See Note 11).
Costs associated with developing and designing new packaging, including design, artwork, films and labeling, are expensed as incurred and included within Cost of products sold.
Selling and Administrative Expenses
Selling and Administrative Expenses
Selling and administrative expenses represent costs incurred by the Company in generating revenues and managing the business and include market research, commissions and certain administrative expenses. Administrative expenses include salary, benefits, incentive compensation, professional fees and services and other operating costs (such as software and licensing costs) associated with the Company’s non-manufacturing, non-research and development operations.
Advertising and Research and Development Costs
Advertising and Research and Development Costs
The Company expenses advertising and research and development costs in the period incurred.
Income Taxes
Income Taxes
The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective
tax basis. Management reviews the Company’s deferred tax assets to determine whether their value can be realized based upon available evidence. A valuation allowance is established when management believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s income tax provision in the period of change. In addition to valuation allowances, the Company provides for uncertain tax positions when such tax positions do not meet certain recognition thresholds or measurement standards. Amounts for uncertain tax positions are adjusted in quarters when new information becomes available or when positions are effectively settled.
Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion and determined that none of the undistributed earnings of its foreign subsidiaries are indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable.
The Company accounts for the tax on global intangible low-taxed income (GILTI) as a period cost.
Foreign Currency Transactions and Translations
Foreign Currency Transactions and Translation
Local currencies are the functional currencies for substantially all of the Company’s foreign operations. When the transactional currency is different than the functional currency, transaction gains and losses are included as a component of Other (income) expense, net. In addition, certain assets and liabilities denominated in currencies other than a foreign subsidiary’s functional currency are reported on the subsidiary’s books in its functional currency, with the impact from exchange rate differences recorded in Other (income) expense, net. Assets and liabilities of foreign operations are translated into U.S. dollars using the exchange rates in effect at the balance sheet date, while income and expenses are translated at the respective average monthly exchange rates during the year.
Gains and losses on foreign currency translations are reported as a component of Other comprehensive (loss) income. The income tax effect of currency translation adjustments is recorded as a component of deferred taxes with an offset to Other comprehensive (loss) income where appropriate.
Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, since it has experienced cumulative inflation of approximately 100 percent or more over a three-year period. As a result, beginning July 1, 2018, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina (collectively, “Clorox Argentina”). Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities for Clorox Argentina prior to divestment were recognized in Other (income) expense, net in the consolidated statements of earnings.
Derivative Instruments
Derivative Instruments
The Company’s use of derivative instruments, principally exchange-traded futures and options contracts, and over-the counter swaps and forward contracts, is limited to non-trading purposes and is designed to partially manage exposure to changes in commodity prices, foreign currencies and interest rates. The Company’s contracts are hedges for transactions with notional amounts and periods consistent with the related exposures and do not constitute investments independent of these exposures.
The changes in the fair value (i.e., gains or losses) of a derivative instrument are recorded as either assets or liabilities in the consolidated balance sheets with an offset to Net earnings or Other comprehensive (loss) income depending on whether, for accounting purposes, it has been designated and qualifies as an accounting hedge and, if so, on the type of hedging relationship. The criteria used to determine if hedge accounting treatment is appropriate are: (a) formal designation and documentation of the hedging relationship, the risk management objective and hedging strategy at hedge inception; (b) eligibility of hedged items, transactions and corresponding hedging instrument; and (c) effectiveness of the hedging relationship both at inception of the hedge and on an ongoing basis in achieving the hedging objectives. For those derivative instruments designated and qualifying as hedging instruments, the Company must designate the hedging instrument either as a fair value hedge or as a cash flow hedge. The Company designates its commodity futures, options and swaps contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges. During the fiscal years ended June 30, 2024, 2023 and 2022, the Company had no hedging instruments designated as fair value hedges.
For derivative instruments designated and qualifying as cash flow hedges, gains or losses are reported as a component of Other comprehensive (loss) income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. From time to time, the Company may have contracts not designated as hedges for accounting purposes, for which it recognizes changes in the fair value in the consolidated statements of earnings in the current period. Cash flows from hedging activities are classified as operating activities in the consolidated statements of cash flows.
Recently Issued Accounting Standards
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
Recently Adopted Accounting Standards
In September 2022, the FASB issued ASU No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the consolidated financial statements, results of operations, or cash flows.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of June 30, 2024 and 2023, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
Segment Reporting
The Company operates through strategic business units (SBUs) that are organized into the Company’s operating segments. Operating segments with shared economic and qualitative characteristics are aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. The four reportable segments consist of the following:
Health and Wellness consists of cleaning, disinfecting and professional products marketed and sold in the United States.
Household consists of bags and wraps, cat litter and grilling products marketed and sold in the United States.
Lifestyle consists of food, water-filtration and natural personal care products marketed and sold in the United States.
International consists of products sold outside the United States. Products within this segment include laundry additives; home care products; bags and wraps; cat litter; water-filtration products; professional cleaning and disinfecting products; natural personal care products; food; grilling products and digestive health products marketed primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands.
Corporate and Other includes certain non-allocated administrative costs, various other non-operating income and expenses, as well as the results of the Better Health VMS business. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes, as well as the assets related to the Better Health VMS business.
The principle measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding
interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, relating to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).
Management uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance and allocate resources to each segment as it removes the impact of the items that management believes do not directly reflect the performance of each segment's underlying operations.
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Schedule of Estimated Useful Lives of Property, Plant and Equipment The table below provides estimated useful lives of property, plant and equipment by asset classification.
Estimated
Useful Lives
Buildings and leasehold improvements
5 - 40 years
Land improvements
10 - 30 years
Machinery and equipment
3 - 15 years
Computer equipment
3 - 5 years
Capitalized software costs
3 - 7 years
The components of property, plant and equipment, net, consisted of the following as of June 30:
20242023
Land and improvements$174 $168 
Buildings816 810 
Machinery and equipment2,398 2,355 
Capitalized software costs413 400 
Computer equipment137 131 
Construction in progress198 186 
Total4,136 4,050 
Less: Accumulated depreciation and amortization(2,821)(2,705)
Property, plant and equipment, net$1,315 $1,345 
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DIVESTITURE OF ARGENTINA BUSINESS (Tables)
12 Months Ended
Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Summary of Net Assets Divested and Net Sales of Divested Business
The major classes of assets and liabilities of the Argentina business divested as of March 20, 2024 were as follows:
Divestiture
Working capital, net
$31 
Property, plant and equipment, net
18 
Goodwill (1)
16 
Other assets
Other liabilities
(3)
Net assets divested
$65 
(1)Goodwill corresponding to the International reportable segment.
The following table presents net sales of the Argentina business, which includes the financial results up to March 20, 2024, the date of sale, for fiscal years ended:
20242023
Net sales
$123 $172 
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CYBERATTACK (Tables)
12 Months Ended
Jun. 30, 2024
Unusual or Infrequent Items, or Both [Abstract]  
Schedule of Recognition of Costs, Net of Insurance Recoveries The following table summarizes the recognition of costs, net of insurance recoveries, as reflected in the consolidated statements of earnings and comprehensive income for the fiscal year ended June 30:
2024
Costs of products sold
$17 
Selling and administrative expenses
12 
Total$29 
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RESTRUCTURING AND RELATED COSTS (Tables)
12 Months Ended
Jun. 30, 2024
Restructuring and Related Activities [Abstract]  
Schedule of Total Restructuring and Related Implementation Costs, Net
The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model plan as reflected in the consolidated statements of earnings and comprehensive income for the fiscal years ended June 30 were:
20242023
Costs of products sold$— $(3)
Selling and administrative expenses16 12 
Research and development— (1)
Other (income) expense, net:
Employee-related costs10 52 
Asset impairments— 
Total Other (income) expense, net:16 52 
Total, net$32 $60 
Schedule of Accrual for Restructuring and Related Implementation Costs
The following table reconciles the accrual for the streamlined operating model restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets as follows for the fiscal years ended June 30:
Employee-Related CostsOtherTotal
Accrual Balance as of June 30, 2023
$23 $$28 
Charges
10 19 29 
Cash payments
(25)(13)(38)
Accrual Balance as of June 30, 2024$$11 $19 
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVENTORIES, NET (Tables)
12 Months Ended
Jun. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories, net consisted of the following as of June 30:
20242023
Finished goods$556 $595 
Raw materials and packaging172 182 
Work in process
LIFO allowances(98)(87)
Total inventories, net639 698 
Non-current inventories, net (1)
Total current inventories, net$637 $696 
(1)Non-current inventories, net is recorded in Other assets.
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)
12 Months Ended
Jun. 30, 2024
Property, Plant and Equipment, Net [Abstract]  
Schedule of Components of Property, Plant and Equipment, Net The table below provides estimated useful lives of property, plant and equipment by asset classification.
Estimated
Useful Lives
Buildings and leasehold improvements
5 - 40 years
Land improvements
10 - 30 years
Machinery and equipment
3 - 15 years
Computer equipment
3 - 5 years
Capitalized software costs
3 - 7 years
The components of property, plant and equipment, net, consisted of the following as of June 30:
20242023
Land and improvements$174 $168 
Buildings816 810 
Machinery and equipment2,398 2,355 
Capitalized software costs413 400 
Computer equipment137 131 
Construction in progress198 186 
Total4,136 4,050 
Less: Accumulated depreciation and amortization(2,821)(2,705)
Property, plant and equipment, net$1,315 $1,345 
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS (Tables)
12 Months Ended
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
The changes in the carrying amount of goodwill by reportable segment and Corporate and Other for the fiscal years ended June 30, 2024 and 2023 were as follows:
Goodwill
Health and Wellness
HouseholdLifestyleInternational
Corporate and Other (1)
Total
Balance as of June 30, 2022$323 $85 $244 $600 $306 $1,558 
Goodwill impairment
— — — — (306)(306)
Balance as of June 30, 2023$323 $85 $244 $600 $— $1,252 
Divestiture (2)
— — — (16)— (16)
Effect of foreign currency translation— — — (8)— (8)
Balance as of June 30, 2024$323 $85 $244 $576 $— $1,228 
(1)Reflects goodwill related to the Better Health VMS reporting unit, which was previously included within the Health and Wellness reportable segment prior to the segment changes effective in the fourth quarter of fiscal year 2023.
(2)Reflects goodwill related to the divestiture of the Argentina business. See Note 2 for additional information.
Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets
The changes in the carrying amount of trademarks and other intangible assets for the fiscal years ended June 30, 2024 and 2023 were as follows:
As of June 30, 2024As of June 30, 2023
Gross
carrying
amount
Accumulated
amortization / Impairments
Net carrying
amount
Gross
carrying
amount
Accumulated
amortization / Impairments
Net carrying
amount
Trademarks with indefinite lives (1)
$493 $— $493 $494 $— $494 
Trademarks with finite lives (1)
83 38 45 89 40 49 
Other intangible assets with finite lives578 435 143 579 410 169 
Total$1,154 $473 $681 $1,162 $450 $712 
(1)As of June 30, 2023 reflects changes to the useful lives of certain Better Health VMS and International indefinite-lived trademarks to finite-lived effective April 1, 2023.
Schedule of Pre-Tax, Noncash Impairment Charges
Based on the outcome of these assessments, the following pre-tax, noncash impairment charges were recorded during fiscal year 2023:
Impairment Charges
Better Health VMS reporting unit
International reporting unitTotal
Goodwill$306 $— $306 
Trademarks, net127 12 139 
Total$433 $12 $445 
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
12 Months Ended
Jun. 30, 2024
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consisted of the following as of June 30:
20242023
Accounts payable$950 $1,021 
Compensation and employee benefit costs190 262 
Trade and sales promotion costs156 157 
Dividends25 23 
Other165 196 
Total$1,486 $1,659 
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT (Tables)
12 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
Long-term debt, carried at face value net of unamortized discounts, premiums and debt issuance costs, included the following as of June 30:
20242023
Senior unsecured notes and debentures:
3.10%, $400 due October 2027
$399 $398 
3.90%, $500 due May 2028
498 497 
4.40%, $500 due May 2029
495 495 
1.80%, $500 due May 2030
495 494 
4.60%, $600 due May 2032
594 593 
Total2,481 2,477 
Less: Current maturities of long-term debt— — 
Long-term debt$2,481 $2,477 
Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements
The Company’s borrowing capacity under the revolving credit agreements and other financing arrangements as of June 30 was as follows:
20242023
Revolving credit facility$1,200 $1,200 
Foreign and other credit lines34 35 
Total$1,234 $1,235 
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER LIABILITIES (Tables)
12 Months Ended
Jun. 30, 2024
Other Liabilities Disclosure [Abstract]  
Schedule of Other Liabilities
Other liabilities consisted of the following as of June 30:
20242023
Venture Agreement terminal obligation, net$510 $495 
Employee benefit obligations263 259 
Taxes25 19 
Environmental liabilities24 24 
Other26 28 
Total$848 $825 
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
12 Months Ended
Jun. 30, 2024
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows during the fiscal years ended June 30:
Gains (losses) recognized in Other comprehensive (loss) income
202420232022
Commodity purchase derivative contracts$(8)$(6)$17 
Foreign exchange derivative contracts— — 
Interest rate derivative contracts— — 89 
Total$(8)$(6)$107 
Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings
Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
202420232022
Commodity purchase derivative contractsCost of products sold$(6)$$23 
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense13 13 (9)
Total$$19 $14 
Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities The following table provides information about the balance sheet classification and the fair values of the Company's derivative instruments:
20242023
Balance Sheet ClassificationFair Value
Hierarchy
Level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Commodity purchase options contractsPrepaid expenses and other current assets1$— $— $$
Commodity purchase swaps contractsPrepaid expenses and other current assets2— — 
Foreign exchange forward contractsPrepaid expenses and other current assets2— — — — 
$$$$
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$$$— $— 
Commodity purchase swaps contractsAccounts payable and accrued liabilities2— — 
$$$$
The following table provides information about the balance sheet classification and the fair values of the Company's other assets and liabilities for which disclosure of fair value is required:
20242023
Balance sheet classificationFair value
hierarchy
level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash equivalents (1)
1$95 $95 $243 $243 
Time deposits
Cash and cash equivalents (1)
2
Trust assets for nonqualified deferred compensation plansOther assets1154 154 129 129 
$258 $258 $381 $381 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$$$50 $50 
Long-term debt
Long-term debt (3)
22,481 2,341 2,477 2,327 
$2,485 $2,345 $2,527 $2,377 
(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.
(3)Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS (Tables)
12 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Purchase Obligations As of June 30, 2024, the Company’s purchase obligations by purchase date were approximately as follows:
YearPurchase
Obligations
2025$181 
2026128 
202781 
202843 
202927 
Thereafter45 
Total$505 
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES (Tables)
12 Months Ended
Jun. 30, 2024
Leases [Abstract]  
Schedule of Supplemental Balance Sheet Information
Supplemental balance sheet information related to the Company’s leases as of June 30 was as follows:
Balance sheet classification20242023
Operating leases
Right-of-use assetsOperating lease right-of-use assets$360 $346 
Current lease liabilitiesCurrent operating lease liabilities$84 $87 
Non-current lease liabilitiesLong-term operating lease liabilities334 310 
Total operating lease liabilities$418 $397 
Finance leases
Right-of-use assetsOther assets$33 $29 
Current lease liabilitiesAccounts payable and accrued liabilities$13 $
Non-current lease liabilitiesOther liabilities21 21 
Total finance lease liabilities$34 $30 
Schedule of Components of Lease Cost, Supplemental Cash Flow Information and Noncash Activity Related to Leases and Weighted-Average Remaining Lease Term and Discount Rate
Components of lease cost were as follows for the fiscal years ended June 30:
20242023
Operating lease cost$97 $89 
Finance lease cost:
Amortization of right-of-use assets$11 $
Interest on lease liabilities
Total finance lease cost$12 $10 
Variable lease cost$94 $87 
Short term lease cost$$
Supplemental cash flow information and noncash activity related to the Company’s leases were as follows during fiscal years ended June 30:
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases, net$97 $88 
Operating cash flows from finance leases
Financing cash flows from finance leases11 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$113 $84 
Finance leases17 21 
Weighted-average remaining lease term and discount rate for the Company’s leases were as follows as of fiscal year ended June 30:
2024
Weighted-average remaining lease term:
Operating leases5 years
Finance leases3 years
Weighted-average discount rate:
Operating leases3.6 %
Finance leases5.1 %
Schedule of Maturities of Operating Lease Liabilities
Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:
YearOperating leasesFinance leases
2025$97 $14 
202694 12 
202784 
202869 
202956 
Thereafter61 — 
Total lease payments$461 $36 
Less: Imputed interest43 
Total lease liabilities$418 $34 
Schedule of Maturities of Finance Lease Liabilities
Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:
YearOperating leasesFinance leases
2025$97 $14 
202694 12 
202784 
202869 
202956 
Thereafter61 — 
Total lease payments$461 $36 
Less: Imputed interest43 
Total lease liabilities$418 $34 
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Jun. 30, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Dividends Per Share Paid to Stockholders
Dividends per share paid to Clorox stockholders during the fiscal years ended June 30 were as follows:
202420232022
Dividends per share paid$4.80 $4.72 $4.64 
Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the fiscal years ended June 30:
Foreign currency
translation adjustments
Net
unrealized
gains
(losses) on
derivatives
Pension and
postretirement
benefit
adjustments
Accumulated
other
comprehensive net
(loss) income
Balance June 30, 2021$(403)$21 $(164)$(546)
Other comprehensive (loss) income before
reclassifications
(45)107 63 
Amounts reclassified from Accumulated other
comprehensive net (loss) income
— (14)15 
Income tax benefit (expense)— (4)
Net current period other comprehensive (loss) income
(45)100 12 67 
Balance June 30, 2022(448)121 (152)(479)
Other comprehensive (loss) income before
reclassifications
(6)(4)
Amounts reclassified from Accumulated other
comprehensive net (loss) income
— (19)(13)
Income tax benefit (expense)(2)
Net current period other comprehensive (loss) income
(22)(14)
Balance June 30, 2023(445)99 (147)(493)
Other comprehensive (loss) income before
reclassifications
(16)(8)17 (7)
Amounts reclassified from Accumulated other
comprehensive net (loss) income (1) (2)
223 (7)174 390 
Income tax benefit (expense)(1)(45)(45)
Net current period other comprehensive (loss) income
206 (14)146 338 
Balance June 30, 2024$(239)$85 $(1)$(155)
(1)Includes the release of currency translation adjustment from the Argentina business divestiture. See Note 2 for additional details.
(2)Includes recognition of pension settlement charge reclassified into Net earnings (losses). See Note 20 for additional details
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1
NET EARNINGS PER SHARE (EPS) (Tables)
12 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares Outstanding
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS for the fiscal years ended June 30:
202420232022
Basic124,174 123,589 123,113 
Dilutive effect of stock options and other630 592 793 
Diluted124,804 124,181 123,906 
Antidilutive stock options and other2,704 1,444 2,448 
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS (Tables)
12 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Schedule of Compensation Cost and Related Income Tax Benefit
Compensation cost and the related income tax benefit recognized for stock-based compensation plans were classified as indicated below for the fiscal years ended June 30:
202420232022
Cost of products sold$$$
Selling and administrative expenses63 61 42 
Research and development costs
Total compensation costs$74 $73 $52 
Related income tax benefit$18 $17 $12 
Schedule of Fair Value of each Stock Option Award Granted The fair value of each stock option award granted during fiscal years 2023 and 2022 was estimated on the date of grant using the Black-Scholes valuation model and assumptions noted in the following table:
20232022
Expected life5.3 years
5.4 years
Weighted-average expected life5.3 years5.4 years
Expected volatility
24.2%
21.7% to 25.0%
Weighted-average volatility24.2%21.8%
Risk-free interest rate
3.7%
0.9% to 2.1%
Weighted-average risk-free interest rate3.7%0.9%
Dividend yield
3.4%
2.9% to 3.7%
Weighted-average dividend yield3.4%2.9%
Schedule of Stock Option Activity
Details of the Company’s stock option activities are summarized below:
Number of
Shares
(In thousands)
Weighted-
Average
Exercise
Price
per Share
Average
Remaining
Contractual
Life
Aggregate
Intrinsic
Value
Options outstanding as of June 30, 2023
4,075 $147 5 years$69 
Granted— 
Exercised(234)104 
Canceled(51)170 
Options outstanding as of June 30, 2024
3,790 $150 4 years$16 
Options vested as of June 30, 2024
3,052 $148 4 years$16 
Schedule of Restricted Stock Awards
A summary of the status of the Company’s restricted stock awards is presented below:
Number of
Shares
(In thousands)
Weighted-Average
Grant Date
Fair Value
per Share
Restricted stock awards as of June 30, 2023
544 $155 
Granted405 139 
Vested(173)162 
Forfeited(55)142 
Restricted stock awards as of June 30, 2024
721 $145 
Schedule of Performance Share Awards
A summary of the status of the Company’s performance share awards is presented below:
Number of
Shares
(In thousands)
Weighted-Average
Grant Date
Fair Value
per Share
Performance share awards as of June 30, 2023
368 $158 
Granted176 $140 
Distributed(39)$189 
Forfeited(22)$177 
Performance share awards as of June 30, 2024
483 $148 
Performance shares vested and deferred as of June 30, 2024
83 $164 
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER (INCOME) EXPENSE, NET (Tables)
12 Months Ended
Jun. 30, 2024
Other Income and Expenses [Abstract]  
Schedule of Major Components of Other (Income) Expense, Net
The major components of Other (income) expense, net, for the fiscal years ended June 30 were:
202420232022
Amortization of trademarks and other intangible assets$29 $30 $31 
Trust investment (gains) losses, net(20)(14)21 
Net periodic benefit cost
14 16 16 
Foreign exchange transaction (gains) losses, net (1)
25 13 
Income from equity investees(5)(4)(6)
Interest income(23)(16)(5)
Restructuring costs (2)
16 52 — 
Gain on sale-leaseback transaction(16)— (14)
Other(9)
Total$24 $80 $37 
(1)Foreign exchange losses are primarily related to the Company’s operations in Argentina, prior to the divestiture.
(2)Restructuring costs related to the Company's streamlined operating model plan (see Note 5).
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES (Tables)
12 Months Ended
Jun. 30, 2024
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes
The provision for income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:
202420232022
Current
Federal$132 $153 $71 
State18 33 17 
Foreign56 40 43 
Total current$206 $226 $131 
Deferred
Federal$(99)$(120)$
State(5)(28)(2)
Foreign(1)
Total deferred(100)(149)
Total$106 $77 $136 
Schedule of Components of Earnings Before Income Taxes
The components of Earnings before income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:
202420232022
United States$311 $154 $483 
Foreign87 84 124 
Total$398 $238 $607 
Schedule of Reconciliation of Effective Tax Rate
A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate on operations follows for the fiscal years ended June 30:
202420232022
Statutory federal tax rate21.0 %21.0 %21.0 %
State taxes (net of federal tax benefits)2.5 1.6 1.9 
Foreign tax rate differential7.7 8.6 3.1 
Federal excess tax benefits(0.3)(1.8)(0.9)
Net U.S. tax on foreign income(5.2)(2.3)(1.7)
Loss on divestiture
10.5 — — 
International legal entity reorganization
(6.1)—  
VMS goodwill impairment— 8.6 — 
Federal research and development credits(1.2)(2.7)(0.8)
Other differences(2.4)(0.6)(0.2)
Effective tax rate26.5 %32.4 %22.4 %
Schedule of Components of Net Deferred Tax Assets (Liabilities)
The components of net deferred tax assets (liabilities) as of June 30 are shown below:
20242023
Deferred tax assets
Compensation and benefit programs$109 $123 
Loss and tax credit carryforwards
153 94 
Operating and finance lease liabilities111 104 
Accruals and reserves33 46 
Capitalized research and development43 34 
Inventory costs29 32 
Other33 34 
Subtotal511 467 
Valuation allowance(115)(59)
Total deferred tax assets$396 $408 
Deferred tax liabilities
Property, plant and equipment and intangible assets
$(84)$(157)
Lease right-of-use assets(100)(96)
Other(36)(36)
Total deferred tax liabilities(220)(289)
Net deferred tax assets (liabilities)$176 $119 
The net deferred tax assets and liabilities included in the consolidated balance sheet at June 30 were as follows:
Net deferred tax assets (1)
$198 $147 
Net deferred tax liabilities(22)(28)
Net deferred tax assets (liabilities)$176 $119 
(1)Net deferred tax assets are recorded in Other assets.
Summary of Changes in Valuation Allowance
Changes in the valuation allowance on deferred tax assets were as follows for the years ended June 30:
202420232022
Valuation allowance at beginning of year$(59)$(52)$(42)
Net increase/(decrease) for U.S. capital loss carryfowards(46)— — 
Net decrease/(increase) for other foreign deferred tax assets(2)(1)(1)
Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits(8)(6)(9)
Valuation allowance at end of year$(115)$(59)$(52)
Summary of Tax Credit Carryforwards
The Company's carryforwards for capital losses, net operating losses, and tax credits, with related valuation allowances were as follows as of June 30:
2024
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions46 (46)— 
2029
Net operating losses
U.S. jurisdictions(5)2030 - 2042
U.S. jurisdictions (with no expiration)(8)N/A
Foreign jurisdictions18 (16)2025 - 2044
Foreign jurisdictions (with no expiration)— N/A
Total net operating losses41 (29)12 
Income tax credits
U.S. jurisdictions30 — 30 2025 - 2034
U.S. jurisdictions (with no expiration)— N/A
Foreign jurisdictions30 (30)— 2026
Foreign jurisdictions (with no expiration)(3)
N/A
Total income tax credits66 (33)33 
Total carryforwards$153 $(108)$45 
2023
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions— — — N/A
Net operating losses
U.S. jurisdictions(4)— 2030 - 2042
U.S. jurisdictions (with no expiration)(5)N/A
Foreign jurisdictions21 (16)2024 - 2040
Foreign jurisdictions (with no expiration)(1)N/A
Total net operating losses40 (26)14 
Income tax credits
U.S. jurisdictions23 — 23 2024 - 2033
U.S. jurisdictions (with no expiration)— N/A
Foreign jurisdictions (with no expiration)29 (28)N/A
Total income tax credits54 (28)26 
Total carryforwards$94 $(54)$40 
Summary of Operating Loss Carryforwards
The Company's carryforwards for capital losses, net operating losses, and tax credits, with related valuation allowances were as follows as of June 30:
2024
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions46 (46)— 
2029
Net operating losses
U.S. jurisdictions(5)2030 - 2042
U.S. jurisdictions (with no expiration)(8)N/A
Foreign jurisdictions18 (16)2025 - 2044
Foreign jurisdictions (with no expiration)— N/A
Total net operating losses41 (29)12 
Income tax credits
U.S. jurisdictions30 — 30 2025 - 2034
U.S. jurisdictions (with no expiration)— N/A
Foreign jurisdictions30 (30)— 2026
Foreign jurisdictions (with no expiration)(3)
N/A
Total income tax credits66 (33)33 
Total carryforwards$153 $(108)$45 
2023
CarryforwardsValuation AllowancesNet CarryforwardsFiscal Year Expiring
Capital losses in U.S. jurisdictions— — — N/A
Net operating losses
U.S. jurisdictions(4)— 2030 - 2042
U.S. jurisdictions (with no expiration)(5)N/A
Foreign jurisdictions21 (16)2024 - 2040
Foreign jurisdictions (with no expiration)(1)N/A
Total net operating losses40 (26)14 
Income tax credits
U.S. jurisdictions23 — 23 2024 - 2033
U.S. jurisdictions (with no expiration)— N/A
Foreign jurisdictions (with no expiration)29 (28)N/A
Total income tax credits54 (28)26 
Total carryforwards$94 $(54)$40 
Schedule of Reconciliation of Gross Unrecognized Tax Benefits
The following is a reconciliation of the beginning and ending amounts of the Company’s gross unrecognized tax benefits:
202420232022
Unrecognized tax benefits at beginning of year$17 $17 $21 
Gross increases - tax positions in prior periods— — 
Gross decreases - tax positions in prior periods(4)(3)(7)
Gross increases - current period tax positions
Gross decreases - current period tax positions— — — 
Lapse of applicable statute of limitations— — (1)
Settlements— — — 
Unrecognized tax benefits at end of year$22 $17 $17 
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS (Tables)
12 Months Ended
Jun. 30, 2024
Retirement Benefits [Abstract]  
Schedule of Retirement Income and Retirement Health Care Plans
Summarized information for the Company’s retirement income and retirement health care plans as of and for the fiscal years ended June 30 is as follows:
Retirement
Income
Retirement
Health Care
2024202320242023
Change in benefit obligations:
Benefit obligation as of beginning of year$476 $513 $26 $28 
Service cost— — 
Interest cost12 18 
Actuarial loss (gain)(26)(11)(2)(1)
Plan amendments— — (4)— 
Plan settlement(312)— — — 
Benefits paid(26)(45)(2)(2)
Translation and other adjustments(2)— — — 
Benefit obligation as of end of year$123 $476 $19 $26 
Change in plan assets:
Fair value of assets as of beginning of year$381 $412 $— $— 
Actual return on plan assets(13)— — — 
Employer contributions15 15 
Plan settlement
(312)— — — 
Benefits paid(26)(45)(2)(2)
Transfer to domestic defined contribution plan
(19)— — — 
Translation and other adjustments(1)(1)— — 
Fair value of plan assets as of end of year25 381 — — 
Accrued benefit cost, net funded status$(98)$(95)$(19)$(26)
Schedule of Amounts Recognized in Balance Sheets
Amount recognized in the balance sheets consists of:
Pension benefit assets$$24 $— $— 
Current accrued benefit liability(12)(13)(2)(2)
Non-current accrued benefit liability(93)(106)(17)(24)
Accrued benefit cost, net$(98)$(95)$(19)$(26)
Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets
Retirement income plans with ABO or PBO in excess of plan assets as of June 30 were as follows:
ABO Exceeds the Fair Value of Plan AssetsPBO Exceeds the Fair Value of Plan Assets
2024202320242023
Projected benefit obligation$105 $119 $108 $121 
Accumulated benefit obligation104 118 105 119 
Fair value of plan assets— — 
Schedule of Components of Net Periodic Benefit Cost
The net cost of the retirement income and health care plans for the fiscal years ended June 30 included the following components:
Retirement IncomeRetirement Health Care
202420232022202420232022
Service cost$$$$— $— $— 
Interest cost12 18 15 
Expected return on plan assets(2)(10)(15)— — — 
Amortization of unrecognized items     (2)(2)(1)
Curtailment gain recognized
(6)— — — — — 
Settlement loss recognized179 — — — — 
Total$187 $17 $17 $(1)$(1)$— 
Schedule of Items Not Yet Recognized as a Component of Postretirement Expense
Items not yet recognized as a component of postretirement expense as of June 30, 2024 consisted of:
Retirement
Income
Retirement
Health Care
Net actuarial loss (gain)$20 $(14)
Prior service benefit— (4)
Net deferred income tax (assets) liabilities(5)
Accumulated other comprehensive loss (income)$15 $(14)
Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income
Net actuarial loss (gain) recorded in Accumulated other comprehensive net (loss) income for the fiscal year ended June 30, 2024 included the following:
Retirement
Income
Retirement
Health Care
Net actuarial loss (gain) as of beginning of year$213 $(14)
Amortization, curtailment and settlement during the year
(182)
Loss (gain) during the year(11)(2)
Net actuarial loss (gain) as of end of year$20 $(14)
Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs
Weighted-average assumptions used to estimate the actuarial present value of benefit obligations were as follows as of June 30:
Retirement IncomeRetirement Health Care
2024202320242023
Discount rate5.52 %4.37 %5.38 %5.10 %
Rate of compensation increase3.23 %3.62 %n/an/a
Interest crediting rate5.40 %2.67 %n/an/a
Weighted-average assumptions used to estimate the retirement income and retirement health care costs were as follows as of June 30:
Retirement Income
202420232022
Discount rate4.63 %3.72 %2.56 %
Rate of compensation increase3.20 %3.09 %3.02 %
Expected return on plan assets3.39 %2.67 %3.00 %
Interest crediting rate2.69 %2.69 %2.57 %
Retirement Health Care
202420232022
Discount rate5.10 %4.65 %2.61 %
Schedule of Expected Benefit Payments
Expected benefit payments for the Company’s retirement income and retirement health care plans as of June 30, 2024, were as follows:
Retirement
Income
Retirement
Health Care
2025$15 $
202614 
202713 
202813 
202912 
Fiscal years 2030 through 203448 
Schedule of Target Allocation and Weighted Average Allocation of Plan Assets and Retirement Income Plans Assets Carried at Fair Value
The target allocations and weighted average asset allocations by asset category of the investment portfolio for the Company’s qualified domestic retirement income plans as of June 30, 2023, prior to its termination, were as follows:
% Target Allocation% of Plan Asset
Fixed income80 %79 %
Cash equivalents20 %21 %
Total100 %100 %
The following table sets forth the retirement income plans’ assets carried at fair value as of June 30:
20242023
Cash equivalents — Level 1$— $74 
Total assets in the fair value hierarchy— 74 
Common collective trusts measured at net asset value
Bond funds$$289 
International equity funds16 15 
Domestic equity funds— — 
Short-term investment fund— 
Real estate fund
Other
— 
Total common collect trust measured at net asset value$25 $307 
Total assets at fair value$25 $381 
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT REPORTING (Tables)
12 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Schedule of Reportable Segment Information and Reconciliation of Segment Information
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other.
Net Sales
Fiscal year
202420232022
Health and Wellness$2,485 $2,532 $2,427 
Household1,950 2,098 1,984 
Lifestyle1,275 1,338 1,253 
International1,162 1,181 1,180 
Reportable segment total6,872 7,149 6,844 
Corporate and Other221 240 263 
Total$7,093 $7,389 $7,107 

Segment adjusted earnings (losses) before interest and income taxes
Fiscal year
202420232022
Health and Wellness$719 $594 $381 
Household260 308 234 
Lifestyle253 284 280 
International122 89 97 
Reportable segment total1,354 1,275 992 
Corporate and Other(309)(358)(223)
Total$1,045 $917 $769 
Interest income23 16 
Interest expense(90)(90)(106)
Loss on divestiture (1)
(240)— — 
Pension settlement charge (2)
(171)— — 
Cyberattack costs, net of insurance recoveries (3)
(29)— — 
VMS impairment (4)
— (445)— 
Streamlined operating model (5)
(32)(60)— 
Digital capabilities and productivity enhancements investment (6)
(108)(100)(61)
Earnings (losses) before income taxes$398 $238 $607 
(1)Represents the loss on divestiture of the Argentina business corresponding to International. See Note 2 for additional details.
(2)Represents costs related to the settlement of the domestic qualified pension plan corresponding to Corporate and Other. See Note 20 for additional details.
(3)Represents incremental costs, net of insurance recoveries, related to the cyberattack. See Note 3 for additional details relating to the cyberattack. All insurance recoveries are recorded in Corporate and Other. For informational purposes, the following table provides the approximate cyberattack costs, net of insurance recoveries, corresponding to the Company’s reportable segments as a percentage of total net costs:
2024
Health and Wellness30 %
Household24 
Lifestyle23 
International
Corporate and Other15 
Total100 %
(4)Represents a noncash impairment charge of $445 related to the Better Health VMS business recorded in fiscal year 2023.
(5)Represents restructuring and related implementation costs, net for the streamlined operating model of $32 and $60 in fiscal year 2024 and 2023, respectively. For informational purposes the following table provides the approximate restructuring and related implementation costs, net corresponding to the Company's segments as a percent of the total costs for the fiscal years ended June 30:
Inception to date ended
202420232024
Health and Wellness%%%
Household
Lifestyle— 
International16 11 
Corporate and Other91 73 80 
Total100 %100 %100 %
(6)Represents expenses related to the Company's digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Fiscal
Year
Health and WellnessHouseholdLifestyleInternational
Corporate and Other
Total
Company
(Income) Loss from equity investees included in Other (income) expense, net
2024— — — (5)— (5)
2023— — — (4)— (4)
2022— — — (6)— (6)
Total assets20241,124 1,088 1,110 1,327 1,102 5,751 
20231,184 1,082 1,091 1,410 1,178 5,945 
Capital expenditures202447 84 36 21 24 212 
202351 97 29 24 27 228 
202261 112 24 27 27 251 
Depreciation and amortization202458 77 24 45 31 235 
202359 78 25 46 28 236 
202257 67 24 47 29 224 
Significant noncash charges included in earnings (losses) before interest and income taxes:
Stock-based compensation202414 11 35 74 
202314 10 38 73 
202214 21 52 
Schedule of Concentration Percentage
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the fiscal years ended June 30:
202420232022
Cleaning30 %30 %29 %
Professional Products%%%
Health and Wellness35 %35 %33 %
Bags and Wraps11 %12 %12 %
Cat Litter%%%
Grilling%%%
Household28 %28 %28 %
Food11 %10 %10 %
Water Filtration%%%
Natural Personal Care%%%
Lifestyle18 %18 %18 %
International16 %16 %17 %
Corporate and Other3 %3 %4 %
Total100 %100 %100 %
The Company’s products are marketed and sold globally. The following table provides the Company’s global product lines, which were sold in the U.S. and International, that accounted for 10% or more of consolidated net sales for the fiscal years ended June 30:
202420232022
Cleaning products43 %42 %42 %
Bags and wraps15 %16 %16 %
Food products11 %11 %11 %
Cat litter products10 %10 %%
Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area
Net sales and property, plant and equipment, net, by geographic area for and as of the fiscal years ended June 30 were as follows:
Fiscal
Year
United
States
ForeignTotal
Company
Net sales2024$5,956 $1,137 $7,093 
20236,237 1,152 7,389 
20225,951 1,156 7,107 
Property, plant and equipment, net20241,188 127 1,315 
20231,192 153 1,345 
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ in Millions
12 Months Ended
Jun. 30, 2024
USD ($)
hedgingInstrument
Jun. 30, 2023
USD ($)
hedgingInstrument
Jun. 30, 2022
USD ($)
hedgingInstrument
Jun. 30, 2021
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Restricted cash $ 5 $ 1 $ 3 $ 5
Hosting arrangement term (in years) (up to) 10 years      
Performance period for performance awards (in years) 3 years      
Minimum percentage for calculating the amortization of actuarial gains and losses under the corridor approach 5.00%      
Contract term (in years) one year or less      
Allowance for doubtful accounts $ 5 3    
Non-customer receivables 39 14    
Allowance for credit loss $ 3 $ 3    
Number of hedging instruments designated as fair value hedges | hedgingInstrument 0 0 0  
Minimum        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Estimated useful life (in years) 7 years      
Maximum        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Estimated useful life (in years) 30 years      
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)
Jun. 30, 2024
Buildings and leasehold improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 5 years
Buildings and leasehold improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 40 years
Land improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 10 years
Land improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 30 years
Machinery and equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 3 years
Machinery and equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 15 years
Computer equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 3 years
Computer equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 5 years
Capitalized software costs | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 3 years
Capitalized software costs | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives (in years) 7 years
XML 78 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DIVESTITURE OF ARGENTINA BUSINESS - Narrative (Details)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Mar. 20, 2024
productionPlant
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Pre-tax loss on divestiture   $ 240 $ 0 $ 0  
Argentina Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Number of production plants disposed of | productionPlant         2
Pre-tax loss on divestiture $ 240        
Cumulative translation adjustment losses $ 223        
XML 79 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DIVESTITURE OF ARGENTINA BUSINESS - Major Classes of Assets and Liabilities (Details) - Argentina Business - Disposal Group, Disposed of by Sale, Not Discontinued Operations
$ in Millions
Mar. 20, 2024
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Working capital, net $ 31
Property, plant and equipment, net 18
Goodwill 16
Other assets 3
Other liabilities (3)
Net assets divested $ 65
XML 80 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DIVESTITURE OF ARGENTINA BUSINESS - Net Sales (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Argentina Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Net sales $ 123 $ 172
XML 81 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CYBERATTACK - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Unusual or Infrequent Item, or Both [Line Items]        
Incurred incremental costs, net of insurance recoveries   $ 29 $ 0 $ 0
Cyberattack        
Unusual or Infrequent Item, or Both [Line Items]        
Incurred incremental costs, net of insurance recoveries   $ 29    
Insurance recoveries $ 30      
XML 82 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CYBERATTACK - Schedule of Recognition of Costs, Net of Insurance Recoveries (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Unusual or Infrequent Item, or Both [Line Items]      
Incurred incremental costs, net of insurance recoveries $ 29 $ 0 $ 0
Cyberattack      
Unusual or Infrequent Item, or Both [Line Items]      
Incurred incremental costs, net of insurance recoveries 29    
Costs of products sold | Cyberattack      
Unusual or Infrequent Item, or Both [Line Items]      
Incurred incremental costs, net of insurance recoveries 17    
Selling and administrative expenses | Cyberattack      
Unusual or Infrequent Item, or Both [Line Items]      
Incurred incremental costs, net of insurance recoveries $ 12    
XML 83 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SUPPLY CHAIN FINANCING PROGRAM (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Supplier Finance Program [Line Items]    
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Amount due to suppliers $ 205 $ 220
Maximum    
Supplier Finance Program [Line Items]    
Supplier finance program, payment timing, period 120 days  
XML 84 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RESTRUCTURING AND RELATED COSTS - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Restructuring and Related Activities [Abstract]      
Restructuring and related costs $ 32 $ 60 $ 0
XML 85 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RESTRUCTURING AND RELATED COSTS - Schedule of Total Restructuring and Related Implementation Costs, Net (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]      
Total, net $ 32 $ 60 $ 0
Costs of products sold      
Restructuring Cost and Reserve [Line Items]      
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of products sold Cost of products sold  
Total, net $ 0 $ (3)  
Selling and administrative expenses      
Restructuring Cost and Reserve [Line Items]      
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling and administrative expenses Selling and administrative expenses  
Total, net $ 16 $ 12  
Research and development      
Restructuring Cost and Reserve [Line Items]      
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development costs Research and development costs  
Total, net $ 0 $ (1)  
Other (income) expense, net      
Restructuring Cost and Reserve [Line Items]      
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Other (income) expense, net Other (income) expense, net  
Total, net $ 16 $ 52  
Other (income) expense, net | Employee-related costs      
Restructuring Cost and Reserve [Line Items]      
Total, net 10 52  
Other (income) expense, net | Asset impairments      
Restructuring Cost and Reserve [Line Items]      
Total, net $ 6 $ 0  
XML 86 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RESTRUCTURING AND RELATED COSTS - Schedule of Accrual for Restructuring and Related Implementation Costs (Details)
$ in Millions
12 Months Ended
Jun. 30, 2024
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning accrual balance $ 28
Charges 29
Cash payments (38)
Ending accrual balance 19
Employee-Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning accrual balance 23
Charges 10
Cash payments (25)
Ending accrual balance 8
Other  
Restructuring Reserve [Roll Forward]  
Beginning accrual balance 5
Charges 19
Cash payments (13)
Ending accrual balance $ 11
XML 87 R68.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVENTORIES, NET - Schedule of Inventories (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 556 $ 595
Raw materials and packaging 172 182
Work in process 9 8
LIFO allowances (98) (87)
Total inventories, net 639 698
Non-current inventories, net 2 2
Total current inventories, net $ 637 $ 696
XML 88 R69.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INVENTORIES, NET - Narrative (Details)
Jun. 30, 2024
Jun. 30, 2023
Inventory Disclosure [Abstract]    
Percentage of LIFO inventory 36.00% 36.00%
XML 89 R70.htm IDEA: XBRL DOCUMENT v3.24.2.u1
PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Components of Property, Plant and Equipment, Net (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 4,136 $ 4,050
Less: Accumulated depreciation and amortization (2,821) (2,705)
Property, plant and equipment, net 1,315 1,345
Land and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 174 168
Buildings    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 816 810
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 2,398 2,355
Capitalized software costs    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 413 400
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 137 131
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 198 $ 186
XML 90 R71.htm IDEA: XBRL DOCUMENT v3.24.2.u1
PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) - USD ($)
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Property, Plant and Equipment [Line Items]      
Depreciation and amortization $ 235,000,000 $ 236,000,000 $ 224,000,000
Noncash capital expenditures 5,000,000 9,000,000 6,000,000
Capitalized software costs      
Property, Plant and Equipment [Line Items]      
Amortization 10,000,000 10,000,000 8,000,000
Buildings      
Property, Plant and Equipment [Line Items]      
Asset retirement obligations 0 0  
Property, Plant and Equipment      
Property, Plant and Equipment [Line Items]      
Depreciation and amortization $ 206,000,000 $ 206,000,000 $ 193,000,000
XML 91 R72.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Goodwill [Roll Forward]    
Beginning balance $ 1,252 $ 1,558
Goodwill impairment   (306)
Divestiture (16)  
Effect of foreign currency translation (8)  
Ending balance 1,228 1,252
Corporate and Other    
Goodwill [Roll Forward]    
Beginning balance 0 306
Goodwill impairment   (306)
Divestiture 0  
Effect of foreign currency translation 0  
Ending balance 0 0
Health and Wellness | Operating Segments    
Goodwill [Roll Forward]    
Beginning balance 323 323
Goodwill impairment   0
Divestiture 0  
Effect of foreign currency translation 0  
Ending balance 323 323
Household | Operating Segments    
Goodwill [Roll Forward]    
Beginning balance 85 85
Goodwill impairment   0
Divestiture 0  
Effect of foreign currency translation 0  
Ending balance 85 85
Lifestyle | Operating Segments    
Goodwill [Roll Forward]    
Beginning balance 244 244
Goodwill impairment   0
Divestiture 0  
Effect of foreign currency translation 0  
Ending balance 244 244
International | Operating Segments    
Goodwill [Roll Forward]    
Beginning balance 600 600
Goodwill impairment   0
Divestiture (16)  
Effect of foreign currency translation (8)  
Ending balance $ 576 $ 600
XML 92 R73.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]    
Accumulated amortization / Impairments $ 473 $ 450
Total gross carrying amount 1,154 1,162
Total net carrying amount 681 712
Trademarks    
Indefinite-lived Intangible Assets [Line Items]    
Gross carrying amount 493 494
Net carrying amount 493 494
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 83 89
Accumulated amortization / Impairments 38 40
Net carrying amount 45 49
Other intangible assets with finite lives    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 578 579
Accumulated amortization / Impairments 435 410
Net carrying amount $ 143 $ 169
XML 93 R74.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]        
Amortization of intangible assets $ 29,000,000 $ 30,000,000 $ 31,000,000  
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]        
2025 28,000,000      
2026 28,000,000      
2027 29,000,000      
2028 28,000,000      
2029 11,000,000      
Impairment tax benefit   $ 83,000,000    
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]   Goodwill, trademark and other asset impairments    
Goodwill impairment   $ 306,000,000    
Goodwill $ 1,228,000,000 1,252,000,000 $ 1,558,000,000  
Better Health VMS reporting unit        
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]        
Goodwill impairment   306,000,000    
Goodwill   0    
Trademarks        
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]        
Intangible asset impairment charges   $ 139,000,000    
Trademarks        
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]        
Impaired trademarks, remaining net carrying value       $ 28,000,000
Estimated useful life (in years)   20 years    
XML 94 R75.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Pre-Tax, Noncash Impairment Charges (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Indefinite-lived Intangible Assets [Line Items]      
Goodwill   $ 306  
Trademarks, net   139  
Total $ 0 445 $ 0
Better Health VMS reporting unit      
Indefinite-lived Intangible Assets [Line Items]      
Goodwill   306  
Trademarks, net   127  
Total   433  
International reporting unit      
Indefinite-lived Intangible Assets [Line Items]      
Goodwill   0  
Trademarks, net   12  
Total   $ 12  
XML 95 R76.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Accounts payable $ 950 $ 1,021
Compensation and employee benefit costs 190 262
Trade and sales promotion costs 156 157
Dividends 25 23
Other 165 196
Total $ 1,486 $ 1,659
XML 96 R77.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT - Narrative (Details) - USD ($)
1 Months Ended 12 Months Ended
Jun. 30, 2022
Nov. 30, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
May 31, 2022
Debt Instrument [Line Items]            
Notes and loans payable     $ 4,000,000 $ 50,000,000    
Weighted average interest rate on notes and loans payable     4.77% 3.48% 0.54%  
Weighted average interest rates on long-term debt, including the effect of interest rate swaps     3.25% 3.25% 3.25%  
Long-term debt, weighted average interest rate, at point in time     3.25% 3.25%    
Long-term Debt, Fiscal Year Maturity [Abstract]            
2025     $ 0      
2026     0      
2027     0      
2028     900,000,000      
2029     500,000,000      
Thereafter     1,100,000,000      
Line of credit facility, borrowing capacity     1,234,000,000 $ 1,235,000,000    
Foreign and Other Credit Lines            
Long-term Debt, Fiscal Year Maturity [Abstract]            
Line of credit facility, borrowing capacity     34,000,000 35,000,000    
Line of credit facility, amount outstanding     9,000,000 5,000,000    
Line of credit facility, remaining borrowing capacity     25,000,000 30,000,000    
Revolving credit facility            
Long-term Debt, Fiscal Year Maturity [Abstract]            
Line of credit facility, borrowing capacity     1,200,000,000 1,200,000,000    
Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029            
Debt Instrument [Line Items]            
Face value     $ 500,000,000      
Annual fixed interest rate     4.40%      
Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032            
Debt Instrument [Line Items]            
Face value     $ 600,000,000      
Annual fixed interest rate     4.60%      
Revolving Credit Agreement, Matures March 2027 | Revolving credit facility            
Long-term Debt, Fiscal Year Maturity [Abstract]            
Line of credit facility, borrowing capacity       1,200,000,000,000    
Line of credit facility, amount outstanding     $ 0 $ 0    
Senior Notes            
Debt Instrument [Line Items]            
Face value           $ 1,100,000,000,000
Senior Notes | Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029            
Debt Instrument [Line Items]            
Face value           $ 500,000,000
Annual fixed interest rate           4.40%
Effective interest rate           3.89%
Senior Notes | Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032            
Debt Instrument [Line Items]            
Face value           $ 600,000,000
Annual fixed interest rate           4.60%
Effective interest rate           3.25%
Senior Notes | Senior Long-Term Notes And Debentures; 3.05%, $600 Due September 2022            
Debt Instrument [Line Items]            
Face value $ 600,000,000       $ 600,000,000  
Annual fixed interest rate 3.05%       3.05%  
Senior Notes | Senior Long-Term Notes And Debentures; 3.50%, $500 Due December 2024            
Debt Instrument [Line Items]            
Face value $ 500,000,000       $ 500,000,000  
Annual fixed interest rate 3.50%       3.50%  
Loss on extinguishment of debt $ 13,000,000          
Redemption price and carrying amount of debt extinguished 5,000,000          
Accelerated amortization of losses on settlement of interest rate contracts and issuance costs associated with debt extinguished $ 8,000,000          
Senior Notes | Senior Long-Term Notes And Debentures; 3.80%, $300 Due November 2021            
Debt Instrument [Line Items]            
Annual fixed interest rate   3.80%        
Repayments of short-term debt   $ 300,000,000        
XML 97 R78.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT - Schedule of Long-Term Debt (Details) - USD ($)
Jun. 30, 2024
Jun. 30, 2023
Debt Instrument [Line Items]    
Total $ 2,481,000,000 $ 2,477,000,000
Less: Current maturities of long-term debt 0 0
Long-term debt $ 2,481,000,000 2,477,000,000
3.10%, $400 due October 2027    
Debt Instrument [Line Items]    
Annual fixed interest rate 3.10%  
Face value $ 400,000,000  
Total $ 399,000,000 398,000,000
3.90%, $500 due May 2028    
Debt Instrument [Line Items]    
Annual fixed interest rate 3.90%  
Face value $ 500,000,000  
Total $ 498,000,000 497,000,000
4.40%, $500 due May 2029    
Debt Instrument [Line Items]    
Annual fixed interest rate 4.40%  
Face value $ 500,000,000  
Total $ 495,000,000 495,000,000
1.80%, $500 due May 2030    
Debt Instrument [Line Items]    
Annual fixed interest rate 1.80%  
Face value $ 500,000,000  
Total $ 495,000,000 494,000,000
4.60%, $600 due May 2032    
Debt Instrument [Line Items]    
Annual fixed interest rate 4.60%  
Face value $ 600,000,000  
Total $ 594,000,000 $ 593,000,000
XML 98 R79.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEBT - Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Line of Credit Facility [Line Items]    
Total $ 1,234 $ 1,235
Revolving credit facility    
Line of Credit Facility [Line Items]    
Total 1,200 1,200
Foreign and other credit lines    
Line of Credit Facility [Line Items]    
Total $ 34 $ 35
XML 99 R80.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER LIABILITIES - Schedule of Other Liabilities (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Other Liabilities Disclosure [Abstract]    
Venture Agreement terminal obligation, net $ 510 $ 495
Employee benefit obligations 263 259
Taxes 25 19
Environmental liabilities 24 24
Other 26 28
Total $ 848 $ 825
XML 100 R81.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER LIABILITIES - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Class of Warrant or Right [Line Items]    
Option to extend agreement (in years) 7 years  
Venture agreement terminal obligation, fair value $ 531 $ 527
Venture agreement terminal obligation, recognized $ 510 $ 495
Glad    
Class of Warrant or Right [Line Items]    
Percentage of ownership by venture partner 20.00% 20.00%
XML 101 R82.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
May 31, 2022
Derivative [Line Items]        
Maximum contract duration (in years) 2 years      
Maximum duration, interest rate contracts (in years) 3 years      
Cash flow hedge gain (loss) to be reclassified within twelve months $ 8,000,000      
Derivative instruments subject to contractually defined counterparty liability position limits 0 $ 1,000,000    
Asset impairment charges 0 445,000,000 $ 0  
Goodwill impairment   306,000,000    
Better Health VMS reporting unit        
Derivative [Line Items]        
Asset impairment charges   433,000,000    
Goodwill impairment   306,000,000    
Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029        
Derivative [Line Items]        
Face value 500,000,000      
Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032        
Derivative [Line Items]        
Face value 600,000,000      
Senior Notes        
Derivative [Line Items]        
Face value       $ 1,100,000,000,000
Senior Notes | Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029        
Derivative [Line Items]        
Face value       500,000,000
Senior Notes | Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032        
Derivative [Line Items]        
Face value       $ 600,000,000
Trademarks        
Derivative [Line Items]        
Trademarks, net   139,000,000    
Interest rate derivative contracts        
Derivative [Line Items]        
Derivative, notional amount, additional contracts     650,000,000  
Settlement of interest rate derivative contracts     114,000,000  
Interest rate derivative contracts | Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029        
Derivative [Line Items]        
Settlement of interest rate derivative contracts     $ 25,000,000  
Amortization period of settlement payment (in years)     7 years  
Interest rate derivative contracts | Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032        
Derivative [Line Items]        
Settlement of interest rate derivative contracts     $ 89,000,000  
Amortization period of settlement payment (in years)     10 years  
Commodity purchase derivative contracts        
Derivative [Line Items]        
Cash margin balances amount $ 3,000,000 0    
Total Commodity Purchase Derivative Contracts        
Derivative [Line Items]        
Maximum duration, commodity contracts (in years) 2 years      
Derivative, notional amount $ 38,000,000 41,000,000    
Jet Fuel Swaps        
Derivative [Line Items]        
Derivative, notional amount 11,000,000 12,000,000    
Soybean Oil Futures        
Derivative [Line Items]        
Derivative, notional amount 27,000,000 29,000,000    
Purchases of Inventory | Foreign exchange derivative contracts        
Derivative [Line Items]        
Derivative, notional amount 29,000,000 $ 51,000,000    
Carrying Amount | Total assets in the fair value hierarchy        
Derivative [Line Items]        
Increase in deferred compensation plan $ 25,000,000      
XML 102 R83.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]      
Gains (losses) recognized in Other comprehensive (loss) income $ (8) $ (6) $ 107
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 7 19 14
Commodity purchase derivative contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Gains (losses) recognized in Other comprehensive (loss) income (8) (6) 17
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings (6) 5 23
Foreign exchange derivative contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Gains (losses) recognized in Other comprehensive (loss) income 0 0 1
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 0 1 0
Interest rate derivative contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Gains (losses) recognized in Other comprehensive (loss) income 0 0 89
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings $ 13 $ 13 $ (9)
XML 103 R84.htm IDEA: XBRL DOCUMENT v3.24.2.u1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Assets    
Cash and cash equivalents, carrying value $ 202 $ 367
Total assets 5,751 5,945
Liabilities    
Notes and loans payable, carrying value 4 50
Current maturities of long-term debt and Long-term debt, carrying value 2,481 2,477
Carrying Amount    
Assets    
Derivative assets 1 2
Total assets 258 381
Liabilities    
Derivative liabilities 2 1
Total liabilities 2,485 2,527
Estimated Fair Value    
Assets    
Derivative assets 1 2
Total assets, estimated fair value 258 381
Liabilities    
Derivative liabilities 2 1
Total liabilities, estimated fair value 2,345 2,377
Total assets in the fair value hierarchy | Carrying Amount    
Assets    
Trust assets for nonqualified deferred compensation plans, carrying value 154 129
Total assets in the fair value hierarchy | Carrying Amount | Commodity purchase derivative contracts    
Assets    
Derivative assets 0 2
Liabilities    
Derivative liabilities 2 0
Total assets in the fair value hierarchy | Carrying Amount | Interest-bearing investments, including money market funds    
Assets    
Cash and cash equivalents, carrying value 95 243
Total assets in the fair value hierarchy | Estimated Fair Value    
Assets    
Trust assets for nonqualified deferred compensation plans, estimated fair value 154 129
Total assets in the fair value hierarchy | Estimated Fair Value | Commodity purchase derivative contracts    
Assets    
Derivative assets 0 2
Liabilities    
Derivative liabilities 2 0
Total assets in the fair value hierarchy | Estimated Fair Value | Interest-bearing investments, including money market funds    
Assets    
Cash and cash equivalents, estimated fair value 95 243
Fair Value, Inputs, Level 2 | Carrying Amount | Long-term debt    
Liabilities    
Current maturities of long-term debt and Long-term debt, carrying value 2,481 2,477
Fair Value, Inputs, Level 2 | Carrying Amount | Commodity purchase derivative contracts    
Assets    
Derivative assets 1 0
Liabilities    
Derivative liabilities 0 1
Fair Value, Inputs, Level 2 | Carrying Amount | Foreign exchange forward contracts    
Assets    
Derivative assets 0 0
Fair Value, Inputs, Level 2 | Carrying Amount | Time deposits    
Assets    
Cash and cash equivalents, carrying value 9 9
Fair Value, Inputs, Level 2 | Estimated Fair Value | Long-term debt    
Liabilities    
Current maturities of long-term debt and Long-term debt, estimated fair value 2,341 2,327
Fair Value, Inputs, Level 2 | Estimated Fair Value | Commodity purchase derivative contracts    
Assets    
Derivative assets 1 0
Liabilities    
Derivative liabilities 0 1
Fair Value, Inputs, Level 2 | Estimated Fair Value | Foreign exchange forward contracts    
Assets    
Derivative assets 0 0
Fair Value, Inputs, Level 2 | Estimated Fair Value | Time deposits    
Assets    
Cash and cash equivalents, estimated fair value 9 9
Notes and loans payable | Fair Value, Inputs, Level 2 | Carrying Amount    
Liabilities    
Notes and loans payable, carrying value 4 50
Notes and loans payable | Fair Value, Inputs, Level 2 | Estimated Fair Value    
Liabilities    
Notes and loans payable, estimated fair value $ 4 $ 50
XML 104 R85.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 28 $ 28
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] Accounts payable and accrued liabilities, Other Liabilities, Noncurrent Accounts payable and accrued liabilities, Other Liabilities, Noncurrent
Letter of credit $ 18 $ 14
Letter of credit, amount outstanding 0 0
Alameda County, California Matter    
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 12 12
Remediation period (in years) 30 years  
Maximum undiscounted costs $ 28  
Dickinson County, Michigan Matter    
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 10 $ 10
Remediation period (in years) 30 years  
Percentage of liability for aggregate remediation and associated costs, other than legal fees 24.30%  
XML 105 R86.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Schedule of Purchase Obligations (Details)
$ in Millions
Jun. 30, 2024
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2025 $ 181
2026 128
2027 81
2028 43
2029 27
Thereafter 45
Total $ 505
XML 106 R87.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Narrative (Details)
$ in Millions
12 Months Ended
Dec. 14, 2023
USD ($)
option
May 25, 2022
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]          
Operating leases, remaining lease terms     33 years    
Finance leases, remaining lease terms     33 years    
Minimum lease payments signed but not yet commenced     $ 505    
Proceeds from sale of productive assets $ 19 $ 16      
Sale-leaseback transaction, carrying value 3 2      
Gain on sale-leaseback transaction $ 16 $ 14 16 $ 0 $ 14
Lease term 8 years 10 years      
Number of renewal options | option 2        
Lease renewal term 5 years        
Option to terminate, period   7 years      
Operating Lease, Lease Not yet Commenced          
Unrecorded Unconditional Purchase Obligation [Line Items]          
Minimum lease payments signed but not yet commenced     2    
Financing Lease, Lease Not yet Commenced          
Unrecorded Unconditional Purchase Obligation [Line Items]          
Minimum lease payments signed but not yet commenced     $ 3    
XML 107 R88.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Schedule of Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Operating leases    
Right-of-use assets $ 360 $ 346
Current lease liabilities 84 87
Non-current lease liabilities 334 310
Total operating lease liabilities $ 418 $ 397
Finance leases    
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets Other assets
Right-of-use assets $ 33 $ 29
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Current lease liabilities $ 13 $ 9
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent Other Liabilities, Noncurrent
Non-current lease liabilities $ 21 $ 21
Total finance lease liabilities $ 34 $ 30
XML 108 R89.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Schedule of Components of Lease Cost (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Leases [Abstract]    
Operating lease cost $ 97 $ 89
Finance lease cost:    
Amortization of right-of-use assets 11 9
Interest on lease liabilities 1 1
Total finance lease cost 12 10
Variable lease cost 94 87
Short term lease cost $ 3 $ 4
XML 109 R90.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Schedule of Supplemental Cash Flow Information and Noncash Activity Related to Leases (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases, net $ 97 $ 88
Operating cash flows from finance leases 1 1
Financing cash flows from finance leases 11 8
Right-of-use assets obtained in exchange for lease obligations:    
Operating leases 113 84
Finance leases $ 17 $ 21
XML 110 R91.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)
Jun. 30, 2024
Weighted-average remaining lease term:  
Operating leases 5 years
Finance leases 3 years
Weighted-average discount rate:  
Operating leases 3.60%
Finance leases 5.10%
XML 111 R92.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LEASES - Schedule of Maturities of Operating Lease and Finance Lease Liabilities (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Operating leases    
2025 $ 97  
2026 94  
2027 84  
2028 69  
2029 56  
Thereafter 61  
Total lease payments 461  
Less: Imputed interest 43  
Total lease liabilities 418 $ 397
Finance leases    
2025 14  
2026 12  
2027 7  
2028 2  
2029 1  
Thereafter 0  
Total lease payments 36  
Less: Imputed interest 2  
Total lease liabilities $ 34 $ 30
XML 112 R93.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY - Schedule of Dividends Per Share Paid to Stockholders (Details) - $ / shares
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Stockholders' Equity Note [Abstract]      
Dividends per share paid (in dollars per share) $ 4.80 $ 4.72 $ 4.64
XML 113 R94.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY - Narrative (Details) - $ / shares
12 Months Ended
Jul. 30, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Dividends Payable [Line Items]        
Dividends per share declared (in dollars per share)   $ 4.80 $ 4.72 $ 3.48
Subsequent Event        
Dividends Payable [Line Items]        
Dividends per share declared (in dollars per share) $ 1.22      
XML 114 R95.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance $ 220    
Total other comprehensive (loss) income, net of tax 338 $ (14) $ 67
Ending balance 328 220  
Accumulated other comprehensive net (loss) income      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (493) (479) (546)
Other comprehensive (loss) income before reclassifications (7) (4) 63
Amounts reclassified from Accumulated other comprehensive net (loss) income 390 (13) 1
Income tax benefit (expense) (45) 3 3
Total other comprehensive (loss) income, net of tax 338 (14) 67
Ending balance (155) (493) (479)
Foreign currency translation adjustments      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (445) (448) (403)
Other comprehensive (loss) income before reclassifications (16) 1 (45)
Amounts reclassified from Accumulated other comprehensive net (loss) income 223 0 0
Income tax benefit (expense) (1) 2 0
Total other comprehensive (loss) income, net of tax 206 3 (45)
Ending balance (239) (445) (448)
Net unrealized gains (losses) on derivatives      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 99 121 21
Other comprehensive (loss) income before reclassifications (8) (6) 107
Amounts reclassified from Accumulated other comprehensive net (loss) income (7) (19) (14)
Income tax benefit (expense) 1 3 7
Total other comprehensive (loss) income, net of tax (14) (22) 100
Ending balance 85 99 121
Pension and postretirement benefit adjustments      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (147) (152) (164)
Other comprehensive (loss) income before reclassifications 17 1 1
Amounts reclassified from Accumulated other comprehensive net (loss) income 174 6 15
Income tax benefit (expense) (45) (2) (4)
Total other comprehensive (loss) income, net of tax 146 5 12
Ending balance $ (1) $ (147) $ (152)
XML 115 R96.htm IDEA: XBRL DOCUMENT v3.24.2.u1
NET EARNINGS PER SHARE (EPS) (Details) - shares
shares in Thousands
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]      
Basic (in shares) 124,174 123,589 123,113
Dilutive effect of stock options and other (in shares) 630 592 793
Diluted (in shares) 124,804 124,181 123,906
Antidilutive stock options and other (in shares) 2,704 1,444 2,448
XML 116 R97.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS - Narrative (Details)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Nov. 30, 2021
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of additional shares authorized (in shares) 5,000,000      
Number of shares authorized (in shares)   5,000,000    
Number of shares available for grant (in shares)   3,000,000    
Issuance of common stock for employee stock plans and other | $   $ 23 $ 52 $ 35
Stock option awards granted (in shares)   0    
Weighted average fair value per share (in dollars per share) | $ / shares     $ 26.95 $ 22.26
Total intrinsic value of options exercised | $   $ 12 $ 27 $ 18
Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)   4 years    
Expiration period (in years)   10 years    
Compensation cost not yet recognized | $   $ 5    
Compensation costs not yet recognized, period for recognition (in years)   2 years    
Restricted Stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Compensation cost not yet recognized | $   $ 41    
Compensation costs not yet recognized, period for recognition (in years)   2 years    
Fair value of shares vested | $   $ 28 $ 22 $ 20
Granted (in dollars per share) | $ / shares   $ 138.51 $ 143.20 $ 157.50
Nonvested awards outstanding (in shares)   721,000 544,000  
Weighted-average grant date fair value per share of nonvested awards (in dollars per share) | $ / shares   $ 145 $ 155  
Vested (in shares)   173,000    
Restricted Stock | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)   3 years    
Restricted Stock | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)   4 years    
Performance Shares        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)   3 years    
Compensation cost not yet recognized | $   $ 15    
Compensation costs not yet recognized, period for recognition (in years)   1 year    
Fair value of shares vested | $   $ 12 $ 12 $ 11
Granted (in dollars per share) | $ / shares   $ 140.39 $ 141.90 $ 162.46
Nonvested awards outstanding (in shares)   400,000 306,000  
Weighted-average grant date fair value per share of nonvested awards (in dollars per share) | $ / shares   $ 145.06 $ 162.77  
Vested (in shares)   58,000    
Deferred Stock Units for Nonemployee Directors        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock conversion ratio   1    
Deferred stock units for nonemployee directors granted (in shares)   19,000    
Deferred stock units for nonemployee directors reinvested dividends (in shares)   4,000    
Deferred stock units for nonemployee directors distributed (in shares)   24,000    
Deferred stock units for nonemployee directors granted weighted average fair value on grant date (in dollars per share) | $ / shares   $ 141.85    
Deferred stock units for nonemployee directors reinvested weighted average fair value on grant date (in dollars per share) | $ / shares   145.15    
Deferred stock units for nonemployee directors distributed weighted average fair value on grant date (in dollars per share) | $ / shares   $ 89.91    
Deferred stock units for nonemployee directors outstanding (in shares)   127,000    
Deferred stock units for nonemployee directors outstanding weighted average fair value on grant date (in dollars per share) | $ / shares   $ 140.22    
XML 117 R98.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS - Schedule of Compensation Cost and Related Income Tax Benefit (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total compensation costs $ 74 $ 73 $ 52
Related income tax benefit 18 17 12
Cost of products sold      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total compensation costs 7 7 6
Selling and administrative expenses      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total compensation costs 63 61 42
Research and development costs      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total compensation costs $ 4 $ 5 $ 4
XML 118 R99.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS - Schedule of Fair Value of each Stock Option Award Granted (Details) - Stock Option
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected life 5 years 3 months 18 days 5 years 4 months 24 days
Weighted-average expected life 5 years 3 months 18 days 5 years 4 months 24 days
Expected volatility 24.20%  
Expected volatility, minimum   21.70%
Expected volatility, maximum   25.00%
Weighted-average volatility 24.20% 21.80%
Risk-free interest rate 3.70%  
Risk-free interest rate, minimum   0.90%
Risk-free interest rate, maximum   2.10%
Weighted-average risk-free interest rate 3.70% 0.90%
Dividend yield 3.40%  
Weighted-average dividend yield 3.40% 2.90%
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Dividend yield   2.90%
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Dividend yield   3.70%
XML 119 R100.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Number of Shares    
Outstanding, beginning balance (in shares) 4,075,000  
Granted (in shares) 0  
Exercised (in shares) (234,000)  
Canceled (in shares) (51,000)  
Outstanding, ending balance (in shares) 3,790,000 4,075,000
Options vested (in shares) 3,052,000  
Weighted- Average Exercise Price per Share    
Outstanding, beginning balance (in dollars per share) $ 147  
Exercised (in dollars per share) 104  
Canceled (in dollars per share) 170  
Outstanding, ending balance (in dollars per share) 150 $ 147
Options vested (in dollars per share) $ 148  
Average Remaining Contractual Life    
Average remaining contractual life, options outstanding (in years) 4 years 5 years
Average remaining contractual life, options vested (in years) 4 years  
Aggregate Intrinsic Value    
Options outstanding $ 16 $ 69
Options vested $ 16  
XML 120 R101.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS - Schedule of Restricted Stock Awards (Details) - Restricted Stock - $ / shares
shares in Thousands
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Number of Shares      
Outstanding, beginning balance (in shares) 544    
Granted (in shares) 405    
Vested (in shares) (173)    
Forfeited (in shares) (55)    
Outstanding, ending balance (in shares) 721 544  
Weighted-Average Grant Date Fair Value per Share      
Outstanding, beginning balance (in dollars per share) $ 155    
Granted (in dollars per share) 138.51 $ 143.20 $ 157.50
Vested (in dollars per share) 162    
Forfeited (in dollars per share) 142    
Outstanding, ending balance (in dollars per share) $ 145 $ 155  
XML 121 R102.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION PLANS - Schedule of Performance Share Awards (Details) - Performance Shares - $ / shares
shares in Thousands
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Number of Shares      
Outstanding, beginning balance (in shares) 368    
Granted (in shares) 176    
Distributed (in shares) (39)    
Forfeited (in shares) (22)    
Outstanding, ending balance (in shares) 483 368  
Vested and deferred (in shares) 83    
Weighted-Average Grant Date Fair Value per Share      
Outstanding, beginning balance (in dollars per share) $ 158    
Granted (in dollars per share) 140.39 $ 141.90 $ 162.46
Distributed (in dollars per share) 189    
Forfeited (in dollars per share) 177    
Outstanding, ending balance (in dollars per share) 148 $ 158  
Vested and deferred (in dollars per share) $ 164    
XML 122 R103.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER (INCOME) EXPENSE, NET (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 14, 2023
May 25, 2022
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Other Income and Expenses [Abstract]          
Amortization of trademarks and other intangible assets     $ 29 $ 30 $ 31
Trust investment (gains) losses, net     (20) (14) 21
Net periodic benefit cost     14 16 16
Foreign exchange transaction (gains) losses, net     25 13 3
Income from equity investees     (5) (4) (6)
Interest income     (23) (16) (5)
Restructuring costs     16 52 0
Gain on sale-leaseback transaction $ (16) $ (14) (16) 0 (14)
Other     4 3 (9)
Total     $ 24 $ 80 $ 37
XML 123 R104.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Schedule of Provision for Income Taxes and Components of Earnings Before Income Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Current      
Federal $ 132 $ 153 $ 71
State 18 33 17
Foreign 56 40 43
Total current 206 226 131
Deferred      
Federal (99) (120) 6
State (5) (28) (2)
Foreign 4 (1) 1
Total deferred (100) (149) 5
Total 106 77 136
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]      
United States 311 154 483
Foreign 87 84 124
Earnings (losses) before income taxes $ 398 $ 238 $ 607
XML 124 R105.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Narrative (Details) - USD ($)
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]      
Income taxes paid, net of refunds $ 347,000,000 $ 73,000,000 $ 100,000,000
Undistributed earnings of foreign subsidiaries 0    
Remaining valuations related to other foreign deferred tax assets 2,000,000 1,000,000 1,000,000
Accrued interest and penalties related to uncertain tax positions 3,000,000 2,000,000  
Interest and penalties related to uncertain tax positions included in income tax expense, expense (net benefit) 1,000,000 0 0
Unrecognized tax benefits that would impact effective tax rate $ 15,000,000 $ 14,000,000 $ 14,000,000
XML 125 R106.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Schedule of Reconciliation of Effective Tax Rate (Details)
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]      
Statutory federal tax rate 21.00% 21.00% 21.00%
State taxes (net of federal tax benefits) 2.50% 1.60% 1.90%
Foreign tax rate differential 7.70% 8.60% 3.10%
Federal excess tax benefits (0.30%) (1.80%) (0.90%)
Net U.S. tax on foreign income (5.20%) (2.30%) (1.70%)
Loss on divestiture 10.50% 0.00% 0.00%
International legal entity reorganization (6.10%) 0.00% 0.00%
VMS goodwill impairment 0.00% 8.60% 0.00%
Federal research and development credits (1.20%) (2.70%) (0.80%)
Other differences (2.40%) (0.60%) (0.20%)
Effective tax rate 26.50% 32.40% 22.40%
XML 126 R107.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Liabilities) (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Deferred tax assets        
Compensation and benefit programs $ 109 $ 123    
Loss and tax credit carryforwards 153 94    
Operating and finance lease liabilities 111 104    
Accruals and reserves 33 46    
Capitalized research and development 43 34    
Inventory costs 29 32    
Other 33 34    
Subtotal 511 467    
Valuation allowance (115) (59) $ (52) $ (42)
Total deferred tax assets 396 408    
Deferred tax liabilities        
Property, plant and equipment and intangible assets (84) (157)    
Lease right-of-use assets (100) (96)    
Other (36) (36)    
Total deferred tax liabilities (220) (289)    
Net deferred tax assets (liabilities) 176 119    
Net deferred tax assets 198 147    
Net deferred tax liabilities $ (22) $ (28)    
XML 127 R108.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Summary of Changes in Valuation Allowance (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Deferred Tax Assets, Valuation Allowance [Roll Forward]      
Valuation allowance at beginning of year $ (59) $ (52) $ (42)
Net increase/(decrease) for U.S. capital loss carryfowards (46) 0 0
Net decrease/(increase) for other foreign deferred tax assets (2) (1) (1)
Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits (8) (6) (9)
Valuation allowance at end of year $ (115) $ (59) $ (52)
XML 128 R109.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Schedule of Carryforwards with Related Valuation Allowances (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Net operating losses    
Carryforwards $ 41 $ 40
Valuation Allowances (29) (26)
Net Carryforwards 12 14
Carryforwards 153 94
Valuation Allowances (108) (54)
Net Carryforwards 45 40
Subject to Expiration | U.S. jurisdictions    
Net operating losses    
Carryforwards 6 4
Valuation Allowances (5) (4)
Net Carryforwards 1 0
Subject to Expiration | Foreign jurisdictions    
Net operating losses    
Carryforwards 18 21
Valuation Allowances (16) (16)
Net Carryforwards 2 5
Not Subject to Expiration | U.S. jurisdictions    
Net operating losses    
Carryforwards 9 6
Valuation Allowances (8) (5)
Net Carryforwards 1 1
Not Subject to Expiration | Foreign jurisdictions    
Net operating losses    
Carryforwards 8 9
Valuation Allowances 0 (1)
Net Carryforwards 8 8
Capital losses | U.S. jurisdictions    
Tax Credit Carryforwards    
Carryforwards 46 0
Valuation Allowances (46) 0
Net Carryforwards 0 0
Income tax credits    
Tax Credit Carryforwards    
Carryforwards 66 54
Valuation Allowances (33) (28)
Net Carryforwards 33 26
Income tax credits | Subject to Expiration | U.S. jurisdictions    
Tax Credit Carryforwards    
Carryforwards 30 23
Valuation Allowances 0 0
Net Carryforwards 30 23
Income tax credits | Subject to Expiration | Foreign jurisdictions    
Tax Credit Carryforwards    
Carryforwards 30  
Valuation Allowances (30)  
Net Carryforwards 0  
Income tax credits | Not Subject to Expiration | U.S. jurisdictions    
Tax Credit Carryforwards    
Carryforwards 2 2
Valuation Allowances 0 0
Net Carryforwards 2 2
Income tax credits | Not Subject to Expiration | Foreign jurisdictions    
Tax Credit Carryforwards    
Carryforwards 4 29
Valuation Allowances (3) (28)
Net Carryforwards $ 1 $ 1
XML 129 R110.htm IDEA: XBRL DOCUMENT v3.24.2.u1
INCOME TAXES - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefits at beginning of year $ 17 $ 17 $ 21
Gross increases - tax positions in prior periods 0 1 0
Gross decreases - tax positions in prior periods (4) (3) (7)
Gross increases - current period tax positions 9 2 4
Gross decreases - current period tax positions 0 0 0
Lapse of applicable statute of limitations 0 0 (1)
Settlements 0 0 0
Unrecognized tax benefits at end of year $ 22 $ 17 $ 17
XML 130 R111.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]      
Curtailment gain, before tax $ (171) $ 0 $ 0
United States      
Defined Benefit Plan Disclosure [Line Items]      
Aggregate cost of the defined contribution plans 19    
Domestic Defined Contribution Plan      
Defined Benefit Plan Disclosure [Line Items]      
Aggregate cost of the defined contribution plans 63 64 58
International Defined Contribution Plan      
Defined Benefit Plan Disclosure [Line Items]      
Aggregate cost of the defined contribution plans 5 6 6
Retirement Income      
Defined Benefit Plan Disclosure [Line Items]      
Employer contributions 15 15  
Accumulated benefit obligation 105 474 512
Retirement Income | United States      
Defined Benefit Plan Disclosure [Line Items]      
Curtailment gain, before tax 171    
Curtailment gain, after tax 130    
Employer contributions $ 14 $ 14 $ 15
XML 131 R112.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income and Retirement Health Care Plans and Amounts Recognized in Balance Sheets (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Retirement Income      
Change in benefit obligations:      
Benefit obligation as of beginning of year $ 476 $ 513  
Service cost 1 1 $ 1
Interest cost 12 18 15
Actuarial loss (gain) (26) (11)  
Plan amendments 0 0  
Plan settlement (312) 0  
Benefits paid (26) (45)  
Translation and other adjustments (2) 0  
Benefit obligation as of end of year 123 476 513
Change in plan assets:      
Fair value of assets as of beginning of year 381 412  
Actual return on plan assets (13) 0  
Employer contributions 15 15  
Plan settlement (312) 0  
Benefits paid (26) (45)  
Transfer to domestic defined contribution plan (19) 0  
Translation and other adjustments (1) (1)  
Fair value of plan assets as of end of year 25 381 412
Accrued benefit cost, net funded status (98) (95)  
Amount recognized in the balance sheets consists of:      
Pension benefit assets 7 24  
Current accrued benefit liability (12) (13)  
Non-current accrued benefit liability (93) (106)  
Accrued benefit cost, net (98) (95)  
Retirement Health Care      
Change in benefit obligations:      
Benefit obligation as of beginning of year 26 28  
Service cost 0 0 0
Interest cost 1 1 1
Actuarial loss (gain) (2) (1)  
Plan amendments (4) 0  
Plan settlement 0 0  
Benefits paid (2) (2)  
Translation and other adjustments 0 0  
Benefit obligation as of end of year 19 26 28
Change in plan assets:      
Fair value of assets as of beginning of year 0 0  
Actual return on plan assets 0 0  
Employer contributions 2 2  
Plan settlement 0 0  
Benefits paid (2) (2)  
Transfer to domestic defined contribution plan 0 0  
Translation and other adjustments 0 0  
Fair value of plan assets as of end of year 0 0 $ 0
Accrued benefit cost, net funded status (19) (26)  
Amount recognized in the balance sheets consists of:      
Pension benefit assets 0 0  
Current accrued benefit liability (2) (2)  
Non-current accrued benefit liability (17) (24)  
Accrued benefit cost, net $ (19) $ (26)  
XML 132 R113.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets (Details) - Retirement Income - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
ABO Exceeds the Fair Value of Plan Assets    
Projected benefit obligation $ 105 $ 119
Accumulated benefit obligation 104 118
Fair value of plan assets 0 0
PBO Exceeds the Fair Value of Plan Assets    
Projected benefit obligation 108 121
Accumulated benefit obligation 105 119
Fair value of plan assets $ 2 $ 2
XML 133 R114.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]      
Total $ 14 $ 16 $ 16
Retirement Income      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 1 1 1
Interest cost 12 18 15
Expected return on plan assets (2) (10) (15)
Amortization of unrecognized items      3 8 9
Curtailment gain recognized (6) 0 0
Settlement loss recognized 179 0 7
Total 187 17 17
Retirement Health Care      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 0 0 0
Interest cost 1 1 1
Expected return on plan assets 0 0 0
Amortization of unrecognized items      (2) (2) (1)
Curtailment gain recognized 0 0 0
Settlement loss recognized 0 0 0
Total $ (1) $ (1) $ 0
XML 134 R115.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Items Not Yet Recognized as a Component of Postretirement Expense (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Retirement Income    
Defined Benefit Plan Disclosure [Line Items]    
Net actuarial loss (gain) $ 20 $ 213
Prior service benefit 0  
Net deferred income tax (assets) liabilities (5)  
Accumulated other comprehensive loss (income) 15  
Retirement Health Care    
Defined Benefit Plan Disclosure [Line Items]    
Net actuarial loss (gain) (14) $ (14)
Prior service benefit (4)  
Net deferred income tax (assets) liabilities 4  
Accumulated other comprehensive loss (income) $ (14)  
XML 135 R116.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income (Details)
$ in Millions
12 Months Ended
Jun. 30, 2024
USD ($)
Retirement Income  
AOCI Attributable to Parent, Net of Tax [Roll Forward]  
Net actuarial loss (gain) as of beginning of year $ 213
Amortization, curtailment and settlement during the year (182)
Loss (gain) during the year (11)
Net actuarial loss (gain) as of end of year 20
Retirement Health Care  
AOCI Attributable to Parent, Net of Tax [Roll Forward]  
Net actuarial loss (gain) as of beginning of year (14)
Amortization, curtailment and settlement during the year 2
Loss (gain) during the year (2)
Net actuarial loss (gain) as of end of year $ (14)
XML 136 R117.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs (Details)
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Retirement Income      
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]      
Discount rate 5.52% 4.37%  
Rate of compensation increase 3.23% 3.62%  
Interest crediting rate 5.40% 2.67%  
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]      
Discount rate 4.63% 3.72% 2.56%
Rate of compensation increase 3.20% 3.09% 3.02%
Expected return on plan assets 3.39% 2.67% 3.00%
Interest crediting rate 2.69% 2.69% 2.57%
Retirement Health Care      
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]      
Discount rate 5.38% 5.10%  
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]      
Discount rate 5.10% 4.65% 2.61%
XML 137 R118.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Expected Benefit Payments (Details)
$ in Millions
Jun. 30, 2024
USD ($)
Retirement Income  
Defined Benefit Plan Disclosure [Line Items]  
2025 $ 15
2026 14
2027 13
2028 13
2029 12
Fiscal years 2030 through 2034 48
Retirement Health Care  
Defined Benefit Plan Disclosure [Line Items]  
2025 2
2026 2
2027 2
2028 2
2029 2
Fiscal years 2030 through 2034 $ 7
XML 138 R119.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Target Allocation and Weighted Average Allocation of Plan Assets (Details) - Retirement Income
Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]  
% Target Allocation 100.00%
% of Plan Asset 100.00%
Fixed income  
Defined Benefit Plan Disclosure [Line Items]  
% Target Allocation 80.00%
% of Plan Asset 79.00%
Cash equivalents  
Defined Benefit Plan Disclosure [Line Items]  
% Target Allocation 20.00%
% of Plan Asset 21.00%
XML 139 R120.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans Assets Carried at Fair Value (Details) - Retirement Income - USD ($)
$ in Millions
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value $ 25 $ 381 $ 412
Total assets in the fair value hierarchy      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 0 74  
Total common collect trust measured at net asset value      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 25 307  
Cash equivalents — Level 1 | Total assets in the fair value hierarchy      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 0 74  
Bond funds | Total common collect trust measured at net asset value      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 6 289  
International equity funds | Total common collect trust measured at net asset value      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 16 15  
Domestic equity funds | Total common collect trust measured at net asset value      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 0 0  
Short-term investment fund | Total common collect trust measured at net asset value      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 0 1  
Real estate fund | Total common collect trust measured at net asset value      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value 2 2  
Other | Total common collect trust measured at net asset value      
Defined Benefit Plan Disclosure [Line Items]      
Total assets at fair value $ 1 $ 0  
XML 140 R121.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT REPORTING - Narrative (Details) - segment
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Concentration Risk [Line Items]      
Number of reportable segments 4    
Net Sales | Walmart Stores, Inc. | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration percentage 25.00% 26.00% 25.00%
XML 141 R122.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT REPORTING - Schedule of Reportable Segment Information and Reconciliation of Segment Information (Details) - USD ($)
$ in Millions
12 Months Ended 24 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Net Sales $ 7,093 $ 7,389 $ 7,107  
Interest income 23 16 5  
Interest expense (90) (90) (106)  
Loss on divestiture (240) 0 0  
Pension settlement charge (171) 0 0  
Cyberattack costs, net of insurance recoveries (29) 0 0  
VMS impairment 0 (445) 0  
Streamlined operating model (32) (60) 0  
Digital capabilities and productivity enhancements investment (108) (100) (61)  
Earnings (losses) before income taxes 398 238 607  
(Income) Loss from equity investees included in Other (income) expense, net (5) (4) (6)  
Total assets 5,751 5,945   $ 5,751
Capital expenditures 212 228 251  
Depreciation and amortization 235 236 224  
Stock-based compensation $ 74 $ 73 52  
Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 100.00%      
Restructuring and Related Costs Benchmark | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 100.00% 100.00%   100.00%
Operating Segments        
Segment Reporting Information [Line Items]        
Net Sales $ 6,872 $ 7,149 6,844  
Segment adjusted earnings (losses) before interest and income taxes 1,354 1,275 992  
Operating Segments | Health and Wellness        
Segment Reporting Information [Line Items]        
Net Sales 2,485 2,532 2,427  
Segment adjusted earnings (losses) before interest and income taxes 719 594 381  
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0  
Total assets 1,124 1,184   $ 1,124
Capital expenditures 47 51 61  
Depreciation and amortization 58 59 57  
Stock-based compensation $ 14 $ 14 14  
Operating Segments | Health and Wellness | Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 30.00%      
Operating Segments | Health and Wellness | Restructuring and Related Costs Benchmark | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 3.00% 6.00%   5.00%
Operating Segments | Household        
Segment Reporting Information [Line Items]        
Net Sales $ 1,950 $ 2,098 1,984  
Segment adjusted earnings (losses) before interest and income taxes 260 308 234  
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0  
Total assets 1,088 1,082   $ 1,088
Capital expenditures 84 97 112  
Depreciation and amortization 77 78 67  
Stock-based compensation $ 11 $ 10 8  
Operating Segments | Household | Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 24.00%      
Operating Segments | Household | Restructuring and Related Costs Benchmark | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 2.00% 1.00%   2.00%
Operating Segments | Lifestyle        
Segment Reporting Information [Line Items]        
Net Sales $ 1,275 $ 1,338 1,253  
Segment adjusted earnings (losses) before interest and income taxes 253 284 280  
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0  
Total assets 1,110 1,091   $ 1,110
Capital expenditures 36 29 24  
Depreciation and amortization 24 25 24  
Stock-based compensation $ 8 $ 7 6  
Operating Segments | Lifestyle | Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 23.00%      
Operating Segments | Lifestyle | Restructuring and Related Costs Benchmark | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 0.00% 4.00%   2.00%
Operating Segments | International        
Segment Reporting Information [Line Items]        
Net Sales $ 1,162 $ 1,181 1,180  
Segment adjusted earnings (losses) before interest and income taxes 122 89 97  
(Income) Loss from equity investees included in Other (income) expense, net (5) (4) (6)  
Total assets 1,327 1,410   $ 1,327
Capital expenditures 21 24 27  
Depreciation and amortization 45 46 47  
Stock-based compensation $ 6 $ 4 3  
Operating Segments | International | Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 8.00%      
Operating Segments | International | Restructuring and Related Costs Benchmark | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 4.00% 16.00%   11.00%
Corporate and Other        
Segment Reporting Information [Line Items]        
Net Sales $ 221 $ 240 263  
Segment adjusted earnings (losses) before interest and income taxes (309) (358) (223)  
(Income) Loss from equity investees included in Other (income) expense, net 0 0 0  
Total assets 1,102 1,178   $ 1,102
Capital expenditures 24 27 27  
Depreciation and amortization 31 28 29  
Stock-based compensation $ 35 $ 38 21  
Corporate and Other | Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 15.00%      
Corporate and Other | Restructuring and Related Costs Benchmark | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 91.00% 73.00%   80.00%
Operating Segments and Corporate and Other        
Segment Reporting Information [Line Items]        
Segment adjusted earnings (losses) before interest and income taxes $ 1,045 $ 917 $ 769  
XML 142 R123.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT REPORTING - Schedule of Concentration Percentage (Details) - Net Sales - Product Concentration Risk
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Concentration Risk [Line Items]      
Concentration percentage 100.00% 100.00% 100.00%
Corporate and Other      
Concentration Risk [Line Items]      
Concentration percentage 3.00% 3.00% 4.00%
Cleaning products      
Concentration Risk [Line Items]      
Concentration percentage 43.00% 42.00% 42.00%
Bags and wraps      
Concentration Risk [Line Items]      
Concentration percentage 15.00% 16.00% 16.00%
Food products      
Concentration Risk [Line Items]      
Concentration percentage 11.00% 11.00% 11.00%
Cat litter products      
Concentration Risk [Line Items]      
Concentration percentage 10.00% 10.00% 9.00%
Health and Wellness | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 35.00% 35.00% 33.00%
Health and Wellness | Cleaning products | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 30.00% 30.00% 29.00%
Health and Wellness | Professional Products | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 5.00% 5.00% 4.00%
Household | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 28.00% 28.00% 28.00%
Household | Bags and wraps | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 11.00% 12.00% 12.00%
Household | Cat litter products | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 9.00% 9.00% 8.00%
Household | Grilling | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 8.00% 7.00% 8.00%
Lifestyle | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 18.00% 18.00% 18.00%
Lifestyle | Food products | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 11.00% 10.00% 10.00%
Lifestyle | Water Filtration | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 4.00% 4.00% 4.00%
Lifestyle | Natural Personal Care | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 3.00% 4.00% 4.00%
International | Operating Segments      
Concentration Risk [Line Items]      
Concentration percentage 16.00% 16.00% 17.00%
XML 143 R124.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT REPORTING - Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net sales $ 7,093 $ 7,389 $ 7,107
Property, plant and equipment, net 1,315 1,345  
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net sales 5,956 6,237 5,951
Property, plant and equipment, net 1,188 1,192  
Foreign      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net sales 1,137 1,152 $ 1,156
Property, plant and equipment, net $ 127 $ 153  
XML 144 R125.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED PARTY TRANSACTIONS (Details) - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Related Party Transactions [Abstract]      
Percentage ownership of equity investments, maximum 50.00%    
Equity method investments $ 45 $ 43  
Payments to related parties $ 77 $ 87 $ 117
EXCEL 145 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�/KC5LWFD!Z.S MTTK.U)V*OU6?/>Y&G91"E\H&[:SP:OIV<'[PYMT1K><%OVNU#+UK09Y,G/M" M-U?%V\$^&:2,RB-)D/BW4!?*&!($,[XV,@>=2MK8OVZE?V#?XNN4OJO'GF.3ES@3^*Y9I[?%X(/(Z1%1GEVZMU2>%H-:73!KO)N&*4N>ORJL2^> M?;K_Y?)67'RZN;^Z^7AY9>)C[^=WY[?W%]>WHGSF_?X]?KZZO[Z\N;^ M[G04H92VCO)&P;ND8/R$@H.QN'8VSH.XM(4J-@6,8&UG\K@U^=WX68F_UG8H M#OQURXT+M ME?CW^21$CSKZSZXP)"5'NY50;[T)E+7_\S,N''4N M'#TG_7^1Q6<5[#;_.[5N!?9^KO"DK*1="1V$M@MG%JK AQ">VR)#DI(Z-[X1,@@W%1,7)P+E)OJRHT+!!>' G@H-"HFS"5* XOE M;.;53$8EIG6D!38DZ-Q(^2FR'$ZM,7"""V&JU'(HK*V[<0I43R!GO'[S*2$1R M[6NM0B35"%@-DYU/G<=6T1)8JD.4-F<#MWVQ 9 KT:Y9WW;,E0GZF"R3XH.2 M03=QNXMUL<)*J%<+:6HVOJT25R7W*/REM')&%3#S\*=88J%OC6;/R<94?) M%W3)X>Y29E@T!WLH/CB#B4?BIK7'[UX4@)(Z!-;7N=H+ 0**0+W>]*HK!&D% MC(*(IF#6A4&VIPRW-A54 A-%QM;>XQ:)@"LHF91;/V$BEZ@..%WJHIMQL<'&96LI"9%OKA%,(6+0I-\)#*P-(KIDP%: M!^?I5-\Y;<3OLD(0KFST-=.%6X7[2"9NQIBM_%7:&@2$>R9[E(00:I9KP2@H M\F26)PZ!3/9M(,/IGB-LHZ@\=0NBY)86FZ :E5K4.?7-;8(" ^T+RM$LH4(C MPF*OJ@A&=A:NZ\J6-[2P@NS"D#QRNP<$(>NG(^-'*'.*2ZK;PM&E1J;^F&NC M-IR9**,53&-(8Q")FP7^&,Q^6L-PJM.N*K['F-:)%T(R9,J VI@8E?*"NF$3 M-M03?FAZP ,;NZR+8@7^.M4H*_T7]TJQG5>TC2G:O1N^PV(885C@AJ)VJ%!_ M2< >1E?;.J@,$>47U:_G9GD+[4EA Q>]SMQHXA3*IM76$P0!KRLR3%8HJP?> M:58\F5(GVY[ [::&:4^XR187>CI57+'=T$RP5ON^-PV*G2.XU)II;)&E[W7^ M15NDJ4/]:[B+DK;9!EC"A^\:,!3E%+FXR0S^=-I&DQHNH$B]-+@C^*,RV9Z@ M^W]G@A)5@$99DD@Z<]#A(>QT0")7J602U"9[V(CQT?#P'ZT9ZZ1NE!84]L9Q M*@/:&TE_$^RJ]J&628/D-2^);7#'==H9)R7M\X4 B,05,"ZI[CVC.-;<6"2L MDJM-[I+BU7*I'LB0K6YB&L#:0N%2$G"T&W7K?JB1P]XFX,W?FNMTM"0Z&)X9 M@HA5RJ! M75>U3=VG,9<+(IXD MW1-%Y?@&[B"$ L'4["LE%]MK'K[./^(L&1TC=L$5A<(977";$T5#H)C]XT&J M-:(E-IT5EG-G !T?P<\Q"!2J]8KXIOT3,62?>=S!$@(2ANI>.K@B.Q:V/:D: M]T5<54 &0PZITFJ"B41 ?E+#V3![_'S*A*J9+W)-F9;<,/SN((U,"GJ3EU[8 M.>-4\UM5&>5#KW"5ZK^,>)'0GU.#M)3-S%G0J06!+VJ_IA%-(BK'ZBF!':1S MF])KC=XXICU$* M9R3'AX?V()'L3<,-@9_(;J+IF$JO1-+3".HJ#[0D%40?H33SX\V49.QX=V9A MN0G 'X_13NB2^?C_:\5OOZ(B.WM'_UZ4^N^L&@,D2I0E(SA8/EMWSS)W2\Y:-$6S&L)S#P3SVFP<%9L3 M0DHR: 7SK1R-I1G/\%,Z$NSMW6C.WYT8XC$&J, M?&1Z@](V;^)0^DVMDUO=THYIMW6&=I<(FFD^=WB*H,=I>I2#BZF_C-_>VO1-BT"Q8VNK!LM3 MA=*+;IV0<@'KGNC1Q;E[;A"Z!ON.JGA@@)ML: U$'Y-4CLBL5,DF8^#\(-N M3H^2WFNFEXYK_KPKLYVN?DC[Q!KGH,< DGU[E4Q6Z^>$MF*IO-IZ9R(IV61Q M>"/^1<>QS^T.*#L6>^+@Y( N7XF#\0E=O!;IP8DX.J3__Q1XA!Q@N$SI5'YT M+.YYINZ)X_UCL>OKS:CW/:Y4?L9?'?D5E(WITUSWM/NP>9Z^YZV7IZ^BU]+/ MZ.AKU!1;]X>OCP?"IR^-Z2:ZBK_N >.C*_D2?!?4DQ;@]ZD#,6AN2$'WN??L MOU!+ P04 " ##@@A98W$I'"4' "K(0 &0 'AL+W=O+J$2J)!77^_6[(V5'JR\' )CF6PO9UA8K>9-J4PM&C60QL95"DGJ@L!J/A<#(HA52]FRN_]L[< M7.G:%5+A.P.V+DMA5G=8Z.5U+^JM%WZ2B]SQPN#FJA(+?$#W2_7.T--@PR65 M)2HKM0*#V77O-KJ\.^?]?L.O$I>V=0^LR5SK#_SP.KWN#1D0%I@XYB#HZQ'O ML2B8$<'XV/#L;40R8?M^S?V5UYUTF0N+][IX+U.77_=F/4@Q$W7A?M++[[#1 MQP-,=&']%99A;T2;D]HZ73;$A*"4*GR+3XT=6@2SX3,$HX9@Y'$'01[EM\*) MFRNCEV!X-W'C&Z^JIR9P4K%3'IRAMY+HW,V;E[CN MWH M&;IH!&^UCO1R_KU4?XN$IC(:C\1Y^\4:SV/.+ MG],,R5D6?K^=6V?(^7_L4C*P&.]FP0EQ:2N1X'6/(MZB><3>S5=?1)/ABST MQQN XWW<]YC^$#KX.4>XUV4EU J*H.NC,%+7%BI#26OI4J@7H+),)GL)2&,R)DM9.*;I4G9'!:L-;F)9U%R;)_4.*CY3* MGA70-EE()TEV1T:?T5E"&T9R[(/PE"J+]2A2(;ZEU!C%)& M[I[#2T;W!J3,0PEV'>U((:R7Y.PC@+.-+##]2K-#:VC$6 M?&4^T]E9S3:Q%LD>6YO [-AS O%DR-?Q!.YK8SA"PNY"BODZ4-9O]!;']IX3 MF(WY,H4?M#I+GN7U1JO%&Q,M'6P1(.M:*)OXR,QDS8AWCY7 ;GVK^/O M\OF8"BQ)GRE[]:)K6__R$FY+;9S\L\GO[)D(BR)OEM>4;YQ@0'L_5R^"W29H M4-#919<\/BBTWW/?AEWTS@1-H>,S-1)8?:MTLJ_],V' M=*L#\WK;^&FHQ8?9_IX%5D*FWF>B#!$7BCY1<#DDR25)JHW7X,GS+2->MGRX MT8\0&?U9LE'-5OCDWMD>RJR;5.RH$ N';(Y@MC,-]9QK=% -/R6Y4 OTN@>E M]+R0"^^2CE(-5PZI.!2KT,T\IDRX52G6D"W4W;_ ME.]F,+D OW8!YQ.N(U1A461D6)A$X/&-7C35)6A'M3ST#%07)I$_!>$-6@+V MNJQJY^.RJ5;CF'BW:7<>/N.6,AQ8W2*V$>=;4N6>4MJ%(V5.S0;G :<[G(P\ MBY/XE!N2"GT_4E!G2&:E;DJ6=;G-U\H%)].\=KX%6G'OH$MZE]#J#H?TX4<% MWV*"Y9R,%(W]*LEKMV7$@,HE8Q4JI"U84>"9%ST7R0>@'EU9$48U+IZ;GA19 MO5="FDQBD9Y2>2LD18V2HM/*D7H)DFXI=[\)8NJ!GD07H3C1/8V"A2\S5,=M MH U(J'DGV%/.*2_I@*L2_R&/$,#M<4 J_'<=R@*%]KK]X124?00W,6FE88G.U&# M*T(7@4V!Y]Y[NR0'JM 995Y$<#)1SYJD7TJ2N.FCN4%VV&@;]OK47.JF> ) MD#JUWMMOQ0I&Y][1HW_MZ#"CL*'H,"49[&(ETL/<._D7[B7HA_AW_,_]R\,, M:6 J[<\$EN9W_[=.%6R]!+TK(65!Q(_ZFV:>\H[FW<'9OO5H1BGL MX?9\,]R>_\/A]A"ZXW!['&Z/P^UQN#T.M\?A]CC<'H?;XW!['&Z/P^UQN#T. MM\?A]O\8;@>M']!+- O_-P$+'G3X+7VSNODGPFWX ?YI>_@;PUMA%E)QC<^( M=-B?TKQKPE\#PH/3E?\Y?JZ=TZ6_S5&D:'@#O<^T=NL'%K#Y?\;-7U!+ P04 M " ##@@A9+?:>RZ,$ "="P &0 'AL+W=OALH+#UYI>DM@'G96BVMLF2=L,P[ ,MG2TN%.F2 M5!S_^QTI1;$')UWR110IWG///<<[<;)1^M84B!;N2R'--"BL71_W^R8KL&2F MI]8HZ:9OT6)>80>O2&>Z^ M/Z#_[&.G6!;,X*D2?_#<%M-@'$".2U8)>ZTV'[&)9^#P,B6,?\*FWIN, L@J M8U79&!.#DLMZ9/>-#CL&X_ )@[@QB#WOVI%G><8LFTVTVH!VNPG-O?A0O361 MX](EY<9J^LK)SLYNOEZ>_OKQ\M/9^?7-3W#^V[>+KW].^I:0W?=^UJ"Q!$KZ'.(S39_"2-L[$XR5/ MQ6E5=ELHD:,V%.?WBMLM?%$6X:_YPEA-I^/O0W'7J.EA5%B'4>R'80J7DH#%MCT%[X%!QDP!>0,#&_*58R8()P%%:X_5@GF5560EFB=@EF6DX524=D<*ULSN$+]1N.Y^4,5VXD.0: MX;1@=]U;1D1AG8I7K"!),9/EA[*2)*9B<-DRZ-]20:IF[2 M&:3#;B/-?G3[D2V0>-)B.NA"%(X@@F$"ITHD&<9?FHZ,7*$)F)&#D:;Y.#_(VI"'I/J](3"IT MXE=KX8S)>E GX) 4B9."!#LZ0H?%XQ9Q35A\ _7J5;' Z;,YL.(4G&!Z5+727%R9&KJ/' EY;4%37\^:4@17]#Y/]3%2D?3R^5LYGI%QQ24W-R4A-2M*/R-1BH>GN,@B?H'#H5]S?N3*52 [=Q=!0 M1NCHU+>G=K6]>\[K*]?C]OKB^IGXR&?_ E!+ P04 " ##@@A94[:N! X# #) M!@ &0 'AL+W=O>>.\Z7 M\4[I!U,A6GBJA323H+*VN0I#DU=8,W.F&I1T4RI=,TM;O0U-HY$5WJ@681)% MP[!F7 ;3L3];ZNE8M59PB4L-IJUKIG_-4:C=)(B#P\&*;ROK#L+IN&%;7*/] MTBPU[<*>I> U2L.5!(WE))C%5_/,X3W@*\>=.5J#BV2CU(/;W!63('*"4&!N M'0.CZ1&O40A'1#)^[CF#WJ4S/%X?V-_[V"F6#3-XK<0W7MAJ$HP"*+!DK; K MM;O%?3SGCB]7PO@1=ATVC0+(6V-5O3]GDX,A@]9Y#L#1*ONW/D M5=XPRZ9CK7:@'9K8W,*'ZJU)')?N3UE;3;><[.ST?O$9%K/5_=W]AS4L%RM8 MW\Y6"WBS6*[?CD-+'APNS/=L\XXM>88M3N"3DK8RL) %%G\3A"2MUY<<],V3 M%QD_MO(,TF@ 291D+_"E?;RIYTN?X5LP+;G<&EBBAG7%-,+WV<983>7QXU3 M'5UVFLX]F2O3L!PG ;T)@_H1@^GK5_$P>O>"V*P7F[W$_L]_SO^SP><*H52" MWBAE![@!2P<:&";.L-99.NC4NH 7K\QC)9 M.*HW7)*5:@WMS5MH#1E:!3D3>2N81?>F> Z2^@\)<5>$-G@"6'#1.K<'*'4D MKZ?DAD#P"YDV@*[N@*H&J6JN?-6X(75# G/O*TZR07R1T9P.SD>7?H[C%&Z< M ^H1@&5)3<,'9%7^ *IQ\1N@$$"12PW#-(+SRP0N+O=FY-31CJ*LHQ_%GO8R M&L),6EXJPL6#S7;$-"GV!O>'.7C%(1^??+(C83[ M8R"S5O--:]E&H,OSM5!:/9V=JMKPJ+W4J+>^B1K(52MMUVGZT[Y/S[KV] ?> M-?E/3&\Y!2ZP)-/H[.(\ -TUSFYC5>.;U499:GU^6=&W!K4#T'VIE#ULG(/^ MZS7]#5!+ P04 " ##@@A9'714KBX, # )P &0 'AL+W=O3B^#%98SC:< O4MQ7O>\,+5DJ]1%__)2] MFOBHD,A%:E "AW]WXK7(25>J_Q7F9G- MJ\EBPC*QXG5NWJG[/PMG3X+R4I57],GN[=B9/V%I71FU=9-!@ZTL['_^V?FA M-V%Q;$+H)H2DMUV(M+SBAI^_U.J>:1P-TO +F4JS03E98%!NC8:[$N:9\]OW M;U__]>3RXO;ZBKU^^_/-]9O;B_<_O7W#;OYV\>;VY:F!-7#D:>KD75IYX1%Y M0K 5^G[(WJDAYM6'7GP'YE6!_OUA61@-\_C'F M#KM8/+X8IM2+JN2I>#6!G*F$OA.3\^^_"V;^#P^8$K>FQ ])_P/!^QIY[*<" M?',GMDNA,1C!E)F-8*_5MN3%[OOO%F$P_Z%B -GTXT;EF= 5NU,&W&P4XV6I M82[-X.!GP ;C109Y71F.8X!%$G:+:YW(E80'2ZV1)<4]A!L266V*XYSJKIDP6 M:5YGLEC;H4R5>!MNH(Y:IJ81,L75B0]!458AGF 44('0NAG#Z@+4F[H?:+U( MI5U/(U%49+T"]?5 ,ZM,SU!>C?L+W2DS@1[@AMP K""W]985-45(K9QJ['XC MTPW@T3-&L\"Z>0YWDV 8_(&?$T&+#"6 X[[M*QU MJ2H!AEQ4J DDL6B3>( ;=H\6UF:CM/S=8L4&L2Y;W(!=8'.^.Z8>!"2'05642-#$&,*2=L5F$9L%+ [9 M.Z!=KB$!<'0F[D"MDD@??5*Q&$ 5L_?*@';IOLLJ7#+&CP@^$A1VU'5/6+# M#U01JN!K+"'@3@%:P;JU1H4'7K"A)KM1-;)]I=5V2#]@D="IK-JK!EA?$'I2U$ ;6-6 M;QH\E(ADH07P0+H!&2TIH@7(V]>0%VLM1,%NM +$;C%+U6H%:41X 9HC^(.K M05Y*@,AD7EL&=5' Q![ASBMA(!\P/]9P ?V.$N]X7CO"1]BDJ:J! 3 HC;7' M&;^M$8?$[V!UR/TD%RK0B=B6N=H)H .@D=0HC;=R2 [/U;NW+M+@/L@G2JI" M#51RZ]O4[N"TEUB$*!N%%9>:+!;H.,$!_H?R]L7MH[.'2\13%Q(00/0&/U"\ MX^NJ4>DRYQ"3VQ2: /!/Y_>M D*TW@>X;9W5A;()9:TAQY @Y+,7/5K =HPB M O4<"I47.443+W;??J467&0G'.E\;ST0Z3N:YG ,)I7\F1 MU9R-^P*/K=^U:"M.B6O-/!:HOJFX3*. ]3UF'?O@W8*,AC9_%UJ= ^5Z!MD M8.H>8)BM[)0&T.=V;8SI.YEN.8NLQE:]O9CO:P5E]3Q9$L"5N?^%R\8LFL[/?%PV\5G<+AO,6@%W M "#;/(W,]:%^H\J+X5R,\_U^LO=(OPUA2__.YU],^=,>W[M06YZG@!\C>[<* M(@0'$.-/73[*5HW %.> MA'.['1Q'+9L;?-? M#3L^UU-;!L-.&W%W@H<'R"S +Z0)]5B(&7 :P$^J##8WUI_@@Z8)@A#F@-1NMZO6F M[=6Y;-%F1^Q0TTJC[CGY_BPVD,[SM3NU^7E:]4J!P8]Z321'IUY$#LAB&"E4++5"F0,1+ MK! HU6UQ:]SG;7![ 27P7=<<6Y2Z*!_VG4?::%+]X69R4+%<[MBR,\@=1+VL MO@ .CT.W\?G0+ZVW$75=_D6XD$N];XORW?\\S#N>[@Z:C@6Z#U#B+ Q6]EM- M%D)/ 1T 8@E[6K$Z#T<)^TAW?JN=RUQU,W M#KXR=X]N*/^]N=R/UC U*8=ZAV).3ZBJMEM8'9[:'*VPX0(KK#MG"/VQPGZ@ M,N'UA. Y5&QOIVM+>+3PD@ 6">+("WU7RI.Y!RU5U^E@ICVF\+YN%\W3J(Y7 MN*F/MJ\/$!H=[Q?MP==H\]KTKL= /=:U)G%,S6/2MJFQG[ @.F._V) ]"^81 M=*2SD/W8GD<^2Q*X9 ^_OG"EF,W#@%K-A-WT3CEN+4@.R7WD*.2_S.OL&_#Z M_R6E/T9_08+$\(>(;P0EI/M7,EY?;,=Z 87OFS!.['O1&3%.X)TUC#,+O7CV MGV6< __]0T[GW69][PI N MSN?_RJ(QBQ>1V^D>3.OVR/VSUC$A5L8L)@@\#,/']NTN@)$]D(U]?^K[%@B1 M/\/OP\A.V\3S5UY)O*4M(3"8=OMY5MVC#R.:GY;H:G",_^Z8\&F?QP4!)Y7 MJA75$V*W.Q_:T_TWJFCY]ZH]W.]?[8[\&XO=H9OS S[5&'MVT#TEW">$1N+> M0QGW$ 5#D\*NGUR%1K;+P@8:'V"R$NL/S+#QD+I12./!72'<4<(*"UY[)F_/ M&<<4=2>.8R8\W*'WW:V%++I#L/'GZ/340 ^JA*V 4@_P/7J8@TAVQVACT6@>R)+(WL,+&(KQR47C:]X&KCL+M07Y@<3N/R9O MRE-P1LD^[J6>)UM@X^HQS;%QX?U0P, P[K%'$Y8-!_\^>,+H/-WC-EB'RN4B MF5IB"]QQW^+,.PN.\]IH]Q&$\Y[.1,$]POYZ-7T/-BRM2M[8RSBGO;>JMD*O MZ=TQ#'E=&/N"57NU?3WMPKZ5U0VW[[;]S/5:PK8T%RN8ZGOS9&+!UOPPJJ1W MM);*&+6EKQO!@0-P -Q?*66:'[A ^]+>^3\!4$L#!!0 ( ,.""%FXXS!L MGP, *H' 9 >&PO=V]R:W-H965T%E6<6V M-BSRH%25<=KKG<25D"J:C,+>G9F,]-J54O&=(;NN*F&V5USJS3A*HOW&O5P5 MSF_$DU$M5OS [I?ZSF 5'U!R6;&R4BLRO!Q'E\GYU<#+!X%?)6_LBSEY3Q9: M/_K%33Z.>IX0EYPYCR#P>^)K+DL/!!I?=IC1P:17?#G?H_\8?(_ MR=P5X^@LHIR78EVZ>[WYQ#M_AAXOTZ4-(VT:V?YI1-G:.EWME,&@DJKYB^== M'%XHG/5>44AW"FG@W1@*+'\03DQ&1F_(>&F@^4EP-6B#G%0^*0_.X%1"STT^ MSS]-[ZEU,[O^?#MMT_3WN^GL8=JAV70^BAT,>+$XVX%=-6#I*V!)2K=:N<+2 M5.6L0 M^@+AG);29J*D+0MCB7WZ"!(K;37IE8R:%.:T P;-1NI?;< ME!5-&SEJ( 'TD)(^]?>UM32Z(OZREFZ[H\DS!,M9%(E2RWZ,NE M<,BUTZ$*KE$X0FV#O=,+5 ]"'5)LX29=FA5R))7H> 1?.(U6+GV ))SE;O#R MF/?'+7UG":(L*E_H^=X>E"J=ZQ"QF_Z)\5@Z1_)2SL MKI5K6NEA]_ 073;]]Q_QYA6[%6:%^J"2EU#M=4^'$9GF96@63M>A&R^T0V\/ MTP*/*1LO@/.E!M'=PALX/,^3KU!+ P04 " ##@@A94GN>1%0, !,(P M&0 'AL+W=O'P_VP(E?27BE2Y9*6U;_^OIE=4J1,.4EQ*)!0M+@S M.\]O9I9ZN<_RW\Q&J4(\;)/4O.IMBF+W?#0RT49MI1EF.Y7BR2K+M[+ G_EZ M9':YDC$3;9.1/QY/1UNIT][52_[N0W[U,BN+1*?J0RY,N=W*_/!:)=G^5<_K M55]\U.M-05^,KE[NY%K=J>*7W8<JM3H+!6Y6KWJ77O/7X>TGA?\ MJM7>-.X%:;+,LM_HC]OX56], JE$105QD/BX5SS56Q)A\[[B M_CWK#EV6TJB;+/F'CHO-J]Z\)V*UDF52?,SV/RJGSX3X15EB^"KV=FT0]$14 MFB+;.F)(L-6I_90/S@X-@OGX#('O"'R6VV[$4KZ1A;QZF6=[D=-J<*,;5I6I M(9Q.R2EW18ZG&G3%U>W[FY_?O16?KO_Y]N[EJ !'^GX4.>K7EMH_0^WYXEV6 M%ALCWJ:QBML,1A"EEL>OY'GM/\GQ[V4Z%,%X(/RQ'S[!+ZCU"YA?<$Z_-,JV M2GR2#^*--E&2F3)7XM_72U/DB(C_=.EL.8;='"E+GIN=C-2K'M+ J/Q>]:Z^ M_<:;CE\\(6]8RQL^Q?VS_OAR:O%IH\0NS^XU)Q#R5VAKC$(^*#,0RP/=B?^6 MN3:QYB09B"A#OIE"Q2);B0(<5EF"Q-7IFCGP-["C3,1!R=P(17X7\)J"UYZS MU^@2T,47-V6>J[00WZM8Y:"Y$%[@TW42X#KSQ%TA"R6\N0@"X"$X3]Q#[\=ZS&6\]%;<-8XJ=U/% I !1 MF VX4J8Q++Q7B+6+()P)F<;B8A9TV;!M0AOXO)[,. SLU,,72J,!"#APPSE6BUB;C$WAF0 M+BT4"D0!>&4-;F2B(4:JI=440NZRE*4#T[<23]*U$4N%1>JOC^9?4DVL.)X, MHB#P/([E$-=P'M11-9^)>2@\T%:A$RSF%+8!7:?CF;B&=2!;I!,MN3@Y\0Q8 MES#'0:QGAVV_FOC=[ <%7*QLDQY7$%6' _(U3W/P9 MM>\>"57OX7O#L7AV\F'SS>9%WZ5$DW*I4K72A;D4_G BO.$4_Q>U\6K>L89. M%,P:=+,A;(J5P="K4UT]1,J8%DO1'P\#RMPA)?IXB/Q]#P%^&=X->9W%0=[' M&;8_&?J$"8YL=BE^RL 4"V-8TQ2ZH'KAC2$I&]M_47_>4O2F;%](DZ@UR01Q MBP.\BS9)IOH/Z]W^= B8.:7_]=V=6&=9O-<)_ Q_ZIPRL7Y.^E;WE M;3@O8P50R'9,!$B(V0">TV?&!H 9?H:[\]J:$3G%'X;\=,I7K'_[.'S\*51^ M)@*L)=?:#TK*VW256+4^JKBTO=5U5(@^A17)ZX]?X&^^\UY<,@896!P1AGS/ M1"+W9-[KDA'VJC2DE^6 @Y(JP[XV*U':) MF\!KV,$T"CQ @^,W;FT1HD"'9+UXH -$K*F,W,DL&8 [&1T#[-"MR0 M"FAC41FDC3<8VRGAS/ WPXB9)3J6I/)*IY"6EA,P*5LGR"RD"S%5#U2;L!)^ MY9T^MT/#T!VLG>"4HD8IN4QP7U("#L4'J,UI_,/U]8=!G<5[76PV61*32RWB MR%P=:PXV+]-<;77!ZC@B5142KFF5+AH@"*D \0DEL$XI_EB1T+22>:EO<6753+HV.-?H!$D-Q%>U4 M>RBNCR5]T'0A@M@9V)71,XYPCC\OET1(=\MES;+;)3JB(*ARXO$>%-1IQO"B M5U@,\SP==JWPMLJ9KEZ#,K=N;BC)R.H$KRC82U3M G)>)A0)\!&RVFN_RY;?5>:>J$;$!;3JKSV ZJE M=.D0NRE6WZ>Q!(.(:TT^'V3P_XS''6_!@7HN-$FEYDZGY: 5^DN9L+WMP0\@ MK@IBQ@19]XO/SPOIL6CG=89]>(K( M%H<)#+LX42M!G.Z1/2S'@2!$BM]+F:.@ 1N7$J,$8)$K_FG< A,!FP K#8O& MA& M_"%$T(H2BTL.B6I(9 M;*(.N_+*V.J\5!"K+HZH,SEU<*J3-Y[*;582'O(4A?Z34<"9B%#YIFX\ZD[H MU"[41W<)WHZR>BKYDG&D"S9DT6[M>*Z^L#A"'SY_A+Z-I&J 'O5C9>\N60+N M+R*+>2(AP'4(:P&V'TX?-_$V,BM^%6?+SS9K58GKC'I*"^^R$>/=G"H>E.,L M)7>6-=(W9775H%TJL!,-1(11L,@9"\+L3=LQ$K=M^*G=*K8VY%Z\8;NZ_VU) MR9UO6[0!UW4Z+F!DZHBBQ_'2*KPN0FY:XAQUO#ZR(1.WEWUO^_U_D+/-FT<+ALIC*R @PX(W.%6XBWC*QU$>B "YW^$C]+N6]=DR:' 4 MB<;J7(H%^](3[T?7]=#<)O/F\!Y$\TFHB>4?GEG;N<7\.(/R-K:F=7E3A!Z" M&!'B^8T#L3KJ.G2"PA5SW-8"HD'X4@/X1YL_800P[P?CEG^F7V.#$.25F:W^ M^K%^4S@RP+*@/JEL15=UT(EV84Y)%$XLCOW%H7J*635V0;4OC5B8(VP:\^OC MMHKY\R[S/1NW$YO0S'_\-3ZSS<+G8Q:AX6,?+_S"F(7+:LV#HW#P^O\W9KM) M%[9S^DPH3D*[#%'>'8J+D&&<^UM8H-D4&V ZJVT'=9X.213;$A2; M/"O7F^8IN3>A5L?*T2TZ2W=>+.X>W8%YKAIZFJMIHK.G;7]2-#JRN[!G_Q?^Z2N(VS_-MCF1/-;5 MC>/V,;KAZFMH=.'1=\UW)K4=)*=X-3K3VC&M7:+W.O\VPYTV'E\&:'O6T74D M?^PK>8),^?2AZHS/G"*N+%P9N6YQM:;51=@Y@^\6]4P M&D#3J=GI'1!2RKX4.M8#K[ZS+*KN\PM84#&@^MC'F/QX_Y.W4&U>"T!@V+'C MDT3G2MA/.Y+9YT3KMG]OV&;VY/YN]&AIZ- MC'9C:]-]T Y=]U9QEQ7NU4A-RXDR&>!B4P.?[=P%Z49'&Z%71P2+\656)D@D M/BNW)YR/W@8,G[)"QUEPXT".D=6]L$0 51[GIM]9)E4/!3606_XIP;#K+?JH M\0N'K],WLD<"65$HE8@'0]GDYX] MXZG^*+(=_UX"&%)D6[[=*(GB10OP?)7!]NX/VJ#^ U]5@T_#@ I2L !D !X;"]W;W)K&UL MS5K[;]LX$OY7B&QVSP%2Q_([W;9 DJ;8+OH(VMXN#H?[@99H6ZTLJ:24U/O7 M[S=#4@_;2M+B#CBTL629' [G\G:7Z2]FK50AOFV2U#P_6A=%_O3LS(1K MM9&FG^4JQ2_+3&]D@:]Z=69RK63$DS;)V7 PF)YM9)P>O7C&SV[TBV=9621Q MJFZT,.5F(_7V4B79W?.CX,@_^!"OU@4].'OQ+)*-2 M$V>IT&KY_.@B>'HYIO$\X(]8W9G&O:"=+++L"WUY'3T_&A!#*E%A010D+K?J M2B4)$0(;7QW-HVI)FMB\]]1?\=ZQEX4TZBI+_HRC8OW\:'XD(K6495)\R.Y^ M4VX_$Z(79HGA3W%GQXZP8EB:(MNXR?B^B5-[E=^<'!H3YH.."4,W8RD"^>Z>Q.:!H-:G3#6^798"Y.22D?"XU?8\PK7ER_O7GS_E_7U^+R^MWU MJ]>?Q,V;BW2_'W,NV+T>!4# ?#\3WT1M5.1TQOU$'O@RIBK6!/A;A4J5K&A1'_OEB8 M0L,R_G-HQY;>^# ]\I:G)I>A>GX$=S!*WZJC%[_\%$P'O][#[;CB=GP?]>_0 MRX_0$0UAO$[#;*/$32)3@R^B6"MA5)BED?A:2ETH+;*E6,8FE(G8*JE9(:<\ M[BK;Y#+=8GQ1)"H2.8B(A91R"^@TS DHX"LQ8L2=T@I^'RE1&A(&LRX- M>+5C'US$@#IO1(ELD<0KZ46")<2R+$K0]TJH-$BL.1)"1I!<3.Y"."K(X.-0 MF5,>9 JRE @2]HG]%LKN M#2O *5)LV\H+!@*+7Y,H(:;8>E>N8\2\&"Z E=@H$378?L(0$8IDZBRJF\P"&-]V-JFE?\Y"YC] M(UZ4Q"*YX@$95\" N H@B^HY%39$I::EK-E\:F 0#8W34K&U$4>PA%3<0GB0 MEI.)KF'/*X9A#[8A%)PB7B2J9H*T"3)*6W>'#M0F3[*M4L[GZIU7<[I6D)"C M1;]]KKU0C@/ *CYXX>-@0ALA+WR0N)-) Z.- VE\CI@WV]&F=^43.#3 M5R0'&VJ:4G 8 QM1FM6VML-#&EZA$6O):T#;ZQ&DJG0%$C! M!U78_=?2\0.%% UQ6EE881(>LGM34-(A?L4";,AA=JLH&*AO!)1X9A&$\!]B MAR.6$"TLR#0<:D/ I#U!K>+-HM3&\5#F)#PI2"DV#$;P,$DY\\+$T=9)NU\G M++F,X3SR"P&+58PA>+>[KN!VL15O512S]$AHY&J5$=$NF_OE024E;81-82+C MC7U(:UET;X9Z!#:+4Y3NLNZS*%YN:9-U=HTY<8M.9GUL?KN:BW3%>FG*4P01?.,\Z%N/9%)^3 M8(3/(=T.Y^*CL^8P,X4(\(]%,ORUNKXFR(*NW8BA".8\[J(52D2/ N2)Z VG M^ @"NJ.;$Y=:8'^1M:9=^KWQ277/8QL)4V\4#$_V9OAKVXSMRN.)6QE_GY"T MF*0V$ O:,OJ,.LCRTGN8^KYD51HU9!H,1Y5D$9E8L+7.&K'KJ7@E8XT(DI2* M#<=&M&YMC>8!48;$CRNFZCL6?T(66FJ$]M92D/NH>V/7%O-T*QH:@0"!_T/\ M^Q]H84FI4?:8@-P+SKO7>H1& VMUNS/;LF_*:E^IPPG+?I<$&+T,?G6 MAZX5J-HA5L )A$ 6YC+I@Y;O(Q27A,T8122N,5%%5@[L0G]X%V*0N+"$;AX] M\E"$N[E/C0#5P80^&5N#P9PA-V@5* >F!8,QILQY,DWM=O]=+R< ? >[O>$J M!5#EX\ 5A3_2,EDUQT)0.FR]I+']?.$Q68(OP7A<51Y1[85:-2W:F8-KM72D MQ2U1#W>_ML(^1-KXVP>3X_N3@0GG P%,(+=Z[ A*C#<#^IAT0SP0$JGW7U5' MI$R;8(DJV8B1F(OS"K4([:]V"O4FP/:FW8OM7C_608^3F@:98'9>#9MU!ZBL M@&HAQSEAKZW=K0*<-!7E0&24N9[IVS.).JP5/L]+26=>]K/ZP]IO-'QMK:T'MFN&>= MZ<371QQ.^N(UFT":%2#1"J3<"6F),8<<&L[IZ!Q"6A]OJ=NQ[,K."17DP:07 M47C ZD4DO('*=%4C>I4TDUVB@_Q'<2?0=T_D-]&S?G)2Q=J8>DMPE?&#[1C+ MC!?8,;FD8Z>;Z6:#ZOO;/0? K(UE3K"'$>W[1=R=)@^YG.'--K'CM-6]XZ9B M;;2NPT$\,95>, >2#,6;QHK[8UQ1\Q"3[?J@MHQFAZ*D>I\=I-"22M\GU&FG M KT&/]3ZZ\P6ERT0S%L6QL[.^_.-C3X%VW*3V[3^3SY(4M$3>8O"?J5LZ];] M"#:X>49)^<:WL>N]\4$$Q%4%S@,EZ&[>T':O'XU7[NXEK,LFS,3[!"X-M:+.^:@/8C_C,B4"Z9GDOSJ8P1-C M;IFZ=<9$F$,4NH2+46ZPO4QHSN-2F%UK8,5CCQ-++\"%?$QY;I,L M73VA+I*=@#T[_FO-43"E4]B(]Z0SGU^[D8:2?Z D X$-?53KU4U\5RT5=&S@ M"C.*N5G(8K550>U/!Q)5SE8@?7LNM-]YM3*@HJ'N^4<:'*;4EO-J,S[>1DT1 MU2EGP^9<9<4-3G"ZA5B6Q#53NU6VCF:V# 1X1W7[6J:U4&L3:!X7/;S'PUL; M_7]OK3)\7P3<^)YH]-7N^:,D\4>5^#(6XSERW^ZMQ-'-[DYC),;J);.@@Y7WL:= ME7#J4&%JY ^0JH37QJ%6FMS[! M;5A0CB -Z<=9IZ[K@^B'3W+V=#PZ=2'>G=?X/C@G-7O:!^;9S5Y4N\"S5MD- MK7ZK4\TYH>:,P/>*CCSI$ /QG?7'T#]D'.4Z)F DMY]-L>Y(C7TX4I9/LHNF M"60Y:2^I&EP+5=SQT6!LOG@/8$Q.Z70 4!IOZ!282-J^GC48&:YC=6L-A@17 MB9H.4:C*:>@G6WQV*(Z)*U@7PW_CB(D.\4L=*N,/K*NNESV@=NT(CG%-JZ2U MF ,H5WG#>$##%A\;KQU(.A1D2X7U\+ET9P/,;=+'62"#)IN"E)9U/V,G16B< M'.RJUQ"/EMU!CNE?-C:H-W=O9L[%HR[H\&L+="VTORH M>= E0K<_@E0J=O,2=A@BIJ%>X+,UAC/\R/28$[G'2YD2.FLJ$YKNN;5>Y%&L M&KJ\YLA[2,==*P*K2 MUJK^"-[]S.\=R*) 4"AV@ *,'T(%4R<$?#1=)1\@[HO?BHD=(W+K\8$LO2R" MO$AG(+5H$5R^7CP,J^^$)8M=KVQ4MW0G+5/"'9/^JF\U,OD&ULI5K;;WBVD#H_>/V2 MG]T4KU^:59GI7-T4PJX6"UFL+U5F'EX=A ?5@T]Z-B_IP=GKETLY4[>J_&-Y M4^#;64TEU0N56VUR4:CIJX,WX?EEG\;S@#^U>K"M>T&:W!GSE;Z\3U\=]$@@ ME:FD) H2'_?J2F49$8(8?WF:!S5+FMB^KZB_9=VARYVTZLID7W1:SE\=C ]$ MJJ9RE96?S,,ORNLS('J)R2Q?Q8,;&TT.1+*RI5GXR9!@H7/W*1^]'5H3QKT= M$R(_(6*Y'2.6\F=9RM"MQKSR]>WUNP_7 M'S^+3]NH];NI49B/WC#^&P=[%'UGXM:W\?]>R5%:4\\*L9G-!UBG53"?B;F5!WUJQRG5I MQ='MY1_V&.-D*62A!/*!S/7?*A4Z+PV>UT1__&$9I^*OE*ENN,8>&O,_! M)Y>4/636*7)NRBWNLH,UBXET0[F(Q\%&!09A%G/Z'68K3MDCNX07L(B%TL), MV"CD$O9.@!SX M$[;EI[-"9QG)\=UL&Z^UV4Z-@4J,\,QE #3ATU5!BJK"LL8)^>>[ M^6_@9$.&FB1304VT.E5=I&ZJ@10$S$W;&CPZ3[(5YF5RE:?%6L@TU10,]D+, MS4)M2G_QQ-X7+7M?;)NCF;8!@0HJ3&<#+,O"XU[G:V1>%)@A3-+9@KS&(AWF81O;XPJRT!<%D@.^%@5Y4]67"H%C-T@ M99W8>T7J!#Q=YRD&7\U7CRS(6R3(.=R@EJ"#!_!%1VA6+D \*<0E M')2;_$0B A,.?)FB-&O.F9RD#/P?B'N(CX@0ADG0C"83@B"YCCBH1W18EJ26 M\#\"ESY)6XB&WL)6$7^I.&9\E/_YX;9.S:?BC;4*([L32PV@1%J7'OA&_;72 M]S*CY!+ VFHI=2,,#W.")ZNBX!S&/&@HJ5&NG? @LB24!JTT#VM;B$\-T8F9 MGB IU),=RB07.V1Y,=S[H'G@?=MRK=6S7$]U(DG74BUL4],=>DX"><$CD> ML%$VJQ"H]< .E#@]F5Y38.(*H03]Q)+.>SQBI5?F%5 M5<$K/'(+^:BLD4\1[UYBH,S6:+O8I22 1N+'>Q2UO-33==TUD@2&Q"W@WPW: MQ*O*FR0 NIW$C582N*H#!+_ ?">VT[W*A2VPML+U3F5:T834<&N6:ABS M1 7QK9?'[(:F;;8_65=KLC6;WQD*&KI4POV8)2;HZ+FQSLNN7@^UDM>+5;?(0IEV#[T.7>-W=-#44YA,IPPF"B,K,X^;9Z6'P#77BJ6*> M>5?S^>W>]2.DNF6IWFI+"%E#,E[ T26F2]39H;X04= ?#_AS$$?N>S1J-9-A M,!GT\+0W&=/]N-_J^,(@&@UPC6-Z%PWB)]U8&(3#B*[CD*\]OPC<\%AI*/R' MP7@4B5$0]B=TW^]WUM(H"D74ASC#6'SF>2\PIS>)^3,>3_@S[(VVD_MW5(Y_ M;,M12 (,)GU<8^C<6#$:]K"F'HLH;MN/+!;!HA$L\\1RX %M)J/=%H/9!WWO M@LDDZK374=R;'.,Z&.,:1?%Q;;4PZ/7)[9-P1((/)TZ IG1!5!$.Q:!Y7E6P MHTGOV%_"WO!8_ 9["H1/*ZOB#3'L8PR'4711?][LJEH83Q1'X?:%Q02: M[DY4NUT,F"#=4PC>FJ)=TFB!N,(P7N!L;%RX@DKHO->IK_)RB:^/6/B5&S(] MRR);KNFJI%W%#O/'"PY1Q$[YGSNDF]7RHU[XK"=93>2Z]-J-.Y, MD>' YT0$'HA13F@!0U)3R NV5M[P^0J2OD#6>/ZB:,-]T\WB$I]R8FFQIIQ; M('.LBFHKH&($45SN\_6 M^]#US\#U/:KM ]A/MAM/55YQ@'))J#)12VDLX&CO7/RZRA&UO7/@)E'+JB6D MOL\/V&@"=B 2&!KB?[ )3(&^I87-JFJ VA.0]JGHAF$G5">A&,4"O4(;L.TK ME9$6@NKMA"<(;:SVKQ9?STS'OHOJ,E9CH,8TF^;H,H/3_N@]5T'??DP+L^#M M$(CK)%3*5ELO'&^^(=)^EK>-PQ9[\VFS4'<&K;Z [MG_.P=OM!3'KEG<.7AX MO''O%/-;+2P3FF:^]L;48(=AC[H^M.>X[T5B$(P&H9.'NFLWD/KMWH3Z[3X/ M#T=C#)P@3UW))3N;54_]ZI?9]$<"L^.AX/8:U\A1!75TH-&$'^(F&CN%AB!/ M8]Q3_&'@SX2[1+=67@LZ[OG;/6 V@[$8C6@6A(G!*1YX-A,!(:.!Z$,"ZI&' MCLU@)(9NO!,"=[>MY7Z5F:N-A;:W_WFW?XZFSR1?3^B4,>45-O#1$C[L4UB. M$=P0>^33 #WLB1&B%MW7R*\-\)"'D34'D2_HX%JU[W[Y"&&P8EZ@\ZIVNZM% M85N1;Y31>CGJUH".]([JF[&92G^PJ8I ?)'90A8E:5Y0$4=(G3K#4"*=3GG1 MS M8V P..@RPD#ETY6%PR*<:W6MC2K*\MJ_.2W8F6W?,&#AS^KH3;=:=P&W1 M)+P5"BLE!44\5LX5]6>T&3"/J7=4G?H@D22T) =-DC?L'=*FS\(TO?$S=P(T M 7[M)]E-;:MSI1V5L7%:5Q_T;!'X4*EU%G:WWC[W"YY5^IZLGXM=5'.FENU"=O*S.2K[060F%%PI95%VN9(FRP+T4 M<:3_,?[?54<:]&7D'[8J+7UM+F^-23WA7G7Y0L;6C$0U$!2],\U0IESP,:!W.GMZ?91;> WN/;%UIZL\;WXK&W2 M9XM&U>5RXSR.NOW#EFL8'O54AY/Z*Q MU5Y0'S 8\N9/&(_JK3.VYC"(8NXK!I'?27,E&#-X[P[SW,;:S3>UK%L7:EJX M68G#0=VF3% @!W07HPOH^LG&6>OW-$C3,_[5$"4^P,G]M*9^6O\PZ8W[/4XS MW/VJZ0,J'I:K(E-33.V=C@8'[F"L^E*:)?\ZY\Z4J E\.U M?R$&]<^U7O\?4$L#!!0 ( ,.""%E.$0R5& 0 "P) 9 >&PO=V]R M:W-H965T<'I;^8"M'"MUI( MLX@J:YO;.#99A34S0]6@I)M"Z9I9VNHR-HU&E@>E6L3):/0FKAF7T7(>SM9Z M.5?."BYQK<&XNF;Z>(="'1;1.#H=;'A967\0+^<-*W&+]G.SUK2+>Y2YXMHY!U"@9GU"(S^]GB/0G@@ MB3]X;JM%=!-!C@5SPF[4X1?L^%Q[O$P) M$W[AT,I.2#ASQJJZ4R8/:B[;?_:MB\.9PLWH&86D4TB"WZVAX.4[9MERKM4! MM)E3\K6:KKEI&>7FX??5KN'=[!>;79_PFZS^KA=W>_>?_JX MG<>6\+U4G'58=RU6\@S6.($/2MK*P(/,,7\,$)-CO7?)R;N[Y$7$7YTCM"TY/>Z>G+Z'_QQ3]7RS850CWJFZ8/$*E M1&Y@SS17S@!^=9S"Q>4>C:6&M(:*U%:@#A*UJ7@##>J,SJF+#:@"7 -6P?7H M)](!!M+5*6I_D5&D74WK1JO<9024.D,N&H-F (>*9X1*8)0D2!69\'8\ALR! M)HKA.8(E/S]+[M.XM21HAL'U'YT<0$B&])*$\8D4-3 R168](,LRY<(MS39P M5+(Z@'=(-=I*Y>05:H2KZ770N9I.",)3\9(%-QD3<$2F*4J^YH$J%ON*#2JT MF QH?ID&PP02Q^'C6!.>5*!DJ;@L(6,-MP2:J;KF)R)",3\"R3&-W5'I&)6O M11]QHD5 *A"TQZ9- M-T7[;B9^PLZCK<RQ>O[I)QK.W M3RK.4R16G$(MCN1M7=<&AH.'!?CUQFPN4>YJD_@V#3."I7>TXH;ZW^F]H(OY-3 MA21=F>L51VD"#H0;8O9D#Q)[%DJL"7/CF&= M,L%DAJ9G280O1?Y)$%JWI+)@>"EY04F@R',YD,9WFD#@5/[F/6G_:? JGT!OXNWWQ$?F"XYY4)@0:JCX>PZ MV^ MS>W&JB:\AS1@Z'4-RXH^9U![ ;HOE+*GC3?0?R M_P%02P,$% @ PX(( M6TI#L @ >@8 !D !X;"]W;W)K&ULE97? M3]LP$,?_E5,F[0DU)2V,L;82[3JQ20Q&@3U,>W"3:^/AV,'GM/2_W]E)0T%0 M;2^)?]Q]_+V+[S)8&WM/.:*#QT)I&D:Y<^5I'%.:8R&H8TK4O+,PMA".IW89 M4VE19,&I4''2[1['A9 Z&@W"VI4=#4SEE-1X98&JHA!V,T9EUL/H,-HN7,ME M[OQ"/!J48HDS=+?EE>59W%(R6: F:3187 RCL\/3<=_;!X,[B6O:&8./9&[, MO9]\S891UPM"A:GS!,&O%4Y0*0]B&0\-,VJ/](Z[XRW]2XB=8YD+PHE1/V7F M\F%T$D&&"U$I=VW6Y]C$<^1YJ5$4GK"N;9./$:05.5,TSJR@D+I^B\0=)/^'EZOC;$7>+VW8JSFA \5:@?3%3\)?IW-R5F^$;]?B[>F M]5^G^2HYI5*D.(RX# CM"J/1^W>'Q]U/>[3V6ZW]??1_^A[_1[C4\*U2&TCZ M=4(/P.4($U.40F^ TX$6,Y#:&1#^/DLM?:& 6%K$PB>-=[B,5/ ;HV,'.$>A M7 YW%S.85\0*B#IPP_N<54VBKCA)@(\EEQ_SF9$J0\@'!;1PA@& $?0D)A?72]2QZV7RD(ZW6DJN+[RO7F MV+KPB=DTEO20:/4KUI<5DHXPX:B+*U9"=5Y[<[%._V@ M0+L,78\86FE7MX9VM6VL9W4_>3*ON_*%L$NI"10NV+7;^7 4@:T[73UQI@S= M96XA&(2T]J.9! M%(;CH*9,D"SU>S.5I;(UG F<*=!M75-U/T4NUQ,R(IN-*[:LC-L(LK2A2[Q& M<]/,E(V"@:5D-0K-I "%BPDY&YWFB(Z<.R+;QI^>DPPE'7![O6'_ZF>WL\RIQG/)?[/25!-R0J#$!6VY MN9+K;]C/<^3X"LFU_X5UEWN4$"A:;63=@VT'-1/=D][U.FP!1N-G %$/B!X# MGJL0]X#XM8"D!WBI@VX4KT-.#@7+9ER M&;V'E889*O\7$@5"SG3!I6X5PD>XNJ;,*()+*4REX8LHL7Q($-B>A\:C3>/3Z$7&[ZTXA#C\ %$8)3L:.G\] M/-X!SU\/CUZ8)AZN(?9\\?]V9GEJLL.@G38+4MU-.<4?+I84[^-"<91T-.-U:P]<+6J);>^#04 MLA6F>P6&W<%;S[RE/-J?6L_M+/(?36?8EU0MF=# <6$IP\/C(P*J,\$N,++Q MMC"7QIJ,7U;VNX'*)=CSA91F$[@"PYNI.W! M! &1, !D !X;"]W;W)K&ULM5A=;^,V$/PK MA Z]MH OLN38SH=CP/&EN!1-+TC2ZT/1!UI:6T0H4B4IV_GW75**K!0R@W.3 MAT02Q1GM+,GEF).-5(\Z S!DFW.A+X+,F.(L#'6204[UD2Q X)NE5#DU^*A6 MH2X4T-2!=4/5T"EYN+( J>&^[8 M*C.V(9Q."KJ">S!_%+<*G\*&)64Y",VD( J6%\$L.IM'(PMP/;XQV.C6/;%2 M%E(^VH?K]"+HVXB 0V(L!<7+&N; N67"./ZI28/FFQ;8OG]F_\6)1S$+JF$N M^9\L-=E%[0'$-2#^#^"DOPZ/P+4.PA"E-;HBY_U7<9>QE]+<40&_1Z)^_$QT1E5T*5K M_G]97@0W:)(_<+2#/;1=2>^1Q1.Y%BE;L[2DO&L,*M+C;E*[[L]T01.X"'!A M:U!K"*8?/T2C_GF7\#Z'_N-%_[&.?_B[%I[N2 XGZB^&GJ)T',DME83KG MT*6?=$FYABZE7MB!2H>-TJ$WJ'TJ'T#AHJ9[A/HY]PKUP@X4.FJ$C@X>4K]8 M/^]>L5[8@6+'C=BQ-Z@9*N.4?&'Q?L&Y&]$'S2"#YY MCX)U\I;ZWXCLA?[31O^I=\!O^V94!+^WW9L ?XU=!<+L" M,JYVJQYIS=(>N?IV2SY^.(FCZ)S,,P9+\ANL4-#7Y9(EH'H$!8""E#!A)*'$ MU/H*3@7:(\U6 E_B*TT-T\LG8C(@%,'64J$ALQ8*31[8W+3JP$_)SZ04UFC8 M_E?;)+/9(K/$')$';''TA9(XAT 3=*?(S\%EN"SLYZ+>>#"H=U[;:FGF,B^H M>/I1DT3F.7I"=$O)8XL0:X9\R6IAEGE'' ]_L \[9KP8Q1*L4A4?QLV,)E2D MI #EC+-(H&Y=8V>;GK14]F+I\98ZAUI':2/!M&X37KI,8L3/7]LPDV7 4[N" M6H+:Z64"M0$Q=%OUEMR1*,B9,2X0N>!LY;ZHC\@-_MF!=D,\/M=5'A:P8@+% M"7(/N*G:.D5&M9FQND"DNIHT5>N08*HV&=@,\F<== +[3&,N19U%% M_9T'[?LW#9IWU?;+5V"MB=UI-;WH RM%U#+6D3>Z!V9XMRH_[I45VJG4RWBH MTGBG-#[(W'@LW"N,1I6=F[T?=JC0G5V/O&YXZ@39I8T_M;J'UH]OU^5.>>]A MQJ.=&X_\SOEJ6["Z=NT5Z&=HUY!.@>_AP:.="8_\CKD].3_79;I3I9\F'@]( M2I\Z?T?ZH8]*RG$>ZODW#] M0LLKO:H8P];A0PYJY&ULI53;CM,P$/T5RT@\H29-+Z"21&H7$(M8J=KE\H!X<.-I8JTOP9YLE[_' M=M)04+="XB7VV'/.G.-XG!^,O7<- ))');4K:(/8KI+$50THYB:F!>UW]L8J MACZT=>):"XQ'D)))EJ;+1#&A:9G'M:TM<].A%!JVEKA.*69_;D":0T&G]+AP M*^H&PT)2YBVKX0[P<[NU/DI&%BX4:">,)A;V!5U/5YMYR(\)7P0P5**'[D3T.YW " MF"Z? &0#((NZ^T)1Y1N&K,RM.1 ;LCU;F$2K$>W%"1U^RAU:ORL\#LMK?[P< M+/ED&1>Z)ELC127 $:8YV5I3 >\LN#Q!7RQ DFH@WO3$V1/$TXS<&(V-(V\U M!_XG0>)5CE*SH]1-=I'Q0Z- _L M'S^;+I,7U_P,!\]S"^Q_[.'-3OF7"Z#MX)S.Y.3**;!U;"Q'*M-I[&_?N#KV[KJ_LK_3^\:_8;86VA$)>P]- M)R\7E-B^F?H 31LO\,Z@;XFMO:#+%W;:F1=CZZ4 MQ//K]SSO0Y8=Z.Z9V@_[!6);]W7N>;_TPZWM/KN5,7UVMVY:]^.#5=]OGCY\ MZ,J561=N9C>FA5\6MEL7/7SLE@_=IC-%18/6SN*7VMRZZ.\,CS*W]C-^N*I^?'"* M.S*-*7NK' M!]\]R"JS*(:F_V!O_V+D0$]POM(VCO[-;OG9;[Y_D)6#Z^U:!L,.UG7+_Q=W M HAHP'>G>P:B+YS]T]C;K\&F8#?^@H])HV%S=XJU<]QW\ M6L.X_OGUIY]_OOCP]^S=J^SZZO7;JU=7EQ=O/V87EY?O/KW]>/7V=?;^W9NK MRZN7U]G1>]O496W<\0\/>U@:)WA8RC(O>)GS/QE6YDJG> A M[-EO_%PW_N+\X(Q_'=I9]N@TS\Y/SQ\?F.^1!\0CFN_1GODNRM(.;5^WRTS/ MF?WWQ=SU'2#._TR=F.=[/#T?4M-3MRE*\^,#(!=GNAOSX/F?_N/LF]-G!W;[ MV._V\:'9G[\M^J$SF5UD[S:F*Q#!75:T5?:B<+7#[]_CHFU//TWM_H^K@0@R!S3N/AN".,[L MBH86+&&I86TZ?=3!N,X.RQ4\[QQP@KZH&].Y/%MVMC3=-D-F8WKXXK;HS,H. MSF1E,\SAB\HV30$\J+>PVSQ;V;7)5D57X8-9"=NG>:IN6.;9!E@@[F-=-W4/ M#,J/ZE=U5YULBJ[?T@/VMH7SF)/2KF&;)4RT*MK6-/ H_ES5@#/U?(#1;D:0 MP1,!2E5%#^,6=5L <(H&YHW*(F1Y M'_@E+-!W\!U\='#NNJJ+#O!WEETTL$R];.M%719M#^O B4N9#C"[=449[K9@ M$H %#(#'-#7P&]HSW%TX SP^.X#!3SP&/SF(89\!S7W8!^! *N1IN^;;N5]G2M(#Y"&B B]G@T"+P"$'QQCC%[$]M MC<]<][076/L"L / GAU]FEW/LM<7%^^/ 7O_,=2 58#++9 %+I[U%KXNRE5F M-W7+E^'P2^,/1I?C@"HV?%G]J@!<72Q LL'0C>UH;F%[?_J/[\[/OGWF1MOY=:B6">[F MN &8S,)L2%3Q?H&% -&VM)9%*'9#T;@,P!VH'2<%C*R(1:PM;03^6G;%&F9; M#,2/RL*ML@5H$@@C9^$6\91T734@==TQ0'&KN)5%MK2VNJV!"HAP<6M9 [L\ M:4 5()@2WQC:DG>8]<5=MK&NIGWG]/&F: :&"R"#O07<8:9@HE^$4'^!U7&; M%\O.R-V:#HFHR>R\J9<%\SU@+.7G$]0ED'37H& Y^068&V 'C02P(K?:-(50 M9V.619,#/[VI.]OB,P4?JP8(=K@MN+4>.1K0?=D#A&$Z!\J)@T6&IL)? 2$) MHZL:D*?+%@#I VBVAMLX1.K?>%+_YB"A7L*MY1G^F[T$G .P&474#P:998FW MB+]/,8$_:F[^QT0/(>X!L\;;6X'R!G!I:OBY8C8)HT_FIB *4"1-\7N$V_HB;7I5[82@.(@OQ*I+R07*KP- MG 9H'DB%%!/$E2YK#7+=HJG_6P ,<.9MGKUO4'_!0R"9;XA%XJ=72$3FY WQ\RO@B>VRQOU?$&N? MPLI_[8I9F&#C)S#)! N>@$50'29@:832.0(PPG26_61 KT%IIS<)--SU<%7T MA;E#$6)H). 1@+\&7E8633FP&@ 6DVE$I/(U^!?VU0H'=V1O6 MOQC1>L*\.7H*$(EO:B2D?;M:X",'( U;)(""*0#_DP),JJO7%\&6&>JF@M.K M?)W:6?8D.\D>GV9;D 0.6$H[^OGL%'Y_I+__#&H< *C;CC;S"!XZ>R(/(:,; M )2CW_W/Q0;L#Z!#U.;MHF=;A5@)/O:M//;J?BP2)('?8;L=7@.(CFEX*O\" M/6)I6"_X%B]63S;[8_"Z,S>UN44E'+ JTMAN5Z!LXQ[-#1L^'1E52]:NR[HK MAS70!*I>F2W+H6,5N&XKO%;#GR:$'*()"%I&A".8E?\"PW'8@!@HMEEK 57@ MQ .J14!C""E$0\;(KG:?<8YHJ[53N=TPACE4XUB9(^+T$%:M$&0^J.&X'5,E M&FQ@G\ WB7L37$225+ :H"W11#3*W-7($:["C@@@CF"8PL!K":3@3\, !8FI MW(@!B+J];^=L&D6<97KR6?8WW-,8>'QG54XJ4/@-+KP#W*L=74-7"9;@]*RN M$K.9F_[6_):#JO$<'1(U*5',1-P!GS5M1;9#&R;+#PTB+)J;F#N:FN0LP&9@ MIE=D4W $U; RI!>,V6E8#C4'?T+B>D)-0!8.['/T;@"K957BD,3]WDO<[^_1 MIX7[>,/F6GG0)?*@*8GZ^V9,E+_2,S]0S\4F^P>8,O6"+IK9("A90]<%GU)1 M A]BFXT],$A*EAD3+.>9*#$=5.W1((.KR45=4P'(LPL:Z:C\(D4=G0\5QF",;%^Z)MF\#9",NBZ+:\A71 MP6"MBH54OHL!(^D&USY2;N;LIA2QYR]SQYD12<$%P#J6O3&F!!RJO<.#T.^@ M5)Q-RW* %&S7=#=U.3&? 898*5A=I+83;'$)9@ J'?TO8I7Y&\N@DI0[";U M/@\;9%N*]"O+GA-@K"A]13:3. (1L=W 5>+%M1:XJD&R0,G;HA+$6L(!!G1V M&B(2IX<-PR 3/I"^@+M['3MRK@ U%E^M^/\;EDUX&;JAV(Y5+U3.'BX4'^(% MJ/V4HM>&^PX_[5>IVG:@"QFI4\(7%R!T"M0IA@Z6 B+J\,:&%IT)^$#')H-( M9/)8"!\IO,@5GW&]1B=>;2NO:CF_"Q2 J^(&93.YK'@CR ;^AD<$%KE!'@1R M+8)#!*=5P>J');<3/K= @UV4*R9^Y%0W1DW7'!@)X*2,"^X3C"* $8$._*VB M-/M'\5 #P#*7$4OX&QWN\A";TXEO! $(IZG['H@<[G* M= ^94T>L,%[X7CQUP'KKLK, Q]:NT5-+C#?^QD.@0#<](J8#T_U6%6=R!27J M,NZJ[)45V"B:TT_ A]7068+'/,:$. SRD]XL83=S9#((.1SKLJ/K%Y_S="A0T4B%JHRLS1*5T,D M!X,2O:)3"U\ILN UL,H6XQVNYS57\;_7I,X"NT72_6Q07B(O1(." 3 &;>T\ M:>0\/^PV68!0"H,02#Q73,0[CZ7$0\&X3H0P"F&>SCLFPA7 MW#V5\!-4YW>F_,.U?/7NW7="P&$;E/*)(3OW SB#03ZR]WIW'^ ')T"?5.V/ M?KI\=>Q=+,#)^8CBU">/7U&NB(IK-$";VMPH8O6KVOE'2/ BRT*]#34[L@<% M%6VG9T^/AMM7TA29,OV0V'D@NUOO!PEVWBS[)#N/-N0]!1K)BN.+/BJ4PBJ$ M&&@;.[$#U+#\1+1 MFI>(;)AE<,&0@$O3.V.G"\4'2 FJR>\,O&87">K6JZRD+Z(FV!+W9T@M2;"G MGET*@U&,QK/0'E"_>>#"J1:H<'Y#ESF>S M'85WU/>[Y]0^EC=#4%RV"3!K $Q2QY=?3)NETTD4\S1,NB"4&)#IX@$OOA1'+V4>RR:.@B MZ,KC4U2JA0<%N5W**8;0:83$/4R!-U0NQS$1%0L5$U$OH2ALCJZ=8WW!C)(@Q(3Z@NH!&2YV,4)[N;HP[M/ MQZIW=F;#.2@Q27IMS)\(QP'8B DW[!LDOY"G' (<64'>#9PAGT4U$B-/A]<) M@5U<;%U\UADWQ99=Q 7P'5R6U$>_(ISLW:?8-QK[Z]6;&/:G&P(MM_IU<+W( M3423T7)D/XJVA9(9GZ*;FAND0\&!]1I9#-T;ID5(()GCD17P];(?NQC$U1PBZ$QLF9VV7"0H$S[ZE!&LW@Z MQC_+WNS<*SND2[MD%34!NMYXHF"(X$)R6@_K,=R]01T0BD\:(1B:2IKK S@9 M+![TZR M=,H#>Q/-1:Y=UK4P=<.VH 1LO7_,.[\5I*0MFSO3E;43W[BL5'CW MUBX&R ^T8J[N!.^P)^8[=T#M.(")W"%+ :X-I+8T9#>2%2(.Z1G8Q),4TS"G M"^Z$RI*<$69&BEE180A+N1?K/&OD\@ %E JI?A$QRKV7-R8C=H^PX"XYYP*E ML>V Y9-%1E311V-W039!IYZ/$)#)95-NTSV0NZK$S+0>$XP4^6J V"_ *^BP M.RR$T8'4(Y9RHR>\S8607-1W4= G0UYCL)<(8]=760DI)ZQ&#>=BGP?J/&:)BI^I*O@SN:H^8M@ MA,FG=BW>.+CQ)KIG_I'OT2J;R]P*P']"-\PXG&?DHF&("5J/DSO4O79VCJD@ MF $KZ1PY\\5:$E%\?MJ\: ARE--[4"DY#TK)^4'=@C)AAK)GY\Z;P ,G]93? M.%>:!-I23*I+'E:!@N=M)2N;P(6)V\# 2^3'DAWJGJ4IAQ02Y%0V-MY 82!" M?B:)HX%SJAJ8D;L3_E*M^5F$8I+W.,NN$6F]J*-[5B]],N/ $J4!!FTP#T,IX#@?;U55LB%)% ,, 8SE#!^.9 M9A%.( MI(XY&!UE+&+1TG;3YXHEHA6W_9;8 >7: +'.Z10D[TGSQD\+.@[&2G&(I^A@ MZ8Z9/H4MV>?B1V&:]7:6O;QW6T./.N,H'?;^J<<27K@YW1T8A>8&5=@0DA'N M29IN'KE)HT=(LLX-)R&WS&?0; OL#7[=6C)F5$V 9U$CPG1&5HU)\<3<6XY8 MJ0\+S2&Q&"E9@AB>%U?B,)&3@' B%<"S>%%-=!.\TDPB!!(S&25,%B/J1(V> M%/J[N@_)2AAWPL()NHG XB40IL$A0( %YB-9--X6AFP^H4^>3R)&'@,!_+:4 MI$>X7EB[5(N&0TME"1?$,>8J3G[Q8=V@('[9T?(Q-FA".E^*A_T.V+T"K-8F M+Q^<>0=Y="@_.#M8+_#\.DH*O8R20B=9]&^;*F$*RPZCF* C=>3+!D[#4394 MIO7HO([7JXT7YO, MO+"-SBQA05* [S:L@(C"C6%%2?AE;TAV8]'ET6B\PFH,3]T4L^PU)BRP4\PS M'E+O*,BB4?]5C?4)J$$'57]NX!&4--Y[!9R)L@@H)]Y(I"B<57G/2(GR!XLO M 8@2=URK\ V$B.ET4AU0[K.><,)M<

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

+H^HC_4L5,L&Z9Q M)L6?/#'9V!DXD&#**F%>Y.XW/,33M7BQ%+H>8=?H]D@YKK21^<&8&.2\:&;V M^9"'$X.!=\$@.!@$->_&4Y@_SV?1I#=/9[/GU:3U_^@#+Y\?Y;'Z_@O=KMA&H M;T:N(JN(70 MZT#@!=$5O+!-0UCCA1?PIG$LJ\+P8@M+*7C,43S; M2D-=LAC'#O6*1O6&SN3''_R>]\L5ME'+-KJ&/EE1:R:50) IW&O#J3@Q@5>- M:27@D:I<6\E24>LJL^_ 4K#" "L2N/]4\9)ZRIP+Z:K3\R&M,P1CRP(VMK^A M5/*-)^0?6UI50TL<:94MK;*EA4=:L-D#TYHNHUC0S%,>,]N]MR=QWE5<)/2G M=&TJD'HRDR(!GEOO:&$T=.$GB#S8(U,:'JWB-V+?(WEXE"]8G%&T:O\=F9"4 M_.Y!:2;SLC*HOI.W8E9RPP3_0@RU3,V.*818:G)FU?H'-9NPF)!D4?/XOWQT MH$ :8DFWH+;!DX$AB%0*2KMZ\$CB(5"'5GDEZ@I(D"HPYJRYUVV8N52&?VD.W@>= M0>#?V+GO=6].^N!2@FT^.B']Z7J.NG"N1]V32S9'M:V?$@WUO='PU"S5H# ?!P &0 'AL+W=O MQZ;2R'(?5(HX[?='<^+ZQ;B&>3BNUQC?:Y>M0TBSN4G)!'%,(! M$8U?+6;4I72!Q^,#^F>OG;1LF<&/2GSCN2VFT6T$.>Y8+>R3:O[&5L^-P\N4 M,/X+3? =C2+(:F-5V083@Y++\&>_VSH/2; MUZO[Y7H-EQNV%6BN)K&E?"XJSEKL1#?^=983:?H^ZE*A#S#TWGCJ&-0O&,W>OTM&_;_. MJ!AV*H;GT&?K<*% [>">KO'<&+2&^+^@L:3+B7'K:T;;Z)PZRZ(V!&7,*4%G M4YX6M"F0CN8/I2$3C$CX9"RP<20$9ULNN.7!8LE]KO?HZL]@VW*!O./MO;XP MG16TWV'/H4&-SK)3@OJ)&;=BN*UI_1LU "[WD+&*6R9Z($GV!0P2>-34QK1] M[4$EF+2>#OZJ>47]Q0:_Y!;NE,H;+@1<)E>0C."!*.J#@D$[/59Q.;CRI6U= M.NH7,+KQ(!UBIC35J5(R=P2M\NI7TJ*6_LS1.=-8*6W=90.#>T?L&EQ)@U0? MYHV^X)+2.=;FL*FGJ]F#IN!4/RXS4>?DZ=QVY"$S[E,:ZEX&ZLI1^K/4/>^; M,XL.WN7I$15-T2:CT%=DV@"ZBST.6T.?@:]&X'0!"&UL?51M;]HP$/XKIZR: M-@DU(="7,8@$K-/8U*D"NFF:]L$D%V+5L5/;@7:_?F<',BI1OL0^^^ZYYYQ[ M;KA5^L$4B!:>2B'-*"BLK09A:-("2V;.5862;G*E2V;)U.O05!I9YH-*$<91 M=!F6C,L@&?JS.YT,56T%EWBGP=1ER?3S!(7:CH)NL#^8\W5AW4&8#"NVQ@7: M^^I.DQ6V*!DO41JN)&C,1\&X.YCTG;]W^,%Q:P[VX"I9*?7@C%DV"B)'" 6F MUB$P6C8X12$<$-%XW&$&;4H7>+C?HW_VM5,M*V9PJL1/GMEB%%P'D&'.:F'G M:OL%=_5<.+Q4">._L&U\+^, TMI85>Z"B4')9;.RI]T[' 1<1Z\$Q+N V/-N M$GF6GYAER5"K+6CG36ANXTOUT42.2_=3%E;3+:\YK$)Q&_UO(< M>E$'XBCNG\#KM77V/%[O%;Q[69N:"5 :9C+7^%BCM#"S6)J..YPH6\#O\;8.:HSE6S,ETQXM9%@BY$B1C M+M=@7:_LM,S_H@%+U_HEM;2A)AMJO*6F6VH=8,9IVXD4,W+Q,*F21@F>,7=F M+"TT!JQQ(,BTI/0&F,S(KR1ZA1L1&Z1@LAU%[4%R;E+ZX<\4 >BZ$JBGD'IJ MX'NJ>3<'66F5U2GM*6<&9]"]@@5-"5>D2\(RDAUW?>'F!^ 3S4-#]5+/+Y6E M#&<0?X!C_S@\D&6)>NV'CR'6M;2-0MO3=KZ-&UG_=V^&XRW3:WH_$)A3:'1^ M=1& ;@9.8UA5>9&OE*61X;<%S6C4SH'N&UL ME59M<^(V$/XK.[[,#76F\D^J;SA -O.6BT),@,Z8E85D;P I\4Z"K/F7J_0R%W MDR *]B^6_"4S]D4X'9?L!5=HGLLG1;.P04EYCH7FL@"%VTDPBT9W?;O>+?B# MXTX?C,%&LI'RFYT\I).@8PFAP,18!$9_KSA'(2P0T?BGQ@P:E];P<+Q'_]G% M3K%LF,:Y%'_RU&238!A BEM6";.4NU^QCL<13*30[@D[O_::/":5-C*OC6F> M\\+_L[&3<=*[D#9U81F!RY49TWD>&$W9644 M?>5D9Z;+Q6J]?)ZOGYEHO?9^O%/<[V+SR+^5A57T.U<0MR)>V?P MNDWL78?7/14[:J.JQ%2*%R_ BA26*)C!%&96*]QPU/#7;$.K2#Q_'TN!=] [ M[L 6U$B7+,%)0!6C4;UB,/W\*1IT;L_0[S7T>^?0IRLJT+02"'(+:VF8@-,! M/>2E0*HEPUPMS*4V^A(>T1P+ZJS;XT&M,P3C.*C_<5 U!_X]A\1S**CQ,*UE MPMVB'3<9&$*;R[QDQ?OG3\,XNK[50*C(^"@>2R$)+P5,'K*IE2$HBV%"E<@ LCOJ51J]N&%36A M?7982E7-K<1L>P)\HW:K27?1 *B":$?);9*YI2F^4A,M;0@-8"MJPU=BJ:#E M:;?W$"ZU(UA0UN4[XD_[;7!YAZ@#_1AF6E/Z:6,85SXS@P;92^HL-G$D$+?0 M;^0%=&-Z##IP1M_]1M_]#^M[EB2J(CIV3WY,Y<<$?M;O:8%OI: SS#HUMBF2 MW$A?":?VZ'3"#CC:^3G%_EB50$H2K&BO2"X;^4KIWV73EM-_'N]H1<]52(USZ(KH ]^C;P1#F&5,OZ 0;W4!\ W.F,QNI M"*BH6MUA^P/X/8(=TB^*[./FJ%##@_,T1W)O;PT:7&+]T=J\;2XF,W\>_[?< MWVJ^$'M>:!"X)=/.U35I3_F;@I\86;K3>2,-G?5NF-'E"I5=0-^W4IK]Q#IH MKFO3?P%02P,$% @ PX((62/_A*7' @ _ 4 !D !X;"]W;W)K&UL?91M;]HP$,>_RBFK)I"Z)H1G!I%*2S6FE5; VA?3 M7ICD(%8=F]E.:;_]S@DPM@%",GZX^_E_%]_U-TJ_F!31PELFI!EXJ;7KGN^; M.,6,F2NU1DDG2Z4S9FFI5[Y9:V1)X90)/PR"EI\Q+KVH7^P]ZJBO*-RB$ Y&,7UNFM[_2 M.1[.=_2[(G:*9<$,WBCQS!.;#KR.!PDN62[L5&V^X#:>IN/%2IABA$UI6P\] MB'-C5;9U)@49E^4_>]OFX<"A$YQP"+<.8:&[O*A0>V M*<)2"2I/+E? C-NCS"-EOE=DW@UUN..2TSM+8*548N "FLV6&[M-F+(-O4F+ MFC-A@,D$*"]"J]N!B9*?XEQK.OW?J%*K0DB_DG'2[()H;3=V6X7+ M628WU(%BI>E=NR >*&>:4F60.N*Q+^T?5&2&>E7T'4-YSZ4MBW._NV]MUV5% M_S$O^^(]TY1( P*7Y!IZ++7E NKUD5]+Y2E;E%,4VK/J)T!G2^5LKN% MNV#?\*/?4$L#!!0 ( ,.""%FE3<_1? , ,\' 9 >&PO=V]R:W-H M965T[:W:7 M;AB&?5!L.A8J2ZXD7YK^^E%VXN6Z)/M@O9%\R(+U"HW=0+O>/!$]\6UAWXLTG%MOB,]F.UTK3S.Y2,ER@-5Q(T MYE-O'HX7B=-O%'[GN#,G:W!,-DI]E^RG/5I.4DYV=K9X^K)9/ZS][L+J?/ZYA_O@.EK]]?+]Z6#ZN M>_"X7,.;-=L(-#<3WY)#9^:G!_!%"QY= \C>%#2%@:6,L/L-8!/D7;A1L=P M%]%5Q%]K>0MQT(,HB)(K>'%'/V[PXDOT-96WMGNB+YBTP&0&R\\UKZCN+-&G MKOAKOC%64_7\?2X!+7QR'MYUU-A4+,6I1RUC4+^@-_OANW 0_'0E^*0+/KF& M/GNF#LUJ@:!RN%-EI20%;=SN_VF=XW+5VWDNZP+!NO* C>MOJ+1ZX1D:0&,Y M]0QF4!O,:P&"FJ^)K>IBJ[K8\!@;;/; C*&TIX)FGO.4N>Z]A64'N*BYR+C< MFL94(/5DH40&O'3>L6R2T(>WD 2P1Z8-W#O%5^(P('E\E#^PM""V>O]-,#$I MA?V#DLMP;5%_(^_$K.*6"?Z5(C0JMSNF$5)ER)E3&Q[47,+25__J:CYZ()&& M5-$M:!QY,K $D2M!Z:8D4+;<&?4%$I]QTQ=NB%O2_R'^/83#Q(V#T4DB1^& MON!B(J)>_./(C?W^-:))&%/2@W.I"N,A?2&))'53W5[)7#KV6ZHF^B/D(!P- M8*T('))>& ]H#/H!W)-X#/,TK MN'D8]&].FN%2@ET^>C']Z69.^G"N.?V32[9$O6V>$D/,:VG;^[8[[5ZK>7M) M_ZO>/G4/3&^Y-%2[.9D&M\.^![I]/MJ-555S96^4I0>@61;TXJ)V"B3/E;+' MC7/0O>&S?P!02P,$% @ PX((67P89,@K!0 KPT !D !X;"]W;W)K M&ULK5=;4]LZ$/XK.VFG S.4^!H"A7>_U7[?6CY="/E#991J^%7D M7)WU,JWG)_V^BC-:$'4HYI3C2BID030.Y:ROYI*2Q!H5>=]SG$&_((SW1J=V M[D&.3D6I<\;I@P15%@61RS'-Q>*LY_::B4M:+W)/QP#QO'_C.Z$*MW8/)Y%F('V9PG9SU' .(YC36Q@/! MOQ=Z3O/<.$(8/VN?O3:D,5R_;[Q_M;EC+L]$T7.1/[%$9V>]80\2FI(RUX]B M<47K?$+C+Q:YLE=8U,\Z/8A+I451&R."@O'JG_RJ]^$]!EYMX%G<52"+\H)H M,CJ58@'2/(W>S(U-U5HC.,9-429:XBI#.SWZ=G]_\71]OQ[ M M'=!=Q/KRX?X?IN&MU]NQ[?7$(TF5Q.)[ W)<\Y5?NG?8WAC9-^7(<:5Z&\ M+:%<#VX%UYF"2Y[0Y+6#/N)NP7L-^+&WT^-?)3\$WSD S_&"'?[\=C-\Z\_? MMAE") N6YT!X M=<$SYCF"Q$2E&MX(*I.!>JE!3^C9Z5EDBI_[KVH8H2=$X8TXQ"O/*MS;#Q3UK_LV8WGY9??()A<^I4G E2D4SD2=PPU*J]!(Q8:VIY,3T"0S9A6K/ MW8>IT+@Z)CGAL0V(2:Y#\N C^(CG(PQ#O'A!@->!XYAI9X!7]R ,ARMTK)@3 M)NUF?/HP]%SOR];_/72P7U^W _"W V@<&1!>Z"&77S!WI@V9][S][8'=P?[K MP66:8D<^'X[J5EI6%MRI@]@D;$X@P5"06&^,"1* MOD2"QWEIV+=@.JO9WL6K#HK/)3-DKL(WDXUPJ-U'+$,CH524$IW^+(DT.,T& MKR1@RWMH2K6C1X1MCPC_4(^82I+@*0!/"&M:V.B,71UD-X+W=1#].KJPT=DJ M.JGZ\A_H&%$'^S;G?/@F!98ZBN.R*"MRW>'!J87^F^6UW31DPE3P_,"0>A1R MHT?+XX\0'/NO.%Z-@^/@S6RPX7##V= '?PA!",-C"!RTJ4NXN8F;]N$16OHA MN(&/]VCO.N .CNLV:*3GA@92<&3@#89N-3^0=&UD[*1:T.# M6B;8G-,RKR&@54Q15$B13?76+^FUQKW:S\_&/EDG$+I_M;227X0RS1%Y);$= M\AJT\AJ\6UX/DGZ>DE\'<"=X3%0&UZNFC]*3F'F7>G8&Z#Y!C/%LBAJIQ(3' M[U@4%@$.555EI4Q8=5!W&T-]PTIT\5D;B+R&N/9>BBN(E6 DC84TJDI*:0S? MMJ>3CN1^VW7?E/#-8L6U]HW9O$A7*C#CE0HP!]2;ZQWA#UQ_Q=7 -QQU+351 M#5U%[J\=H@N*V,VG M+3-*/J/-W.ME\C474(7SU>?;V2/XL-![P[6V&7U14F@=P/15"-P,3H/U&&_T/4$L#!!0 ( M ,.""%E0'S%'S0( T& 9 >&PO=V]R:W-H965TF.=(>QW"[;&.=J'8J9I%]8H&<]1&JXD:%SU@D&C,VPY?^_PE>/6'*S! M*5DJ]D"#]=[]$]>.VE9,H,C M);[QS&YZP64 &:Y8*>R]VG[&G9ZVPTN5,'Z$;>6;$&-:&JOR73#M!<0^[XK(9SEFEO6[6FU!.V]"\?KLP_L%6PHT'[JA)5H7 M'*8[BF%%$;]"T8CA1DF[,7 M,\S^!@@IWSKI>)_T,#Z)^*64Y]",SB".XM8) MO&9]"4V/UWSM$M)4E=(:F+%GIQ*8S(",NL0,IIPMN>"6HSF#4:DU2@L_!DMC M-7U2/X_=1\76.L[FRJQC"I9B+Z Z,J@?,>B_>]-(HH\GM+1J+:U3Z/TYE6U6 MD@:U@O_5=4S#29;C&FJZXH".[>C$"QVDBHK:6+)2DG:#L%*"N@.7:V#&V>B! MD1ZXXQ_8#4WX!_PM7+4C&AMG4=R D^T;D;H(T5=5:6^M>-ZA*_,6]:I0W3*^Y M-"!P1:'1^44[ %TUGVIC5>$+?JDLM0^_W%"_1NT7>J!)A'$6W8<6X#!8SO_:H%S-56\$E/FHP M=54Q_;)"H8[S8!"\+CSQ<52L.5!(W%/%@. MIJNAPWO 'QR/YN09G"=;I;ZXR>_Y/(B<(!286_DRY897"OQ)\_M;AZ, \BQ8+6P3^KX&[;^>(&9$L;?X=ABHP"R MVEA5M<:DH.*R&=G7]CW\B$'<&L1>=W.05WG/+%O,M#J"=FAB56]-XKAT M07FVFG8YV=G%_;O5!G[>L*U \\LLM$3I-L*L-5\UYO%WS R1SS MA!'<7J%+^D<3#Q?\CT'<6OAGIM,*%-KA+^6 M6V,U)5>E+K2',B[4'&M.:8 [-0$!0.3-0(DKX$ MI*"6K%+:\F\$R.GUJ5I:TP-BJWA=&6 R]S3 C:F9)/-,&8?@,A,UY0+8'4*A M!)4]ER4PXU@INDC1G?KHNEL"SRBYTG2>P8P"E(-4%CM^E)86S122_B#ZJ0.!NX]&\!$-.;&NM2:/J(#) M*VXY^I-9G:N67G-1:>9G6@^SU@X M,K_2)+0Y3>"G_Q]"Q<2%$W(#@QYUQVZD/D)=0IX\"2TT MX_!BE,.3SWZ%NO3-S8 OU:8#=*M=_UPV;>,_>--\'Y@NN30@L"#3J#^BZ.BF MH343J_:^B6R5I9;D'W?T#X#: 6B_4%2U[<0=T/U5+/X%4$L#!!0 ( ,." M"%E0$1]'H@( *X% 9 >&PO=V]R:W-H965TLFC:I:D((C#*(!"U3F5JM*JS[,.V#22Z)5T_W[G!#*F M4;[XY7SW^+FSGYMLE7XR!:*%EU)(,_4*:ZNQ[YNDP)*9"U6AI)-,Z9)9VNK< M-Y5&EC9!I?##(!CZ)>/2BR>-[5['$U5;P27>:S!U63+].D>AME.OY^T-#SPO MK#/X\:1B.:[0?J_N->W\#B7E)4K#E02-V=2;]<;SR/DW#H\MV5+O!PO4?_TN1.N6R8P2LE?O#4 M%E-OY$&*&:N%?5#;&]SE,W!XB1*F&6';^D:!!TEMK"IWP<2@Y+*=V1/Q:RPOH!^<0!F%T J_?9=MO\/IO96L+U'#+V88+;CD:N.8F M$_?]8;!YQ.THXYV M= H]7I$4TUH@J S^2^$8V9-PQ\FVN.*@-(DBZ1F+J;N63B%3@C3,90[,.!N] M#M+KC)O7<4,?'E%:5\M9KA%)NQ8L:OJV3(#:")XS)\5SD-1MSF#0"VB,+@>P M*"NA7A%A@Q(S;@^<#83#/H2#2UBS%V(5#J!W21_LF6LEW0T$?746;MF-&LU^->][61W3.>< MB O,*#2X^#3P0+?=H=U8536*W"A+^FZ6!354U,Z!SC.E['[C+NA:=/P'4$L# M!!0 ( ,.""%G:3'UF;08 $T3 9 >&PO=V]R:W-H965T9^(^8RJ?5.W-BM[IVHS$8R M$;>:F2R.N9Z=B4A-3VNMVGS@3DY"2P.-WDG*)^)>V,?T5N.N44H)9"P2(U7" MM!B?UOJMX[-]6N\6?)-B:I;ZC"P9*?6=;BZ#TUJ3 (E(^)8D<%R>Q4!$$0D" MC*="9JU421N7^W/I%\YVV#+B1@Q4])L,;'A:.ZRQ0(QY%MD[-?TJ"GNZ),]7 MD7$MFQ9KFS7F9\:JN-@,!+%,\BM_*?RPS0:OV. YW+DBA_*<6]X[T6K*-*V& M-.HX4]UN@),)'/=\-\;N>!CR)A=D\:%OI)2L,O=)WENKPW=+4\=JT2&QHV M3 (1K IH 'B)WINC/_,V2OPE2^JLW=QC7M/K;)#7+KW1=O+:_YHW?N^/C-7@ MUA]5_LBU=:JU4;P=FY3[XK2&@#)"/XM:[].'UG[SRP9;.J4MG4W2>_>(WR"+ M!%-C-AR/$06&NN="RV=.H< N$T#/$&&8.1=&3A)N1<"X85]%,)')9&4%0NC7 MP665E1MQ5%OY$ HF%J""!2BYI#)8 146H.0:*!L*S7P50WI(V0)"=B)ES"Y6 M8E@PG@3L!OE-<)U @&%3H05)'*L(20EZ,DV"(8B-I?%YQ&98:Y@@FC*03(!D MQ^QGY#B3RP;_D9)\-4GDGU@BMX%!'*6F38W'!BJ.52#MC*69]D-DEF4W^ @4 MHI5A']G.X2ZU^]2V#ABR$7)-PL0+=B63-[9]^G#HM;POY;6%P[2PVUBFX='M M-AT>L0=EX8\U$,T#MH&AW9*AW?^:H73,P^*8JZBZ$5 U5:^4S]T#!- FKQ@0 M<6/D6 +46*N8]7T_B[/(H505C$B ;Y45,K%JE9VO:?:/E5 $K-)U1>,[F3E0 M(!.\DFH59#1@5!24).GB!XG;L;5:U(*[\]X6'"Z7B!=4+L#>:M/_SM%NR>4# MXO 1-9U-/-XO>;R_-8_/>,037[![5U$-BI,K&$3'<,&E9M]XE(E-9*]8F2>8 M/DA1S%])/I*1M%)44GTS9DK >?ISF8\>Z>3\9XF<"W[DU9[#/$(IYU+CJ# M M+Q;]UZ:Y_$F@GTO0- 0ZI3R9_63>2//'2_S;Z+Z%0]B :STCY$-C9>PBH6*H M<%8%GU5*$LT2;6ZU2+D,YJS)75Q$5Z8U@"+M.'$M$&?.Q^6>YWX5RLR4I^]3 MY4%9ZU56?A52.*TIU\$[5:R+7[]^=!:W2@N7>%=E[3BS&>)O"0SRE1XN)I$+"0R:9#JGS*I15 5697 +A;;_U9DS7/MYQ&>)7EM]HQ;%]9[ M]/")LH"&8Y6(&5Y;]'?H'F=) .9P$SKS?.H08.AWN6^GM>O\?]2=-UZG7;0/ M>"%$&DF5D?9',CQV5/P]:+Q(S5U*+DQ4\I3Q*'^FXAU.("0"]Q1%M.0N2>$N M4R3=,O!;W4[^\X[<#Z"ZAV7;/FP5[7*(W"A;Q%^D2.2X8@$=V_7:G3;N\O0ZT>WOM#K6=@P/J>_2XHQGG2LSEUVXQWL8J M9QGI4#S:4)EZE+$N_QS\ 59#!248.E$ M"U&XC$<1*2RPO\LNT&*-*2X_K(JIYYEND02@=&W7E-/CF^Y12 0L,V2]@9PD MX+H\S%1+,OLI4Y0D1C-(UZERM=H(*R$!AZ3),MP R%)E"_E7XEE$S*M7E62- MI4\<D(5=B3&V-JL'^"E0.&UL?51M M;]HP$/XKIW2J-JEJ7H#"*" !92V3H CHIFG:!Y,=8QHX#T1J>XZL3%9VW5U&&/"]*W,,*67M50),W15&U=G M"EE4)"7"#3SOSDT83YU>I_#-5*\CU"W\47 #XY;?6*#K60EY:N] MC*.NXUE!*# T%H'1\89#%,("D8R_>TRGHK2)I_8!_5M1.]6R8AJ'4OSDD8F[ M3LN!"-Z2J%#YP SK=93<@K+1A&:-HM0BF\3QU/XI"Z/HE5.>Z3TOGT9S M&#Y/E^/IXV@Z'(\6-_#XTI_WI\O1: ']Z0.]3B;CY60T72[@\Y*M!.HO'=<0 MN\5PPSW3H&0*/F#R YC(U,0:1FF$T?\ +LFNM <'[8/@(N+W/+V%FG<#@1?4 M+^#5JE[4"KS:!WA#F23D&TY"CA@>N0R%UKA!^]U?:*/J@ M_IQK0TE2/T]BAZRM,Q9BUZ$ITJC>T.E=7_EWWOV%$NI5"?5+Z+T%#6V4"P2Y MAEFNPI@^6'A>";YA=@CT.;T7$<_K[6M+0/W'JO\W8&*DEB492W?75ZW ;]YK MR X:Y%$#K'9'?\0,PA:IJ2S+E'SG-&@H=L TK*6@E:';\ N9.E9#9 WX!'[+ MM^8=^$'+&DTH'2VHU^SY%:A_URS$\AI?+;,+4AE.I M>4ZMTV&PZH&UL[5AM;]LV$/XK!_<%&]#$ MEN6WN(D!)TVQ#.U6Q%V+8=@'6J)LHA*ID53=[-?OCI1ER5%48Q_V:4 @2WQY M[IZ[>TYB+G=*?S%;SBU\RU)IKGI;:_-YOV^B+<^8.5Y MYBQVF[*T/QP,)OV,"=E;7+JQ#WIQJ0J;"LD_:#!%EC']<,U3M;OJ!;W]P+W8 M;"T-]!>7.=OP%;>_Y1\T/O4KE%AD7!JA)&B>7/66P?QZ2NO=@D^"[TSM'HC) M6JDO]' 77_4&Y!!/>60)@>'/5W[#TY2 T(V_2LQ>99(VUN_WZ&\==^2R9H;? MJ/2SB.WVJC?K0%%*C7N"KMR[: '46&LRLK-Z$$FI/]E MW\HXG+)A6&X8.K^](>?E&V;9XE*K'6A:C6ATXZBZW>B0.4:+J$ M\&O.-8[)S1[5=8DSE9P5AB.@X=8<+P+=LN8YA),!74<3N"FT1H[EZE2PM4B% M%8B^GU%'B/4USV$VHLL4?E'R+'H2ZYV2FS/+==:)%H8C"(,!?%04\VZ[HV!& M#"ZF\%9(%[VNH&!J=(U]B)?A10?W912I0N+BG#V0^(')&)MDI M,==.1@, N MOL/?.U ?&0;TYYDF=09'\"'%%VNF0TKC2DKCDZ5$=:HD)XKXY+H CAG[JBFR M&V:V\!:KM"XP%PSD&]'DDMX3:Q+RD8R0$.RXYC6UX:]V2DW0'C)\X$P;X-2> M]_JXF47N#K!2\#^,2T<%7:]+%4YFJ+_H 37V.>ZG;43+?+:$+I%D?IEF6ZV3[= MI_6]X^#'A:98GA9[5WPY$['+&3D?ON> M62Q])VI\.OCAF^"[0[FV=;Y.,^U?+TU[CSO+^J&1H^\DN?'YXK\]CQ,_A]\) MZ%&$CV*+6\=[@05.YQ-J5-C)\'9*Q3NENQE,+L"-7N..S09K&ULG59M;]LV$/XK!W7H;&"P]>:WU#;@.!V:K6V\.-TP M#/M 2V>+BT2Z)!4G_WY'2E'MP7:7?!%%B7?/<\^1QQOOI+K7&:*!QR(7>N)E MQFPONEV=9%@PW9%;%/1G+57!#$W5IJNW"EGJC(J\&_I^OULP+KSIV'U;J.E8 MEB;G A<*=%D43#U=8BYW$R_PGC_<\DUF[(?N=+QE&URB^;)=*)IU&R\I+U!H M+@4H7$^\67!QV;/KW8+?.>[TWCO82%92WMO)=3KQ?$L(, YYKEU M1#2^UCZ]!M(:[K\_>__9Q4ZQK)C&N1S"1 MN79/V%5K!Y$'2:F-+&IC8E!P48WLL=9ASV#HGS (:X/0\:Z ',LK9MATK.0. ME%U-WNR+"]59$SDN;%*61M%?3G9FNKR[F?_ZX>;CU?O;Y8_P_K5N_"$NR"$3U*83,-[D6)ZZ*!+W!J"X3/!R_"LQU]* MT8'(_PE"/XS/^(N:@"/G+SH5L)')?2;S%)6F@+^6W#S!9VD0_IJMM%&T3?X^ M%G?E-3[NU1Z="[UE"4X\.AL:U0-ZT[=O@K[_[@SGN.$XW"O?^M\#QC8H,:N(!9DI1%F3-#W&\H)@5S69 XF:U* M#PB?J6JV/DJMVW M$EG@,=7/(Y] DPXM.4 3%BUW:-RA 3-&\55I[''=R\CJ MR5E*@<+\5VL:U7?24+UD.1,)/EN[DQI0 M;EJQ'[5IK"9!/[:35B_NMVLM#Z,[C&R%Q),^QKTV!/X NA',"MD*8RFRR#) MF=9\S0E^K61Q1+JW;X9A$+XC8,(->N2@RA 81@*AP#4G-?&1;C>-[6;Y@"#; M$+F J^B-W8-<'D_)(>F:K0]4!ON#H\*$M"@>TBI2I17TPC;-!Z,7*$)F)&#@ M:+Y.#T+KTQ"USRL2D@JM\-5:6&.R[E4)."9%9*4@P48CNV9@E1A%+]D; 0G1 MLEI2T@8O4^-[!ZL5M%WPH64YL! Q1"/_O&+6**@V@7N\2K?0[]=[-NY#% V/ M2A?;DQ1&(WNBACUWO-SA"GJ]B@;QS,N4RHH]Z8IZ(&I<;&UK#C1==$*3(NY MI_]0HU%8FDXN:S-3&YISP6!5:BI9FDH[D=6&FU)A!Y:(U:T9NH+"TI1;7U10 M4C2,Y[KC]&MX4%+D1K@UEL>VKB4:C&UL?55=;]HP%/TK5YDTM1)J/@B4=H $+5L[J1V";GV8]F"2&V+5L9GM ME/;?[]J!M),H+_Z\Y]QSX/IFN%7ZR92(%EXJ(IB_RX\N4,'Z$;1/;H^"L-E95.S IJ+AL M9O:R^QW> 0;1!X!D!TB\[B:15WG-+!L/M=J"=M'$YA;>JD>3."[=G[*TFFXY MX>SX?O8 L\GB_O;^VQ+FLP4L;R:+&9S,YLM3.'E@*X'F=!A:2N4 8;:CG3:T MR0>T<0)W2MK2P$SFF/]/$)+&5FBR%SI-CC)^K^49=*,.)%&2'N'KML:[GJ_[ M =^,:WEL)T^V\DPC M3[W)@Q,N":5J0WMS"K4AH%60,9'5@EET+XYG(*D[446Z*XHV>" PYZ)V:?>A MU*^\GH(;"H)79-H NF($*B6D4KKTI>2&KAL2F/I<<9)VXO.4YFZG-[CP&PO=V]R M:W-H965TW*5H@L?5J.6EBP$[2K=N: M&''6?ACV@9;.-A%)=$G:3O;K=R1EU6EE+1OVP;)(\9Y[>^Y(GF^%?%!+1 V/ M15ZJB\Y2Z]59KZ?2)19,=<4*2_HR%[)@FH9RT5,KB2RS0D7>"SROWRL8+SO# M9B>]'Q.[N).[Y8:C/1&YZOV *GJ']?322- M>C5*Q@LL%1/51SV! ;> 8&@$@BLW4Z1 MM?**:38\EV(+TJPF-/-B7;729!PO35*F6M)73G)Z.+V_O?SU9#R:7E_!Y>VG MR?7-='3_\?8&)K^-;J;P]I[-UZ:/'"0ZXOF<23,:4T@PE[ M(J9I&$G)R@6:]V.X$67*U!*N'ZD$%,(?HYG2DGCT9U,XG+*H69FIK3.U8BE> M=*AX%,H-=H9O7OE][WV+*U'M2M2&/IQ2K6;K'$',X5(4QEQF27\IE 969G"' M.=/DZ,@STU\LBM$Y MYRIE.3PADPK0$!"(/DCT.;/T,8_0/ (7(HK;2HILG6H%2N09O(:D^O5A2CV# MEPOK$,NH"+FA@>DF@(X:"OHA]'V( @JT(J7ITJ[.<$-FK2RU3$P41!#3[UYH MLB[]/F3*J(S,(Z1''-19:PC=:_ 'YF%,I%IK(5%J;#Y!^%4,*MBX51 MI8F M!<_R:G-HPFSSN"4ZH-*\L!$C ,.#C 8&WL+ 6AD,,S_.&3&-/!;4W:P5+@N% MR#!WB5:T3UE+%)3")<%12^3$- MD>N/9'I5,HTC-TIS/$>)N6!D:=Z/J[8O= M)3 [81N4M.E9 K6+U* ;063@.==/$$3=X @"OYL<@180Q%WOZ$?L)H'!$=QQ M]7 REXCDD::2(OI+$Z;0H'G=4P?9]1L0Y3^*7O$-SZC@X(DCE5'8C4AMA6E7 M_8"9'9!H872_9G3_Q8Q^3E]S%J"X-#&W%;*Y]UVA9CQ71HUAB&F%K'QZ\VH0 M^,E[]1VMG6I.M*/MISH,V0YH.]@9W*R+&4J#58<*1E6L1HN%Q(6)^&U%33IG M*4U\M?W)6E#UN6/'R^C82V+3(J*$.H]C%/6TTUWM@K4R>$\T0YERTWG?!F'T M#GPO@DM6IG1^HJG8IYG$>Z':",+CY-0S:F,/HEJMWZ\!-L0=U\(;9#UJ?<;D MP7/9%D8D-2.2%S.".K66W):6(X=M:JJ)$ZV@S9P8[#'Y["9Y>([PR(!W46_:1OH^U1,S8YFJUMXL+3=_;0<+J?S2"P MDTGR;Y1&$ W"JD!_$/M6VO;\,TW%3=$I:E]K= M;NK9^FXXB;\O=Q?(3DPM.+2?'.8EZW83.)M)=UMQ BY6](,V$INN6?5W2 M_1:E64#?YX+V_VI@%-0WYN'?4$L#!!0 ( ,.""%EW,(C?M , +<' 9 M >&PO=V]R:W-H965TJF4=N-DY7U]GJ:N6'$E7,?4K+&S,+82'J]VF;K:LBBC4Z72O-L= MII60.IF,XK=[.QF9M5=2\[TEMZXJ8;=7K,QFG&3)_L.#7*Y\^)!.1K58\B/[ M7^M[B[?T@%+*BK631I/EQ3BYS,ZO^L$^&OPF>>->/5-0,C?F*;S_:>H'5KFPO&U4;_+TJ_&R5E")2_$ M6OD'L_G,.SV#@%<8Y>)*F\9VV$VH6#MOJITS&%12-__B99>'5PYG;SGD.X<\ M\FX"198_"B\F(VLV9(,UT,)#E!J]04[J4)1';[$KX>/TA.ZF,VK-Q%RQ:X]2CTC!/BUVJ%<-:OX&:I;3K=%^Y6BJ2RZ_ M!4A!\< SW_.\RM]%_&6M.]3KGE#>S?OOX/4.NGL1K_>6;K]B2S>Z,!63T"5- M7]#GCAW]>3EWWJ);_CJFNT'M'T<-)^CX=P_ M<.Z_ASYYQ(DLUXK)+.A6_&TL79NJ-IJU=^%;HZG5B&KO%:&6[(])>3_8;,7H MLQ"D.!9$[H+P/HAF?T(8$H1]6DA7"$5;%M81AQ8@%)!10-JPY?-8Q;#TPI+3 M966LE_^(>% 1!/DO,7PPF&)M3(PIM1=Z*=&2))QCT/F.\D]8@(HEHYG%>8'9 M,SN/N>&IM<14S/,LOZ&=P M(9!R0O$/BC&JYJ)X^I9O0-S;QR0TY>R#:^M3FV;&HVQ(:Q_+64SK:13TORPT MBDE8IMI*E$JJ+8:T$AZU]B9V0>A.H;ICB5VD$F7=HD:22U. D)H MG,:KE"%!$F*Y$U4>4W\\TO>.8,JB"LU<[N/!J3(E*ZJ50 H<,]T9SS1H=XX= MRO35,*T8),.5X1!WK7TS5P]?#[?293.,_S-OKK1;89?H#U*\@&NWT9VW':='*;.$G;Z?0!(B$)78K0 I 5[Z_O.0\/L=KT6 MYOY*YGIWWN.]ZL$'M5PY?#"Z.-N(I;R5[M/FO8&[44TE4VM96*4+9N3BO'?) MGUUQFD C/BNYLXUKAJK,M?X%;UYEY[T )9*Y3!V2$'"ZD]N*^DM2'I29"RNO=?XWE;G5>6_:8YERS=6J?7Y6208*T*?Q9?2D,T)DR#$Q/"7K][<\,^7O[]YI;U/XIY+NW@;.2 - X8 MI269*T\F/$&&A^R-+MS*LILBD]DA@1'(5 L65H)=A9T4_[HMABP*GK P".,. M>E&M:$3THE.*%JE>2_91?&$OE$US;;=&LG]>SJTS (U_M>GL*<;M%#%>GMF- M2.5Y#P+"2G,G>Q<__\"3X'F'O'$M;]Q%_>(6XB_;YI+I!7MO])VB.( P9'M- MI&V3NI-NN]0?5Y)M#I@HS\0ADR=L?H]7[-];HVRF*)Z>L%1#;%HG,Q31 86% MSB'(5;$D"O0$+"UR=B^%L4PB,ACX58)?GY%?\1#A(6376V-DX=A+F4D#(*-DY8'+ X8A^U@VEI2>9'H)K@,4R( M%&,EFZPBUNPQ'",IU'MMNF$36/&86[EFV@V15Q$ M>$R"29=SDMHYR:.=\T&"HJG*E:"J@[9:+"35'DH^'T#@-K=T<[B$"GA,%RUF M0?^MT^:>+4I4[SW!#(+9:1J(F!'%_<\_3$,^>0[6K86J1R+5#=! ^K;TCOT] MOKE](%3-(^3#@/UT=/)11]AA_0(Z$5"N.7,N"[E0S@Y8.!PS/DS@-ZL]7-/. M%.B$P:]@WF0(CH>1T9#7 2^_I-+: Y*L'PPCC-\AAGLPA"A^"P)\&MX.:9S/ MAL2G-&Q_/ PQ,Y33)@/V6@-1&)B!-:U3#NL*#T!2,G;XO#Z_*IPT!=D7I,GE M$F4"<=T]>!<:*U&HW[QW^\D0DLWQ_,]O;ME2ZVRG:ZZCWJ6UU7 M.F,,"Y.NF"@RR%IWT(9M:%(*V8L,P$M])F0 ,,,[<+>IK9FB4\)A3&\3.L+X MFX?P"1-0^2<6P5AT+9TZ8FM2Q];D=R8^=%2=U#&T+JV5J-%K)>80*$Z=:&6Z M&3Y,=@C).N&COJ)DE#<8P4,<6\8$$P "N]*[ J &<=2,D1</(C999J:K<@]\3+]6RRX<<*NQ49!!E6_R>PTJJ .1S$ M_0YN, &DVH)VX0Q@4>(JHA&WV[FC?#P&SG$R89]%OBVUQ[Q#:+Q3A1/%4D'[NR?< MG\:^/1ACE)/1##;Y3_7BZ=;6 \L68)94H=./,$[PT")V4ZQ^B(T'M!IEVODZ MR,#_$VIH^(PA4$]!$U5JF?XE\..3#2M M,]&T.Q/YA2LEHA6 A^4QR&=XM"[ 6!E,"Y&_4SZJP%)0/4S]0F#Y9BM MRO3DLU,_3AY6-^_6BEY%V=/3Y,JJ$K="!C'%!PV M%.J:&" D)34;]1ILBEK MF4H/\RQPPDX! QPLF?$)VRFW@GC-*06U(/XAM@\J;(GF X7; M@M$2' Z'O?2][#_0/S=?-LJ@H-<':F H$CZ:BQB+=? O"##C!@<*]PV.:&5 M)8=)D%N?PBD.VX;UR3*%AGX51"-U!FQ&N./L[>BR[GP/I\'*N,]!M!"%&GOZ M\8FQK2RF^T:2V/CBU>9-%G,(.$ S#ZOE9C-"6G0"A2OB<%D+")W 8PT0[FW> M800@WH^" _\DWV(#6.5'E9F]_NJA?@DX,H)A4;WI<("N:L\"^H(I!GP\]CGW M#X;J<7ZM\RRH]EC$@CGBIC&_';<5YD^[+.0>MV,?T$0_^!:?^:[@ZY@%:(3 MA\>/Q"RXK-8\V@L'7O_?8K9]ZLRW2%^!XCCVPP#E[5"_0*#UB1?+3_=E+_7G^_UYWO]^5Y_OM>?_\?ZT_ADR?^+[?8_&ZQ$ MGPK<"E@6M%V%"Z2KWM2IU\CM=E?9?,!14AQ-;]/OE-.TZ%1E=KO6VW%UL MVYU?D@[;I@[-7>N6KR$G1IY:S_-)=0#X>XM5ZV0+*$,2&VV5!PC$]\8HJ+0 M::6S?6CS^LJ3J!;=CR"!<8VIKC\9M/"OON+YT4>T9H#FN(5CYZ13V>BUV%@" MDMALT4WR*1:=S#K<*PK#AF[98&36^ M]*^E6=+_&: I0C3YC_[UT_H_$Y?^GP+[X?X/%V^$ 5Q8ELL%3 V&DW'/;V]6 M-TYOZ'\#<^V<7M/E2HI,&AP [Q=:N^H&&=3_)+GX#U!+ P04 " ##@@A9 MWNX,$E\) #:'@ &0 'AL+W=O'^H"7:YJXDNB25Q/OI;X;4 MTY85MW>'-A(ED_.>WPRIRQJKC60T-(OBJ.\YSJ@?4YYTKB_-N[F\OA2ICGC"YI*H-(ZIW-ZP M2+Q<==Q._N*!K]8:7_2O+S=TQ1Z9_G4SE_#4+ZB$/&:)XB(ADBVO.C/WXL;U M<(&9\1MG+ZHR)JC*0HB_\.$^O.HX*!&+6*"1!(7;,[ME48240(YO&=%.P1,7 M5L5!F016[%='O/-3KJ\ZD0T*VI&FD'\3++RQ3R$=Z@8B4N9*7;*[3 M(4&JM(BSQ2!!S!-[IZ^9(8Y9X&4+C"'ZEI&1\@/5]/I2BA?_KZQ]T=N;G[AFG$B%B2BN3W22!B1F@2 M5M_^PFBDU^262D;F$4U4DS9O\#/IR?]F(>&)S7K,'A@1O6;D5L0;FFQ__FGB MN>/W"A*S8,Y+D2IOUU:D $7:H$B$*M0%I^5$EUP%-");1J4B#,.&@-,9.)UP M,W\I(H /=5'5M3+$P,#+H#*Z7=-DQ4 HLK!.)F(1\971!@C=[+W,Y%JP%4\2 MGJSP 24B)V0X'L'5=P=P]7#H3<@C^)D'C 1":>+"/V,2[WUQOT\T@W#0V0R/ MN!,S;Q;H% P,^D9"*=)= 72>D:XW@HOKX@@'9\9_A()^(>JH]NAWAV?%V,Q5 M3.O(&J0[<+VSO17YO8CZ#>5AQGGH9YSA[TF"FZ+,*. F 3Z2A(9_ AQ96;IO M4]^W+$-2A4U=;U!8UIU:PY8^VQCE%:@$OOI(N23/-$I-$MBW+=X:3%RD#!8_ M*80J1\;\$49H*A,B:JS [H/#BMW%FTALP1(!X)ODB]2$$G%]_._!O_^#%Y; M3@L20F(IS0.L-Y"O84T$JT'7G1[F=81'71MUNROKMJ_::M^IGF]LOTMB%@0R M!9GS/,1\."<)=!S+U.2ZTE2G"GS4G4[.S,TW-]3HQ%BF!4?] D?]HW%T%HL4 ME7Y@@5@E&=:1&PK:048_8C%M1,YV#I8J1%:5*,+;(B-LJK1"WRFN-)KO@LRS M!BP^-UKP)2)39./ M,V/0)F^VX$"42MO2 +E9Z$RD6.R[[<\^RKZ M&"['S6PJCG,I_H2VN.+4"EH#'CL^7@TLN\[$H#46KB"-4T"1YF6N,X0E$[,8 MEQY&CEV 0.QLB9=Q$2_CH^,%VQ21&&2#IR\0JW,FN0@!0O/Z= MAW!06K4R: MP^()'(#Y8"H]\$.'-#=&^]W0,3U0$D0IOC#S3*Q@Q0L*'2\:\N- 5UB+!F_W ML=;4@-ZOBFVW$A2C--+!PFE1A M5K-8D0&9D&F!=UC+ "AR1],5PL>P XMT\2 !CBO M$K7HMT2QIA1I9V]9)L!RRVKET+ ,JBPW=9;,LJRCI-WWY563A:9L-N\#,,]I M8WL-M=0QIH9Z-@<@D$1EH9XC6;6M1CK0:3$HEV&>O9J^DJZ-V;.B8G(&'"!L MAS5PM-T5*BK9&NO[,\N$L;10'-?/Q&GQ][3P]_1H?Z/HY0[CD^'Z#V,"]+T, M;5=2E?:KD?:V)BU2Z>+BLPQ.FJ*@7:C#OI '!&DR&Z)J-S*"9'YHP,LZ7&;Q MT@R:WQ\YA_<9GMD/FI"JPM,Y"2JX@Z!?V1*$J40B*).ATG4G %9>YBC+<7]. MMBM\2\CZ!JL(^)8(TRC5Y1S--:$63 M--.$534I[;_)-"E:G(9SAMT.KXYL/UJVL]$'R "[XT#A_)[OD5,R[ W&J-Q9?;W&_*[#HZPK_@!8^YT-W6##7LCJ_;8,_KXHV,LY9@ESM3><.4; M_?%QS7">W&PW&\:"C;^FYY+0-!RK'Q>[1.%!H MGN?PG&[-:4)C)K;2;>ZK"P9Y:FTR!O_[X\A:\3C?WYD=/'CT\V)NFND1<8=V M-"90'LQH4HRFV!M[Y&.UU?<L)60VWR?QI-G9@_!H!N5&AS.Q<'P^I;2B"]1Q>)$;C_B M#H75X!QJ!K:> (5X[@<0$/,DZQGV NZTP6.G=9] (+V6#>H$$WZ,N'%+U9JP M;RF'TF2RQ: 6[.!/LYV(:T#(7I]J>TJ-GWV(<2;8 !*E&:J-BIE5X(\_]#'@^UW_9VDFLPZCMT?#7N<&XQQ84D0Q9X*,KL3X@9MDMW=[:404U! MJUVK+H36(C9#@/"029P OR^% MT/D#,B@^9U__!U!+ P04 " ##@@A9&+U!:E<) Y&@ &0 'AL+W=O MB MS01-.OVPV ^TQ-C<2J(JRDTSOW[/)6E93F1/N@,DU(N\//?RW ?IDWO5?-5+ M(5KVHRPJ?3I:MFU]/)GH;"E*KH]4+2I\N5--R5L\-HN)KAO!_>,-)DK]94>WN>G M(X\ B4)D+4G@N'P7%Z(H2!!@?',R1]V4-+!_OY;^QN@.7>9B.6K72K2C<8"$I9V2O_X>SPG &! M&Q 8W'8B@_(U;_G92:/N64.](8UNC*IF-,#)BA;EIFWP56)<>W9S^?;CY=4M M^W1Y_?NGV_=7;]G!+9\70A^>3%K(IUZ3S,DZM[*"';+\@'U45;O4[++*1;XM M8 )@';I@C>X\V"OQ7ZOJB(7>F 5>$.V1%W;:AD9>N$M;L0"A6O9)U*II9;5@ M_WXUUVT#;OQG2%\K+1J61OYRK&N>B=,1'$*+YKL8G?WZBY]XO^W!&G58HWW2 MSV[@?_FJ$$S=.;RT+FRMPOO*>J2A=I6C2Z:J3!;2OL*@@9Y#.NY%,:SC[5(P M@T:S.;DU,Y\P5;/!J=WL\A%.CDZ/D;;+X?ZM,I\N5%GSZN'77Z:!G_ZF&89K M55%A6S0X*I358#("0)R V4R6A_B'T&#[6+ADOU:IJ M-:;@+>/H4REB!(0; [QC3'+$KH+HQJ-Y( MG?&"/0"983$U(34!>R=X03@P[ O"4B6T9B]8,(ZFL;G&86"?@Y2]4RLMEJK( MF3^>Q1[>>K,IW4\C]D'>"=T^ *$_#M(8;1C2MR .L?BM:"IC3J#PQWX24#OU M3>OUF;5>@5:UZ)J,IVG TK$?S>@^BH8494'@LR "G"1DMV;<"XSQ9J&YAM.9 MN?I>VK&1Y_]%5!-[EPJ0H9"9IK]N/V_+U"< \2Q"&T+GC16#Q$-@F;(@[-N/ M+!; H@$L\\ARF /:S-+=%H/9X\@MP6P6#-KK(/1FAVCC*=H@" \[J_EC+Z)E MG_DI 4]F%@#9P=D JOH)BS?OQ0^D9BW8P>6C9GW(-IT.8BB>/.$ MD"1X2<$I9RA(,#<%[U+EHF ',5F4L"8]]5[+A23+9KSF[#&QDAM MHDHQL$0N$+Z"Z2NHQ]E\I:4A AL, MAAMXWFY\X18^6+0Q2&@%_Y)@X\>:9!M^]J8/=\QN1SL-G@Q_513#K*:408]- MOB<1H'3LIS1,6J_031-HFNI.(>',/J]QD9/V%I:6)432=F?G8!M^AD!MZ[&4_RFX%U\?9:#H8(OW8 MQ40X'H113.@1@R-+5QG7RW[<WG5S" M(Q-8>E-3S&T0.58-690 KR<"%.LWMFSI+0\1SKC6GOA%L)'I2> +9*6G4"+S MC3 1T74MS$ZF>-C'KI\CU_^CVCZ"_4,/\VD=5RRA;!!:FZBGM$9PGP3>C=7ROY6UGA>.714U9*R-@3:FV3;'D!FL]@?O M319TY<==HTHFOJT(KD4HA GKQ#"46S:;TI%=B^[U'5A_(<]U[ XG$:^Q8/ M5=>V(]7;WHSJ[RF MF3& #&(6 0'5R(F=)DY98OM;$+B[D8L*A4'&0;]U9+;A>'NU?[[:/T;1I[*O M_Z0SEQS4+HD?/?!^1&XYA7,#=NK" +WT6 JO1?65NKT!7IIN9,TX8'OVYG&W M-X^?O3>_@-9POL9"N^X2Y]!>>[_4VWTA^VJSSQU(T,_>)8\18C1?+!JQ,!_F M#[U\Y&+V^%DQ^=$&[*(0G%;8E@"F 45>LNM&(9)H&SVN;133)AK3?T11>2AJ MTT?;4 _YPL;!K\TO-:T[HBPP;JYP/[]@S1)GF:D_RG^WS:R* @1/:3N92\% MT..F>:-4[@1[Z^8+)YEO9+%>WCMRVF&3?-H M:TGIR3:$1AA#LLPSIYD7?^EEEVM0%6"J0Y"/^[J@ADR4DQW(=+N$#,FO>/\4B"5TH\6 M%-#A)O9DOWO;_2[RROXD&ULQ5EMC^(V$/XK M%CU5>U)O\P+[6A:))=D[JH-%RVVKJNH';V+ NB2FMK/L5?WQ'3L0"!O,YF3I MOD 29AY[YAE/_.#NBO&O8D&(1"]IDHF;UD+*Y;7CB&A!4BQ.V9)D\,N,\11+ MN.5S1RPYP;%V2A/'=]US)\4T:_6Z^MF$][HLEPG-R(0CD:X2S\F4R,?EA,.=4Z+$-"69H"Q#G,QN6GWO.O0NE8.V^)V2 ME=BY1BJ4)\:^JIMA?--RU8Q(0B*I(#!\/9,!21*%!//X9PW:*L=4CKO7&_0[ M'3P$\X0%&;#D#QK+Q4WKLH5B,L-Y(A_8ZA-9!W2F\"*6"/V)5FM;MX6B7$B6 MKIUA!BG-BF_\LD[$CD/GD(._=O#?ZM!>.[3?ZM!9.W3V''S_@,/9VD&'[A2Q MZ\0%6.)>E[,5XLH:T-2%SK[VAGS13!7*5'+XE8*?[$T?1Z/^PY_H_@Y-AQ_' MP[OAH#_^@OJ#P?WC^,MP_!%-[C\/!\-PBCZ@,>8<*V+124 DIHEXC]XAFJ$1 M31*@770="7-2R$ZT'O^V&-\_,+[GHQ'+Y$*@,(M)7 5P()@R(G\3T:UO1/PM MSTY1V_T%^:[?08_3 )V\>X\6))[3;#[,A.0Y%+JLF>K@[<#M1L#!VX']1L#A MVX&]#; AQ>VR:-H:MWT =PSKOQ]%+,\DS!!-.,O@.B)JE@(QC@8+G,V)JHR* M&J3;# )EAH":Q"8:>DL&-"[ST0*"L:21*C"(M%'0L%P(4&4.^;Y]Y9UWG> M3>UK"Z]J$;RV:%&4 MQ0CNU67Y&*\PC\4./W6\F$=I'Z;%Z-B4%IM@H26P"BT7)2T7QH2-:$;3/%4\ M1+!"8$^H:8EP$N4)U@M(+H":E'%)_\5Z4\=F:E^78TYQ@N:P"14(9S%*F!!$ MH!S>WUP[18QS&@,:7BXYPU%M=RFF=[6S[MU3=[_!&&-HRIU-L- 26(6[RY*[ M2R-W ]@P<6!BOZW5I=F,Q. UK'S5.SLAHG;]&!&:[G_:A)<-PD M- ?[O=U?J@L]XR2LC&1-M$" MJVBA+;0JD5L%ZYE59@@*-M6M)Q=$;2L2.B-'-GI'("\."R2S9V,BK"I76VA5 M(K;:U3/+RA%^.=C5;$K!@56TP"I:: NMRL%6J'H7/[:KV=2% ZMH@56TT!9: ME&PO=V]R:W-H965T9-=%G!CQID51](&Q:)M82M225)P4_?A2LB.Z0'SD"N&+ M)5[.:'@T.F-RL)'JFUXS9M!S*C(]#-;&Y.=AJ!=KEE)](G.6V9&E5"DUMJE6 MH%HD-,5FS/SD,^4;84U2L)3EFDN,Z38WW>@0?W,,G#__A7]NEJ\7\\,>MAZ"+8.4 M9]LK?=XE8B\ =PX$D%T J7AO'U2Q_$0-'0V4W"!5SK9HY4VUU"K:DN-9^5;F M1ME1;N/,:/XPG5[<_X'NKM%\\OEV/:"9H9A#-$G3U MO>"Y?9D&??C$#.5"_S0(C>5?L@@7.ZZ76Z[D -=?B^P$Q=%'1"+2^6]X:)== MKYW4:R<57N< WF7!1<*SE:XH"F9?[EJ*!/$T5_*)E70U^@=-><;3(GV++XA? M?E#G.J<+-@SL%Z.9>F+!Z,(9>&%5O2P.&[&XC 7+=FESW741!GP^) L1O MF=I>S;[G410]#\S[-?/^^XL"ANQ$C:HXK=F=@E W92*/KPL@6,M$GM54SSQ* MX,P#7P0-F+A9!7C/+?'_U\'A4@"CM4VG\S=,/$H!^W W[.P-@Q[4 M4@LP9GR$%IR+8=ASIG2QMEWJI6&8.K8ZP' M\TF'%\':NE28:,/N'-1'NG=.69]Y3JE8\TTBPI86* M3OJV JGM,?*V861>'=T^2F-D6MVN&4V8*B?8\:64YK51G@;7A_FC?P%02P,$ M% @ PX((68TY"Q/W P '1, !D !X;"]W;W)K&ULU9A?C]HX$,"_BI6K3JU$-Y ^^< "4C2XW1+T;+;>SC=@TD,^.K$ MJ>TL6ZD?_L9)R *%+$A^N1>('<]OQC/C<>S>AHNOCQ3C"9D M)I#,XAB+[R/"^*9OM:QMQP-=K97NL >]%*_(G*BG=":@95>4B,8DD90G2)!E MWQJV[H);/3X?\(62C=QY1GHF"\Z_ZL8DZEM-;1!A)%2:@.'OF8P)8QH$9GPK MF5:E4@ON/F_I03YWF,L"2S+F["\:J77?NK%01)8X8^J!;WXGY7PZFA=R)O-? MM"G'-BT49E+QN!0&"V*:%/_XI?3#CH#CG!!P2@'G7 &W%'#/%6B7 NUS!3JE M0.= P#TUZ6XIT,U]7S@K][2'%1[T!-\@H4<#33_DX4I!3 M V_RQ9\_3AZ?'GST.4##AT_^]'$R':+1TWPR]>=S]!%-L1!8)P!Z[Q&%*9,? MT#M$$W1/&8/TD#U;@2D::(>EVE&AUCFAUD7W/%%KB?PD(M$1^7&]?,NI =C@ M@\H1SM81(Z>6>(_%%7);#>0TG39ZFGOH_;L/QPRKQ_R1)8!IOHGQSL>X-1C_ M?(Q3@PG.\(VSG50J>)3E=6'&<*)J?.]62>CF?/<$?Y*$/"9HKK B4+14 XTP MH$/HRHLK3B(TC"*J=6*&/"I#QF4FB$2+[[J9<@G]GP3/4ME @&-91)-5/A+2 MA"89B=#GE.@TAGQ%?_\)%J ):)/_'$O>PMSV<7-UK;^3*0Y)WX)B+HEX)M;@ MUU]:W>9OQQ+&),PS"?--P@)#L+T$:E<)U*ZC#V:"?%3X!4%62 3[503%2BJJ M($6.A;<6=FEX"]AU#M/;^// :3=[]O-NU'X>&@J3,-\D+# $VXO:;16UV]JHC;,X8\4A3PF<2(:+@W_T M+YQ!=67/XTF.;MJW/X?0<0]"6*O]TA":A/DF88$A6!%">^=8'Q/X!-,7,!*% M/$M4<;"M>JL[GF%^M7'0/V[=^<55S2NFN#B"D]V*PK;*R!*0S:MK^)@0Q65, MT5 \S2\/%EPI'N>/:X(C(O0 >+_D7&T;6D%U(S;X#U!+ P04 " ##@@A9 M\]\"LPT# !>!P &0 'AL+W=OF_[&ZF>]!K1P&LL$CUPUL:DYZZKPS7&3)_)%!/:64H5,T-3M7)U MJI!%>5 L7*]>[[@QXXGC]_.UF?+[,C.")SA3H+,X9NIMA$)N!D[#>5^8\]7: MV 77[Z=LA0&:AW2F:.:6*!&/,=%<)J!P.7"&C?-1SY[/#_S@N-$[8["9+*1\ MLI-)-'#J5A *#(U%8/1XP0L4P@*1C..21 M60^!I."F"?%D[UN?=@) M\+P] =XVP,MU%T2YRC$SS.\KN0%E3Q.:'>2IYM$DCB?V4@*C:)=3G/''DQ^7 MP?WD_F%^"7=7,)Q?7T[O)],AC!Z"R?0R". 4;MEOJ>!",*U1@US"D 9& TLB MN.%LP04WG':.QV@8%_J$8H9JA8GA"8-1IHE3:UH<T<(XNY M>(. ":S!5!J[$4H;GM'F78J*V2O4< 0\@5LNA)WU74,&V#3<<)OLJ$C6VY/L M+5-GX-5K]/-:\!",X?CHY".,2_Z5)GJEB5Z.V]R#.TE"&2,$AAFD%];48,0$ M2T):R@O+&C6,(FZ3H.QM=D+J3)%GE/9'5W0-"$YD$4]6>WWX>4,*8$)L^E>5 M#87<5K5<6^?G.F4A#APJ9(WJ!1W_ZY=&I_[M@!G-THSF(73_D:K0:@]9R@T3 M-4C05&DL4+HYBFT=+WZST7=?*IA;)7/K(/-,4:]2YJT&*;E?V([/&4^+.]FC MH\#L[.AH]*IUM$L=[8,ZKJ6,-O225K&U/[-UJMDZ)5OG(-N=6:,"EI=D%6/G M$V.SFK!;$G;_@U#\+?PJUNXGUM,]M+V2MG>0=FH+J6@\$35R;3"J(NY]>JTZ M[7^(W9UV:;\\U!96G*I*X)*"ZF==NB15=/-B8F2:=]"%--2/\^&:/H"H[ ': M7TIIWB>V*9>?5/\/4$L#!!0 ( ,.""%E%'&C?V0( $$' 9 >&PO M=V]R:W-H965TAB;7R%(/RD08-9O'8<:X#/I= M'[O6_:XJK. 2KS68(LN8?AJB4.M>T J> S=\N;(N$/:[.5MBC':67VN:A35+ MRC.4ABL)&A>]8- Z/3MR^3[ACN/:;(S!53)7ZMY-)FDO:#I!*#"QCH'1ZP'/ M4 A'1#)^5YQ!O:4#;HZ?V<]][53+G!D\4^('3^VJ%WP.(,4%*X2]4>NO6-7C M!29*&/^$=97;#" IC%59!28%&9?EFSU6/FP 6L<[ %$%B%X#.CL [0K0]H66 MRGQ9(V99OZO5&K3+)C8W\-YX-%7#I?N*L=6TR@EG^Z/)W3B^G=S.;L9P=0Z# MFXOQ]'8R'H'S#H M?_S0.FY^V>;1.Y&]<*Q3.];Q[.T=CDUDHC*$V#*+U#!L X9,,)E0R#ZYO] 9Y,.P,.F^"TY)U&=4VH*-[I1AO3W MNR9M(%&%M.4IKJ/U/3#P[>]5?$CW0]G._]&4E\LETTM.'T[@@BB;AR>D2Y<- MNYQ8E?N>-U>6.J@?KNB.0^T2:'VAE'V>N WJ6[/_%U!+ P04 " ##@@A9 M@3^Z""4# .#@ &0 'AL+W=OK+IFG:!Q,.B)K8U':@_?<[)R$#&E+0 MLGV!V+[G.=\]SL7767%Q+^< BCQ&(9-=8Z[4XL(TI3^'B,ISO@"&*U,N(JIP M*&:F7 B@DP04A:9M64TSH@$SW$XR=R7<#H]5&#"X$D3&443%4Q]"ONH:-6,] M<1W,YDI/F&YG06=P ^IN<25P9.8LDR ")@/.B(!IU^C5+KRVMD\,O@6PDAO/ M1$#T:3KF'I#4$(OM(,%/^6,( PU$2XC8>,T\A=:N#F\YK]0Q([QC*F M$@8\_!Y,U+QKM TR@2F-0W7-5Q\ABZ>A^7P>RN27K%+;!AK[L50\RL"X@RA@ MZ3]]S/*P 4">8H"= >Q=0',/P,D SBZ@O@=0SP#U0P&-#)"$;J:Q)XD;4D7= MCN K(K0ULNF')/L)&O,5,'U.;I3 U0!QRAW\Z'O7O=O;WN S>4N^4B&H5HZ< M#D'1()1O50RXY4W-) M/#:!20%^4(ZOV24$)L:=!V^O@^_;I8R?8G9.'.N,V)9=+]K0W\&'A\.= KAW M.-PN28:3GP0GX7/V\-VQ6,8T)%R0$9L*>(B!*3)2$)WIN3Y7<_+S"X*2.?FK MZ "D'NK%'G3)NY +ZD/7P)HF02S!<%^_JC6M]T7)KY)L6"695Q'9EDSU7*9Z M&;L[8GXL!$SP7?0%8,56J)G/I9)GA.%WA4]Q1<:",A^PD/M\"2* PM>UU-&Q M:J5DK81,?YR6KOVN8RXW-7AN8FU;>&466]EJY-EJE&9K\#0&K&B*^O=%&2@% M'YN!*LF&59)Y%9%M*=#,%6C^\[+2K%*F*LF&59)Y%9%MR=3*96K]K[)2ZNA8 MM5HOEY4J_7D5D6UIT,XU:+^@P6$);C_+B;-32 >ECHX]Y%62>161I0DV-RZ^ M$8A9TG%(/+1QC@T;"&V ZU/.U7J@'>0MH/L;4$L#!!0 ( M ,.""%F4/8(*K , ) 2 9 >&PO=V]R:W-H965TG7J^RI=0D'5 MH5@!QR]S(0NJL2L7OEI)H)D%%;D?!<' +RCC7CRR8YCKU:7$GM^P9*P KIC@1,)\[)V%ITG8 M,P [XS.#C=IJ$Q/*C1"WIG.>C;W > 0YI-I04/Q;PQ3RW#"A'U]K4J^Q:8#; M[7OV=S9X#.:&*IB*_ O+]'+L'7LD@SDM OE6F"L7JD%!- MXY$4&R+-;&0S#2NF16/XC)MUGVF)7QGB=#S]9_+VZNS3I[/I7^0/,L-ME94Y M$#$G5Y"*!6=V=; [%4JK _(W;D7LG7-52LI3L-/6(!DH\CH!35FNWB#3]2PA MKU^](:\(X^2"Y3G2J)&OT65CV$]K]R:5>]$3[H41N1!<+Q5YRS/(V@0^QMH$ M'-T'/(DZ&3^4_)#T@@,2!5%_AT/3Y\-[.^#)\^%11S2]9OEZEJ_W!-\U+U5) MDG^_8@@.Z;^V[4"E87^;@OFW#E5*YK"V,.# M18%<@Q?__ELX"/[ENW'*4%[1M(UHQ7@41/@46> TV\W M(*G6-+W=Y70G>-]=X9(L<436$FW0B#9X\7P;N%36)5GBB*RE[+!1=OBK\JTR M-.C*MTY?]I7-$5E+MN-&MN/N+#8*&7%64F1EBFTE\HS\3WZ2WIVL^VY"EV2) M([*6FB>-FB](U>/.]K$Z[D=@%S8DH=",4JNJT=L,]J45'1^,246VP)X(&FJM5<4+E .4D. M&ULM59K;]HP%/TK5UDUM1)K0GA-'42B],54* )UTU3M@TDN8-6Q,]L! M^N]GAQ"!%% KT2^)'=]S[CTGOG':*R%?U0)1PSIF7'6NJ<($Q49\IAL3RIV@G3T;R: M4LTHQY$$E<8QD6_7 MR,2JXU2=[8,QG2^T?> &[83,<8+Z.1E),W,+EHC&R!45'"3..DZW>M5KV?@L MX!?%E=H9@U4R%>+53OI1Q_%L0<@PU):!F-L2>\B8)3)E_,LYG2*E!>Z.M^QW MF7:C94H4]@3[32.]Z#C?'8AP1E*FQV+U@+F>AN4+!5/9%59YK.= F"HMXAQL M*H@IW]S).O=A!U"O'@#X.C1[_0.^AVQ_"77_8'?;ZPWL8C9_NQ]T!G-^@)I2I M"_@&SY,;.#^[@#.@' :4,?,:5-O5I@K+Y89YQNM-1O] QI\IOX2:5P'?\^LE M\-[[X;5]N&NT%P;XA0%^QE<[9$":)(RBA#O*"0\11E+,)8GAY=%$0E]CK/Z6 MJ=S0ULMI;?-=J82$V'%,=RF42W2"KU^J3>]'F>83D>TY4"LL*3#0QGI@AB%D.H83!2"B:->;+[5K;+I\RA%N>QB@SAE(/ MCQ?6#4.1F;X/98H1,$JFE)F46+8'>Y_!O.=NO7"W?CQ5;#-! ME")H83Z6&Z]+^V9#U,J([-=W&?A>H^TN=W65Q/A>$;-78:.HL'&TP@%9TSB- MRRHZ"OSH'C\1V9[&9J&Q^3E=WCRE RE^7SW('DFV7FQ[(VEE3 M<[[,S1PE%5&9&<&WKMLF9TF M-\?W9J)%DIV 4Z'->9H-%^:/!Z4-,.LS(?1V8@_5XA\J^ ]02P,$% @ MPX((63\?B&&- @ L@8 !D !X;"]W;W)K&UL MK55=;YLP%/TK%JNF5MH* 9I.78*4A&SKM'852;:':0\.W 2KQJ:V2;I_/]L0 MFK:DZD-?P+Z^Y]PO?!ALN;B5.8!"]P5E2@#%:XHBKAVV_0U'-F^%).I7VB;>U[KIW32BI>-&"=04%8_<;W M31_V +W^ 8#? /RG@/ (&@ P6L!80.PK7;K4FP?8JQP-!!\BX3QUFQF89MI MT;I\PLS89TKH4Z)Q*DJFLWFRF,P7R>7U5S2ZCE$R_3&:3V,T^3F;S]!'=(V% MP&8XZ#@&A0F5)]JZF,7H^.@$'2'"T!6A5 ]1#ERE4S+$;MJ$']?A_0/A>SZZ MXDSE$DU9!MEC E?7TA;D[PH:^R\R?J_8*0J\#\CW_+ CHO^OUO<]=S7M+LOB-R!XU-FP;&[[$WM%8T30V MY5)U?LDUX;DE-&JZB0(]XLU^>YZ[]+W'+O%SEP>/NA)W[S87(-96%:7.JV*J MO@>MM17>D=6;)_:Q%N1:/Q]H:C6_PF)-F$045IK2.ST_*%Y:S5AR MI17(+G/]4P%A'/3YBG.UVY@ [6\J^@]02P,$% @ PX((6:!@/4PK!0 M:B( !D !X;"]W;W)K&ULS5I1;^(X$/XK5FYU M:J6V(8:FW1X@M9B[ZVG;K:#=>UC=@TL,1)O$.=N4KG0_?FTG) 2"*=1H[P6( M,_,Q\XUG/*.D/:?L&Y\2(L!K'"6\XTR%2*]B2*%).WX-P=UBO]4BLN_%^B_:^>E M,\^8DQZ-_@X#,>TXEPX(R!C/(C&@\S])[M"YPAO1B.M/,,]E&PX8S;B@<:XL M+8C#)/O&KSD12PI-?X,"S!7@6Q6:N4)S1<%K;5!HY0HMS4SFBN8!88&[;4;G M@"EIB:9^:#*UMG0_3%3.H]/@UN[_\ U_<(#/J?KA_[ M"/0^#Q^'X!0,Y58+9A$!= P>J< 1&! NV&PD9BQ,)@ G@5R)L" !N(W3B,A= M(; .:H]RP4_ O=R^1X@('$;\6"(^#1$X^G ,/H P 7=A%$E9WG:%=$<9Y8YR MTV\RT^$&TST([F@BIASTDX $50!7\E"0 1=DW$ CXE^SY PT&R< -F"KQJ#> MV]6;->KH[>K0X$VS"&U3XS4WA;82)A6+/%:$0ZCJPW&M'I_OJ+YS=^JR/.)ABR!%8AM560VC*A=W4&G("$B#K. M,MT+K:LJ[DNW*2/YLLS$NHC?J(J@=9%2HF+T>6'TN=%HG8,:N6>U"@MEHJF,3D!<2T51MNUJ7K8X&5M&0 M+;0JC>5TX+4.6B:-P\?.S-I$0[;0JLR6(XQGGF%^4IG<:E1MUH"1FKAJ8V(9 M$)D!]PU+.1EYQAEA6W'TM[:1-2*GWFIM/,24,7>U=:F36,_00 PDL!Q)H?EYASM!KSN5W&*WTW#IZ M(+,)N[KH+CV$ETW31+_,P.69-TM$]@BZ6"U>F+C6KPFLK-]X5RA[[:&$R=[" MN,-L$B8<1&0L(1MG%S)&+'NQ(;L0--6/^I^I$#36/Z<$!X0I 7E_3*E87*@_ M*%XOZ?X 4$L#!!0 ( ,.""%G:-2(]< , -H, 9 >&PO=V]R:W-H M965TQD M^S#L R.=+:$4J9)4W/S[D9(LV;/$-6GSQ18IWO/<'>\>GR<[+C[+&$"AKREE M>#\LUE<1U/',QX!A5 9"**_'F$! ME!HD[<>7"M2I.8WAX?,>_7T1O [F@4A8Y FK/PF7ZM$'!CX?H>!7QGXA=\E4>'EDB@2 M3 3?(6%.:S3S4(1:6&OG$F9N9:V$?IMH.Q6LKM9WJ_O%W?WJ^N,'-/NX1*NK M/V9W5TNT^+2^6Z,SM-:%$.44$-^@61B*G%"DJP&M0"J1ARH7"=LBPB*]0XF" M"%VG&05]@FH52_E!-7Z2B,+VY8>3PO/?8[ M/,8^NN%,Q1)=L0BB8P!7AU_GP-_G8.Y;$7_/V3GJ>;\@W_,OT/UZB=Z^>6?! M[=6Y[16XO:[<'F5(KT \ OI[Q2E%NJ1V1$3_M,5?HEZTHYHVO909"6'JZ#XL M,)W@YY_PP/O5XO-%[?.%#3V8PS9AK+C1ZJX?""4LA#9'2ZAA 67:_S'P1Q/W ML86^7]/WK?2+F(@MM%9%:3@X)!NWDPUJLH&=C,@89>3)E&HKY>"$\JS7$>"P MYAQ:.77-?F-RAR?DN"/>4U9+7P>VIOEV <:- F.[!/]_TXQ.FP9W:4,CJ=BJ?L]I MFO');SK&_Z%W#\;-%'3^S% M4&ULK99K;]HP%(;_BI554RNU#2202P>16F@UII56T,N':1],8L"J8S/; M0/OO=YS0B(M!3-J7Q$[.^_HY)[ZDM13R34T)T>@]9URUG:G6LRO75>F4Y%A= MBAGA\&8L9(XU=.7$53-)<%:(9YC M^7%#F%BVG;KS^6! )U-M'KA):X8G9$CT\^Q10L^M7#*:$ZZHX$B2<=NYKE]U M8A-?!+Q0LE1K;60R&0GQ9CJ]K.W4#!!A)-7& <-M03J$,6,$&']6GDXUI!&N MMS_=[XK<(9<15J0CV"O-]+3M1 [*R!C/F1Z(Y7>RRJ=I_%+!5'%%RS(V#!V4 MSI46^4H,!#GEY1V_K^JP)J@W]@B\E< [5N"O!'Z1:$E6I-7%&BK,Y+))F,VBYB_4,+#%QLXK9 &M48(V#8 .\ MA FOB:28*81YAJ &;WA"^<1&69H%:P3UT-NBM,1$GIVR65$V#U*^PF9EUL), MBI0H:_V:.Z/&6UR[$9&=*JBH@H-4/WMW#P@SV*HQ!RP;5; SYD4<;7%98J+0 M3A969.%!LB>A,8."5=O+.>)$VP##G<$#?[MPEIAX3^FB"C Z"-@7_"*=2PE\ M1V%&.PC;L^Y0Q 9B7"'&1]3P7R#CG>49^.$6IB4F#K9 W;4#QQSV]UC">E2( MD3&H:I]!3#HJ>!")WAK3#DD1&=;**CN MR1*$O3@ ],]/ ,(6$+X6$+4 GSG21.9EC:FA::QDC93SMFQNXW/CT58- M$^XO+HVRM\SB3#J=/4QF]W>+Z61YAF:3>_0!S:A2U"47O1N#H8SK]S$Q]BV' M(%G+>]WPAB=XOU2BAZ+@#(5!>'X$/GH]/'H))U9A)S/L9(:>+SHE4^Q &*F> MT9CIC$M=*4 _KU;:*%M(OX[I:PC/CQ.ZYAKJDF:08-L]&M0.==JCO[&GW"&V3\&ULM5AK;]LV%/TKA%8,+9!&HN17,MM MXGA8AB1U\]@P#/O 2+1-5")5DK*;_OJ1DJ*'36MU)GU(+,KW'I][>"4=W?&6 M\2]BC;$$WZ*0BHFUEC(^MVWAKW&$Q"F+,57?+!F/D%1+OK)%S#$*TJ0HM%W' M&=@1(M2:CM-S"SX=LT2&A.(%!R*)(L1?+G'(MA,+6J\G[LEJ+?4)>SJ.T0H_ M8/D4+[A:V05*0"),!6$4<+R<6!?P?.9Z.B&-^(/@K:@< UW*,V-?].(ZF%B. M9H1#[$L-@=3'!L]P&&HDQ>-K#FH5OZD3J\>OZ+^FQ:MBGI' ,Q;^20*YGE@C M"P1XB9)0WK/M;S@OJ*_Q?!:*]#_8YK&.!?Q$2!;ER8I!1&CVB;[E0E028.] M@ILGN#^:X.4)J7)VQBPMZPI)-!USM@5<1RLT?9!JDV:K:@C5V_@@N?J6J#PY M7=Q_6LSO'_\Z 8N;B[M'<'%W!>:?GZX7M_.[QQ-P-W\$'\&#:IX@"3%@2S!C M4 4+!+0E#M9-B;$M5B*9C^SGIRXRT>X#T[PD]!9YS ES'[1G29S^>[M73 M;25?H:%;:.BF>-XA#9M$ '_?J'!P+7$D_C&5FF'WS-CZ*CX7,?+QQ%*7J(4,7A-Z18:XD &7O;#B3!CW.D,=IJCZKK.9]J W M&-N;:F&&(*?O%$$UPKV"<*^1\ T6XAQ<^'X2)2&2.%#7O]+%)RB[PRC^*&)< MDN_I"1/W[ <&%5H?W9$+=\B;HH9.W\R^7[#O_Q^Y*98FPOT]*M"#_1V^IJ#> M ;J#@NZ@6>Q43O5'HIBS#=8LC>W0"'/L]= 26*WB85'QL,/;PK!-&5H"J\DP M*F08=7);&.TWX;"WTZB&F,'(W*=G!=VS1KJ7"0D#0E=&3HVIQVY*2V"U*J%3 M/O>=#KLS!V])B;;0ZE)4+!#LI$-SV&K[C>#N@\L8=.#!!4O' 1N?Y--;Y*_5 M*?Y2)VMDV:K!: NM7G=I,:#79=(8^ S8;8"S6!'[U=+:/722_\# M!UVV;JNVJ"VTNA2E,8*-AN/MK3O<:TKUJK#;N88@Y] -MS0QL-G%Z-?>1&+^ M'_?:1I"C=ZDEM'K)I1&"9UTV;*M>J2VT^OM]:9;<1@?RYH;-8>MO4L.=AC4& M07/#NJ6I<9M-S8Q1(7F2#JE:Z6D,=-LA#IZ!M$26KWPRC"FTVE,N^.8 M+MR26[HEMYN)C+L_;8%[#L$4-!KLM*U=F4SJL? MXBM"!0CQ4F4YIT/U3.;9 MI#5;2!:GP\IG)B6+TL,U1@'F.D!]OV1,OB[T_+.8=T__!5!+ P04 " ## M@@A9&,I:1[D# #X$0 &0 'AL+W=O$YH#AU=B9^!?0[RD' M;?$GP5N^5P:*RCVE7U3E,AD[GAH13G$L% 22CP<\PVFJD.0XOM:@3M.GTL1Y"1O'JBQUJ(/0>__X)#4#L$APZ]%QS"VB$\UJ%7.VBIW8J*U@$B M@:(1HUO E+5$4P4MIO:6]$FNYOU&,/F62#\1+:]_7\ZO;_\^ \A%HBD_(-LO;N!X/V[#R-7R'$H-#>N M^YQ6?08O].D'X(KF8L/!/$]PT@9P)8&&1?#$8AIT(OY6YJ<@]$Y X 4]PX!F MQ[N'!G=XO'O0P29LYB34>.%+<\)D6#/Q32%#+>!/CGLS0' MEP)G_%^3]A5VSXRMMI$+7J 8CQVY3W#,'K 3_?R3W_=^,>EF$PQ: FMIVFLT M[76A1Q!+T)B@:K.1@J*,,D&^ZP:3C!7<0,.IS?,A"L(S3_]&[L.^1B;+OLD2 M&BR#WH%EB]U9P^ZLD]V"YC'B&Q"C@@B4 OPHOPL)$:44TD2N0NOO#<1,[;G= MN9'8<[M# 5JT^@VM?B>M646'?,<)X'0EMHAA$%,NC*0ZL5Z[\&V"04M@+0T' MC8:#-]Q,!C8UM0D&+8&U-!TVF@X[U^7D!WO'\%DX^)XQOHXUA,\-AUT!=MX0 M.>\D,BU)FI!\;8RG3M?7SKU-,&@)K"69[^TR)N\-(ZH&MR2K531H"ZTM[%XJ MZG>'%>?RH,.P( QK+>E]2M8ZRHP+M(;;CXK# /NQ">P>U/\E'>Q(!YVD.U>3 MD74GWJL7D$TT: NMK>4N;_;?,G'VK6;.5M&@+;2VL+ODV;>P=3 MW8E<(;8F.0XW5Q@U&"F3*0[U>4BJ>* MZJ"Y[(G^ U!+ P04 " ##@@A9T:R9(N,% #D) &0 'AL+W=OK+@(B)278JE%:\%)7Y2*0HM;-L]*R(! MZXR&R;TO8C3D&QD&C'X1*-Y$$1'/%S3DV_..TWFY<1\L5U+?L$;#-5G2&95? MUU^$NK*R*'X0418'G"%!%^>=L7,V\5Q=(2GQ9T"W\=YOI*$\J\ M,^@@GR[()I3W?'M%4T!='6_.PSCYB[9I6;N#YIM8\BBMK#*( K;[3WZD';%7 MP>F]4@&G%?!A!>^5"FY:(>DY:Y=9 FM*)!D-!=\BH4NK:/I'TC=);84F8'H8 M9U*HIX&J)T>?[NZFWZYO;MZAA_OQ]/)V?/_'#(T_3]'=P]7E/;K^_##^_.GZ MXN82C6>SRX<9>H]F:BKYFY BOD"3%6%+&J. H0D1XCE@2S2.^(9)_?03Y_XV M"$/T=DHE"<+X%U7]ZVR*WK[Y!;W1E6[54S6:\="2"HQ.R9JGB5_L$L>O).Y@ M=,N97,7HDOG4SP>P5"]D78%?NN("@Q%_W[ /R+7?(6QCKR2A2?WJ+I".FXV, MF\1S7QN9E\[[ZYZKOVK2;HGP_R[KJ5T@KSR0)H*S>$WF]+RC5GI,Q1/MC'[^ MR>G9OY:A;"E8#K.78?:@Z*,+N@P8TY/HD82$S6D9VEV(?A)"L]23F@M=/+2> M]E&4%.IV!UFA7';=++LNF%TV(D&T)H%09";+\@.#'#L:NV"]/1SO7;M7CJ.7 MX>B!.*:*.&,9R(TH[=]>L4FG=]"]8 ,-)TD_2[\/IG^Y6"@-T/RB5$S1-%,\ M*01E\VX3^$1'&,2'-@EU"/HH@EP]5M)?GK"A?+Y&:?@P%:A+D6WZA72:#56 M&C8. (-*6\7/:6UH_<,--)PIV$@YAJ6\.3_C:GV'VVZ*S1@!#!N!:G[&1=4N M+H&*0OGDC+)C6-FO^":F*Q[ZM9D9#GCL:F@K6AZ^\078:XN9<4LJG^(^A6? MQC-@V#/48F9<] 2#[N&L!,ODLS/& _YS7FYJ-@%;&#;3;$9]<>P^M?@Y:)4%Q< 6":_G6KT MW(7U_"98J'GS'-+:K P'/'IC]11NP#5NP'5:VT]N2=M3W*=P"JYQ"B[L%&JQ MLEOT =CS#F9E1:%\?GO;_+!9J,G+<)2CQP3:7,@#,;+OPML!%;SL5K_SPPTT MG2E&O]V*=_[&O.Q6[P7 ;3?%9M3?A=6_FI?=HE27+ &X4#XYH^@NK.C73%+! MDMXE87UV;O6MOJUH^2XPGL =M,;.+2E\BOL4?L$U?L&%_4(]=B[:@9Y=6&!P MH?SW2&,:/-@TU&1G.,JQ8^)!6PMY($;^/7@SH(*=O>(;?_&K']Q$TV_#1LF] MBG?^QOSLE>S@'WXV@QMO"L[8 ^V =4$G0;8_Z;=[1>&J%BHN JLO?,B$17+ MY!A-C.;ZW,;NO$1V-SNJ,TX.J!S2KY-3*8]<2AXE/U>4^%3H NKY@G/Y&PO=V]R:W-H965TS0T2H->Q']Q[XL,\.,B 4/W @ M#F&(^,\K'+#CP(+6\XTYV>ZDOF$/^WNTQ0LLO^P?N%K9*#.P M1O!R#'O:(;+X2O!1Y*Z!#N61L>]Z,5T/+$20V!U,\3'N,@T$B*QS\) MJ)7^3^V8OWY&_Q0%KX)Y1 */6?"-K.5N8'4ML,8;= CDG!T_XR2@CL9;L4!$ M?\$QL74LL#H(R<+$63$("8U_T8\D$3D'Z)8XM!*'5EV'=N+0C@*-F45A39!$ MPSYG1\"UM4+3%U%N(F\5#:%Z&Q>2JZ=$^CN9GHUNP:CQ>)ZN0 ?P$*5TOH08, V8+Q#=(L%(!2, M$><_"=V"4<@.5.JG2X[6JNI410)$U^!>[C '4RJ5#WE4 ",AL!3@[01+1 +Q M3H%_64S VS?OP!L->4N"0.VUZ-M2A:H)VZLDK*LXK%9)6'\6BG>6A7H0]'J]4A/ 1( MJC2@D'%)_D51-]M@&NX1X6I 2.-VQ[A^A*M'T]/0]=7./.4C,]ATG-3FA+"; M$G8K"2^91 '8R\RSD_+LU.!)U=BO MP;)3(.!UX1G)HHT/2SAZ*4>OFF,Z#4RD*GU?6N,-@9V$Z:=A^I6]/J5*1>)^ M#_YGO_M-YJ(AL)-<=--<="NW_*9NXW0+Y>;VSMO;9..:2[*7\NM5\KNKUS"] M&NQ,-B7LH).)L_,++5/M_-(Z:0KM--3<.02^ID0FZ$WEHB&TTUQDIP58*<+U MVR;!R5==][PP33:]DL+,=!R^EI GP'DZ[>XYY:*-6R+D,%-R6"WE-7L=%N79 M[9SS,]B4I313<%@MX?'IF&25C^+*/Q*Y [&@ "THYJQ68K^X_!M".\U$=DZ MWJN.@D:/$DVAG>8B.TS 2GU^P2CP"S79\0N-93(JJ]Q,Y&&URO_",#!H>KO0 M;08C6#8.,N6'C4A_@I)_J8!N8<0:C+SSM-JYEW3]A>06\2VA @1XH[R<"U\U M'8\_.L0+R?;1>_LCDY*%T>4.J_, UP;J^88Q^;S0GP+23S_#_P!02P,$% M @ PX((68:/,X'M!0 ^"< !D !X;"]W;W)K&ULS9I=<]HX%(;_BH;=V4EG:+'-1TB6,$.PVK*;I)V0MK/3V0L%1-#4MJ@D MAV1__4JVL7$02FC/17O18*'S6'J/+.DU&JRY^":7E"KT$$>)/&LLE5J=MEIR MMJ0QD6_XBB;ZFP47,5'Z4MRUY$I0,L^"XJ@5>%ZO%1.6-(:#K.RC& YXJB*6 MT(\"R32.B7@\IQ%?GS7\QJ;@FMTME2EH#0G5'U:?13ZJE52YBRFB60\ M08(NSAHC_Q0'71.0U?C,Z%IN?4:F*[>TP1N?][0WV:=UYVY)9*.>?2%S=7RK-%OH#E=D#12UWS]GA8= MRAHXXY',_D?KHJ[70+-4*AX7P;H%,4ORO^2A$&(KP._M"0B*@.!)0*>_)Z!= M!+2?WJ&[)Z!3!'2>!G3V!'2+@*SKK;SOF7 A460X$'R-A*FM:>9#IGX6K?5B MB1DH4R7TMTS'J>&[#Q_"+Y.+BR:ZN1Z%^')T_?<4C:Y"].'F/;Y&DZN;T=6[ MR?D%1J/I%-],T6MT180@)KWH**2*L$B^TJ6?IB$Z^OW5H*5TJPR[-2M:<)ZW M(-C3 C] ESQ12XEP,J?S.J"ENU/V*=CTZ3QP$O]*DS>H[351X 4=2X/&+P]O M6\+#EX<'EG#L#K\D0H?[MKO7Q&B7"6YGO/8>WEN6,$5?7^A\S=$D422Y8[<1 M12,IJ9+HZX6NCR:*QO)?6^YR>,<.-[/8J5R1&3UKZ&E*4G%/&\,_?O-[WI\V MW2%A(20, \%J&>J4&>JXZ,-1S(5B_Y%LXN0+Q*HDD2Q)MKSDR.,,:1:#^V%P MXF7_!JW[;]IDK: M1&^9G)$(_4.)0)=$I8*I1_1U="N5T*N5=?!W(0<_)"R$A&$@6"VAO3*A/>?@ MU[-). MXA5A0IMFA11Y0+R/ M(:A5A:+5Q:[,JN]VJQNQK0KO>D@_V+-D%W5K2U#0#>P"6KC=KI6+W^1_4_T+1ZF)7 M#MAW6V#G_ _I2,?^KJO>41;4 D/1ZLI6)MAWN^";S6;.^L+7'7RPMJ".&92& MH6CUWXXJSQQXO] B$4 ZXC$H+02E82A:/:V56P^><>M/?E796BS0;$G$';4^ M=F[JP?G9M>Y^V_JF, 2],8:BU<6OO'O@=JSNJW\Z;N$>B8J]Q^XW3^6BL5$Z52DDB[2 M"$5L0=$12]"C?G"D]72,&WFP\.X&!E[>$JO*H%8?BI9GHK5UPBFF>K$V1\LD MFO$T4?G!H+*T/+XVR@YM/2D_]T_#_!!:AZ R(_ M9I9?*+[*SE'=&UL MM9A=;^(X%(;_BI4=K6:DMODLM%U L*T[):V F;F8K47+CD0:Q*;M4WI_ONU MDS002*.FD]Z4.,G[^IS'R0K4ZPYX" 1Q9'I6%;+C#&A1J^3G'O@O0[;R(A0>.!(;.(8\_\& M$+%MU["-EQ-3L@JE/F'V.FN\@AG(;^L'KD9F[A*0&*@@C"(.RZ[1MZ]\NZ4% MR1W?"6S%WC'2J3PR]E,/QD'7L'1$$,%":@NL?IY@"%&DG50<_V:F1CZG%NX? MO[A_39)7R3QB 4,6_2"!#+O&A8$"6.)-)*=L>P-90N?:;\$BD?Q%V^Q>RT"+ MC9 LSL0J@IC0]!<_9R#V!"K1*P,T$[EL%7B;P$C)I*@D''TO< MZW"V15S?K=ST00(S4:OT"=7K/I-<725*)WO7]_?^C_'M[0F:3_O^:-*?_C5# M_3L?W<]O1E,TOIOW[Z['@]L1ZL]FH_D,G:*9>O:"302(+=$#A],Y?CY!=XPN ML C1.%YCPM6#(=$PQ'P% GWV06(2B2]*^VWFH\^?OJ!/B% T(5&DUEYT3*DR MT?&8BRSJ01JU\TK4MH,FC,I0H!$-("@:F I!SL%YX3!P*AW_W- SY%HGR+$< MKR2@X=OE;HGVC%BELBZQU*R=F.G:_=1SK5;'?-H'T="$!1#G M.8CS2A!SC@/U!5)?IQ-$09;QJ#2HRR,U:^WQL-W+ QX-35C@T=F6\ Y 2.+H!',D0?9_,U$=\S;@D M=(4VJG"4I5+I6'=!FS3S&S(KD+S(25Y\=*V]:!)LDV9^0V8%L)Y2Y&?S[;1^LHET<'Z@M]F2K9^=3;I'-\%\1:A $2R5I7765DO)TVVO M="#9.MD(>F12LC@Y#$$]@US?H*XO&9,O SU!OOG8^Q]02P,$% @ PX(( M6?;<+!;M @ / @ !D !X;"]W;W)K&ULK9;1 M;MHP%(9?Q1('0:$VU1*9NF:1 DU*44MMUG,!.,! M![)<23U@A]T<+V$*$4K4@HFM+Q:-=[7@[]Z":VSTR][L5+$,2LR*= $O^ Y!82S!*E!7D""Q@3/ M"262@+A$4<$Y9!+]ZL^%Y&HG_C8E7\W6-,^FO\YKD>,8>I;Z_ 3P-5CAQP^- MP/EL*L5_,GM3&*\NC'?*_5]A\JHPIF0KAU;IH$^.==CQG:Z]WLWA,*;AN(TZ MZ U;LV9KGF2+6*H.-(&K,T$M&*0Y92\ : X9+(A$,1/2N#DKXV 7I[./?!CC M!JZ9V*^)_9/$CQPGU=X2F((J*F&ULM9WO;]LV'L;_ M%<*W.VQ %EN_["1+ R2AR.MA[15M=\-AN!>*3<="9/1?FE6@@AR==EEE=O!@LI5Q?#835=B&52G18K MD:N?S(MRF4CU;7D_K%:E2&9-IV4V]$>C\7"9I/G@ZK+9]J&\NBS6,DMS\:$D MU7JY3,JG&Y$5CV\&WN!YP\?T?B'K#<.KRU5R+SX)^=OJ0ZF^&VXILW0I\BHM MDBM%TKRVXB=9JI^FJI^\HO'-9_(S>9^495*; M@OQ(A4S2K/I);?WM$R4__O#3Y5"JD>KVPVE+O=E0_0ZJ1]X5N5Q4),YG8F;I M3U_H[SL 0[6+V_WTG_?SQG<2_['.3TDP.B'^R/[;].7[T MT-(]/KY[8.G.7K?OW-W]7?)$ L_6VU BV#HN:'!!E^/$G21O\TJ6:W5(D^2/ M7U4#\E:*9?4?F],VM-!.JX_4%]4JF8HW W4HKD3Y( 97?_N+-Q[]8E,9":-( M6(R$,22,@V"&6<*M64(77?W>25&1))^1K$CRBJR2I^0N$S:?.$%]?8*$T0UL MTL#JTN#A*APU_UT.'W8M<-@N&MD:,N3L. AFR!MMY8V<\O[>5 IB1I('4:K* MAZ2Y%&H82=392!!5JN3'&\ Y5%\#(&%T _-&.\J.3D?A9+)G 'N[(#S;T]_> M;A2%9CL.V@E#VO%6VO$KI*UJ;;,BO_]9;5RJVO%.GJ@6TVP]2_-[(A>"B/E< ME:NDF.^9HGI,5I5-?^=\^NJ/A-&Q75<_VM/_R';LR'8PT89?(=9G*)_+']9TJ!]55J;4 /$.JCH11)"Q&PA@2 MQD$PPS_G6_^<.P\CZJ(CLIG"V:NO*9 P>GY0Q>W7>0P=F$%I'$4SE=>Q MG^<,BFKESZW*0P,^*(VVM%WEHR[EH0$>E,91-%-YG>%Y[A#O\T)=Z"5S=15@ MU1\:W$%IM*7MZN]Y709 CLR@-(ZBF0;0*9_GCOF:A+^8DVDI9JDD\V2:9NJZ M[X3<%:6"U8G/-%'CJVU6AT"3/2B-MC3#(7Y@SW?;MA.S;62->*&SY"B:J;^. M CUW%LB*4J3W>1/C_E.JHP&YW3BA-H8URW,#>TL.3?.@M!A*8U :1]%,V^@$ MT9M\[^S(@T:&4!J%TF(HC4%I'$4S?:0C2,^94+WZ] ,-(*$TVM)V3S]=)Q]+ MRXY3#S0\1-%,[75\Z+GSPT[MDV6QSB4IUK*2ZKRD3'IHS0FFTI5DN2_>E M/VS8H3PT3$31S/4^.DWTW6EBI_*EJ)?HU;_UQ_W^N\?IZP$HC?J'\:-OU3:V MM SLJPN@,^0HFND"G3#Z[H3QHW@HLH=&8M,'5J6AL2.41J&T&$IC4!I'T4S' MZ(32][]WU>E#PTPHC4)I,93&H#2.HID^TGFG[\X[7UEUNNF]/02-1?W#6-3S M.V*Q'FT9=)8<13/UUZFG[TX]/XD\+4K2'$X^UX>3S5K&ZWQ6'UA$KHXDHOJ% MA*?AZ*\GY =UUB9T+4B]VK8K*G>/V-L3T*@42HNA- :E<13-])4.4_W(>7[J MNW[:AZ:G4!J%TF(HC4%I'$4S3:,36/^%!%:AR4.2K:WKZMR=>UL$FK:V--NJ MZ(-3#31*A=(XBF;JKZ-4W[T:\SK/UZJ(G:=?Q6GU S0UA=*H;U]"&8;[ M9H#FH5 :1]%,,^@\U'?GH4=7)N.F,AD;E4E@NX/HQCUB;\= ,U(H+8;2&)3& M43335SIK]<^QE0DT7(72*)060VD,2N,HFGDSH(YI W=,ZZY,W)W[6@1*HRUM MMS(9=U0FT($9E,91-%-_'= &[H"V7V7BAO7V S2A;6D'EDXZ]*1U[5SKVMO3O$>\&.MX- MW/'N*^-]-[VWAZ!1+I06MS3['P ._P8 '9RC:*9)=%8;?./"U^-6G[CIO4T" MC6Z#P\6L!U7OBTT8=$X<13/5UB%KX Y9VURE25.L'9ZMS3 _H=#5PKV3=/;NH*]_OL+S /8'>/H+FL5!:#*4Q*(VC M:.;SMG0>&XZ@YZ<0FM!":11*BZ$T!J5Q%,TTC0YQ0W>(ZSX_N3OWM@@TM(72 M8BB-06F\I;D74ICZZ]PV=.>V_4)\-ZRW'Z Y+)060VD,2N,MS;&0PC2#3EA# M]\+7N'EP6_TLV9>= $U2H30*I<50&H/2>$L[>"K9V7F'%7:>WND.2;^U9CU^ MX8E[ KT=!,U1H;082F-0&D?13)OIF#7$+HD-H;DJE$:AM!A*8U :1]%,T^BT M-GS-DEAWY]X6@6:U4%H,I3$HC8>'BW\/E]B8^NL@-D0NB77#>OL!&L-":3&4 MQJ T'G8L_AUWF$$'K*$[8.U3LT+35BB-0FDQE,:@--[27$_2-:V@<];P>^2L MP>DHVJU9/XF5*C_N1-GUTH4;]S1Z^PB:MD)I,93&H#2.HIF/O]=I:X1-6R-H MV@JE42@MAM(8E,91--,T.FV-7I.V1HRY%OW.+WUAT:I4!H[_D/AJ(%- M<764&B&CU,@>X@6C:%]J:$H*I<50&COV(^&H84VA=4P:N6/2;ZTS(N/ON51, MMV6&[+.SONR[YUC]-;?VA "J6QXS\4CAK8%%>GGY$[_>Q9 M9G2\<>B@RH#FG%!:#*6Q(S\1CAK5E%F'G-%+;V&JFE=MB:\RS>_7:;5HCO_% MO'DKDU7JR>$RML#^:PT-,:&T&$IC4!I'T4Q+Z*@S='\5,+%?->X!79:H. M\?53F:=)63[5]ZP\WYBP,R-U)CIV/Q'@6R^,SYH+XZ"],'Y?/&POC&UO;+YQSZ+O-0Z41J&T&$IC M4!I'T4ROZ2AU[$$OC,?0I:Q0&H728BB-06D<13--HR/:,3*B=<-Z6Z8CW=Q[ M13"%CAI#:0Q*XRB::08=XX[=,>Y'L4J>ZF-'5=<^U4+52/JUMU8_0 /9EK9; M# 7VQ(%"!XZA- :E<11M8XFA*D2%I(E,KBZ7HKP7MR++*E7!J@NE^LRRLY64 M8EZ_D^#BVA\,#[;?>!>WGF4[]2Y8LWVH\5>7J^1>O$O*^S2O2";F:JC1Z20: MD+)^C_+S-[)8J8/!@-P54A;+YLN%2&:BK!NHG\\+52RUW]0#/!;EEV9WKOX/ M4$L#!!0 ( ,.""%E-5(K%>@0 $4; 9 >&PO=V]R:W-H965TGETB3C8VW1#,OG-DK(4"WG*5B[?,((715*:N,CS(C?%<>9,1L6U6S89 MT5PD<49N&>!YFF+V\Y(D=#=VH/-XX5N\6@MUP9V,-GA%[HCXOKEE\LRM5!9Q M2C(>TPPPLAP['^'%U/=40A'Q5TQVO'$,E)49I3_4R?5B['BJ(I*0N5 26'YL MR90DB5*2=?Q7BCK5F"JQ>?RH_JDP+\W,,"=3FOP=+\1Z[ P J6BII@Z*>U-D2S=QIA[CG6#RVUCFB7A&!XX2_DV'?[Z[ VS?O1JZ00RL!=UX. M<[D?!AT9YG.>]8#OO0?(0X$F??K\=+^=[DK#E6M4N4:%GG_,M3)VG7'!GL[#7CAIU'59NBF@5'%8%A^:" MGRPJ?/Y]#3O5/75?HZK,R%BFWX/>K^_!F\#SP"(GX.MH!> M_6/KG=9^R[RF W\XU#HH0Z-6Z,#4)F #!N 3C6)8-(JP;!1?\$_5) ;:DHU2 M+UTLMM3:QFL>@':! %HE EMJ;?,U$T S%+RL691BG6XQ/)RGQD%/-56C!#2S MA+EAE,G-]18>Z1CF<4[U41,&-"/&\9;118N@TP=*"UVT"(9&LH U6D S6P2] M0-X=S4 :J*0/9I RDIPPX.)RGYZ ,5%,&>@UEH.=3 MAGF<4WW4E(%.I RDHXPC+4-'&8&Q9=24@9ZBC*AH&5&[92!MR58IPY9:VWA- M&<@N92"KE&%+K6V^I@QDDS+0$Z=D" !="@ &0 'AL+W=OMA6-WMMO"O]^U$[(&0@>H MO"1V?,_)N>?>..ZOI;K1_8,+ M-IL;^\"/^PLZ@PF8J\6YPIE?LJ0L Z&9%$3!=. =-XY&/1OO GXP6.N-,;&9 M7$MY8R>GZ< +K"#@D!C+0/&V@A%P;HE0QI^"TRM?:8&;XWOV$Y<[YG)--8PD M_\E2,Q]X78^D,*5+;B[D^@L4^;0L7R*Y=E>R+F(#CR1+;616@%%!QD1^I[>% M#QN 1O,)0%@ PN<"H@(0N41S92ZM,34T[BNY)LI&(YL=.&\<&K-APE9Q8A2N M,L29>/QY>$D^D@EV1[KD0.24#*5"$B9F9$07-&'FCER)%!2Y@)7D*[>@(&6& M',\4 );4:$)%2KZ;.4:=,$%%8J..E:)B5@3LC\%0QO4!ONUJ,B;[>P=DCS!! MSACG6%#=]PWF8U7Y2:%]F&L/G]#^=2D.211\(&$0-FO@H^?#HRK<1P-**\/2 MRM#Q14_P?<.Y]:\PYP2MX]:\7V[AU$"F?]ZE'=$5C$@*@V(MK''E])07I=A#NLXF-U65G$CC+!BJTWEM4&M M,JBBJ%DJ:FY5]*]CD[PHTZ(H=2JW4KVT#CLBJV3=*K-NO4DCMG9IP([(*@:T M2P/:KVO$'-:N]%@0/&C$_P15%'5*19VMBO"7@S\4X;9)Z;;)HB%M8.W6MY7O MI<78$5DE]6Z9>O=-NK&[2P-V1%8QH%<:T'M=-_8>[7B/-L6:D(=;HK_Q\[<' MKS.J9DQHPF&*H."P@U^BR@\S^<3(A3L/7$N#IPLWG./Y#Y0-P/6IE.9^8H\8 MY8DR_@M02P,$% @ PX((60?@I@;8 @ +@@ !D !X;"]W;W)K&ULK9;1;MHP%(9?QALN7N4*0*&WA#+9=U9* MI1>N*V)Z+$NKZGM=Q$TR8$_?R>P\B[O%, M4<+@02"9)0D6[Y= ^:;OM)R/&X]DN5+FAAOW4KR$":CG]$'HF5NYS$D"3!+. MD(!%WQFT+H:1B<\#7@AL9&V,3"93SE_-9#SO.YX! @HS91RPOJQA")0:(XWQ MI_1TJE<:87W\X7Z=YZYSF6()0TY_DKE:]9W(07-8X(RJ1[ZY@3*?MO&;<2KS M7[0I8ST'S3*I>%**-4%"6''%;V4=:H)6>$#@EP+_LX*@% 1YH@59GM8(*QSW M!-\@8:*UFQGDM'FS+75V.JB9^51,_]PL.U60O MYQ&1,\IE)@#]&DRE$KK[?MOR+(Q#N['9D1OP!3)MW!4@#H7:N0 J'[#U/$IY0LL=F$IXB!LI6A\.[F MWN8[LH[;+:_GKNO9[<>$Y^TJ9@LZK*##1NBK)*7\'0!-@<&"J!JJM2L+MTX- MP>\$.YB6F/:Y';-=8;8;,9_P&UAYVI9W[>#LA[0.T'0JFDYST=B:",[,&NO% MI?^ZWD;8V2<,=P@;0[8(NQ5AMY$PWX\VFJYE_79H+"&1G2:J:*+FU>.Z3C:: M:*^AHS#:P;'$^+M-[]:^YN8DO<-B29A$%!9:Y9UU=0^(XG0J)HJG^0=^RI4^ M+O+A2A_H($R ?K[@7'U,S)E1_46(_P)02P,$% @ PX((6< #354: P M^PD !D !X;"]W;W)K&ULM59=;]HP%/TK5UDU MM5)'0O@J'41J:;P';N.?>< M&]_8G8603VJ*J.$Y85QUO:G6Z;'OJWB*"5$5D2(W3\9")D2;J9SX*I5(1@Z4 M,#\,@J:?$,J]J./6;F34$3/-*,<;"6J6)$2^G"(3BZY7]5X7;NEDJNV"'W52 M,L$!ZOOT1IJ9G[.,:()<4<%!XKCKG52/>VT;[P(>*"[4RABLDZ$03W;2'W6] MP I"AK&V#,3\S;&'C%DB(^/'DM/+4UK@ZOB5_9/S;KP,B<*>8(]TI*==[\B# M$8[)C.E;L;C I9^&Y8L%4^X7%EELL^Y!/%-:)$NP49!0GOV3YV4=5@#5YA9 MN 2$FX!M&6I+0,T9S90Y6V=$DZ@CQ0*DC39L=N!JX]#&#>7V+0ZT-$^IP>GH M^N[B_!8N^R>G_G\.KY7(J>45K3F^VA:^'B-*@1C#HRTCUR DN.: ;YO^NV@P^%IG>$=E:">IY">IE[-%U MZEI4"\!GC7P$9"(13>]KV#>;YP6)5 =%%2BG;67((K>EP']TV\C=-DIE/1A? M,XDK)C5*TZJ$@1@R.B&V&(-6K7CSU=-%L2$ MK3QF37LSU][ZJL&&]K8+[=N2J0VRT5ER+C;*YLNJ(0;&[,\)A/MKYRO"B*R GE"AB.#32HM$Q3R^RJD4VT2-UI/13:G/UN.#6W M,Y0VP#P?"Z%?)S9!?M^+?@%02P,$% @ PX((6&ULM9U;<^(X&H;_BHJ=W>JIRC3X M1)*>)%4$*3N9ZF2[0KKW8FLO%!#@;1]8VR3-UOSXE0]!*!8"3[WIBPX8ZY'\ MO?BS7TD6%R]I]CU?"E&0'W&4Y)>]95&L/O7[^70I8IY_3%U+=G61KHLH3,27C.3K..;9YEI$Z461B+) _3A&1B?MD;.9_8T"T+ M5'M\"\5+OO.:E(?RE*;?RS>WL\O>H&R1B,2T*!%<_GD68Q%%)4FVX[\-M+>M MLRRX^_J5?E,=O#R8)YZ+<1K],YP5R\O>68_,Q)ROH^(A??E-- <4E+QI&N75 M_^2EV7?0(]-U7J1Q4UBV( Z3^B__T01BIX SW%/ ;0JX;POX>PIX30'OV )^ M4\!_6^!L3X&@*5 =>K\^]BIPE!?\ZB)+7TA6[BUIY8LJ^E5I&:\P*;\HDR*3 MGX:R7'%UTIN1KR626\/VV:<%TWP=W3!,3$FYR)Y%[^IO?W&&@U]-(4;"*!+&0#!-#7^KAF^C2W%_A/$Z M)E/YA<]DDB2S=7DJR8SY(4S(1O L-YY!=JI;ES3)8"W8508DC(%@F@S!5H;@ M*!E>HW]"PJ00LIZ"R UB*T]^0!9[+=Y^6:P%N\J"A#$03)-EN)5E: W8F.=+ M,I?W+F0I9@M!%O)&AWR(TEQ>8(J4/ EY:S*->)Z'\U#,Y)6R6,H=BA<1R>P6 M5]<0DTIUI:=5I>6-T_/5V:#Z=]%_WA7%VKBNHB!A# 331#G=BG)J%67G A(F M>9&MY6VB/#'R]=-_Y,U>J%,9A8=2K;L]P1Z^W2IVV%'5,BE+KD745 0331#C;BG!F%6&4Y](T MA/&*AUD9?S)=\FPAC.$[.QB^]AZ^'Q@#>-8*])L]F+7=?S(JY]NHG%NC\O9TQ0T(H9BJ9'7-E1193.[30N1DE,P(%4\R]&M9ZZ_$_^@/ M_GI"?I+W%H2N!2F[-MR!>VX4!FDNQU :A=(8BJ9KIZRO$\ N%TAG.8;2*)3& M4#1=$^5[';OQO9%H\LRCM3#*,&QEF>9NO65A[?5TCC'4Q*)H>HR5C77L/O;H MG#6LJ2/WVEYCY_,#2:-0&D/1=.V4^W7.8#D+9$@;39 T"J4Q%$W7 M1'EOQVZ^#^2LMD\>[LM92*-,H32&HNG#6,IWNW;?W>2L*E.9HFPOWO7+#J51 M*(VA:+H0RF.[,(_M0CTVE$:A-(:BZ9HHC^W:/;8] =D+=Y8!2:-0&FMH6F^X M,U#_MNE6C[-RUJ[=6>\F(?('>0?O9V] 9ZV@0\]0&D/1="F5;W=]6!J#^G$H MC4)I#$73-5%^W+6/$A](8U +#J51*(TU-+O+U6.L_+5K]]=_-H4=;P7M#>BL M$]3&0VD,1=.E5#;>/86E,*@]A](HE,90-%T39<]=^^CT@10&=>10&H72F-L> M+F^;7CW&RFZ[=KO]F/&9B'GVW6P$H6/<4!J%TAB*ID^F5([<&Z#2CPEY<1''A$>EW,C3PB?S<)FD_T,@GIQ*(TV-*VC/S!V]#-4Q;H4 MRFA[=J,]$441B6HV3CI_,^'[Z%P&M>-0&O7:!MIQ?+,2[S'<[2D[[MGM^.'K MR/OT,]J;U5D]J$F'TAB*I@NL3+H',^D>U*1#:11*8RB:KHDRZ9[=I$/2']3* M0VG4:YMOUSBIG:'JU8503MZS._E17,Z<_E_]V-=*1CZ=E8KD2I\5WU1_[0\? MV:OI+ ;4\Q\(P>G>)Z,8JAWZXWG*W_OV$7?LI>GX_F-[L[J*":51*(VA:+K MJK/ AXWD^]!. RB-0FD,1=,U4?T*OKU? 7%ILE?162QH+X/?'J$_,W87,52] MNA"J!\&W#_6C+DWV:CJ+ >U>.! "9[#_VH1JB*[.SK/C]KZ$<1K'Z:QZB'*= M39<\[W!V0'L0H#0*I3$43==(=3+XL-GU/K0O 4JC4!I#T71-5'>#?\1CY3'/ M%C)G/?&()U-YLU;WP1EU:3\O;GQ^:NRWY^6_[?ZWMZQS'-_#U?O*U?OV&?2/ M:<$CHK+0E]FVS/IV/5&#E1A6P<&:N^A-(:BZ4O!*,L?V"V_98C&I$%#TRX/ MYO5$FCVU1W'-ZU386]@UGBB:'D_EL /[< M;J C["B:'D_EB@.[*YZDFR?!$_*/,))II^IZ-<81ZH"A- JE,11-UV-G:368 M PZ@#AA*HU :0]%T390##NP.N&O.:1M;]]2<X6=3P6H-8;2&(JF M2Z>L<0"SQ@'4&D-I%$IC*)JNB;+&@=VW=DU/[6?+S4EGW.RYZ]6"/0X,ZFA1 M-'T53>5HAW9'.^99MBG79AM5,91YJ>ZZX^6J5#DIU\Q<"C+G858_M4&6H@AUT% :A=(8BJ9KHAST\-"4]VDF MRCYN>=+,Q%QD6;6T:;P22=X,DT8\,4K4'O0UST<:VYO0.?Q0LXRBU>'O[RQ4 M'XML4?U"0%XO%5LO[[[=NOT5@E&U]OZ;[=?.)UK_EH#"U#]M<%>-\^0D$G.) M''P\E7?>6?UK ?6;(EU5R^$_I461QM7+I>#R/JW<07X^3]/B]4U9P?8W&Z[^ M#U!+ P04 " ##@@A9SOU#,VT$ "/%@ &0 'AL+W=OVR?W+B]8?R;6!(BT4O@4]'1EE*N M[G1=.$L28''+5H3"DSGC 99PRQ>Z6'&"W2@H\'7+,.IZ@#VJ==M1VQ/OMEDH M?8^2)XY$& 28_[@G/MMT-%-[;9AXBZ54#7JWO<(+,B5RMGKB<*>G+*X7$"H\ M1A$G\X[6,^]LLZ$"(L17CVS$SC52J3PS]DW=#-V.9J@1$9\X4E%@^%N3/O%] MQ03C^)Z0:FF?*G#W^I7](4H>DGG&@O29_Z_GRF5':VK()7,<^G+"-I](DE!- M\3G,%]$OVB180T-.*"0+DF 80>#1^!^_)$+L!)CU(P%6$F#M!U2/!%22@,JY M =4DH!HI$Z<2Z6!CB;MMSC:(*S2PJ8M(S"@:TO>HFO>IY/#4@SC9?1B.>^/^ ML/>(AN/IE\EL-!A_F:+>V$8/O>$$?>T]S@9H-.A-9Y-!_.P&36'QN:%/$)NC MP7P.,RC4I4VXM\9J&M&0"LE#6![PQ";"6U LB8NP0)^(N_#H(H. Z?_<'R), M732&E3[ G )$H"N;2.SYXAKZG$UM=/7A&GU 'D4CS_=AT8BV+D$"E8CN).G> MQ^E:1](U+31B5"X%&E"7N%D"';1+!;1>!;RW"AG_">DMJA@?D658U9P!]<\/ MK^2$V^>'6P795-+E4(GX*D?X\N?P(_H;' 1=/3(!D_'?(P2AH22!^#]O!N(> MJOD]*!^[$ROLD(X&1B4(7Q.M^^U]W M;YIM?;VK7@ZDGH78AQ#3:*283*JU--7:A:GZ6 AO[D&R<\X"U'.<, C]R!-8 M3NH47""3?N0-6!.'5V%N1H7$E^ZK,LGLDL@R@C9201MO[EB- M,I4MD\PNB2RC;#-5MOF;':MYL)T.'"L'LN]8AQ#SB&&UTDQ;[]^P6B:VMO-9OMJZDP]V=9>SMSM,0.P=B'MF>VXK=+"Q; MWX=Y)6,LE.<08N[+4\22E6=;=IO%=?>02@)+3"(. IQO786D%^^M,MGLLMBR M@FZ+>[/V]M95^ %QL;QELMEEL67EW7X?F,4?"&]@7?73>_,DQ,Z!-%M'-N>V M=C<+"]AWXEV-PT_@RKY IS%V#N9F7R%]YZ0N('P1G7@*2"JD,CYS2EO34]5> M=):XUWZO3ENC$\ M37Q4.\)\H53UR1PHC=L&K&<>GW[&-Y*MHO/ 9R8E"Z++ M)<'@C H S^>,R=<;U4%Z!MW]!5!+ P04 " ##@@A9>/2Z=.\( "61@ M&0 'AL+W=OC[9<+Y]/YVFRPV-2/HNV=)8O+-.6$2X>,J>INF6 M4;+:#8K"J3V;>=.(!/%D?K9[[3.;GR49#X.8?F8HS:*(L-SB?6Y.<+ M=\'3AN./-(4GJ1A/\&*[XYGYQ,T(JN21;RN^3E+UHZA'-]RR1,=W_12RD[ MFZ!EEO(D*@<+"Z(@+OZ3'^5$5 98;LL NQQ@]QW@E .\[$NX$8Q^?7-[>+VXN;Q4=T[AT]7M MEWNTN+U$UXN;._1U\?'A"GVZ6MP_W%T5[[U%]R*65EE(4;)&'TA(XB5%][N8 MNPA)F@;K8$F*-8I7Z)H$#'TE84;37/Z2LN"9Y$N';N*4LTR$!$]UDO_P#65H MD::T?/]C0!Z#,."!>/_W2\I)$*9_"',>[B_1[[_^@7Y%08P^!6$H+IV>3;F8 MG=S'Z;*VJQE^T7^XHPZ?BC79+XR]7QA[I\]I MT54(66*B\[>10?2 M/K\@Z6:WLLO\ ?V>B<@(\W!X(UYA[#6(G]!S'@^Z62A4^SO5>:YZGHN)/YL^ M5YUKRCB>OY=1;';W-KN@S5\23D)$6A>G&.U5+HE];-7LT@B=NEAO&-X;AL%X MJ7PZ='9ADT%C2)GBI[?WTP,7X#;AM,@'84+B%&W)*WD,:9^0\1K3[M86IBF! M9_IE\??F^G",9XR)D!8IFV>LR%TBMX5)_/264Q:)BO/(B^RFO-3'';]AK.V> MU$--)^2W? 9.]CZ=='QN2],649+%7&<;J&!HN!E2IOAZNO?U=&0:/C7IHB%E MBHO63#+ #%S02E%NSVRECFHHU8--(V+K0\VJ\(EU4,(MARO7Q"=UPYI"3N6C MHIHF*[0%E^B.E&L9+=2FM*F^RE)MP;6Z$B)AA]L.$ 2E+TV1ML60==GJ4YB[ M;&M67I$S<=T\C12V6Y*F)0NT!=;%^57* U$&:)5TM48:K=6FM*E.RVIM>2/S MIP76^<%N&M*FNBFKO 67^7X9M%F,&QE44Z];XDY6:PLNU]4,^@;1?12N\RAL MI8M2:4=>;0JUYU59IOQ;;^(61K2K/CUK.M5JH-4>W*]ADLB$K4YXT!OJ$5<]$FH(RPY>85 M_8=Z\"Q\L<&;[F/4N$H3B) MOV2*$I6 7]%VTP(D92*F=BGH&42DKB@C[1CE:9_%*.P.PI4,7WI0V=5XE/CG6R#SC@-PUV$U#VE0W)6TY,&T= MULJW&_%\6J=$C8SM.BU17SF @+L: Z*^[^X=ON+@93T&0CD2H1QW;/2"[#78 M34/:5#%/ONA4H+8%[4";7QHB-1QX%/3 X,\L.@$;9M<)P<@Z8< M25../_;C &+88#<-:5/=E&#FP VC7M#H-%L_=6C4B+1 HR-!RCFH-^08[0V9 MTJ:>-$LF9TJ9.C^0J]Z![4ERC#253VE1?)66Y,&4=\48/MWE; MBN9.#ZU46Q_=E;[\A?"5G *@8T8O*;'0",LT0B/ M/:?#1IM,IK2I;DJ(PC!$]4HAN'F4UHA:2$2UK7)3+=P9&AJU7X(HKW?;) U: M_#![(^XQF =+YL%C#]&PT;:/*6VJFQ*!<,<]O(.>5JIMELK/4D_'DP_HZ+]@)T*;,[0T#"E39T\26;>V$:39Y2F3&E3 MW90TY?6^@[D=,SSHSN32C:9("V9X$H$\^)RM(Q-Y1IM"IK2IODJD\F"DZK]3 M\9K'877FTXBT[%2\RA>,X$[.J&0R;KL"6S)X88^!29[$)&_LZ9AGM+%C2IOJ MIB0KS\#IF-=].@:*J+9)HO'@;LRHT.W%VJ/4-]H/ M,J5-=5,2D0\3D8%C%;_9!:KO7$ 1U7*)(S[<*&KY@F>>8X=LQK4>&>494]K4 M>9(\X\/=H0YF\(VVB$QI4WV5?.3#+:(#OO3K-[M"]=MN-"*M7_N5F./#F#,V MC/O>9P9??O#Z'J.1Y$OD\N%&4E[2:VQW#LO%_I]***; M(HV(GE9^-"3_Q99/A#T%PIZ0KL6@V;L\)%CQ(RC%$YYL=[\C\IAPGD2[AQM* MQ)8Y%Q#OKQ/A6?DD_VF2_4_1S/\'4$L#!!0 ( ,.""%DID4E+:P0 -,1 M 9 >&PO=V]R:W-H965T2SFA.BT6O&N.IY95B^71(FECTO]-X'[FDZUV; M[W<7."53HA\7=Q+N_!(EH1GAB@J.))GUO$%X,0P[QL%:_$G)4FU<(R/E28AG MT;DL MZ$0[Z(01&@NNYPJ->$*2*H /VDJ!T;O R\B)^$?.3U S:* HB%HUA(8_[]YT MT&F6Z]VT>,T=>#="*30$B92GA,>4*/3M!FS0M2:9^KMNQ0K 5CV@V>87:H%C MTO-@'RLB7XC7__67L!W\7J?V0& 5[:U2>\N%WK^A^(DRJM\0E!^$TU22%&N" M9KG.)8&BD)&$8KN[8Z%T;?H4,W3L#*9$O?2CLZ[_LBG1:5(A?EH2/W42'_$7 M*@6'ZJ4Q0ULA?&N@J089YBD2,_29<@R!!<,[H:A5\VWTJDWE>V($\CK/B+0J M:Z/M9C*(8Y%SK= "OV$#AWD"I3"6.4D06ZTO)%4#W>HYD>AF)Q+"3SK M,N-_F+@2C'89C+8[BXC6, &L="PA7^JT7+9_2(%P.TMJ3%KU6=(IB77V(M9 M.#-KAN#T5!K6"_*ECFR!VMY@$FQQ=5E4J)Z55,_TQ1S1]%Q8^Z[\PZ%5EV!=?\3M@Y=>$)G2[6W_@.A5?6OVZC0W40< MI/2<_EAZML]+MTV5_+KM"-U]Q_ZEQXWG+#U.UX_&:=W(A.Y.YH[(V/2Z*3'= M#-L1M/+5?$Q2RM;9X@RY'RR\6 _N>[J_-B\\=8RQ3J&T@7L".P@U>PQSDRV;*5<^NLR0D@UP0EB,.JZ[5:]P_=/3Z6^@#I3J1DO&VSVG52!UXV/[(_JWTKKPL ML8 ^HS])(M.N%5@H@14NJ)RQW1/L_7@Z7\RH*)]HMU_K6"@NA&39/E@IR$A> MO?'[?A\. ESW1("[#W!+W16H5#G $DAY/^:#B_18\OO5EOLA@.YZ@W&:C9\7BT& \GBSGZ M@N;J7"0%!<16:%KP.%5[@IZ7E*RQWF>!K@<@,:'B!ETADJ,QH52/A[94>C75 MCO?:'BIM[@EMWXO\#C6=6^0Z;@N]S ?H^NKFWS2VLEM[=FO/;IFW>2)OGV49 MD>ID28%PGJ ^RR7)UY#'! 0:$!%3)@H.Z%=O*217!^>W27P%:9DA^C+=BPV. MH6NIVR* ;\&*/G]J^,[7,Q::M87FN>R1VA'/I*F*:I=1^CYNHT;0".VM =6J M4:U+*-^$JJ+\0Y0;F%%>C?(NH=HFE'>$.F7*KTG^)5)@(OE'I%;33&K7I/8E M4L=$:A^1M'<3*:A)P5G2(@55EE<2N(D7'#OSS+Q.S>N:9'S<60NQN;8L'JU)BODEW9!,?EE2EF(A7]G*XAM&\$(;I8GEVG;? M2G&<=28CG?;()B.:BR3.R"-#/$]3S%YN24*WXX[3V25\BU=KH1*LR6B#5V1& MQ-/FD:= [UZ!?&O1UWQ>=I7O:QP)/ M1HQN$5.Y)4T]:+FTM>S@.%,C:R:8_!I+.S&Y"VYFP0Q]1@^8,:Q41A]](G"< M\$_H XHS=!\GB1P#?&0)69ZRLJ*2[1=L]P3;<=$]S<2:HR!;D$4=8,F*5K5U M=[6]=8U$GT27R.E>(-=V/?0T\]''#Y\0W:A!VE"_J9EVCU^0V],P=P=K:J69 M\GN>72+/UIBN 1.J\:)I[G>">Y3QDA$F901/641S1:Q MZG.<16LYM='7>1*OL'87?]U):_1%D)3_W="$VZ*H;G-1RI=>\PV.R+@C MG24G[)ET)C__Y/3M7YHTAH3YD+ $A8"P6KB=ROQNR;ZY.N&*-^0K5!"I-3\ M0JXI:M6J4I @+&WR$+=&<%NI(6&^NAUX(9DUM"B"K$0+!:KKV*EU[QD:& M<8:SB+17U8AMJRHDS#CY4 M$[+ $ A64W-0J3DPJOG(:$3(@J,EHRGB."&(+M&&T46N-^4(E M"Q3)K?2+\J+/.,E)DS(%NW_0[=Z1,*]SN$>Z&.O75A=(6 @$J^DRK'09&G7Y M52Y@2&Y!^4E]FO08OCD-I@U9ND>*#%]I=DP)7E/L>H[06$ZM2QQ[?\:SC9UR M5ZWF38U_P_CJY)(Y?IJ'9S('6.W/>3IG##EY1G) MR%:>L8H#+D?_GC[JWI90@\>8FLMMNPJ#T@)06@A%JROH[A5TSYAO._5.SCLS MI&>8=T;+UD)"T@)06@A%JPNY#WHXQF.U//CJ>(:@6D1Y6A+D LG#<$P;M\QF M6ML]\QMU&QB<*V@8 Y060M'JBNXC&IC8!\2<=XE)F(NI;7Z MH%&1DF;8 :@!890M+JD^[B(8PZ,%,'+_^G)(>,04U":#TH+0&DA%*TN^3[F MXER]HR>'C'E,06D^*"T I850M/H8V,=W''. !\J3&TMIK3XDS7=>QX"\8T\. M66 (12LDM0YN(Z2$K?2]$2[ER#-1_*N_2JWNIMSH&QE'Z;ZZLZ)O.>PQQ867 M>\Q6<<;E(%A*I'TYD+L+5MPA*5X$W>@[#W,J!$WUXYK@!6$J@_R^I%3L7E0! MU4V>R7]02P,$% @ PX((6>^T;R"? P 00X !D !X;"]W;W)K&ULM5=M;],P$/XK5I@02-ORNKZ,-M+6;0(TV$08?$!\ M<%.WM7#L8#OK]N^QG2Q-6C=CJ'QI\W+WY+E[?.?S:,7X+[%$2(*'C% Q=I92 MYJ>N*](ERJ X9CFBZLV<\0Q*=FT%,G7ADGMWR>,0* M23!%MQR((LL@?SQ'A*W&CN\\/?B"%TNI'[CQ*(<+E"!YE]]R=>?6*#.<(2HP MHX"C^=@Y\T\G?J0=C,4WC%:B<0UT*%/&?NF;#[.QXVE&B*!4:@BH_N[1!!&B MD12/WQ6H4W]3.S:OG]"O3/ JF"D4:,+(=SR3R[$S<, ,S6%!Y!>V>H^J@$XT M7LJ(,+]@5=EZ#D@+(5E6.2L&&:;E/WRH$M%PB/P=#D'E$/RM0U@YA";0DID) MZP)*&(\X6P&NK16:OC"Y,=XJ&DRUC(GDZBU6?C*^OCQ++A-P!!*U0&8%08#- M05+D.4%*+ D).(<$TA2!Q*RJ#[1<.EJ"-Q=(0DS$6^5^EUR -P=OP0' %'S" MA"@#,7*EHJ@_Y*85G?.23K"#SL>"'H/0.P2!%T06]\G?NX=M=U.UMX M>P)K!1O6P89=Z+$IX2,V/RH$ E ()*WQEB!] Z*;Q'T<]KR1>]\,PV(3]6J; M%KNH9A=ULIL4G*L%60H!"(933+#$=DU*J%[C^X-H@Z+%I&]G>%(S/.ED^)G1 MH_0E+$^V*(3A)DV+C>_9>?9JGKU.GE^9+FO67MK/<>UM*1KY@PVNVS;A<$=. M^S77?FTR(S"C/ZTY:V;S(U<(KZ["4S^ MU;N5F6&=F>$^&M-P>_F%&RMTVR08VA>H[ZTW4.\ENEU7=?1X"*J6M5_=GF%S MEJ:LH%* '#Y"C0?I3,U**2_0[)D:G_P7Z'96&V.)O[]V7V$U=?4WI;?8[))^ M/1WXG?MQA_1J+TC_B_K=A,K"NUYGJ\G$*OG>\-HI7,\)-T]^>+0)_ M4^M.FS;3]?SA=P\@Y;8Y;VY(SW*-+'/0)E>+S>8&[S;F>WVX^@3Y E.A2,R5 MDW?<5U,"+\\KY8UDN1GYITRJ X2Y7*HS'N+:0+V?,R:?;O0IHCXUQG\ 4$L# M!!0 ( ,.""%D#&SU0(P, ,D) 9 >&PO=V]R:W-H965TI CIU20GWHR!H^ EEPHN[KN].Q5VY-)P)N%-$+Y.$ MJC\#X'+5\T)OW7'/Y@MC._RXF](YC, \I'<*6WZA,F4)",VD( IF/:\?=H9A M8!-]KS $@&'B;$2%/^>80B<6R7D^)V+>L68-G'S M>:U^Y60*,[KDYEZNOD!NZ-SJ3237[I>L\MC (Y.E M-C+)DY$@82+[IR]Y(382PL:!A"A/B'83Z@<2:GE"S1G-R)RM"VIHW%5R192- M1C7[X&KCLM$-$W8:1T;A6X9Y)KZY[(\N1^24C'"!3)<!S MF;]W$MMR6R_[_O.FC?V0 M5KL(V8([+^#.*Z?BB@DJ)K"!UBEC.W_/R7@GL2V_C<)OHW(R^HE4AOVE[H.) M.UG9;]JIG)TNT3[5&DSIALU$&QN%#\.=N=D/.3 US0*U68EZ+0Q@ 0Q!TFQZ M.*-CQIEA4 K9W(?<8:R*V&)L%8RM2L;OTE!.9GN+J ROM3]XM,-7$A*4 [8+ MP'8EX"-56#3^%EM[?_+J.VS[(:UF.5L8O)XT027=:(&KD> T)V_PY3J;.[^V MPU<24M_A\S<.Q034W-T5- ZZ%"8[3(K>XC[2=Z?P3O_ WE/<8?LJDUUR;JF: M,Z'1S@PE@[,F;G:5W1NRAI&I.WK'TN!![AX7>-<"90/P_4Q*LV[8 8K;6_P/ M4$L#!!0 ( ,.""%FFJ*^"1P, -H) 9 >&PO=V]R:W-H965T9ED86 M48I422I._[Y#2M'Z(AM!D1=;)&<.SYR9(3G;*/W=Y(@6G@LAS3S(K2TOP] D M.1;,G*L2):UD2A?,TE"O0U-J9*EW*D08]7JCL&!*8J*[C$!PVF M*@JF?UZC4)MYT ]>)A[Y.K=N(HQG)5OC$NVW\D'3*&Q14EZ@-%Q)T)C-@ZO^ MY6+J[+W!OQPW9NL;7"0KI;Z[P9=T'O0<(1286(? Z.\)%RB$ R(:/QK,H-W2 M.6Y_OZ#?^=@IEA4SN%#B/Y[:?!Y, D@Q8Y6PCVKS&9MX+AQ>HH3QO[!I;'L! M))6QJFB,0[3L,CS@,&H>!#[1FYL.Z89;%,ZTV MH)TUH;D/KXWWIFBX=%E<6DVKG/QL_/7V:GF[A#-84GVDE4!0&2RKLA1(N;), MP(*9'.XHV_!%UE7CY9"<,PLM!2%XQ(F#>/KFG%TA'$_@GLE;6[@5J:8[@*$ M%'ZK0?2BP75T$O&O2I[#H/<)HEXT[""T>+W[X 2=09N2@<<;','S@I>,IT!R M RM4):TAS1)14;Q./)LC%"1PI7V27,J$TQL$9RLNN.5H+KN4K3<>=F_L#HQ+ M4[($YP&=" ;U$P;Q'^_ZH]Z?7:J\$=B.1L-6H^$I]/B?$C45HER#K\",RM- MIE4!JEWQDIA/(-%V:5%O,/8;N+/N*9Z.9^'3=H2')I-):[+#^Z+E??&;O#,N MF4RP8=U%N$8>;;'I[_$]9;%#=]32'9VD>^=)_1[=T2&9?;Z')D?D';=\QR=; MQU]"9RH[JZ@9F#%(C:-6= +)NG'P.T0YO)L#MKTY;9]!55=JJ6I@>-V-_OU4.3:+_X MPZUKLD"]]J\' XD[8.O;HIUM'RA7_E[>F[^FATO]SO@?IG[UW#.]YM)0*!E! M]L['U)*Z?DG4 ZM*?QFOE*6KW7_F]/A"[0QH/5/*O@S&PO=V]R:W-H965T$)_FG^_WD$EZD.I1[P ,>2JYT--@9TPU"4.=[Z"DNB9@& M_>"XL&3;G;$+8996= LK,-^KA<)9Z%4*5H+03 JB8#,-9OW)?&S/NP,_&!ST MR9A8)VLI'^WD4S$-(@L$'')C%2@^]G -G%LAQ/C9:@8^I0T\'1_5[YQW]+*F M&JXE?V"%V4V#]P$I8$-K;I;R\!%:/XG5RR77[I<&%@+@-B!UWD\A1WE!#LU3) U'V-*K9@;/JHA&."5N4E5&XRS#. M9/>WL]7MBER1%9:[J#D0N2$/S@L45[,]*"P-68*M+Q-;<@]X!>0;J))049 ; MIG-9"T.6U !Y<,17^#X7(L>&43O2!S%P]_#0[3D M?<7>5^ST!A?TO 7:6E#> G<6#%J8G.-L=(?G=>T[,M$5S6$:X$N@0>TAR%Z_ MZH^B#QW4 T\]Z%+/OE8(:SRD/L?7K9"09Z!*=[ ,/&ULM9CA;YLX&,;_%8M-TR;= M%0P)2;H$:6LWW4ZMKEIN=Y_=\":Q9C"SG6;[[\\&"A2H6_G2+PT&OX]_CUUX M+"^/7'R7>P"%?F8LERMOKU1Q[OMRLX>,R#->0*Z?;+G(B-)-L?-E(8"D95'& M_# (8C\C-/>297GO1B1+?E",YG CD#QD&1&_/@+CQY6'O?L;7^ENK\P-/UD6 M9 =K4-^*&Z%;?J.2T@QR27F.!&Q7W@=\?A&6!66/?R@<9><:&2NWG'\WC2_I MR@L,$3#8*"-!],\=7 !C1DES_*A%O69,4]B]OE?_7)K79FZ)A O._J6IVJ^\ MN8=2V)(#4U_Y\0^H#4V-WH8S6?Y%Q[IOX*'-02J>U<6:(*-Y]4M^UA/1*<"3 M1PK"NB!\;D%4%T2ET8JLM'5)%$F6@A^1,+VUFKDHYZ:LUFYH;I9QK81^2G6= M2JX^?5A_6J/?T5K_@Z0'!HAOT351!T$5!6E:?Q4@B*+Y#EV!GC!$\A1]ICG) M-U#?N:+DEK*JX.TE*$*9?*7OM+<9G1_4S-^ MK!C#1QC_/.1G* I^0V$03D;*+YY?'CTL]_5L-5,6-E,6EGK1(WKM?##C?M10 MI3 95S"OYKDLR 96GG[W)(@[\)(WKW 1_;*NR('3?8\5/8\S'L>( =+WK85F%'[%F#/7L*>S&&/1M@3^,>ME78 M$7O>8,^MV'_O00?V5H$8@Y\/YQSWX*WRCO"+!GYAA^>*L.K#B0KR2V\(U.@' M=#&P,1GXL([DZ ,';7 &5B=7(.4Y^I(5!P6I#CB]'B#5:+H%0S-1SXM],%VBW MC5[LEKUU67<%<#\.[-*NZ&W\8K?\Q<, QF$?_242&+<1C-TR& ]#N+_CL2N[ MDK##G+Y'#N UB[);$>!C%_1"P*[N2MUF,_T\8XV$:!WW^ETAC MW,8Q/DT>XV$@1_U-D7TH1RMA&\CAJ0(Y' 9R_X6PC^7JI*9^7E'D@* MPG30S[>&ULK55=3]LP%/TK5]FT#6EKTC04 MQ-I(E##!-D9'8=,T[<%-;AL+QPZVT\*_G^V$4%"*>. E\<<]Q_<>WYR,UD)> MJQQ1PVW!N!I[N=;E@>^K-,>"J)XHD9N=A9 %T68JE[XJ)9+,@0KFAT$P] M" MN1>/W-I4QB-1:48Y3B6HJBB(O)L@$^NQU_?N%R[H,M=VP8]')5GB#/55.95F MYK!?PB^):;8S!5C(7XMI.3K.Q%]B$D&&J+0,Q MKQ4>(6.6R*1QTW!Z[9$6N#F^9__B:C>US(G"(\%^TTSG8V_?@PP7I&+Z0JQ/ ML*EGU_*E@BGWA'43&WB05DJ+H@&;# K*ZS>Y;738 /2'6P!A PB? J(M@$$# M&+P4$#4 )[5?E^)T2(@F\4B*-4@;;=CLP(GIT*9\RNVUS[0TN]3@=#R[/#_Z M=G+^/3F^F+V'XY]7IY=_X!/,3'ME%4,0"TCHBF;(,P53E##+B428$IJ!%C#3 M(KW.!&,NCM[7H@:P>M)UJ4SE/F M0AN'F2#C@ M(!/%Q+3:[9X9XX@:[B";FW!WP%))(@H3CD0:QY@_G@)AJZ'1,=83U]$BE'K" M= <)7L 4Y&TRX6IDEI0@BH&*B%'$83XT3CK'7E_;9P8_(EB)C7>D=S)C[$X/ MSH.AT=8! 0%?:@)6CR6,@! -4F'<%TRC=*F%F^]K^N=L[VHO,RQ@Q,C/*)#A MT#@R4 !SG!)YS59G4.RGJWD^(R+[1*O)"K"*((YH_\4.1APU! MQ]DAL J!]5RPRX-=".Q]/3B%P-E7T"T$V=;-?.]9XL988G? V0IQ;:UH^B7+ M?J96^8JH_IY,)5>KD=))=WIS-?IZ=G4Q]JZG[Y'W_?;\YA?ZB+YASK$N(3H8 M@\01$8=J]BTRD0@Q!S$PI7*N$:9?.!KECJP=CCH6NF14A@)Y-(!@&V"JJ,O0 MK77HIU8M\4M*6LAN?T!6VW*J OJ7G-;*Q_O+[0JYM[_<28O&G(K[3G.=4\_3U="P2[,/04/>/ +X$PWWW MIM-K?ZI*=9.P<9,PKR'85E&B59>@U?)GTFBQ*D[!QDS"O M(=A64?IE4?K_XS+IOSBVG9;U[&R/:B-Y;06:A'D-P?(*F!M]4PQ\D36L ODL MI3+O0\K9LB<^R5K!9_,CU2OGK>T3)F^T+S%?1%0@ G.%;+?ZZESSO'G-!Y(E M67MEKJ/I]X-I K<\9D^N!=E#^@W#_ E!+ P04 " ##@@A9(NFY M,K4& !\* &0 'AL+W=O?W;I+)F&]$&,3L)D'I)HIH\N62 MA7Q[WG$[SS=N@^5*9#>ZD_&:+MD=$Y_6-XF\ZE8L\R!B<1KP&"5L<=ZY<,]\ M,LP:Y(A? [9-=SZC3,H#YY^SBZOY>L1"-A,9!97_'MF4A6'&)/OQ=TG: MJ9Z9-=S]_,S^0RY>BGF@*9OR\+=@+E;GG6$'S=F";D)QR[?O62FHG_'->)CF M?]&VQ#H=--ND@D=E8]F#*(B+__2I#,1. ]=K:8#+!EAMT&MI0,H&Y- &O;)! M+X],(26/@T\%G8P3OD5)AI9LV8<\F'EK*3^(LW&_$XG\-I#MQ.3N_GKZT_OK M#_Z[V[OOT+M?/EW=_XY.T9V<7_--R!!?H.F*QDN6HB!&%[/9)MJ$5+ YNA8K MEJ IC^1\6V43X9&AG^5$/?G T_0UNHIG/&+HQ&>"!J&\<8H^W?GHY-5K]"JC M^AB$H1SX=-P54D;6F>ZL[/)ET67G #-_<.;8X,:4@TIR?E("]_%]?0*70B1! \; M01_D( J.;FC"8O$F'R$YIO?T"?UQR\,0R;=G2Y/YG] X%,_IP<_),M)9NJ8S M=MZ14R!ER2/K3+[]QO6<[Z$8VB3S+9$UXMNKXMLSL4\NV3*(XR!>RH03TGC& MH- 5%(.<(LN]CQ.,G7'W<3>"AHCG"6'62 @G M89X,@CP9O$%Q,?L$?8)B5CS$VXD9(4,E9GTMKJ=NKXGQ=8PWJ" -@5XET#,* ME(EFSWA[>M^QVG<=H\T)W]B/_SB,@TKEP*AR-[M#@YF-7F- H4 8'W%LSK!) MYELB:X1V6(5V^$(Y>6@SOC;)?$MDC?B.JOB._G].'FGOWVEO1)27% (-1LI; M"H#Z/0_.,:Y36S''*.)Z7P)%#TPZ?2;]]BRD:1HL@AD5K2;*T3LY4,1" M AB/M$C=<9VN.=5$?!.+=$>)S#F+A$?(2A(JG]Y(QR.U_ *@4Y>HZG60VR(> MU^*Q47QIC645E ,:LT4@%;$GN9)+V6M0#09&J:^JT4&:%A.DJ:7VFJ[1:MDJ M_>53S+4? .G%'P"U57^W=GRNV?+MK_\E0;-O?6V0 )26@GP0M9.#FB)JD^:: M79JL*G(5',M592+KSNP+$@F-TY 6Z^_Y7W*Q*1?T DXF1NICRXY5-M\66S.L MM35TO13:F;IF:WI0?2\YFN^-GBA!U%!]!R&4TY8N M:QOH&EV0[1(_!)*.I^K50:XJ%N#9B5M3:VW)7+,G^]HU7C=A&*MN#@"I*RXC MI+F=5#LY;'9RQU9X#/@P99"F 8K4@!(FY3:J6&S4[-4X+'NH["C3E4 I-9& M -(Z57'MR+#9D>VO[QCP8)B,5 &04U,SD ^CABTB:BN&S58LJS6;.&$T#/Z1 M+]:2!G%:#!*3PR1K_)PEP2/-]MG!;&*F/[;\6&7S;;$U0UO[/]Q[H1J/;6[Z M3:VR^;;8FD&N_2DV^].#:CS6-PE'VENH8URLUCP A%M6=KCV@MB\3VBWO&-] MP_!471-!&$^5JF-ANG@ ,&KZ\0&,VY9:2.W#B-F'W92_M=-XCM8\%0D30<*R!7LU M ?>LX2^DEM!HEY,]!ND2?Z9I^KR04PJE83I"FT-F3$;,B^ M0'QY3[E^Z97QR$JVF*N!"\"C_N&)TSI(,(+]?<"Z>+[('5 <.)_\" M4$L#!!0 ( ,.""%FX1&PO=V]R:W-H965T" MHY(+FC=DN8(<)_"!]!.%T\W#U\68)YN #+V^DB M!!?A?'D)+@(D(,[X)?@(> H9XKL7)N QI26').9C7A9T\WJZW4,/7D^W MSKBQVTVQ*SW[A%X(&<%DS<$<,;!4$0<_IRLNF/Q+?O6%NY9S^N54YKCF!8S0 M1).I@2.V09K__IWI&I_Z0O668L$;B1V$T6G#Z)Q3]V>0XPA@0H M262^!#0!,C%$3X 6*GER(']#0$4J3\L+;@='ZW-MHV/U&#,861V?QQAO=,*D MVYIT7S:)XI<40NHB_8_F?H*<0_9&LL09"B1DL:5)P\1J\MRW1&TJ K5B@I9]JIF*F\RB"F M_)Y0*G8=-4%[-_+_ E!+ P04 " ##@@A9%B8Z(HL) V4P &0 'AL M+W=O5CL@V(QL5!]>"3:21;SXY?ZL&A*]+65WB!]:&R9/)>ZA[SD MN91X^I!F/_(EYX(\QE&2GPV60JP^CD;Y8LEC/Q^F*Y[(7^[2+/:%_)K=C_)5 MQOV@K!1'(SH>3T:Q'R:#^6EY[3J;GZ9K$84)O\Y(OHYC/WOZQ*/TX6Q@#;87 MOH;W2U%<&,U/5_X]O^'B^^HZD]]H0QCS)PS0A&;\[&YQ;'YE+BPIEB=]# M_I#O?";%K=RFZ8_BR^?@;# N6L0COA %A"__;/@%CZ("2;;CSQITT-@L*NY^ MWJ+_4MZ\O)E;/^<7:?1'&(CEV6 V( &_\]>1^)H^_(O7-^06>(LTRLO_R4-= M=CP@BW4NTKBN+%L0ATGUUW^L';%3@5I[*M"Z FU5_G5_=D _DRL\ROR"3O/6X\,,H M?T?>D!')EW[&7 OL'<\L-T+F!T/3 W @&OMIM?9I0E[7Z\K@#X4 SP@ M%VDLHU[NEW'C7':VY)[+2"3([1/9+7?M/Y67SQ_\+"#_^4U"DL^"Q_E_39VM MLN^8[1?1]V.^\A?\;"##:\ZS#1_,__XW:S+^AXEA3# /$XPA@6DD.@V)#H0^ MOUK'MSPCZ1WQ@R LZ/.C;=_SUV*99N'_)&]O95BHKKXS$579F)0VBEEM,W?' MY;_3T6:7 [ M?3G !&-(8!H';L.!>R0'O1T/ O<=(>YQ+'J81AD2F.;X2>/X M24_';^3!28,'!(HUC.7O(U=+B1^E_'J^B](GS^M(J\A-)41*05"PE;7^1-R9"0(-] M":G ICN$4+O%1;>(2_4BK%O$=ILBFM]FC=]FH-]N2H^DJVJ=7DRF>=5=#X<, M$+BO?V:=#MONJICF&!*8YO*3QN4GH,O_*.6*]*^_X9F47^3.#S.R\:,U)RO9 M'4N7E\X/TBCRLUQ=?5?TU3U+KXH4T'1?4C#!O ILMCL")L,3M]7##:7HD$[, MG=P:*UTS!GW^+15R.1(F(@NEJEW4WI:QHNKY.>&//%N$QF]78*)YJ&@,"TTG@BHB MZ"L+H[H!6%1BHGFH: P+3:=225P+%%_SBHX-ST68W!4#5J%AH.@]*I5JP3&6/JS"K!M%Q)&"*PXL#C;/& NH*A4+ M36=!Z50+%JI:,%NDN2!)*N2]"Y+Q17J?E(IUWT2,*E5K-&W5W9Z'464J%IKN M>254+5BI=CR?&US_?CLV"O%47RXK'!@KJ!+VP(U08*B@JEHL-)TPI6LM6-A^ ME5-&%BX*O5"NRXR.1Y6JJ&@>*AK#0M/)4&+9FKWV@@Q55:.B>:AH# M-IU*) M< M6X3\U!:&J[!IM=PIRK/8K&XJ9-8:(J8R[?RIJ7F59K4_:?..:=KD0L_"0IU?"#O#$/W=IC=R3Q/J=7=*3&4^/=2K464M[6[!6E/;T*M1M2T6FNYHI6TI+ G;4DEVV,LP M">-U;'0XJEI%1?-0T1@6FDZ+4K!T^LJBB:+J7U0T#Q6-8:'I5"K]2^'=XF=D ML6'$WMS [;.!!3FJ>,5"TWE0XI7"XM44Z?S'O9$.5:ZBHGFH: P+37^,40E; M>_S*DH:!XJ&L-"TZE4DM>&)>\S(AV,V)L;N'W ?AUJ.Q@6FLZ#$M5:^_U \VG6S5WG (+U=C[J-C8K&L-!T.G:>U'[U1[5QG]7&?5@;]VGM ME\@4V"I38,.9@N=$.%2!?Z!]P%H.M1T,"TWG0:4'[)?;"X>A>Q/2W0NWV@D7 M5(L,"TUWO4H8V*^W&0Z;[DT-?"-6V1#C4$'-)&"AZ7RI3((-[X4_8Q\"1NQ- M0_48:8RECFG;BMQ;L/B]R?W(6#TWIZ:&?87QD/[I.TM4SEK>-)V MF*'8A Z=/0\&VTI)V["2_IF-"!BZM\=..BE;Q_3*AJ&_#::T ML /OC;[F1@3G[6>VL5JG$Z.4K0,KQ^.V(V"0 MWBZTNIMGLV[71C7*L-!T/ROEZL#*U>-W/,N:#%WY7G2YAI AIWDAR0OEBD*D MQF7N)]A ;PY052TJ&L-"TZE2JM9Y;57KH*I:5#0/%8UAH>E4[KR%#*O&:K M MBHDDJXZO*)@T4H(J9FLT;<.U'=U052L6FNYGI5H=6+4VT:UZI7+=1+=D)[H% MV^AV["N%L-'>G!@VP4\,LPZJI,5"TWE1DM:!E6!/7C(>;I=<0;@) Y[4JRZ( M)%1EZW1?5>X^5>.AVF18:#I'2L8ZL(SMR5$0%IM]M^MCQ@^JVJW1=JFA)FY0 M=[BQT'1NE(AV8!']S+CV +S3*R>A'>WS7$F#JLX=L^J>M;-]J%89%II.K9+Z M#BSUGQ\:7YY=U$Q"C699+<7:2>:BFF58:/K1)RKAX,()AY^(JB_.+]STOORZ MW43#[&1XTEYOHAIE6&@ZNRIKX<)9BY[L]LCBP89[<]/-=%AT:CCZ!C75@86F MDZ-2'>Z1J8[^Y+S\T$--HKBFQ^;'P_:+!AZJ58:%5M$[VCD?,.;9?7DP8RXU M\SH1U7EXS=7F\,?S\LC#UO4+ZR.KCG!4,-6)DI=^=A\F.8GXG80<#Z=2%&75 M(8W5%Y&NRE,(;U,ATKC\N.1^P+.B@/S]+DW%]DMAH#DJ<_Y_4$L#!!0 ( M ,.""%D-%%&PO=V]R:W-H965TDH3PL?61HCLRK9YN($4\TN: M 9%W5I2E6,@E6]L\8X CK90FMNGUPC165)Z7>UN(G&EJ,L@@1"H2"P_-O!'))$(4D[?A2@5OE,I7AZ M?4#_79.79):8PYPF_\21V(RMH84B6.%M(A[H_@\H"/447D@3KG_1OI!U+!1N MN:!IH2PM2&.2_^.GPA$G"F[_C()7*'AUA>X9A4ZAT'FM0K=0T*ZV#)B=(^8DI9HZD([4VM+^C%1<0\$DW=CJ2/]_*^+V32X]M'\_G9Q?1=, M'V_N[]#BZ_0N0!B6'7BN'0W''>7$+6=S+O+B;6.18_9/GN\,:BP:108U%@\@9 M%OV21;^5A4YB>8!EC$;;4'#$:1(U$6B%>6LBFP3S#8%5W#)RTTZZQ^BR@*L55>Z//FV3<6HTVR'3/O#!=[TC$^\F+GP-FX487:@0[^868 MZ:PY3Z<5\,U981+--X56=>:Q)W??85/N&NW*C:+YIM"J\3@VYJZYSMQ]V537 M._,&D5Z]1MM0&PO=V]R:W-H M965TZ5C=-1>O<@Z@T%L4 MQK+GS)5:7+NNG,PAHO*2+R#6;Z9<1%3IIIBY@YUMQS.;S572X?:["SJ#,:B_%R.A6VZ! M$K (8LEXC 1,>\X 7P]):I".^,)@+7>>44+EA?/7I'$?]!PO\0A"F*@$@NJ? M%0PA#!,D[<>W'-0IYDP,=Y^WZ!]3\IK,"Y4PY.%7%JAYSVD[*( I78;JF:__ M@)Q0,\&;\%"F_]$Z'^LY:+*4BD>YL?8@8G'V2]_R0.P8D.81 Y(;D*H&?F[@ MIT0SSU):MU31?E?P-1+):(V6/*2Q2:TU&Q8GRSA60K]EVD[UQY^?AG]=W S& M=[=H^/0PNGL<#S[?/SVBT:?!XQA=H+%.G& 9 N)3])$R@;[0<)FV@$[F:*SX MY!4]+=(U&:RI"-#O@L8* O3++2C*0OEK@K(SK.LJ[7@RO3O)G;S)G"1'G,0$ M/?!8S26ZBP,(]@%C-%\!YI.UX=TM60:I"^*DA?55O8%0]U\H=,;4Q,,Q#LI2C) M(;7J>Y>DH:MPM4O#.M>)*=HJF+3J,OF0[-TL6D8F2E:TNK79,L8'MXKX[%%J M%Y3:)U"B;\NVF<\L4+PCNS IS"RUHD=LFY6 MY6B'@?+:G?V_(VM'2J;D1*;'R\<.69LI,3(E^ BU4K5@ZTG__R(2-?+4KYBG MYG%5EZF4%=A^G-^R%0L@#M"&01@8/6Z8/6X<>FR=Z-3**K4#KBD>@O>9-2LR M,X\CQX)?'OW8?O8_6(K^3"=YSN![Z )<"@/<^L$Z'Y]53)P+;3]C =M51 MH2;/*C1RM,KY78H-;%<;#Y:MWFI9F\&9T/8_JDN=0KP?G-_D3+(E_\K_'B*( ME"*(V$70^_EM!ZA-URQY_,./ W?G/BD",4NOV22:\&6LLCN6HK>XRAND%U@' M_3?X>IA=R)4PV?W@ Q4S%DL4PE1#>I&ULM9CO4^(X&,?_E4QOYT9GU/Z@ M@'C #*)WY^ZJC*R[KV/[ !G3ADU2T/_^TK2T0&M$#M] 6_(\>3Y/GCS]DNZ2 M\6<7MBV"&418G+$YQ.J7">,1ENJ63VTQYX!#;111VW.< MEAUA$EO]KGXVXOTN2R0E,8PX$DD48?YZ"90M>Y9KK1X\D.E,I@_L?G>.IS & M^3@?<75G%UY"$D$L"(L1ATG/&K@70T\;Z!$_"2S%VC5*49X8>TYO;L*>Y:01 M 85 IBZP^EK $"A-/:DX?N=.K6+.U'#]>N7];PVO8)ZP@"&COT@H9SWKW$(A M3'!"Y0-;_@LY4#/U%S J]"=:YF,="P6)D"S*C54$$8FS;_R2)V+-P&V]8>#E M!MZV@?^&02,W:&C0+#*-=84E[GCE;>T@N=&VVM:$B<+N-8CD87U^AX?WMZ/IN//AQ$;W M<[T @W0!B'Q%1U<@,:'B6(U^'%^AHR_'Z NRD9AA#@*1&#W&1(H3]5!=WQ)* ME;GHVE*%GP9A!WFHEUFHWANANAZZ9;&<"70=AQ!N.K 5=P'OK> O/:/'KTE\ MAAK."?(<,03J-8BX;VUWC#WUT2/0'7B=:IJTM1YL&O]Y#N^0LQ MQP'T++6I!? %6/T__W!;SE]U> =RM@'K%["^R7O_/I%"XC@D\?0$/<&4Q+&Z M5%N2XC@ =*1*)2N@X[HT9+Y;VG?:J19]WVDW'Q(V"\*FD? ? MCF,)X7LHS0K*-H1QFCTA6@5$RPAQ_0(\(.)]C%8%X]1K^-45,4ZW)TR[@&D; M889I:='W6=I5EJ9;13%.MB?*>8%ROOOV ?V]Z]XYK] UVAVGBE<=M[W'-B+O M%)%WS)'KUX= "Q [[(Y.-5BGZ56#-HL$"N)(_ M:+5OT(@3M21SU==U4Z]][3F';.J'\K:9BC4]X?[?OAXR2C$7.BEZZ6M7/I^G MO;;TKM_>6G9S,/O">B6L]X'NN".75REIU_&WN8SS[LM5"A'7^.K?;)0[8C6J M6.WM76J>=E^L4G*X'] <-4US1]*J^'";%5+?6+V; *6B<,V2HJ9W[AASLR:< M\^V8/T-HN*72<%O&)KIJG0^0_OU,UV:HY#Y7?_023-%W,JEOG@<2%'D*/D.> MN*4^<1],IQRF6 *Z40D@L2 !^HEI M4E_^!Q(^.?EGR"BOE%&>49L4[6VMM.N8W7*[6-]XZV MV:B_VM!J1$LEM(-J%GOM["<"/M5'8D)MGB26V4E(\;0X=AOHPZ:MYY?NQ3 [ M/"O=9&=YMY@K&2<0A8ERZ9RUU7N"9\=CV8UDFT,P5?N20%9KBD MN]W=)$Q(T\_"/H GMD4E&;K_?B79&'R):W;]!5M&Y]4YC^6C(XV.A+ZR'0!' M/\,@8F-MQ_G^5M>9NX,0LR[90R3^V1 :8BZ:=*NS/07L*:,PT"W#Z.LA]B-M M,E+/EG0R(C$/_ B6%+$X##']9P8!.8XU4SL]>/*W.RX?Z)/1'F]A!?S;?DE% M2\]4/#^$B/DD0A0V8VUJWBY,1QJH'B\^'-G%/9*AK EYE8VOWE@SI$<0@,NE M!!:7 \PA"*22\.-'*JIE8TK#R_N3^A<5O AFC1G,2?#=]_ANK TUY,$&QP%_ M(L<_( VH)_5<$C#UBXYI7T-#;LPX"5-CX4'H1\D5_TQ!7!B8_3<,K-3 *AHX M;QC8J8'=U,!)#11J/0E%<5A@CB;% 2"R04_ ./5= M#AY:<>*^HND14X^A#PO@V _81]&_U*>#?D,Z8CM,@9TN?H2>=R1F./+82.AFJ M7BVJWRF.Y$?^"R:]$A/'Z!68U YT+9.6Q'),^AF3?BV3%Y'[?HVD7T+2,0=V M@4GM0-I:*BV)Y:@,,RK#YHD& MU+5IEAF6. TLL\"IW*>4B1:U#O['\&^R\&]J5ZCOJAP#KS,] !7E)5+9!(D* M!M 7[%/T@H,8T%ZL8FH)J^)PT^8*UJ;8HB6Q'%G3.!=TQO]=PSP2!)@RQ5?- MM,J)EHXSN)A%9NF+K'?F6G)MJ>717=3"9N,UK2&CM+HV+R'9PVZO^$6F'8>7 M_1R[:Q4^RJINO4'W3#T?F76.S&JZ,C4,S"JE$+-O%8.J'?3JE]^26A[1N6@V M:RO+PD+5D))=IN24*+5:'K>EEJ=T+I#-*RKDBH6K(3>GG%J<4FJIZ%3,/XMZ M=Z_%H5]LI$.@6W4@P9!+XH@GN\GL:7;H,55;_<+SF3P,41OTLTQRDG*/J4C) M# 6P$9)&=R *5IH<3B0-3O9JN[XF7&S^U>T.L =4=A#_;PCAIX8<(#LBFOP+ M4$L#!!0 ( ,.""%D\/(=B*P0 (\4 : >&PO=V]R:W-H965TY>$*;GTM< + M>&I;G"1#[]M7DAV#L:.8GM]@2VC_VOUY1[NCT8'0;VP+P-'W)$[9V-AROKLQ M3;;:0H)9C^P@%?^L"4TP%T.Z,=F. @Z541*;CF7Y9H*CU)B,U-R<3D8DXW&4 MPIPBEB4)IO_-(":'L6$;+Q-?HLV6RPES,MKA#2R _[.;4S$R2Y4P2B!E$4D1 MA?78F-HW@>U+ [7B.8(#.WE',I0E(=_DX%,X-BSI$<2PXE("B\<>;B&.I9+P MX]]"U"CWE(:G[R_J'U7P(I@E9G!+XJ]1R+=C8VB@$-8XB_D7)!$:?[$WPL0)P8BT&8#IS!PS@V\5PSB. 28X\F(D@.BI_.X+3L6_D;#CD\73X^U?5[/I MXBY MX_W\[N'Q?3IT^,#FO\]?5B@*[00F19F,2"R1G.@*M/2%:#%%E- TP.F M(4/O N XBME[85!;Q,3DK\A$+!\4CRA%3UN2,9R&;&1R$8ITR%P5;L]RMYU7 MW+8==$]2OF7H+@TAK J8@D$)PGD!,7.TBI^SM(=0\G?KD,>.,BZ2,TLT'M(1-E*;B59PML](,:YR\H7O& MJ;ZF=AH%6@=_,OSK,OQK;?C/P&1&" "R50-*WTZ/ZUI(M:BU>UZ:'1V)5?#8 MUK$YL[1E_*MJ6R&\FNZ!BC8<;&RFKRSK? MJ5K0E5H5[TGO:__?6A^2.,:4*<0J+1NSLMAG<%KC^N=U7^_,Q>@Z4JNBV+&A:YCL][]A:5$,[MLZVMK^LE?"6 MX;GU-F=8"ZW3-KDKM2JG8Z-LZSOE:DEO2:G>(-N#P3FE3CODKM2JE(X]LJUO MDM\J\2VY-3317NV Z;]]"@5Z=W\6Q[$]MO7]\6LEOR4&OQZA[YUCZ+1I[DHM MYV6>W-0D0#?JQHNA%&ULK9AM3^LV%,>_BI5=32 !>6I38&TE(.%>)L%%P-TF37OAIJ>M M16+WVBZ%??HY3@AMXGI4RILV2?_G;^?GT^.'X9KQ9[$ D.@USZ@8.0LIE^>N M*](%Y%B9,/99H(%7+'L3S*5BY%SZJ IS/ JDP]L_0VJ%^H7 M?BG+A/Y$ZU(;!0Y*5T*RO I6/<@)+;_Q:P5B(\#O[0@(JH"@&1#N" BK@+ 9 M$.T(Z%4!O<]VJ5\%]#\;$%4!D69?PM*D8RSQ>,C9&O%"K=R*"SU<.EH!)K3( MK$?)U:]$Q_T"P?L+7 96QQC2$^3WCE#@!:&A0U?V\%O\AH*^C@Y,KV./_GU%3U#HZ?"> M(3SY?+BI[]>?#P\L*,,Z%T+M%^[*!;D CFYHRG) F$Y1\JH*F "!_KZ8",E5 M%?C'T,O+TK5G=BU*X[E8XA1&CJI] O@+..-??_$C[S?3<'5I%G=IEG1I=MV1 MV=8X]^IQ[MGAM2ZX-$K^6;+'OU^S[5O9/ M7-5T!?<%A%03M$0'H35"M!OM"[=(L/C,4XT9.)@9- MJUH8-'TS5M_[V&EX5K /"BI?I7+%"9WK.FS,6+O+OG0[=8LK-UNA30R:?M# M:]!X._!N;.1\*]ZOJN B57D%SN X [7;GN#T>;,H&VG[K25.*QNNC*+&/S&N M1-:\2@RBYIK+Z-/;02?XH!-8Z>B]C1& -6[O=.O2+:[<-E$T9WZ#I#D'&23' M9SMX?FP5?>L.9?S$),Z,/#O=#7;J%E=N6[N"%M"VYK25HFU-.&@0=3?.9'+@ MKP0J-]GC,GWFZ*!^CQS_!]02P,$% M @ PX((6:>ZQJ9A! FA$ !H !X;"]W;W)KDFD=K0T72UG:DF[>Y*JWUPPTV"!NR, M[22=OU\;* G&H&Z5EP3#.=?'U_;EF/&>\>]B#2#12Y92,7'64FZN>CVQ6$-& MQ"7; %5/EHQG1*HF7_7$A@.)0LOW$P<[KC6_):BWUC=YTO"$KF(-\VCQPU>I54>(D RH21A&'Y<2Y MQE<1#C4A1_R9P%X<72,]E&?&ONO&73QQ7*T(4EA('8*HOQW,($UU)*7C1QG4 MJ?K4Q./KU^B?\L&KP3P3 3.6_I7$(B+)=,S9'G&-5M'T19[,G*V&GU ][W/)U=-$\>3T[LOLZ_TM>KS^^W:. M+M!0"!"8S1CV891H%)H\"WA-*$K M@6Y H:$./XM DB05'U4/3_,(G7WXB#Z@A*+[)$U5!V+J^*71[ M+;JQA^X9E6N!;FD,<3U 3R6ARH3WFHD;KS/B[UMZB7SW''FN%U@$S=Y.]RWT MZ.UTKV,T?C6O?A[/;XDWVW*NYL:6V((8V(FZSER)#5G Q%&%1 #?@3/]]1<\ M<'^S)>64P:(3!:LE+*@2%G1%GWZ"&#A);0DKB&%.U'5T-\6^FJ/=<1XLF+Y? MQT1-3(@K2$UTOQ+=[Q0]ET2"37)!&QS+&1J*FQ#?%&R)$MH%#RK!@^XLJ]J0 MK*A-\J#167]@2&Y" M>0;('X=LEA)3GLE/S()$E5*6[=3V&C2\\UE5LPGH&) MFACLMZR/8:5]V%D%(EB"TAW;9 ]/609.&2PZ4;!:QD95QD;O+0.CQOQ4B\@*:I%]9#[P>\M!R:SM M9%-W$W*!3=E-3,N>PMY!M?>&BA!W[*TR0%V9ZYKZ;:A@9(Z@B>JWC.!@#G#G MJ[08@56XWTQ7HYA90&%HJK8$\MN6^>$=C8/.>E:ZRK,_F%!F"Q=Z^V.;R)_H'N2:Q1?:[8Z+<7_K:$GC1:=*EI]I@[&!'<[DR>:2(A1 M7I?L]M[B/S V5YK%@?0#IVB6@]DFY&9)BQ4N]XJW#"AO^U!^9KM$"\OS&NZ()&KBF M<^P='5HSX*O\\"_0@FVI+$YMU=WJ \-U?JPV[M_H#P_Y8?@0IOAJ<4_X*E'5 M((6E"NE>AFJE\.)#0-&0;),?C9^95 ?M_'(-1#D #5#/EXS)UX;NH/H<,_T/ M4$L#!!0 ( ,.""%F.=ZU\HP, /T+ : >&PO=V]R:W-H965T;*$5J)&5[^^MWI&3-/QC%*Y(/,4G=/=U[.IW>8"W5-[T$,&23Q!.!H4= %/8)Z+!X6[L$')6 Y",RF( M@ODP&'=NIM2_LJ7;FH==A(ZO1<2XCHA/DSHOI"0U G)J0G=.J'K ME*FH.!VFU-#10,DU438:T>S"B>FRD3X3]K$_&857&>:9T:]W M3^0G\H4J1>V3(&=3,)1Q_1Y/GY^FY.S']X/0X!UM7IC6Z+<5>OP">B(73^BG1(WNJ I# ,< M QK4"H+1NQ\ZO>B#3ZVW!)N^$=B>DMU&R6X;^E9)0S>@24%9=DX$#DTYM[.I M%)GV25E!]AVDG8^K4=+M1^YO$*YV=3J.[">^P.EQ8">*#B+W"%XV!"];"3Z+ MC&%7L%EI("- E6!BH2U!G/TXW01.[IEF&:.*@9=MA=_;*>V096L%_[<;W@AL M3ZQ>(U:O5:Q'L%\\%(BL*"^I_<)H; 1.K79&$FF6H!KA\#,!2MDK^!Y2K<%X M]>L=Z1=[>^4XKN-ME=?C]KCW&^[]5N[C-%4EDF'" "IK"!4909= N<'&V%6A M%"DH'/+"$2^D9DXH'_?^4:W>]I\?;!3FSHV<& N;,>+^:5Z>UR.0X[E#(MH@]=:X;=:Y?F3,* M4KD0[)_ZA:AY:&*6U*"+*SGRS_'I& +S.3C?Y@+1.("/[/7Q2+STLO4$=KW= M-AQ\ZZ'9S?HK>MK.A_,)4QOJ=JP; W M.,P1,KKHX]Q3E=FL-D86SG[-I$$SYY9+].>@; !>GTMIMAM[@\;QC_X%4$L# M!!0 ( ,.""%G0F'-N/ 0 / / : >&PO=V]R:W-H965T7@2! M2C:04^6++7!\LQ(RIQIOY3I06PDTM: \"^(P' 8Y9=R;3>RS.SF;B)W.&(<[ M2=0NSZE\OH),[*=>Y+T\N&?KC38/@MED2]>P!/UI>R?Q+JA84I8#5TQP(F$U M]2ZCBT74-P ;\9G!7AU=$R/E08@OYN8FG7JAF1%DD&A#0?'G$>:0988)Y_&U M)/6J,0WP^/J%_7N<>26%%=YF^%_L_H!0T,'R)R)3] M3_9%[*COD62GM,A+,,X@9[SXI4^E$4> :-@ B$M ? IH&J%7 GIO!?1+@+4Z M**18'Q94T]E$BCV1)AK9S(4UTZ)1/N-FW9=:XEN&.#V[>3__<'M-/E[^?;TD MOY(E[JMTEP$1*W(/B> )RQBU*X1/KET]+P1.2%U0NFDDRHG03RS^6#TA*/R[\N MQPO&OIO1Y) +M:4)3#U,$@KD(WBSGWZ(AN%O+K>^)]GB.Y'5G.Q73O;;V&=+ M3?5."_E,5I""I!G1:*K$_>ORL. :6RZ3-A]GH1]'D^#QV)NW!"TZ@FI:!I66 M0:<6,/,'1@ .*Z;=![*@CL+:C,)X<"+.'18-3^0UA(W= H>5 MP&&K0$SGF*QYM40D99AV)'#-:.82-71.8S0Z$>4..Q^,:W\G$MV@7L,:CBJ) MHW:)Y7K!4P)*U9;-);"=["ST>^&/KN6>=P C_]P-7'2..'X%K!EQ7AEQWLKT M'O?O)W_I6POP&[,JUY[9U.?RHIWO;.#'#5YT .,F$Q<=P,@?M7LQKKP8MS*] M$[@5T(,4OZ]*,XW)WF7 V+4CH_#T"(]?IYZ3K=T641,0A8=:(FR5<,,U2&[+ M!=S=&:S-'L=SJY^Q1,3:E'+VS;YU%@OMW&=#5.E>VA+9)K8UI*[VJ'**6F?T M^79)UD*D>Y9EA.5;RB06Q-JI+>J:X;P,^9_YJ96XKBL^Z(K?E)W,=YC*9$,H M3[&4?L0>86L$DD1"VI"J.JCQM#2=SRYD[#AGI0<=R-"1YNK6'"JRJ+5,F7W0 M&Y#5!PF3M].#=@Y4TF_RH ,9^L,F#SJ1KWVO>W"HI:+V8NK0!+05427)R7:. MAZ=YRAW7,^5[?:.[^8[B"CG!42N4@US;EE*11.RX+AJ)ZFG5ME[:9NWD^95I M9VV+=: I>N%;*M>,*\QO*Z0,_1'60;)H+XL;+;:VX7H0&MLW>[G!EARD"<#W M*R'TRXT9H&KR9_\!4$L#!!0 ( ,.""%F7S!2H'P4 *D< : >&PO M=V]R:W-H965T;3!"V7A$MSPF*7YD(-\F"6(OGW!,]S<.=%X_^$K6&RX_<,>C#*WQ M'/-OV2,39VZELB0)3G-"4\#PZL:YA= M.)ZL",)B%BC'$QK_0Y9\ M<^,,'+#$*[2-^5>Z_PN7%]25>A&-\^(OV)>QG@.B;[CV MP4<30>,;H'3$8+-7E0 MT"^R!2^2RD:9B N6C$Y3;&@*[ A"8937'* M:],GIZ8$F M?7IZNJ])GYV>#IOIKABI:KC\:KC\0B]X0Z\: 2Y& !4CH"-Z$ GU(G+NNRJZ*$L(52$^.U M61H+/)>E);$&RU[%LF=D>1M%;(OB0U.6\EIR/85*T.Y!-23LM;@9BSF7FR6Q M!K=^Q:UOG@Y11CB*R7_X@ VQ:%,P7.*=V(UF8F_)=1C[*J,V1C4D:+>?L;9S M,5H2:V <5!@'1HQWZ4Z HNP%1#37K^T#!8??7D+4D,!O$3.6<2XQ2V(-8L.* MV- \^?$-9CI.P_=O4$U(N[.,/WXN)TMB#4[0JW?ZGI'4?+O@5-RCVBVXIZ#H M*@N!)BCL]5O S$6<2\R66A/9D3F"1F3?4;PM=WBQL-1R7=72@PJ8#H3=-CY- M5'?8Q@>5[5^GV[IY9[J@L YJ7FQM+:!QOSQ^DLTA3?8I#J/4:MP[PU[[BM6@ MT!NTK]BJ);"EUF18FP(8G.[/WME[09N[^(E5M:E5M9DMM>:@U!X#FDW&(Z-B MA\Q?/H(L1BDOMB7XYY84FY+BC*07:;FLLZ&^"MW,5!U$9U F6A/")J:*SB;UZ]P&["V&]#L-S2+U7O3K>HC.KZO=)XN M:J"LTE8-ARVU)LK:5NV(+;4F MS]J00+,C>8.GEJ#J0.!PT":H"0J5%<6J4;&EUGS&73L5W^Q4%(+OW-JE7+]Y M:[6<)L7A!J,E9C) ?+^BE+^>R'=)U=O)\?]02P,$% @ PX((657V MG5!B P ?0H !H !X;"]W;W)KDX^3O.Z1DQ588 M-RCZ8I/4F<,Y,QQR)ENIOND"P)"'D@L]#0ICUF=AJ+,"2JH[<@T"ORRE*JG! MJ5J%>JV YLZHY&$<1<.PI$P$R<2M7:MD(C>&,P'7BNA-65+U> Y<;J=!-]@M MW+!58>Q"F$S6= 4+,+?K:X6SL&')60E",RF(@N4TF'7/TK'%.\ 7!EN]-R96 MR9V4W^SD,I\&D74(.&3&,E#\NXC7!GT7F4J*BT-*#4TF2FZ)LFADLP,7 M3&>-\IFP:5\8A5\9VIGD\N/\T]4%^3S[]V)!WI%%E7TBEV1>4+$"39@@7RC? M4)>F&<=S0D4&Y"0%0QG7IVAUNTC)R9M3\L:"KQCG"-63T*!_=IJ3N/CS+^LQ$=THO>DCB*^QZ'YJ\W[WG, MT]>;QT?4])I<]1Q?[P6^%):@%.3D,WT@,ZW!Z+?>W/QW(SDG6!=;JO+_?8FH M-NK[-[)7S9E>TPRF =XE&M0]!,F??W2'T5^^(/Y.LO0WD1T$N-\$N'^,/7F* M)6UB20VY@Q43@HF5+8M'H,H7T8IYY)CM77N?O!N\GX3W^X'R8>)#3.K!])\P M![(&C:S!45D?\?5@(L-704-XDD,U.B7X:)#;SJ)#,KIFAG+"I=8X4>IQ*>W1 M\=9PM=?PP,%A2^AS3-22>0QQ('+8B!S^5.1.6GBRDUN)E*8 94?X"@C[*E1E M9+",J"LCG\[AJ%5#1D3H=/Z^O M;G?0TN,!M8LY]6':A1KN/&PO=V]R:W-H M965T_T?=Z7>4-=VGV?=\+81$ M]YLXR:]&:RFW+\;C?+D6&YZ?I5N1J&]NTFS#I3K-;L?Y-A-\50[:Q&,E)5AO>:2SZ99ND=98:V\%0?EVI2C M53114ES&AO\&?7[YSYL%>HX6*DU6NUB@] ;->9;]4(FR MY]DJ5[+D>2,9=BA;[R>,?+R_ R5HG DZ7(T=/70O(HSI\I/U\6K]'3)\_0 M$Q0EZ'T4Q\HVGXZE4ES,.UY6ZEX=U.$.=7_NDC-$@M\0#C!U#)\?/YR8P\=J MG>K%PO5BX=(?Z?#W0965*J!,A9[Y_:U"H.+ECR'$>O0=U'KNQA^ M02^L>2EK27.8=%3"9:WLTJMLL;O^IGB(9(K>W&^C[+"*_Z$O9XLS]&V71?DJ M*G'IE.SUW?3,6(8PT!0+0.[,E1N@F*&\F4$WT!T.*^=J?#/C)JV<=)AT M5$NH*1EZF71T/5=NS%IMZW/8= G45 O]6#NJH"L?QLVP+X;#J*!VMH8P!HXX>A[34QM6EH8S^T?85]-+C]<_1.\U. &VMP8QAP8U!P M0WDS@];@Q@/!C6TH6[7CV%]WI*?&-H;!-K:)'+3EN:#=H4\S&P,P&]M MM;. M9V)JT\S&?F;/^3:2/*Y2^&A0^[WVSNM3@)IH4!,_J#_S>S3/Q"HZXC(14%A# M>3,#U[ F V%-'-OG=I_KL.G8)1)-:P)#:^+:/EL";:,N@8T'QP"T)K[]U4P*)*AO)F!:R23 M@4@F-F\G5H'8-EW/E(F&,H&!,G$0E[0?RKN,< ?[B.8R > RL:%KRW/LMSMV M+$23F?C);)>QHO.P[;5_QMZI?PIJ4TUM"D=M"DIM*&]FX)K:=""UJ4UDT@:/ MPP83=\I2C6T*@VWJ(W*E[VAH4PUM"@!M:A/97CS;IG/Q&K_Z]L6VI]Z/WG7[ M)^V=^:? /-68IW"8IZ"8A_)F!JXQ3P=BGMH(M[/6.\=C8] - 85I"*BK(;!B M\<[UV%ATYT !.@=J=P56&-YI'AN&;C'H(UJ,X4_Q_;/V+KU3M!E,MQD,KLU@ MH&T&E#,$-KLU@H&T&E#&PO=V]R:W-H965T_74_GG0\ MC392?=)K $.>,R[TV%L;DU_[OD[6D%%]+G,0N+*4*J,&AVKEZUP!39U3QOTH M" 9^1IGP)B,W]Z F(UD8S@0\***++*/J\Q2XW(R]T-M.S-AJ;>R$/QGE= 5S M,(_Y@\*17ZND+ .AF11$P7+LW837<>@8!=5P*_GO+#7KL7?ID126 MM.!F)C<_0@5T8?42R;7[)9O*-O!(4F@CL\H9(\B8*/_I<[41.P[AX(A#5#E$ MAP[](PZ]RJ'W4H=^Y=!W.U.BN'V(J:&3D9(;HJPUJMD+MYG.&_&9L'F?&X6K M#/W,Y,,OM[_>WY&/-W_-SE18[XA>,TE'T_.>W#TGO$B96)&;3!8",_8 "C,F M[)21N$[Q$:O<9F *)33YVOO7E'08[404':$V+\("L2V,/;%"##5X EL+_ M 1LT@CKK'Y"UF/0.T%I,ANULPYIM^,JD)852($P%LX_:1C9LQ'1U -:TB ZX MFA;]=JS+&NORE2E[+=;ER2?QI$7<9;&'=55C775B_4QS[0YAFN><)72!1[(V MU!3&S7*6,4./(EV=1#II$3&ULM5EM;ZLV%/XK M%KN:[I7N+9B\M5T2J:ESM4YM%[7KIFG:!X><).@"SFS3]$K[\;.!0@C$;2;G M2P+FG,<^#^?8C_%PR_@WL0:0Z"6.$C%RUE)N+EU7!&N(J3AC&TC4DR7C,97J MEJ]% %YE3'+F^Y_7=F(:),QYF;3,^'K)41F$",XY$&L>4?Y] Q+8C!SNO M#0_A:BUU@SL>;N@*'D$^;69+" M68T@#I/\G[X41.PXX/X!![]P\/<=N@<<.H5#Y[T.W<*AFS&3AY+Q0*BDXR%G M6\2UM4+3%QF9F;<*/TST>W^47#T-E9\<3^]FM[_^.9VBR?1^^O7F-S2[O;I_ M1%_0/>6"/A*0-(S$)]7Z]$C0QP^?T <4)N@NC"+U[L30E6HD&L\-BEXG M>:_^@5ZQC^Y8(M<"39,%+.H K@JAC,-_C6/B&Q%_29,SU/$^(]_SNRT#NGZ_ M>Z?%G;S?W3=$TRG?2B?#ZQS ([!4+0LT@41=232+:()(*(*(B90#^NM6/48W M$F+Q=QO[.7JW'5U/)9=B0P,8.6JN$,"?P1G_^ /N>S^U,6<3C%@"J[':+5GM MFM#'URG7B:QF+8E6:DK\C.:@9DY DKZTL9BC#3(T/7\^C[_@ 1ZZS[OL-(V\ MN@4Q6=3BZ)5Q](QQ/"6A5,GQ**F$UN(SNA_[^FV"$4M@-=KZ)6W]DQ95WR:K M-L&(); :JX.2U8$Q&:]6*PXKE8DH8$(BMD1R#7KES;@.U"S/PWF:K?$;17AK MON8]]'YD2_"8A R#-!K.E[O4J1SLHTA(^:Q MN6<3C%@"JW%Y47)Y<=**OK#)JDTP8@FLQBKV*DWHG;RFBRYVB[K?V2OJ-ION MWNK98M,[;U\_\8[HQ<8 ;Q()/*$Z AH=5XEFY&.3QBH:L8569]6O6/5/6HX% MO"UJ;:(16VAU:JO] #8*8SL5V6E6TGY!-DWZ^_5H,JE'5^ER;!;F#R!##IDN MOTD"M4"V#M^(<71VV$0CMM#J_%7[ =P[;>%9W3!812.VT.K45GL&;!3/XVF\ MB=AWX+4::R^O?E/%-NKK;1MB'M#_#;B2\_@-/1\$:9Q&5.\PYT4^L7D4KK+5 MLC7P%OGN-2)O&G4'C;6^:=3#_H'9I1+]N84V8QY=$E8EMRVT M.I^5Z,:G5=W8JNRVBD9LH=6_85;"VS<+[V._4/E-<=S\0F7N\UB&;*'5&:J4 MNV]6[DV&Z%)I^8,$X29!'6^?(*LBW!9:G:!*A/M&)7K$@E4 [7Z8Q-U]:MZV M(6TVO;U)V]TYH8B!K[*3'J'&F"8R_\A?MI:G25?9&^P1?DOQ,J(+)CZCN M*%^%B4 1+!6D=S90PH'GIS[YC62;[!QDSJ1D<7:Y!KH K@W4\R5C\O5&=U"> MO8W_ U!+ P04 " ##@@A9L4PG(A8( R. &@ 'AL+W=O7B:;[H%NNG:[I@ M=XQ_7]_FXEEW%V46KUA:Q%F*RLTY,9L81-N0Q!Q7_W;,R21$82>?Q;!>WLWE,.W'_\%/UC:5Z8F=""C;/D MKWC&EV>=40?-V)QN$OXU>_C$*D-]&6^:)47Y+WJHM+T.FFX*GJVJP2*#59QN M_Z<_JT+L#0@&!P;@:@#6!T0'!H35@+#I@*@:4):ZN[52UH%03L]/\^P!Y5(M MHLD'93'+T<)^G,KK?L=S\==8C./G5S>WG__X^^H*75Y]N?IX_0W=?K[X. MT)V88;--PE V1U\9CW,FKC9'U^DT6S%$T]G^JY\83?@2C6G.T&U"TZ(47*RR M3H3=2=Q,G MB9@9Q6F7"Y\RV^ZT\G2Y]80/> HPNLE2OBS053ICLWJ KBC0KDKXJ4J7&(SX M^R;]@,+>>X1[.+(D-&X^/+0,)\V'8\!-N+OF81DO.A#/N)RV$H,AY&IT4JSI ME)UUQ')3L/R>=HA6LBE9L(6<9K& MZ4(^>60TM]5T&WM8QI8;V_UY-!R<=N_W2V5J^D%8UQ P1\\*#'85&( 5N!/Q M8K$,3K."VSQN1P_V\@\TATX%&1@U4(I:TL-=TD,PZ>N4,U$*?C#KH9D3UM*V M2$9:WA9)WY[X:)?X"$S\8LHW-(]I@I*L$)O.0A#1.YN!D?'61UB?6A9-H)<> M3,=S:AWOS!Z#9N4.C*A8WV=RC;=NH,>&A9YFTJD@8!*>%H.>XI:>VV3!.$_* MG"ZNP]24WU.V;(F/')!;1_I99]Z6 *6A*3.MR62K$9]9.2D&KJ-1J M--)6M'H1%2T%,"Y]I'&.[FFR*;^.;6OX'&"JPN]?VG"D\X1%%.FK)8$3]2V$ M@J8 IJ9R'T]0SO@F3U%6FU16XR8D'>D8.+:(C,4!3,O7ML*N .:NJ]4ZR1[% M4C@5WVOS>++A![\9@^Q4^75K")R0KV&%:P',:TUV=PN&679W4V5I;V=[RW0QWL ER6%_?+!ICMR,6T?YN5W>G* [#%'8;,9N?3H?D]^3W M*&4?"V:KP\3;/# (1- MJ!OJ<\J4R$/N^I1Z#>S#"OLPC'WC39[+XVJJ?;R2F$[B).:/5NLV]M/YP"K2 MSPGA['S=*_K#,/U]R=*CJ5<%3- [.M;IUR8*>OJ70SA%WQ(H'L2N\[L#ZZK5 MMH4,S974)C)6TM= 0ZS0$,-H:.^P62VW1'95;=J,1MJ*5N]U*>H,>RVW;,*6 MZ+#J?;49C;05K5Y,1:YAHZ-(S[Y-:.*I\47&IM'[ W"2OD50"!O"".MJW83. MP\:Q6T) 23WSO<8OC*?._DUH.4W44W=*""BIIZZH,@21JGD'IXH#'@?;-(:) MUT"\4"%>Z$ \=Q,G-,'M*-*=FAICHKT&VX6*[4*8[1H<]83. [JQ6T+@/'Q] M*HH+88ISGO.$%A S)JY;0^ \?'TJ5 MA5/,ZW B=QW1CMX3 F?DZ5[@6-CK) M>W8+)S3/[HQ#+8M&WSJ)33.RK[N1PJ>H*3ZY^C=1J]C4:C325K1Z$14V13 V MO;1_$YE0I'\\W!(")^E;!(5-$8Q-S^W=1&Z,S^/@RFMP68>F>QE7%:GA,!Y^/I4=!8U^OW:XM3P5D$P]G+6S:1F]W<$@*GZ5L&Q6X1S&Y>3!.9K&8X=TH(G)FOT*F)++U6 ]AL(H/8X!Q]?X.KV*X/ MLUU;G9I^J^37:C325K1ZB17Y]6'R:]ZIZ;L9SRTA<#J^=A7C]6'&\VK4]!O\ M@*^!AL"Y^7I7J->'4<^[3=.W-'4#O4MG$QEM.CA#WPHH^NN[SNB>T:6I8@W! M5=0F,E91.*OGNN[NW4RU8OFBO"E-KH%BJ=S>,;1[=7?CVT5YNY?V^F5P0K:W MKZDPV[OI;F@NOO05*&%S$;+W82@@+]_>H+9]PK-U>&PO=V]R:W-H965T$I7)@Q4HM+FU;AC$F1%[P!:;ZS8R+A"@]%7-;+@22* Q,@]LO[\@EX$0L_L MBB6B"::2\A0$S@;6T+V\ZIGX/."%XDINC,$XF7+^:B:WT-5#RPNA9$.",94T]\]0U+ M/RW#%W(F\RNLREC'@C"3BBH"&7R3!._)SN'Y\DUG)Z,Z166?5MI@T:F M'99F1H49;X^9[UEZ 0WG"WB.UZR!7WTSM?8PVFB^N,%VR=G,W\@Y:^Z[3Z]G+3 M3TV,VZMBMF0V*YG-@S*'89@E&2,?%UKPM;>$-G>$UL2XW7JAK4IHZZ#0O(J6 MZRI:F"HB>ZNH]>[[SH["0Q%;^MJ5OO;!J@_^I^K;QZSZ(Y%M9:%39:%SU*KO MU!13=V>I:F(\MWZQNI7,[I&KOELC=+<]:V+VM6>O$MH[7M7WWOT>O!V%AR(* M??;&GFK.,_=$S*G>\QC.-,:YZ.C&$<49H9@HOLBWV2E7>M/.A[$^5J$P ?K] MC'.UGIB=NSJH^?\ 4$L#!!0 ( ,.""%F/"WB1F 0 /X6 : >&PO M=V]R:W-H965TB'RRH2SRA!RRK-K3FH4[TP"CZ]?V#^DR*"'CY G=)[P^33DZ2\ZY%C+0'[,!8WR8*D@PB3[]Y[S0AP%V*.6 M "&W , \8II7)4DGKX'K"FTT8/2"6H"5;]6MW_^LURB^?)^^>'F$UK=7M^OT7NTEC,LB$- =(,6--I3 M D3P9'0O9^,*&*8!]M$<"&RPD! NT%L7A(=#_D[&?UZ[Z.V;=^@-P@3=X3"4 M7>834TC-R9M-/],?,3E# M ^LWY%C.4"%H\?KP@2+@1Y&+NAY3' M#-"_M_(QNA$0\?]4U<_8AVKV9-.YXGO/AZDA=Q4.[ F,V:^_V"/K=U7E^B1S M>R*K5'585'6H8Y]]HL(+5>7*PL9I6+*E/LUL.8>>CHN@@(RJ$%<+J0@^+P2? M:P4_@, ,Y'XLT WQ:00J\5J*4WO=)YG;$UFE=*.B=*.?NH)&?5:U3S*W)[)* M5<=%5 G4UE$GPM4A*J(O"M$76M$W1( LA6A5 M?=%\HU.3K8!%\$NM\.7S7OHH.8D9B)@1) W5/IG&'N<@E%_= MRX:&]_5,%!#;JJ6BPK3D8ENE);%.GYG7$64"?_=2MRA=2$P8^'1+\'>9-DY6 M9S9WVWZ5UL-JR!_4BJ" U-NI@%RVE.#(E=G:ABYBECBI=$/?2O>.RF25B=C- M/HSJF30Q]6YJ(=5,G#(3IV,C$"+,ODQR0^5=B3C-M3&^K&?2!#4R:4+&+9F4 M3LO66HYV4Y#'5=?\N"Y: 1K756LQ5=FEE;'U7N;(&GP$+Q0[M/"8TA_HB4[] ME/7*YO;%5BUB::_L\Y]J$NQ>O5>O;&Y?;-72EO;+UOJ03J>0AVM6^Z(;XFHA M5>6EQ;'U'J?3+MC=+J<;XFHA5>FET;'U3N=TPV W74NC#9T05PNIYE)Z'UMK M?OY'N_ *T_0*C*O"M'34*4V3HS5-ISH&IVE:ZNWLAKA:2#61TOHX>NMSFF%P M.EW-HAOB:B'5/$KCX^B-3ZM=R./&ZO;GFKLQK@)3%VT>'0Q&P+;I 2N7^U5, M1'9B5MPM#G&OTZ/+VOVY?>5F1[$E378R?.>Q+28!LD+BB/OV0]02P,$% @ PX((65'X MU J+ P #0X !H !X;"]W;W)KM&!)@C5[LV$EF&TAL%\V09$:\;BB&?:#ELT64$EV2LK/]^ATE1;$2 M6UW-CQA-G-,C69FHTD*D1/,&9 IW&,5-_7Z&0NZ'C M.X\+]WP=&;O@C@8;ML8YFD^;F:*96Z(L>8R)YC(!A:NA<^E?C/V.=<@L?N>X MTWMCL%(64GZQD^OET/$L(Q08&@O!Z&^+8Q3"(A&/KP6H4^YI'??'C^@?,O$D M9L$TCJ7X@R]--'3.'%CBBJ7"W,O=1RP$G5J\4 J=_<*NL/4<"%-M9%PX$X.8 M)_D_>R@"L>?@=P\X!(5#\%J'3N&01<[-F66R)LRPT4#)'2AK36AVD,4F\R8U M/+&O<6X4/>7D9T;3V]G-KY^G4[B:WDT_7/\&LYO+NSF\ASDES#(5"'(%UP9C M#7?2P&=*K'L,Y3KA_^ 2F 8&8QEO9(*)L:8SJ8U"PQ7&=F7Z0/FF$8XF:!@7 M^IB0/\TG#]!X 7= M&O?QZ]T[57>78E@&,B@#&61XW0-X]T^BKY-0QEBGJ!'"GM@+O6$A#ATZDAK5 M%IW1CS_X/>_G.GTM@574=DJUG0R]TLH0K3&AD8"98 A.N0R%UJA#^ MO*''>=[\51>(3IN!: FL$HAN&8ANXVN_HP-!I2AEBC,!I%[#T9JJYW&=ZARJ MGT'9^KH=!=[ W>YKJ3'Q.Z5-A>)I2?&TD>),<4F%FX3S$&&1O[$Z>CE,;V_O MY^P:-WICI'NEC-Y_1IKJ,RI%><>S(P:&/< 1TQH-51;!V8(+;CC65I/>"W7O M3Y_):R3P1GG]4EZ_4=YE&*9Q*I@A==)$J( 4TCZ1_61NL4BM7'=MY7!CU#QA5>>YU0WX[M;+ J7!\0;%QK[?&_*DA M\9L[DF\MF 7\OL07"K]'#^(_-2%^XZ?]VVMF@7\HB0J1K?87[EZO;B]*MTRM M>:)!X(K@O9,^?6-5?O?()T9NLO9](0U=!K)A1/R,H;X"C M?P%02P,$% @ PX((63,G[9YQ P 7 L !H !X;"]W;W)K8%%N@>( %+KWO:%P3M5:=3 M/YAD(%8=F]H.;/OK.W:R@55#U%Y?OD#L>)YY9N899_H[J3[H%,"0AXP+/?!2 M8S:7OJ_C%#*JS^4&!+Y92951@TNU]O5& 4V<4<;]* @Z?D:9\(9]MS=3P[[, M#6<"9HKH/,NH^C0&+G<#+_0>-^9LG1J[X0_[&[J&!9BWFYG"E5^A)"P#H9D4 M1,%JX(W"RW'8M@;NQ#\,=OK@F=A0EE)^L(OK9. %EA%PB(V%H/BWA0EP;I&0 MQ\<2U*M\6L/#YT?T5RYX#&9)-4PD?\<2DPZ\GD<26-&44-'?:5W!%E M3R.:?7"A.FLDQX2MRL(H?,O0S@RGM[.;^W^G4S*>WDU?7;\ALYO1W8*\( NL M?Y)S(')%[E =H]CD5#'*R8W4FIS\A14_)7.(I4H@(4S@B3C/+J[(R?/3 M!MQ6E>^6PVT?P9V#80I0UJ9,0EVPC1"V3R_UAL8P\#"[&M06O.$?S\).\&<# MP79%L.W06T<(CNXGUV1DC&++W- E"L!(,J,*&9^Y$J(>WM '\M]<_KHFC_@B@NJB@N&M-LB=)*L=PI=NT42[6-8 EK)@03:[OX!%35!5"XZ#H7 M]G;;#J.PU?>W-;PZ%:].(Z]1)I5AGZF]D3&C4]+:7 8&PO=V]R:W-H965TV+:,- MI$1>\ R8?K+B(B5*WXJU+3,!)"ZP4T*9-1T7:TLQ'?-<)93!4B"9 MIRD1_\PAX;N)A:WGA7NZWBBS8$_'&5G# ZB/V5+H.[M"B6D*3%+.D(#5Q)KA MJQ /C4-A\8G"3AY=(T/ED?,OYN8FGEB.V1$D$"D#0?37%JXA20R2WL??):A5 M_:9Q/+Y^1G];D-=D'HF$:YY\IK':3*Q+"\6P(GFB[OGN'92$!@8OXHDL/M&N MM'4L%.52\;1TUCM(*=M_DZ:+N\7; MF]_1\OWL[@']@AYTA<5Y HBOT.A"CV1:$K@8TD[I.,I,XB3Y*_4!QM)"* MZCP 4AMM$*F<"$H2M!0@@2GTB21Y 38'!BNJT(?'A*[)'H.P&-V#H@)28WO# M(IY"??4=D$1MT#41@*ZY5!+]%((B-)$_CVVE8V$8V5')>[[G[;;PQBZZY4QM M)%JP&.)3 %L'L8JD^QS)N=N)^%O.+I#GO$&NX_H-&[H^W]UK< _/=W<[V'A5 M77@%GM^"]R(;32'NA# 3ZTIF)(*)E9DB$%NPIC_^@ /GUZ;P] D6]@1V$CJ_ M"IU?H'LMH0MU>3/=$\^%ODP(>W-&#U&F:SN)\D0W!5LW] GZ<_8HE="C\J^F M;/A]9J-/L+ GL)-L#*IL##H+.:0RXKDN8Z%G4U/8]N[8*?S-:W([=2Z1OF *-JI"F&].BA]IR/FS.N5]CW6SF!O64 M=^[KE:PO*]:7_\>TN=,29@$];YKMO.&];YKMG,'065WP@,[!WGH]#M12KR7(Z7&K,W.&=6HM1JZ M+=R.I"_NY+9XRO2_#]T+ E0N&-+,,MT]B$@)2C:2P\U[\49U=LV&+T=':3BJ M ;909;U)6PQQO4?_"YF*#SH5 M!]^S:L$]Z=0RYGVBA7VAG6;F(*)QMXK^>BFVB&='^QO%L^(P[9$KQ=/B<@,D!F$,]/,5Y^KYQOQ =8 [_1=02P,$ M% @ PX((6=014H ; P &0L !H !X;"]W;W)KV M ^V_GQW2D T'V+2^$#OVN>=<._=PNRLN'F4(H-!3Q&+9<\[QV0"W M#"#;\87"2I;&R*3RP/FCF8QG/<U"DX#; \ M?HE^F26ODWD@$BXX^TIG*NPY;0?-8$Y2IN[XZ@KRA!HF7L"9S'[1*M_K.2A( MI>)1#M8*(AJOG^0I/X@2P/CR_%G-+D^OYVB]VBJ[W^6,D!\CD9/ MB3Y$F*$!Q#"G"DW(L[X9)='Q$!2A3)Z@(T1C=$,9TV.^1[?AW=3X?H^.CD]S"N3JW(SR_R\[.X]8JX=Z"H ",6C>. M1V"3MC.$J8LSF9 >H[^\"6()3C]MV]PT_NP0V"M$%C+HM:*_O/%Q]5PV;IC6JE:&,+2S[6.]; M6I@:!5-C'U/3QK1&-AF=1M&CI;&NIM MNP;L;3S-.[3HKX P%:(+(JR5OSO0/Y8/+IDO?M7BS\/_9_D;;\6[S;6J_G-8 M^5(KOBN\L4F\T\DJ'2"''<*UL36\U]>L'I###N':&!O>ZVQ6%\#;UE;%M;$V MO-?;K#Z M\VMBFMC;GBWN_V]$^0!RW\;K3]4N*5&QS2--T0L:"P1@[G&>*M)XHG6>_SP)7NI+)AJ'M7$&:#7I]SKEXFIITJNN'^+U!+ P04 M" ##@@A9HMAPA&ULM59;3]LP%/XK5J9-F[212TLO+(W4TJ)U E91-C1->S#)26OAQ,%V6O;O M=YR$4"#M$(.7Q+?OYYBR%F20J3Q(J_XR B_7 MPO JP#%1MBE4.%R3#4-?"G61)K5R&8:1:@%&LVQU&1EKB7. M,L3I8'(R._[V;X-6;X!5\K2U\8XAQ)"(C M2+&E2^MCID(N5"Z!_#K&:3+5D*C?36Y+]G8SN_FN#E1&0QA8^.$HD"NP@G=O MW([S>8?W5NV]M8L]>/LX.TT62Y)^06*^U%7@^O:J0;==Z[;_H7LOQTV:[:=J M[M>:^SLUC]@-9HEMK9J=Z&?FH5-[Z[QJ#75>P7NW]MY]B1KJ/LJGL]=KSFBO M5N[];Q7U&E2[_6;9?BW;WRE[2-62P'7.5I3C0:2:='HJ(KE?G*]YMRZ=Z>YN_/ ?4I150P/A!\>3_;&O6K^44XP)I8J MPB%&&)8A'CBRO/;+CA99<=5>"HT7=]%&ULM5IK;]LV%/TKA%H4+;!$$OU,:AMHP@3+D+1&W'88AGU@;#H2 M*HDN2=L-L!\_4E8DRW(8R[OZ8NMQ[Q'O$8_)8W*PYN*'#!A3Z%<<)7+H!$HM MSEU73@,64WG*%RS1=^9>#\ASFYF0T=S[2(16RJ# 357RMV MR:+((.EV_,Q G?R9)G'[^!G].BU>%_- );ODT9_A3 5#I^^@&9O39:3N^?IW MEA74,7A3'LGT$ZVS6,]!TZ54/,Z2=0OB,-E\TU\9$5L)?ON%!)PEX$,36EE" MZ]"$=I;03IG9E)+R0*BBHX'@:R1,M$8S!RF9:;8N/TS,>Y\HH>^&.D^-KN[& MMU_^NKI"%U>?KZYOOJ+Q[:?/$W2")KJ'S9810WR.[ID*!=-O6Z&;9,ICAL81 M323Z)"53$EU2(4(V0U2A:QH*])U&2X;>$Z9H&,D/&JP*<(*^30AZ__8#>HO" M!-V%4:2[@1RX2A=EFN9.LP(N-@7@%PKX8YF;N])OSP\O;4GG1R> MCLOIKGX3^>O ^>O *5[K!3S"YOK*#%VP1!^IE&=$0CF-N%P*AOZ^U;?1C6*Q M_&1WMP^O0JE$!VZH%!2$35$R#IWU569'K]@Q(, ($5F*TDS/::51O M'4A6(<$($%B)U6[.:A=0;QNL[I90O!VY52-Z[1VU61MT9+F]O-S> >7J82W6 M$QD]()LY#5)"#]XH9M3THW1L3/0L+N7D92JLSZG;G2#!"!!8B=]^SF^_49'V M(5F%!"- 8"56SW)6SP!%>E:18&50K(:TO-Z.3*U-.K)@WROFNIZUY$LJ \1^ M+D-=IIZ+2O3N31_[^".Z92L6(1_]B_[/$&M_>MV.!HI&H-#*S&^Y#+]1"6?P M4-1"HA$HM#*UA6/PK5/GFCK.P&RC[9Z0RG!K;].Q-1?S>=\^H;_@R0S-E\E, MYI*%&'[M3ZW=RR#1"!1:F?'">?CM9@4,ZC] T0@46IG:PH+XUKEX70%W*NKL M[@JX&H+[9[L*;L(@^(5#\.T6X2913"34_/>GBS=CLGIJ0M% OB C%A*-0*&5 MWT!A6OQ>LXH&-2N@: 0*K4QMX5=\Z\2]KJ+[%;GZ%4GOB>GL*KH)-^$7=L*W M^PG"8R95.&U0S$#N(:,4$HU H97_-2Z<#?::_=\8U+J HA$HM#*UA77!UOE[ M33%G8+;Y]>LAQ-ZD8TO>6H2P6XI)P(4ZT0-TK"WP2JLZ7;DQ@@;5L[T5M3L= M[')%$P8'%P8'MYK5,ZB3 44C4&AE:@LG@VLLHKRNY_;K>JZ&[*X%V9MT;,F% MP\!VAW'/S!Q;*JI8 RH&70,!12-0:&7>"Y.#N\VJ&-2]@*(1*+0RM85[P8>L MN1RLXE[5$>^J^-408F_2L247K@+;7<47%3 !*UW0E1%0- *%5B:[<#/XK%GI M@GH54#0"A5;>BU%XE99]%:;F;@ROLH_"W]V-40W9G5#;FU2W9'=KOY79'7=' MQ6.82!2QN8;W3GMZV!&;#6>;$\47Z1:L!ZX4C]/#@-$9$R9 WY]SKIY/S*ZN M?-O?Z#]02P,$% @ PX((65'V7##D @ 4PH !H !X;"]W;W)KNJ>1EVM+]Q^!;#3AZ,B:YDSOF]-D:+GN7HA(!!I#0#Q;\M#( Q381I M_"PXK3*D!AZ.]^P?3.U8RYQ*&'!V%R_4NF>]M<@"EG3#U)3O/D)13UOS19Q) M\TMVN:_O623:2,63 HP9)'&:_].'0H<#0-,_ 7 +@/L8T#H!\ J ]U1 JP"T MC#)Y*4:'D"H:= 7?$:&]D4T/C)@&C>7'J5[VF1+X-4:<"F;#ZYOA^)9,AY,O MT]O1^)J\(6,J!-7+05Z%H&C,Y&N"-%TR0U/ MU5J28;J Q3&!C?F62;O[I/ON6<9/F[1!/.>"N([;JDAH\'2X5P$/GPYWSU3C ME4O@&3[O!-^ IQ$*JR7'@S"-Y3WY_AE]R$A!(G]4"9X3MJH)]4UQ*3,:0<_" MJT""V((5O'S1])WW56+521;61'8D9*L4LG6./1AODCD(PI=X'V5<*#IGL-^V MLDK&G,XW=/I^W :XF[:'VIP-^%QM:B([TJ9=:M,^KPV^(#/*0)+?Y(XRO.+1 M5AP#79!1&C5P>F!N&Q3PWPU9)=[9>,_=@W62A361'>GLESK[=1]FOTXAZR0+ M:R([$K)3"MDYNV&/AYTLD_=@K_PY178A\\ MMWA>5J9MD23BFU3ECU@Y6W9&5Z8A>#3?QXXI;W#^TN3MU@T5JSB5A,$2*9U& M!_>TR%N8W% \,X_ZG"L\M&:XQJX/A'; [TO.U=[0 &PO=V]R:W-H965T>9H;>?G@;.[\KJ8[WGO+$^'_*B?GVV;YK; M5ZM5O=WS0UI_7][R0OS+=5D=TD9\K&Y6]6W%TUUWT"%?.>MUL#JD67%V<=Y] M][ZZ."^/39X5_'UEU??ZS#Y[^.(RN]DW[1>KB_/;](9?\>:W MV_>5^+0ZH>RR R_JK"RLBE^_/ON[_8K9ZZ ]HC/Y/>-W]>!OJQW+A[+\V'YX MNWM]MFY=XCG?-BU&*O[WB6]XGK=0PI$_>]2STTG; X=_/Z#_HQN]&,V'M.:; M,O\CVS7[UV?1F;7CU^DQ;R[+NQ]Y/R*_Q=N6>=W]U[KK;==GUO98-^6A/UAX M<,B*^_^GGWLF!@?8P2,'./T!CGZ ]\@!;G^ ^]0#O/X [ZDN^?T!W=!7]V/O MB$O2)KTXK\H[JVJM!5K[1\=^=[3@*RO:E7+55.)?,W%<W//U@OK2NQ''?'G%OEM77);\NJ23^(3U?\1BR1QGI;W"_0;IZ+G3#9 MEL4VR[/[K\1!D.6+A#=IEM??BA/\=I58+[[YUOK&R@KK79;GPJ ^7S5B/*U7 MJVWO^YM[WYU'?+<=ZUU9-/O:8L6.[P A@,X'@*P$DR>Z'0>Z'SCH(C_/!;? M6^[Z.\M9.Q[@T.;IA[O X?^-G%7_]B!^N_0;13 M@B648(P(3)D@[S1!'H9^\;/X);I*>_>'AMVA[>_-IXMP'8M%^6G(*V#D M1K%JE !&]CI4C1CJZ4P>_!,//LK#VZ+A K41X6A;'CC$QCU ,!B#HW-AFMB! MQH1IXFLTH([.I"$XT1 \C0;^620B-KZ7&H< M28V#4I-D-UF3YM8VO4T_""G1B*NF$Q>W5;D[MF(R:[Y8O-BW5U:[E&IQH;6! M^=%EY4 _,)'.'FAET =8!;9.(#K N03*5-M&$\4+EE:%6$VU]2(7/UQA'G#*-'#?2:3*- B/-PX+_WELU];]9/U1?6+4!7N03,]< M*;[.)6#CZ50"-GIRA(]T+I,R9;;QG/G7LKU>4['6&GA= ;ENZ.MY &05FZ&= M*"ONB?,-/:)XIA(BDV<;SYXWZ6T7PKHULNL21I@8,_5U;".L T:.<<$!1CK# M#/=Z[C*16;2-I]$)%[#;3%:+TD-;"_AO]P5(CYD*.ZYQ#4%&NMB"C!Q/IV>) MO-J6B;6-9]973;G]^+*M=.Y$'GEHH\OCS$2FCO9T8@ ;5^?%3*U]1Z=EB>3: MEMFU_?3T^G_6^_L_:*K[Q729U1]!FH@RWIY02K2$%(U1H:F53IG; M.^L%RWL.42[>EU4IT1)2-$:%IDZ35!T.KCK4JT;(CO93"FOW'BH>UK"T"(.? M;3+3E&B,"DUE6HH8!Q2+A1(M(45C5&CJ%$H9Y2RY9>&0[EF0HB6D:(P*39TF*>,<7,9-BFG> M>$P;-4EPAR;3AYU0Y40*,@<79+^<*DK](@;5!PXR>8E2HB6D:(P*39T.*0>= M8,E(0J3:^FFB1$M(T1@5FCI-4I\ZN#Y%MT#[8X=J*HA"7:L#5J'MZ9N@CJE& M@\C3Y2CN[5PVI!QU1N1HOVC3W7^.=9NX\,?+BOU>89OFC-48'5-QVJZO:U?( MR@GU6A!@%<>Z?,6'.9=&*5\=7+Z:H5AD?#_R-&_V'5]_\#PO> US12I?2=$2 M4C1&A:;VIDCYZBXI7UU2^4J*EI"B,2HT=9JD?'5Q^8H&:-?SN7#2DQ75QB+A2@77.'*[3UW6C R(_UG0O R(WTFC0^R+DD M#MK2\+VRA3>!7',?3-_1'C=)QDT8/LRY-$H1YN(B;&P'R#4WL6Q;+\!O0*O( M6%:D\LLU.](4SU1"I )S<07VU!T@U]ST\D*=%F!C3->D@(VQ+8V[/'>-2!7D MXIMBD[=_7'-/R]=WHR$;/=V&;(Q8OH3T<*7T<''I,67OQS4UAFU<2>,VB6NJ M$-V&X6[/I45J$!?7($]-GL6WS]DFPKV8G,!1HB6D:(P*39U/*8;<>,D\FU0. MD:(EI&B,"DWM!)=RR,,[]::45'NH8?ER_;W1&DZJ:4C1&!6:RK74-!ZN:2:$ MN.7VE' ?IUY9I&@)*1JC0E-G6VHVSUDP 'JD6W^D: DI&J-"4Z=)JD(/5X63 M J +!,"U$0%!*[U-"7=K,HG@.7U8VGB#&X5PK0='K/)8\WV90W?>O<$!)Z]; M2K2$%(U1H:E3(U6GYR\97DCW TG1$E(T1H6F3I-4PAZNA/%[[0)3NL6^7C4" MK)RUWJN=>*;RM6.]H,)P;^>R(;6O-Z)]EZEC>D#+IWXWQ 8PU(I>[A27KB.Z8W>@K49-TG&31@^S+DT2H'JX;MU8W5,S[S)REY'>E$* MMM(W&7!7)H>TV P;0\_4FV&E%/1'I. 3ZYB^><>5'F$2P,;6.^(9 M[O/<&X2E9/-QR3:YD.F;VTFA7N2%;/1 !-@$>B$3]WTN-U+@^".;4A,*F3V4 M6GK7:0%L]+#BF_M,D<[*$GK"EWK"Q_4$GC(_LWJ)GWMJVD:*EI"B,2HT=1:E M\/&]!;-KGU0$D:(EI&B,"DV=IL$#'$:VWB:(]QY*E3+RC2ODA2-$:%ILZQ%&A^N&3<(Q)&_311HB6D:(P* M39TF*0%]7 ).BGL15!K4NUEA*[WU '=K,HDCGJGD2&'GSVC#_"F[%M'I2PY3 M1+K;2(J6D*(Q*C3U04-28@9+-E\&I,V7I&@)*1JC0E.G2:K>X!G-E_VQBDPS M^K4WD)5K/#LB,%6N[?C:A@K#O9W+AM2YP5=IO@Q,*6L,?0,9&5URH)%>;<,' M.9=$*8N#K]I\&8PW7XZ;).,F#!_F7!JE+@V>UWP90&V5>A5E UFM8_W''G=E M*"(KHLA&_T>G2?@,-SWN=Q(?1/0-5\&9F.E7OT'3/0J=P#< *9SLH28"*28 M"&9T7I[RY6=6+/%S3\[92/LM2=$8%9HZBU+U!$OV6P:D"H@4+2%%8U1HZM-% MI0(*Z?HM0ZC?TGC^+'["J623HC$J-)5LJ6/"&0V7P\BV7,42]VSJ!46*EI"B M,2HT=8ZE.@N7;+,,2=LL2=$24C1&A:9.D]1_(5V;90@T,^I!#^QWU(4Q[M-D M!L%S/E*N#*6D"V?T6';/Y"XZLE+P*;$XZ.2%2[K%2(K&J-#4Z9$",URRSS(D M[;,D14M(T1@5FCI-4O2&S^BS#($^2SO0MT! *_TFYB0$^BQMH]J&>SN7C<%# M[+]*GV4(W$;H:1L:K(0 ;O3V,X4.<2Z%4Q>%7[;(,@>?EZS5TR,;XB0-L M]/H"/M*Y3$IE&CZOT3($6BA=_0D,&\C*,_K#<%>8:B:12BXC[+"-SYTA_?O0&LM%OPX%L#&Z6 M4#B15#@179]E9/90ZE5NP,18,,#3/'1.EI 3D903T8PN2R5I?F;=$C__U,2- M%"TA16-4:.I,2OD3+=EI&9'*(%*TA!2-4:&ITR1E4$37:1E!G9;&2SCP$TXF MFU3,4*&I9$LQ$\WHM-2CVW*U2]R[R1<5:;?YP)-5=-/+.AK(2 MBU?$G2X$=2H8Y(5T@Y$4+2%%8U1HZ@OJI+B,EVRQC$E;+$G1$E(T1H6F3I,4 MO/$S6BQCLWG2,90_9*2_@C*)@:=;!KJ6PUV=2X74M_%7Z:^,@=>WN6OC78N0 ME?[HN02R(:/,?<$&X:[/'>-2($6 M$[=8QN:ND6L$=*!]TE@P@$VL<[.$J(FEJ(GI6BQCLW_2>.D;9&/0 CRV0W\D M*N[V7%JDB(C'1(21)S^S1(F?<'*N1MI:28K&J-#4J1N\]'G)ULJ85/F0HB6D M:(P*37OI]/"MTW3-E0]8FAXV7CF)GW(JX;1PC Q.HWSP;NOUV&OFH+"V7&UR MQ)^IEQ,M7$(+Q\C@M.EU!M.[9'?E SK99)'V5]+",3(X;;(&[P)?T_58/F"I MX4^_!VP#FYGOEL4]FTXE=-9''G!EKP>O 5]/[K5L@],3:Y@CZ-.7,^EV(RT< M(X/3)FOPIO'UDIV7#^ADDT6Z74D+Q\C@M,D:O 5]C2OBA8IX#Z=5'PIF=/I M9K&M%Q8@JS#0Y?/(2*=RN:KWG#=)VJ07YP=>W? -S_-:*.-C(>#;7^+3MU;% MKUNJ7_W=.5L9W[^Q7R5V^_U*PER!:+HKUD#\^W59-@\?VA/%X.6J=]WW4'_76<9+W)N'QNRB=C MMA5IDM$I=_+M>AWS[S(I6:Y$\41_,M[$2_I,Q1^;*9>/^A5E MGJQIEB>%!@0EI79IU+6@<0BGHPYVSF\B):TXJ L9CE:II]D MQ?O^++C\;2+'B^=7YUF>7/-M2AVV<&Y9-J.9 MX''Y+DTI+Q[)$\+YB5 1)VG^LQSP*,_/YSBEN3R>[<97,ZUP%]F6F5KO^:[HUO)?Z^S2Z

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end XML 146 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 147 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 150 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 454 631 1 false 123 0 false 8 false false R1.htm 0000001 - Document - COVER Sheet http://www.clorox.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Document - AUDIT INFORMATION Sheet http://www.clorox.com/role/AUDITINFORMATION AUDIT INFORMATION Cover 2 false false R3.htm 9952151 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS Sheet http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS CONSOLIDATED STATEMENTS OF EARNINGS Statements 3 false false R4.htm 9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 4 false false R5.htm 9952153 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 6 false false R7.htm 9952155 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 9952156 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 8 false false R9.htm 9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 9 false false R10.htm 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 9952159 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS Sheet http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESS DIVESTITURE OF ARGENTINA BUSINESS Notes 11 false false R12.htm 9952160 - Disclosure - CYBERATTACK Sheet http://www.clorox.com/role/CYBERATTACK CYBERATTACK Notes 12 false false R13.htm 9952161 - Disclosure - SUPPLY CHAIN FINANCING PROGRAM Sheet http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAM SUPPLY CHAIN FINANCING PROGRAM Notes 13 false false R14.htm 9952162 - Disclosure - RESTRUCTURING AND RELATED COSTS Sheet http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTS RESTRUCTURING AND RELATED COSTS Notes 14 false false R15.htm 9952163 - Disclosure - INVENTORIES, NET Sheet http://www.clorox.com/role/INVENTORIESNET INVENTORIES, NET Notes 15 false false R16.htm 9952164 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET Sheet http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNET PROPERTY, PLANT AND EQUIPMENT, NET Notes 16 false false R17.htm 9952165 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS Sheet http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETS GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS Notes 17 false false R18.htm 9952166 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 18 false false R19.htm 9952167 - Disclosure - DEBT Sheet http://www.clorox.com/role/DEBT DEBT Notes 19 false false R20.htm 9952168 - Disclosure - OTHER LIABILITIES Sheet http://www.clorox.com/role/OTHERLIABILITIES OTHER LIABILITIES Notes 20 false false R21.htm 9952169 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Notes 21 false false R22.htm 9952170 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS Sheet http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTS OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS Notes 22 false false R23.htm 9952171 - Disclosure - LEASES Sheet http://www.clorox.com/role/LEASES LEASES Notes 23 false false R24.htm 9952172 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 24 false false R25.htm 9952173 - Disclosure - NET EARNINGS PER SHARE (EPS) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPS NET EARNINGS PER SHARE (EPS) Notes 25 false false R26.htm 9952174 - Disclosure - STOCK-BASED COMPENSATION PLANS Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANS STOCK-BASED COMPENSATION PLANS Notes 26 false false R27.htm 9952175 - Disclosure - OTHER (INCOME) EXPENSE, NET Sheet http://www.clorox.com/role/OTHERINCOMEEXPENSENET OTHER (INCOME) EXPENSE, NET Notes 27 false false R28.htm 9952176 - Disclosure - INCOME TAXES Sheet http://www.clorox.com/role/INCOMETAXES INCOME TAXES Notes 28 false false R29.htm 9952177 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANS EMPLOYEE BENEFIT PLANS Notes 29 false false R30.htm 9952178 - Disclosure - SEGMENT REPORTING Sheet http://www.clorox.com/role/SEGMENTREPORTING SEGMENT REPORTING Notes 30 false false R31.htm 9952179 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.clorox.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 31 false false R32.htm 9952180 - Disclosure - SUBSEQUENT EVENT Sheet http://www.clorox.com/role/SUBSEQUENTEVENT SUBSEQUENT EVENT Notes 32 false false R33.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 33 false false R34.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 34 false false R35.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 35 false false R36.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 36 false false R37.htm 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 37 false false R38.htm 9954473 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS (Tables) Sheet http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSTables DIVESTITURE OF ARGENTINA BUSINESS (Tables) Tables http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESS 38 false false R39.htm 9954474 - Disclosure - CYBERATTACK (Tables) Sheet http://www.clorox.com/role/CYBERATTACKTables CYBERATTACK (Tables) Tables http://www.clorox.com/role/CYBERATTACK 39 false false R40.htm 9954475 - Disclosure - RESTRUCTURING AND RELATED COSTS (Tables) Sheet http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSTables RESTRUCTURING AND RELATED COSTS (Tables) Tables http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTS 40 false false R41.htm 9954476 - Disclosure - INVENTORIES, NET (Tables) Sheet http://www.clorox.com/role/INVENTORIESNETTables INVENTORIES, NET (Tables) Tables http://www.clorox.com/role/INVENTORIESNET 41 false false R42.htm 9954477 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables) Sheet http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETTables PROPERTY, PLANT AND EQUIPMENT, NET (Tables) Tables http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNET 42 false false R43.htm 9954478 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSTables GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETS 43 false false R44.htm 9954479 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES 44 false false R45.htm 9954480 - Disclosure - DEBT (Tables) Sheet http://www.clorox.com/role/DEBTTables DEBT (Tables) Tables http://www.clorox.com/role/DEBT 45 false false R46.htm 9954481 - Disclosure - OTHER LIABILITIES (Tables) Sheet http://www.clorox.com/role/OTHERLIABILITIESTables OTHER LIABILITIES (Tables) Tables http://www.clorox.com/role/OTHERLIABILITIES 46 false false R47.htm 9954482 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS 47 false false R48.htm 9954483 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS (Tables) Sheet http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSTables OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS (Tables) Tables http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTS 48 false false R49.htm 9954484 - Disclosure - LEASES (Tables) Sheet http://www.clorox.com/role/LEASESTables LEASES (Tables) Tables http://www.clorox.com/role/LEASES 49 false false R50.htm 9954485 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.clorox.com/role/STOCKHOLDERSEQUITY 50 false false R51.htm 9954486 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables NET EARNINGS PER SHARE (EPS) (Tables) Tables http://www.clorox.com/role/NETEARNINGSPERSHAREEPS 51 false false R52.htm 9954487 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables) Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSTables STOCK-BASED COMPENSATION PLANS (Tables) Tables http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANS 52 false false R53.htm 9954488 - Disclosure - OTHER (INCOME) EXPENSE, NET (Tables) Sheet http://www.clorox.com/role/OTHERINCOMEEXPENSENETTables OTHER (INCOME) EXPENSE, NET (Tables) Tables http://www.clorox.com/role/OTHERLIABILITIES 53 false false R54.htm 9954489 - Disclosure - INCOME TAXES (Tables) Sheet http://www.clorox.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.clorox.com/role/INCOMETAXES 54 false false R55.htm 9954490 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables EMPLOYEE BENEFIT PLANS (Tables) Tables http://www.clorox.com/role/EMPLOYEEBENEFITPLANS 55 false false R56.htm 9954491 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://www.clorox.com/role/SEGMENTREPORTINGTables SEGMENT REPORTING (Tables) Tables http://www.clorox.com/role/SEGMENTREPORTING 56 false false R57.htm 9954492 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details 57 false false R58.htm 9954493 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details) Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details) Details 58 false false R59.htm 9954494 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Narrative (Details) Sheet http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails DIVESTITURE OF ARGENTINA BUSINESS - Narrative (Details) Details 59 false false R60.htm 9954495 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Major Classes of Assets and Liabilities (Details) Sheet http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails DIVESTITURE OF ARGENTINA BUSINESS - Major Classes of Assets and Liabilities (Details) Details 60 false false R61.htm 9954496 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Net Sales (Details) Sheet http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails DIVESTITURE OF ARGENTINA BUSINESS - Net Sales (Details) Details 61 false false R62.htm 9954497 - Disclosure - CYBERATTACK - Narrative (Details) Sheet http://www.clorox.com/role/CYBERATTACKNarrativeDetails CYBERATTACK - Narrative (Details) Details 62 false false R63.htm 9954498 - Disclosure - CYBERATTACK - Schedule of Recognition of Costs, Net of Insurance Recoveries (Details) Sheet http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails CYBERATTACK - Schedule of Recognition of Costs, Net of Insurance Recoveries (Details) Details 63 false false R64.htm 9954499 - Disclosure - SUPPLY CHAIN FINANCING PROGRAM (Details) Sheet http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails SUPPLY CHAIN FINANCING PROGRAM (Details) Details http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAM 64 false false R65.htm 9954500 - Disclosure - RESTRUCTURING AND RELATED COSTS - Narrative (Details) Sheet http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSNarrativeDetails RESTRUCTURING AND RELATED COSTS - Narrative (Details) Details 65 false false R66.htm 9954501 - Disclosure - RESTRUCTURING AND RELATED COSTS - Schedule of Total Restructuring and Related Implementation Costs, Net (Details) Sheet http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails RESTRUCTURING AND RELATED COSTS - Schedule of Total Restructuring and Related Implementation Costs, Net (Details) Details 66 false false R67.htm 9954502 - Disclosure - RESTRUCTURING AND RELATED COSTS - Schedule of Accrual for Restructuring and Related Implementation Costs (Details) Sheet http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails RESTRUCTURING AND RELATED COSTS - Schedule of Accrual for Restructuring and Related Implementation Costs (Details) Details 67 false false R68.htm 9954503 - Disclosure - INVENTORIES, NET - Schedule of Inventories (Details) Sheet http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails INVENTORIES, NET - Schedule of Inventories (Details) Details 68 false false R69.htm 9954504 - Disclosure - INVENTORIES, NET - Narrative (Details) Sheet http://www.clorox.com/role/INVENTORIESNETNarrativeDetails INVENTORIES, NET - Narrative (Details) Details 69 false false R70.htm 9954505 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Components of Property, Plant and Equipment, Net (Details) Sheet http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Components of Property, Plant and Equipment, Net (Details) Details 70 false false R71.htm 9954506 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) Sheet http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) Details 71 false false R72.htm 9954507 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 72 false false R73.htm 9954508 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets (Details) Sheet http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets (Details) Details 73 false false R74.htm 9954509 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSTables 74 false false R75.htm 9954510 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Pre-Tax, Noncash Impairment Charges (Details) Sheet http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Pre-Tax, Noncash Impairment Charges (Details) Details 75 false false R76.htm 9954511 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables 76 false false R77.htm 9954512 - Disclosure - DEBT - Narrative (Details) Sheet http://www.clorox.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 77 false false R78.htm 9954513 - Disclosure - DEBT - Schedule of Long-Term Debt (Details) Sheet http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails DEBT - Schedule of Long-Term Debt (Details) Details 78 false false R79.htm 9954514 - Disclosure - DEBT - Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements (Details) Sheet http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails DEBT - Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements (Details) Details 79 false false R80.htm 9954515 - Disclosure - OTHER LIABILITIES - Schedule of Other Liabilities (Details) Sheet http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails OTHER LIABILITIES - Schedule of Other Liabilities (Details) Details 80 false false R81.htm 9954516 - Disclosure - OTHER LIABILITIES - Narrative (Details) Sheet http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails OTHER LIABILITIES - Narrative (Details) Details 81 false false R82.htm 9954517 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) Details http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 82 false false R83.htm 9954518 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details) Details 83 false false R84.htm 9954519 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities (Details) Details 84 false false R85.htm 9954520 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Narrative (Details) Sheet http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Narrative (Details) Details 85 false false R86.htm 9954521 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Schedule of Purchase Obligations (Details) Sheet http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Schedule of Purchase Obligations (Details) Details 86 false false R87.htm 9954522 - Disclosure - LEASES - Narrative (Details) Sheet http://www.clorox.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 87 false false R88.htm 9954523 - Disclosure - LEASES - Schedule of Supplemental Balance Sheet Information (Details) Sheet http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails LEASES - Schedule of Supplemental Balance Sheet Information (Details) Details 88 false false R89.htm 9954524 - Disclosure - LEASES - Schedule of Components of Lease Cost (Details) Sheet http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails LEASES - Schedule of Components of Lease Cost (Details) Details 89 false false R90.htm 9954525 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information and Noncash Activity Related to Leases (Details) Sheet http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails LEASES - Schedule of Supplemental Cash Flow Information and Noncash Activity Related to Leases (Details) Details 90 false false R91.htm 9954526 - Disclosure - LEASES - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details) Sheet http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails LEASES - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details) Details 91 false false R92.htm 9954527 - Disclosure - LEASES - Schedule of Maturities of Operating Lease and Finance Lease Liabilities (Details) Sheet http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails LEASES - Schedule of Maturities of Operating Lease and Finance Lease Liabilities (Details) Details 92 false false R93.htm 9954528 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Dividends Per Share Paid to Stockholders (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofDividendsPerSharePaidtoStockholdersDetails STOCKHOLDERS' EQUITY - Schedule of Dividends Per Share Paid to Stockholders (Details) Details 93 false false R94.htm 9954529 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 94 false false R95.htm 9954530 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details) Details 95 false false R96.htm 9954531 - Disclosure - NET EARNINGS PER SHARE (EPS) (Details) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails NET EARNINGS PER SHARE (EPS) (Details) Details http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables 96 false false R97.htm 9954532 - Disclosure - STOCK-BASED COMPENSATION PLANS - Narrative (Details) Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails STOCK-BASED COMPENSATION PLANS - Narrative (Details) Details 97 false false R98.htm 9954533 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Compensation Cost and Related Income Tax Benefit (Details) Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails STOCK-BASED COMPENSATION PLANS - Schedule of Compensation Cost and Related Income Tax Benefit (Details) Details 98 false false R99.htm 9954534 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Fair Value of each Stock Option Award Granted (Details) Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails STOCK-BASED COMPENSATION PLANS - Schedule of Fair Value of each Stock Option Award Granted (Details) Details 99 false false R100.htm 9954535 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Stock Option Activity (Details) Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails STOCK-BASED COMPENSATION PLANS - Schedule of Stock Option Activity (Details) Details 100 false false R101.htm 9954536 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Restricted Stock Awards (Details) Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails STOCK-BASED COMPENSATION PLANS - Schedule of Restricted Stock Awards (Details) Details 101 false false R102.htm 9954537 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Performance Share Awards (Details) Sheet http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails STOCK-BASED COMPENSATION PLANS - Schedule of Performance Share Awards (Details) Details 102 false false R103.htm 9954538 - Disclosure - OTHER (INCOME) EXPENSE, NET (Details) Sheet http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails OTHER (INCOME) EXPENSE, NET (Details) Details http://www.clorox.com/role/OTHERLIABILITIESTables 103 false false R104.htm 9954539 - Disclosure - INCOME TAXES - Schedule of Provision for Income Taxes and Components of Earnings Before Income Taxes (Details) Sheet http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails INCOME TAXES - Schedule of Provision for Income Taxes and Components of Earnings Before Income Taxes (Details) Details 104 false false R105.htm 9954540 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://www.clorox.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 105 false false R106.htm 9954541 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Effective Tax Rate (Details) Sheet http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails INCOME TAXES - Schedule of Reconciliation of Effective Tax Rate (Details) Details 106 false false R107.htm 9954542 - Disclosure - INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Liabilities) (Details) Sheet http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Liabilities) (Details) Details 107 false false R108.htm 9954543 - Disclosure - INCOME TAXES - Summary of Changes in Valuation Allowance (Details) Sheet http://www.clorox.com/role/INCOMETAXESSummaryofChangesinValuationAllowanceDetails INCOME TAXES - Summary of Changes in Valuation Allowance (Details) Details 108 false false R109.htm 9954544 - Disclosure - INCOME TAXES - Schedule of Carryforwards with Related Valuation Allowances (Details) Sheet http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails INCOME TAXES - Schedule of Carryforwards with Related Valuation Allowances (Details) Details 109 false false R110.htm 9954545 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details) Sheet http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails INCOME TAXES - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details) Details 110 false false R111.htm 9954546 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails EMPLOYEE BENEFIT PLANS - Narrative (Details) Details 111 false false R112.htm 9954547 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income and Retirement Health Care Plans and Amounts Recognized in Balance Sheets (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income and Retirement Health Care Plans and Amounts Recognized in Balance Sheets (Details) Details 112 false false R113.htm 9954548 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets (Details) Details 113 false false R114.htm 9954549 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Components of Net Periodic Benefit Cost (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails EMPLOYEE BENEFIT PLANS - Schedule of Components of Net Periodic Benefit Cost (Details) Details 114 false false R115.htm 9954550 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Items Not Yet Recognized as a Component of Postretirement Expense (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails EMPLOYEE BENEFIT PLANS - Schedule of Items Not Yet Recognized as a Component of Postretirement Expense (Details) Details 115 false false R116.htm 9954551 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails EMPLOYEE BENEFIT PLANS - Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income (Details) Details 116 false false R117.htm 9954552 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails EMPLOYEE BENEFIT PLANS - Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs (Details) Details 117 false false R118.htm 9954553 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Expected Benefit Payments (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails EMPLOYEE BENEFIT PLANS - Schedule of Expected Benefit Payments (Details) Details 118 false false R119.htm 9954554 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Target Allocation and Weighted Average Allocation of Plan Assets (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails EMPLOYEE BENEFIT PLANS - Schedule of Target Allocation and Weighted Average Allocation of Plan Assets (Details) Details 119 false false R120.htm 9954555 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans Assets Carried at Fair Value (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans Assets Carried at Fair Value (Details) Details 120 false false R121.htm 9954556 - Disclosure - SEGMENT REPORTING - Narrative (Details) Sheet http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails SEGMENT REPORTING - Narrative (Details) Details 121 false false R122.htm 9954557 - Disclosure - SEGMENT REPORTING - Schedule of Reportable Segment Information and Reconciliation of Segment Information (Details) Sheet http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails SEGMENT REPORTING - Schedule of Reportable Segment Information and Reconciliation of Segment Information (Details) Details 122 false false R123.htm 9954558 - Disclosure - SEGMENT REPORTING - Schedule of Concentration Percentage (Details) Sheet http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails SEGMENT REPORTING - Schedule of Concentration Percentage (Details) Details 123 false false R124.htm 9954559 - Disclosure - SEGMENT REPORTING - Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area (Details) Sheet http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails SEGMENT REPORTING - Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area (Details) Details 124 false false R125.htm 9954560 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.clorox.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.clorox.com/role/RELATEDPARTYTRANSACTIONS 125 false false All Reports Book All Reports clx-20240630.htm clx-20240630_d2.htm clx-20240630.xsd clx-20240630_cal.xml clx-20240630_def.xml clx-20240630_lab.xml clx-20240630_pre.xml clx-20240630_g1.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 153 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "clx-20240630.htm clx-20240630_d2.htm": { "nsprefix": "clx", "nsuri": "http://www.clorox.com/20240630", "dts": { "inline": { "local": [ "clx-20240630.htm", "clx-20240630_d2.htm" ] }, "schema": { "local": [ "clx-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "clx-20240630_cal.xml" ] }, "definitionLink": { "local": [ "clx-20240630_def.xml" ] }, "labelLink": { "local": [ "clx-20240630_lab.xml" ] }, "presentationLink": { "local": [ "clx-20240630_pre.xml" ] } }, "keyStandard": 546, "keyCustom": 85, "axisStandard": 42, "axisCustom": 2, "memberStandard": 66, "memberCustom": 50, "hidden": { "total": 24, "http://xbrl.sec.gov/ecd/2024": 1, "http://fasb.org/us-gaap/2024": 19, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 454, "entityCount": 1, "segmentCount": 123, "elementCount": 1065, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1737, "http://xbrl.sec.gov/dei/2024": 40, "http://xbrl.sec.gov/ecd/2024": 12 }, "report": { "R1": { "role": "http://www.clorox.com/role/COVER", "longName": "0000001 - Document - COVER", "shortName": "COVER", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.clorox.com/role/AUDITINFORMATION", "longName": "0000002 - Document - AUDIT INFORMATION", "shortName": "AUDIT INFORMATION", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF EARNINGS", "shortName": "CONSOLIDATED STATEMENTS OF EARNINGS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R4": { "role": "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R5": { "role": "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "9952153 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:ReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R6": { "role": "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalOperatingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R10": { "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESS", "longName": "9952159 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS", "shortName": "DIVESTITURE OF ARGENTINA BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.clorox.com/role/CYBERATTACK", "longName": "9952160 - Disclosure - CYBERATTACK", "shortName": "CYBERATTACK", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAM", "longName": "9952161 - Disclosure - SUPPLY CHAIN FINANCING PROGRAM", "shortName": "SUPPLY CHAIN FINANCING PROGRAM", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplierFinanceProgramTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplierFinanceProgramTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTS", "longName": "9952162 - Disclosure - RESTRUCTURING AND RELATED COSTS", "shortName": "RESTRUCTURING AND RELATED COSTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.clorox.com/role/INVENTORIESNET", "longName": "9952163 - Disclosure - INVENTORIES, NET", "shortName": "INVENTORIES, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNET", "longName": "9952164 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETS", "longName": "9952165 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES", "longName": "9952166 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.clorox.com/role/DEBT", "longName": "9952167 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.clorox.com/role/OTHERLIABILITIES", "longName": "9952168 - Disclosure - OTHER LIABILITIES", "shortName": "OTHER LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS", "longName": "9952169 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "clx:FinancialInstrumentsAndFairValueMeasurementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:FinancialInstrumentsAndFairValueMeasurementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTS", "longName": "9952170 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS", "shortName": "OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.clorox.com/role/LEASES", "longName": "9952171 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITY", "longName": "9952172 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPS", "longName": "9952173 - Disclosure - NET EARNINGS PER SHARE (EPS)", "shortName": "NET EARNINGS PER SHARE (EPS)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANS", "longName": "9952174 - Disclosure - STOCK-BASED COMPENSATION PLANS", "shortName": "STOCK-BASED COMPENSATION PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.clorox.com/role/OTHERINCOMEEXPENSENET", "longName": "9952175 - Disclosure - OTHER (INCOME) EXPENSE, NET", "shortName": "OTHER (INCOME) EXPENSE, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.clorox.com/role/INCOMETAXES", "longName": "9952176 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANS", "longName": "9952177 - Disclosure - EMPLOYEE BENEFIT PLANS", "shortName": "EMPLOYEE BENEFIT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.clorox.com/role/SEGMENTREPORTING", "longName": "9952178 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.clorox.com/role/RELATEDPARTYTRANSACTIONS", "longName": "9952179 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.clorox.com/role/SUBSEQUENTEVENT", "longName": "9952180 - Disclosure - SUBSEQUENT EVENT", "shortName": "SUBSEQUENT EVENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R33": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "clx:PropertyPlantAndEquipmentAndFiniteLivedIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSTables", "longName": "9954473 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS (Tables)", "shortName": "DIVESTITURE OF ARGENTINA BUSINESS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.clorox.com/role/CYBERATTACKTables", "longName": "9954474 - Disclosure - CYBERATTACK (Tables)", "shortName": "CYBERATTACK (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfUnusualOrInfrequentItemsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfUnusualOrInfrequentItemsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSTables", "longName": "9954475 - Disclosure - RESTRUCTURING AND RELATED COSTS (Tables)", "shortName": "RESTRUCTURING AND RELATED COSTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.clorox.com/role/INVENTORIESNETTables", "longName": "9954476 - Disclosure - INVENTORIES, NET (Tables)", "shortName": "INVENTORIES, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETTables", "longName": "9954477 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "clx:PropertyPlantAndEquipmentAndFiniteLivedIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSTables", "longName": "9954478 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables", "longName": "9954479 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.clorox.com/role/DEBTTables", "longName": "9954480 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.clorox.com/role/OTHERLIABILITIESTables", "longName": "9954481 - Disclosure - OTHER LIABILITIES (Tables)", "shortName": "OTHER LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables", "longName": "9954482 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSTables", "longName": "9954483 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS (Tables)", "shortName": "OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.clorox.com/role/LEASESTables", "longName": "9954484 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "clx:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954485 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables", "longName": "9954486 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables)", "shortName": "NET EARNINGS PER SHARE (EPS) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSTables", "longName": "9954487 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables)", "shortName": "STOCK-BASED COMPENSATION PLANS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.clorox.com/role/OTHERINCOMEEXPENSENETTables", "longName": "9954488 - Disclosure - OTHER (INCOME) EXPENSE, NET (Tables)", "shortName": "OTHER (INCOME) EXPENSE, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "clx:MajorComponentsOfOtherIncomeExpenseNetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:MajorComponentsOfOtherIncomeExpenseNetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.clorox.com/role/INCOMETAXESTables", "longName": "9954489 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "clx:ProvisionForIncomeTaxesOnContinuingOperationsByTaxJurisdictionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:ProvisionForIncomeTaxesOnContinuingOperationsByTaxJurisdictionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables", "longName": "9954490 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)", "shortName": "EMPLOYEE BENEFIT PLANS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.clorox.com/role/SEGMENTREPORTINGTables", "longName": "9954491 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9954492 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "longName": "9954493 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-53", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "clx:PropertyPlantAndEquipmentAndFiniteLivedIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-53", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "clx:PropertyPlantAndEquipmentAndFiniteLivedIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "longName": "9954494 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Narrative (Details)", "shortName": "DIVESTITURE OF ARGENTINA BUSINESS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-65", "name": "clx:DisposalGroupIncludingDiscontinuedOperationNumberOfAssetsDisposedOf", "unitRef": "productionplant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R60": { "role": "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "longName": "9954495 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Major Classes of Assets and Liabilities (Details)", "shortName": "DIVESTITURE OF ARGENTINA BUSINESS - Major Classes of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-65", "name": "clx:DisposalGroupIncludingDiscontinuedOperationWorkingCapitalNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-65", "name": "clx:DisposalGroupIncludingDiscontinuedOperationWorkingCapitalNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails", "longName": "9954496 - Disclosure - DIVESTITURE OF ARGENTINA BUSINESS - Net Sales (Details)", "shortName": "DIVESTITURE OF ARGENTINA BUSINESS - Net Sales (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-67", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.clorox.com/role/CYBERATTACKNarrativeDetails", "longName": "9954497 - Disclosure - CYBERATTACK - Narrative (Details)", "shortName": "CYBERATTACK - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonrecurringExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:UnusualOrInfrequentItemInsuranceProceeds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R63": { "role": "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails", "longName": "9954498 - Disclosure - CYBERATTACK - Schedule of Recognition of Costs, Net of Insurance Recoveries (Details)", "shortName": "CYBERATTACK - Schedule of Recognition of Costs, Net of Insurance Recoveries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonrecurringExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-71", "name": "us-gaap:OtherNonrecurringExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R64": { "role": "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails", "longName": "9954499 - Disclosure - SUPPLY CHAIN FINANCING PROGRAM (Details)", "shortName": "SUPPLY CHAIN FINANCING PROGRAM (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:SupplierFinanceProgramObligationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:SupplierFinanceProgramObligationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSNarrativeDetails", "longName": "9954500 - Disclosure - RESTRUCTURING AND RELATED COSTS - Narrative (Details)", "shortName": "RESTRUCTURING AND RELATED COSTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails", "longName": "9954501 - Disclosure - RESTRUCTURING AND RELATED COSTS - Schedule of Total Restructuring and Related Implementation Costs, Net (Details)", "shortName": "RESTRUCTURING AND RELATED COSTS - Schedule of Total Restructuring and Related Implementation Costs, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R67": { "role": "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails", "longName": "9954502 - Disclosure - RESTRUCTURING AND RELATED COSTS - Schedule of Accrual for Restructuring and Related Implementation Costs (Details)", "shortName": "RESTRUCTURING AND RELATED COSTS - Schedule of Accrual for Restructuring and Related Implementation Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails", "longName": "9954503 - Disclosure - INVENTORIES, NET - Schedule of Inventories (Details)", "shortName": "INVENTORIES, NET - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.clorox.com/role/INVENTORIESNETNarrativeDetails", "longName": "9954504 - Disclosure - INVENTORIES, NET - Narrative (Details)", "shortName": "INVENTORIES, NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:PercentageOfLIFOInventory", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:PercentageOfLIFOInventory", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "longName": "9954505 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Components of Property, Plant and Equipment, Net (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Components of Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "longName": "9954506 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:NonCashCapitalExpenditures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R72": { "role": "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "longName": "9954507 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "shortName": "GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R73": { "role": "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails", "longName": "9954508 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets (Details)", "shortName": "GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "longName": "9954509 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails", "longName": "9954510 - Disclosure - GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Pre-Tax, Noncash Impairment Charges (Details)", "shortName": "GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS - Schedule of Pre-Tax, Noncash Impairment Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R76": { "role": "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails", "longName": "9954511 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.clorox.com/role/DEBTNarrativeDetails", "longName": "9954512 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CommercialPaper", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:WeightedAverageInterestRateOnNotesAndLoansPayable", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R78": { "role": "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails", "longName": "9954513 - Disclosure - DEBT - Schedule of Long-Term Debt (Details)", "shortName": "DEBT - Schedule of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R79": { "role": "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails", "longName": "9954514 - Disclosure - DEBT - Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements (Details)", "shortName": "DEBT - Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-167", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R80": { "role": "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails", "longName": "9954515 - Disclosure - OTHER LIABILITIES - Schedule of Other Liabilities (Details)", "shortName": "OTHER LIABILITIES - Schedule of Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-10", "name": "clx:VentureAgreementTerminalObligationNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "clx:EmployeeBenefitObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R81": { "role": "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails", "longName": "9954516 - Disclosure - OTHER LIABILITIES - Narrative (Details)", "shortName": "OTHER LIABILITIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "clx:VentureAgreementOptionToExtendAgreementTermPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:VentureAgreementOptionToExtendAgreementTermPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "longName": "9954517 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails", "longName": "9954518 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails", "longName": "9954519 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities (Details)", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-208", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R85": { "role": "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails", "longName": "9954520 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Narrative (Details)", "shortName": "OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:AccrualForEnvironmentalLossContingencies", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:AccrualForEnvironmentalLossContingencies", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails", "longName": "9954521 - Disclosure - OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Schedule of Purchase Obligations (Details)", "shortName": "OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS - Schedule of Purchase Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.clorox.com/role/LEASESNarrativeDetails", "longName": "9954522 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeaseRemainingLeaseTerm", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeaseRemainingLeaseTerm", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails", "longName": "9954523 - Disclosure - LEASES - Schedule of Supplemental Balance Sheet Information (Details)", "shortName": "LEASES - Schedule of Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "clx:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R89": { "role": "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails", "longName": "9954524 - Disclosure - LEASES - Schedule of Components of Lease Cost (Details)", "shortName": "LEASES - Schedule of Components of Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails", "longName": "9954525 - Disclosure - LEASES - Schedule of Supplemental Cash Flow Information and Noncash Activity Related to Leases (Details)", "shortName": "LEASES - Schedule of Supplemental Cash Flow Information and Noncash Activity Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails", "longName": "9954526 - Disclosure - LEASES - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)", "shortName": "LEASES - Schedule of Weighted-Average Remaining Lease Term and Discount Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails", "longName": "9954527 - Disclosure - LEASES - Schedule of Maturities of Operating Lease and Finance Lease Liabilities (Details)", "shortName": "LEASES - Schedule of Maturities of Operating Lease and Finance Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofDividendsPerSharePaidtoStockholdersDetails", "longName": "9954528 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Dividends Per Share Paid to Stockholders (Details)", "shortName": "STOCKHOLDERS' EQUITY - Schedule of Dividends Per Share Paid to Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "longName": "9954529 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-244", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R95": { "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails", "longName": "9954530 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details)", "shortName": "STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R96": { "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails", "longName": "9954531 - Disclosure - NET EARNINGS PER SHARE (EPS) (Details)", "shortName": "NET EARNINGS PER SHARE (EPS) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R97": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "longName": "9954532 - Disclosure - STOCK-BASED COMPENSATION PLANS - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION PLANS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-266", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-266", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails", "longName": "9954533 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Compensation Cost and Related Income Tax Benefit (Details)", "shortName": "STOCK-BASED COMPENSATION PLANS - Schedule of Compensation Cost and Related Income Tax Benefit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R99": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "longName": "9954534 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Fair Value of each Stock Option Award Granted (Details)", "shortName": "STOCK-BASED COMPENSATION PLANS - Schedule of Fair Value of each Stock Option Award Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-272", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails", "longName": "9954535 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Stock Option Activity (Details)", "shortName": "STOCK-BASED COMPENSATION PLANS - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R101": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails", "longName": "9954536 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Restricted Stock Awards (Details)", "shortName": "STOCK-BASED COMPENSATION PLANS - Schedule of Restricted Stock Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-284", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-281", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R102": { "role": "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "longName": "9954537 - Disclosure - STOCK-BASED COMPENSATION PLANS - Schedule of Performance Share Awards (Details)", "shortName": "STOCK-BASED COMPENSATION PLANS - Schedule of Performance Share Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-289", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-285", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R103": { "role": "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails", "longName": "9954538 - Disclosure - OTHER (INCOME) EXPENSE, NET (Details)", "shortName": "OTHER (INCOME) EXPENSE, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-1", "name": "clx:AmortizationOfTrademarksAndOtherIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "clx:MajorComponentsOfOtherIncomeExpenseNetTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:AmortizationOfTrademarksAndOtherIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "clx:MajorComponentsOfOtherIncomeExpenseNetTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails", "longName": "9954539 - Disclosure - INCOME TAXES - Schedule of Provision for Income Taxes and Components of Earnings Before Income Taxes (Details)", "shortName": "INCOME TAXES - Schedule of Provision for Income Taxes and Components of Earnings Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "clx:ProvisionForIncomeTaxesOnContinuingOperationsByTaxJurisdictionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "clx:ProvisionForIncomeTaxesOnContinuingOperationsByTaxJurisdictionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.clorox.com/role/INCOMETAXESNarrativeDetails", "longName": "9954540 - Disclosure - INCOME TAXES - Narrative (Details)", "shortName": "INCOME TAXES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R106": { "role": "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails", "longName": "9954541 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Effective Tax Rate (Details)", "shortName": "INCOME TAXES - Schedule of Reconciliation of Effective Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails", "longName": "9954542 - Disclosure - INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Liabilities) (Details)", "shortName": "INCOME TAXES - Schedule of Components of Net Deferred Tax Assets (Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.clorox.com/role/INCOMETAXESSummaryofChangesinValuationAllowanceDetails", "longName": "9954543 - Disclosure - INCOME TAXES - Summary of Changes in Valuation Allowance (Details)", "shortName": "INCOME TAXES - Summary of Changes in Valuation Allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:DeferredTaxAssetsValuationAllowanceNetIncreaseDecreaseForU.S.CapitalLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R109": { "role": "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails", "longName": "9954544 - Disclosure - INCOME TAXES - Schedule of Carryforwards with Related Valuation Allowances (Details)", "shortName": "INCOME TAXES - Schedule of Carryforwards with Related Valuation Allowances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R110": { "role": "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails", "longName": "9954545 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details)", "shortName": "INCOME TAXES - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R111": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "longName": "9954546 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-312", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R112": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails", "longName": "9954547 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income and Retirement Health Care Plans and Amounts Recognized in Balance Sheets (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income and Retirement Health Care Plans and Amounts Recognized in Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-315", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-319", "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R113": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails", "longName": "9954548 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R114": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "longName": "9954549 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Components of Net Periodic Benefit Cost (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Components of Net Periodic Benefit Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "clx:MajorComponentsOfOtherIncomeExpenseNetTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-319", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R115": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "longName": "9954550 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Items Not Yet Recognized as a Component of Postretirement Expense (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Items Not Yet Recognized as a Component of Postretirement Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R116": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "longName": "9954551 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-315", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-319", "name": "clx:DefinedBenefitPlanAmortizationCurtailmentAndSettlementDuringTheYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R117": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails", "longName": "9954552 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R118": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails", "longName": "9954553 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Expected Benefit Payments (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Expected Benefit Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R119": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails", "longName": "9954554 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Target Allocation and Weighted Average Allocation of Plan Assets (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Target Allocation and Weighted Average Allocation of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-315", "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-315", "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R120": { "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "longName": "9954555 - Disclosure - EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans Assets Carried at Fair Value (Details)", "shortName": "EMPLOYEE BENEFIT PLANS - Schedule of Retirement Income Plans Assets Carried at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-323", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-331", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R121": { "role": "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "longName": "9954556 - Disclosure - SEGMENT REPORTING - Narrative (Details)", "shortName": "SEGMENT REPORTING - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R122": { "role": "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails", "longName": "9954557 - Disclosure - SEGMENT REPORTING - Schedule of Reportable Segment Information and Reconciliation of Segment Information (Details)", "shortName": "SEGMENT REPORTING - Schedule of Reportable Segment Information and Reconciliation of Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:DigitalCapabilitiesAndProductivityEnhancementsExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R123": { "role": "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "longName": "9954558 - Disclosure - SEGMENT REPORTING - Schedule of Concentration Percentage (Details)", "shortName": "SEGMENT REPORTING - Schedule of Concentration Percentage (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "c-430", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-430", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } }, "R124": { "role": "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails", "longName": "9954559 - Disclosure - SEGMENT REPORTING - Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area (Details)", "shortName": "SEGMENT REPORTING - Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-445", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "unique": true } }, "R125": { "role": "http://www.clorox.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9954560 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "c-1", "name": "clx:PercentageOwnershipOfEquityInvestmentsMaximum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "clx:PercentageOwnershipOfEquityInvestmentsMaximum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "clx-20240630_d2.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails", "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r126", "r127" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities, Current [Abstract]", "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r124", "r127", "r132", "r1456" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r124", "r1172" ] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for aggregate future remediation costs", "label": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": [ "r478", "r1127", "r1294", "r1295", "r1371", "r1376" ] }, "us-gaap_AccruedEnvironmentalLossContingenciesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEnvironmentalLossContingenciesNoncurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental liabilities", "label": "Accrued Environmental Loss Contingencies, Noncurrent", "documentation": "Carrying value of the obligation (known or estimated) arising from requirements to perform activities to remediate one or more sites, payable after twelve months or beyond the next operating cycle if longer." } } }, "auth_ref": [ "r132", "r1370", "r1371", "r1376" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r127", "r212" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and postretirement benefit adjustments", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r5", "r6", "r23", "r40", "r149", "r1312", "r1313", "r1314" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r63", "r259", "r929" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gains (losses) on derivatives", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r275", "r285", "r286", "r759", "r1106", "r1312" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated other comprehensive loss (income)", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r5", "r6", "r40", "r149", "r1429" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r284", "r285", "r814", "r816", "r817", "r818", "r819", "r820" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive net (loss) income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r39", "r40", "r150", "r266", "r925", "r971", "r975" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r284", "r285", "r814", "r816", "r817", "r818", "r819", "r820" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Net (Loss) Income", "verboseLabel": "Accumulated other comprehensive net (loss) income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r23", "r40", "r771", "r774", "r856", "r966", "r967", "r1312", "r1313", "r1314", "r1324", "r1325", "r1326", "r1327" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r4", "r23", "r40", "r147", "r148", "r285", "r286", "r816", "r817", "r818", "r819", "r820", "r1312" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1241" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r139" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r990", "r1324", "r1325", "r1326", "r1327", "r1473", "r1545" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1254" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1254" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1254" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1254" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r14" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r82", "r83", "r642" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "clx_AdvertisingAndResearchAndDevelopmentCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "AdvertisingAndResearchAndDevelopmentCostsPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and Research and Development Costs", "label": "Advertising and Research and Development Costs [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognition of (1) advertising costs and (2) research and development costs." } } }, "auth_ref": [] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising costs", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r685", "r1156" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1288" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1212", "r1223", "r1233", "r1266" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1215", "r1226", "r1236", "r1269" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1289" ] }, "clx_AlamedaCountyCaliforniaMatterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "AlamedaCountyCaliforniaMatterMember", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alameda County, California Matter", "label": "Alameda County, California Matter [Member]", "documentation": "Alameda County, California Matter [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1254" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1261" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1261", "r1270", "r1274", "r1282" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1280" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r267", "r389", "r402" ] }, "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForNotesAndLoansReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit loss", "label": "Financing Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on financing receivable, classified as current." } } }, "auth_ref": [ "r267", "r389", "r402" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r421", "r428", "r1124" ] }, "clx_AmortizationOfTrademarksAndOtherIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "AmortizationOfTrademarksAndOtherIntangibleAssets", "crdr": "debit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of trademarks and other intangible assets", "label": "Amortization Of Trademarks And Other Intangible Assets", "documentation": "Amortization of trademarks and other intangible assets." } } }, "auth_ref": [] }, "clx_AngelaHiltMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "AngelaHiltMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Angela Hilt [Member]", "documentation": "Angela Hilt" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive stock options and other (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r337" ] }, "clx_ArgentinaBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ArgentinaBusinessMember", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Argentina Business", "label": "Argentina Business [Member]", "documentation": "Argentina Business" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 5.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, trademark and other asset impairments", "netLabel": "Goodwill, trademark and other asset impairments", "totalLabel": "Total", "verboseLabel": "Asset impairment charges", "negatedTerseLabel": "VMS impairment", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r14", "r62" ] }, "clx_AssetImpairmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "AssetImpairmentsMember", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairments", "label": "Asset Impairments [Member]", "documentation": "Asset Impairments" } } }, "auth_ref": [] }, "us-gaap_AssetRetirementObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetRetirementObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset retirement obligations", "label": "Asset Retirement Obligation", "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r455", "r456" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r209", "r226", "r263", "r301", "r341", "r347", "r373", "r377", "r391", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r755", "r760", "r806", "r919", "r1024", "r1116", "r1117", "r1172", "r1201", "r1383", "r1384", "r1500" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "verboseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "clx_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.clorox.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Balance Sheet Information", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r254", "r270", "r301", "r391", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r755", "r760", "r806", "r1172", "r1383", "r1384", "r1500" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets, estimated fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r791", "r792", "r1163" ] }, "clx_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.clorox.com/role/AUDITINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1206", "r1207", "r1219" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.clorox.com/role/AUDITINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1206", "r1207", "r1219" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.clorox.com/role/AUDITINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1206", "r1207", "r1219" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1277" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1278" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1273" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1273" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1273" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1273" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1273" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1273" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r670", "r671", "r672", "r673", "r674" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1276" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1275" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1274" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1274" ] }, "clx_BagsAndWrapsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "BagsAndWrapsMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bags and Wraps", "verboseLabel": "Bags and wraps", "label": "Bags And Wraps [Member]", "documentation": "Bags And Wraps [Member]" } } }, "auth_ref": [] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r222" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Operations and Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r173" ] }, "clx_BetterHealthVitaminsMineralsAndSupplementsReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "BetterHealthVitaminsMineralsAndSupplementsReportingUnitMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Better Health VMS reporting unit", "label": "Better Health - Vitamins, Minerals And Supplements Reporting Unit [Member]", "documentation": "Better Health - Vitamins, Minerals And Supplements Reporting Unit" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and leasehold improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r179" ] }, "us-gaap_CapitalLossCarryforwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalLossCarryforwardMember", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital losses", "label": "Capital Loss Carryforward [Member]", "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year." } } }, "auth_ref": [] }, "clx_CarryforwardsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CarryforwardsGross", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails_1": { "parentTag": "clx_CarryforwardsNetOfValuationAllowance", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carryforwards", "label": "Carryforwards, Gross", "documentation": "Carryforwards, Gross" } } }, "auth_ref": [] }, "clx_CarryforwardsNetOfValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CarryforwardsNetOfValuationAllowance", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carryforwards", "label": "Carryforwards, Net Of Valuation Allowance", "documentation": "Carryforwards, Net Of Valuation Allowance" } } }, "auth_ref": [] }, "clx_CarryforwardsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CarryforwardsValuationAllowance", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails_1": { "parentTag": "clx_CarryforwardsNetOfValuationAllowance", "weight": -1.0, "order": 2.0 }, "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Valuation Allowances", "label": "Carryforwards, Valuation Allowance", "documentation": "Carryforwards, Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r106", "r107" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, carrying value", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r44", "r257", "r1099" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r257" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents, estimated fair value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1474", "r1475" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r45", "r207" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of year", "periodEndLabel": "End of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r44", "r170", "r298" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r170" ] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedge gain (loss) to be reclassified within twelve months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r105" ] }, "clx_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash financing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "clx_CatLitterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CatLitterMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cat Litter", "verboseLabel": "Cat litter products", "label": "Cat Litter [Member]", "documentation": "Cat Litter [Member]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1252" ] }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Retirement Income and Retirement Health Care Plans", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans." } } }, "auth_ref": [ "r32" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1249" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1247" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r79" ] }, "clx_CleaningMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CleaningMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cleaning", "verboseLabel": "Cleaning products", "label": "Cleaning [Member]", "documentation": "Cleaning [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1253" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1253" ] }, "us-gaap_CommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaper", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes and loans payable", "verboseLabel": "Notes and loans payable, carrying value", "label": "Commercial Paper", "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days." } } }, "auth_ref": [ "r123", "r210", "r1511" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r133", "r216", "r921", "r1010" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS", "label": "Commitments Contingencies and Guarantees [Text Block]", "documentation": "The entire disclosure for commitments, contingencies, and guarantees." } } }, "auth_ref": [ "r185", "r186", "r1375" ] }, "us-gaap_CommodityContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommodityContractMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity purchase derivative contracts", "label": "Commodity Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to commodity prices." } } }, "auth_ref": [ "r1142", "r1162" ] }, "clx_CommodityPurchaseDerivativeContractsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CommodityPurchaseDerivativeContractsAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity Purchase Derivative Contracts [Axis]", "label": "Commodity Purchase Derivative Contracts [Axis]", "documentation": "Commodity Purchase Derivative Contracts [Axis]" } } }, "auth_ref": [] }, "clx_CommodityPurchaseDerivativeContractsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CommodityPurchaseDerivativeContractsDomain", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity Purchase Derivative Contracts [Domain]", "label": "Commodity Purchase Derivative Contracts [Domain]", "documentation": "Commodity Purchase Derivative Contracts [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofDividendsPerSharePaidtoStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends per share paid (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r191" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends per share declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r191" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1190", "r1191", "r1192", "r1194", "r1195", "r1196", "r1197", "r1324", "r1325", "r1327", "r1473", "r1543", "r1545" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r138" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r138", "r1011" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r138" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance, common (in shares)", "periodEndLabel": "Ending balance, common (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r24", "r138", "r1011", "r1030", "r1545", "r1546" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of June\u00a030, 2024 and 2023; and 124,201,807 and 123,820,022 shares outstanding as of June\u00a030, 2024 and 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r138", "r924", "r1172" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1258" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1257" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1259" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1256" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax assets", "label": "Components of Deferred Tax Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Components of Deferred Tax Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income attributable to Clorox", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r41", "r280", "r282", "r290", "r914", "r937", "r939" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Total comprehensive income attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r12", "r87", "r90", "r280", "r282", "r289", "r913", "r937", "r938" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r90", "r202", "r280", "r282", "r288", "r912", "r937" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "verboseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r52", "r53", "r108", "r109", "r385", "r1082" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r52", "r53", "r108", "r109", "r385", "r977", "r1082" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r52", "r53", "r108", "r109", "r385", "r1082", "r1303" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r52", "r53", "r108", "r109", "r385" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r51", "r52", "r53", "r54", "r108", "r206", "r1082" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r52", "r53", "r108", "r109", "r385", "r1082" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r224", "r307", "r341", "r349", "r371", "r372", "r373", "r374", "r375", "r377", "r378", "r379", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r493", "r1116", "r1117", "r1383", "r1384" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r224", "r307", "r341", "r349", "r371", "r372", "r373", "r374", "r375", "r377", "r378", "r379", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r493", "r1116", "r1117", "r1383", "r1384" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract term (in years)", "label": "Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment", "documentation": "Description of effect, from relationship that timing of satisfaction of performance obligation has on timing of payment, on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and on obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r549" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate and Other", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r31", "r372", "r373", "r374", "r375", "r378", "r1331" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r154", "r155", "r874" ] }, "clx_CostOfGoodsAndServicesSoldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CostOfGoodsAndServicesSoldMember", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs of products sold", "label": "Cost Of Goods And Services Sold [Member]", "documentation": "Cost Of Goods And Services Sold" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Costs of products sold", "terseLabel": "Cost of products sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Liabilities", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": [ "r35", "r182", "r183" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r304", "r305", "r499", "r527", "r861", "r871", "r918", "r1103", "r1105" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r483", "r1381" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r483", "r1381", "r1382" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1304", "r1321", "r1468" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1304", "r1321" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r723", "r1321" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1304", "r1321", "r1468" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r174", "r385" ] }, "clx_CyberattackMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "CyberattackMember", "presentation": [ "http://www.clorox.com/role/CYBERATTACKNarrativeDetails", "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cyberattack", "label": "Cyberattack [Member]", "documentation": "Cyberattack" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r187", "r299", "r441", "r442", "r443", "r444", "r445", "r482", "r483", "r495", "r501", "r502", "r503", "r504", "r505", "r506", "r511", "r518", "r519", "r521", "r823" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r36", "r126", "r127", "r211", "r215", "r307", "r496", "r497", "r498", "r499", "r500", "r502", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r517", "r1133", "r1134", "r1135", "r1136", "r1137", "r1170", "r1319", "r1366", "r1367", "r1368", "r1492", "r1493" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face value", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r496", "r823", "r824", "r1134", "r1135", "r1170" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and Long-term debt, estimated fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r509", "r805", "r1134", "r1135", "r1475", "r1476", "r1477", "r1478", "r1485" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rates on long-term debt, including the effect of interest rate swaps", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r129", "r514", "r1492" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r129", "r523", "r823", "r824", "r1170" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual fixed interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r129", "r497" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r307", "r496", "r497", "r498", "r499", "r500", "r502", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r1133", "r1134", "r1135", "r1136", "r1137", "r1170", "r1319", "r1492", "r1493" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r36", "r307", "r496", "r497", "r498", "r499", "r500", "r502", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r517", "r1133", "r1134", "r1135", "r1136", "r1137", "r1170", "r1319", "r1366", "r1367", "r1368", "r1492", "r1493" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r36", "r69", "r70", "r110", "r189", "r190", "r307", "r496", "r497", "r498", "r499", "r500", "r502", "r507", "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r1133", "r1134", "r1135", "r1136", "r1137", "r1170", "r1319", "r1492", "r1493" ] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trust assets for nonqualified deferred compensation plans, carrying value", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r1307" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1321", "r1467", "r1468" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1321", "r1467" ] }, "clx_DeferredGainLossOnSettlementOfInterestRateCashFlowHedgeAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredGainLossOnSettlementOfInterestRateCashFlowHedgeAmortizationPeriod", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization period of settlement payment (in years)", "label": "Amortization period of settlement payment", "documentation": "Amortization period of settlement payment." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "totalLabel": "Total deferred", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r14", "r242", "r1321" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "clx_DeferredTaxAssetsDeferredTaxLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r134", "r135", "r213", "r714" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r692", "r693", "r920" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1321", "r1467", "r1468" ] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsDistributed": { "xbrltype": "sharesItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsDistributed", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors distributed (in shares)", "label": "Deferred Stock Units For Non-Employee Directors, Distributed", "documentation": "Deferred stock units for nonemployee directors distributed." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsDistributedWeightedAverageFairValueOnGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsDistributedWeightedAverageFairValueOnGrantDate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors distributed weighted average fair value on grant date (in dollars per share)", "label": "Deferred Stock Units For Non-Employee Directors Distributed Weighted Average Fair Value On Grant Date", "documentation": "The weighted-average grant date fair value of the deferred stock units for nonemployee directors dividends distributed during the period." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsGranted", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors granted (in shares)", "label": "Deferred Stock Units For Non-Employee Directors, Granted", "documentation": "Deferred stock units for nonemployee directors granted." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsGrantedWeightedAverageFairValueOnGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsGrantedWeightedAverageFairValueOnGrantDate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors granted weighted average fair value on grant date (in dollars per share)", "label": "Deferred Stock Units For Non-Employee Directors, Granted Weighted Average Fair Value On Grant Date", "documentation": "The weighted-average grant date fair value of the deferred stock units for nonemployee directors granted during the period." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsOutstanding", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors outstanding (in shares)", "label": "Deferred Stock Units For Non-Employee Directors, Outstanding", "documentation": "The number of shares of deferred stock units for nonemployee directors outstanding as of the end of the period." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsOutstandingWeightedAverageFairValueOnGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsOutstandingWeightedAverageFairValueOnGrantDate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors outstanding weighted average fair value on grant date (in dollars per share)", "label": "Deferred Stock Units For Non-Employee Directors Outstanding Weighted Average Fair Value On Grant Date", "documentation": "The weighted-average grant date fair value of the deferred stock units for nonemployee directors outstanding as of the end of the period." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsReinvestedDividends": { "xbrltype": "sharesItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsReinvestedDividends", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors reinvested dividends (in shares)", "label": "Deferred Stock Units For Non-Employee Directors, Reinvested Dividends", "documentation": "Deferred Stock Units For Non-Employee Directors, Reinvested Dividends." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonEmployeeDirectorsReinvestedWeightedAverageFairValueOnGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonEmployeeDirectorsReinvestedWeightedAverageFairValueOnGrantDate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred stock units for nonemployee directors reinvested weighted average fair value on grant date (in dollars per share)", "label": "Deferred Stock Units For Non-Employee Directors Reinvested Weighted Average Fair Value On Grant Date", "documentation": "The weighted-average grant date fair value of the deferred stock units for nonemployee directors dividends reinvested during the period." } } }, "auth_ref": [] }, "clx_DeferredStockUnitsForNonemployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredStockUnitsForNonemployeeDirectorsMember", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Stock Units for Nonemployee Directors", "label": "Deferred Stock Units for Nonemployee Directors [Member]", "documentation": "Deferred Stock Units for Nonemployee Directors [Member]" } } }, "auth_ref": [] }, "clx_DeferredTaxAssetsDeferredTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxAssetsDeferredTaxLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets (liabilities)", "label": "Deferred Tax Assets (Deferred Tax Liabilities), Net", "documentation": "Deferred Tax Assets (Deferred Tax Liabilities), Net" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Subtotal", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r715" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and development", "label": "Deferred Tax Asset, In-Process Research and Development", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } }, "auth_ref": [ "r1466" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory costs", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r1466" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails_1": { "parentTag": "clx_DeferredTaxAssetsDeferredTaxLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1463" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "clx_DeferredTaxAssetsDeferredTaxLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1463" ] }, "clx_DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss and tax credit carryforwards", "label": "Deferred Tax Assets, Net Operating Loss And Tax Credit Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards and foreign tax credit carryforwards." } } }, "auth_ref": [] }, "clx_DeferredTaxAssetsOperatingAndFinanceLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxAssetsOperatingAndFinanceLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating and finance lease liabilities", "label": "Deferred Tax Assets, Operating And Finance Lease Liabilities", "documentation": "Deferred Tax Assets, Operating And Finance Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1466" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefit programs", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r1466" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals and reserves", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r1466" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails", "http://www.clorox.com/role/INCOMETAXESSummaryofChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "negatedPeriodStartLabel": "Valuation allowance at beginning of year", "negatedPeriodEndLabel": "Valuation allowance at end of year", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r716" ] }, "clx_DeferredTaxAssetsValuationAllowanceNetIncreaseDecreaseForForeignAndUSNetOperatingLossCarryforwardsAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxAssetsValuationAllowanceNetIncreaseDecreaseForForeignAndUSNetOperatingLossCarryforwardsAndTaxCredits", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESSummaryofChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits", "label": "Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For Foreign And US Net Operating Loss Carryforwards And Tax Credits", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized resulting from foreign and US net operating loss carryforwards and tax credits." } } }, "auth_ref": [] }, "clx_DeferredTaxAssetsValuationAllowanceNetIncreaseDecreaseForOtherForeignDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxAssetsValuationAllowanceNetIncreaseDecreaseForOtherForeignDeferredTaxAssets", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESNarrativeDetails", "http://www.clorox.com/role/INCOMETAXESSummaryofChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining valuations related to other foreign deferred tax assets", "negatedTerseLabel": "Net decrease/(increase) for other foreign deferred tax assets", "label": "Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For Other Foreign Deferred Tax Assets", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized resulting from other foreign deferred tax assets." } } }, "auth_ref": [] }, "clx_DeferredTaxAssetsValuationAllowanceNetIncreaseDecreaseForU.S.CapitalLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxAssetsValuationAllowanceNetIncreaseDecreaseForU.S.CapitalLossCarryforwards", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESSummaryofChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net increase/(decrease) for U.S. capital loss carryfowards", "label": "Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For U.S. Capital Loss Carryforwards", "documentation": "Deferred Tax Assets, Valuation Allowance, Net Increase (Decrease) For U.S. Capital Loss Carryforwards" } } }, "auth_ref": [] }, "clx_DeferredTaxAssetsValuationAllowanceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxAssetsValuationAllowanceRollForward", "presentation": [ "http://www.clorox.com/role/INCOMETAXESSummaryofChangesinValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Valuation Allowance [Roll Forward]", "label": "Deferred Tax Assets, Valuation Allowance [Roll Forward]", "documentation": "Deferred Tax Assets, Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails_1": { "parentTag": "clx_DeferredTaxAssetsDeferredTaxLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net deferred tax liabilities", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1463" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease right-of-use assets", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r1466" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1466" ] }, "clx_DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofComponentsofNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Property, plant and equipment and intangible assets", "label": "Deferred Tax Liabilities Property, Plant And Equipment And Intangible Assets", "documentation": "The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of capital assets and intangible assets and the basis of capital assets and intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, attributable to different capitalization of costs, depreciation, or amortization methodologies, impairment charges, or other reasons will increase future taxable income when such basis difference is realized. Capital assets include but are not limited to assets such as land, real estate, leasehold improvements, machinery and equipment and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": [ "r585" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial loss (gain)", "negatedPeriodStartLabel": "Net actuarial loss (gain) as of beginning of year", "negatedPeriodEndLabel": "Net actuarial loss (gain) as of end of year", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r40", "r597" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior service benefit", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r40", "r597" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net deferred income tax (assets) liabilities", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r6", "r40", "r597" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r567", "r1144" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Actuarial loss (gain)", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r560" ] }, "clx_DefinedBenefitPlanAmortizationCurtailmentAndSettlementDuringTheYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DefinedBenefitPlanAmortizationCurtailmentAndSettlementDuringTheYear", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization, curtailment and settlement during the year", "label": "Defined Benefit Plan Amortization, Curtailment, And Settlement During The Year", "documentation": "The adjustment out of other comprehensive income for actuarial gains (losses) recognized as a component of net periodic benefit cost during the period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of unrecognized items", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r554", "r592", "r618", "r1144", "r1145" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued benefit cost, net", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r73", "r74" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount recognized in the balance sheets consists of:", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension benefit assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r208", "r551", "r552", "r575", "r1023", "r1144", "r1509" ] }, "us-gaap_DefinedBenefitPlanAssetsTransferredToFromPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsTransferredToFromPlan", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer to domestic defined contribution plan", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from assets transferred into (from) plan." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r599" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r600" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest crediting rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r599" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r601", "r623" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r600" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest crediting rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Benefit obligation as of beginning of year", "periodEndLabel": "Benefit obligation as of end of year", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r555" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefits paid", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r562", "r626" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Plan settlement", "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement", "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement." } } }, "auth_ref": [ "r1391" ] }, "clx_DefinedBenefitPlanBondsFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DefinedBenefitPlanBondsFundsMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bond funds", "label": "Defined Benefit Plan, Bonds Funds [Member]", "documentation": "Defined Benefit Plan, Bonds Funds [Member]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r604", "r1142", "r1143", "r1144" ] }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents \u2014 Level 1", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1142" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in benefit obligations:", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in plan assets:", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employer contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r569", "r579", "r622", "r1142", "r1143", "r1144", "r1145" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "International equity funds", "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]", "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r1142", "r1143", "r1144" ] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesUsMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Domestic equity funds", "label": "Defined Benefit Plan, Equity Securities, US [Member]", "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r1142", "r1143", "r1144" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal years 2030 through 2034", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r586" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r586" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r586" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r586" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r586" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r586" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r554", "r591", "r617", "r1144", "r1145" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value of assets as of beginning of year", "periodEndLabel": "Fair value of plan assets as of end of year", "terseLabel": "Total assets at fair value", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r566", "r577", "r579", "r580", "r1142", "r1143", "r1144" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Translation and other adjustments", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r561" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued benefit cost, net funded status", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r551", "r575", "r1144" ] }, "clx_DefinedBenefitPlanGainLossDuringTheYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DefinedBenefitPlanGainLossDuringTheYear", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss (gain) during the year", "label": "Defined Benefit Plan Gain (Loss) During The Year", "documentation": "The accumulated change in the value of either the projected benefit obligation or the plans assets resulting from experience different from that assumed or from a change in an actuarial assumption that has not been recognized in net periodic benefit cost pursuant to FAS 87 and 106." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r554", "r558", "r590", "r616", "r1144", "r1145" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": 1.0, "order": 3.0 }, "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit cost", "totalLabel": "Total", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r588", "r614", "r1144", "r1145" ] }, "clx_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDueToSettlementAndCurtailmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDueToSettlementAndCurtailmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Curtailment gain, after tax", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due To Settlement And Curtailment, Net Of Tax", "documentation": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due To Settlement And Curtailment, Net Of Tax" } } }, "auth_ref": [] }, "clx_DefinedBenefitPlanOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DefinedBenefitPlanOtherMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Defined Benefit Plan, Other [Member]", "documentation": "Defined Benefit Plan, Other" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1437" ] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r611", "r1144" ] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r611", "r1144" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ABO Exceeds the Fair Value of Plan Assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r611", "r612", "r1144" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r611", "r612", "r1144" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1437" ] }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAmendments", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan amendments", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan." } } }, "auth_ref": [ "r563" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefits paid", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r571", "r1449" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Translation and other adjustments", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r568" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "% Target Allocation", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r576", "r1144" ] }, "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PBO Exceeds the Fair Value of Plan Assets", "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRealEstateMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "verboseLabel": "Real estate fund", "label": "Employee Benefit Plan, Real Estate [Member]", "documentation": "Property composed of building, land, and land improvement; in which employee benefit plan asset is invested." } } }, "auth_ref": [ "r1142", "r1144" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Curtailment gain recognized", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees." } } }, "auth_ref": [ "r553", "r595", "r621" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement loss recognized", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement." } } }, "auth_ref": [ "r553", "r595", "r621" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "crdr": "credit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 8.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 9.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension settlement charge", "negatedLabel": "Pension settlement charge", "terseLabel": "Curtailment gain, before tax", "verboseLabel": "Pension settlement charge", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment." } } }, "auth_ref": [ "r1388", "r1427", "r1446" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r556", "r589", "r615", "r1144", "r1145" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Plan settlement", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r574" ] }, "clx_DefinedBenefitPlanShortTermInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DefinedBenefitPlanShortTermInvestmentMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investment fund", "label": "Defined Benefit Plan, Short-Term Investment [Member]", "documentation": "Defined Benefit Plan, Short-Term Investment" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "% of Plan Asset", "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r1410" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPostretirementHealthCoverageMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Health Care", "label": "Postretirement Health Coverage [Member]", "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate cost of the defined contribution plans", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r627" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r14", "r341", "r352", "r377", "r1116", "r1117" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r271", "r272", "r791", "r792", "r799", "r805", "r992", "r993", "r994", "r995", "r996", "r998", "r999", "r1000", "r1001", "r1002", "r1017", "r1018", "r1067", "r1070", "r1073", "r1074", "r1075", "r1076", "r1105", "r1163", "r1166", "r1192", "r1476", "r1477", "r1478", "r1544" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r1000", "r1002", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1025", "r1026", "r1027", "r1028", "r1040", "r1041", "r1042", "r1043", "r1046", "r1047", "r1048", "r1049", "r1067", "r1068", "r1073", "r1075", "r1190", "r1192", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1486", "r1487" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement of interest rate derivative contracts", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1472" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r96", "r98", "r99", "r204", "r1000", "r1002", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1025", "r1026", "r1027", "r1028", "r1040", "r1041", "r1042", "r1043", "r1046", "r1047", "r1048", "r1049", "r1067", "r1068", "r1073", "r1075", "r1105", "r1190", "r1192", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1486", "r1487" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r25", "r96", "r98", "r99", "r103", "r104", "r764" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r764" ] }, "clx_DerivativeInstrumentsSubjectToContractuallyDefinedCounterpartyLiabilityPositionLimits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DerivativeInstrumentsSubjectToContractuallyDefinedCounterpartyLiabilityPositionLimits", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments subject to contractually defined counterparty liability position limits", "label": "Derivative Instruments Subject To Contractually Defined Counterparty Liability Position Limits", "documentation": "Derivative instruments subject to contractually defined counterparty liability position limits." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r271", "r272", "r791", "r792", "r799", "r805", "r992", "r993", "r994", "r995", "r998", "r999", "r1000", "r1001", "r1002", "r1025", "r1027", "r1028", "r1068", "r1069", "r1070", "r1073", "r1074", "r1075", "r1076", "r1105", "r1476", "r1477", "r1478", "r1544" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r777" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1470", "r1471" ] }, "clx_DerivativeNotionalAmountAdditionalContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DerivativeNotionalAmountAdditionalContracts", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount, additional contracts", "label": "Derivative, Notional Amount, Additional Contracts", "documentation": "Derivative, Notional Amount, Additional Contracts" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r25", "r91", "r92", "r93", "r94", "r97", "r98", "r100", "r102", "r104", "r777" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r25", "r91", "r92", "r94", "r101", "r306", "r324" ] }, "clx_DickinsonCountyMichiganMatterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DickinsonCountyMichiganMatterMember", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dickinson County, Michigan Matter", "label": "Dickinson County, Michigan Matter [Member]", "documentation": "Dickinson County, Michigan Matter [Member]" } } }, "auth_ref": [] }, "clx_DigitalCapabilitiesAndProductivityEnhancementsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DigitalCapabilitiesAndProductivityEnhancementsExpense", "crdr": "debit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Digital capabilities and productivity enhancements investment", "label": "Digital Capabilities and Productivity Enhancements Expense", "documentation": "Digital Capabilities and Productivity Enhancements Expense" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION PLANS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r640", "r645", "r676", "r677", "r679", "r1153" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r252" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r15", "r30" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "crdr": "debit", "calculation": { "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails": { "parentTag": "clx_DisposalGroupIncludingDiscontinuedOperationNetAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r112", "r119", "r180" ] }, "clx_DisposalGroupIncludingDiscontinuedOperationNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationNetAssets", "crdr": "debit", "calculation": { "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets divested", "label": "Disposal Group, Including Discontinued Operation, Net Assets", "documentation": "Disposal Group, Including Discontinued Operation, Net Assets" } } }, "auth_ref": [] }, "clx_DisposalGroupIncludingDiscontinuedOperationNumberOfAssetsDisposedOf": { "xbrltype": "integerItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfAssetsDisposedOf", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of production plants disposed of", "label": "Disposal Group, Including Discontinued Operation, Number Of Assets Disposed Of", "documentation": "Disposal Group, Including Discontinued Operation, Number Of Assets Disposed Of" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "crdr": "debit", "calculation": { "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails": { "parentTag": "clx_DisposalGroupIncludingDiscontinuedOperationNetAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r112", "r119", "r180" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "crdr": "credit", "calculation": { "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails": { "parentTag": "clx_DisposalGroupIncludingDiscontinuedOperationNetAssets", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other liabilities", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r112", "r119", "r180" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails": { "parentTag": "clx_DisposalGroupIncludingDiscontinuedOperationNetAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r112", "r119", "r180" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net sales", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r118", "r253" ] }, "clx_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationWorkingCapitalNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails": { "parentTag": "clx_DisposalGroupIncludingDiscontinuedOperationNetAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital, net", "label": "Disposal Group, Including Discontinued Operation, Working Capital, Net", "documentation": "Disposal Group, Including Discontinued Operation, Working Capital, Net" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 7.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on divestiture", "negatedNetLabel": "Pre-tax loss on divestiture", "terseLabel": "Loss on divestiture", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r438", "r1318", "r1364" ] }, "clx_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalOperatingActivities", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on divestiture", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Operating Activities", "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Operating Activities" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "DIVESTITURE OF ARGENTINA BUSINESS", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r111", "r178" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r1146", "r1149" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends to Clorox stockholders", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r11", "r191" ] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDeclaredTableTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Dividends Per Share Paid to Stockholders", "label": "Dividends Declared [Table Text Block]", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r127" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared and accrued, but not paid", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r127", "r132", "r214", "r1198", "r1510" ] }, "us-gaap_DividendsPayableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableLineItems", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable [Line Items]", "label": "Dividends Payable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableTable", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable [Table]", "label": "Dividends Payable [Table]", "documentation": "Disclosure of information about distribution of earnings to shareholder declared but not yet paid. Includes, but is not limited to, total amount and amount per share of distribution, declaration date, and date to be paid." } } }, "auth_ref": [ "r47" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1206", "r1207", "r1219" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction Flag", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1206", "r1207", "r1219", "r1262" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1240" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1204" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. jurisdictions", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r696" ] }, "clx_DomesticDefinedContributionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "DomesticDefinedContributionPlanMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Defined Contribution Plan", "label": "Domestic Defined Contribution Plan [Member]", "documentation": "Domestic Defined Contribution Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticPlanMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1450", "r1451", "r1452" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1251" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Net earnings per share attributable to Clorox", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net earnings per share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r291", "r316", "r317", "r318", "r319", "r320", "r321", "r327", "r329", "r334", "r335", "r336", "r340", "r744", "r753", "r788", "r789", "r915", "r940", "r1108" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net earnings per share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r291", "r316", "r317", "r318", "r319", "r320", "r321", "r329", "r334", "r335", "r336", "r340", "r744", "r753", "r788", "r789", "r915", "r940", "r1108" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPS" ], "lang": { "en-us": { "role": { "terseLabel": "NET EARNINGS PER SHARE (EPS)", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r326", "r337", "r338", "r339" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r812" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r696", "r1158" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory federal tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r303", "r696", "r729", "r1158" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on divestiture", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation." } } }, "auth_ref": [ "r1322", "r1458", "r1459" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign tax rate differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r697", "r700", "r1158", "r1322", "r1458" ] }, "clx_EffectiveIncomeTaxRateReconciliationInternationalLegalEntityReorganizationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationInternationalLegalEntityReorganizationPercent", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International legal entity reorganization", "label": "Effective Income Tax Rate Reconciliation, International Legal Entity Reorganization, Percent", "documentation": "Effective Income Tax Rate Reconciliation, International Legal Entity Reorganization, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VMS goodwill impairment", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss." } } }, "auth_ref": [ "r1158", "r1322", "r1458", "r1460" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other differences", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1158", "r1322", "r1458", "r1459" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net U.S. tax on foreign income", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings." } } }, "auth_ref": [ "r1322", "r1458", "r1459" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal excess tax benefits", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1299", "r1458", "r1459" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes (net of federal tax benefits)", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r699", "r1158", "r1322", "r1458" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Federal research and development credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1158", "r1322", "r1458", "r1460" ] }, "clx_EmployeeBenefitObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "EmployeeBenefitObligations", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefit obligations", "label": "Employee Benefit Obligations", "documentation": "The sum of the carrying amounts as of the balance sheet date of the portions of obligations to employees under pension, postretirement, and health benefit plans that are due beyond one year." } } }, "auth_ref": [] }, "clx_EmployeeBenefitsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "EmployeeBenefitsPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefits", "label": "Employee Benefits [Policy Text Block]", "documentation": "Disclosure of accounting policy for the entity's various types of employee benefit plans, including retirement, postretirement and postemployment plans." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and employee benefit costs", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r127" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r678" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation costs not yet recognized, period for recognition (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r678" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related income tax benefit", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r675" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee-related costs", "terseLabel": "Employee-Related Costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1203" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1203" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1203" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1291" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1203" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1203" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1203" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1203" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1292" ] }, "us-gaap_EnvironmentalCostsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalCostsPolicy", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Costs", "label": "Environmental Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for obligations that resulted from improper or other-than normal operation of a long-lived asset in the past. This accounting policy may address (1) whether the related remediation costs are expensed or capitalized, (2) whether the obligation is measured on a discounted basis, (3) the event, situation, or set of circumstances that generally triggers recognition of loss contingencies arising from the entity's environmental remediation-related obligations, and (4) the timing of recognition of any recoveries." } } }, "auth_ref": [ "r457", "r458", "r480", "r1126", "r1296" ] }, "us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]", "label": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes accrual for environmental loss contingency." } } }, "auth_ref": [ "r480", "r1127" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1245" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1287" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1287" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1287" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity Components [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r24", "r247", "r284", "r285", "r286", "r308", "r309", "r310", "r313", "r320", "r322", "r324", "r342", "r395", "r401", "r437", "r538", "r724", "r725", "r740", "r741", "r742", "r745", "r752", "r753", "r769", "r771", "r772", "r773", "r774", "r776", "r787", "r814", "r816", "r817", "r818", "r819", "r820", "r826", "r829", "r856", "r936", "r966", "r967", "r968", "r990", "r1053" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r341", "r358", "r377", "r390", "r1306", "r1335" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1255" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1212", "r1223", "r1233", "r1266" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1209", "r1220", "r1230", "r1263" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r509", "r805", "r1134", "r1135" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1261" ] }, "clx_ExpirationPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ExpirationPeriodAxis", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Period [Axis]", "label": "Expiration Period [Axis]", "documentation": "Expiration Period [Axis]" } } }, "auth_ref": [] }, "clx_ExpirationPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ExpirationPeriodDomain", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Period [Domain]", "label": "Expiration Period [Domain]", "documentation": "Expiration Period [Domain]" } } }, "auth_ref": [] }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExtraordinaryAndUnusualItemsAbstract", "lang": { "en-us": { "role": { "label": "Unusual or Infrequent Items, or Both [Abstract]" } } }, "auth_ref": [] }, "clx_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]", "documentation": "Fair Value Assets and Liabilities Measured on Recurring Basis [Line Items]" } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Balance Sheet Classification and Fair Values of Derivative Instruments and Fair Values of Other Assets and Liabilities", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r106" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r509", "r579", "r580", "r581", "r582", "r583", "r584", "r790", "r792", "r793", "r794", "r795", "r798", "r799", "r801", "r866", "r867", "r868", "r1134", "r1135", "r1142", "r1143", "r1144", "r1163", "r1166" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r509", "r1134", "r1135" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r509", "r1134", "r1135" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total assets in the fair value hierarchy", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r509", "r579", "r584", "r792", "r799", "r866", "r1142", "r1143", "r1144", "r1163" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r509", "r579", "r584", "r792", "r793", "r799", "r867", "r1134", "r1135", "r1142", "r1143", "r1144", "r1163" ] }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total common collect trust measured at net asset value", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r579", "r790", "r801", "r1163" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r509", "r579", "r580", "r581", "r582", "r583", "r584", "r790", "r792", "r793", "r794", "r795", "r798", "r799", "r801", "r866", "r867", "r868", "r1134", "r1135", "r1142", "r1143", "r1144", "r1163", "r1166" ] }, "clx_FairValueMeasurementsRecurringTable": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "FairValueMeasurementsRecurringTable", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring [Table]", "label": "Fair Value Measurements, Recurring [Table]", "documentation": "Disclosure about financial instruments measured at fair value on a recurring basis." } } }, "auth_ref": [] }, "clx_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "FinanceLeaseAssetsAndLiabilitiesLesseeAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease Assets And Liabilities Lessee [Abstract]", "documentation": "Finance Lease Assets And Liabilities Lessee" } } }, "auth_ref": [] }, "clx_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "FinanceLeaseCost", "crdr": "debit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total finance lease cost", "label": "Finance Lease, Cost", "documentation": "Finance Lease, Cost" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails": { "parentTag": "clx_FinanceLeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r833", "r838", "r1171" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r835", "r843" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails", "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total finance lease liabilities", "terseLabel": "Total lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r831", "r847" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r831" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r832" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.clorox.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Finance Lease Liabilities", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1497" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r831" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": [ "r832" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r834", "r843" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r830" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails": { "parentTag": "clx_FinanceLeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r833", "r838", "r1171" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r832" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r846", "r1171" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r845", "r1171" ] }, "clx_FinancialInstrumentsAndFairValueMeasurementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "FinancialInstrumentsAndFairValueMeasurementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]", "label": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]", "documentation": "Financial Instruments and Fair Value Measurements [Abstract]" } } }, "auth_ref": [] }, "clx_FinancialInstrumentsAndFairValueMeasurementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "FinancialInstrumentsAndFairValueMeasurementsTextBlock", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "label": "Financial Instruments And Fair Value Measurements [Text Block]", "documentation": "Financial Instruments And Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, estimated fair value", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [ "r1474", "r1475", "r1485" ] }, "us-gaap_FinancingLeaseLeaseNotYetCommencedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingLeaseLeaseNotYetCommencedMember", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Lease, Lease Not yet Commenced", "label": "Financing Lease, Lease Not yet Commenced [Member]", "documentation": "Lease that has not yet commenced, classified as financing." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization / Impairments", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r261", "r406", "r427", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r429", "r1094", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r429", "r1094", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r429", "r1094", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r429", "r1094", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r429", "r1094", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r420", "r422", "r423", "r424", "r426", "r427", "r431", "r432", "r875", "r879", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r406", "r427", "r879", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r420", "r427", "r431", "r432", "r434", "r875", "r1094", "r1124" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r420", "r422", "r423", "r424", "r426", "r427", "r431", "r432", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net carrying amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r875", "r1357" ] }, "us-gaap_FixedIncomeFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixedIncomeFundsMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed income", "label": "Fixed Income Funds [Member]", "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments." } } }, "auth_ref": [ "r1411" ] }, "clx_FoodProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "FoodProductsMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Food", "verboseLabel": "Food products", "label": "Food Products [Member]", "documentation": "Food Products [Member]" } } }, "auth_ref": [] }, "clx_ForeignAndOtherCreditLinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ForeignAndOtherCreditLinesMember", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign and Other Credit Lines", "label": "Foreign and Other Credit Lines [Member]", "documentation": "Foreign and Other Credit Lines [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign jurisdictions", "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r696", "r697" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange transaction (gains) losses, net", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r808", "r809", "r810", "r811", "r1050" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Transactions and Translations", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r807" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange derivative contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1105", "r1142", "r1161", "r1163" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange forward contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r1017", "r1021", "r1027", "r1042", "r1048", "r1071", "r1072", "r1073", "r1192" ] }, "us-gaap_ForeignLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignLineOfCreditMember", "presentation": [ "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign and other credit lines", "label": "Foreign Line of Credit [Member]", "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, outside the reporting entity's home country." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1270" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1270" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1270" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1270" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1270" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1250" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Trust investment (gains) losses, net", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r161", "r163", "r1293" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.clorox.com/role/DEBTNarrativeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r14", "r67", "r68" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "crdr": "credit", "calculation": { "http://www.clorox.com/role/DEBTNarrativeDetails": { "parentTag": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Redemption price and carrying amount of debt extinguished", "label": "Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff", "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs." } } }, "auth_ref": [ "r67", "r68" ] }, "clx_GladBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "GladBusinessMember", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Glad", "label": "Glad Business [Member]", "documentation": "Glad Business [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r260", "r407", "r910", "r1117", "r1123", "r1164", "r1172", "r1339", "r1346" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1337", "r1349" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails": { "parentTag": "us-gaap_AssetImpairmentCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill impairment", "verboseLabel": "Goodwill impairment", "terseLabel": "Goodwill", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r14", "r408", "r414", "r419", "r1123", "r1164" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r1123" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign currency translation", "label": "Goodwill, Translation and Measurement Period Adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation and measurement period adjustments of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r1338" ] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Divestiture", "label": "Goodwill, Written off Related to Sale of Business Unit", "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r413", "r1123" ] }, "clx_GrillingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "GrillingMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grilling", "label": "Grilling [Member]", "documentation": "Grilling [Member]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r151", "r156", "r225", "r301", "r391", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r806", "r1110", "r1116", "r1328", "r1330", "r1332", "r1333", "r1334", "r1383" ] }, "clx_HealthAndWellnessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "HealthAndWellnessMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health and Wellness", "label": "Health And Wellness [Member]", "documentation": "Health and Wellness [Member]" } } }, "auth_ref": [] }, "clx_HostingArrangementServiceContractTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "HostingArrangementServiceContractTerm", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hosting arrangement term (in years) (up to)", "label": "Hosting Arrangement, Service Contract, Term", "documentation": "Hosting Arrangement, Service Contract, Term" } } }, "auth_ref": [] }, "clx_HouseholdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "HouseholdMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Household", "label": "Household [Member]", "documentation": "Household [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1206", "r1207", "r1219" ] }, "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill." } } }, "auth_ref": [ "r1363" ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails": { "parentTag": "us-gaap_AssetImpairmentCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks, net", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r14", "r421", "r433" ] }, "clx_ImpairmentOfIntangibleAssetsExcludingGoodwillIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwillIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment tax benefit", "label": "Impairment Of Intangible Assets (Excluding Goodwill), Income Tax Expense (Benefit)", "documentation": "Impairment Of Intangible Assets (Excluding Goodwill), Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charges", "verboseLabel": "Trademarks, net", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r421", "r1318", "r1358", "r1362" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment Review of Goodwill and Indefinite-Lived Intangible Assets", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r302", "r695" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings (losses) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r152", "r220", "r225", "r916", "r932", "r1110", "r1116", "r1328", "r1330", "r1332", "r1333", "r1334" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r302", "r695" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income from equity investees", "negatedTerseLabel": "(Income) Loss from equity investees included in Other (income) expense, net", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r14", "r153", "r219", "r341", "r354", "r377", "r390", "r931" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r1146", "r1149" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSMajorClassesofAssetsandLiabilitiesDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails", "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNetSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r18", "r30", "r37", "r112", "r113", "r114", "r115", "r116", "r117", "r120", "r121", "r122", "r181" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r439", "r446", "r463", "r796", "r797", "r800", "r961", "r963", "r1037", "r1094", "r1165", "r1514" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r446", "r463", "r796", "r797", "r800", "r961", "r963", "r1037", "r1094", "r1165", "r1514" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r297", "r696", "r697", "r705", "r720", "r1158", "r1465" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r297", "r696", "r697", "r705", "r720", "r1158", "r1465" ] }, "clx_IncomeTaxCreditCarryforwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "IncomeTaxCreditCarryforwardMember", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax credits", "label": "Income Tax Credit Carryforward [Member]", "documentation": "Income Tax Credit Carryforward" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r303", "r687", "r696", "r701", "r702", "r703", "r712", "r718", "r730", "r732", "r735", "r736", "r984", "r1158" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 }, "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesandComponentsofEarningsBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "totalLabel": "Total", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r232", "r243", "r323", "r324", "r341", "r355", "r377", "r694", "r696", "r731", "r941", "r1158" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r283", "r690", "r691", "r712", "r713", "r717", "r722", "r980" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.clorox.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid, net of refunds", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r46", "r297", "r719", "r720" ] }, "clx_IncreaseDecreaseDeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "IncreaseDecreaseDeferredCompensationPlanAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in deferred compensation plan", "label": "Increase (Decrease) Deferred Compensation Plan Assets", "documentation": "Increase (Decrease) Deferred Compensation Plan Assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes payable/prepaid", "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes." } } }, "auth_ref": [ "r1317" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivables, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of stock options and other (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r330", "r331", "r332", "r336", "r644" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r420", "r425", "r430", "r1124" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r420", "r430", "r434", "r1124" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net carrying amount", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r406", "r430", "r1124" ] }, "clx_IndefiniteLivedIntangibleAssetsExcludingGoodwillBeforeImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillBeforeImpairment", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Before Impairment", "documentation": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Before Impairment" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r420", "r425", "r430", "r1124" ] }, "clx_IndefiniteLivedIntangibleAssetsRemainingCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "IndefiniteLivedIntangibleAssetsRemainingCarryingValue", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impaired trademarks, remaining net carrying value", "label": "Indefinite-Lived Intangible Assets, Remaining Carrying Value", "documentation": "Indefinite-Lived Intangible Assets, Remaining Carrying Value" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1261", "r1270", "r1274", "r1282" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1280" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1208", "r1286" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1208", "r1286" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1208", "r1286" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total gross carrying amount", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r260" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net carrying amount", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r420", "r1357", "r1358" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r341", "r347", "r351", "r357", "r377", "r822", "r1116", "r1117" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r292", "r295", "r296" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateContractMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate derivative contracts", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r1096", "r1105", "r1142", "r1163" ] }, "us-gaap_InternalUseSoftwarePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalUseSoftwarePolicy", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalization of Software Costs", "label": "Internal Use Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally." } } }, "auth_ref": [ "r435" ] }, "clx_InternationalDefinedContributionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "InternationalDefinedContributionPlanMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International Defined Contribution Plan", "label": "International Defined Contribution Plan [Member]", "documentation": "International Defined Contribution Plan [Member]" } } }, "auth_ref": [] }, "clx_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "InternationalMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International [Member]", "documentation": "International [Member]" } } }, "auth_ref": [] }, "clx_InternationalReportingUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "InternationalReportingUnitMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International reporting unit", "label": "International Reporting Unit [Member]", "documentation": "International Reporting Unit" } } }, "auth_ref": [] }, "clx_InventoryCurrentAndNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "InventoryCurrentAndNoncurrentNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total inventories, net", "label": "Inventory, Current And Noncurrent, Net", "documentation": "Inventory, Current And Noncurrent, Net" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/INVENTORIESNET" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES, NET", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r403" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails_1": { "parentTag": "clx_InventoryCurrentAndNoncurrentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r177", "r1101" ] }, "us-gaap_InventoryLIFOReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLIFOReserve", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails_1": { "parentTag": "clx_InventoryCurrentAndNoncurrentNet", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "LIFO allowances", "label": "Inventory, LIFO Reserve", "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods." } } }, "auth_ref": [ "r1309" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails": { "parentTag": "clx_InventoryCurrentAndNoncurrentNet", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "verboseLabel": "Total current inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r269", "r1100", "r1172" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails": { "parentTag": "clx_InventoryCurrentAndNoncurrentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current inventories, net", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r1307" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r233", "r256", "r268", "r403", "r404", "r405", "r873", "r1107" ] }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails_1": { "parentTag": "clx_InventoryCurrentAndNoncurrentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and packaging", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments." } } }, "auth_ref": [ "r177", "r1310" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails_1": { "parentTag": "clx_InventoryCurrentAndNoncurrentNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/INVENTORIESNETScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r177", "r1102" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "terseLabel": "Interest income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r159", "r160" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trust assets for nonqualified deferred compensation plans, estimated fair value", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r1474", "r1475", "r1485" ] }, "clx_IssuanceOfCommonStockForEmployeeStockPlansAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "IssuanceOfCommonStockForEmployeeStockPlansAndOther", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for employee stock plans and other", "label": "Issuance Of Common Stock For Employee Stock Plans And Other", "documentation": "The cash inflow associated with the amount received from holders exercising their stock options. Also includes the net cash inflow (outflow) from other financing activities." } } }, "auth_ref": [] }, "clx_JetFuelSwapsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "JetFuelSwapsMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jet Fuel Swaps", "label": "Jet Fuel Swaps [Member]", "documentation": "Jet Fuel Swaps [Member]" } } }, "auth_ref": [] }, "us-gaap_LandAndLandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandAndLandImprovementsMember", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land and improvements", "label": "Land and Land Improvements [Member]", "documentation": "Real estate held and assets that are an addition or improvement to real estate held." } } }, "auth_ref": [] }, "us-gaap_LandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandImprovementsMember", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements [Member]", "documentation": "Additions or improvements to real estate held." } } }, "auth_ref": [] }, "clx_LeaseCostFinanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "LeaseCostFinanceAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease cost:", "label": "Lease, Cost, Finance [Abstract]", "documentation": "Lease, Cost, Finance" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.clorox.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Lease Cost, Supplemental Cash Flow Information and Noncash Activity Related to Leases and Weighted-Average Remaining Lease Term and Discount Rate", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1496" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "clx_LeasesWeightedAverageDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "LeasesWeightedAverageDiscountRateAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate:", "label": "Leases, Weighted Average Discount Rate [Abstract]", "documentation": "Leases, Weighted Average Discount Rate" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseRemainingLeaseTerm", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases, remaining lease terms", "label": "Lessee, Finance Lease, Remaining Lease Term", "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r849", "r1494" ] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.clorox.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r837" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.clorox.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1497" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r847" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases, remaining lease terms", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r849", "r1494" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.clorox.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r828" ] }, "clx_LetterOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "LetterOfCredit", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit", "label": "Letter of Credit", "documentation": "Borrowing capacity under the letter of credit without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit, amount outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r36", "r126", "r127", "r128", "r131", "r132", "r133", "r136", "r301", "r391", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r756", "r760", "r761", "r806", "r1009", "r1109", "r1201", "r1383", "r1500", "r1501" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r143", "r218", "r928", "r1172", "r1320", "r1336", "r1488" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r128", "r255", "r301", "r391", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r756", "r760", "r761", "r806", "r1172", "r1383", "r1500", "r1501" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r792", "r1474" ] }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent." } } }, "auth_ref": [ "r132" ] }, "clx_LifestyleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "LifestyleMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lifestyle", "label": "Lifestyle [Member]", "documentation": "Lifestyle [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, amount outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r36", "r215", "r1512" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r125", "r130", "r1319", "r1381", "r1382" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r125", "r130", "r1319", "r1381" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r483", "r1319", "r1381" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, borrowing capacity", "verboseLabel": "Total", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r125", "r130" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r125", "r130", "r483" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r125", "r130", "r483", "r1319", "r1381" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Current maturities of long-term debt and Long-term debt, carrying value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r36", "r215", "r508", "r522", "r1134", "r1135", "r1170", "r1512" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]", "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: Current maturities of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r264" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r307", "r1386" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r307", "r513" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r307", "r513" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r307", "r513" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r307", "r513" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r307", "r513" ] }, "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r265" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r36", "r1366", "r1367", "r1368" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r36", "r66", "r1366", "r1367", "r1368" ] }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtWeightedAverageInterestRate", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, weighted average interest rate, at point in time", "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r475", "r476", "r477", "r481", "r684", "r976", "r1132", "r1377", "r1378" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r475", "r476", "r477", "r481", "r684", "r1132", "r1377", "r1378" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r475", "r476", "r477", "r481", "r684", "r1132", "r1377", "r1378" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r475", "r476", "r477", "r481", "r684", "r976", "r1132", "r1377", "r1378" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "verboseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "clx_MajorComponentsOfOtherIncomeExpenseNetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "MajorComponentsOfOtherIncomeExpenseNetTableTextBlock", "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Major Components of Other (Income) Expense, Net", "label": "Major Components Of Other (Income) Expense, Net [Table Text Block]", "documentation": "Tabular disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r385", "r1141", "r1182", "r1187", "r1387", "r1513", "r1515", "r1516", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "us-gaap_MarginDepositAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarginDepositAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash margin balances amount", "label": "Margin Deposit Assets", "documentation": "The amount of cash or securities placed with a broker or counterparty as security for a trading or derivatives securities position which was partially obtained with funds provided by the broker dealer." } } }, "auth_ref": [ "r1001", "r1307" ] }, "clx_MaximumExposureUndiscountedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "MaximumExposureUndiscountedCost", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum undiscounted costs", "label": "Maximum Exposure, Undiscounted Cost", "documentation": "Maximum potential amount of future payments (undiscounted) that the Company could incur over an estimated remediation period." } } }, "auth_ref": [] }, "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum contract duration (in years)", "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge", "documentation": "Maximum period of hedging exposure to variability in future cash flows for forecasted transaction of foreign currency cash flow hedge, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transaction for payment of variable interest on existing financial instrument." } } }, "auth_ref": [ "r22" ] }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum duration, commodity contracts (in years)", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r22" ] }, "us-gaap_MaximumLengthOfTimeHedgedInInterestRateCashFlowHedge1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumLengthOfTimeHedgedInInterestRateCashFlowHedge1", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum duration, interest rate contracts (in years)", "label": "Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge", "documentation": "Maximum period of hedging exposure to variability in future cash flows for forecasted transaction of interest rate cash flow hedge, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transaction for payment of variable interest on existing financial instrument." } } }, "auth_ref": [ "r22" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r476", "r477", "r479", "r480", "r633", "r684", "r795", "r872", "r960", "r962", "r976", "r1001", "r1002", "r1060", "r1062", "r1064", "r1065", "r1077", "r1092", "r1093", "r1122", "r1138", "r1152", "r1166", "r1167", "r1168", "r1169", "r1183", "r1385", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1253" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1253" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r476", "r477", "r479", "r480", "r633", "r684", "r795", "r872", "r960", "r962", "r976", "r1001", "r1002", "r1060", "r1062", "r1064", "r1065", "r1077", "r1092", "r1093", "r1122", "r1138", "r1152", "r1166", "r1167", "r1168", "r1183", "r1385", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507" ] }, "clx_MinimumPercentageForCalculatingTheAmortizationOfActuarialGainsAndLossesUnderTheCorridorApproach": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "MinimumPercentageForCalculatingTheAmortizationOfActuarialGainsAndLossesUnderTheCorridorApproach", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum percentage for calculating the amortization of actuarial gains and losses under the corridor approach", "label": "Minimum Percentage For Calculating The Amortization Of Actuarial Gains And Losses Under The Corridor Approach", "documentation": "Represents the minimum percentage of the greater of the projected benefit obligation or the market-related asset value that actuarial gains and losses must exceed in order to be amortized to pension expense under the corridor approach for purposes of determining the amortization of actuarial gains and losses related to the entity's employee benefits." } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r142", "r217", "r301", "r391", "r484", "r487", "r488", "r489", "r493", "r494", "r806", "r927", "r1013" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends to noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r191" ] }, "clx_MiscellaneousOtherExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "MiscellaneousOtherExpenseIncome", "crdr": "debit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Miscellaneous Other Expense (Income)", "documentation": "Represents the sum of miscellaneous other income and expense recognized by the entity in the period that is not otherwise specified." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1273" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest-bearing investments, including money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1411" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1281" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r385", "r1141", "r1182", "r1187", "r1387", "r1513", "r1515", "r1516", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1254" ] }, "clx_NaturalPersonalCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "NaturalPersonalCareMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Natural Personal Care", "label": "Natural Personal Care [Member]", "documentation": "Natural Personal Care [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used for financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r294" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used for investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r294" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operations", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r170", "r171", "r172" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings attributable to Clorox", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r157", "r172", "r221", "r253", "r278", "r281", "r286", "r301", "r312", "r316", "r317", "r318", "r319", "r320", "r323", "r324", "r333", "r391", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r744", "r753", "r789", "r806", "r935", "r1032", "r1051", "r1052", "r1199", "r1383" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net earnings attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r89", "r203", "r278", "r281", "r320", "r323", "r324", "r934", "r1314" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r245", "r246", "r247", "r248", "r249", "r250", "r311", "r312", "r313", "r314", "r315", "r318", "r325", "r340", "r386", "r387", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r436", "r437", "r454", "r724", "r725", "r726", "r727", "r728", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r802", "r803", "r825", "r826", "r827", "r851", "r852", "r853", "r854", "r855", "r856", "r876", "r877", "r878", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r978" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r48", "r245", "r246", "r247", "r248", "r249", "r250", "r311", "r312", "r313", "r314", "r315", "r318", "r325", "r340", "r386", "r387", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r436", "r437", "r454", "r724", "r725", "r726", "r727", "r728", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r802", "r803", "r825", "r826", "r827", "r851", "r852", "r853", "r854", "r855", "r856", "r876", "r877", "r878", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r978" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "clx_NonCashCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "NonCashCapitalExpenditures", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash capital expenditures", "label": "Non-Cash Capital Expenditures", "documentation": "Amount of non-cash capital expenditures incurred during the period." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1253" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1216", "r1227", "r1237", "r1261", "r1270" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1244" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1243" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1261" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1281" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1281" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1547", "r1548", "r1549", "r1550" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r85", "r538", "r1324", "r1325", "r1326", "r1327", "r1545" ] }, "us-gaap_NontradeReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NontradeReceivablesCurrent", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-customer receivables", "label": "Nontrade Receivables, Current", "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1308" ] }, "clx_NotSubjectToExpirationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "NotSubjectToExpirationMember", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Subject to Expiration", "label": "Not Subject to Expiration [Member]", "documentation": "Foreign benefits not subject to expiration." } } }, "auth_ref": [] }, "clx_NotesAndLoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "NotesAndLoansPayableMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes and loans payable", "label": "Notes and Loans Payable [Member]", "documentation": "Notes and Loans Payable" } } }, "auth_ref": [] }, "clx_NumberOfHedgingInstrumentsDesignatedAsFairValueHedges": { "xbrltype": "integerItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "NumberOfHedgingInstrumentsDesignatedAsFairValueHedges", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of hedging instruments designated as fair value hedges", "label": "Number Of Hedging Instruments Designated As Fair Value Hedges", "documentation": "The number of hedging instruments designated as fair value hedges held by the entity." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1111", "r1121", "r1329" ] }, "clx_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OperatingLeaseAssetsAndLiabilitiesLesseeAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease Assets And Liabilities Lessee [Abstract]", "documentation": "Operating Lease Assets And Liabilities Lessee" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r839", "r1171" ] }, "us-gaap_OperatingLeaseLeaseNotYetCommencedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseNotYetCommencedMember", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Lease Not yet Commenced", "label": "Operating Lease, Lease Not yet Commenced [Member]", "documentation": "Lease that has not yet commenced, classified as operating." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/LEASESScheduleofMaturitiesofOperatingLeaseandFinanceLeaseLiabilitiesDetails", "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "terseLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r831" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "verboseLabel": "Current lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r831" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "verboseLabel": "Non-current lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r831" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases, net", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r836", "r843" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/LEASESScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r830" ] }, "clx_OperatingLeaseRightOfUseAssetAndLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OperatingLeaseRightOfUseAssetAndLiabilityNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets and liabilities, net", "label": "Operating Lease, Right-of-Use Asset And Liability, Net", "documentation": "Operating Lease, Right-of-Use Asset And Liability, Net" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r846", "r1171" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r845", "r1171" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": "clx_CarryforwardsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r721" ] }, "clx_OperatingLossCarryforwardsNetOfValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OperatingLossCarryforwardsNetOfValuationAllowance", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": "clx_CarryforwardsNetOfValuationAllowance", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carryforwards", "label": "Operating Loss Carryforwards, Net Of Valuation Allowance", "documentation": "Operating Loss Carryforwards, Net Of Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsValuationAllowance", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": "clx_OperatingLossCarryforwardsNetOfValuationAllowance", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation Allowances", "label": "Operating Loss Carryforwards, Valuation Allowance", "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r1464" ] }, "clx_OperatingSegmentsAndCorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OperatingSegmentsAndCorporateNonSegmentMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments and Corporate and Other", "label": "Operating Segments And Corporate, Non-Segment [Member]", "documentation": "Operating Segments And Corporate, Non-Segment" } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r371", "r372", "r373", "r374", "r375", "r378", "r1116", "r1117" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r127" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r262" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r40", "r285", "r814", "r817", "r820", "r936", "r1312" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gains (losses) on derivatives, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r273", "r274", "r936" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) recognized in Other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r273", "r274", "r762", "r763", "r765" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsonOCIandNetEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r239", "r274", "r276" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency adjustments, net of tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4", "r936" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cumulative translation adjustment losses", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation." } } }, "auth_ref": [ "r9", "r10", "r150", "r277", "r813" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive (loss) income, net of tax", "terseLabel": "Other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r34", "r279", "r282", "r287", "r320", "r814", "r815", "r820", "r911", "r936", "r1312", "r1313" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedLabel": "Pension and postretirement benefit adjustments, net of tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r5", "r6", "r149", "r150", "r936" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit (expense)", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r7", "r284", "r287", "r694", "r733", "r734", "r814", "r818", "r820", "r911", "r936" ] }, "clx_OtherEmployeeStockPlanActivitiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OtherEmployeeStockPlanActivitiesAmount", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other employee stock plan activities", "label": "Other Employee Stock Plan Activities, Amount", "documentation": "Amount includes the value of stock granted during the period as a result of exercises of employee stock options or vesting of other share-based awards." } } }, "auth_ref": [] }, "clx_OtherEmployeeStockPlanActivitiesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OtherEmployeeStockPlanActivitiesShares", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other employee stock plan activities (in shares)", "label": "Other Employee Stock Plan Activities, Shares", "documentation": "Number of shares issued during the period as a result of exercises of employee stock options or the vesting of other share-based awards." } } }, "auth_ref": [] }, "clx_OtherExpenseIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OtherExpenseIncomeNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 7.0 }, "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "totalLabel": "Total", "label": "Other Expense (Income), Net", "documentation": "The net amount of other income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENET" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER (INCOME) EXPENSE, NET", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r1305", "r1455" ] }, "clx_OtherIncomeExpenseNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OtherIncomeExpenseNetMember", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "label": "Other Income (Expense), Net [Member]", "documentation": "Other Income (Expense), Net" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets with finite lives", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r1124", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1357", "r1358", "r1359", "r1360" ] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "label": "Other Intangible Assets, Net", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities Disclosure [Abstract]", "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER LIABILITIES", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r127", "r132", "r1365" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 }, "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "totalLabel": "Total", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r132" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r172" ] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonrecurringExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonrecurringExpense", "crdr": "debit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.clorox.com/role/CYBERATTACKNarrativeDetails", "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred incremental costs, net of insurance recoveries", "negatedNetLabel": "Cyberattack costs, net of insurance recoveries", "label": "Other Nonrecurring Expense", "documentation": "Amount of other expense that is infrequent in occurrence or unusual in nature." } } }, "auth_ref": [ "r165" ] }, "clx_OtherObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "OtherObligations", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Obligations", "documentation": "Other Obligations" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1253" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Income", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r551", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r599", "r601", "r602", "r604", "r607", "r610", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r627", "r628", "r629", "r1144", "r1145", "r1146", "r1147", "r1148" ] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r1128", "r1129", "r1130", "r1131" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1214", "r1225", "r1235", "r1268" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1217", "r1228", "r1238", "r1271" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1217", "r1228", "r1238", "r1271" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1242" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1300", "r1315" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock purchased", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r168" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r462", "r1316" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends paid to Clorox stockholders", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r168" ] }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsMinorityInterest", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends paid to noncontrolling interests", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests." } } }, "auth_ref": [ "r168" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r167" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1252" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1252" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE BENEFIT PLANS", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r550", "r576", "r578", "r584", "r603", "r605", "r606", "r607", "r608", "r609", "r624", "r625", "r627", "r1144" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current accrued benefit liability", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r127", "r551", "r552", "r575", "r1144" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-current accrued benefit liability", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r132", "r551", "r552", "r575", "r1144" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1244" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1261" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1254" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1243" ] }, "us-gaap_PercentageOfLIFOInventory": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PercentageOfLIFOInventory", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of LIFO inventory", "label": "Percentage of LIFO Inventory", "documentation": "The percentage of LIFO (last in first out) inventory to total inventory as of the balance sheet date if other than 100 percent." } } }, "auth_ref": [] }, "clx_PercentageOfLiabilityForAggregateRemediationAndAssociatedCostsOtherThanLegalFees": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "PercentageOfLiabilityForAggregateRemediationAndAssociatedCostsOtherThanLegalFees", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of liability for aggregate remediation and associated costs, other than legal fees", "label": "Percentage Of Liability For Aggregate Remediation And Associated Costs, Other Than Legal Fees", "documentation": "The percentage of costs that the entity has agreed to under cost-sharing arrangements with other potentially responsible parties for an individual site." } } }, "auth_ref": [] }, "clx_PercentageOwnershipOfEquityInvestmentsMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "PercentageOwnershipOfEquityInvestmentsMaximum", "presentation": [ "http://www.clorox.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage ownership of equity investments, maximum", "label": "Percentage Ownership Of Equity Investments, Maximum", "documentation": "Maximum ownership percentage in equity investments." } } }, "auth_ref": [] }, "clx_PercentageofOwnershipbyVenturePartner": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "PercentageofOwnershipbyVenturePartner", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership by venture partner", "label": "Percentage of Ownership by Venture Partner", "documentation": "The percentage of ownership interest by the venture partner." } } }, "auth_ref": [] }, "clx_PerformancePeriodForPerformanceAwards": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "PerformancePeriodForPerformanceAwards", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance period for performance awards (in years)", "label": "Performance Period For Performance Awards", "documentation": "Period over which performance is measured for performance-based awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r604", "r1142", "r1143", "r1144" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1245" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1290" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1244" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r804" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r137", "r525" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r137", "r1011" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r137", "r525" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r137", "r1011", "r1030", "r1545", "r1546" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r137", "r923", "r1172" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1311" ] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture, net of cash divested", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt borrowings, net of issuance costs paid", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r43", "r981" ] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebt", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Notes and loans payable, net", "label": "Proceeds from (Repayments of) Short-Term Debt", "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of productive assets", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r166" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for employee stock plans and other", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r8", "r29" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r175" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r381", "r874", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r1097", "r1139", "r1181", "r1183", "r1184", "r1188", "r1189", "r1379", "r1380", "r1387", "r1513", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r381", "r874", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r1097", "r1139", "r1181", "r1183", "r1184", "r1188", "r1189", "r1379", "r1380", "r1387", "r1513", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "clx_ProfessionalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ProfessionalProductsMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional Products", "label": "Professional Products [Member]", "documentation": "Professional Products [Member]" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings", "terseLabel": "Net earnings", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r253", "r278", "r281", "r293", "r301", "r312", "r320", "r323", "r324", "r391", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r493", "r494", "r744", "r753", "r754", "r757", "r758", "r789", "r806", "r916", "r933", "r989", "r1032", "r1051", "r1052", "r1159", "r1160", "r1200", "r1314", "r1383" ] }, "clx_PropertyPlantAndEquipmentAndFiniteLivedIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "PropertyPlantAndEquipmentAndFiniteLivedIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment and Finite-Lived Intangible Assets", "label": "Property, Plant And Equipment And Finite-Lived Intangible Assets, Policy [Policy Text Block]", "documentation": "Property, Plant And Equipment And Finite-Lived Intangible Assets, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r16", "r848" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNET" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r178", "r236", "r240", "r241" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r179", "r258", "r930" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r848" ] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r16", "r848", "r917", "r930", "r1172" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net [Abstract]", "label": "Property, Plant and Equipment, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETTables", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Useful Lives of Property, Plant and Equipment", "verboseLabel": "Schedule of Components of Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r179", "r848" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives (in years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "clx_ProvisionForIncomeTaxesOnContinuingOperationsByTaxJurisdictionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ProvisionForIncomeTaxesOnContinuingOperationsByTaxJurisdictionTableTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Income Taxes", "label": "Provision For Income Taxes On Continuing Operations By Tax Jurisdiction [Table Text Block]", "documentation": "A schedule that reflects the provision for income taxes on continuing operations, by tax jurisdiction." } } }, "auth_ref": [] }, "clx_PurchasesofInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "PurchasesofInventoryMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of Inventory", "label": "Purchases of Inventory [Member]", "documentation": "Purchases of Inventory [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1242" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1242" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r476", "r477", "r479", "r480", "r576", "r633", "r671", "r672", "r673", "r684", "r795", "r869", "r870", "r872", "r960", "r962", "r976", "r1001", "r1002", "r1060", "r1062", "r1064", "r1065", "r1077", "r1092", "r1093", "r1122", "r1138", "r1152", "r1166", "r1167", "r1168", "r1169", "r1183", "r1192", "r1369", "r1385", "r1477", "r1503", "r1504", "r1505", "r1506", "r1507" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails", "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "verboseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r476", "r477", "r479", "r480", "r576", "r633", "r671", "r672", "r673", "r684", "r795", "r869", "r870", "r872", "r960", "r962", "r976", "r1001", "r1002", "r1060", "r1062", "r1064", "r1065", "r1077", "r1092", "r1093", "r1122", "r1138", "r1152", "r1166", "r1167", "r1168", "r1169", "r1183", "r1192", "r1369", "r1385", "r1477", "r1503", "r1504", "r1505", "r1506", "r1507" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, net", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r1172" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from Accumulated other comprehensive net (loss) income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r40", "r285", "r814", "r819", "r820", "r936", "r1312" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1209", "r1220", "r1230", "r1263" ] }, "clx_RelatedPartyTransactionPaymentsToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "RelatedPartyTransactionPaymentsToRelatedParty", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to related parties", "label": "Related Party Transaction, Payments To Related Party", "documentation": "Related Party Transaction, Payments To Related Party" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r857", "r858", "r859", "r860", "r862", "r985", "r986", "r987", "r1035", "r1036", "r1037", "r1057", "r1059" ] }, "clx_RemediationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "RemediationPeriod", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remediation period (in years)", "label": "Remediation period", "documentation": "Estimated time frame of disbursements over which remediation efforts are estimated to occur for an individual site." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Long-term debt repayments", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r169", "r982" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of short-term debt", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r169" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r418", "r419", "r1123" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r418", "r419", "r1123" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r304", "r305", "r499", "r527", "r861", "r871", "r918", "r1104", "r1105" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development costs", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r686", "r1094", "r1116", "r1508" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "terseLabel": "Research and development costs", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1210", "r1221", "r1231", "r1264" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1211", "r1222", "r1232", "r1265" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1218", "r1229", "r1239", "r1272" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r44", "r207", "r257", "r298", "r922" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r257" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r50" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTS" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRUCTURING AND RELATED COSTS", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r459", "r460", "r462", "r465", "r470" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSNarrativeDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring and related costs", "terseLabel": "Total, net", "negatedLabel": "Streamlined operating model", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r461", "r464", "r467", "r469" ] }, "clx_RestructuringAndRelatedCostsBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "RestructuringAndRelatedCostsBenchmarkMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Costs Benchmark", "label": "Restructuring and Related Costs Benchmark [Member]", "documentation": "Restructuring and Related Costs Benchmark" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r14", "r466", "r467", "r1372" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r461", "r462", "r467", "r468" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r461", "r462", "r463", "r464", "r467", "r468", "r469" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r14" ] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r1297", "r1298" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning accrual balance", "periodEndLabel": "Ending accrual balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r462", "r468" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r140", "r191", "r926", "r970", "r975", "r983", "r1012", "r1172" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r247", "r308", "r309", "r310", "r313", "r320", "r322", "r324", "r395", "r401", "r437", "r724", "r725", "r740", "r741", "r742", "r745", "r752", "r753", "r769", "r772", "r773", "r776", "r787", "r826", "r829", "r966", "r968", "r990", "r1545" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Axis]", "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r1152", "r1301", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Domain]", "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r1152", "r1301", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r604", "r607", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r1450", "r1451", "r1452" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r604", "r607", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r1450", "r1451", "r1452" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r551", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r599", "r601", "r602", "r604", "r607", "r610", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r627", "r628", "r629", "r639", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r551", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r599", "r601", "r602", "r604", "r607", "r610", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r627", "r628", "r629", "r639", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Net Sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r223", "r224", "r341", "r348", "r349", "r371", "r377", "r381", "r383", "r385", "r547", "r548", "r874" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Sales", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r385", "r1302" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition and Cost of Products Sold", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r244", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r1095" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "clx_RevolvingCreditAgreementMaturesMarch2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "RevolvingCreditAgreementMaturesMarch2027Member", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Agreement, Matures March 2027", "label": "Revolving Credit Agreement, Matures March 2027 [Member]", "documentation": "Revolving Credit Agreement, Matures March 2027" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofBorrowingCapacityUnderRevolvingCreditAgreementsandOtherFinancingArrangementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r844", "r1171" ] }, "clx_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:", "label": "Right-of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right-of-Use Asset Obtained In Exchange For Lease Liability" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofSupplementalCashFlowInformationandNoncashActivityRelatedtoLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r844", "r1171" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1281" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1281" ] }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleAndLeasebackTransactionGainLossNet", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails": { "parentTag": "clx_OtherExpenseIncomeNet", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails", "http://www.clorox.com/role/OTHERINCOMEEXPENSENETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale-leaseback transaction", "negatedTerseLabel": "Gain on sale-leaseback transaction", "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale." } } }, "auth_ref": [ "r842", "r850", "r1171" ] }, "clx_SaleLeasebackTransactionLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SaleLeasebackTransactionLeaseRenewalTerm", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease renewal term", "label": "Sale Leaseback Transaction, Lease Renewal Term", "documentation": "Sale Leaseback Transaction, Lease Renewal Term" } } }, "auth_ref": [] }, "us-gaap_SaleLeasebackTransactionLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionLeaseTerm", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Sale Leaseback Transaction, Lease Term", "documentation": "Lease term for sale and leaseback transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1499" ] }, "us-gaap_SaleLeasebackTransactionNetBookValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionNetBookValue", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale-leaseback transaction, carrying value", "label": "Sale Leaseback Transaction, Net Book Value", "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller." } } }, "auth_ref": [ "r229", "r230", "r231", "r1498" ] }, "clx_SaleLeasebackTransactionNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SaleLeasebackTransactionNumberOfRenewalOptions", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of renewal options", "label": "Sale Leaseback Transaction, Number Of Renewal Options", "documentation": "Sale Leaseback Transaction, Number Of Renewal Options" } } }, "auth_ref": [] }, "clx_SaleLeasebackTransactionOptionToTerminatePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SaleLeasebackTransactionOptionToTerminatePeriod", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to terminate, period", "label": "Sale Leaseback Transaction, Option To Terminate, Period", "documentation": "Sale Leaseback Transaction, Option To Terminate, Period" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Retirement Income Plans with ABO or PBO in Excess of Plan Assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1144", "r1437", "r1438" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r40", "r1489", "r1490" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Target Allocation and Weighted Average Allocation of Plan Assets and Retirement Income Plans Assets Carried at Fair Value", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r193" ] }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recognized in Balance Sheets", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Actuarial Loss (Gain) Recorded in Accumulated Other Comprehensive Net (Loss) Income", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost." } } }, "auth_ref": [ "r192" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Assumptions Used to Estimate the Actuarial Present Value of Benefit Obligations and Retirement Income and Retirement Health Care Costs", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r598" ] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": [ "r205" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.clorox.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r36", "r69", "r70", "r110", "r189", "r190", "r1134", "r1136", "r1323", "r1492" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Net Deferred Tax Assets (Liabilities)", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1463" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofComponentsofNetPeriodicBenefitCostDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofExpectedBenefitPaymentsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofItemsNotYetRecognizedasaComponentofPostretirementExpenseDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofNetActuarialLossGainRecordedinAccumulatedOtherComprehensiveNetLossIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlansAssetsCarriedatFairValueDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomePlanswithABOorPBOinExcessofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofRetirementIncomeandRetirementHealthCarePlansandAmountsRecognizedinBalanceSheetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofTargetAllocationandWeightedAverageAllocationofPlanAssetsDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSScheduleofWeightedAverageAssumptionsUsedtoEstimatetheActuarialPresentValueofBenefitObligationsandRetirementIncomeandRetirementHealthCareCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r19", "r75", "r76", "r77", "r78" ] }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r95" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.clorox.com/role/DIVESTITUREOFARGENTINABUSINESSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Assets Divested and Net Sales of Divested Business", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r18", "r30", "r37", "r112", "r113", "r114", "r115", "r116", "r117", "r120", "r121", "r122", "r181" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Effective Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r698", "r1158", "r1458" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r81" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Compensation Cost and Related Income Tax Benefit", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r81" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Benefit Payments", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r194" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r420", "r427", "r431", "r432", "r434", "r875", "r1094", "r1124" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Trademarks and Other Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1124", "r1356" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r1123" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1123", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348" ] }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pre-Tax, Noncash Impairment Charges", "label": "Schedule of Impaired Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported." } } }, "auth_ref": [ "r1361" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Earnings Before Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1321" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofPreTaxNoncashImpairmentChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r420", "r430", "r434", "r1124" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r38", "r144", "r145", "r146" ] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": [ "http://www.clorox.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Borrowing Capacity Under Revolving Credit Agreements and Other Financing Arrangements", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r125", "r130" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Net Periodic Benefit Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r195" ] }, "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Items Not Yet Recognized as a Component of Postretirement Expense", "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]", "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation." } } }, "auth_ref": [ "r196" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r16", "r848" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r461", "r462", "r463", "r464", "r467", "r468", "r469" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Restructuring and Related Implementation Costs, Net", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r64", "r182", "r183" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrual for Restructuring and Related Implementation Costs", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r65", "r184" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Sales and Property, Plant and Equipment, Net by Geographic Area", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r61", "r151" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r61", "r151" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r58", "r59", "r60" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reportable Segment Information and Reconciliation of Segment Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r58", "r59", "r60" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r641", "r643", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r670", "r671", "r672", "r673", "r674" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Awards", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r197" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r27", "r28", "r197" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of each Stock Option Award Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r201" ] }, "us-gaap_ScheduleOfUnusualOrInfrequentItemsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnusualOrInfrequentItemsTextBlock", "presentation": [ "http://www.clorox.com/role/CYBERATTACKTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognition of Costs, Net of Insurance Recoveries", "label": "Schedule of Unusual or Infrequent Items, or Both [Table Text Block]", "documentation": "Tabular disclosure of the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r165" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Number of Shares Outstanding", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r49" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Concentration Percentage", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r51", "r52", "r53", "r54", "r108", "r206" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1202" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1205" ] }, "clx_SegmentAdjustedEBIT": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SegmentAdjustedEBIT", "crdr": "credit", "calculation": { "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment adjusted earnings (losses) before interest and income taxes", "label": "Segment Adjusted EBIT", "documentation": "Segment Adjusted EBIT" } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r341", "r344", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r361", "r362", "r363", "r371", "r372", "r373", "r374", "r375", "r377", "r378", "r379", "r385", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r434", "r464", "r469", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r1113", "r1116", "r1117", "r1123", "r1186", "r1513", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures", "label": "Segment, Expenditure, Addition to Long-Lived Assets", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": [ "r341", "r359", "r377", "r1116", "r1117" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r383", "r384", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r994", "r997", "r999", "r1061", "r1063", "r1066", "r1078", "r1081", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1098", "r1140", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1185", "r1192", "r1387", "r1513", "r1515", "r1516", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTING" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r226", "r341", "r343", "r344", "r345", "r346", "r347", "r360", "r362", "r363", "r375", "r376", "r377", "r378", "r379", "r381", "r382", "r385", "r1111", "r1114", "r1115", "r1116", "r1118", "r1120", "r1121" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r380", "r383", "r1112", "r1113", "r1119" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r158" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling and administrative expenses", "verboseLabel": "Selling and administrative expenses", "netLabel": "Selling and administrative expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Selling and Administrative Expenses", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r1457" ] }, "clx_SeniorLongTermNotesAndDebentures180500DueMay2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures180500DueMay2030Member", "presentation": [ "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.80%, $500 due May 2030", "label": "Senior Long-Term Notes And Debentures; 1.80%, $500 Due May 2030 [Member]", "documentation": "Senior Long-Term Notes And Debentures; 1.80%, $500 Due May 2030" } } }, "auth_ref": [] }, "clx_SeniorLongTermNotesAndDebentures3.05600DueSeptember2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures3.05600DueSeptember2022Member", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Long-Term Notes And Debentures; 3.05%, $600 Due September 2022", "label": "Senior Long-Term Notes And Debentures; 3.05%, $600 Due September 2022 [Member]", "documentation": "Senior Long-term Notes and Debentures Instrument Due September 2022 [Member]" } } }, "auth_ref": [] }, "clx_SeniorLongTermNotesAndDebentures3.10400DueOctober2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures3.10400DueOctober2027Member", "presentation": [ "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.10%, $400 due October 2027", "label": "Senior Long-Term Notes And Debentures; 3.10%, $400 Due October 2027 [Member]", "documentation": "Senior Long-Term Notes and Debentures; 3.10%, $400 Due October 2027 [Member]" } } }, "auth_ref": [] }, "clx_SeniorLongTermNotesAndDebentures3.50500DueDecember2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures3.50500DueDecember2024Member", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Long-Term Notes And Debentures; 3.50%, $500 Due December 2024", "label": "Senior Long-Term Notes And Debentures; 3.50%, $500 Due December 2024 [Member]", "documentation": "Represents information pertaining to senior long term notes and debtentures 3.50%, due December 2024." } } }, "auth_ref": [] }, "clx_SeniorLongTermNotesAndDebentures3.80300DueNovember2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures3.80300DueNovember2021Member", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Long-Term Notes And Debentures; 3.80%, $300 Due November 2021", "label": "Senior Long-Term Notes And Debentures; 3.80%, $300 Due November 2021 [Member]", "documentation": "Senior Long Term Notes And Debentures Instrument Due November Two Thousand Twenty One [Member]" } } }, "auth_ref": [] }, "clx_SeniorLongTermNotesAndDebentures3.90500DueMay2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures3.90500DueMay2028Member", "presentation": [ "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.90%, $500 due May 2028", "label": "Senior Long-Term Notes And Debentures; 3.90%, $500 Due May 2028 [Member]", "documentation": "Senior Long-Term Notes and Debentures; 3.90%, $500 Due May 2028 [Member]" } } }, "auth_ref": [] }, "clx_SeniorLongTermNotesAndDebentures440500DueMay2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures440500DueMay2029Member", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029", "terseLabel": "4.40%, $500 due May 2029", "label": "Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029 [Member]", "documentation": "Senior Long-Term Notes And Debentures; 4.40%, $500 Due May 2029" } } }, "auth_ref": [] }, "clx_SeniorLongTermNotesAndDebentures460600DueMay2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SeniorLongTermNotesAndDebentures460600DueMay2032Member", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/DEBTScheduleofLongTermDebtDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032", "terseLabel": "4.60%, $600 due May 2032", "label": "Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032 [Member]", "documentation": "Senior Long-Term Notes And Debentures; 4.60%, $600 Due May 2032" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "clx_SettlementOfInterestRateDerivativeContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SettlementOfInterestRateDerivativeContracts", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement of interest rate derivative contracts", "label": "Settlement Of Interest Rate Derivative Contracts", "documentation": "Cash inflows (outflows) related to the settlement of interest rate derivative contracts." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofCompensationCostandRelatedIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "terseLabel": "Total compensation costs", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation [Abstract]", "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1153" ] }, "clx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDistributedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDistributedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributed (in dollars per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Distributed Weighted-Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for distributed equity-based awards issued during the period on other than stock (or unit) option plans." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r661" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r661" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Nonvested awards outstanding (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r658", "r659" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average grant date fair value per share of nonvested awards (in dollars per share)", "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r658", "r659" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "clx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferred": { "xbrltype": "sharesItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferred", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and deferred (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred", "documentation": "The number of shares under a share-based award plan other than a stock option plan that were vested and deferred during the reporting period." } } }, "auth_ref": [] }, "clx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested and deferred (in dollars per share)", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and deferred in period weighted average grant date fair value." } } }, "auth_ref": [] }, "clx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndNonvestedWeightedAverageGrantDateFairValuePerShare", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Vested And Nonvested Weighted-Average Grant Date Fair Value Per Share", "documentation": "The weighted average fair value of vested and nonvested awards on equity-based plans excluding option plans outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested (in shares)", "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r662" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of shares vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r662" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r672" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r671" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r673" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "clx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendRate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Rate", "documentation": "Share based compensation arrangement by share based payment award fair value assumptions weighted average expected dividend." } } }, "auth_ref": [] }, "clx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average expected life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Term", "documentation": "Weighted average expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "clx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average risk-free interest rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Risk Free Interest Rate", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Risk Free Interest Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r671" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r641", "r643", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r670", "r671", "r672", "r673", "r674" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributed (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r198", "r199" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1155" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r80" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r652" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r652" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock option awards granted (in shares)", "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r1454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r664" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r80" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r650", "r651" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r650", "r651" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofPerformanceShareAwardsDetails", "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofRestrictedStockAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r670", "r671", "r672", "r673", "r674" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r655" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r640", "r649", "r668", "r669", "r670", "r671", "r674", "r680", "r681", "r682", "r683" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Performance Share Awards", "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares." } } }, "auth_ref": [ "r33" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1154" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofFairValueofeachStockOptionAwardGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r670" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r80" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average remaining contractual life, options vested (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r80" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average remaining contractual life, options outstanding (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r200" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r126", "r1366", "r1367", "r1368" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r124", "r1366", "r1367", "r1368" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r840", "r1171" ] }, "us-gaap_ShorttermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShorttermDebtFairValue", "crdr": "credit", "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofBalanceSheetClassificationandFairValuesofDerivativeInstrumentsandFairValuesofOtherAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes and loans payable, estimated fair value", "label": "Short-Term Debt, Fair Value", "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date." } } }, "auth_ref": [ "r1474" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofComponentsofPropertyPlantandEquipmentNetDetails", "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized software costs", "verboseLabel": "Capitalized software costs", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "clx_SoybeanOilFuturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SoybeanOilFuturesMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Soybean Oil Futures", "label": "Soybean Oil Futures [Member]", "documentation": "Soybean Oil Futures [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofReportableSegmentInformationandReconciliationofSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r251", "r341", "r344", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r361", "r362", "r363", "r371", "r372", "r373", "r374", "r375", "r377", "r378", "r379", "r385", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r434", "r440", "r464", "r469", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r1113", "r1116", "r1117", "r1123", "r1186", "r1513", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r24", "r138", "r141", "r142", "r247", "r284", "r285", "r286", "r308", "r309", "r310", "r313", "r320", "r322", "r324", "r342", "r395", "r401", "r437", "r538", "r724", "r725", "r740", "r741", "r742", "r745", "r752", "r753", "r769", "r771", "r772", "r773", "r774", "r776", "r787", "r814", "r816", "r817", "r818", "r819", "r820", "r826", "r829", "r856", "r936", "r966", "r967", "r968", "r990", "r1053" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r383", "r384", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r994", "r997", "r999", "r1061", "r1063", "r1066", "r1078", "r1081", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1098", "r1140", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1185", "r1192", "r1387", "r1513", "r1515", "r1516", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r308", "r309", "r310", "r342", "r829", "r874", "r979", "r991", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1011", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1025", "r1026", "r1027", "r1028", "r1029", "r1031", "r1033", "r1034", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1053", "r1193" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionLocationActivityAccrualAxis", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Axis]", "label": "Statement of Financial Position Location, Activity, Accrual [Axis]", "documentation": "Information by location in statement of financial position in which disaggregated accrual activity has been included." } } }, "auth_ref": [ "r1469", "r1491" ] }, "us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionLocationActivityAccrualDomain", "presentation": [ "http://www.clorox.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Domain]", "label": "Statement of Financial Position Location, Activity, Accrual [Domain]", "documentation": "Location in statement of financial position in which disaggregated accrual activity has been included." } } }, "auth_ref": [ "r1469", "r1491" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r308", "r309", "r310", "r342", "r388", "r829", "r874", "r979", "r991", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1011", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1025", "r1026", "r1027", "r1028", "r1029", "r1031", "r1033", "r1034", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1053", "r1193" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1213", "r1224", "r1234", "r1267" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "clx_StockConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "StockConversionRatio", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock conversion ratio", "label": "Stock Conversion Ratio", "documentation": "Stock Conversion Ratio" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.clorox.com/role/STOCKBASEDCOMPENSATIONPLANSScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r24", "r137", "r138", "r191", "r655" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Clorox stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r138", "r141", "r142", "r176", "r1013", "r1030", "r1054", "r1055", "r1172", "r1201", "r1320", "r1336", "r1488", "r1545" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r85", "r86", "r88", "r247", "r248", "r285", "r308", "r309", "r310", "r313", "r320", "r322", "r395", "r401", "r437", "r538", "r724", "r725", "r740", "r741", "r742", "r745", "r752", "r753", "r769", "r771", "r772", "r773", "r774", "r776", "r787", "r814", "r816", "r820", "r827", "r856", "r967", "r968", "r988", "r1013", "r1030", "r1054", "r1055", "r1079", "r1200", "r1320", "r1336", "r1488", "r1545" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r188", "r300", "r524", "r526", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r778", "r1056", "r1058", "r1080" ] }, "clx_SubjectToExpirationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "SubjectToExpirationMember", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subject to Expiration", "label": "Subject to Expiration [Member]", "documentation": "Foreign benefits subject to expiration." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r821", "r864" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r821", "r864" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r821", "r864" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.clorox.com/role/SUBSEQUENTEVENT" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENT", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r863", "r865" ] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Gross Unrecognized Tax Benefits", "label": "Summary of Income Tax Contingencies [Table Text Block]", "documentation": "Tabular disclosure for tax position taken on unrecognized tax benefit." } } }, "auth_ref": [ "r227", "r1461", "r1462" ] }, "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfOperatingLossCarryforwardsTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Operating Loss Carryforwards", "label": "Summary of Operating Loss Carryforwards [Table Text Block]", "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r1465" ] }, "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfTaxCreditCarryforwardsTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Tax Credit Carryforwards", "label": "Summary of Tax Credit Carryforwards [Table Text Block]", "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances." } } }, "auth_ref": [ "r1465" ] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.clorox.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Valuation Allowance", "label": "Summary of Valuation Allowance [Table Text Block]", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r1464" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramLineItems", "presentation": [ "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program [Line Items]", "label": "Supplier Finance Program [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r449", "r451", "r452" ] }, "us-gaap_SupplierFinanceProgramObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationCurrent", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount due to suppliers", "label": "Supplier Finance Program, Obligation, Current", "documentation": "Amount of obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r451", "r452", "r453" ] }, "us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r452" ] }, "us-gaap_SupplierFinanceProgramPaymentTimingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramPaymentTimingPeriod", "presentation": [ "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier finance program, payment timing, period", "label": "Supplier Finance Program, Payment Timing, Period", "documentation": "Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r449" ] }, "us-gaap_SupplierFinanceProgramTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramTable", "presentation": [ "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAMDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program [Table]", "label": "Supplier Finance Program [Table]", "documentation": "Disclosure of information about supplier finance program." } } }, "auth_ref": [ "r449", "r451", "r452" ] }, "us-gaap_SupplierFinanceProgramTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramTextBlock", "presentation": [ "http://www.clorox.com/role/SUPPLYCHAINFINANCINGPROGRAM" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLY CHAIN FINANCING PROGRAM", "label": "Supplier Finance Program [Text Block]", "documentation": "The entire disclosure for supplier finance program." } } }, "auth_ref": [ "r447", "r448", "r449", "r450", "r1125" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1260" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": "clx_CarryforwardsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carryforwards", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r721" ] }, "clx_TaxCreditCarryforwardAmountNetOfValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "TaxCreditCarryforwardAmountNetOfValuationAllowance", "crdr": "debit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": "clx_CarryforwardsNetOfValuationAllowance", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carryforwards", "label": "Tax Credit Carryforward, Amount, Net Of Valuation Allowance", "documentation": "Tax Credit Carryforward, Amount, Net Of Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r721" ] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Line Items]", "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r721" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r721" ] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Table]", "label": "Tax Credit Carryforward [Table]", "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance." } } }, "auth_ref": [ "r721" ] }, "us-gaap_TaxCreditCarryforwardValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardValuationAllowance", "crdr": "credit", "calculation": { "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails": { "parentTag": "clx_TaxCreditCarryforwardAmountNetOfValuationAllowance", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofCarryforwardswithRelatedValuationAllowancesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation Allowances", "label": "Tax Credit Carryforward, Valuation Allowance", "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r1464" ] }, "clx_TotalCommodityPurchaseDerivativeContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "TotalCommodityPurchaseDerivativeContractsMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Commodity Purchase Derivative Contracts", "label": "Total Commodity Purchase Derivative Contracts [Member]", "documentation": "Total Commodity Purchase Derivative Contracts [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1252" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1259" ] }, "clx_TradeAndSalesPromotion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "TradeAndSalesPromotion", "crdr": "credit", "calculation": { "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and sales promotion costs", "label": "Trade And Sales Promotion", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for trade and sales promotion costs of the entity. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.clorox.com/role/GOODWILLTRADEMARKSANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofTrademarksandOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r84", "r1124", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1357", "r1358", "r1359", "r1360" ] }, "clx_TrademarksNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "TrademarksNet", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks, net", "label": "Trademarks, Net", "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite or finite period of benefit." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1280" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1282" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.clorox.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionDomain", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction [Domain]", "label": "Transaction [Domain]", "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r1105" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionTypeAxis", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Type [Axis]", "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r1105" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1283" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1284" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1284" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1282" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1282" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1285" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1283" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r71" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost (in shares)", "negatedPeriodStartLabel": "Beginning balance, treasury (in shares)", "negatedPeriodEndLabel": "Ending balance, treasury (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r71" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost: 6,539,654 and 6,921,439 shares as of June\u00a030, 2024 and 2023, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r71", "r72", "r141" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock purchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r24", "r138", "r191" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock purchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r24", "r71", "r191" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofAccrualforRestructuringandRelatedImplementationCostsDetails", "http://www.clorox.com/role/RESTRUCTURINGANDRELATEDCOSTSScheduleofTotalRestructuringandRelatedImplementationCostsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r461", "r462", "r467", "r468" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofNetSalesandPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]", "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement." } } }, "auth_ref": [ "r471", "r472", "r473", "r474" ] }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsOfForeignSubsidiaries", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undistributed earnings of foreign subsidiaries", "label": "Undistributed Earnings of Foreign Subsidiaries", "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile." } } }, "auth_ref": [ "r20", "r21", "r228", "r688" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1279" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unrecognized tax benefits at beginning of year", "periodEndLabel": "Unrecognized tax benefits at end of year", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r689", "r706", "r1157" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross decreases - current period tax positions", "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r708" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross decreases - tax positions in prior periods", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r707", "r1157" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r709", "r1157" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest and penalties related to uncertain tax positions", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r704", "r1157" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and penalties related to uncertain tax positions included in income tax expense, expense (net benefit)", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r704", "r1157" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross increases - current period tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r708", "r1157" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross increases - tax positions in prior periods", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r707", "r1157" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESScheduleofReconciliationofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Lapse of applicable statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r710" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r711", "r1157" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails", "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Minimum lease payments signed but not yet commenced", "label": "Unrecorded Unconditional Purchase Obligation", "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts." } } }, "auth_ref": [ "r472", "r1495" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "label": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "documentation": "Information by category of product and service for unrecorded unconditional purchase arrangement to acquire product or service or both." } } }, "auth_ref": [ "r471", "r472", "r473" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails": { "parentTag": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSScheduleofPurchaseObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, after Year Five", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": [ "r1374", "r1495" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationLineItems", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecorded Unconditional Purchase Obligation [Line Items]", "label": "Unrecorded Unconditional Purchase Obligation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r471", "r472", "r473" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationTable", "presentation": [ "http://www.clorox.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecorded Unconditional Purchase Obligation [Table]", "label": "Unrecorded Unconditional Purchase Obligation [Table]", "documentation": "Disclosure of information about unrecorded unconditional purchase obligation arrangement to purchase product and service. Includes, but is not limited to, information about asset pledged to secure payment and payment due in each of next five years and thereafter." } } }, "auth_ref": [ "r471", "r472", "r473" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationsDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESGUARANTEESANDCOMMITMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Purchase Obligations", "label": "Unrecorded Unconditional Purchase Obligations Disclosure [Table Text Block]", "documentation": "Tabular disclosure of unconditional purchase obligation not recognized as liability." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_UnusualOrInfrequentItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemAxis", "presentation": [ "http://www.clorox.com/role/CYBERATTACKNarrativeDetails", "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Axis]", "label": "Unusual or Infrequent Item, or Both [Axis]", "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r165" ] }, "us-gaap_UnusualOrInfrequentItemDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemDomain", "presentation": [ "http://www.clorox.com/role/CYBERATTACKNarrativeDetails", "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Domain]", "label": "Unusual or Infrequent Item, or Both [Domain]", "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r165" ] }, "us-gaap_UnusualOrInfrequentItemInsuranceProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemInsuranceProceeds", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/CYBERATTACKNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Insurance recoveries", "label": "Unusual or Infrequent Item, or Both, Insurance Proceeds", "documentation": "Amount of insurance proceeds for an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r165" ] }, "us-gaap_UnusualOrInfrequentItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemLineItems", "presentation": [ "http://www.clorox.com/role/CYBERATTACKNarrativeDetails", "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]", "label": "Unusual or Infrequent Item, or Both [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_UnusualOrInfrequentItemTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemTable", "presentation": [ "http://www.clorox.com/role/CYBERATTACKNarrativeDetails", "http://www.clorox.com/role/CYBERATTACKScheduleofRecognitionofCostsNetofInsuranceRecoveriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Table]", "label": "Unusual or Infrequent Item, or Both [Table]", "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r165" ] }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "presentation": [ "http://www.clorox.com/role/CYBERATTACK" ], "lang": { "en-us": { "role": { "terseLabel": "CYBERATTACK", "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]", "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r164" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r55", "r56", "r57", "r234", "r235", "r237", "r238" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofComponentsofLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r841", "r1171" ] }, "clx_VentureAgreement.TerminalObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "VentureAgreement.TerminalObligation", "crdr": "credit", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Venture agreement terminal obligation, fair value", "label": "Venture Agreement. Terminal Obligation", "documentation": "Venture Agreement. Terminal Obligation" } } }, "auth_ref": [] }, "clx_VentureAgreementOptionToExtendAgreementTermPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "VentureAgreementOptionToExtendAgreementTermPeriod", "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to extend agreement (in years)", "label": "Venture Agreement, Option To Extend Agreement Term Period", "documentation": "Venture Agreement, Option To Extend Agreement Term Period" } } }, "auth_ref": [] }, "clx_VentureAgreementTerminalObligationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "VentureAgreementTerminalObligationNet", "crdr": "credit", "calculation": { "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/OTHERLIABILITIESNarrativeDetails", "http://www.clorox.com/role/OTHERLIABILITIESScheduleofOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Venture Agreement terminal obligation, net", "verboseLabel": "Venture agreement terminal obligation, recognized", "label": "Venture Agreement, Terminal Obligation, Net", "documentation": "Venture Agreement, Terminal Obligation, Net" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1248" ] }, "clx_WalmartStoresIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "WalmartStoresIncMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Walmart Stores, Inc.", "label": "Walmart Stores, Inc. [Member]", "documentation": "Walmart Stores, Inc. and its affiliates [Member]" } } }, "auth_ref": [] }, "clx_WaterFiltrationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "WaterFiltrationMember", "presentation": [ "http://www.clorox.com/role/SEGMENTREPORTINGScheduleofConcentrationPercentageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Water Filtration", "label": "Water Filtration [Member]", "documentation": "Water Filtration [Member]" } } }, "auth_ref": [] }, "clx_WeightedAverageInterestRateOnNotesAndLoansPayable": { "xbrltype": "percentItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "WeightedAverageInterestRateOnNotesAndLoansPayable", "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate on notes and loans payable", "label": "Weighted Average Interest Rate On Notes And Loans Payable", "documentation": "Reflects the calculation as of the balance sheet date of average interest rate incurred during the reporting period weighted by the amount of short-term debt outstanding by type or by instrument during that time." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r328", "r336" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding (in thousands)", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.clorox.com/role/CONSOLIDATEDSTATEMENTSOFEARNINGS", "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r327", "r336" ] }, "clx_WeightedAverageRemainingLeaseTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.clorox.com/20240630", "localname": "WeightedAverageRemainingLeaseTermAbstract", "presentation": [ "http://www.clorox.com/role/LEASESScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term:", "label": "Weighted Average Remaining Lease Term [Abstract]", "documentation": "Weighted Average Remaining Lease Term" } } }, "auth_ref": [] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "calculation": { "http://www.clorox.com/role/DEBTNarrativeDetails": { "parentTag": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.clorox.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated amortization of losses on settlement of interest rate contracts and issuance costs associated with debt extinguished", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r162" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1246" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-16" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)(b)(c)", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220-20/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/460/tableOfContent" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(j)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-50" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-51" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-52" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-40/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-50/tableOfContent" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481999/410-20-25-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/410-30/tableOfContent" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482620/740-10-25-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481724/830-30-40-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1072": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1073": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1074": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1075": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1076": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1077": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1078": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1079": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1080": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r1081": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1083": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1084": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1085": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1086": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1088": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1089": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1090": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1092": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1093": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1094": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-3" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-14" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-16" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r1199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1242": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1243": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1244": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1245": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1246": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1293": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1294": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1295": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1296": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-8" }, "r1297": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1298": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-7" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 154 0000021076-24-000030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000021076-24-000030-xbrl.zip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

K=6/LE)8IQD@CE&J, ?TN*T+/6)9!-M.5_U M@M7NO?@B29QJ*+P53U,;P?=.UM,$S-^5IZF5HIYD[3E&RKVK7@1 ATL 4;G0 M.7"%/E,)NRQC7,?,1,RULV0OG:>IGL;;"'<@GB8NA714:F)-B9:\#02=[7+E M(0;NH@VP[06])IZF5@)OP-/41EH]\S0E .":41)U0@#"!^*,RR2XDEX#:>1V M6=%KX&DZ6F$=I-,S3Y,0UJQFXQ(&MI0G8EU$OU/2K'@P-&ZWLWX-/$W'*JJ+ M= ;@:3(^I^CQ!8]\F;E6BE@;%,Z2I2 EXRJJ!LIZ@3Q-QRJLJY1Z*#G_?./G M#S=H*V*(P"Q1NE3 R\"(MV5]YMQI;Q1%N+5]EL<0SBE,Z2#/L&0'6"[[-K>64*T+$[Y.Q*<@"*,24BXM,57M MKF\#*?RY\*17?;<1:VUNHW&"R6AR==?J0.HL&>".DCCZ L(03[,FW 3K?% Z MX35KL)+<*K]W;^"JU++^-8/K#1IIE [4:>(T_L!/ M'&-<@8$N M.1N6A";*#%W2>_9NUUE%/E>.4M+#Z.%NB-KZ$X+B$H%0C$+ JE M6?E-61(=!KE"8;C+FV0 MA[[FO7514(5XY0"Y9?9:%E NZ&?8\%Q;2E)$98$ MW[AE9X4@I6 M1\5(\#$0:2TCCK) <+Z"^BCTSA6%O8K;^_#7K+ONTJIX1;( ^@2+FQFZ1&DV M+Z[16YAM$H)2,QL<*P7!$MTBEA2Q22K"G6*)>683;;)2'AS@-:NQCM1ZN.3X M+#NOC3(&R3-QK%RDD[@3^Y0YVEMPH+/1B==O%O WDZ+U: M2QLM]& ESW#DW;4600E0]'7 *(,!1G#$,^-QR^7&):X0;&W*ET; 7@#M92=] MMB,L/$(9%1.9I8/G.H+Y;?8YS;Z/PHH"5CHJ4HZ9>"C7T3+7!'BI]5&!A6PY M^F0U&MCO&_L,O) J8JT8U#_ 4[)W:T0;W[L)J(H-Z@\"&;Y#?7<=[2J\DH K M;@M/@XL\,F8Q,-*48>1E<\E8&,0JO F129VT>7U:?Z)%_4!*;R/7?@\1F6-1 M2AV)40&(I+0DZ'&"PG-@P4I/O!_-=915SP>'X+QPP0EBH)QAN5M_@"4 M87,$=?2TW7"@@I![:.OW=CJ[GB*P]&DZ62-; PN" 4"DQ ($(E4N*4/+BM/A M792![Q2S5O#\#X Y _W7$?00T=]#BE[@(F5!!5%:% Z+XM%$X1&;M"R+[*/M MO:?T21F2AR*&.E;H!Y>$0>CG/J7%9QBG.2P)[G&%6]R61CP+_%S8>Z^+E>-W M_.TO:7HU@^NOHW Q2] '/5U'*#W2U]444B5ZNW6YS8IF^)[QK)MT2PB@6M MBFIO$-O;N;X\G#)/3=A7/)@[ M8JK[)07&R]@E6B.BPDGDM.Q:CGZ,C;M1V]9D0[B" 4V5LAC2 M:6U%5([OU^[G0TB;,] &H"IF=PX"&3Z]4TE1T[ZD/)P))!P]V$04%1B-4(V6 M[H4E3ALE(6-$8FM4N@VL^B>2/(-JOH5P:Y;A3&\PUKB]_/,S;J*!&Y%+>TL, M7*5DD;A@P_)C"6@D=T^M__,4_OMJ^OVG]1-7&EY_N%?P_7C#!NZ5!#_M)+4> MDC2?II,_-_DBI7 KHD$18R-&G31SXB//A*L002*0Z&M3,S\8_C7KLZLTA[^# M\OY'&-_$TFH071'\%[_ CTNJDPJ9"I*D,&B+EA'KLR-:">N"P(FG1AYY2 N'N<@+JU7QN'N1IS2)<.)JYW';8YPDR5E#%1* M/9SL'\3S-[&B:BHYN$0=F0U\M.>G$'^Z^#^8Q5+J\-MD?/M\_FZO[U">L[*+ M$._-X?&36Z7CVJ"LE$#;WSGD8C:#R=6JL>>;V_OO_ ZWY6]+6'?82E-0U/H#8HVFQJ.P2/'S8AHVQ3NU-ZM]8PS/WM"CA>QM2WQ(K#W4&/^> M9LM./).0EE.8]Z+(0Z.W M*;T;S5+ _WWC+GO! _-<$J&U)U*7 U!=KB5(IZ7PR5BZE=3>WR:ZW;#GJ?&^ MY7^PEKR6+[ 4Z(=)''T?Q1L8SZN[!-O/[N84/ ^WHV^ @UQ>C,>U_I M[><.]\X^)_:'[UNGV1^\777D"[6S)RYGFU+\]E.)/";SD1^G]Y.;;^LNW!]' M\T6#,_,6^VX9R-;#NY;;+;ZFV>J1 MI6GZ#6X D]J(]X\Q^#ZZ7RL[I7%/":2'K-O'$?C1&*>>^C*8?2-T[3H=EOGH M.3H;Y42R="\-87:3XH.QWO9B2VU&'MS"GM#E3I/I]A+LH]BV&/N#$?M= O8/ M])*U]+Q\>N@6L6H\?W<2V-.J<&B4[DF5A-(H;:?>I>]I/+V^ZY,]K]V_Y.FQ M!K>K9_2V)T_RO*0JTQ\L[7D]Q KN,JD++H@096%A,$3ZQ(D-B9'L58:8DE*F M22"]]^$O5@UUQ-'#Z[_T/3Y\NX;1K.!_BY']59KWX43N#O)2E=5,-@>3BP=B MHO6?RP\/\_0___7_4$L#!!0 ( ,2""%G;AL6#YC< )HZ 3 8VQX M+3(P,C0P-C,P7V)"DH3$*G2(B)-1$"I(D1% MI(F(5"4D @)*$0$!1044 6E&I D"H8,"(KV7!*67A!(&TG[#=_?=]X]]]YS= M/6?W@S_W\WDF]#'Z',!WR=3"%&!@8 !>0C\ '0?HFH1YWP4 M*RM $0 =H#)E@]@@,X8#C]L^0'FPW/@\%S@O\\/!WT2, 88&1@.?__WP<3" M=#A8F9F96-A8V=@.#W8.+@YV=DYV-C9.;DY.KB/08./@X>4^PG-X?OB0P]L/ M[X)^C["SL1_Y?SSH30 _.V#!^(")X03 R,_ Q,] ;P-@D*TL#/\9_V4R R,3 M,PLK9!(G%W1!%1]D/A,3(V0L"S/D&D,$]'^ F9]%X+B:$:N@[2VV$P%"9R-3 M/K#+7"AO%K[:3Y!5O_TPBH-31%1,7.+D*3EY!44-32UMG7.ZQA=-3,W,+2Y= ML[-W<'1RONY^Q^.NIY>W3V!0<$AHV*/'T4]C8N.>/8]/37N5GI'Y^DW6Q[Q/ M^06%GXN*OU545E77?*^M:VEM:^_H[/KY:V!P:'AD=&Q\ H>?__MO87%I>86X MM;VS2]H#]P\._6( F!C^:_R/?O%#?C%":\#,=N@7 V/HX07\S"S'U5@%C&S9 M;@4(GC@;R2YT(>5#>3.'C/I5@O#MA_V<(K(:N)/$0]?^X]G_/<>B_E]Y]G\X M]M]^30!'F!B@Q6/B!^ E?)Y0\6]ZOG?]!&=^:L;:\WVY_^FAC-) M8ZONG][D#]1\^O"1"UOQ>L>_O14]?*-I4:GJX@#F8UU5EF7X,\F@AZ:3SKSE MF*DB$)UAVUH<)$-N)^67^/=]='ONTD,1%>P<+SB%-7A$SND^*N#FZK)[[^# MVS]@ !:M[8 Q#KTCTFZ7CG@;F#\/8F6:7]DW6+]@@ V?Q@,]E>9 M=+@MH&U;K5>Q3AVE YX?UI?=DK+V;]Q%* H&!?"-$E"^M>LWB;0!PXFGLS]_ M9"?AK">4; :GW8<_O#B0FNL6XU!,+ISV'V@(;#54^DJ\GU5S';FJ8<"C<\

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

  •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�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®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end XML 155 clx-20240630_htm.xml IDEA: XBRL DOCUMENT 0000021076 2023-07-01 2024-06-30 0000021076 2023-12-29 0000021076 2024-07-23 0000021076 2024-04-01 2024-06-30 0000021076 clx:AngelaHiltMember 2023-07-01 2024-06-30 0000021076 clx:AngelaHiltMember 2024-04-01 2024-06-30 0000021076 clx:AngelaHiltMember 2024-06-30 0000021076 2022-07-01 2023-06-30 0000021076 2021-07-01 2022-06-30 0000021076 2024-06-30 0000021076 2023-06-30 0000021076 us-gaap:CommonStockMember 2021-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000021076 us-gaap:RetainedEarningsMember 2021-06-30 0000021076 us-gaap:TreasuryStockCommonMember 2021-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2021-06-30 0000021076 2021-06-30 0000021076 us-gaap:RetainedEarningsMember 2021-07-01 2022-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2022-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-06-30 0000021076 us-gaap:TreasuryStockCommonMember 2021-07-01 2022-06-30 0000021076 us-gaap:CommonStockMember 2022-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000021076 us-gaap:RetainedEarningsMember 2022-06-30 0000021076 us-gaap:TreasuryStockCommonMember 2022-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2022-06-30 0000021076 2022-06-30 0000021076 us-gaap:RetainedEarningsMember 2022-07-01 2023-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2022-07-01 2023-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2023-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-06-30 0000021076 us-gaap:TreasuryStockCommonMember 2022-07-01 2023-06-30 0000021076 us-gaap:CommonStockMember 2023-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000021076 us-gaap:RetainedEarningsMember 2023-06-30 0000021076 us-gaap:TreasuryStockCommonMember 2023-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2023-06-30 0000021076 us-gaap:RetainedEarningsMember 2023-07-01 2024-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2023-07-01 2024-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2024-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2024-06-30 0000021076 us-gaap:TreasuryStockCommonMember 2023-07-01 2024-06-30 0000021076 us-gaap:CommonStockMember 2024-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000021076 us-gaap:RetainedEarningsMember 2024-06-30 0000021076 us-gaap:TreasuryStockCommonMember 2024-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2024-06-30 0000021076 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-06-30 0000021076 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-06-30 0000021076 srt:MinimumMember us-gaap:LandImprovementsMember 2024-06-30 0000021076 srt:MaximumMember us-gaap:LandImprovementsMember 2024-06-30 0000021076 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-06-30 0000021076 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-06-30 0000021076 srt:MinimumMember us-gaap:ComputerEquipmentMember 2024-06-30 0000021076 srt:MaximumMember us-gaap:ComputerEquipmentMember 2024-06-30 0000021076 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0000021076 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0000021076 srt:MinimumMember 2024-06-30 0000021076 srt:MaximumMember 2024-06-30 0000021076 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember clx:ArgentinaBusinessMember 2024-03-20 0000021076 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember clx:ArgentinaBusinessMember 2024-01-01 2024-03-31 0000021076 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember clx:ArgentinaBusinessMember 2023-07-01 2024-06-30 0000021076 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember clx:ArgentinaBusinessMember 2022-07-01 2023-06-30 0000021076 clx:CyberattackMember 2023-07-01 2024-06-30 0000021076 clx:CyberattackMember 2024-04-01 2024-06-30 0000021076 us-gaap:CostOfSalesMember clx:CyberattackMember 2023-07-01 2024-06-30 0000021076 us-gaap:SellingGeneralAndAdministrativeExpensesMember clx:CyberattackMember 2023-07-01 2024-06-30 0000021076 clx:CostOfGoodsAndServicesSoldMember 2022-07-01 2023-06-30 0000021076 clx:CostOfGoodsAndServicesSoldMember 2023-07-01 2024-06-30 0000021076 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2024-06-30 0000021076 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2023-06-30 0000021076 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2023-06-30 0000021076 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2024-06-30 0000021076 clx:OtherIncomeExpenseNetMember 2022-07-01 2023-06-30 0000021076 clx:OtherIncomeExpenseNetMember 2023-07-01 2024-06-30 0000021076 clx:OtherIncomeExpenseNetMember us-gaap:EmployeeSeveranceMember 2023-07-01 2024-06-30 0000021076 clx:OtherIncomeExpenseNetMember us-gaap:EmployeeSeveranceMember 2022-07-01 2023-06-30 0000021076 clx:OtherIncomeExpenseNetMember clx:AssetImpairmentsMember 2023-07-01 2024-06-30 0000021076 clx:OtherIncomeExpenseNetMember clx:AssetImpairmentsMember 2022-07-01 2023-06-30 0000021076 us-gaap:EmployeeSeveranceMember 2023-06-30 0000021076 us-gaap:OtherRestructuringMember 2023-06-30 0000021076 us-gaap:EmployeeSeveranceMember 2023-07-01 2024-06-30 0000021076 us-gaap:OtherRestructuringMember 2023-07-01 2024-06-30 0000021076 us-gaap:EmployeeSeveranceMember 2024-06-30 0000021076 us-gaap:OtherRestructuringMember 2024-06-30 0000021076 us-gaap:LandAndLandImprovementsMember 2024-06-30 0000021076 us-gaap:LandAndLandImprovementsMember 2023-06-30 0000021076 us-gaap:BuildingMember 2024-06-30 0000021076 us-gaap:BuildingMember 2023-06-30 0000021076 us-gaap:MachineryAndEquipmentMember 2024-06-30 0000021076 us-gaap:MachineryAndEquipmentMember 2023-06-30 0000021076 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0000021076 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-06-30 0000021076 us-gaap:ComputerEquipmentMember 2024-06-30 0000021076 us-gaap:ComputerEquipmentMember 2023-06-30 0000021076 us-gaap:ConstructionInProgressMember 2024-06-30 0000021076 us-gaap:ConstructionInProgressMember 2023-06-30 0000021076 us-gaap:PropertyPlantAndEquipmentMember 2023-07-01 2024-06-30 0000021076 us-gaap:PropertyPlantAndEquipmentMember 2022-07-01 2023-06-30 0000021076 us-gaap:PropertyPlantAndEquipmentMember 2021-07-01 2022-06-30 0000021076 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-07-01 2024-06-30 0000021076 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-07-01 2023-06-30 0000021076 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2022-06-30 0000021076 us-gaap:CorporateNonSegmentMember 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2022-07-01 2023-06-30 0000021076 us-gaap:CorporateNonSegmentMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2023-06-30 0000021076 us-gaap:CorporateNonSegmentMember 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2023-07-01 2024-06-30 0000021076 us-gaap:CorporateNonSegmentMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2024-06-30 0000021076 us-gaap:CorporateNonSegmentMember 2024-06-30 0000021076 us-gaap:TrademarksMember 2024-06-30 0000021076 us-gaap:TrademarksMember 2023-06-30 0000021076 us-gaap:TrademarksMember 2024-06-30 0000021076 us-gaap:TrademarksMember 2023-06-30 0000021076 us-gaap:OtherIntangibleAssetsMember 2024-06-30 0000021076 us-gaap:OtherIntangibleAssetsMember 2023-06-30 0000021076 clx:BetterHealthVitaminsMineralsAndSupplementsReportingUnitMember 2022-07-01 2023-06-30 0000021076 clx:InternationalReportingUnitMember 2022-07-01 2023-06-30 0000021076 us-gaap:TrademarksMember 2022-07-01 2023-06-30 0000021076 us-gaap:TrademarksMember 2023-03-31 0000021076 clx:BetterHealthVitaminsMineralsAndSupplementsReportingUnitMember 2023-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.10400DueOctober2027Member 2024-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.10400DueOctober2027Member 2023-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.90500DueMay2028Member 2024-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.90500DueMay2028Member 2023-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures440500DueMay2029Member 2024-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures440500DueMay2029Member 2023-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures180500DueMay2030Member 2024-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures180500DueMay2030Member 2023-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures460600DueMay2032Member 2024-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures460600DueMay2032Member 2023-06-30 0000021076 us-gaap:SeniorNotesMember 2022-05-31 0000021076 clx:SeniorLongTermNotesAndDebentures440500DueMay2029Member us-gaap:SeniorNotesMember 2022-05-31 0000021076 clx:SeniorLongTermNotesAndDebentures460600DueMay2032Member us-gaap:SeniorNotesMember 2022-05-31 0000021076 clx:SeniorLongTermNotesAndDebentures3.05600DueSeptember2022Member us-gaap:SeniorNotesMember 2022-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.50500DueDecember2024Member us-gaap:SeniorNotesMember 2022-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.50500DueDecember2024Member us-gaap:SeniorNotesMember 2022-06-01 2022-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.80300DueNovember2021Member us-gaap:SeniorNotesMember 2021-11-01 2021-11-30 0000021076 clx:SeniorLongTermNotesAndDebentures3.80300DueNovember2021Member us-gaap:SeniorNotesMember 2021-11-30 0000021076 us-gaap:RevolvingCreditFacilityMember clx:RevolvingCreditAgreementMaturesMarch2027Member 2023-06-30 0000021076 us-gaap:RevolvingCreditFacilityMember clx:RevolvingCreditAgreementMaturesMarch2027Member 2024-06-30 0000021076 us-gaap:RevolvingCreditFacilityMember 2024-06-30 0000021076 us-gaap:RevolvingCreditFacilityMember 2023-06-30 0000021076 us-gaap:ForeignLineOfCreditMember 2024-06-30 0000021076 us-gaap:ForeignLineOfCreditMember 2023-06-30 0000021076 clx:ForeignAndOtherCreditLinesMember 2024-06-30 0000021076 clx:ForeignAndOtherCreditLinesMember 2023-06-30 0000021076 clx:GladBusinessMember 2023-06-30 0000021076 clx:GladBusinessMember 2024-06-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2023-07-01 2024-06-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2024-06-30 0000021076 clx:SoybeanOilFuturesMember 2024-06-30 0000021076 clx:JetFuelSwapsMember 2024-06-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2023-06-30 0000021076 clx:SoybeanOilFuturesMember 2023-06-30 0000021076 clx:JetFuelSwapsMember 2023-06-30 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2024-06-30 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2023-06-30 0000021076 us-gaap:InterestRateContractMember 2021-07-01 2022-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures440500DueMay2029Member us-gaap:InterestRateContractMember 2021-07-01 2022-06-30 0000021076 clx:SeniorLongTermNotesAndDebentures460600DueMay2032Member us-gaap:InterestRateContractMember 2021-07-01 2022-06-30 0000021076 us-gaap:CommodityContractMember 2023-07-01 2024-06-30 0000021076 us-gaap:CommodityContractMember 2022-07-01 2023-06-30 0000021076 us-gaap:CommodityContractMember 2021-07-01 2022-06-30 0000021076 us-gaap:ForeignExchangeContractMember 2023-07-01 2024-06-30 0000021076 us-gaap:ForeignExchangeContractMember 2022-07-01 2023-06-30 0000021076 us-gaap:ForeignExchangeContractMember 2021-07-01 2022-06-30 0000021076 us-gaap:InterestRateContractMember 2023-07-01 2024-06-30 0000021076 us-gaap:InterestRateContractMember 2022-07-01 2023-06-30 0000021076 us-gaap:CommodityContractMember 2024-06-30 0000021076 us-gaap:CommodityContractMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-07-01 2024-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableMember 2024-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2024-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2024-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2024-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2023-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2024-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2023-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2023-07-01 2024-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2024-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2023-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingLeaseLeaseNotYetCommencedMember 2024-06-30 0000021076 us-gaap:FinancingLeaseLeaseNotYetCommencedMember 2024-06-30 0000021076 2023-12-14 2023-12-14 0000021076 2023-12-14 0000021076 2022-05-25 2022-05-25 0000021076 2022-05-25 0000021076 us-gaap:SubsequentEventMember 2024-07-30 2024-07-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2022-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2022-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2022-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2023-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2023-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2023-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2024-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 2024-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 2024-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-30 0000021076 2021-11-01 2021-11-30 0000021076 us-gaap:CostOfSalesMember 2023-07-01 2024-06-30 0000021076 us-gaap:CostOfSalesMember 2022-07-01 2023-06-30 0000021076 us-gaap:CostOfSalesMember 2021-07-01 2022-06-30 0000021076 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2022-06-30 0000021076 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2022-06-30 0000021076 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000021076 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000021076 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000021076 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000021076 us-gaap:EmployeeStockOptionMember 2023-07-01 2024-06-30 0000021076 us-gaap:EmployeeStockOptionMember 2024-06-30 0000021076 srt:MinimumMember us-gaap:RestrictedStockMember 2023-07-01 2024-06-30 0000021076 srt:MaximumMember us-gaap:RestrictedStockMember 2023-07-01 2024-06-30 0000021076 us-gaap:RestrictedStockMember 2024-06-30 0000021076 us-gaap:RestrictedStockMember 2023-07-01 2024-06-30 0000021076 us-gaap:RestrictedStockMember 2022-07-01 2023-06-30 0000021076 us-gaap:RestrictedStockMember 2021-07-01 2022-06-30 0000021076 us-gaap:RestrictedStockMember 2023-06-30 0000021076 us-gaap:PerformanceSharesMember 2023-07-01 2024-06-30 0000021076 us-gaap:PerformanceSharesMember 2024-06-30 0000021076 us-gaap:PerformanceSharesMember 2022-07-01 2023-06-30 0000021076 us-gaap:PerformanceSharesMember 2021-07-01 2022-06-30 0000021076 us-gaap:PerformanceSharesMember 2023-06-30 0000021076 clx:DeferredStockUnitsForNonemployeeDirectorsMember 2024-06-30 0000021076 clx:DeferredStockUnitsForNonemployeeDirectorsMember 2023-07-01 2024-06-30 0000021076 us-gaap:DomesticCountryMember us-gaap:CapitalLossCarryforwardMember 2024-06-30 0000021076 us-gaap:DomesticCountryMember clx:SubjectToExpirationMember 2024-06-30 0000021076 us-gaap:DomesticCountryMember clx:NotSubjectToExpirationMember 2024-06-30 0000021076 us-gaap:ForeignCountryMember clx:SubjectToExpirationMember 2024-06-30 0000021076 us-gaap:ForeignCountryMember clx:NotSubjectToExpirationMember 2024-06-30 0000021076 us-gaap:DomesticCountryMember clx:IncomeTaxCreditCarryforwardMember clx:SubjectToExpirationMember 2024-06-30 0000021076 us-gaap:DomesticCountryMember clx:IncomeTaxCreditCarryforwardMember clx:NotSubjectToExpirationMember 2024-06-30 0000021076 us-gaap:ForeignCountryMember clx:IncomeTaxCreditCarryforwardMember clx:SubjectToExpirationMember 2024-06-30 0000021076 us-gaap:ForeignCountryMember clx:IncomeTaxCreditCarryforwardMember clx:NotSubjectToExpirationMember 2024-06-30 0000021076 clx:IncomeTaxCreditCarryforwardMember 2024-06-30 0000021076 us-gaap:DomesticCountryMember us-gaap:CapitalLossCarryforwardMember 2023-06-30 0000021076 us-gaap:DomesticCountryMember clx:SubjectToExpirationMember 2023-06-30 0000021076 us-gaap:DomesticCountryMember clx:NotSubjectToExpirationMember 2023-06-30 0000021076 us-gaap:ForeignCountryMember clx:SubjectToExpirationMember 2023-06-30 0000021076 us-gaap:ForeignCountryMember clx:NotSubjectToExpirationMember 2023-06-30 0000021076 us-gaap:DomesticCountryMember clx:IncomeTaxCreditCarryforwardMember clx:SubjectToExpirationMember 2023-06-30 0000021076 us-gaap:DomesticCountryMember clx:IncomeTaxCreditCarryforwardMember clx:NotSubjectToExpirationMember 2023-06-30 0000021076 us-gaap:ForeignCountryMember clx:IncomeTaxCreditCarryforwardMember clx:NotSubjectToExpirationMember 2023-06-30 0000021076 clx:IncomeTaxCreditCarryforwardMember 2023-06-30 0000021076 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-01 2024-06-30 0000021076 country:US 2023-07-01 2024-06-30 0000021076 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2023-06-30 0000021076 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2022-06-30 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-06-30 0000021076 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2023-06-30 0000021076 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2022-06-30 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-01 2024-06-30 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2023-06-30 0000021076 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2023-07-01 2024-06-30 0000021076 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2022-07-01 2023-06-30 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2024-06-30 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2022-06-30 0000021076 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2021-07-01 2022-06-30 0000021076 us-gaap:FixedIncomeFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 clx:DefinedBenefitPlanBondsFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 clx:DefinedBenefitPlanBondsFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 clx:DefinedBenefitPlanShortTermInvestmentMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 clx:DefinedBenefitPlanShortTermInvestmentMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 clx:DefinedBenefitPlanOtherMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 clx:DefinedBenefitPlanOtherMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0000021076 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0000021076 clx:DomesticDefinedContributionPlanMember 2023-07-01 2024-06-30 0000021076 clx:DomesticDefinedContributionPlanMember 2022-07-01 2023-06-30 0000021076 clx:DomesticDefinedContributionPlanMember 2021-07-01 2022-06-30 0000021076 clx:InternationalDefinedContributionPlanMember 2023-07-01 2024-06-30 0000021076 clx:InternationalDefinedContributionPlanMember 2022-07-01 2023-06-30 0000021076 clx:InternationalDefinedContributionPlanMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember 2021-07-01 2022-06-30 0000021076 us-gaap:CorporateNonSegmentMember 2021-07-01 2022-06-30 0000021076 clx:OperatingSegmentsAndCorporateNonSegmentMember 2023-07-01 2024-06-30 0000021076 clx:OperatingSegmentsAndCorporateNonSegmentMember 2022-07-01 2023-06-30 0000021076 clx:OperatingSegmentsAndCorporateNonSegmentMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:CyberattackMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:CyberattackMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:CyberattackMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:CyberattackMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2023-07-01 2024-06-30 0000021076 us-gaap:CorporateNonSegmentMember clx:CyberattackMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 clx:CyberattackMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2022-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2022-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2022-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2022-07-01 2024-06-30 0000021076 us-gaap:CorporateNonSegmentMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 us-gaap:CorporateNonSegmentMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 us-gaap:CorporateNonSegmentMember clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2024-06-30 0000021076 clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 clx:RestructuringAndRelatedCostsBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2024-06-30 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CleaningMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CleaningMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CleaningMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsAndWrapsMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsAndWrapsMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsAndWrapsMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:GrillingMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:GrillingMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:GrillingMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2021-07-01 2022-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2023-07-01 2024-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2022-07-01 2023-06-30 0000021076 us-gaap:OperatingSegmentsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2021-07-01 2022-06-30 0000021076 us-gaap:CorporateNonSegmentMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 us-gaap:CorporateNonSegmentMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 us-gaap:CorporateNonSegmentMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2022-06-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2022-06-30 0000021076 clx:CleaningMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 clx:CleaningMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 clx:CleaningMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2022-06-30 0000021076 clx:BagsAndWrapsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 clx:BagsAndWrapsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 clx:BagsAndWrapsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2022-06-30 0000021076 clx:FoodProductsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 clx:FoodProductsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 clx:FoodProductsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2022-06-30 0000021076 clx:CatLitterMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2024-06-30 0000021076 clx:CatLitterMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2023-06-30 0000021076 clx:CatLitterMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2022-06-30 0000021076 country:US 2023-07-01 2024-06-30 0000021076 us-gaap:NonUsMember 2023-07-01 2024-06-30 0000021076 country:US 2022-07-01 2023-06-30 0000021076 us-gaap:NonUsMember 2022-07-01 2023-06-30 0000021076 country:US 2021-07-01 2022-06-30 0000021076 us-gaap:NonUsMember 2021-07-01 2022-06-30 0000021076 country:US 2024-06-30 0000021076 us-gaap:NonUsMember 2024-06-30 0000021076 country:US 2023-06-30 0000021076 us-gaap:NonUsMember 2023-06-30 iso4217:USD shares iso4217:USD shares pure clx:hedgingInstrument clx:productionPlant clx:option clx:segment false 2024 FY 0000021076 P273D http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://www.clorox.com/20240630#OtherExpenseIncomeNet http://www.clorox.com/20240630#OtherExpenseIncomeNet http://fasb.org/us-gaap/2024#AssetImpairmentCharges http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 10-K true 2024-06-30 --06-30 false 1-07151 THE CLOROX COMPANY DE 31-0595760 1221 Broadway Oakland CA 94612-1888 (510) 271-7000 Common Stock – $1.00 par value CLX NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 17700000000 123861545 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders (the “Proxy Statement”), to be filed within 120 days after June 30, 2024, are incorporated by reference into Part III, Items 10 through 14 of this Annual Report on Form 10-K.</span> false false false <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2024, Angela Hilt, EVP – Chief Legal Officer, entered into a trading plan designed to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for sales of up to 1,733 shares of the Company's common stock. The plan also provides for the sale of up to 25% of shares of restricted stock units and performance units vesting during the duration of the plan, excluding any shares withheld by the Company to satisfy income tax withholding remittance obligations. Ms. Hilt’s plan begins on September 6, 2024 and ends June 6, 2025 or when all of the shares have been sold.</span></div> June 7, 2024 Angela Hilt EVP – Chief Legal Officer true 1733 June 6, 2025 true 42 Ernst & Young LLP San Francisco, California Ernst & Young LLP San Francisco, California 7093000000 7389000000 7107000000 4045000000 4481000000 4562000000 3048000000 2908000000 2545000000 1167000000 1183000000 954000000 832000000 734000000 709000000 126000000 138000000 132000000 -240000000 0 0 -171000000 0 0 0 445000000 0 90000000 90000000 106000000 24000000 80000000 37000000 398000000 238000000 607000000 106000000 77000000 136000000 292000000 161000000 471000000 12000000 12000000 9000000 280000000 149000000 462000000 2.26 1.21 3.75 2.25 1.20 3.73 124174000 123589000 123113000 124804000 124181000 123906000 292000000 161000000 471000000 206000000 3000000 -45000000 -14000000 -22000000 100000000 -146000000 -5000000 -12000000 338000000 -14000000 67000000 630000000 147000000 538000000 12000000 12000000 9000000 618000000 135000000 529000000 202000000 367000000 695000000 688000000 637000000 696000000 88000000 77000000 1622000000 1828000000 1315000000 1345000000 360000000 346000000 1228000000 1252000000 538000000 543000000 143000000 169000000 545000000 462000000 5751000000 5945000000 4000000 50000000 84000000 87000000 1486000000 1659000000 0 121000000 1574000000 1917000000 2481000000 2477000000 334000000 310000000 848000000 825000000 22000000 28000000 5259000000 5557000000 1.00 1.00 5000000 5000000 0 0 0 0 0 0 1.00 1.00 750000000 750000000 130741461 130741461 124201807 123820022 131000000 131000000 1288000000 1245000000 250000000 583000000 6539654 6921439 1186000000 1246000000 -155000000 -493000000 328000000 220000000 164000000 168000000 492000000 388000000 5751000000 5945000000 131000000 130741000 1186000000 1036000000 -1396000000 7961000 -546000000 181000000 592000000 462000000 9000000 471000000 67000000 67000000 3.48 430000000 430000000 17000000 17000000 52000000 52000000 -36000000 -20000000 75000000 524000 19000000 25000000 152000 25000000 131000000 130741000 1202000000 1048000000 -1346000000 7589000 -479000000 173000000 729000000 149000000 12000000 161000000 -14000000 -14000000 4.72 588000000 588000000 17000000 17000000 73000000 73000000 -30000000 -26000000 100000000 668000 44000000 131000000 130741000 1245000000 583000000 -1246000000 6921000 -493000000 168000000 388000000 280000000 12000000 292000000 338000000 338000000 4.80 600000000 600000000 16000000 16000000 74000000 74000000 -31000000 -13000000 60000000 381000 16000000 131000000 130741000 1288000000 250000000 -1186000000 6540000 -155000000 164000000 492000000 292000000 161000000 471000000 235000000 236000000 224000000 74000000 73000000 52000000 -100000000 -149000000 5000000 -238000000 0 0 -171000000 0 0 0 445000000 0 0 0 114000000 -26000000 -38000000 -19000000 34000000 13000000 84000000 -55000000 -58000000 18000000 -25000000 1000000 -16000000 -140000000 157000000 -47000000 0 1000000 -1000000 -147000000 152000000 35000000 695000000 1158000000 786000000 212000000 228000000 251000000 17000000 0 0 -20000000 -5000000 -22000000 -175000000 -223000000 -229000000 -45000000 -188000000 237000000 0 0 1405000000 0 0 1085000000 0 0 25000000 595000000 583000000 571000000 16000000 15000000 15000000 1000000 33000000 5000000 -655000000 -753000000 -689000000 -26000000 0 -6000000 -161000000 182000000 -138000000 368000000 186000000 324000000 207000000 368000000 186000000 102000000 99000000 89000000 347000000 73000000 100000000 16000000 16000000 14000000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Operations and Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is principally engaged in the production, marketing and sale of consumer products through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. The consolidated financial statements include the statements of the Company and its wholly owned and controlled subsidiaries. All significant intercompany transactions and accounts were eliminated in consolidation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to reach opinions as to estimates and assumptions that affect reported amounts and related disclosures. Specific areas requiring the application of management’s estimates and judgments include, among others, assumptions pertaining to accruals for consumer and trade promotion programs, future cash flows associated with impairment testing of goodwill and other long-lived assets, uncertain tax positions, tax valuation allowances, the valuation of the Venture Agreement terminal obligation, stock-based compensation, retirement income plans and legal, environmental and insurance matters. Actual results could materially differ from estimates and assumptions made.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid interest-bearing accounts, time deposits held by financial institutions and money market funds with an initial maturity at purchase of 90 days or less. The fair value of cash and cash equivalents approximates the carrying amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash position includes amounts held by foreign subsidiaries and, as a result, the repatriation of certain cash balances from some of the Company’s foreign subsidiaries could result in additional withholding tax costs in certain foreign jurisdictions. However, these cash balances are generally available without legal restriction to fund local business operations. In addition, a portion of the Company’s cash balance is held in U.S. dollars by foreign subsidiaries whose functional currency is their local currency. Such U.S. dollar balances are reported on the foreign subsidiaries’ books in their functional currency, and the impact on such balances from foreign currency exchange rate differences is recorded in Other (income) expense, net. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, 2023, 2022 and 2021, the Company had $5, $1, $3 and $5 of restricted cash, respectively, which was included in Prepaid expenses and other current assets and Other assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories using both the First-In, First-Out (FIFO) and the Last-In, First-Out (LIFO) methods. The FIFO inventory is stated at the lower of cost or net realizable value, which includes any costs to sell or dispose. In addition, appropriate consideration is given to obsolescence, excessive inventory levels, product deterioration and other factors in evaluating net realizable value. The LIFO inventory is stated at the lower of cost or market.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Finite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment and finite-lived intangible assets are stated at cost. Depreciation and amortization expense are primarily calculated by the straight-line method using the estimated useful lives or lives determined by reference to the related lease contract in the case of leasehold improvements. The table below provides estimated useful lives of property, plant and equipment by asset classification.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are amortized over their estimated useful lives, which range from 7 to 30 years. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be fully recoverable. The risk of impairment is initially assessed based on an estimate of the undiscounted cash flows at the lowest level for which identifiable cash flows exist. Impairment occurs when the carrying value of the asset (or asset group) exceeds the estimated future undiscounted cash flows generated by the asset (or asset group). When impairment is indicated, an impairment charge is recorded for the difference between the carrying value of the asset (or asset group) and its estimated fair market value. Depending on the asset, estimated fair market value may be determined either by use of a discounted cash flow model or by reference to estimated selling values of assets in similar condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capitalization of Software Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain qualifying costs incurred in the acquisition and development of software for internal use, including the costs of the software, materials, consultants, interest and payroll and payroll-related costs for employees during the application development stage. Internal and external costs incurred during the preliminary project stage and post implementation-operation stage, mainly training and maintenance costs, are expensed as incurred. Once the application is substantially complete and ready for its intended use, qualifying costs are amortized on a straight-line basis over the software’s estimated useful life. Capitalized internal use software is included in Property, plant and equipment. Capitalized software as a service is included in Prepaid expenses and other current assets or Other assets and is amortized using the straight-line method over the term of the hosting arrangement which is typically no greater than 10 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment Review of Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its goodwill, trademarks with indefinite lives and other indefinite-lived intangible assets annually for impairment in the fiscal fourth quarter unless there are indications during a different interim period that these assets may have become impaired.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to goodwill, the Company has the option to first assess qualitative factors, such as the maturity and stability of the reporting unit, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other reporting unit specific operating results, microeconomic and macroeconomic factors, as well as new events and circumstances impacting the operations at the reporting unit level. The Company operates through strategic business units (SBUs) that are organized into the Company's operating segments. Reporting units for goodwill impairment testing purposes were identified as the Company's individual operating segments. If the result of a qualitative test indicates that it is more likely than not that a reporting unit is impaired, a quantitative test is performed. In the quantitative test, the Company compares the estimated fair value of the reporting unit to its carrying value. If the estimated fair value of any reporting unit is less than its carrying value, an impairment charge is recorded for the difference between the carrying value and the fair value of the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value of a reporting unit as part of its quantitative test, the Company uses the discounted cash flow (DCF) method under the income approach, as it believes that this approach is the most reliable indicator of the fair value of its businesses and the fair value of its future earnings and cash flows. Under this approach, which requires significant judgments, the Company estimates the future cash flows of each reporting unit and discounts these cash flows at a rate of return that reflects their relative risk. The cash flows used in the DCF method are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced, and the broader business strategy for the long term. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates, </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commodity prices, foreign exchange rates, inflation and a terminal growth rate. Changes in such estimates or the application of alternative assumptions could produce different results.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For trademarks and other intangible assets with indefinite lives, the Company has the option to first assess qualitative factors, such as the maturity and stability of the trademark or other intangible asset, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other specific operating results, as well as new events and circumstances impacting the significant inputs used to determine the fair value of the intangible asset. If the result of a qualitative test indicates that it is more likely than not that the asset is impaired, a quantitative test is performed. When a quantitative test is performed, the estimated fair value of an asset is compared to its carrying value. If the carrying value of such asset exceeds its estimated fair value, an impairment charge is recorded for the difference between the carrying value and the estimated fair value. The Company uses the DCF method under the relief from royalty income approach to estimate the fair value of its trademarks and other intangible assets with indefinite lives. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows, as well as the appropriate discount and foreign exchange rates applied to those cash flows to determine fair value. Changes in such estimates or the use of alternative assumptions could produce different results. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration and other facts and circumstances. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date and initial direct costs incurred by the Company and excludes any lease incentives received from the lessor. The Company reviews ROU assets for impairment consistent with the approach applied for its other long-lived assets. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. The lease term may include an option to extend or terminate the lease when it is reasonably certain that the Company will exercise that option as of the commencement date of the lease, and is reviewed in subsequent periods if a triggering event occurs. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date based on the lease term and the currency of the lease on a collateralized basis. Variable lease payments are the portion of lease payments that are not fixed over the lease term. Variable lease payments are expensed as incurred, and include certain non-lease components, such as maintenance and other services provided by the lessor, and other charges included in the lease, as applicable. The Company elected to combine lease and non-lease components as a single lease component and to exclude short-term leases, defined as leases with an initial term of 12 months or less, from its consolidated balance sheet.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs restructuring costs in connection with workforce reductions; consolidation or closure of a facility; sale or termination of a line of business; and other actions. Such costs include employee termination benefits (one-time arrangements and benefits attributable to prior service), termination of contractual obligations, noncash asset charges and other direct incremental costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee termination liabilities once they are both probable and estimable for severance provided under the Company’s existing severance policy. Employee termination liabilities outside of the Company’s existing severance policy are recognized at the time relevant employees are notified, unless the employees will be retained to render service beyond a minimum retention period for transition purposes, in which case the liability is recognized ratably over the future service period. Other costs associated with a restructuring plan or exit or disposal activities, such as consulting and professional fees, facility exit costs, employee relocation, outplacement costs, accelerated depreciation or asset impairments associated with a restructuring plan, are recognized in the period in which the liability is incurred or the asset is impaired.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants various nonqualified stock-based compensation awards to eligible employees, including stock options, restricted stock awards and performance shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock options, the Company estimates the fair value of each award on the date of grant using the Black-Scholes valuation model, which requires management to make estimates regarding expected option life, stock price volatility and other assumptions. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The Company estimates stock option forfeitures based on historical data for each employee grouping. The total number of stock options expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For restricted stock awards, the fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. Forfeitures are estimated based on historical data. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance shares provide for the issuance of common stock to certain managerial staff and executive management if the Company achieves specified performance targets. The number of shares issued is dependent upon the achievement of specified performance targets. The performance period is three years and the payout determination is made at the end of the three-year performance period. Performance shares receive dividends earned during the vesting period upon vesting. The fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. The total amount of compensation expense recognized reflects estimated forfeiture rates and management’s assessment of the probability that performance goals will be achieved. A cumulative adjustment is recognized to compensation expense in the current period to reflect any changes in the probability of achievement of performance goals.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for stock-based payment arrangements (excess tax benefits) are classified as operating cash inflows.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its retirement income and retirement health care plans using actuarial methods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These methods use an attribution approach that generally spreads “plan events” over the service lives or expected lifetime (for frozen plans) of plan participants. Examples of plan events are plan amendments and changes in actuarial assumptions such as the expected return on plan assets, discount rate, rate of compensation increase and certain employee-related factors, such as retirement age and mortality. The principle underlying the attribution approach is that employees render service over their employment period on a relatively “smooth” basis and, therefore, the statements of earnings effects of retirement income and retirement health care plans are recognized in the same pattern. One of the principal assumptions used in the net periodic benefit cost calculation is the expected return on plan assets. The expected return on plan assets may result in recognized expense or income that differs from the actual returns of those plan assets in any given year. Over time, however, the goal is for the expected long-term returns to approximate the actual returns and, therefore, the expectation is that the pattern of income and expense recognition should closely match the pattern of the services provided by the participants. The Company uses a market-related value method for calculating plan assets for purposes of determining the amortization of actuarial gains and losses. The differences between actual and expected returns are recognized in the net periodic benefit cost calculation over the average remaining service period or expected lifetime (for frozen plans) of the plan participants using the corridor approach. Under this approach, only actuarial gains (losses) that exceed 5% of the greater of the projected benefit obligation or the market-related value of assets are amortized to the Company’s net periodic benefit cost. In developing its expected return on plan assets, the Company considers the long-term actual returns relative to the mix of investments that comprise its plan assets and also develops estimates of future investment returns by considering external sources.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes an actuarial-based obligation at the onset of disability for certain benefits provided to individuals after employment, but before retirement, that includes medical, dental, vision, life and other benefits.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in certain environmental remediation and ongoing compliance activities. Accruals for environmental matters are recorded on a site-by-site basis when it is probable that a liability has been incurred and based upon a reasonable estimate of the liability. The Company’s accruals reflect the anticipated participation of other potentially responsible parties in those instances where it is probable that such parties are legally responsible and financially capable of paying their respective shares of the relevant costs. These accruals are adjusted periodically as assessment and remediation efforts progress or as additional technical or legal information becomes available. Actual costs to be incurred at identified sites in future periods may vary from the estimates, given the inherent uncertainties in evaluating environmental conditions. The accrual for environmental matters is included in Accounts payable and accrued liabilities and Other liabilities in the Company’s consolidated balance sheets on an undiscounted basis due to uncertainty regarding the timing of future payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is primarily generated from the sale of finished product to customers. Revenue is recognized at the point in time when performance obligations under the terms of customer contracts are satisfied, which is </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when ownership, risks and rewards transfer, and can be on the date of shipment or the date of receipt by the customer, depending upon the particular customer arrangement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Shipping and handling activities are accounted for as contract fulfillment costs and included within Cost of products sold. After the completion of the performance obligation, there is an unconditional right to consideration as outlined in the contract. A right is considered unconditional if nothing other than the passage of time is required before payment of that consideration is due. The Company typically collects its customer receivables within two months. All performance obligations under the terms of contracts with customers have an original duration of one year or less.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has trade promotion programs, which primarily include shelf price reductions, in-store merchandising and consumer coupons. The costs of such activities, defined as variable consideration under Accounting Standards Codification 606, “Revenue from Contracts with Customers,” are netted against sales and recorded when the related sales take place. Accruals for trade promotion programs are established based on the Company’s best estimate of the amounts necessary to settle existing and future obligations for products sold as of the balance sheet date. Amounts accrued for trade promotions are based on various factors such as contractual terms and sales volumes, and also incorporate estimates that include customer participation rates, the rate at which customers will achieve program performance criteria, product availability and historical consumer redemption rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides an allowance for doubtful accounts based on its historical experience and ongoing assessment of its customers’ credit risk and aging. Customer receivables are presented net of an allowance for doubtful accounts of $5 and $3 as of June 30, 2024 and 2023, respectively. Receivables, net, include non-customer receivables of $39 and $14 as of June 30, 2024 and 2023, respectively, and related allowance of $3 as of both June 30, 2024 and 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold represents the costs directly related to the manufacture and distribution of the Company’s products and primarily includes raw materials, packaging, contract manufacturing fees, shipping and handling, warehousing, package design, depreciation, amortization, direct and indirect labor and operating costs for the Company’s manufacturing and distribution facilities, including salary, benefit costs and incentive compensation, and royalties and other charges related to the Company’s Glad Venture Agreement (See Note 11).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with developing and designing new packaging, including design, artwork, films and labeling, are expensed as incurred and included within Cost of products sold. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and administrative expenses represent costs incurred by the Company in generating revenues and managing the business and include market research, commissions and certain administrative expenses. Administrative expenses include salary, benefits, incentive compensation, professional fees and services and other operating costs (such as software and licensing costs) associated with the Company’s non-manufacturing, non-research and development operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising and Research and Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses advertising and research and development costs in the period incurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax basis. Management reviews the Company’s deferred tax assets to determine whether their value can be realized based upon available evidence. A valuation allowance is established when management believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s income tax provision in the period of change. In addition to valuation allowances, the Company provides for uncertain tax positions when such tax positions do not meet certain recognition thresholds or measurement standards. Amounts for uncertain tax positions are adjusted in quarters when new information becomes available or when positions are effectively settled.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion and determined that none of the undistributed earnings of its foreign subsidiaries are indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the tax on global intangible low-taxed income (GILTI) as a period cost.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Transactions and Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Local currencies are the functional currencies for substantially all of the Company’s foreign operations. When the transactional currency is different than the functional currency, transaction gains and losses are included as a component of Other (income) expense, net. In addition, certain assets and liabilities denominated in currencies other than a foreign subsidiary’s functional currency are reported on the subsidiary’s books in its functional currency, with the impact from exchange rate differences recorded in Other (income) expense, net. Assets and liabilities of foreign operations are translated into U.S. dollars using the exchange rates in effect at the balance sheet date, while income and expenses are translated at the respective average monthly exchange rates during the year.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses on foreign currency translations are reported as a component of Other comprehensive (loss) income. The income tax effect of currency translation adjustments is recorded as a component of deferred taxes with an offset to Other comprehensive (loss) income where appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, since it has experienced cumulative inflation of approximately 100 percent or more over a three-year period. As a result, beginning July 1, 2018, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina (collectively, “Clorox Argentina”). Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities for Clorox Argentina prior to divestment were recognized in Other (income) expense, net in the consolidated statements of earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s use of derivative instruments, principally exchange-traded futures and options contracts, and over-the counter swaps and forward contracts, is limited to non-trading purposes and is designed to partially manage exposure to changes in commodity prices, foreign currencies and interest rates. The Company’s contracts are hedges for transactions with notional amounts and periods consistent with the related exposures and do not constitute investments independent of these exposures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value (i.e., gains or losses) of a derivative instrument are recorded as either assets or liabilities in the consolidated balance sheets with an offset to Net earnings or Other comprehensive (loss) income depending on whether, for accounting purposes, it has been designated and qualifies as an accounting hedge and, if so, on the type of hedging relationship. The criteria used to determine if hedge accounting treatment is appropriate are: (a) formal designation and documentation of the hedging relationship, the risk management objective and hedging strategy at hedge inception; (b) eligibility of hedged items, transactions and corresponding hedging instrument; and (c) effectiveness of the hedging relationship both at inception of the hedge and on an ongoing basis in achieving the hedging objectives. For those derivative instruments designated and qualifying as hedging instruments, the Company must designate the hedging instrument either as a fair value hedge or as a cash flow hedge. The Company designates its commodity futures, options and swaps contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges. During the fiscal years ended June 30, 2024, 2023 and 2022, the Company had no hedging instruments designated as fair value hedges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments designated and qualifying as cash flow hedges, gains or losses are reported as a component of Other comprehensive (loss) income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. From time to time, the Company may have contracts not designated as hedges for accounting purposes, for which it recognizes changes in the fair value in the consolidated statements of earnings in the current period. Cash flows from hedging activities are classified as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASU No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the consolidated financial statements, results of operations, or cash flows.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Operations and Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is principally engaged in the production, marketing and sale of consumer products through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. The consolidated financial statements include the statements of the Company and its wholly owned and controlled subsidiaries. All significant intercompany transactions and accounts were eliminated in consolidation.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to reach opinions as to estimates and assumptions that affect reported amounts and related disclosures. Specific areas requiring the application of management’s estimates and judgments include, among others, assumptions pertaining to accruals for consumer and trade promotion programs, future cash flows associated with impairment testing of goodwill and other long-lived assets, uncertain tax positions, tax valuation allowances, the valuation of the Venture Agreement terminal obligation, stock-based compensation, retirement income plans and legal, environmental and insurance matters. Actual results could materially differ from estimates and assumptions made.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid interest-bearing accounts, time deposits held by financial institutions and money market funds with an initial maturity at purchase of 90 days or less. The fair value of cash and cash equivalents approximates the carrying amount.</span></div>The Company’s cash position includes amounts held by foreign subsidiaries and, as a result, the repatriation of certain cash balances from some of the Company’s foreign subsidiaries could result in additional withholding tax costs in certain foreign jurisdictions. However, these cash balances are generally available without legal restriction to fund local business operations. In addition, a portion of the Company’s cash balance is held in U.S. dollars by foreign subsidiaries whose functional currency is their local currency. Such U.S. dollar balances are reported on the foreign subsidiaries’ books in their functional currency, and the impact on such balances from foreign currency exchange rate differences is recorded in Other (income) expense, net. 5000000 5000000 1000000 1000000 3000000 3000000 5000000 5000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories using both the First-In, First-Out (FIFO) and the Last-In, First-Out (LIFO) methods. The FIFO inventory is stated at the lower of cost or net realizable value, which includes any costs to sell or dispose. In addition, appropriate consideration is given to obsolescence, excessive inventory levels, product deterioration and other factors in evaluating net realizable value. The LIFO inventory is stated at the lower of cost or market.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Finite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment and finite-lived intangible assets are stated at cost. Depreciation and amortization expense are primarily calculated by the straight-line method using the estimated useful lives or lives determined by reference to the related lease contract in the case of leasehold improvements. The table below provides estimated useful lives of property, plant and equipment by asset classification.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are amortized over their estimated useful lives, which range from 7 to 30 years. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be fully recoverable. The risk of impairment is initially assessed based on an estimate of the undiscounted cash flows at the lowest level for which identifiable cash flows exist. Impairment occurs when the carrying value of the asset (or asset group) exceeds the estimated future undiscounted cash flows generated by the asset (or asset group). When impairment is indicated, an impairment charge is recorded for the difference between the carrying value of the asset (or asset group) and its estimated fair market value. Depending on the asset, estimated fair market value may be determined either by use of a discounted cash flow model or by reference to estimated selling values of assets in similar condition.</span></div> The table below provides estimated useful lives of property, plant and equipment by asset classification.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of property, plant and equipment, net, consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,821)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,705)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table> P5Y P40Y P10Y P30Y P3Y P15Y P3Y P5Y P3Y P7Y P7Y P30Y <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capitalization of Software Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain qualifying costs incurred in the acquisition and development of software for internal use, including the costs of the software, materials, consultants, interest and payroll and payroll-related costs for employees during the application development stage. Internal and external costs incurred during the preliminary project stage and post implementation-operation stage, mainly training and maintenance costs, are expensed as incurred. Once the application is substantially complete and ready for its intended use, qualifying costs are amortized on a straight-line basis over the software’s estimated useful life. Capitalized internal use software is included in Property, plant and equipment. Capitalized software as a service is included in Prepaid expenses and other current assets or Other assets and is amortized using the straight-line method over the term of the hosting arrangement which is typically no greater than 10 years.</span></div> P10Y <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment Review of Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its goodwill, trademarks with indefinite lives and other indefinite-lived intangible assets annually for impairment in the fiscal fourth quarter unless there are indications during a different interim period that these assets may have become impaired.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to goodwill, the Company has the option to first assess qualitative factors, such as the maturity and stability of the reporting unit, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other reporting unit specific operating results, microeconomic and macroeconomic factors, as well as new events and circumstances impacting the operations at the reporting unit level. The Company operates through strategic business units (SBUs) that are organized into the Company's operating segments. Reporting units for goodwill impairment testing purposes were identified as the Company's individual operating segments. If the result of a qualitative test indicates that it is more likely than not that a reporting unit is impaired, a quantitative test is performed. In the quantitative test, the Company compares the estimated fair value of the reporting unit to its carrying value. If the estimated fair value of any reporting unit is less than its carrying value, an impairment charge is recorded for the difference between the carrying value and the fair value of the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value of a reporting unit as part of its quantitative test, the Company uses the discounted cash flow (DCF) method under the income approach, as it believes that this approach is the most reliable indicator of the fair value of its businesses and the fair value of its future earnings and cash flows. Under this approach, which requires significant judgments, the Company estimates the future cash flows of each reporting unit and discounts these cash flows at a rate of return that reflects their relative risk. The cash flows used in the DCF method are consistent with those the Company uses in its internal planning, which gives consideration to actual business trends experienced, and the broader business strategy for the long term. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates, </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commodity prices, foreign exchange rates, inflation and a terminal growth rate. Changes in such estimates or the application of alternative assumptions could produce different results.</span></div>For trademarks and other intangible assets with indefinite lives, the Company has the option to first assess qualitative factors, such as the maturity and stability of the trademark or other intangible asset, the magnitude of the excess fair value over carrying value from a previous period’s impairment testing, other specific operating results, as well as new events and circumstances impacting the significant inputs used to determine the fair value of the intangible asset. If the result of a qualitative test indicates that it is more likely than not that the asset is impaired, a quantitative test is performed. When a quantitative test is performed, the estimated fair value of an asset is compared to its carrying value. If the carrying value of such asset exceeds its estimated fair value, an impairment charge is recorded for the difference between the carrying value and the estimated fair value. The Company uses the DCF method under the relief from royalty income approach to estimate the fair value of its trademarks and other intangible assets with indefinite lives. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows, as well as the appropriate discount and foreign exchange rates applied to those cash flows to determine fair value. Changes in such estimates or the use of alternative assumptions could produce different results. <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration and other facts and circumstances. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date and initial direct costs incurred by the Company and excludes any lease incentives received from the lessor. The Company reviews ROU assets for impairment consistent with the approach applied for its other long-lived assets. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. The lease term may include an option to extend or terminate the lease when it is reasonably certain that the Company will exercise that option as of the commencement date of the lease, and is reviewed in subsequent periods if a triggering event occurs. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date based on the lease term and the currency of the lease on a collateralized basis. Variable lease payments are the portion of lease payments that are not fixed over the lease term. Variable lease payments are expensed as incurred, and include certain non-lease components, such as maintenance and other services provided by the lessor, and other charges included in the lease, as applicable. The Company elected to combine lease and non-lease components as a single lease component and to exclude short-term leases, defined as leases with an initial term of 12 months or less, from its consolidated balance sheet.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs restructuring costs in connection with workforce reductions; consolidation or closure of a facility; sale or termination of a line of business; and other actions. Such costs include employee termination benefits (one-time arrangements and benefits attributable to prior service), termination of contractual obligations, noncash asset charges and other direct incremental costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee termination liabilities once they are both probable and estimable for severance provided under the Company’s existing severance policy. Employee termination liabilities outside of the Company’s existing severance policy are recognized at the time relevant employees are notified, unless the employees will be retained to render service beyond a minimum retention period for transition purposes, in which case the liability is recognized ratably over the future service period. Other costs associated with a restructuring plan or exit or disposal activities, such as consulting and professional fees, facility exit costs, employee relocation, outplacement costs, accelerated depreciation or asset impairments associated with a restructuring plan, are recognized in the period in which the liability is incurred or the asset is impaired.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants various nonqualified stock-based compensation awards to eligible employees, including stock options, restricted stock awards and performance shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock options, the Company estimates the fair value of each award on the date of grant using the Black-Scholes valuation model, which requires management to make estimates regarding expected option life, stock price volatility and other assumptions. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The Company estimates stock option forfeitures based on historical data for each employee grouping. The total number of stock options expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For restricted stock awards, the fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. Forfeitures are estimated based on historical data. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Changes to the actual and estimated forfeitures will result in a cumulative adjustment in the period of change. Compensation expense is recorded by amortizing the grant date fair values on a straight-line basis over the requisite service period, adjusted for estimated forfeitures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance shares provide for the issuance of common stock to certain managerial staff and executive management if the Company achieves specified performance targets. The number of shares issued is dependent upon the achievement of specified performance targets. The performance period is three years and the payout determination is made at the end of the three-year performance period. Performance shares receive dividends earned during the vesting period upon vesting. The fair value of each grant issued is estimated on the date of grant based on the current market price of the stock. The total amount of compensation expense recognized reflects estimated forfeiture rates and management’s assessment of the probability that performance goals will be achieved. A cumulative adjustment is recognized to compensation expense in the current period to reflect any changes in the probability of achievement of performance goals.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for stock-based payment arrangements (excess tax benefits) are classified as operating cash inflows.</span></div> P3Y P3Y <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its retirement income and retirement health care plans using actuarial methods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These methods use an attribution approach that generally spreads “plan events” over the service lives or expected lifetime (for frozen plans) of plan participants. Examples of plan events are plan amendments and changes in actuarial assumptions such as the expected return on plan assets, discount rate, rate of compensation increase and certain employee-related factors, such as retirement age and mortality. The principle underlying the attribution approach is that employees render service over their employment period on a relatively “smooth” basis and, therefore, the statements of earnings effects of retirement income and retirement health care plans are recognized in the same pattern. One of the principal assumptions used in the net periodic benefit cost calculation is the expected return on plan assets. The expected return on plan assets may result in recognized expense or income that differs from the actual returns of those plan assets in any given year. Over time, however, the goal is for the expected long-term returns to approximate the actual returns and, therefore, the expectation is that the pattern of income and expense recognition should closely match the pattern of the services provided by the participants. The Company uses a market-related value method for calculating plan assets for purposes of determining the amortization of actuarial gains and losses. The differences between actual and expected returns are recognized in the net periodic benefit cost calculation over the average remaining service period or expected lifetime (for frozen plans) of the plan participants using the corridor approach. Under this approach, only actuarial gains (losses) that exceed 5% of the greater of the projected benefit obligation or the market-related value of assets are amortized to the Company’s net periodic benefit cost. In developing its expected return on plan assets, the Company considers the long-term actual returns relative to the mix of investments that comprise its plan assets and also develops estimates of future investment returns by considering external sources.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes an actuarial-based obligation at the onset of disability for certain benefits provided to individuals after employment, but before retirement, that includes medical, dental, vision, life and other benefits.</span></div> 0.05 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in certain environmental remediation and ongoing compliance activities. Accruals for environmental matters are recorded on a site-by-site basis when it is probable that a liability has been incurred and based upon a reasonable estimate of the liability. The Company’s accruals reflect the anticipated participation of other potentially responsible parties in those instances where it is probable that such parties are legally responsible and financially capable of paying their respective shares of the relevant costs. These accruals are adjusted periodically as assessment and remediation efforts progress or as additional technical or legal information becomes available. Actual costs to be incurred at identified sites in future periods may vary from the estimates, given the inherent uncertainties in evaluating environmental conditions. The accrual for environmental matters is included in Accounts payable and accrued liabilities and Other liabilities in the Company’s consolidated balance sheets on an undiscounted basis due to uncertainty regarding the timing of future payments.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is primarily generated from the sale of finished product to customers. Revenue is recognized at the point in time when performance obligations under the terms of customer contracts are satisfied, which is </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when ownership, risks and rewards transfer, and can be on the date of shipment or the date of receipt by the customer, depending upon the particular customer arrangement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Shipping and handling activities are accounted for as contract fulfillment costs and included within Cost of products sold. After the completion of the performance obligation, there is an unconditional right to consideration as outlined in the contract. A right is considered unconditional if nothing other than the passage of time is required before payment of that consideration is due. The Company typically collects its customer receivables within two months. All performance obligations under the terms of contracts with customers have an original duration of one year or less.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has trade promotion programs, which primarily include shelf price reductions, in-store merchandising and consumer coupons. The costs of such activities, defined as variable consideration under Accounting Standards Codification 606, “Revenue from Contracts with Customers,” are netted against sales and recorded when the related sales take place. Accruals for trade promotion programs are established based on the Company’s best estimate of the amounts necessary to settle existing and future obligations for products sold as of the balance sheet date. Amounts accrued for trade promotions are based on various factors such as contractual terms and sales volumes, and also incorporate estimates that include customer participation rates, the rate at which customers will achieve program performance criteria, product availability and historical consumer redemption rates.</span></div>The Company provides an allowance for doubtful accounts based on its historical experience and ongoing assessment of its customers’ credit risk and aging.<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold represents the costs directly related to the manufacture and distribution of the Company’s products and primarily includes raw materials, packaging, contract manufacturing fees, shipping and handling, warehousing, package design, depreciation, amortization, direct and indirect labor and operating costs for the Company’s manufacturing and distribution facilities, including salary, benefit costs and incentive compensation, and royalties and other charges related to the Company’s Glad Venture Agreement (See Note 11).</span></div>Costs associated with developing and designing new packaging, including design, artwork, films and labeling, are expensed as incurred and included within Cost of products sold. one year or less 5000000 3000000 39000000 14000000 3000000 3000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and administrative expenses represent costs incurred by the Company in generating revenues and managing the business and include market research, commissions and certain administrative expenses. Administrative expenses include salary, benefits, incentive compensation, professional fees and services and other operating costs (such as software and licensing costs) associated with the Company’s non-manufacturing, non-research and development operations.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising and Research and Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses advertising and research and development costs in the period incurred.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax basis. Management reviews the Company’s deferred tax assets to determine whether their value can be realized based upon available evidence. A valuation allowance is established when management believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s income tax provision in the period of change. In addition to valuation allowances, the Company provides for uncertain tax positions when such tax positions do not meet certain recognition thresholds or measurement standards. Amounts for uncertain tax positions are adjusted in quarters when new information becomes available or when positions are effectively settled.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion and determined that none of the undistributed earnings of its foreign subsidiaries are indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the tax on global intangible low-taxed income (GILTI) as a period cost.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Transactions and Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Local currencies are the functional currencies for substantially all of the Company’s foreign operations. When the transactional currency is different than the functional currency, transaction gains and losses are included as a component of Other (income) expense, net. In addition, certain assets and liabilities denominated in currencies other than a foreign subsidiary’s functional currency are reported on the subsidiary’s books in its functional currency, with the impact from exchange rate differences recorded in Other (income) expense, net. Assets and liabilities of foreign operations are translated into U.S. dollars using the exchange rates in effect at the balance sheet date, while income and expenses are translated at the respective average monthly exchange rates during the year.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses on foreign currency translations are reported as a component of Other comprehensive (loss) income. The income tax effect of currency translation adjustments is recorded as a component of deferred taxes with an offset to Other comprehensive (loss) income where appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, since it has experienced cumulative inflation of approximately 100 percent or more over a three-year period. As a result, beginning July 1, 2018, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina (collectively, “Clorox Argentina”). Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities for Clorox Argentina prior to divestment were recognized in Other (income) expense, net in the consolidated statements of earnings.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s use of derivative instruments, principally exchange-traded futures and options contracts, and over-the counter swaps and forward contracts, is limited to non-trading purposes and is designed to partially manage exposure to changes in commodity prices, foreign currencies and interest rates. The Company’s contracts are hedges for transactions with notional amounts and periods consistent with the related exposures and do not constitute investments independent of these exposures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value (i.e., gains or losses) of a derivative instrument are recorded as either assets or liabilities in the consolidated balance sheets with an offset to Net earnings or Other comprehensive (loss) income depending on whether, for accounting purposes, it has been designated and qualifies as an accounting hedge and, if so, on the type of hedging relationship. The criteria used to determine if hedge accounting treatment is appropriate are: (a) formal designation and documentation of the hedging relationship, the risk management objective and hedging strategy at hedge inception; (b) eligibility of hedged items, transactions and corresponding hedging instrument; and (c) effectiveness of the hedging relationship both at inception of the hedge and on an ongoing basis in achieving the hedging objectives. For those derivative instruments designated and qualifying as hedging instruments, the Company must designate the hedging instrument either as a fair value hedge or as a cash flow hedge. The Company designates its commodity futures, options and swaps contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges. During the fiscal years ended June 30, 2024, 2023 and 2022, the Company had no hedging instruments designated as fair value hedges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments designated and qualifying as cash flow hedges, gains or losses are reported as a component of Other comprehensive (loss) income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. From time to time, the Company may have contracts not designated as hedges for accounting purposes, for which it recognizes changes in the fair value in the consolidated statements of earnings in the current period. Cash flows from hedging activities are classified as operating activities in the consolidated statements of cash flows.</span></div> 0 0 0 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASU No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the consolidated financial statements, results of operations, or cash flows.</span></div> DIVESTITURE OF ARGENTINA BUSINESS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2024, the Company completed the sale of its Argentina business, which consisted of two production plants in Argentina as well as the rights to the Company’s brands in Argentina, Uruguay and Paraguay, to Apex Capital and an investment group. The transaction is in support of the Company’s IGNITE strategy and the commitment to evolve the Company’s portfolio to increase focus on its core business to drive more consistent, profitable growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was executed pursuant to a stock purchase agreement, which covered all the outstanding stock of the Clorox Argentina S.A. and Clorox Uruguay S.A. As a result of the transaction, the Company recorded a pre-tax loss of $240 during the third quarter of fiscal year 2024, primarily due to the one-time noncash impact of the release of the cumulative translation adjustment losses of $223 related to these entities that had previously been recorded in Accumulated other comprehensive net (loss) income. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major classes of assets and liabilities of the Argentina business divested as of March 20, 2024 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:127%">Divestiture</span></div></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Working capital, net</span></div></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">31 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Property, plant and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">16 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(3)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets divested</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">65 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill corresponding to the International reportable segment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales of the Argentina business, which includes the financial results up to March 20, 2024, the date of sale, for fiscal years ended:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Net sales</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">123 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">172 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The divestiture of the Company’s Argentina business does not meet the criteria to be reported as discontinued operations in the consolidated financial statements as the Company’s decision to divest this business did not represent a strategic shift that will have a major effect on the Company’s operations and financial results.</span></div> 2 -240000000 -223000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major classes of assets and liabilities of the Argentina business divested as of March 20, 2024 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:127%">Divestiture</span></div></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Working capital, net</span></div></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">31 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Property, plant and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">16 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(3)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets divested</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">65 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill corresponding to the International reportable segment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales of the Argentina business, which includes the financial results up to March 20, 2024, the date of sale, for fiscal years ended:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Net sales</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">123 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">172 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 31000000 18000000 16000000 3000000 3000000 65000000 123000000 172000000 CYBERATTACK<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its Information Technology (IT) systems. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the quarter ended September 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impacts of these system disruptions included order processing delays and significant product outages, resulting in a negative impact on net sales and earnings. The Company has since transitioned back to automated order processing. The Company experienced lessening operational impacts in the second quarter and has since returned to normalized operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> incremental costs, net of insurance recoveries, of approx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">imately $29 in fiscal year 2024 as a result of the cyberattack. The Company recognized insurance recoveries of $30 in the fourth quarter of fiscal year 2024. The following table summarizes the recognition of costs, net of insurance recoveries, as reflected in the consolidated statements of earnings and comprehensive income for the fiscal year ended June 30:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Costs of products sold</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Selling and administrative expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">29 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs incurred relate primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs incurred from the resulting disruption to the Company’s business operations. The Company does not expect to incur significant costs related to the cyberattack in future periods. The timing of recognizing further insurance recoveries may differ from the timing of recognizing the associated expenses.</span></div> 29000000 30000000 The following table summarizes the recognition of costs, net of insurance recoveries, as reflected in the consolidated statements of earnings and comprehensive income for the fiscal year ended June 30:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Costs of products sold</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Selling and administrative expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">29 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 17000000 12000000 29000000 SUPPLY CHAIN FINANCING PROGRAM<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier by selling the Company’s payables to the financial institution. Participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets, cash flows or liquidity. The Company has not pledged any assets as security or provided guarantees under the SCF program.</span></div>All outstanding amounts related to suppliers participating in the SCF program are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets and the associated June 30, 2024 and 2023, the amount due to suppliers participating in the SCF program and included in <span style="-sec-ix-hidden:f-493"><span style="-sec-ix-hidden:f-494">Accounts payable and accrued liabilities</span></span> was $205 and $220, respectively. P120D 205000000 220000000 RESTRUCTURING AND RELATED COSTS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first quarter of fiscal year 2023, the Company recognized costs related to a plan that involves streamlining its operating model to meet its objectives of driving growth and productivity. The streamlined operating model is expected to enhance the Company’s ability to respond more quickly to changing consumer behaviors and innovate faster. The implementation of this new model was completed in fiscal year 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $32 and $60 of costs in fiscal year 2024 and 2023, respectively. Costs incurred are expected to be settled primarily in cash.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model plan as reflected in the consolidated statements of earnings and comprehensive income for the fiscal years ended June 30 were:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-501"><span style="-sec-ix-hidden:f-502">Costs of products sold</span></span></span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(3)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-505"><span style="-sec-ix-hidden:f-506">Selling and administrative expenses</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-509"><span style="-sec-ix-hidden:f-510">Research and development</span></span></span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Other (income) expense, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-513"><span style="-sec-ix-hidden:f-514">Employee-related costs</span></span></span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">10 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">52 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Total Other (income) expense, net:</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">16 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">52 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Total, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">32 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">60 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily include severance and other termination benefits calculated based on salary levels, prior service and statutory requirements. Other costs primarily include consulting fees incurred for the organizational design and implementation of the streamlined operating model, related processes and other professional fees incurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, decide to pursue additional restructuring-related initiatives that involve costs in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the accrual for the streamlined operating model restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets as follows for the fiscal years ended June 30:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:127%">Employee-Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Accrual Balance as of June 30, 2023</span></div></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">23 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">5 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">28 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Charges</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Cash payments</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(25)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(13)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(38)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">8 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">11 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">19 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 32000000 60000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model plan as reflected in the consolidated statements of earnings and comprehensive income for the fiscal years ended June 30 were:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-501"><span style="-sec-ix-hidden:f-502">Costs of products sold</span></span></span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(3)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-505"><span style="-sec-ix-hidden:f-506">Selling and administrative expenses</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-509"><span style="-sec-ix-hidden:f-510">Research and development</span></span></span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Other (income) expense, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%"><span style="-sec-ix-hidden:f-513"><span style="-sec-ix-hidden:f-514">Employee-related costs</span></span></span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">10 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">52 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Total Other (income) expense, net:</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">16 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">52 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Total, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">32 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">60 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 -3000000 16000000 12000000 0 -1000000 10000000 52000000 6000000 0 16000000 52000000 32000000 60000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the accrual for the streamlined operating model restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the consolidated balance sheets as follows for the fiscal years ended June 30:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:127%">Employee-Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Accrual Balance as of June 30, 2023</span></div></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">23 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">5 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">28 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Charges</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Cash payments</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(25)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(13)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">(38)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">8 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">11 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">19 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 23000000 5000000 28000000 10000000 19000000 29000000 25000000 13000000 38000000 8000000 11000000 19000000 INVENTORIES, NET<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and packaging</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current inventories, net</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Non-current inventories, net is recorded in Other assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LIFO method was used to value approximately 36% of inventories as of June 30, 2024 and 2023, respectively. The carrying values for all other inventories are determined on the FIFO method. The effect on earnings of the liquidation of LIFO layers was insignificant for each of the fiscal years ended June 30, 2024, 2023 and 2022.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and packaging</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current inventories, net</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Non-current inventories, net is recorded in Other assets.</span></div> 556000000 595000000 172000000 182000000 9000000 8000000 98000000 87000000 639000000 698000000 2000000 2000000 637000000 696000000 0.36 0.36 PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of property, plant and equipment, net, consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,821)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,705)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Depreciation and amortization expense related to property, plant and equipment, net, was $206, $206 and $193 in fiscal years 2024, 2023 and 2022, respectively, of which $10, $10 and $8 were related to amortization of capitalized software, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncash capital expenditures were $5, $9 and $6 for fiscal years, 2024, 2023 and 2022, respectively. There were no significant asset retirement obligations recorded and included in Buildings above for both fiscal years 2024 and 2023.</span></div> 174000000 168000000 816000000 810000000 2398000000 2355000000 413000000 400000000 137000000 131000000 198000000 186000000 4136000000 4050000000 2821000000 2705000000 1315000000 1345000000 206000000 206000000 193000000 10000000 10000000 8000000 5000000 9000000 6000000 0 0 GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by reportable segment and Corporate and Other for the fiscal years ended June 30, 2024 and 2023 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.045%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health and Wellness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency translation</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflects goodwill related to the Better Health VMS reporting unit, which was previously included within the Health and Wellness reportable segment prior to the segment changes effective in the fourth quarter of fiscal year 2023. </span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflects goodwill related to the divestiture of the Argentina business. See Note 2 for additional information. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of trademarks and other intangible assets for the fiscal years ended June 30, 2024 and 2023 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>amortization / Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>amortization / Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks with indefinite lives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks with finite lives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As of June 30, 2023 reflects changes to the useful lives of certain Better Health VMS and International indefinite-lived trademarks to finite-lived effective April 1, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense relating to the Company’s intangible assets was $29, $30 and $31 for the years ended June 30, 2024, 2023 and 2022, respectively. Estimated amortization expense for these intangible assets is $28, $28, $29, $28 and $11 for fiscal years 2025, 2026, 2027, 2028 and 2029, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2023 Impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of fiscal year 2023, management made a decision to narrow the focus on core brands and streamline investment levels in the Better Health VMS business. As a result, revisions were made to the internal financial projections and operational plans of the Better Health VMS business reflecting the Company’s current estimates regarding the future financial performance of these operations and macroeconomic factors. The revised estimated future cash flows reflected lower sales growth expectations and lower investment levels. These revisions were considered a triggering event requiring interim impairment assessments to be performed as part of the preparation of the quarterly financial statements on the global indefinite-lived trademarks, other long-term assets and the Better Health VMS reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the outcome of these assessments, the following pre-tax, noncash impairment charges were recorded during fiscal year 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impairment Charges</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Better Health VMS reporting unit</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International reporting unit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with recognizing these impairment charges, the Company recognized tax benefits related to the impairments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$83</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to the partial tax deductibility of these charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the estimated fair values of the global indefinite-lived trademarks related to the Better Health VMS business, the Company used the DCF method under the relief from royalty income approach. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows as well as the appropriate discount rates applied to those cash flows to determine fair value. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s a result of the interim impairment test, the Company concluded that the carrying value of the global indefinite-lived trademarks exceeded their estimated fair value, and recorded <span style="-sec-ix-hidden:f-664">impairment charges</span> of $139. In addition, the useful lives of the impaired trademarks, with a remaining net carrying value of $28 as of March 31, 2023, were changed from indefinite to finite beginning on April 1, 2023, which reflects the remaining expected useful lives of the trademarks based on the most recent financial and operational plans. The weighted-average estimated useful life of these trademarks is 20 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After adjusting the carrying values of the global indefinite-lived trademarks and concluding that the carrying amounts of the other long-lived assets were recoverable, the Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpany completed a quantitative impairment test for goodwill and recorded a goodwill impairment charge of $306 in the Better Health VMS reporting unit. To determine the fair value of the Better Health VMS reporting unit, the Company used a DCF method under the income approach. In accordance with this approach, the Company estimated the future cash flows of the Better Health VMS reporting unit and discounted these cash flows at a rate of return that reflects its relative risk. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates and a terminal growth rate. The decrease in projected cash flows due to the revisions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adversely impacted key assumptions used in determining the fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Better Health </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VMS reporting unit and assets contained therein, primarily projected net sales. There is no remaining goodwill associated with the impaired reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other significant impairments were identified as a result of the Company’s impairment reviews during fiscal years 2024, 2023 and 2022.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by reportable segment and Corporate and Other for the fiscal years ended June 30, 2024 and 2023 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.045%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health and Wellness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency translation</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Reflects goodwill related to the Better Health VMS reporting unit, which was previously included within the Health and Wellness reportable segment prior to the segment changes effective in the fourth quarter of fiscal year 2023. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span>Reflects goodwill related to the divestiture of the Argentina business. See Note 2 for additional information. 323000000 85000000 244000000 600000000 306000000 1558000000 0 0 0 0 306000000 306000000 323000000 85000000 244000000 600000000 0 1252000000 0 0 0 16000000 0 16000000 0 0 0 -8000000 0 -8000000 323000000 85000000 244000000 576000000 0 1228000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of trademarks and other intangible assets for the fiscal years ended June 30, 2024 and 2023 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>amortization / Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>amortization / Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying<br/>amount</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks with indefinite lives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks with finite lives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets with finite lives</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As of June 30, 2023 reflects changes to the useful lives of certain Better Health VMS and International indefinite-lived trademarks to finite-lived effective April 1, 2023.</span></div> 493000000 493000000 494000000 494000000 83000000 38000000 45000000 89000000 40000000 49000000 578000000 435000000 143000000 579000000 410000000 169000000 1154000000 473000000 681000000 1162000000 450000000 712000000 29000000 30000000 31000000 28000000 28000000 29000000 28000000 11000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the outcome of these assessments, the following pre-tax, noncash impairment charges were recorded during fiscal year 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impairment Charges</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Better Health VMS reporting unit</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International reporting unit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 306000000 0 306000000 127000000 12000000 139000000 433000000 12000000 445000000 -83000000 139000000 28000000 P20Y 306000000 0 ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefit costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and sales promotion costs</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefit costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and sales promotion costs</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 950000000 1021000000 190000000 262000000 156000000 157000000 25000000 23000000 165000000 196000000 1486000000 1659000000 DEBT<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term borrowings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes and loans payable are borrowings that mature in less than one year, primarily consisting of U.S. commercial paper issued by the Company and borrowings under the Company's revolving credit agreements. Notes and loans payable were $4 and $50 as of June 30, 2024 and 2023, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average interest rates incurred on average outstanding notes and loans payable during the fiscal years ended June 30, 2024, 2023 and 2022, including fees associated with the Company’s revolving credit agreements, were 4.77%, 3.48% and 0.54% respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-term borrowings</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, carried at face value net of unamortized discounts, premiums and debt issuance costs, included the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes and debentures:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10%, $400 due October 2027</span></div></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90%, $500 due May 2028</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%, $500 due May 2029</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80%, $500 due May 2030</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%, $600 due May 2032</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current maturities of long-term debt</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company issued $1,100 in senior notes, which included $500 of senior notes with an annual fixed interest rate of 4.40%, payable semi-annually in May and November, final maturity in May 2029 that carry an effective rate of 3.89% (May 2029 senior notes), which includes the impact from the settlement of interest rate contracts in May 2022, and $600 of senior notes with an annual fixed rate of 4.60%, payable semi-annually in May and November, final maturity in May 2032 that carry an effective rate of 3.25% (May 2032 senior notes), which includes the impact from the settlement of interest rate contracts in May 2022. The notes rank equally with all of the Company's existing senior indebtedness. Proceeds from the senior notes were used to redeem prior to maturity $600 of senior notes with an annual fixed interest rate of 3.05% due in September 2022 and $500 of senior notes with an annual fixed interest rate of 3.50% due in December 2024, which were redeemed in June 2022 prior to their maturities, and for general corporate purposes. In connection with the redemption prior to maturity of the $500 of senior notes due in December 2024, the Company recorded a loss on the early extinguishment of debt of $13, which is included in Interest expense in the Consolidated Statements of Earnings, representing the difference paid in cash between the redemption price and the carrying amount of the debt extinguished of $5 and the accelerated amortization of losses on settlement of interest rate contracts and issuance costs associated with the debt extinguished of $8.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, $300 of the Company’s senior notes with annual fixed interest rate of 3.80% became due and were repaid using commercial paper borrowings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average interest rates incurred on average outstanding long-term debt during the fiscal years ended June 30, 2024, 2023 and 2022, were 3.25%, 3.25% and 3.25%, respectively. The weighted average effective interest rates on long-term debt balances as of both June 30, 2024 and 2023 were 3.25% and 3.25%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt maturities as of June 30, 2024, were $0 in fiscal years 2025 through 2027, $900 in fiscal year 2028, $500 in fiscal year 2029 and $1,100 thereafter.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit arrangements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company maintained a $1,200 revolving credit agreement (the Credit Agreement) that matures in March 2027. There were no borrowings under the Credit Agreement as of June 30, 2024 and June 30, 2023, respectively, and the Company believes that borrowings under the Credit Agreement will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations consistent with the previous agreement, with which the Company was in compliance as of June 30, 2024 and June 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s borrowing capacity under the revolving credit agreements and other financing arrangements as of June 30 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign and other credit lines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the $34 of foreign and other credit lines as of June 30, 2024, $9 was outstanding and the remainder of $25 was available for borrowing. Of the $35 of foreign and other credit lines as of June 30, 2023, $5 was outstanding and the remainder of $30 was available for borrowing.</span></div> 4000000 50000000 0.0477 0.0348 0.0054 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, carried at face value net of unamortized discounts, premiums and debt issuance costs, included the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes and debentures:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10%, $400 due October 2027</span></div></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90%, $500 due May 2028</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%, $500 due May 2029</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80%, $500 due May 2030</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%, $600 due May 2032</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current maturities of long-term debt</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0310 400000000 399000000 398000000 0.0390 500000000 498000000 497000000 0.0440 500000000 495000000 495000000 0.0180 500000000 495000000 494000000 0.0460 600000000 594000000 593000000 2481000000 2477000000 0 0 2481000000 2477000000 1100000000000 500000000 0.0440 0.0389 600000000 0.0460 0.0325 600000000 0.0305 500000000 0.0350 500000000 -13000000 -5000000 8000000 300000000 0.0380 0.0325 0.0325 0.0325 0.0325 0.0325 0 0 0 900000000 500000000 1100000000 1200000000000 0 0 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s borrowing capacity under the revolving credit agreements and other financing arrangements as of June 30 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign and other credit lines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1200000000 1200000000 34000000 35000000 1234000000 1235000000 34000000 9000000 25000000 35000000 5000000 30000000 OTHER LIABILITIES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venture Agreement terminal obligation, net</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Environmental liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Venture Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an agreement with The Procter &amp; Gamble Company (P&amp;G) for the Company’s Glad bags and wraps business. In connection with this agreement, P&amp;G provides research and development (R&amp;D) support to the Glad business. As of June 30, 2024 and 2023, P&amp;G had a 20% interest in the venture. The Company pays a royalty to P&amp;G for its interest in the profits, losses and cash flows, as contractually defined, of the Glad business, which is included in Cost of products sold. In December 2017, the Company and P&amp;G extended the term of the agreement and the related R&amp;D support provided by P&amp;G. The term will expire in January 2026, unless the parties agree, on or prior to January 31, 2025, to further extend the term of the agreement for another seven years or agree to take some other relevant action. The agreement can be terminated under certain circumstances, including at P&amp;G’s option upon a change in control of the Company or, at either party’s option, upon the sale of the Glad business by the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon termination of the agreement, the Company is required to purchase P&amp;G’s 20% interest for cash at fair value as established by predetermined valuation procedures. As of June 30, 2024, the estimated fair value of P&amp;G’s interest in the venture was $531, of which $510 has been recognized and is reflected in Other liabilities as noted in the table above. The estimated fair value of P&amp;G's interest in the venture was $527 as of June 30, 2023. The difference between the estimated fair value and the amount recognized, and any future changes in the fair value of P&amp;G’s interest, is charged to Cost of products sold in accordance with the effective interest method over the remaining life of the agreement. Following termination, the Glad business will retain the exclusive core intellectual property licenses contributed by P&amp;G on a royalty-free basis for the licensed products marketed.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities consisted of the following as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venture Agreement terminal obligation, net</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Environmental liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 510000000 495000000 263000000 259000000 25000000 19000000 24000000 24000000 26000000 28000000 848000000 825000000 0.20 0.20 P7Y 0.20 531000000 510000000 527000000 FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Risk Management and Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use commodity futures, options and swap contracts to limit the impact of price volatility on a portion of its forecasted raw material requirements. These commodity derivatives may be exchange traded or over-the-counter contracts and generally have original contractual maturities of less than 2 years. Commodity purchase and option contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, the notional amount of commodity derivatives was $38, of which $27 related to soybean oil futures used for the food business and $11 related to jet fuel swaps used for the grilling business. As of June 30, 2023, the notional amount of commodity derivatives was $41, of which $29 related to soybean oil futures and $12 related to jet fuel swaps.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have original contractual maturities of less than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $29 and $51 as of June 30, 2024 and 2023, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have original contractual maturities of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held no interest rate contracts as of both June 30, 2024 and 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2022, the Company entered into an additional $650 of interest rate contracts. All contracts represented interest rate swap lock agreements to manage the exposure to interest rate volatility associated with future interest payments on forecasted debt issuance, and were terminated in May 2022 upon issuance of $1,100 in senior notes (See Note 10). These contracts resulted in a $114 gain recorded in Other comprehensive (loss) income, comprised of $25 attributable to the May 2029 senior notes and $89 attributable to the May 2032 senior notes, which is being amortized into Interest expense in the consolidated statements of earnings over the 7-year and 10-year term of the notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commodity, Foreign Exchange and Interest Rate Derivatives</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designates its commodity forward, futures and options contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory, and interest rate contracts for forecasted interest payments as cash flow hedges.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows during the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:59.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (losses) recognized in Other comprehensive (loss) income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of June 30, 2024 that is expected to be reclassified into Net earnings within the next twelve months is $8. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Risk Management and Derivative Contract Requirements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions, $0 and $1 contained such terms as of June 30, 2024 and 2023, respectively. As of both June 30, 2024 and 2023, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the Company's credit ratings, as assigned by Standard &amp; Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both June 30, 2024 and 2023, the Company and each of its counterparties had been assigned investment grade ratings by both Standard &amp; Poor’s and Moody’s.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s exchange-traded futures and options contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of June 30, 2024 and 2023, the Company maintained required cash margin balances related to exchange-traded futures and options contracts of $3 and $0, respectively, which are classified as Prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trust Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the consolidated balance sheets. The gains and losses on the trust assets are recorded in Other (income) expense, net in the consolidated statements of earnings. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, the balance of the trust assets related to the Company’s nonqualified deferred compensation plans increased by $25 as compared to June 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024 and 2023, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company's derivative instruments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase options contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the balance sheet classification and the fair values of the Company's other assets and liabilities for which disclosure of fair value is required:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:27.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value<br/>hierarchy<br/>level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest-bearing investments, including money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust assets for nonqualified deferred compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, impairment charges of $445 were record during fiscal year 2023, of which $306 and $139 related to goodwill and certain indefinite-lived trademarks, respectively. These adjustments were included as noncash charges in the consolidated statements of earnings. The nonrecurring fair values utilized included unobservable Level 3 inputs based on management’s best estimates and assumptions. See Note 8 for additional information.</span></div> P2Y 38000000 27000000 11000000 41000000 29000000 12000000 P2Y 29000000 51000000 P3Y 650000000 1100000000000 114000000 25000000 89000000 P7Y P10Y <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows during the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:59.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (losses) recognized in Other comprehensive (loss) income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -8000000 -6000000 17000000 0 0 1000000 0 0 89000000 -8000000 -6000000 107000000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -6000000 5000000 23000000 0 1000000 0 13000000 13000000 -9000000 7000000 19000000 14000000 8000000 0 1000000 3000000 0 25000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024 and 2023, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.</span></div> The following table provides information about the balance sheet classification and the fair values of the Company's derivative instruments:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase options contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the balance sheet classification and the fair values of the Company's other assets and liabilities for which disclosure of fair value is required:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:27.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair value<br/>hierarchy<br/>level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest-bearing investments, including money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust assets for nonqualified deferred compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377 </span></td><td style="background-color:#c0c0c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.</span></div> 0 0 2000000 2000000 1000000 1000000 0 0 0 0 0 0 1000000 1000000 2000000 2000000 2000000 2000000 0 0 0 0 1000000 1000000 2000000 2000000 1000000 1000000 95000000 95000000 243000000 243000000 9000000 9000000 9000000 9000000 154000000 154000000 129000000 129000000 258000000 258000000 381000000 381000000 4000000 4000000 50000000 50000000 2481000000 2341000000 2477000000 2327000000 2485000000 2345000000 2527000000 2377000000 445000000 306000000 139000000 OTHER CONTINGENCIES, GUARANTEES AND COMMITMENTS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of both June 30, 2024 and 2023 for its share of <span style="-sec-ix-hidden:f-897"><span style="-sec-ix-hidden:f-898">aggregate future remediation costs</span></span> related to these matters. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One matter, which accounted for $12 of the recorded liability as of both June 30, 2024 and 2023 relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing groundwater at the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study related to groundwater. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators. In January 2023, the regulators issued a new order directing the Company and the current property owner to conduct a Remedial Investigation and then prepare a Feasibility Study to evaluate and remediate impacts to soil, groundwater, soil vapor and indoor air. While the Company believes its latest estimates of remediation costs </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including any related to soil, groundwater, soil vapor and indoor air impacts) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs in the aggregate of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability as of both June 30, 2024 and 2023. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing agreement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements (including costs connected to the transition and unwinding of certain supply and manufacturing relationships), product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s consolidated financial statements taken as a whole.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s consolidated financial statements taken as a whole.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had not recorded any material liabilities on the aforementioned guarantees as of both June 30, 2024 and 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was a party to letters of credit of $18 and $14 as of June 30, 2024 and 2023, respectively, primarily related to one of its insurance carriers, of which $0 had been drawn upon.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to certain purchase obligations, which are defined as purchase agreements that are enforceable and legally binding and that contain specified or determinable significant terms, including quantity, price and the approximate timing of the transaction. For purchase obligations subject to variable price and/or quantity provisions, an estimate of the price and/or quantity must be made. Examples of the Company’s purchase obligations include contracts to purchase raw materials, commitments to contract manufacturers, commitments for information technology and related services, advertising contracts, capital expenditure agreements, software acquisition and license commitments and service contracts. The Company enters into purchase obligations based on expectations of future business needs. Many of these purchase obligations are flexible to allow for changes in the Company’s business and related requirements. As of June 30, 2024, the Company’s purchase obligations by purchase date were approximately as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase<br/>Obligations</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28000000 28000000 12000000 12000000 P30Y 28000000 P30Y 10000000 10000000 0.243 P30Y 18000000 14000000 0 0 As of June 30, 2024, the Company’s purchase obligations by purchase date were approximately as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase<br/>Obligations</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 181000000 128000000 81000000 43000000 27000000 45000000 505000000 LEASES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases various property, plant and equipment, including office, warehousing, manufacturing and research and development facilities and equipment. These leases have remaining lease terms of up to 33 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the Company’s leases as of June 30 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-933"><span style="-sec-ix-hidden:f-934">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-937"><span style="-sec-ix-hidden:f-938">Accounts payable and accrued liabilities</span></span></span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-941"><span style="-sec-ix-hidden:f-942">Other liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of lease cost were as follows for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and noncash activity related to the Company’s leases were as follows during fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:57.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term and discount rate for the Company’s leases were as follows as of fiscal year ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease payments presented in the table above exclude $2 and $3, respectively, of minimum lease payments signed but not yet commenced as of June 30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the Company completed an asset sale-leaseback transaction on a warehouse in Fairfield, California. The Company received proceeds of $19, net of selling costs. The asset had a carrying value of $3 and the transaction resulted in a $16 gain, which was recognized in Other (income) expense, net in the Health and Wellness segment. The leaseback is accounted for as an operating lease. The term of the lease is 8 years with options to extend the lease for two 5 year periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, the Company completed an asset sale-leaseback transaction on a plant in Ontario, Canada. The Company received proceeds of $16, net of selling costs. The asset had a carrying value of $2, and the transaction resulted in a $14 gain, which was recognized in Other (income) expense, net, in Corporate and Other. The leaseback is accounted for as an operating lease. The term of the lease at inception date is 10 years, with the option to terminate the lease at 7 years.</span></div> LEASES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases various property, plant and equipment, including office, warehousing, manufacturing and research and development facilities and equipment. These leases have remaining lease terms of up to 33 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the Company’s leases as of June 30 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-933"><span style="-sec-ix-hidden:f-934">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-937"><span style="-sec-ix-hidden:f-938">Accounts payable and accrued liabilities</span></span></span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-941"><span style="-sec-ix-hidden:f-942">Other liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of lease cost were as follows for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and noncash activity related to the Company’s leases were as follows during fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:57.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term and discount rate for the Company’s leases were as follows as of fiscal year ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease payments presented in the table above exclude $2 and $3, respectively, of minimum lease payments signed but not yet commenced as of June 30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the Company completed an asset sale-leaseback transaction on a warehouse in Fairfield, California. The Company received proceeds of $19, net of selling costs. The asset had a carrying value of $3 and the transaction resulted in a $16 gain, which was recognized in Other (income) expense, net in the Health and Wellness segment. The leaseback is accounted for as an operating lease. The term of the lease is 8 years with options to extend the lease for two 5 year periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, the Company completed an asset sale-leaseback transaction on a plant in Ontario, Canada. The Company received proceeds of $16, net of selling costs. The asset had a carrying value of $2, and the transaction resulted in a $14 gain, which was recognized in Other (income) expense, net, in Corporate and Other. The leaseback is accounted for as an operating lease. The term of the lease at inception date is 10 years, with the option to terminate the lease at 7 years.</span></div> P33Y P33Y <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the Company’s leases as of June 30 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-933"><span style="-sec-ix-hidden:f-934">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-937"><span style="-sec-ix-hidden:f-938">Accounts payable and accrued liabilities</span></span></span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-941"><span style="-sec-ix-hidden:f-942">Other liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 360000000 346000000 84000000 87000000 334000000 310000000 418000000 397000000 33000000 29000000 13000000 9000000 21000000 21000000 34000000 30000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of lease cost were as follows for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease cost</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and noncash activity related to the Company’s leases were as follows during fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:57.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term and discount rate for the Company’s leases were as follows as of fiscal year ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 97000000 89000000 11000000 9000000 1000000 1000000 12000000 10000000 94000000 87000000 3000000 4000000 97000000 88000000 1000000 1000000 11000000 8000000 113000000 84000000 17000000 21000000 P5Y P3Y 0.036 0.051 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities by fiscal year for the Company’s leases as of June 30, 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 97000000 14000000 94000000 12000000 84000000 7000000 69000000 2000000 56000000 1000000 61000000 0 461000000 36000000 43000000 2000000 418000000 34000000 2000000 3000000 19000000 3000000 16000000 P8Y 2 P5Y 16000000 2000000 14000000 P10Y P7Y STOCKHOLDERS' EQUITY<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends per share paid to Clorox stockholders during the fiscal years ended June 30 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends per share paid</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.72 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2024, a cash dividend was declared in the amount of $1.22 per share payable on August 30, 2024 to common stockholders of record as of the close of business on August 14, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Net (Loss) Income</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency<br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>unrealized<br/>gains<br/>(losses) on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and<br/>postretirement<br/>benefit<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive net<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2021</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other<br/>comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net current period other comprehensive (loss) income </span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before<br/>reclassifications</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other<br/>comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net current period other comprehensive (loss) income</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">comprehensive net (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net current period other comprehensive (loss) income </span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes the release of currency translation adjustment from the Argentina business divestiture. See Note 2 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes recognition of pension settlement charge reclassified into Net earnings (losses). See Note 20 for additional details</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends per share paid to Clorox stockholders during the fiscal years ended June 30 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends per share paid</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.72 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4.80 4.72 4.64 1.22 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency<br/>translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>unrealized<br/>gains<br/>(losses) on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and<br/>postretirement<br/>benefit<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive net<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2021</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other<br/>comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net current period other comprehensive (loss) income </span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before<br/>reclassifications</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other<br/>comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net current period other comprehensive (loss) income</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before<br/>reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">comprehensive net (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net current period other comprehensive (loss) income </span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#b6b6b6;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance June 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes the release of currency translation adjustment from the Argentina business divestiture. See Note 2 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes recognition of pension settlement charge reclassified into Net earnings (losses). See Note 20 for additional details</span></div> -403000000 21000000 -164000000 -546000000 -45000000 107000000 1000000 63000000 0 14000000 -15000000 -1000000 0 -7000000 4000000 -3000000 -45000000 100000000 12000000 67000000 -448000000 121000000 -152000000 -479000000 1000000 -6000000 1000000 -4000000 0 19000000 -6000000 13000000 -2000000 -3000000 2000000 -3000000 3000000 -22000000 5000000 -14000000 -445000000 99000000 -147000000 -493000000 -16000000 -8000000 17000000 -7000000 -223000000 7000000 -174000000 -390000000 1000000 -1000000 45000000 45000000 206000000 -14000000 146000000 338000000 -239000000 85000000 -1000000 -155000000 NET EARNINGS PER SHARE (EPS)<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,174 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,589 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,113 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,804 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,181 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,906 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive stock options and other</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,704 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,174 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,589 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,113 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,804 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,181 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,906 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive stock options and other</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,704 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 124174000 123589000 123113000 630000 592000 793000 124804000 124181000 123906000 2704000 1444000 2448000 STOCK-BASED COMPENSATION PLANS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company’s stockholders voted to approve the amended and restated 2005 Stock Incentive Plan (the Plan). The Plan permits the Company to grant various nonqualified stock-based compensation awards, including stock options, restricted stock, performance shares, deferred stock units, stock appreciation rights and other stock-based awards. The Plan as amended and restated provides that the maximum number of shares which may be issued under the Plan will be 5 million common shares that may be issued for stock-based compensation purposes. As of June 30, 2024, the Company was authorized to grant up to approximately 5 million common shares, plus additional shares equal to shares that are potentially deliverable under an award that expires or are canceled, forfeited or settled without the delivery of shares, under the Plan. As of June 30, 2024, approximately 3 million common shares remained available for grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost and the related income tax benefit recognized for stock-based compensation plans were classified as indicated below for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development costs</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax benefit</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received during fiscal years 2024, 2023 and 2022 from stock options exercised under all stock-based payment arrangements was $23, $52 and $35, respectively. The Company issues shares for stock-based compensation plans from treasury stock. The Company may repurchase stock under its Evergreen Program to offset the estimated impact of dilution related to stock-based awards.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details regarding the valuation and accounting for stock options, restricted stock awards, performance shares and deferred stock units for non-employee directors follow.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no stock option awards granted during the fiscal year 2024. The fair value of each stock option award granted during fiscal years 2023 and 2022 was estimated on the date of grant using the Black-Scholes valuation model and assumptions noted in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 years</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2%</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7% to 25.0%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7%</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% to 2.1%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9% to 3.7%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected life of the stock options is based on historical exercise patterns. The expected volatility is based on implied volatility from publicly traded options on the Company’s stock at the date of grant, historical implied volatility of the Company’s publicly traded options and other factors. The risk-free interest rate is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected term of the option. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of the Company’s stock option activities are summarized below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average<br/>Remaining<br/>Contractual<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding as of June 30, 2023</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,075 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value per share of each option granted during fiscal years 2023 and 2022, estimated at the grant date using the Black-Scholes option pricing model, was $26.95 and $22.26, respectively. The total intrinsic value of options exercised in fiscal years 2024, 2023 and 2022 was $12, $27 and $18, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards outstanding as of June 30, 2024, have been granted at prices that are equal to the market value of the stock on the date of grant. Stock option grants generally vest over 4 years and expire no later than 10 years after the grant date. The Company recognizes compensation expense on a straight-line basis over the vesting period. Awards to employees eligible for retirement prior to the award becoming full vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award. As of June 30, 2024, there was $5 of total unrecognized compensation cost related to non-vested options, which is expected to be recognized over a remaining weighted-average vesting period of 2 years, subject to forfeiture changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock awards is estimated on the date of grant based on the market price of the stock and is amortized to compensation expense on a straight-line basis over the related vesting periods, which are generally 3 to 4 years. Awards to employees eligible for retirement prior to the award becoming fully vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award. The total number of restricted stock awards expected to vest is adjusted by actual and estimated forfeitures. Restricted stock awards receive dividend distributions earned during the vesting period upon vesting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, there was $41 of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a remaining weighted-average vesting period of 2 years. The total fair value of the shares that vested in each of the fiscal years 2024, 2023 and 2022 was $28, $22 and $20, respectively. The weighted-average grant-date fair value of awards granted was $138.51, $143.20 and $157.50 per share for fiscal years 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company’s restricted stock awards is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards as of June 30, 2023</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance shares is estimated on the date of grant based on the market price of the stock and is amortized to compensation expense on a straight line basis over the related vesting periods, which are generally 3 years. Awards to employees eligible for retirement prior to the award becoming fully vested are amortized to compensation expense from the grant date through the date that the employee is no longer required to provide service to earn the award.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024, there was $15 in unrecognized compensation cost related to non-vested performance shares that is expected to be recognized over a remaining weighted-average performance period of 1 year. The weighted-average grant-date fair value of awards granted was $140.39, $141.90 and $162.46 per share for fiscal years 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company’s performance share awards is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share awards as of June 30, 2023</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributed</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share awards as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance shares vested and deferred as of June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-vested performance shares outstanding as of June 30, 2024 and 2023 were 400,000 and 306,000, respectively, and the weighted average grant date fair value was $145.06 and $162.77 per share, respectively. During fiscal year 2024, 58,000 shares vested. The total fair value of shares vested was $12, $12 and $11 during fiscal years 2024, 2023 and 2022, respectively. Upon vesting, the recipients of the grants receive the distribution as shares or, if previously elected by eligible recipients, as deferred stock. Deferred shares continue to earn dividends, which are also deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Units for Nonemployee Directors</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonemployee directors receive annual grants of deferred stock units under the Company’s director compensation program and can elect to receive all or a portion of their annual retainers and fees in the form of deferred stock units. The deferred stock units receive dividend distributions, which are reinvested as deferred stock units, and are recognized at their fair value on the date of grant. Each deferred stock unit represents the right to receive one share of the Company’s common stock following the completion of a director’s service.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, the Company granted 19,000 deferred stock units, reinvested dividends of 4,000 units and distributed 24,000 shares, which had a weighted-average fair value on the grant date of $141.85, $145.15 and $89.91 per share, respectively. As of June 30, 2024, 127,000 units were outstanding, which had a weighted-average fair value on the grant date of $140.22 per share.</span></div> 5000000 5000000 3000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost and the related income tax benefit recognized for stock-based compensation plans were classified as indicated below for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development costs</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax benefit</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7000000 7000000 6000000 63000000 61000000 42000000 4000000 5000000 4000000 74000000 73000000 52000000 18000000 17000000 12000000 23000000 52000000 35000000 0 The fair value of each stock option award granted during fiscal years 2023 and 2022 was estimated on the date of grant using the Black-Scholes valuation model and assumptions noted in the following table:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 years</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2%</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7% to 25.0%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7%</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% to 2.1%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9% to 3.7%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9%</span></td></tr></table> P5Y3M18D P5Y4M24D P5Y3M18D P5Y4M24D 0.242 0.217 0.250 0.242 0.218 0.037 0.009 0.021 0.037 0.009 0.034 0.029 0.037 0.034 0.029 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of the Company’s stock option activities are summarized below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average<br/>Remaining<br/>Contractual<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding as of June 30, 2023</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,075 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4075000 147 P5Y 69000000 0 234000 104 51000 170 3790000 150 P4Y 16000000 3052000 148 P4Y 16000000 26.95 22.26 12000000 27000000 18000000 P4Y P10Y 5000000 P2Y P3Y P4Y 41000000 P2Y 28000000 22000000 20000000 138.51 143.20 157.50 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company’s restricted stock awards is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards as of June 30, 2023</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 544000 155 405000 139 173000 162 55000 142 721000 145 P3Y 15000000 P1Y 140.39 141.90 162.46 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company’s performance share awards is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares<br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share awards as of June 30, 2023</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributed</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share awards as of June 30, 2024</span></div></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance shares vested and deferred as of June 30, 2024</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 368000 158 176000 140 39000 189 22000 177 483000 148 83000 164 400000 306000 145.06 162.77 58000 12000000 12000000 11000000 1 19000 4000 24000 141.85 145.15 89.91 127000 140.22 OTHER (INCOME) EXPENSE, NET<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of Other (income) expense, net, for the fiscal years ended June 30 were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of trademarks and other intangible assets</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust investment (gains) losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction (gains) losses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from equity investees</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale-leaseback transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Foreign exchange losses are primarily related to the Company’s operations in Argentina, prior to the divestiture.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Restructuring costs related to the Company's streamlined operating model plan (see Note 5).</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of Other (income) expense, net, for the fiscal years ended June 30 were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of trademarks and other intangible assets</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust investment (gains) losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction (gains) losses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from equity investees</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale-leaseback transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Foreign exchange losses are primarily related to the Company’s operations in Argentina, prior to the divestiture.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Restructuring costs related to the Company's streamlined operating model plan (see Note 5).</span></div> 29000000 30000000 31000000 20000000 14000000 -21000000 14000000 16000000 16000000 -25000000 -13000000 -3000000 5000000 4000000 6000000 23000000 16000000 5000000 16000000 52000000 0 16000000 0 14000000 4000000 3000000 -9000000 24000000 80000000 37000000 INCOME TAXES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid, net of refunds, were $347 and $73 for the fiscal year ended June 30, 2024 and 2023, respectively. The increase in payments in the current period was primarily driven by income tax payments for fiscal years 2023 and 2024 that were previously deferred as a result of tax relief provided by the IRS due to winter storms in California.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Earnings before income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate on operations follows for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal tax benefits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal excess tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net U.S. tax on foreign income</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on divestiture</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International legal entity reorganization</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VMS goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act (the “Act”) was signed into law on August 16, 2022. The Act introduced a new 15% corporate minimum tax for certain large corporations, effective at the beginning of the Company’s fiscal 2024 and it enacted a 1% excise tax on the value of share repurchases, net of new share issuances, after December 31, 2022. These provisions, as well as other corporate tax changes included in the Act, have not had a material impact on the Company's consolidated financial statements and are not expected to have a material impact on the Company’s financial statements in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per U.S. GAAP, foreign withholding taxes are provided on unremitted foreign earnings that are not indefinitely reinvested at the time the earnings are generated. The Company regularly reviews and assesses whether there are any changes to its indefinite reinvestment assertion. None of the undistributed earnings of its foreign subsidiaries were indefinitely reinvested. As a result, the Company is providing foreign withholding taxes on the undistributed earnings of all foreign subsidiaries where applicable. These withholding taxes had no significant impact on the Company’s consolidated results.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets (liabilities) as of June 30 are shown below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit programs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and tax credit carryforwards</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating and finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment and intangible assets</span></div></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The net deferred tax assets and liabilities included in the consolidated balance sheet at June 30 were as follows:</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:29.94pt">Net deferred tax assets are recorded in Other assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its deferred tax assets for recoverability on a quarterly basis. A valuation allowance is established when the Company believes that it is more likely than not that some portion of its deferred tax assets will not be realized. Valuation allowances have been provided to reduce deferred tax assets to amounts considered recoverable.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance on deferred tax assets were as follows for the years ended June 30: </span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase/(decrease) for U.S. capital loss carryfowards</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease/(increase) for other foreign deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's carryforwards for capital losses, net operating losses, and tax credits, with related valuation allowances were as follows as of June 30:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation Allowances</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Expiring</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses in U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 - 2042</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2044</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax credits</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carryforwards</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation Allowances</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Expiring</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses in U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 - 2042</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2040</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2033</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax credits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carryforwards</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal and various state, local and foreign jurisdictions. The federal statute of limitations has expired for all tax years through June 30, 2015. Various income tax returns in state and foreign jurisdictions are currently in the process of examination.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of June 30, 2024 and 2023, the total balance of accrued interest and penalties related to uncertain tax positions was $3 and $2, respectively. Interest and penalties related to uncertain tax positions included in income tax expense resulted in an expense of $1 in fiscal year 2024 and a net benefit of $0 in both fiscal years 2023 and 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the beginning and ending amounts of the Company’s gross unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of year</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in prior periods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - tax positions in prior periods</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - current period tax positions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of applicable statute of limitations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of June 30, 2024, 2023 and 2022, were potential benefits of $15, $14 and $14, respectively, which if recognized, would affect the effective tax rate. Unrecognized tax benefits are not expected to significantly increase or decrease within the next 12 months.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 132000000 153000000 71000000 18000000 33000000 17000000 56000000 40000000 43000000 206000000 226000000 131000000 -99000000 -120000000 6000000 -5000000 -28000000 -2000000 4000000 -1000000 1000000 -100000000 -149000000 5000000 106000000 77000000 136000000 347000000 73000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Earnings before income taxes, by tax jurisdiction, consisted of the following for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 311000000 154000000 483000000 87000000 84000000 124000000 398000000 238000000 607000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate on operations follows for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal tax benefits)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal excess tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net U.S. tax on foreign income</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on divestiture</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International legal entity reorganization</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VMS goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.025 0.016 0.019 0.077 0.086 0.031 -0.003 -0.018 -0.009 0.052 0.023 0.017 0.105 0 0 -0.061 0 0 0 0.086 0 0.012 0.027 0.008 -0.024 -0.006 -0.002 0.265 0.324 0.224 0 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets (liabilities) as of June 30 are shown below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit programs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and tax credit carryforwards</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating and finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory costs</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment and intangible assets</span></div></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The net deferred tax assets and liabilities included in the consolidated balance sheet at June 30 were as follows:</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:29.94pt">Net deferred tax assets are recorded in Other assets.</span></div> 109000000 123000000 153000000 94000000 111000000 104000000 33000000 46000000 43000000 34000000 29000000 32000000 33000000 34000000 511000000 467000000 115000000 59000000 396000000 408000000 84000000 157000000 100000000 96000000 36000000 36000000 220000000 289000000 176000000 119000000 198000000 147000000 22000000 28000000 176000000 119000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance on deferred tax assets were as follows for the years ended June 30: </span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase/(decrease) for U.S. capital loss carryfowards</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease/(increase) for other foreign deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease/(increase) for foreign and U.S. net operating loss carryforwards and tax credits</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 59000000 52000000 42000000 -46000000 0 0 2000000 1000000 1000000 8000000 6000000 9000000 115000000 59000000 52000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's carryforwards for capital losses, net operating losses, and tax credits, with related valuation allowances were as follows as of June 30:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation Allowances</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Expiring</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses in U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 - 2042</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2044</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax credits</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carryforwards</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation Allowances</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Expiring</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses in U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 - 2042</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2040</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2033</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax credits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carryforwards</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's carryforwards for capital losses, net operating losses, and tax credits, with related valuation allowances were as follows as of June 30:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation Allowances</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Expiring</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses in U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></div></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 - 2042</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2044</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 - 2034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax credits</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carryforwards</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation Allowances</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carryforwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Expiring</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses in U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 - 2042</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2040</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credits</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 - 2033</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdictions (with no expiration)</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax credits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carryforwards</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 46000000 46000000 0 6000000 5000000 1000000 9000000 8000000 1000000 18000000 16000000 2000000 8000000 0 8000000 41000000 29000000 12000000 30000000 0 30000000 2000000 0 2000000 30000000 30000000 0 4000000 3000000 1000000 66000000 33000000 33000000 153000000 108000000 45000000 0 0 0 4000000 4000000 0 6000000 5000000 1000000 21000000 16000000 5000000 9000000 1000000 8000000 40000000 26000000 14000000 23000000 0 23000000 2000000 0 2000000 29000000 28000000 1000000 54000000 28000000 26000000 94000000 54000000 40000000 3000000 2000000 1000000 0 0 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the beginning and ending amounts of the Company’s gross unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of year</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - tax positions in prior periods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - tax positions in prior periods</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - current period tax positions</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of applicable statute of limitations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000000 17000000 21000000 0 1000000 0 4000000 3000000 7000000 9000000 2000000 4000000 0 0 0 0 0 1000000 0 0 0 22000000 17000000 17000000 15000000 14000000 14000000 EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Income Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of fiscal year 2024, the Company settled plan benefits of its previously frozen domestic qualified pension plan (the Plan), following the Company’s Board of Directors' approval of a resolution to terminate the Plan in May 2022. The settlement occurred through a combination of an annuity contract purchase with a third-party insurance provider and lump sum payouts. These payments were made using Plan assets. The third-party insurance provider assumed the obligation to pay future pension benefits and provide administrative services, and started making direct payments to participants in January 2024. In </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conjunction with this settlement, a one-time noncash charge, net of curtailment gain, of $171 before taxes ($130 after tax) was recorded in the Company’s consolidated statements of earnings and comprehensive income primarily as a result of accelerating the recognition of actuarial losses previously included in Accumulated other comprehensive net (loss) income that would have been recognized in future periods. Following settlement, remaining excess plan assets of $19 was contributed to the Company’s domestic defined contribution plan during 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to maintain various other retirement income plans for eligible domestic and international employees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining domestic retirement income plans are frozen.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contributed $14, $14 and $15 to its domestic retirement income plans during fiscal years 2024, 2023 and 2022, respectively. The Company’s funding policy is to contribute amounts sufficient to meet benefit payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Health Care Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain health care benefits for employees who meet age, participation and length of service requirements at retirement. The plans pay stated percentages of covered expenses after annual deductibles have been met or stated reimbursements up to a specified dollar subsidy amount. Benefits paid take into consideration payments by Medicare for the domestic plan. The plans are funded as claims are paid, and the Company has the right to modify or terminate certain plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit Obligation and Funded Status</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information for the Company’s retirement income and retirement health care plans as of and for the fiscal years ended June 30 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligations:</span></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation as of beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss (gain)</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlement</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other adjustments</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation as of end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets as of beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlement</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer to domestic defined contribution plan</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets as of end of year</span></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued benefit cost, net funded status</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recognized in the balance sheets consists of:</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current accrued benefit liability</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current accrued benefit liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued benefit cost, net</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the retirement income plans, the benefit obligation is the projected benefit obligation (PBO). For the retirement health care plan, the benefit obligation is the accumulated benefit obligation (ABO).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ABO for all retirement income plans was $105, $474 and $512 as of June 30, 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement income plans with ABO or PBO in excess of plan assets as of June 30 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ABO Exceeds the Fair Value of Plan Assets</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PBO Exceeds the Fair Value of Plan Assets</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Periodic Benefit Cost</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cost of the retirement income and health care plans for the fiscal years ended June 30 included the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized items     </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain recognized</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service cost component of the net periodic benefit cost is reflected in employee benefit costs, and all other components, except for the net settlement loss recognized in relation to the settlement of the Plan recognized in the second quarter of fiscal year 2024, are reflected in Other (income) expense, net.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items not yet recognized as a component of postretirement expense as of June 30, 2024 consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax (assets) liabilities</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (income)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net actuarial loss (gain) recorded in Accumulated other comprehensive net (loss) income for the fiscal year ended June 30, 2024 included the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain) as of beginning of year</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization, curtailment and settlement during the year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) during the year</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain) as of end of year</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the straight-line amortization method for unrecognized prior service costs and benefits. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assumptions</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to estimate the actuarial present value of benefit obligations were as follows as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.52 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.38 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to estimate the retirement income and retirement health care costs were as follows as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.72 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.39 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return assumption is based on prospective returns according to the fund’s current target asset allocation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial benefit obligation gain incurred during fiscal year 2024 was primarily driven by increases in the discount rates for the retirement plans, partially offset by investment gains lower than expected return on assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actuarial benefit obligation gain during fiscal year 2023 was primarily driven by increases in the discount rates for the retirement plans, partially offset by investment gains lower than expected return on assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expected Benefit Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments for the Company’s retirement income and retirement health care plans as of June 30, 2024, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal years 2030 through 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The target allocations and weighted average asset allocations by asset category of the investment portfolio for the Company’s qualified domestic retirement income plans as of June 30, 2023, prior to its termination, were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Target Allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Plan Asset</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The target asset allocation was determined based on the optimal balance between risk and return and, at times, was adjusted to achieve the plan’s overall investment objective to generate sufficient resources to pay current and projected plan obligations over the life of the domestic retirement income plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the retirement income plans’ assets carried at fair value as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents — Level 1</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets in the fair value hierarchy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common collective trusts measured at net asset value</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bond funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International equity funds</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic equity funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment fund</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate fund</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common collect trust measured at net asset value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common collective trust funds are not publicly traded and were valued at a net asset value unit price determined by the portfolio’s sponsor based on the fair value of underlying assets held by the common collective trust fund on June 30, 2024 and 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common collective trusts are invested in various trusts that attempt to achieve their investment objectives by investing primarily in other collective investment funds that have characteristics consistent with each trust’s overall investment objective and strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various defined contribution plans for eligible domestic and international employees. The aggregate cost of the domestic defined contribution plans was $63, $64 and $58 in fiscal years 2024, 2023 and 2022, respectively. The aggregate cost of the international defined contribution plans was $5, $6 and $6 for the fiscal years ended June 30, 2024, 2023 and 2022, respectively.</span></div> 171000000 130000000 19000000 14000000 14000000 15000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information for the Company’s retirement income and retirement health care plans as of and for the fiscal years ended June 30 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligations:</span></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation as of beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss (gain)</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlement</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other adjustments</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation as of end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets as of beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlement</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer to domestic defined contribution plan</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets as of end of year</span></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued benefit cost, net funded status</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 476000000 513000000 26000000 28000000 1000000 1000000 0 0 12000000 18000000 1000000 1000000 26000000 11000000 2000000 1000000 0 0 -4000000 0 312000000 0 0 0 26000000 45000000 2000000 2000000 2000000 0 0 0 123000000 476000000 19000000 26000000 381000000 412000000 0 0 -13000000 0 0 0 15000000 15000000 2000000 2000000 312000000 0 0 0 26000000 45000000 2000000 2000000 -19000000 0 0 0 -1000000 -1000000 0 0 25000000 381000000 0 0 -98000000 -95000000 -19000000 -26000000 <div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recognized in the balance sheets consists of:</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current accrued benefit liability</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current accrued benefit liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued benefit cost, net</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7000000 24000000 0 0 12000000 13000000 2000000 2000000 93000000 106000000 17000000 24000000 -98000000 -95000000 -19000000 -26000000 105000000 474000000 512000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement income plans with ABO or PBO in excess of plan assets as of June 30 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ABO Exceeds the Fair Value of Plan Assets</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PBO Exceeds the Fair Value of Plan Assets</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 105000000 119000000 108000000 121000000 104000000 118000000 105000000 119000000 0 0 2000000 2000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cost of the retirement income and health care plans for the fiscal years ended June 30 included the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retirement Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized items     </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain recognized</span></div></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1000000 1000000 1000000 0 0 0 12000000 18000000 15000000 1000000 1000000 1000000 2000000 10000000 15000000 0 0 0 -3000000 -8000000 -9000000 2000000 2000000 1000000 6000000 0 0 0 0 0 -179000000 0 -7000000 0 0 0 187000000 17000000 17000000 -1000000 -1000000 0 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items not yet recognized as a component of postretirement expense as of June 30, 2024 consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax (assets) liabilities</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (income)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -20000000 14000000 0 -4000000 5000000 -4000000 15000000 -14000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net actuarial loss (gain) recorded in Accumulated other comprehensive net (loss) income for the fiscal year ended June 30, 2024 included the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain) as of beginning of year</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization, curtailment and settlement during the year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) during the year</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain) as of end of year</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -213000000 14000000 182000000 -2000000 11000000 2000000 -20000000 14000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to estimate the actuarial present value of benefit obligations were as follows as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.52 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.37 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.38 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average assumptions used to estimate the retirement income and retirement health care costs were as follows as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.72 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.39 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Health Care</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0552 0.0437 0.0538 0.0510 0.0323 0.0362 0.0540 0.0267 0.0463 0.0372 0.0256 0.0320 0.0309 0.0302 0.0339 0.0267 0.0300 0.0269 0.0269 0.0257 0.0510 0.0465 0.0261 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected benefit payments for the Company’s retirement income and retirement health care plans as of June 30, 2024, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement<br/>Health Care</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal years 2030 through 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 15000000 2000000 14000000 2000000 13000000 2000000 13000000 2000000 12000000 2000000 48000000 7000000 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The target allocations and weighted average asset allocations by asset category of the investment portfolio for the Company’s qualified domestic retirement income plans as of June 30, 2023, prior to its termination, were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Target Allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Plan Asset</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#b6b6b6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the retirement income plans’ assets carried at fair value as of June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents — Level 1</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#b3b3b3;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets in the fair value hierarchy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common collective trusts measured at net asset value</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bond funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International equity funds</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic equity funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment fund</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate fund</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#b3b3b3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b3b3b3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common collect trust measured at net asset value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b3b3b3;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#b3b3b3;padding:0 1pt"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#b3b3b3;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.80 0.79 0.20 0.21 1 1 0 74000000 0 74000000 6000000 289000000 16000000 15000000 0 0 0 1000000 2000000 2000000 1000000 0 25000000 307000000 25000000 381000000 63000000 64000000 58000000 5000000 6000000 6000000 SEGMENT REPORTING<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates through strategic business units (SBUs) that are organized into the Company’s operating segments. Operating segments with shared economic and qualitative characteristics are aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. The four reportable segments consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Health and Wellness </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of cleaning, disinfecting and professional products marketed and sold in the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Household</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of bags and wraps, cat litter and grilling products marketed and sold in the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lifestyle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of food, water-filtration and natural personal care products marketed and sold in the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of products sold outside the United States. Products within this segment include laundry additives; home care products; bags and wraps; cat litter; water-filtration products; professional cleaning and disinfecting products; natural personal care products; food; grilling products and digestive health products marketed primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate and Other includes certain non-allocated administrative costs, various other non-operating income and expenses, as well as the results of the Better Health VMS business. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes, as well as the assets related to the Better Health VMS business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principle measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, relating to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance and allocate resources to each segment as it removes the impact of the items that management believes do not directly reflect the performance of each segment's underlying operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment total</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,872 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,844 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,093 </span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389 </span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,107 </span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment adjusted earnings (losses) before interest and income taxes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment total</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on divestiture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension settlement charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyberattack costs, net of insurance recoveries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VMS impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Streamlined operating model </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital capabilities and productivity enhancements investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (6)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents the loss on divestiture of the Argentina business corresponding to International. See Note 2 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents costs related to the settlement of the domestic qualified pension plan corresponding to Corporate and Other. See Note 20 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents incremental costs, net of insurance recoveries, related to the cyberattack. See Note 3 for additional details relating to the cyberattack. All insurance recoveries are recorded in Corporate and Other. For informational purposes, the following table provides the approximate cyberattack costs, net of insurance recoveries, corresponding to the Company’s reportable segments as a percentage of total net costs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:79.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.294%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents a noncash impairment charge of $445 related to the Better Health VMS business recorded in fiscal year 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restructuring and related implementation costs, net for the streamlined operating model of $32 and $60 in fiscal year 2024 and 2023, respectively. For informational purposes the following table provides the approximate restructuring and related implementation costs, net corresponding to the Company's segments as a percent of the total costs for the fiscal years ended June 30:</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:40.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inception to date ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents expenses related to the Company's digital capabilities and productivity enhancements investment corresponding to Corporate and Other. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Company</span></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) Loss from equity investees included in Other (income) expense, net</span></div></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,751 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="42" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant noncash charges included in earnings (losses) before interest and income taxes: </span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intersegment sales are eliminated and are not included in the Company’s reportable net sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales to the Company’s largest customer, Walmart Stores, Inc. and its affiliates, were 25%, 26% and 25% of consolidated net sales for each of the fiscal years ended June 30, 2024, 2023 and 2022, respectively, and occurred across all of the Company’s reportable segments. No other customers accounted for 10% or more of the Company’s consolidated net sales in any of these fiscal years.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and Wraps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat Litter</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grilling</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Water Filtration</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natural Personal Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate and Other</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s products are marketed and sold globally. The following table provides the Company’s global product lines, which were sold in the U.S. and International, that accounted for 10% or more of consolidated net sales for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning products</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and wraps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food products</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat litter products</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales and property, plant and equipment, net, by geographic area for and as of the fiscal years ended June 30 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Company</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,956 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,093 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,951 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,107 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates through strategic business units (SBUs) that are organized into the Company’s operating segments. Operating segments with shared economic and qualitative characteristics are aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. The four reportable segments consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Health and Wellness </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of cleaning, disinfecting and professional products marketed and sold in the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Household</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of bags and wraps, cat litter and grilling products marketed and sold in the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lifestyle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of food, water-filtration and natural personal care products marketed and sold in the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of products sold outside the United States. Products within this segment include laundry additives; home care products; bags and wraps; cat litter; water-filtration products; professional cleaning and disinfecting products; natural personal care products; food; grilling products and digestive health products marketed primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate and Other includes certain non-allocated administrative costs, various other non-operating income and expenses, as well as the results of the Better Health VMS business. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes, as well as the assets related to the Better Health VMS business.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principle measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental costs, net of insurance recoveries, relating to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance and allocate resources to each segment as it removes the impact of the items that management believes do not directly reflect the performance of each segment's underlying operations.</span></div> 4 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment total</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,872 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,844 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,093 </span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389 </span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,107 </span></td><td style="background-color:#b6b6b6;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment adjusted earnings (losses) before interest and income taxes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segment total</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on divestiture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension settlement charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyberattack costs, net of insurance recoveries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VMS impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Streamlined operating model </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital capabilities and productivity enhancements investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (6)</span></div></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (losses) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents the loss on divestiture of the Argentina business corresponding to International. See Note 2 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents costs related to the settlement of the domestic qualified pension plan corresponding to Corporate and Other. See Note 20 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents incremental costs, net of insurance recoveries, related to the cyberattack. See Note 3 for additional details relating to the cyberattack. All insurance recoveries are recorded in Corporate and Other. For informational purposes, the following table provides the approximate cyberattack costs, net of insurance recoveries, corresponding to the Company’s reportable segments as a percentage of total net costs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:79.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.294%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents a noncash impairment charge of $445 related to the Better Health VMS business recorded in fiscal year 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restructuring and related implementation costs, net for the streamlined operating model of $32 and $60 in fiscal year 2024 and 2023, respectively. For informational purposes the following table provides the approximate restructuring and related implementation costs, net corresponding to the Company's segments as a percent of the total costs for the fiscal years ended June 30:</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:40.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inception to date ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Household</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and Other</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents expenses related to the Company's digital capabilities and productivity enhancements investment corresponding to Corporate and Other. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Company</span></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) Loss from equity investees included in Other (income) expense, net</span></div></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,751 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="42" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Significant noncash charges included in earnings (losses) before interest and income taxes: </span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2485000000 2532000000 2427000000 1950000000 2098000000 1984000000 1275000000 1338000000 1253000000 1162000000 1181000000 1180000000 6872000000 7149000000 6844000000 221000000 240000000 263000000 7093000000 7389000000 7107000000 719000000 594000000 381000000 260000000 308000000 234000000 253000000 284000000 280000000 122000000 89000000 97000000 1354000000 1275000000 992000000 -309000000 -358000000 -223000000 1045000000 917000000 769000000 23000000 16000000 5000000 90000000 90000000 106000000 -240000000 0 0 -171000000 0 0 29000000 0 0 0 445000000 0 32000000 60000000 0 108000000 100000000 61000000 398000000 238000000 607000000 0.30 0.24 0.23 0.08 0.15 1 445000000 32000000 60000000 0.03 0.06 0.05 0.02 0.01 0.02 0 0.04 0.02 0.04 0.16 0.11 0.91 0.73 0.80 1 1 1 0 0 0 5000000 0 5000000 0 0 0 4000000 0 4000000 0 0 0 6000000 0 6000000 1124000000 1088000000 1110000000 1327000000 1102000000 5751000000 1184000000 1082000000 1091000000 1410000000 1178000000 5945000000 47000000 84000000 36000000 21000000 24000000 212000000 51000000 97000000 29000000 24000000 27000000 228000000 61000000 112000000 24000000 27000000 27000000 251000000 58000000 77000000 24000000 45000000 31000000 235000000 59000000 78000000 25000000 46000000 28000000 236000000 57000000 67000000 24000000 47000000 29000000 224000000 14000000 11000000 8000000 6000000 35000000 74000000 14000000 10000000 7000000 4000000 38000000 73000000 14000000 8000000 6000000 3000000 21000000 52000000 0.25 0.26 0.25 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and Wraps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat Litter</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grilling</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Water Filtration</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natural Personal Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate and Other</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s products are marketed and sold globally. The following table provides the Company’s global product lines, which were sold in the U.S. and International, that accounted for 10% or more of consolidated net sales for the fiscal years ended June 30:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning products</span></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and wraps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food products</span></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat litter products</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.30 0.30 0.29 0.05 0.05 0.04 0.35 0.35 0.33 0.11 0.12 0.12 0.09 0.09 0.08 0.08 0.07 0.08 0.28 0.28 0.28 0.11 0.10 0.10 0.04 0.04 0.04 0.03 0.04 0.04 0.18 0.18 0.18 0.16 0.16 0.17 0.03 0.03 0.04 1 1 1 0.43 0.42 0.42 0.15 0.16 0.16 0.11 0.11 0.11 0.10 0.10 0.09 <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales and property, plant and equipment, net, by geographic area for and as of the fiscal years ended June 30 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Company</span></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,956 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,093 </span></td><td style="background-color:#b6b6b6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,951 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,107 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5956000000 1137000000 7093000000 6237000000 1152000000 7389000000 5951000000 1156000000 7107000000 1188000000 127000000 1315000000 1192000000 153000000 1345000000 RELATED PARTY TRANSACTIONS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds various equity investments with ownership percentages of up to 50% in a number of consumer products businesses, which operate both within and outside the United States. The equity investments, presented in Other assets and accounted for under the equity method, were $45 and $43 as of the fiscal years ended June 30, 2024 and 2023, respectively. The Company has no ongoing capital commitments, loan requirements, guarantees or any other types of arrangements under the terms of its agreements that would require any future cash contributions or disbursements arising out of an equity investment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions with the Company’s equity investees typically represent payments for contract manufacturing and purchases of raw materials. Payments to related parties, including equity investees, for such transactions during the fiscal years ended June 30, 2024, 2023 and 2022 were $77, $87 and $117, respectively. Receipts from and ending accounts receivable and payable balances related to the Company’s related parties were not significant during or as of the end of each of the fiscal years presented.</span></div> 0.50 45000000 43000000 77000000 87000000 117000000 SUBSEQUENT EVENTOn July 24, 2024, the Company entered into a definitive agreement to sell the Better Health VMS business. The transaction is expected to close in the first quarter of fiscal year 2025 and is expected to result in a loss on sale. The results of the Better Health VMS business are included within Corporate and Other in the fiscal year 2024 consolidated financial statements. The closing of the transaction is subject to customary closing conditions, including regulatory approval.

  •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̑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